ceftazidime profile

ID Source	ID
PubMed CID	5481173
CHEMBL ID	44354
CHEBI ID	3508
SCHEMBL ID	36849
MeSH ID	M0003729

Synonym
BIDD:GT0734
AB00513848-02
tazidime
fortaz
gr-20263
pentacef
tazicef
ly-139381
ceptaz
(6r,7r)-7-({(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
gr 20263
D07654
ceftazidime (tn)
ceptaz (tn)
CAZ ,
AB00513848
C06889
ceftazidime anhydrous
DB00438
fortaz (tn)
HMS2090M13
CHEBI:3508 ,
7beta-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
ceftazidimum
(6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
ceftazidima
A839420
nsc-759260
AKOS015951273
ceftazidime (arginine formulation)
CHEMBL44354
j01dd07
bdbm50420259
HY-B0593
SCHEMBL36849
Q-200811
cefprozil, antibiotic for culture media use only
DTXSID5022770
1-{[(6r,7r)-7-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium
(6r,7r)-7-((z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (contains ca. 10% na2co3)
CCG-269983
NCGC00179584-05
7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6r,7r)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
EN300-22411480
(6r,7r)-7-((z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate(containsca.10%na2co3)

Excerpt	Reference	Relevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36

Excerpt	Reference	Relevance
" These top candidates were then evaluated for their activity in vivo, and their pharmacokinetic behavior in various animal models was explored."	( Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters. Counter, FT; Draheim, SE; Eudaly, JA; Kasher, JS; Pike, AJ; Ternansky, RJ, 1993)	0.29
"Using an in vitro pharmacodynamic model, a multidrug-resistant strain of Acinetobacter baumannii was exposed to colistin methanesulfonate alone and in combination with ceftazidime."	( Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Hovde, LB; Kroeger, LA; Mitropoulos, IF; Rotschafer, JC; Schafer, J, 2007)	0.53
"In this study we investigated the interplay of antibiotic pharmacokinetic profiles and the development of mutation-mediated resistance in wild-type and hypermutable Pseudomonas aeruginosa strains."	( Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro. Henrichfreise, B; Luhmer-Becker, I; Wiedemann, B; Wiegand, I, 2007)	0.54
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35

Excerpt	Reference	Relevance
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."	( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010)	0.36

Excerpt	Relevance	Reference
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."	( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A, )	0.13
" It was concluded that plasmid-borne bla(SHV) greatly facilitates the selection of ESBL expression, even when the same gene is on the chromosome, and that gene dosage effects are likely to contribute to this phenomenon."	( Selection of SHV extended-spectrum-beta-lactamase-dependent cefotaxime and ceftazidime resistance in Klebsiella pneumoniae requires a plasmid-borne blaSHV gene. Bell, J; Giffard, PM; Hammond, DS; Harris, T; Turnidge, J, 2008)	0.58
"019) than those with the genes chromosomally encoded, which is most likely due to increased gene dosage provided by the higher copy number of associated plasmids."	( Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan. Chang, FY; Chen, TL; Fung, CP; Hsueh, PR; Ko, WC; Kuo, SC; Lee, YT; Siu, LK, 2010)	0.36
"Animal infection models in the pharmacokinetic/pharmacodynamic (PK/PD) evaluation of antimicrobial therapy serve an important role in preclinical assessments of new antibiotics, dosing optimization for those that are clinically approved, and setting or confirming susceptibility breakpoints."	( Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Andes, DR; Lepak, AJ; Zhao, M, 2016)	0.43
" aeruginosa, 2 was shown to have dose-dependent efficacy at 50 and 100 mg/kg q6h dosing in a mouse thigh infection model."	( A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. Bethel, CR; Bonomo, RA; Goldberg, JA; Hoyer, D; Hujer, AM; Hujer, KM; Jacobs, MR; Kreiswirth, BN; Kumar, V; Marshall, SH; Papp-Wallace, KM; Perez, F; Plummer, MS; Spencer, EJ; van den Akker, F; van Duin, D, 2021)	0.62

Role	Description
antibacterial drug	A drug used to treat or prevent bacterial infections.
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor	An EC 2.4.1.* (hexosyltransferase) inhibitor that interferes with the action of peptidoglycan glycosyltransferase (EC 2.4.1.129).
drug allergen	Any drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
cephalosporin	A class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
oxime O-ether	O-organyl oximes R2C=NOR' (R' =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 15 member 1	Homo sapiens (human)	Ki	10,000.0000	0.1800	3.3933	9.8000	AID681115
Solute carrier family 15 member 2	Rattus norvegicus (Norway rat)	Ki	10,000.0000	3.0000	6.4778	8.5000	AID681114
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-lactamase	Citrobacter freundii	Km	320.0000	5.0000	7.0000	9.0000	AID405084
Beta-lactamase	Citrobacter gillenii	Km	1,749.0000	10.0000	10.0000	10.0000	AID285442
Beta-lactamase	Escherichia coli	Km	15.0000	1.1000	4.7667	9.4000	AID394487
Beta-lactamase	Aeromonas caviae	Km	20.0000	7.0000	7.0000	7.0000	AID374363
Beta-lactamase	Shouchella clausii	Km	1,000.0000	0.0100	3.0050	6.0000	AID373209
Beta-lactamase	Acinetobacter baumannii	Km	30.0000	3.0000	5.6667	9.0000	AID567279
Beta-lactamase	Burkholderia cenocepacia	Km	3,000.0000	10.0000	10.0000	10.0000	AID541022
Metallo-beta-lactamase type 2	Klebsiella pneumoniae	Km	181.0000	8.0000	9.3333	10.0000	AID563972
Metallo-beta-lactamase VIM-11	Pseudomonas aeruginosa	Km	110.0000	4.5000	7.0000	9.4000	AID520385
Beta-lactamase	Klebsiella pneumoniae	Km	180.0000	3.2000	5.8250	10.0000	AID562754
Metallo-beta-lactamase VIM-2	Pseudomonas aeruginosa	Km	88.2000	5.5000	7.8750	9.9000	AID520386
Beta-lactamase	Pseudomonas aeruginosa	Km	0.6400	0.3000	2.0063	8.0000	AID495661
Beta-lactamase	Aeromonas allosaccharophila	Km	1,000.0000	1.5000	6.3000	10.0000	AID584846
Metallo-beta-lactamase	Stutzerimonas stutzeri	Km	50.0000	3.5000	4.7500	6.0000	AID518728
Beta-lactamase	Acinetobacter baumannii	Km	10.0000	6.0000	7.6667	10.0000	AID567280
Beta-lactamase	Staphylococcus aureus	Km	29.0000	1.0000	2.2000	3.4000	AID368313
Beta-lactamase	Enterobacter cloacae	Km	29.8250	2.9000	6.4364	9.8000	AID368498; AID368523; AID368527; AID495693
Beta-lactamase SHV-1	Klebsiella pneumoniae	Km	380.6667	4.2000	4.2500	4.3000	AID368307; AID495687; AID519983
Beta-lactamase	Serratia marcescens	Km	570.0000	2.1000	2.1000	2.1000	AID368725
Beta-lactamase	Pseudomonas aeruginosa PAO1	Km	13.6000	0.5000	4.2444	8.0000	AID368539; AID368543; AID368547; AID495747; AID546426
Kappa-type opioid receptor	Cavia porcellus (domestic guinea pig)	Km	1,749.0000	10.0000	10.0000	10.0000	AID285442
Beta-lactamase TEM	Escherichia coli	Km	200.0000	5.4000	6.3000	7.2000	AID368309; AID495686
Beta-lactamase	Morganella morganii	Km	14.0000	7.9000	7.9000	7.9000	AID368531
B2 metallo-beta-lactamase	Chryseobacterium indologenes	Km	22.0000	3.0000	3.0000	3.0000	AID562337
Beta-lactamase	Acinetobacter pittii	Km	26.0900	0.0200	2.1814	6.7300	AID555223
Beta-lactamase	Acinetobacter pittii	Km	110.3400	0.1800	1.3683	3.8500	AID555225
Beta-lactamase	Acinetobacter pittii	Km	84.0200	0.1300	1.5250	4.5400	AID555227
Beta-lactamase	Klebsiella pneumoniae	Km	236.0000	8.7000	8.7000	8.7000	AID562755
Beta-lactamase	Salmonella enterica subsp. enterica serovar Westhampton	Km	174.0000	10.0000	10.0000	10.0000	AID556340
Metallo-beta-lactamase VIM-2	Klebsiella pneumoniae	Km	98.0000	5.0000	7.5000	10.0000	AID563976
Beta-lactamase	Klebsiella pneumoniae	Km	58.0000	5.0000	7.1667	10.0000	AID519982
Beta-lactamase	Escherichia coli	Km	4.5000	0.0046	1.4149	4.5000	AID495691
Metallo-beta-lactamase	Escherichia coli	Km	166.0000	2.0000	6.8571	10.0000	AID583083; AID583084; AID583085; AID583094
Beta-lactamase	Pseudomonas luteola	Km	35.0000	7.0000	7.5000	8.0000	AID495635
Beta-lactamase	Serratia marcescens	Km	170.0000	2.2000	4.6000	8.2000	AID368509; AID495696
Beta-lactamase IMP-1	Pseudomonas aeruginosa	Km	50.0000	6.5000	6.5000	6.5000	AID495698
BlaVIM-1	Escherichia coli	Km	800.0000	1.5000	1.5000	1.5000	AID495914
Beta-lactamase	Pseudomonas aeruginosa	Km	30.0000	0.5000	2.7500	5.0000	AID546429
Beta-lactamase	Escherichia coli	Km	240.0000	7.1000	8.1667	8.7000	AID368492; AID495688
Carbapenem-hydrolyzing beta-lactamase KPC	Klebsiella pneumoniae	Km	162.0000	1.6000	3.8000	6.0000	AID374025; AID495695
Beta-lactamase class B VIM-2	Pseudomonas aeruginosa	Km	130.5000	2.0000	6.6500	9.4000	AID368514; AID495697; AID529659; AID531315
Beta-lactamase	Acinetobacter baumannii	Km	120.0000	1.3000	3.8000	9.6000	AID495699
Beta-lactamase VIM-1	Pseudomonas aeruginosa	Km	1,132.0000	4.0000	4.0000	4.0000	AID530340
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
monoatomic ion transport	Solute carrier family 15 member 1	Homo sapiens (human)
protein transport	Solute carrier family 15 member 1	Homo sapiens (human)
peptide transport	Solute carrier family 15 member 1	Homo sapiens (human)
dipeptide import across plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
tripeptide import across plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
proton transmembrane transport	Solute carrier family 15 member 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
peptide:proton symporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
tripeptide transmembrane transporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
dipeptide transmembrane transporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
brush border	Solute carrier family 15 member 1	Homo sapiens (human)
membrane	Solute carrier family 15 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4823)

Assay ID	Title	Year	Journal	Article
AID301088	Antibacterial activity against methicillin-resistant Staphylococcus aureus SMITH after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID1757604	Antibacterial activity against Enterobacter cloacae 17-10 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285586	Antimicrobial activity against Pseudomonas aeruginosa 65.36-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID567732	Antimicrobial activity against Pseudomonas aeruginosa OC 11053 by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID571215	Antimicrobial activity against Pseudomonas aeruginosa isolate GB61 obtained from patient with non-cystic fibrosis by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID561315	Antimicrobial activity against Enterobacter cloacae isolate 101 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID571695	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 4 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID531654	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC214 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID1757715	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-24 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID546433	Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-5 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID520639	Antimicrobial activity against Escherichia coli MRY05-3283 expressing qepA and rmtB gene by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID564458	Antimicrobial activity against Pseudomonas aeruginosa isolate 896 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID584487	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae KPBj1 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID534097	Antibacterial activity against Acinetobacter baumannii PFGE type A isolate by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
AID587622	Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 infected in sc dosed CD-1 mouse septicemia infection model at 8:1 compound to NXL104 beta-lactamase inhibitor ratio by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID1373297	Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-7 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1757714	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-22 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID517961	Antimicrobial activity against Stenotrophomonas maltophilia by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID285573	Antimicrobial activity against Pseudomonas aeruginosa P21.21 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID556690	Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID495742	Kcat/Km ratio of Pseudomonas aeruginosa VIM-2 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID561675	Antimicrobial activity against Pseudomonas aeruginosa isolate OC17355 harboring plasmid JAK16 expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID1870169	Antibacterial activity against Pseudomonas aeruginosa assessed as reduction in microbial growth measured after 20 cycles by microdilution assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	LEGO-Lipophosphonoxins: A Novel Approach in Designing Membrane Targeting Antimicrobials.
AID534302	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA479	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID373045	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZS15 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID495671	Antimicrobial activity against wild type Escherichia coli ATCC 25922 deficient in beta-lactamase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID544965	Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID518189	Antimicrobial activity against Pseudomonas aeruginosa B4 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID373053	Antimicrobial activity against Escherichia coli DH10B by agar-dilution technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID573200	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB C116T mutant gene selected at 1 ug/ml of azithromycin after 1 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID279184	Antibacterial activity against Escherichia coli DH10B	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.
AID529653	Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID556651	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 6 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID368511	Ratio of Kcat to Km of Serratia marcescens SME3 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID555554	Antimicrobial activity against Pseudomonas aeruginosa isolate M136074 expressing IMP-22 beta lactamase gene by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID523972	Antibacterial activity against Burkholderia pseudomallei 1026b infected in BALB/c mouse assessed as decrease in bacterial burden in spleen at 25 mg/kg, ip administered 6 hrs postinfection at 12 hrs interval for 3 days measured after 48 hrs of bacterial in	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID571238	Antimicrobial activity against Pseudomonas aeruginosa isolate PA113 harboring beta-lactamase AmpDh3 Ala219Thr mutant obtained from patient with cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID495663	Activity at Pseudomonas aeruginosa 51170 beta-lactamase BEL-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID283133	Antibacterial activity against Pseudomonas aeruginosa KG2212 producing MexAB-OprM efflux pump	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID531787	Antibacterial activity against Enterobacter aerogenes obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID533543	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA346	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID584514	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1553 harboring mutation in putative cytochrome c oxidase, cbb3 type, subunit II by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID585452	Antimicrobial activity against ampD, ampDh2, ampDh3 and ampG deficient Pseudomonas aeruginosa PAO1 after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID535695	Antimicrobial activity against Azide-resistant Escherichia coli J53 transconjugant harboring Escherichia coli DH5alpha-5825 qnrB2 gene by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID564536	Antimicrobial activity against Escherichia coli TOP10 harboring pTOPO plasmid by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID1824272	Antimicrobial activity against Klebsiella pneumoniae clinical isolate T2301 expressing NDM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID546424	Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-4 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID681114	TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells	2005	European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID69008	In vitro synergistic activity against Escherichia coli C600N + (SHV-4)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID1757698	Antibacterial activity against Enterobacter cloacae 17-10 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID544422	Antimicrobial activity against translocase tatC-deficient Escherichia coli B1LK0A expressing beta-lactamase TEM-1 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID519734	Antibacterial activity against Escherichia coli DH5alpha with deltaampC by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID521287	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype A by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID1757847	Ratio of MBC to MIC for Carbapenem-resistant Klebsiella pneumoniae KR 15-7 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID340726	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-15 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID1554005	Antibacterial activity against Escherichia coli clinical isolates measured after 16 to 20 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID585437	Antimicrobial activity against ampG deficient Pseudomonas aeruginosa PAO1 harboring pZY0901 conferring resistance to gentamycin after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID532404	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone F isolate RM-11X-09 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID508297	Inhibition of PBP3 in penicillin-resistant Enterococcus faecium D63r membranes assessed as inhibition of fluorescent ampicillin binding after 20 mins at 37 degC	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.
AID1553794	Bactericidal activity against Staphylococcus epidermidis ATCC 12228 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID573376	Antibacterial activity against imipenem-susceptible Acinetobacter by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID164558	In vitro antimicrobial activity against Pseudomonas aeruginosa 1771 M	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID69002	In vitro synergistic activity against Escherichia coli C600N + (L1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID584927	Activity of Beta-lactamase in Pseudomonas aeruginosa PA14 PA4522 harboring ampD mutant gene relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID585175	Activity of Beta-lactamase GES-1 E104, G170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID561386	Antibacterial activity against Escherichia coli isolate ARL04-413 harboring beta-lactamase CMY 2 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID567751	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 37 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID373052	Antimicrobial activity against Escherichia coli DH10B carrying pJIM2246 expressing Bacillus clausii NR beta-lactamase BCL1 by agar-dilution technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID567746	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 15 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID1757627	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-6 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID368488	Ratio of Kcat to Km of Escherichia coli TEM1 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID522388	Activity of Aeromonas enteropelogenes Beta-lactamase TRU1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID532900	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID573402	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB C89T mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID559529	Antibacterial activity against Enterobacter aerogenes assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID342019	Antibacterial activity against plasmid pK29 transconjugant Escherichia coli J53 by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID529657	Activity of Pseudomonas aeruginosa 166301 beta-lactamase VIM-16	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID535839	Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID1808861	Antipseudomonal activity against pseudomonas aeruginosa PAOdeltaC+pUCP-(PDC-1) assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID372611	Antibacterial activity against Escherichia coli DH5alpha by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID524698	Antibacterial activity against Citrobacter freundii clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID574435	Antimicrobial activity against Escherichia coli isolate 547 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from blood of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID558796	Antimicrobial activity against extended spectrum beta-lactamase-deficient Escherichia coli assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID576262	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17829 harboring pSHA2-encoded porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID674593	Antibacterial activity against Staphylococcus aureus ATCC 25923	2012	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16	Design, synthesis and antibacterial activities of a series of new 2-oxaisocephems.
AID495711	Kcat/Km ratio of Serratia marcescens SME-3	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID495848	Antimicrobial activity against Escherichia coli DH10B transfected with pBK-L3 expressing blaLUT-1 by Etest method in presence of 4 ug/ml clavulanic acid	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID556671	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 26 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID533566	Antimicrobial activity against Pseudomonas aeruginosa isolate PA462 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID285623	Antimicrobial activity against Pseudomonas aeruginosa 8C4 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID535143	Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID532894	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID531653	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC223 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID562755	Activity of Klebsiella pneumoniae AH27 CTX-M-15 beta-lactamase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID542719	Antimicrobial activity against ESBL-producing Klebsiella pneumoniae clinical isolate by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases.
AID69033	Minimal inhibitory activity against the Escherichia coli (EC14)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID50559	Minimum inhibitory concentration in Citrobacter freundii, DR 382031 constitutive depressed type 1	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID584712	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1011 harboring mutation in putative lipoprotein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID285629	Antimicrobial activity against Pseudomonas aeruginosa 9B2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID325198	Antibacterial activity against Moraxella catarrhalis ATCC 43617 by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID528606	Activity of Escherichia coli 2138 beta-lactamase KPC-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID511389	Antibacterial activity against Enterobacter cloacae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID529602	Antibacterial activity against Escherichia coli TP1 harboring pBR322 carrying TEM-10 assessed as inhibition of bacterial growth at 256 ug/ml after 18 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Fitness trade-offs in blaTEM evolution.
AID542057	Antibacterial activity against Klebsiella pneumoniae D expressing CTX-M group 1 beta-lactamase by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID279812	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZR01 from patient sputum by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID368505	Activity of Escherichia coli KPC2 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1757756	Bactericidal activity against carbapenem-sensitive Pseudomonas aeruginosa 17-26 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID374136	Antimicrobial activity Enterobacter cloacae 91 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID511399	Antibacterial activity against Haemophilus influenzae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID562748	Antimicrobial activity against Klebsiella pneumoniae AH24-270 expressing blaCTX-M-71 gene by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID1757823	Bactericidal activity against Enterobacter cloacae 17-10 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID368523	Activity of Enterobacter cloacae 4080 AmpC (P99) assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID559277	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv9 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID555210	Antibacterial activity against Acinetobacter genomosp. 3 isolate 103 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID555221	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 109 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID368307	Activity of Klebsiella pneumoniae SHV1 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID546166	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-06 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID1752479	Antibacterial activity against Escherichia coli NIHJ JC-2 strain assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID1757774	Ratio of MBC to MIC for ESBLs negative Carbapenem-sensitive Escherichia coli 17-20 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID531082	Antimicrobial activity against CTX-M-14, TEM-1 beta-lactamase producing Escherichia coli isolate CUMC174 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID520713	Antibacterial activity against Escherichia coli TOP10 harboring pOXA-97	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID587639	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=16:4 mg/kg, sc compound to NXL104	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID1757827	Bactericidal activity against Enterobacter aerogenes 15-3 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285635	Antimicrobial activity against Pseudomonas aeruginosa 12A3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID571696	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 5 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID532193	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii TJ15T harboring wild-type GyrA, ParC, GyrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1373291	Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-2 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1757697	Antibacterial activity against Enterobacter cloacae 17-9 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID546426	Activity at Pseudomonas aeruginosa PDC-1 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID285616	Antimicrobial activity against Pseudomonas aeruginosa 3E2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID558790	Antimicrobial activity against Enterobacter cloacae assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID532103	Antimicrobial against Pseudomonas aeruginosa 3465 harboring tsaA allele by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID508722	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1C3 PTOL1 harboring acquired beta-lactamase OXA-17 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID1808827	Antibacterial activity against Pseudomonas aeruginosa PAO1 deltaC+pUCP-(PDC-5) by broth microdilution method
AID285609	Antimicrobial activity against Pseudomonas aeruginosa 65.68-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID680844	TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 50 uM, Ceftazidime: 2500uM) in PEPT1-expressing HeLa cells	2000	The Journal of biological chemistry, Jan-21, Volume: 275, Issue:3	beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
AID1752453	Antibacterial activity against Enterobacter cloacae IR32 producing class B beta-lactamase, NDM1 assessed as reduction in microbial growth incubated for 16 to 20 hrs by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID495731	Kcat/Km ratio of Escherichia coli TEM-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID545661	Antimicrobial activity against Enterobacteriaceae Extended-Spectrum beta-lactamase positive assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID517947	Antimicrobial activity against Enterobacter aerogenes by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID556695	Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] harboring pDrive plasmid by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID571216	Antimicrobial activity against Pseudomonas aeruginosa isolate TX291 obtained from patient with non-cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID1757860	Ratio of MBC to MIC for ESBLs positive carbapenem-negative Escherichia coli 17-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID531571	Antibacterial activity against Streptococcus constellatus obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID559089	Antimicrobial activity against carbapenem-susceptible Acinetobacter baumannii isolate A1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.
AID565540	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-04 harboring A residue at 105 position in PDC- 2 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID583098	Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 beta-lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID404966	Activity of OXA58 from Acinetobacter baumannii T193 isolate carrying two bla-OXA58 gene copy assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID164559	In vitro antimicrobial activity against Pseudomonas aeruginosa 9027	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID283125	Antibacterial activity against Escherichia coli C600 expressing ESBL OXA2	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID495747	Inhibition of Pseudomonas aeruginosa AmpC assessed as inhibition of nitrocefin hydrolysis	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID542064	Antibacterial activity against Klebsiella pneumoniae C expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID517952	Antimicrobial activity against Enterobacter cloacae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID341111	Antibacterial activity against Pseudomonas aeruginosa 164	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID555555	Antimicrobial activity against Pseudomonas aeruginosa isolate 26285 expressing IMP-13 beta lactamase gene by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID556661	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 16 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID340725	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-1 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID576290	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 6267 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID495719	Activity of Klebsiella oxytoca Beta-lactamase K1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID495753	Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow and treated with Cefixime-cluvulanic acid by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID1056837	Antibacterial activity against TEM-1/SHV-12 expressing Escherichia coli isolate 237 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID445445	Permeability at pH 6.5 by PAMPA method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID368516	Ratio of Kcat to Km of Pseudomonas aeruginosa IMP1 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID559270	Antimicrobial activity against Proteus vulgaris Pv7 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID534771	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus obtained from war-wounded patient assessed as susceptible isolates	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
AID573188	Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMA biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID565422	Antimicrobial activity against Pseudomonas aeruginosa clinical isolate overexpressing AmpC gene assessed as resistant isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID545407	Antimicrobial activity against Pseudomonas aeruginosa PS14 with PFGE phenotype 10C obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1666867	Inhibition of swarming motility of Escherichia coli clinical isolates incubated for 16 to 20 hrs	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	Optimized plant compound with potent anti-biofilm activity across gram-negative species.
AID373758	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1254 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID1553787	Bactericidal activity against Salmonella pullorum ATCC 7913 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID524003	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-66 gene by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID94044	In vitro minimum inhibitory concentration for Klebsiella pneumoniae (ATCC-10031) by agar dilution method	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.
AID545434	Antimicrobial activity against extended-spectrum beta-lactamase-positive Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID1757705	Antibacterial activity against Enterobacter aerogenes 15-4 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID584702	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5443 harboring uvrD mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID585438	Antimicrobial activity against ampG deficient Pseudomonas aeruginosa PAO1 after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID542735	Antimicrobial activity against Klebsiella pneumoniae D10 expressing aac(6')-Ib-cr, qnrB4, CTX-M-1G and DHA-1 genes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID521298	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype B by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID559085	Antibacterial activity against Proteus vulgaris by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID498840	Antimicrobial activity against Klebsiella pneumoniae GZ66T expressing SHV-11, DHA-1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID555647	Antimicrobial activity against ampDDh2 and ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs using 30 ug/ml by agar diffusion method in presence of 0.5 mM nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID667375	Antibacterial activity against Bacillus subtilis ATCC 33712 after 24 hrs by microtiter broth dilution method	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.
AID545449	Antimicrobial activity against extended-spectrum beta-lactamase-positive Klebsiella oxytoca assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID564225	Antimicrobial activity against Escherichia coli TOP10 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID573353	Antibacterial activity against ceftazidime-susceptible Escherichia coli assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID584490	Antibacterial activity against porin deficient OmpA positive Klebsiella pneumoniae KPBj1 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID341109	Increase in ampD gene expression in mexCD-oprJ overexpressing Pseudomonas aeruginosa 164M1-84C harboring p26PAD1 plasmid containing ampD gene by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID1407937	Antifungal activity against Candida albicans ATCC 90028 after 24 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID498826	Antimicrobial activity against Citrobacter freundii SZ63 expressing IMP-4, qnrS1by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID520705	Antibacterial activity against Acinetobacter baumannii phenotype 1 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID67716	In vitro synergistic activity against Enterobacter aerogenes GC 6268 clinical isolate	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID496006	Antimicrobial activity against imipenem resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID1757568	Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumonia 15-2 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID368320	Antibacterial activity against Escherichia coli producing beta lactamase TEM1 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID559539	Antibacterial activity against Proteus mirabilis assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID531578	Antibacterial activity against Lactococcus lactis obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID563157	Antibacterial activity against Pseudomonas aeruginosa isolate 213BR by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
AID323039	Antimicrobial activity against extended-spectrum-beta-lactamase producing Klebsiella pneumoniae isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID528600	Antimicrobial activity against Escherichia coli TOP10 harboring blaKPC-2 and blaTEM-1 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID1586261	Antibacterial activity against Klebsiella pneumoniae 1161486a after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID562814	Antimicrobial activity against Escherichia coli J53 in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID521999	Antimicrobial activity against Klebsiella pneumoniae isolate Kp6A expressing beta-lactamase OXA-48 and TEM-150 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID584486	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae ATCC 138821 by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID567303	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2201 isolated from burn patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID583088	Ratio of Kcat to Km for Escherichia coli XL1-Blue wild-type IMP-1 beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID250258	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH02; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID322320	Antibacterial activity against Escherichia coli INSRA5776 isolates expressing CTX-M-14 and TEM-1B enzymes by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID542066	Antibacterial activity against Escherichia coli TrC C expressing Klebsiella pneumoniae C blaCTX-M beta-lactamase by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID567584	Antimicrobial activity against Acinetobacter baumannii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID524924	Antimicrobial activity against beta lactamase CTX-M-10 producing Escherichia coli MI1443 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID562767	Antimicrobial activity against Escherichia coli DH10B transformant harboring blaTEM-168 gene by broth microdilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID1757532	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-5 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID498842	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae CY75 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1586258	Antibacterial activity against Acr A-deficient Haemophilus influenzae H128 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID278597	Inhibitory activity against azide-resistant Escherichia coli J53 T12-1183	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID534602	Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID364440	Antipseudomonal activity against Pseudomonas aeruginosa clinical isolates by CLSI method	2008	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17	Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.
AID1265633	Antibacterial activity against Staphylococcus warneri after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID535903	Antimicrobial activity against aac(6')-Ib-cr-negative Escherichia coli PU12 harboring GyrA S83L mutant, wild-type GyrB, ParC and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID533559	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA382	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1691821	Antibacterial activity against Pseudomonas aeruginosa PAO1 planktonic cells assessed as reduction in bacterial growth after 18 hrs by resazurin dye based assay	2020	European journal of medicinal chemistry, May-15, Volume: 194	Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1.
AID531680	Antimicrobial activity against Acinetobacter baumannii Ab290 harboring TVICU53 plasmid by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID520724	Activity of Acinetobacter baumannii phenotype 2 beta-lactamase assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID1757611	Antibacterial activity against Enterobacter aerogenes 15-4 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID554988	Antibacterial activity against Acinetobacter genomosp. 3 isolate 56 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID373037	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate DL34 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID524936	Antimicrobial activity against Escherichia coli MI1443 harboring V27A, Q38R, N106S and P167S mutations in beta lactamase CTX-M-3 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID573155	Antibacterial activity against vancomycin-resistant Enterococcus faecium by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID372339	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as reduction of bacterial count in in vitro PK/PD model at 2 g infused every 8 hrs interval measured after second dose relative to initial inoculum	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID156117	Affinity against penicillin binding protein 1a of Escherichia coli UB1005 (DC0) was evaluated.	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.
AID532411	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-02 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID533533	Antimicrobial activity against Pseudomonas aeruginosa PA373 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID542737	Antimicrobial activity against Klebsiella pneumoniae D24 expressing aac(6')-Ib-cr and CTX-M-9G genes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID573346	Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID373984	Antimicrobial activity Escherichia coli 650 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID573187	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMS biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1757575	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID524697	Antibacterial activity against Citrobacter diversus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID1554006	Antibacterial activity against Pseudomonas aeruginosa clinical isolates measured after 16 to 20 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID207947	In vitro antimicrobial activity against Staphylococcus aureus 285	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID520385	Activity at Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-11 by spectrometry	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID574438	Antimicrobial activity against Escherichia coli isolate 1679T expressing beta-lactamase KPC2, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID587526	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 4 ug/ml cavulanate beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID541022	Activity at Burkholderia cenocepacia 07-34 beta-lactamase PenB1 expressed in Escherichia coli Top10 by UV-spectrophotometry	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID496008	Antimicrobial activity against piperacillin-tazobactam resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID372617	Activity of Escherichia coli CF0042 beta-lactamase TEM-35 by microacidimetric method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID340729	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-14 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID495733	Kcat/Km ratio of Escherichia coli CTX-M-15 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID207362	In vitro minimum inhibitory concentration required to produce antibacterial activity against Staphylococcus aureus 887MSSA	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID532031	Antimicrobial activity against Escherichia coli TOP10F' by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Novel chromosome-encoded CTX-M-78 beta-lactamase from a Kluyvera georgiana clinical isolate as a putative origin of CTX-M-25 subgroup.
AID1171213	Antibacterial activity against tolC-deficient Escherichia coli	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID373208	Antimicrobial activity against Bacillus clausii DSM 8716 by agar-dilution technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID559266	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv8 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID534298	Antimicrobial activity against Pseudomonas aeruginosa isolate PA500 expressing VIM-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID520800	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype H by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID423773	Antibacterial activity against ESBL-negative Klebsiella pneumoniae isolate 102 at 1 ug/ml by Etest	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Selection of SHV extended-spectrum-beta-lactamase-dependent cefotaxime and ceftazidime resistance in Klebsiella pneumoniae requires a plasmid-borne blaSHV gene.
AID517963	Antimicrobial activity against Pseudomonas aeruginosa by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID340734	Antimicrobial activity against Escherichia coli HB101 harboring pBC-SK plasmid assessed as drug level at which microbial resistance was observed by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID555644	Antimicrobial activity against ampDh2 gene-deficient Pseudomonas aeruginosa PAO1 using 30 ug/disk by agar diffusion method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID1056838	Antibacterial activity against CTX-15 expressing Escherichia coli isolate 4024 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID1757858	Ratio of MBC to MIC for ESBLs negative carbapenem-negative Escherichia coli 17-9 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534379	Antibacterial activity against Citrobacter freundii KHM243 clinical isolate by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID530323	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pUCP carrying VIM-1 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID562812	Antimicrobial activity against Escherichia coli DH5[alpha]	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID495825	Antimicrobial activity against Providencia stuartii 6858 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID1757747	Bactericidal activity against Enterobacter cloacae 17-10 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID520698	Antimicrobial activity against Escherichia coli isolate DH10B by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID1757612	Antibacterial activity against Enterobacter aerogenes 15-5 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID519805	Inhibition of Bocillin FL binding to PBP1B in Pseudomonas aeruginosa PAO1 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID534306	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA509	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID534338	Antimicrobial activity against Burkholderia pseudomallei Bp250 harboring mini-Tn7T-bpeA+B+ -oprB+ after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID561320	Antimicrobial activity against Escherichia coli isolate 17 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID1373309	Antimicrobial activity against Escherichia coli expressing beta-lactamase VIM-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID545604	Antimicrobial activity against Pseudomonas aeruginosa PS22 with PFGE phenotype 3A obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID405633	Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1b	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID499064	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae GX56 deficient in ompC and expressing low levels of ompF DE by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524699	Antibacterial activity against Enterobacter aerogenes clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID542065	Antibacterial activity against Klebsiella pneumoniae A expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID1757613	Antibacterial activity against Enterobacter aerogenes 15-6 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757798	Bactericidal activity against Carbapenem- resistant Acinetobacter baumannii 17-6 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535170	Antimicrobial activity against imipenem susceptible Acinetobacter assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID561314	Antimicrobial activity against Enterobacter cloacae isolate 37 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID565723	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-28 harboring A residue at 105 position in PDC- 7 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID531605	Activity of Escherichia coli beta-lactamase SHV-11	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID1553832	Antifungal activity against Candida albicans cgmcc2.2086 measured after 48 hrs in presence of FeCl by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID1757828	Bactericidal activity against Enterobacter aerogenes 15-4 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID332075	Antibacterial activity against Pseudomonas aeruginosa by agar dilution method	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Antibacterial activity in serum of the 3,5-diamino-piperidine translation inhibitors.
AID531774	Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4703 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID534904	Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID283127	Antibacterial activity against Escherichia coli C600 expressing ESBL CTX-M18	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID164091	Compound was tested for antimicrobial activity against Pseudomonas aeruginosa PU21 strain	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID405440	f%T>MIC in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 70 mg/kg, ip administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID573368	Antibacterial activity against ceftazidime-susceptible Proteus mirabilis assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524711	Antibacterial activity against Shigella sp. by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID534899	Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1757799	Bactericidal activity against Carbapenem- resistant Acinetobacter baumannii 17-11 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID368532	Activity of Morganella morganii AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID573356	Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID285613	Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID510502	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate C1AC9-24 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID523515	Antimicrobial activity against Pseudomonas aeruginosa isolate 1253 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1379928	Antibacterial activity against Staphylococcus aureus assessed as inhibition of microbial growth incubated for 18 to 22 hrs by broth microdilution method	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID405446	Antibacterial activity against Pseudomonas aeruginosa PAOdeltamutS infected in C57BL/6J mouse assessed as mortality at 70 mg/kg, ip administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID1752476	Antimicrobial activity against Enterobacterales producing NDM assessed as reduction in microbial growth measured after 16 to 20 hrs in presence of avibactam by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID372603	Antibacterial activity against Escherichia coli BER1 producing beta-lactamase TEM-158	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID1757518	Antibacterial activity against Escherichia coli 15-4 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID373766	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh14 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID563594	Inhibition of Pseudomonas aeruginosa PAO1 PBP5/6 by SDS-PAGE	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID1757578	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-8 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID556666	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 21 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID498820	Antimicrobial activity against Klebsiella pneumoniae WH76 expressing IMP-4, TEM-1, SHV-14, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID519817	Antimicrobial activity against Pseudomonas aeruginosa 27853 by CLSI protocol based broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID523960	Antibacterial activity against Burkholderia pseudomallei 1026b infected in BALB/c mouse assessed as increase in survival rate at 25 mg/kg, ip administered 6 hrs postinfection at 12 hrs interval for 3 days measured on day 60 in presence of IFN-gamma-harbor	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID244867	Minimum inhibitory concentration of compound against Escherichia coli derepressed	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID573377	Antibacterial activity against imipenem-susceptible Acinetobacter assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID368509	Activity of Serratia marcescens SME3 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID584506	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0807 harboring ampDh3 mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID540949	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBCSK plasmid by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID582764	Antimicrobial activity against eaeA negative verocytotoxin-producing non-O157 Escherichia coli isolates obtained from human assessed as percentage of resistant isolates	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
AID546172	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-12 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID425866	Antimicrobial activity against Carnobacterium divergens BM4489 expressing beta-lactamase CAD1 at 3 McFarland inoculum size by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID564023	Antibacterial activity against Pseudomonas aeruginosa isolated from lung biopsy specimen of patient by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID164278	Minimum inhibitory concentration in Pseudomonas stuartii, DR 442049 constitutive depressed type 1 lactamase producer	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID523508	Antimicrobial activity against Pseudomonas aeruginosa isolate 1726 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID531781	Antibacterial activity against Acinetobacter baumannii obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID546180	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-20 with PDC-4 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID534611	Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID544949	Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC and extended-spectrum beta-lactamase by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID498838	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae SZ61 deficient in TEM-1, SHV-1a, CMY-2, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID555643	Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by using 30 ug/disk by agar diffusion method in presence of 0.5 mM nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID495512	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4666 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID1442093	Antibacterial activity against Pseudomonas aeruginosa 21328 clinical isolate after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID1407936	Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID531076	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC201 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID533545	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA350	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID524705	Antibacterial activity against Serratia marcescens clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID535718	Activity of Escherichia coli TOP10 beta-lactamase AmpC-B2 S287N mutant	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID404959	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii 186 isolate carrying three bla-OXA58 gene copies by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID529863	Ratio of MIC for Pseudomonas aeruginosa N041 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID301086	Antibacterial activity against Pseudomonas aeruginosa SR-5393 after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID584710	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0766 harboring mucD mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1407926	Antibacterial activity against Acinetobacter baumannii ARC3495 after 24 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID584740	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5001 harboring mutation in putative glycosyl-transferase by Etest method relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID283113	Antibacterial activity against Escherichia coli C600 expressing TEM2	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID372636	Activity of Escherichia coli DH10B beta-lactamase TEM-121 by microacidimetric method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID405423	Half life of free unbound fraction in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 70 mg/kg, ip administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID531770	Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4706 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID499057	Antimicrobial activity against Escherichia coli PU102T expressing TEM-1, CTX-M-14, CMY-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID522027	Antimicrobial activity against Escherichia coli isolate J53 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID368542	Ratio of Kcat to Km of Pseudomonas aeruginosa 4352 AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID405803	Inhibition of bocillin FL binding to penicillin-susceptible Streptococcus pneumoniae OC 8865 penicillin-binding protein 1b	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID70638	Compound was tested for antimicrobial activity against Escherichia coli DC2 strain (permeability mutant)	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID524923	Antimicrobial activity against Escherichia coli MI1443 harboring V27A, Q38R, A77V, N114D, A140S, D240G, D288N mutations in beta lactamase CTX-M-32 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID562472	Antimicrobial activity against Klebsiella pneumoniae isolate 2641/08 obtained from urine of patient with ischemic cardiomyopathy and several comorbidities by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID542522	Antimicrobial activity against Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.
AID556658	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 13 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID563589	Inhibition of Pseudomonas aeruginosa PAO1 PBP1b by SDS-PAGE	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID522571	Antimicrobial activity against Escherichia coli isolate 7010738 with AmpC beta-lactamase H296P mutation	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID1808857	Antipseudomonal activity against pseudomonas aeruginosa PAO deltaDdeltsDh2deltaDh3 assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID529660	Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID540945	Antimicrobial activity against Escherichia coli DH5[alpha] transformant harboring pH205 plasmid expressing cephalosporinase CMY-36 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID519641	Antimicrobial activity against Escherichia coli EPI300 harboring pCC1 carrying beta-lactamase CTX-M-3 gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID245218	Minimum inhibitory concentration of compound against Escherichia coli K12AmpC-Ent in presence of compound 12	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID162795	Minimal inhibitory activity against the Pseudomonas aeruginosa (X528)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID1757574	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-2 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID209631	Minimal inhibitory activity against the Streptococcus pyogenes (C203)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID511411	Terminal half life in healthy human subjects at 2 gram, iv administered in 5 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID69013	In vitro synergistic activity against Escherichia coli GC 6266 clinical isolate	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID1757691	Antibacterial activity against Enterobacter cloacae 17-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534920	Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573124	Antibacterial activity against coagulase-negative and oxacillin-resistant Staphylococcus aureus assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID562736	Antimicrobial activity against Klebsiella pneumoniae AH24-270 expressing blaCTX-M-71 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID511583	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID531568	Antibacterial activity against Streptococcus pyogenes obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID285338	Antimicrobial activity against streptomycin-resistant Escherichia coli J53 transconjugant with qnrA1 producing urinary specimen isolate 13.52 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
AID1757620	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-22 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757559	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-7 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID542524	Antimicrobial activity against Pseudomonas aeruginosa PAO1 infected in in vitro pharmacodynamic model assessed as bacterial killing at 4 mg/L after 24 hrs using 10'6 CFU/ml inoculum by time kill study	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.
AID285691	Antimicrobial susceptibility of Citrobacter freundii CF6010 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID531088	Antimicrobial activity against CTX-M-14-like, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC233 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID1757692	Antibacterial activity against Enterobacter cloacae 17-4 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID584512	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_43090 harboring mutation in hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID559484	Antibacterial activity against non-levofloxacin susceptible Stenotrophomonas maltophilia by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID325193	Antibacterial activity against AmpC hyperproducing Pseudomonas aeruginosa SR24-12 by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID373982	Antimicrobial activity Enterobacter cloacae 641 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID285521	Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID373031	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU4A22 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID396031	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pACYC184 plasmid by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID524704	Antibacterial activity against extended-spectrum beta-lactamase producing Klebsiella pneumoniae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID582925	Ratio of Kcat to Km for Escherichia coli BL21(DE3) VIM-2 W87F mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID549333	Antimicrobial activity against Escherichia coli isolate 36 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID533757	Antibacterial activity against SHV-2a producing Pseudomonas aeruginosa isolate P60 exhibiting PFGE H pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID285637	Antimicrobial activity against Pseudomonas aeruginosa 12B2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID68871	In vitro synergistic activity against Escherichia coli 300 + (TEM-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID495691	Activity of Escherichia coli CMY-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID577224	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring mmsA::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID562340	Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-2 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID531649	Antimicrobial activity against CTX-M-14, TEM-1 beta-lactamase producing Escherichia coli isolate CUMC174 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID573152	Antibacterial activity against vancomycin-resistant Enterococcus faecalis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID531574	Antibacterial activity against Aerococcus viridans obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID283321	Antimicrobial activity against Escherichia coli XL10/vector	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.
AID1757591	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-9 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID508736	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID528783	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID1553768	Antibacterial activity against Escherichia coli UB1005 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID533554	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA370	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1649583	Antimicrobial activity against Klebsiella pneumoniae clinical isolates by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID372355	Antibacterial activity against Pseudomonas aeruginosa PAO1 in in vitro PK/PD model assessed as AAC (0 to 8 hrs) at 2 g infused thrice daily at 8 hrs interval measured after first dose	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID69021	In vivo synergistic activity against Escherichia coli GC6265 (TEM-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID562572	Antimicrobial activity against TEM-10 ESBL producing Escherichia coli clinical isolate by CLSI disk diffusion assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania.
AID533538	Antimicrobial activity against Pseudomonas aeruginosa PA553 expressing SPM-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID523892	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-23 gene by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID574439	Antimicrobial activity against Escherichia coli DH10B by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID524244	Antimicrobial activity against Escherichia coli DH5alpha	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.
AID164281	Minimum inhibitory concentration in Pseudomonas stuartii, I+442019 inducible type 1 lactamase producer	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID1757585	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-18 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID529655	Activity of Pseudomonas aeruginosa 9551 beta-lactamase VIM-15	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID368524	Activity of Enterobacter cloacae 4080 AmpC (P99) assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID530600	Antibacterial activity against Aeromonas sp. isolate A72 by Etest	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Expanded-spectrum beta-lactamase PER-1 in an environmental Aeromonas media isolate from Switzerland.
AID164556	In vitro antimicrobial activity against Pseudomonas aeruginosa 1592 E	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID576286	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17049 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID582979	Antimicrobial activity against ampR::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID1757785	Ratio of MBC to MIC for Enterobacter aerogenes 17-4 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285673	Antimicrobial activity against Pseudomonas aeruginosa 24E6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID520707	Antibacterial activity against Acinetobacter baumannii phenotype 2 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID511687	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PA01 deficient in dacB gene by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID534642	Antimicrobial activity against Non-ESBL Klebsiella pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584724	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3649 harboring mutation in putative membrane-associated zinc metalloprotease by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID285611	Antimicrobial activity against Pseudomonas aeruginosa 65.68-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID560125	Antimicrobial activity against Acinetobacter baumannii CIP70.10 harboring beta-lactamase RTG3 gene by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID405812	Inhibition of bocillin FL binding to penicillin-resistant Streptococcus pneumoniae OC 8819 penicillin-binding protein 2a	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID573119	Antibacterial activity against coagulase-negative and oxacillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID285256	Antimicrobial activity against Escherichia coli DH5-alpha CF1295 isolate expressing CMT and TEM1 by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID522003	Antimicrobial activity against Klebsiella pneumoniae isolate Kp7A expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID562759	Antimicrobial activity against Klebsiella pneumoniae PFGE clone B expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID496005	Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID573359	Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID499065	Antimicrobial activity against carbapenem-resistant Enterobacter aerogenes WH85 deficient in TEM-1, CTX-M-3, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID326199	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by agar dilution method	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure.
AID556647	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 2 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID495518	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4676 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID405640	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 2	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID561673	Antimicrobial activity against Pseudomonas aeruginosa isolate OC14812 harboring plasmid JAK16 expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID562760	Antimicrobial activity against Klebsiella pneumoniae PFGE clone C expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID324864	Antimicrobial activity against Acinetobacter baumannii A24D after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID1056835	Antibacterial activity against SIM-1 expressing Acinetobacter baumannii isolate 170 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID546173	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-13 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID394693	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing MexAB-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID520388	Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID519749	Ratio of Kcat to Km for Klebsiella pneumoniae Beta-Lactamase SHV-72	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID69006	In vitro synergistic activity against Escherichia coli C600N + (PSE-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID517949	Antimicrobial activity against Providencia stuartii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID585449	Antimicrobial activity against Pseudomonas aeruginosa PAK after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID1757801	Bactericidal activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-5 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID520878	Antibacterial activity against Achromobacter xylosoxidans LOL by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID1379931	Antibacterial activity against Streptococcus Streptococcus alpha hemolyticus assessed as inhibition of microbial growth incubated for 18 to 22 hrs by broth microdilution method	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID285614	Antimicrobial activity against Pseudomonas aeruginosa 3D1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1757781	Ratio of MBC to MIC for Enterobacter cloacae 17-9 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID70412	In vitro antimicrobial activity against Escherichia coli 055	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID544963	Antimicrobial activity against Klebsiella pneumoniae expressing extended-spectrum beta-lactamase and beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID509867	Antibacterial activity against Acinetobacter baumannii isolate 2824 isolated from human urine	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID368514	Activity of Pseudomonas aeruginosa VIM2 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID531570	Antibacterial activity against Streptococcus sp. 'group G' obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID587621	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse septicemia infection model at 4:1 compound to NXL104 beta-lactamase inhibitor ratio by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID562810	Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID575323	Antimicrobial activity against Salmonella London 07-819 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID368759	Antimicrobial activity against Escherichia coli Ec6 expressing CTX-M-14 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID544956	Antimicrobial activity against Proteus mirabilis extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID571220	Antimicrobial activity against Pseudomonas aeruginosa isolate 164CD obtained from patient with non-cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID520970	Antibacterial activity against Escherichia coli harboring pNGR plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID559268	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Providencia stuartii Ps5 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID285645	Antimicrobial activity against Pseudomonas aeruginosa 16D2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID519746	Activity of Klebsiella pneumoniae Beta-Lactamase SHV-1	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID1757711	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-10 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID544429	Antimicrobial activity against Escherichia coli MC4100A harboring beta-lactamase L2 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID584559	Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1808855	Antipseudomonal activity against pseudomonas aeruginosa PAO deltadacBdeltadacC assessed as AmpC RNA expression by RT-PCR analysis relative to Pseudomonas aeruginosa PAO1
AID1808819	Antibacterial activity against Pseudomonas aeruginosa PAO1 deltaampD by broth microdilution method
AID1757704	Antibacterial activity against Enterobacter aerogenes 15-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495664	Ratio of Kcat to Km for Pseudomonas aeruginosa 51170 beta-lactamase BEL-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID523961	Antibacterial activity against Burkholderia pseudomallei 1026b infected in BALB/c mouse assessed as increase in survival rate at 25 mg/kg, ip administered 6 hrs postinfection at 12 hrs interval for 3 days measured on day 20 in presence of IFN-gamma-harbor	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID511386	Antibacterial activity against ciprofloxacin resistant Escherichia coli by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID511413	fT>MIC in cystic fibrosis patient at 6 gram/70kg, iv administered as 2 mg/l infusion every 6 hrs	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID511297	Antibacterial activity against Escherichia coli DH5alpha in presence of 2 ug/ml clavulanic acid	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID523518	Antimicrobial activity against Pseudomonas aeruginosa isolate 17112 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID422287	Antimicrobial activity against Proteus vulgaris by almar blue assay	2009	Journal of natural products, Feb-27, Volume: 72, Issue:2	Polyoxygenated methyl cyclohexanoids from a terrestrial ampelomyces fungus.
AID529460	Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, SHV-12 and Oxa-9 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID532394	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-32 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID544535	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8133 expressing bla TEM-55 gene by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID575326	Antimicrobial activity against Escherichia coli 08-843TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID68040	In vitro antimicrobial activity against Enterobacter 1321 E	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID1447483	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P264-104354 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID285575	Antimicrobial activity against Pseudomonas aeruginosa 65.18-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID530325	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID301092	Antibacterial activity against Moraxella catarrhalis ATCC 43617 after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID533556	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA377	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1752481	Antibacterial activity against Enterobacter cloacae IR32 producing class B beta-lactamase, NDM-1 assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID571223	Antimicrobial activity against Pseudomonas aeruginosa PAO1 expressing beta-lactamase AmpD1 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID573197	Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMAB biofilm harboring nfxB G125T mutant gene selected at 0.5 ug/ml of azithromycin after 1 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID559601	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene selected in presence of ciprofloxacin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID533560	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA395	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID546171	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-11 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID1757778	Ratio of MBC to MIC for Enterobacter cloacae 17-2 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID531573	Antibacterial activity against Staphylococcus intermedius obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID10721	Serum AUC in marmosets (IV dose)	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID534879	Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID535128	Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535365	Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID573211	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB C89T mutant gene selected at 0.5 ug/ml of azithromycin after 3 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1757642	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-12 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID558041	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S4 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID1056834	Antibacterial activity against GIM-1 expressing Pseudomonas aeruginosa isolate 197 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID1757777	Ratio of MBC to MIC for ESBLs positive Carbapenem-sensitive Escherichia coli 17-18 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID544424	Antimicrobial activity against Escherichia coli CU164A harboring beta-lactamase CTX-M-14 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID1553784	Bactericidal activity against Escherichia coli ATCC 25922 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID1752483	Antibacterial activity against Klebsiella pneumoniae PLE producing class D beta lactamase, OXA-48 assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID1265639	Antibacterial activity against Klebsiella oxytoca after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID342018	Antibacterial activity against Klebsiella pneumoniae NK29 by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID394489	Activity of Hafnia alvei beta-lactamase ACC-1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID573117	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID561674	Antimicrobial activity against Pseudomonas aeruginosa isolate OC14812 harboring plasmid MexZ expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID524256	Activity at Escherichia coli beta-lactamase SHV-1	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.
AID519816	Inhibition of Bocillin FL binding to PBP5/6 in Pseudomonas aeruginosa 27853 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID508484	Antimicrobial activity against Pseudomonas aeruginosa isolate BU-20287 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID554442	Ratio of MIC for Pseudomonas aeruginosa 3066 to MIC for Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID577647	Antimicrobial activity against Escherichia coli isolate 157 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 3 isolated from urine of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1757810	Bactericidal activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-12 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1265637	Antibacterial activity against Proteus mirabilis after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID1757741	Bactericidal activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-10 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID529861	Ratio of MIC for Pseudomonas aeruginosa N044 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID285270	Activity of Escherichia coli BL21(DE3) beta-lactamase TEM36	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID524246	Antimicrobial activity against Escherichia coli DH5alpha expressing SHV-84	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.
AID372616	Ratio of Kcat to Km for Escherichia coli DH5alpha beta-lactamase TEM-12	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID582972	Antimicrobial activity against ampD::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID584317	Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID587728	Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-1-pLBII after 18 hrs by microdilution broth method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID541019	Antimicrobial activity against Escherichia coli TOP10	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID573125	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1757664	Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-17 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID544966	Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID373211	Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) relative to benzyl-penicillin	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID394486	Ratio of Kcat to Km for Escherichia coli beta-lactamase ACC4 by UV spectrophotometry	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID562749	Antimicrobial activity against Escherichia coli K-12 transconjugant harboring blaCTX-M-71 gene by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID573141	Antibacterial activity against erythromycin-nonsusceptible Streptococcus agalactiae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1553767	Antibacterial activity against Escherichia coli ATCC 25922 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID278600	Inhibitory activity against Klebsiella pneumoniae 07-006	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID520727	Activity of Escherichia coli TOP10 beta-lactamase OXA-97 assessed as specific activity per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID560131	Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID678721	Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1757826	Bactericidal activity against Enterobacter aerogenes 17-4 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID19544	Plasma half-life in rats after intravenous administration	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.
AID572132	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 33 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1435416	Anti-bacterial activity against Bacillus subtilis ATCC 33712 measured after 24 hrs by microtiter broth dilution method	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.
AID1427883	Antibacterial activity against Enterobacter aerogenes EA298 over-expressing TolC after 18 hrs by broth dilution method	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E. aerogenes Gram-negative bacteria.
AID1757600	Antibacterial activity against Enterobacter cloacae 17-6 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID405642	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 1a	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID520804	Antimicrobial activity against Escherichia coli str. K-12 substr. DH10B harboring plasmid CTX-M-2 in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID534622	Antimicrobial activity against Non-ESBL Escherichia coli by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID519007	Antimicrobial activity against Escherichia coli HB101 expressing plasmid encoded TEM-149 T182M mutant by broth macrodilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID1373322	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-160 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1757690	Antibacterial activity against Enterobacter cloacae 17-2 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1808822	Antibacterial activity against PAOdeltaC by broth microdilution method
AID563968	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase NDM-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID584696	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5001 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID544436	Antimicrobial activity against Escherichia coli CU164A harboring empty plasmid by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID532094	Antimicrobial against Pseudomonas aeruginosa 32455 harboring phzS allele by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID164103	In vitro minimum inhibitory concentration against Pseudomonas aeruginosa (PU21).	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID1757764	Ratio of MBC to MIC for Carbapenem- resistant Pseudomonas aeruginosa 17-1 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757660	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-14 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID250299	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH24; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID524933	Antimicrobial activity against Escherichia coli MI1443 harboring V27A, Q38R, A77V mutations in beta lactamase CTX-M-3 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID529480	Antimicrobial activity against Enterobacter cloacae isolate 1 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID495696	Activity of Serratia marcescens SME-3	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID558052	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S15 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID608337	Antibacterial activity against 1 x 10'4 cfu/mL Bacillus subtilis ATCC 33712 after 24 hrs by NCCLS M7-A6 microtiter broth dilution method	2011	European journal of medicinal chemistry, Aug, Volume: 46, Issue:8	Synthesis and antimicrobial evaluation of new benzofuran derivatives.
AID1379929	Antibacterial activity against Staphylococcus warneri assessed as inhibition of microbial growth incubated for 18 to 22 hrs by broth microdilution method	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID562750	Antimicrobial activity against Escherichia coli K-12 by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID571932	Antimicrobial activity against Escherichia coli MC4100 harboring a weak promoter in beta-lactamase GES-1 by Etest	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID285512	Antibacterial activity against Escherichia coli after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID562818	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID1757856	Ratio of MBC to MIC for ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-17 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID561324	Antimicrobial activity against Klebsiella pneumoniae isolate 132 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID561667	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring plasmid MexZ expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID511585	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant and deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID531334	Antibacterial activity against Pseudomonas aeruginosa TNP030 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID520971	Antibacterial activity against Klebsiella pneumoniae 633 by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID565720	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-25 harboring T residue at 105 position in PDC- 6 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID559589	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutT::Gm mutant gene assessed as doubling time	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID531788	Antibacterial activity against Klebsiella oxytoca obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID164099	Minimum inhibitory concentration in Pseudomonas aeruginosa, 18S inducible type 1 lactamase producer	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID534884	Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID285267	Activity of Escherichia coli BL21(DE3) beta-lactamase TEM29	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID532408	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-28 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1752462	Antibacterial activity against Escherichia coli SR34100 producing class A beta-lactamase, CTX-M-15 assessed as reduction in microbial growth incubated for 16 to 20 hrs by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID587732	Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-1 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID681715	TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.02 uM, Ceftazidime: 2500 uM) in OCTN2-expressing HeLa cells	2000	The Journal of biological chemistry, Jan-21, Volume: 275, Issue:3	beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
AID1447480	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 101885 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID1757825	Bactericidal activity against Enterobacter aerogenes 17-3 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID573373	Antibacterial activity against multidrug-resistant Acinetobacter by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID532093	Antimicrobial against Pseudomonas aeruginosa 30848 harboring phoU allele by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1553831	Antifungal activity against Candida albicans cgmcc2.2086 measured after 48 hrs in presence of ZnCl by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID559534	Antibacterial activity against Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID495793	Antimicrobial activity against Escherichia coli DH10B by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID529488	Antimicrobial activity against Enterobacter cloacae isolate 625 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID1553775	Antibacterial activity against Escherichia coli 078 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID531577	Antibacterial activity against Gemella spp. obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID535371	Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1516026	Antibacterial activity against Acinetobacter baumannii AB1901 clinical isolate incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID1757865	Ratio of MBC to MIC for Enterobacter cloacae 17-8 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID549332	Antimicrobial activity against Escherichia coli isolate 86 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID373043	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate CY7 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1757769	Ratio of MBC to MIC for ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-12 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID584922	Activity of Beta-lactamase in Pseudomonas aeruginosa PA14 PA4109 harboring ampR mutant gene assessed as nitrocefin hydrolysis per mg of protein by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID519005	Antimicrobial activity against Escherichia coli HB101 expressing recombinant plasmid encoded TEM-149 by broth macrodilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID556345	Ratio of Kcat/Km for Beta-lactamase CTX-M-15	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID562752	Antimicrobial activity against Escherichia coli DH5alpha harboring pBC-CTX-M-15 plasmid by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID1757735	Bactericidal activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-16 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID565281	Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A2 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID323690	Antibacterial activity against TEM92 ESBL-producing Acinetobacter baumannii by CLSI method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.
AID523493	Antimicrobial activity against Pseudomonas aeruginosa 1405-con D2 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID535710	Antibacterial activity against Escherichia coli TOP10 expressing AmpC-B2 S287N mutant protein by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID522393	Ratio of Kcat Km for Aeromonas caviae Beta-lactamase CAV1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID1373312	Antimicrobial activity against Escherichia coli expressing beta-lactamase CMY-2 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID584693	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4748 harboring tpiA mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID374362	Ratio of Kcat to Km of Aeromonas caviae A324R metallo-beta-lactamase IMP-19 expressed in Escherichia coli DH5alpha by computerized microacidimetric method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID542058	Antibacterial activity against Klebsiella pneumoniae C expressing CTX-M group 1 beta-lactamase by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID511299	Antibacterial activity against Escherichia coli DH5alpha pB-ges-13 plasmid in presence of 4 ug/ml Tazobactam	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID559828	Antimicrobial activity against Pseudomonas aeruginosa PU21 by agar dilution in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID1757808	Bactericidal activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-2 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID283124	Antibacterial activity against Escherichia coli C600 expressing ESBL SHV4	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID529482	Antimicrobial activity against Enterobacter cloacae isolate 140 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID535691	Antimicrobial activity against beta-lactamase CTX-M-15-producing fluoroquinolone-resistant Escherichia coli FMV5825 expressing qnrB2 and aac(6')-Ib-cr and harboring gyrA Ser83Ile and Asp87Asn mutant gene and ParC Ser80Ile and Glu84Val mutant gene obtained	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID1757819	Bactericidal activity against Enterobacter cloacae 17-2 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID584716	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1483 harboring cycH mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523503	Antimicrobial activity against Pseudomonas aeruginosa isolate 1248c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID372624	Ratio of Kcat for Escherichia coli DH5alpha beta-lactamase TEM-12 to Kcat for Escherichia coli DH5alpha beta-lactamase TEM-1	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID1808847	Antibacterial activity against Pseudomonas aeruginosa PAO1 PAHUAC-14 (ST-966) by broth microdilution method
AID520389	Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2 over Kcat to Km for Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-11	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID529496	Antimicrobial activity against Escherichia coli T-622 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID1373311	Antimicrobial activity against Escherichia coli expressing beta-lactamase DHA by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID285511	Antibacterial activity against Enterobacter sp.	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID531569	Antibacterial activity against Streptococcus sp. 'group C' obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID524749	Antimicrobial activity against Escherichia coli GB20 harboring V27A, Q38R, A77V, N114D, A140S, P167T, D288N mutations in beta lactamase CTX-M-1 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID531782	Antibacterial activity against Pseudomonas fluorescens obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID522014	Antimicrobial activity against Escherichia coli isolate J53 harboring pBEL containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID535130	Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535888	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN41T harboring qnrB gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1553796	Bactericidal activity against Staphylococcus aureus ATCC 29213 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID206865	Antibacterial activity against penicillin G resistance Staphylococcus aureus	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID544430	Antimicrobial activity against Escherichia coli CU164A harboring beta-lactamase L2 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID556693	Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 harboring pDrive plasmid expressing ampC gene by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID587626	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse septicemia infection model at 16:1 compound to NXL104 beta-lactamase inhibitor ratio by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID69014	In vitro synergistic activity against Escherichia coli GC6267 clinical isolate	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID495799	Ratio of Kcat to Km of KPC-2 using nitrocefin hydrolysis	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID1827145	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 assessed as inhibition of bacterial growth after 18 hrs in presence of oxacillin by CLSI protocol based broth microdilution assay	2022	ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3	Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID561326	Antimicrobial activity against Klebsiella pneumoniae isolate 135 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID1757561	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-9 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID283108	Antibacterial activity against Pseudomonas aeruginosa	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID554985	Antibacterial activity against Acinetobacter genomosp. 3 isolate 20 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID206866	Antibacterial activity against penicillin G susceptible Staphylococcus aureus	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID533529	Antimicrobial activity against Pseudomonas aeruginosa PA431 expressing IMP-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID565521	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-14 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID587524	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 4 ug/ml NXL104 beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID559079	Antibacterial activity against Klebsiella pneumoniae by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID368486	Antibacterial activity against Serratia marcescens 4104 producing beta lactamase AmpC by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID559084	Antibacterial activity against Proteus mirabilis by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID498823	Antimicrobial activity against Klebsiella pneumoniae WH77T expressing IMP-4, TEM-1, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID155831	The compound was evaluated for the inhibition of [14C]- Pen G binding to Escherichia coli UB1005 PBP1b 90 kDa.	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.
AID584835	Antimicrobial activity against Aeromonas allosaccharophila AL-1 expressing beta-lactamase PER6 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID1757673	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-10 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID558793	Antimicrobial activity against extended spectrum beta-lactamase-expressing Escherichia coli assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID374024	Ratio of Kcat to Km for Enterobacter cloacae IMI1 beta lactamase Escherichia coli DH5alpha by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID1318935	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 83182	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID532906	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID496007	Antimicrobial activity against Ceftazidime resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID564454	Antimicrobial activity against Pseudomonas aeruginosa isolate 1060 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID157423	In vitro minimum inhibitory concentration for Pseudomonas aeruginosa (ATCC 10145) by agar dilution method	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.
AID524407	Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID285648	Antimicrobial activity against Pseudomonas aeruginosa 19B3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID283115	Antibacterial activity against Escherichia coli C600 expressing OXA1	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID66231	Minimum inhibitory concentration in Enterobacter cloacae, P99+ constitutive depressed type 1 lactamase producer	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID584701	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5192 harboring pckA mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523496	Antimicrobial activity against Pseudomonas aeruginosa isolate 17145c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID544507	Metabolic stability in Escherichia coli TOP10 harboring beta-lactamase KPC-2 assessed as hydrolysis rate per mg of extracts at 50 uM after 5 mins by spectrophotometric analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID544952	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX and SHV by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID585398	Ratio of Kcat to Km for Stenotrophomonas maltophilia 1SML metallo-beta-lactamase L1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID534885	Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1318929	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86079	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID372613	Activity of Escherichia coli DH5alpha beta-lactamase TEM-158 by microacidimetric method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID532896	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID571922	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 25 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID560132	Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay relative to benzylpenicillin	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID576074	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18260 harboring pSHA2-encoded porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID522006	Antimicrobial activity against Klebsiella pneumoniae isolate KpI-2 expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID510511	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-19 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID571900	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 14 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID511422	Total clearance in healthy human subjects at 50 gram, iv administered 20 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID533568	Antimicrobial activity against Pseudomonas aeruginosa isolate PA469 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID564209	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA isolated from wound infection of patient by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID567317	Antimicrobial activity against Proteus mirabilis TUM4660 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID1757637	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-7 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID562811	Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID544435	Antimicrobial activity against Escherichia coli MC4100A harboring empty plasmid by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID531604	Activity of Escherichia coli Inhibitor-resistant beta-lactamase SHV-56	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID544951	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID285588	Antimicrobial activity against Pseudomonas aeruginosa 65.36-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1586250	Antibacterial activity against Acinetobacter baumannii BM4652 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID533531	Antimicrobial activity against Pseudomonas aeruginosa PA386 expressing IMP-13 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID564535	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position and R210P substitution by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID341120	Increase in ampDh2 gene expression in Pseudomonas aeruginosa 164M1 by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID495674	Antimicrobial activity against wild type Klebsiella oxytoca OC 4076 expressing Beta-lactamase K1 assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1373321	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-146 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1757816	Bactericidal activity against ESBLs positive carbapenem-sensitive Escherichia coli 17-3 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID532909	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 ST 327 expressing beta-lactamase TEM-1 and CTX-M-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID519652	Antimicrobial activity against Escherichia coli Irk1224 type 3 mutant harboring beta-lactamase CTX-M-3 Lys136 mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID532911	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 ST 327 expressing beta-lactamase TEM-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID423776	Antibacterial activity against ESBL-negative Klebsiella pneumoniae isolate 114 at 1 ug/ml by Etest	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Selection of SHV extended-spectrum-beta-lactamase-dependent cefotaxime and ceftazidime resistance in Klebsiella pneumoniae requires a plasmid-borne blaSHV gene.
AID534603	Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID519643	Antimicrobial activity against Escherichia coli EPI300 transformant harboring pCC1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID521282	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype F by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID544493	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-4 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID285643	Antimicrobial activity against Pseudomonas aeruginosa 15G10 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID535366	Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID554400	Antimicrobial activity against Pseudomonas aeruginosa isolate 2933 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID565547	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-11 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID324358	Antibacterial activity against Escherichia coli DH10B expressing SCO1 by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID1373304	Antimicrobial activity against Escherichia coli expressing beta-lactamase GIM-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID285266	Activity of Escherichia coli BL21(DE3) beta-lactamase TEM151	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID518816	Antibacterial activity against Acinetobacter genomosp. 3 isolates by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID341108	Antibacterial activity against Escherichia coli 26R793 by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
AID565518	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-17 harboring A residue at 105 position in PDC- 3 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1553779	Antibacterial activity against Staphylococcus aureus ATCC 29213 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID556680	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 7 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID374366	Antimicrobial activity against Escherichia coli DH5alpha by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID368746	Antimicrobial activity against Escherichia coli Ec9 expressing TEM-24b TEM-26 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID368946	Volume of distribution in human	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID519653	Antimicrobial activity against Escherichia coli GM2995 harboring plasmid pCC1 carrying beta-lactamase CTX-M-3 gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID531572	Antibacterial activity against Streptococcus mitis obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID424859	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by E-test	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID1757779	Ratio of MBC to MIC for Enterobacter cloacae 17-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID530817	Antibacterial activity against Escherichia coli J53 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID524741	Antimicrobial activity against beta lactamase CTX-M-10 producing Escherichia coli GB20 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID1553813	Antibacterial activity against Escherichia coli ATCC 25922 measured after 18 to 24 hrs in presence of NaCl	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID498819	Antimicrobial activity against Klebsiella pneumoniae GZ64T expressing IMP-4 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1757583	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-15 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID19542	Plasma half-life in human after intravenous administration	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.
AID285653	Antimicrobial activity against Pseudomonas aeruginosa 19C12 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID324874	Antimicrobial activity against Acinetobacter baumannii C75 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID1649591	Antimicrobial activity against Klebsiella pneumoniae clinical isolates in presence of 1 ug/ml iron by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID374137	Antimicrobial activity Enterobacter cloacae 113 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID508487	Antimicrobial activity against Pseudomonas aeruginosa isolate BNL-1681 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID517951	Antimicrobial activity against Providencia rettgeri by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1318934	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 80621	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID373051	Antimicrobial activity against Bacillus clausii ATCC 21537 by agar-dilution technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID559827	Antimicrobial activity against Pseudomonas aeruginosa PU21 harboring pCHE-A plasmid expressing blaGES-5 gene by agar dilution in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID584735	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4753 harboring mutation in putative RNA-binding protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID495807	Antimicrobial activity against Escherichia coli C600 2878 transconjugate expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID517955	Antimicrobial activity against Klebsiella pneumoniae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID520974	Antibacterial activity against Escherichia coli harboring pBC2303 expressing blaKPC gene plasmid by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID528784	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID405791	Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 4	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID495721	Activity of Escherichia coli CMY-2 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID567312	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2203 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID76915	In vitro relative anticholinergic potential in isolated guinea pig trachea	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID1757625	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID405802	Inhibition of bocillin FL binding to penicillin-susceptible Streptococcus pneumoniae OC 8865 penicillin-binding protein 1a	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID559533	Antibacterial activity against Klebsiella oxytoca assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID511391	Antibacterial activity against Citrobacter freundii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID555676	Antimicrobial activity against Escherichia coli DH5[alpha] harboring phagemid pBK-CMV by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID542062	Antibacterial activity against Klebsiella pneumoniae D expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID529849	Antibacterial activity against beta-lactamase-overproducing Pseudomonas aeruginosa N043 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID341115	Antibacterial activity against Pseudomonas aeruginosa 164M1 harboring p26PAD1 plasmid containing ampD gene	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID575417	Antimicrobial activity against anrB-deficient Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.
AID1757699	Antibacterial activity against Enterobacter aerogenes 17-1 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285269	Activity of Escherichia coli BL21(DE3) beta-lactamase TEM28	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID573340	Antibacterial activity against ceftazidime-susceptible Citrobacter freundii by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID544962	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV and CTX by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID508723	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E1 PpA1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID511419	fT>MIC in healthy human subjects at 6 gram/70kg, iv administered as 12 mg/l infusion every 6 hrs	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID531316	Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID368758	Antimicrobial activity against Klebsiella oxytoca expressing TEM-11 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID521994	Antimicrobial activity against Escherichia coli isolate J53 harboring pBb containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID573338	Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID567752	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 11 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID544533	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8130 expressing bla SHV-1 gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID571224	Antimicrobial activity against Pseudomonas aeruginosa isolate PA22 obtained from patient with cystic fibrosis harboring beta-lactamase AmpD1 Gly148ala and Asp183Tyr mutant by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID573361	Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID373048	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FZ84 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID534900	Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID532091	Antimicrobial against Pseudomonas aeruginosa PAO1 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID554990	Antibacterial activity against Acinetobacter genomosp. 3 isolate 65 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID285658	Antimicrobial activity against Pseudomonas aeruginosa 19E12 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID368956	%fT>MIC in human at 121 mg/kg administered every 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID531586	Antibacterial activity against Morganella morganii obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID495698	Activity of Pseudomonas aeruginosa IMP-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1580091	Antibacterial activity against colistin-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages by checkerboard assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID560488	Antibacterial activity against 5 x 10'5 CFU/ml CMY-30 producing Escherichia coli MC4100 harboring plasmid AC-cmy30 by microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID549347	Antimicrobial activity against Escherichia coli isolate 32 harboring bla CTX-M-3a gene by broth microdilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID1171217	Antibacterial activity against wild-type Pseudomonas aeruginosa	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID1757649	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID517948	Antimicrobial activity against Citrobacter freundii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1757848	Ratio of MBC to MIC for Carbapenem-resistant Klebsiella pneumoniae KR 15-8 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID508726	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1B2 RCA2 harboring acquired beta-lactamase PER-1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID535694	Antimicrobial activity against Azide-resistant Escherichia coli J53 transconjugant harboring Escherichia coli DH5alpha-5825 qnrB2 gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID207267	Compound was tested for antimicrobial activity against Staphylococcus aureus penicillin sensitive Staphylococcus aureus (147N) strain	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID1300875	Antibacterial activity against Proteus mirabilis clinical isolate after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID518823	Antibacterial activity against Pulsotype C Acinetobacter genomosp. 3 isolate 1 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID1757507	Antibacterial activity against Multidrug resistant Klebsiella pneumoniae KR 15-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID571032	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID572136	Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 35 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID584516	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2487 harboring mutation in hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID562947	Antimicrobial activity against Klebsiella pneumoniae PFGE clone D expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID565712	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-17 harboring A residue at 105 position in PDC- 3 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID542721	Antimicrobial activity against ESBL-producing Klebsiella pneumoniae clinical isolate assessed as resistant isolates	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases.
AID244866	Minimum inhibitory concentration of compound against Escherichia coli K12AmpC-Ent	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID534304	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA494	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID531070	Antimicrobial activity against SHV-12-like, SHV-1-like beta-lactamase producing Klebsiella pneumoniae isolate CUMCK9 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID559541	Antibacterial activity against ciprofloxacin-susceptible Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID544498	Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-2 to MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID1318937	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 85322	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1757503	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID546406	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-23 with PDC-5 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID1757564	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-12 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID373033	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ3-23 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID342026	Antibacterial activity against Escherichia coli J53 assessed as inhibition zone diameter by CLSI disk diffusion confirmatory test	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID546160	Antimicrobial activity against Pseudomonas aeruginosa PAO1 with PDC-1 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID326270	Activity of Escherichia coli beta-lactamase SCO1 relative to penicillin G	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID587986	Antibacterial activity against Escherichia coli AS226 after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID562764	Antimicrobial activity against Escherichia coli DH10B transformant harboring blaTEM-168 gene by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID368744	Antimicrobial activity against Escherichia coli Ec7 expressing SHV-12 IRT-6 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID499072	Antimicrobial activity against Citrobacter freundii RJ78 expressing CMY-2, qnrA1, aac(6')-Ib-cr, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID563974	Activity of Klebsiella pneumoniae 05-560 beta-lactamase IMP1 by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID1757716	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-26 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID585180	Activity of Beta-lactamase GES-13 K104, N170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID368951	%fT>MIC in mouse at 9.29 mg/kg administered every 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID542059	Antibacterial activity against Klebsiella pneumoniae B expressing CTX-M group 1 beta-lactamase by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID517956	Antimicrobial activity against Proteus penneri by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID556347	Ratio of Kcat/Km for Escherichia coli beta-lactamase CTX-M-27	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID585185	Ratio of Kcat to Km for Beta-lactamase GES-6 K104, S170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID368498	Activity of Enterobacter cloacae 4092 AmpC (E2) assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID561329	Antimicrobial activity against azide-resistant Escherichia coli J53	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID531086	Antimicrobial activity against CTX-M-14-like, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC203 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID587980	Antibacterial activity against Escherichia coli AS226 carrying pBSDS237A mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID665121	Antibacterial activity against Escherichia coli after 18 to 22 hrs by EUCAST broth microdilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID541013	Antimicrobial activity against Burkholderia cenocepacia 5007902 expressing beta-lactamase PenB4	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID573146	Antibacterial activity against penicillin-nonsusceptible Streptococcus viridans by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID495792	Antimicrobial activity against Escherichia coli DH10B harbouring recombinant plasmid pSau1 expressing beta-lactamase BIC-1 from Pseudomonas fluorescens PF-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID534525	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3696 after 18 hrs by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID584687	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3721 harboring nalC mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID207512	Minimal inhibitory activity against the Staphylococcus aureus (X1.1)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID1757759	Bactericidal activity against Escherichia coli NCTC 13353 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1782791	Antibacterial activity against panel of 198 clinical isolates Acinetobacter baumannii assessed as inhibition of bacterial growth by microdilution method	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID529485	Antimicrobial activity against Enterobacter cloacae isolate 293 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID549335	Antimicrobial activity against Escherichia coli isolate Z1 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID573370	Antibacterial activity against ceftazidime-susceptible Serratia marcescens by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1757685	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-9 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285513	Antibacterial activity against Klebsiella pneumoniae	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID1757676	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-14 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1373318	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-40 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID368726	Activity of Serratia marcescens AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID341130	Increase in ampC gene expression in Pseudomonas aeruginosa 164M1 harboring p26PAD1 plasmid containing ampD gene by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID206552	In vivo activity in murine against Staphylococcus aureus 753(MR) infection after sc administration.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID508292	Antimicrobial activity against penicillin-resistant Enterococcus faecium D63r by microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.
AID1757638	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-8 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID582970	Antimicrobial activity against nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID1808830	Antibacterial activity against Pseudomonas aeruginosa PAO1 23/14-053 (ST-309) by broth microdilution method
AID573128	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID529663	Activity of Pseudomonas aeruginosa 166301 beta-lactamase VIM-16 relative to cephaloridine	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID575327	Antimicrobial activity against Salmonella Typhimurium 08-1537 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID567462	Antimicrobial activity against Salmonella enterica serovar Typhi isolate 080048Ty by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.
AID496004	Antimicrobial activity against drug resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID510512	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate W2AC8-S10 expressing OXA-51	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID559587	Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as microbial doubling time	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID368733	Antimicrobial activity against Enterobacter aerogenes Ea1 expressing TEM-24b AmpC +/- TEM-1 or TEM-2 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID1808858	Antipseudomonal activity against pseudomonas aeruginosa PAO1 AmpC RNA level assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID531575	Antibacterial activity against Bacillus spp. obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID545658	Antimicrobial activity against Acinetobacter sp. assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID1757695	Antibacterial activity against Enterobacter cloacae 17-7 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID524408	Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID565280	Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID524709	Antibacterial activity against Providencia rettgeri clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID534194	Antimicrobial activity against Pseudomonas putida expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
AID1757859	Ratio of MBC to MIC for ESBLs negative carbapenem-negative Escherichia coli 17-20 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID546411	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-28 with PDC-7 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID549334	Antimicrobial activity against Escherichia coli isolate 100 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID556668	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 23 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1056841	Antibacterial activity against TEM-1/SHV-12 expressing Aeromonas hydrophila isolate 268 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID587635	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=64:16 mg/kg, sc compound to NXL104	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID1757706	Antibacterial activity against Enterobacter aerogenes 15-5 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID508490	Antimicrobial activity against Pseudomonas aeruginosa isolate K45-32 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID520730	Activity of Escherichia coli DH10B beta-lactamase assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID368513	Activity of Pseudomonas aeruginosa VIM2 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID524708	Antibacterial activity against Morganella morganii clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID1553793	Bactericidal activity against methicillin-resistant Staphylococcus aureus ATCC 43300 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID535755	Antimicrobial activity against community-acquired Escherichia coli obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID495705	Kcat/Km ratio of Klebsiella pneumoniae Beta-lactamase TEM-26	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID529605	Antibacterial activity against Escherichia coli TP1 harboring pBR322 carrying TEM-12 assessed as inhibition of bacterial growth at 256 ug/ml after 18 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Fitness trade-offs in blaTEM evolution.
AID529664	Ratio of Kcat to Km for Pseudomonas aeruginosa 166301 beta-lactamase VIM-16 relative to cephaloridine	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID576274	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18260 by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID301090	Antibacterial activity against Haemophilus influenzae ATCC 49766 after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID495726	Activity of Serratia marcescens SME-3 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID559540	Antibacterial activity against Proteus vulgaris assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID555185	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox delta ampDh3::lox and wild type nagZ gene after 18 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID542063	Antibacterial activity against Klebsiella pneumoniae B expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID405797	Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID587981	Antibacterial activity against Escherichia coli AS226 carrying pBSDD240S mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID558051	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S14 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID533540	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA340	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID559483	Antibacterial activity against Serratia marcescens by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1553771	Antibacterial activity against Salmonella pullorum ATCC 7913 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID1757836	Bactericidal activity against Acinetobacter baumannii NCTC 13304 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID563976	Activity of Klebsiella pneumoniae 05-560 beta-lactamase VIM2 by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID495819	Antimicrobial activity against Klebsiella pneumoniae 2878 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID559071	Antibacterial activity against Acinetobacter lwoffii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID283112	Antibacterial activity against Escherichia coli C600 expressing TEM1	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID495680	Antimicrobial activity against Pseudomonas aeruginosa OC 13996 expressing beta-lactamase IMP-1 and containing Carbapenemase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID285676	Antimicrobial activity against Pseudomonas aeruginosa 24G1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID495694	Activity of Pseudomonas aeruginosa OXA-10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID535127	Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID498834	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU3 deficient in DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID529659	Activity of Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID524925	Antimicrobial activity against Escherichia coli MI1443 harboring A77V mutation in beta lactamase CTX-M-10 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID584494	Antibacterial activity against porin deficient OmpA positive extended-spectrum beta-lactamase producing Klebsiella pneumoniae KPBj1 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID511298	Antibacterial activity against Pseudomonas aeruginosa NL68 expressing GES-13 beta lactamase in presence of 4 ug/ml Tazobactam	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID522572	Antimicrobial activity against Escherichia coli isolate 7014517 with AmpC beta-lactamase 295 Ins LAA mutation	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID532910	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID522011	Antimicrobial activity against Klebsiella pneumoniae isolate KpE expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID1757821	Bactericidal activity against Enterobacter cloacae 17-8 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID511288	Antibacterial activity against Escherichia coli DH5alpha pB-ges-13 plasmid	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID575331	Antimicrobial activity against Salmonella 4,5,12:i:- 08-2712 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID565543	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-07 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID519748	Ratio of Kcat to Km for Klebsiella pneumoniae Beta-Lactamase SHV-1	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID573360	Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID533552	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA364	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID508735	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring acquired beta-lactamase OXA-2 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID521283	Antimicrobial activity against CTX-M-59 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype G by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID524406	Antibacterial activity against Enterobacteriaceae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID573358	Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID584706	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0420 harboring bioA mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID529583	Antibacterial activity against Escherichia coli TP1 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Fitness trade-offs in blaTEM evolution.
AID278065	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from deployed military patient	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.
AID542772	Antimicrobial activity against Escherichia coli J53 transformed with pHNDU1 carrying qnrB6 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID545401	Antimicrobial activity against Pseudomonas aeruginosa PS7A with PFGE phenotype 11D obtained from urine of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1757506	Antibacterial activity against Multidrug resistant Klebsiella pneumoniae KR 15-2 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495657	Antimicrobial activity against Escherichia coli TOP10 expressing recombinant beta-lactamase BEL-1 by solid agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID283217	Antimicrobial activity against Burkholderia cepacia complex isolated from cystic fibrosis patient by broth microdilution assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
AID573121	Antibacterial activity against coagulase-negative and oxacillin-susceptible Staphylococcus aureus assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID531585	Antibacterial activity against Klebsiella pneumoniae obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID571892	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 10 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID285677	Antimicrobial activity against Pseudomonas aeruginosa 29F6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID325187	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae SR-16675 by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID542742	Antimicrobial activity against Citrobacter freundii D26 expressing qnrB6 and CTX-M-9G genes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID567322	Antimicrobial activity against Proteus mirabilis TUM4660 by broth dilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID1757758	Bactericidal activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID571908	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 18 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1757598	Antibacterial activity against Enterobacter cloacae 17-4 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285649	Antimicrobial activity against Pseudomonas aeruginosa 19B6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID535169	Antimicrobial activity against imipenem susceptible Acinetobacter assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584557	Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID495713	Kcat/Km ratio of Pseudomonas aeruginosa IMP-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID522389	Activity of Aeromonas caviae Beta-lactamase CAV1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID495724	Activity of Pseudomonas aeruginosa OXA-10 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID508295	Inhibition of PBP1 in penicillin-resistant Enterococcus faecium D63r membranes assessed as inhibition of fluorescent ampicillin binding after 20 mins at 37 degC	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.
AID554402	Antimicrobial activity against Pseudomonas aeruginosa isolate 3066 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID531590	Antibacterial activity against Providencia stuartii obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID559075	Antibacterial activity against Enterobacter cloacae by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1757679	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-18 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534177	Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid DU by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID535651	Antimicrobial activity against aac(6')-Ib-cr-positive Escherichia coli FJ3T harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID587612	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID285594	Antimicrobial activity against Pseudomonas aeruginosa 1A9 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID535713	Antibacterial activity against Escherichia coli TOP10 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID535164	Antimicrobial activity against imipenem non-susceptible Acinetobacter by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1757586	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-21 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285607	Antimicrobial activity against Pseudomonas aeruginosa 2A9 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID561442	Antibacterial activity against Escherichia coli YD006 harboring beta-lactamase CMY-33 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID561677	Antimicrobial activity against Pseudomonas aeruginosa isolate OC14551 harboring plasmid JAK16 expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID587636	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=64:16 mg/kg, sc compound to NXL104	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID573367	Antibacterial activity against ceftazidime-susceptible Proteus mirabilis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID561658	Antimicrobial activity against Pseudomonas aeruginosa isolate OC14812 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID565718	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-23 harboring A residue at 105 position in PDC- 5 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1757766	Ratio of MBC to MIC for Carbapenem- resistant Pseudomonas aeruginosa 17-8 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID209864	In vivo activity in murine against Streptococcus pneumoniae 6301 infection after sc administration.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID498836	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU5 deficient in SHV-12, DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1757784	Ratio of MBC to MIC for Enterobacter aerogenes 17-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID324872	Antimicrobial activity against Acinetobacter baumannii C75 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID584690	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4459 harboring mutation in Conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID584921	Activity of Beta-lactamase in Pseudomonas aeruginosa PA14 PA4020 harboring complemented mpl mutant gene relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID368500	Ratio of Kcat to Km of Klebsiella oxytoca beta-lactamase K1 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1373286	Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-3 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1318933	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 79199	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID544431	Antimicrobial activity against translocase tatC-deficient Escherichia coli B1LK0A harboring beta-lactamase L2 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID562776	Antimicrobial activity against Escherichia coli DH10B by broth microdilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID534170	Antimicrobial activity against armA positive Escherichia coli TOP10 harboring plasmid COP1 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID324860	Antimicrobial activity against Acinetobacter baumannii A24B after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID535060	Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID405086	Ratio of Kcat to Km of Citrobacter freundii PER2 beta lactamase relative to cephalothin	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID522019	Antimicrobial activity against Enterobacter cloacae isolate 1 expressing beta-lactamase OXA-48 and SHV-5 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID555224	Ratio of Kcat to Km for Acinetobacter genomosp. 3 isolate 65 ADC-14	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID532095	Antimicrobial against Pseudomonas aeruginosa 3208 harboring phzM allele by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1757867	Ratio of MBC to MIC for Enterobacter cloacae 17-10 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID519894	Antimicrobial activity against Escherichia coli Irk1224 harboring beta-lactamase CTX-M-3 by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID1516022	Antibacterial activity against Escherichia coli UB1005 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID1516024	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID544423	Antimicrobial activity against Escherichia coli MC4100A harboring beta-lactamase CTX-M-14 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID368531	Activity of Morganella morganii AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID372614	Ratio of Kcat to Km for Escherichia coli DH5alpha beta-lactamase TEM-158	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID549331	Antimicrobial activity against Escherichia coli isolate 32 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID575315	Antimicrobial activity against Salmonella Newport 03-8748 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID534880	Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID556341	Ratio of Kcat/Km for Salmonella enterica serotype Westhampton beta-lactamase CTX-M-53	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID529584	Antibacterial activity against Escherichia coli TP1 harboring pBR322 carrying TEM-1 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Fitness trade-offs in blaTEM evolution.
AID556655	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 10 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID508731	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3D2 GM2 harboring acquired beta-lactamase BEL-3 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID1373307	Antimicrobial activity against Escherichia coli expressing beta-lactamase NDM-5 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID559583	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID508298	Inhibition of PBP4 in penicillin-resistant Enterococcus faecium D63r membranes assessed as inhibition of fluorescent ampicillin binding after 20 mins at 37 degC	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.
AID372619	Activity of Escherichia coli DH5alpha beta-lactamase TEM-1 by microacidimetric method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID528492	Antimicrobial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID405790	Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID555223	Activity of Acinetobacter genomosp. 3 isolate 65 ADC-14	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID567308	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2206 isolated from burn patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID1757876	Ratio of MBC to MIC for carbapenem-sensitive Pseudomonas aeruginosa 17-26 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID278066	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from nondeployed military patient	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.
AID524569	Antimicrobial activity against Shigella isolate DH-22451 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID535704	Antibacterial activity against Escherichia coli TOP10 expressing AmpC-A S287N mutant protein by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID564453	Antimicrobial activity against Pseudomonas aeruginosa isolate 1050 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID573352	Antibacterial activity against ceftazidime-susceptible Escherichia coli by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1757655	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-9 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID422495	Antimicrobial activity against Escherichia coli BL21 (DE3) harboring pAT514 by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID573149	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID584503	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0667 harboring mutation in putative metallopeptidase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID368503	Ratio of Kcat to Km of Klebsiella pneumoniae TEM26 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID572060	Antibacterial activity against abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID545617	Antimicrobial activity against Pseudomonas aeruginosa PS39 with PFGE phenotype 8 expressing beta-lactamase IMP-18 obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID542049	Antibacterial activity against rifampicin resistant Escherichia coli J53-2 by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID559078	Antibacterial activity against Klebsiella oxytoca by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID674595	Antibacterial activity against Escherichia coli ATCC 25922	2012	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16	Design, synthesis and antibacterial activities of a series of new 2-oxaisocephems.
AID544960	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1757641	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-11 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID532402	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D4 isolate VA-06X-47 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID542061	Antibacterial activity against Klebsiella pneumoniae A expressing CTX-M group 1 beta-lactamase by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID511387	Antibacterial activity against ciprofloxacin susceptible Escherichia coli by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID372607	Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-158 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID554396	Antimicrobial activity against Pseudomonas aeruginosa isolate 2721 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID373769	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh20 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID585642	Antimicrobial activity against ampD, ampDh1, ampDh2 deficient Pseudomonas aeruginosa PAO1 after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID70413	In vitro antimicrobial activity against Escherichia coli 1507E	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID531677	Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid containing OXA-58-4 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID567748	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 27 fold elevated mexX expression and 16 fold elevated mexY expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID1808807	Antibacterial activity against Pseudomonas aeruginosa PAO1 deltadacBdeltadacC by broth microdilution method
AID519011	Ratio of Kcat to Km for Beta-lactamase TEM-149 T182M mutant expressed in Escherichia coli HB101	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID330964	Antimicrobial activity against wild type EtbuPUG treated Escherichia coli transfected with pCF1 by serial dilution method	2007	The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29	Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID529572	Antimicrobial activity against Erwinia carotovora subsp. atroseptica DSM 30184 after 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID567281	Ratio of Kcat to Km for Acinetobacter baumannii ADC-33 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID1442084	Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID368724	Ratio of Kcat to Km of Pseudomonas aeruginosa MK-1184 AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID301083	Antibacterial activity against AmpC producing Enterobacter cloacae SR-4321 after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID368534	Ratio of Kcat to Km of Morganella morganii AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID372612	Antibacterial activity against rifampin-resistant Escherichia coli C600 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID69011	In vitro synergistic activity against Escherichia coli C600N + (TEM-10)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID1407934	Antibacterial activity against Streptococcus pyogenes ARC838 after 24 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID583181	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID531335	Antibacterial activity against Pseudomonas aeruginosa TNP030 selected after 1.0 ug/ml of azithromycin by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID1757744	Bactericidal activity against Enterobacter cloacae 17-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID511412	Mean residence time in healthy human subjects at 2 gram, iv administered in 5 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID533564	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA774 isolated from patient with cystic fibrosis	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID559074	Antibacterial activity against Enterobacter aerogenes by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID374025	Activity of Klebsiella pneumoniae KPC-1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID584711	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0770 harboring rnc mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID285337	Antimicrobial activity against Escherichia coli qnrA1 producing urinary specimen isolate 13.52 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
AID499054	Antimicrobial activity against carbapenem-resistant Escherichia coli PU101 deficient in TEM-1, CTX-M-14, CMY-2, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1887614	Synergistic antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration incubated for 24 hrs in presence of artocarpin by checkerboard method	2022	Journal of natural products, 10-28, Volume: 85, Issue:10	Developing the Natural Prenylflavone Artocarpin from
AID521998	Antimicrobial activity against Klebsiella pneumoniae isolate Kp5A expressing beta-lactamase OXA-48 and SHV-5 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID209296	In vitro antimicrobial activity against Streptococcus pyogenes A 308	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID545614	Antimicrobial activity against Pseudomonas aeruginosa PS35 with PFGE phenotype 11A obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID404968	Activity of OXA58 from Acinetobacter baumannii T186 isolate carrying three bla-OXA58 gene copy assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID520975	Antibacterial activity against Pseudomonas aeruginosa 2404 plasmid by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID565545	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-09 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID528787	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID544953	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID70414	In vitro antimicrobial activity against Escherichia coli DC 0	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID572130	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 32 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID584923	Activity of Beta-lactamase in Pseudomonas aeruginosa PA14 PA4109 harboring ampR mutant gene relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1257072	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA 300 LAC after 20 hrs by CLSI broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities.
AID546170	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-10 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID588208	Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset	2010	Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5	Predicting phospholipidosis using machine learning.
AID164241	Antibacterial activity against Pseudomonas aeruginosa PS18	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID531679	Antimicrobial activity against Acinetobacter baumannii Ab290 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID1373285	Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-2 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID508300	Inhibition of low-affinity PBP5fm in penicillin-resistant Enterococcus faecium D63r membranes assessed as inhibition of fluorescent ampicillin binding after 20 mins at 37 degC	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.
AID573391	Antibacterial activity against ceftazidime-susceptible Providencia sp. by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1757643	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-13 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID252619	Mean lysis diameter was measured against Enterobacter aerogenes EA289 with D121A mutation by standard disk diffusion method on MH agar	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	Beta-lactam screening by specific residues of the OmpF eyelet.
AID68822	In vivo activity in murine against Escherichia coli 257 infection after sc administration.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID1757869	Ratio of MBC to MIC for Enterobacter aerogenes 17-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID559903	Antimicrobial activity against Escherichia coli TF-KO281 harboring beta-lactamase OXY-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID1553792	Bactericidal activity against Salmonella typhimurium C7731 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID341121	Increase in ampDh3 gene expression in Pseudomonas aeruginosa 164M1 by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID587618	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse septicemia infection model at 2:1 compound to NXL104 beta-lactamase inhibitor ratio by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID69010	In vitro synergistic activity against Escherichia coli C600N + (TEM-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID573191	Antimicrobial activity against mutS::lox,nfxB gene-deficient Pseudomonas aeruginosa PAOMSNB biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID582971	Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID560190	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by M7-A7 dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID368535	Activity of Providencia stuartii AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID529461	Antimicrobial activity against Escherichia coli J53 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID562220	Antimicrobial activity against Desulfovibrio sp. by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Susceptibilities of 23 Desulfovibrio isolates from humans.
AID495714	Kcat/Km ratio of Pseudomonas aeruginosa SPM-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1757731	Bactericidal activity against Carbapenem- resistant Pseudomonas aeruginosa 17-8 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID518519	Antimicrobial activity against Capnocytophaga sputigena isolate NOR after 2 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.
AID558038	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S1 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID544437	Antimicrobial activity against translocase tatC-deficient Escherichia coli B1LK0A harboring empty plasmid by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID532027	Antimicrobial activity against Kluyvera georgiana 14751 expressing beta-lactamase CTX-M-78 obtained from bloodstream of patient by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Novel chromosome-encoded CTX-M-78 beta-lactamase from a Kluyvera georgiana clinical isolate as a putative origin of CTX-M-25 subgroup.
AID556653	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 8 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID562737	Antimicrobial activity against Escherichia coli K-12 transconjugant harboring blaCTX-M-71 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID540947	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c36 plasmid expressing cephalosporinase CMY-36 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID567740	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 31 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID341107	Antibacterial activity against Escherichia coli transconjugant carrying pEC28 isolate eby Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
AID368527	Activity of Enterobacter cloacae 908R AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID531651	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC225 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID576308	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 29459 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID567280	Activity of Acinetobacter baumannii ADC-11 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID523963	Antibacterial activity against Burkholderia pseudomallei 1026b infected in BALB/c mouse assessed as protection against bacterial infection at 25 mg/kg, ip administered as single dose 6 hrs postinfection	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID368517	Ratio of Kcat to Km of Pseudomonas aeruginosa VIM2 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID519656	Antimicrobial activity against Escherichia coli Irk1224 type 1 mutant harboring beta-lactamase CTX-M-3 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID576071	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 50748 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID584726	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3818 harboring suhB mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1516027	Antibacterial activity against Acinetobacter baumannii AB1902 clinical isolate incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID665122	Antibacterial activity against Proteus vulgaris after 18 to 22 hrs by EUCAST broth microdilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID405817	Antimicrobial activity against Pseudomonas putida 12346 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID532196	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae WH42 harboring wild-type GyrA, ParC, GyrB and qnrA genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID285598	Antimicrobial activity against Pseudomonas aeruginosa 2C1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID562951	Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID1757797	Bactericidal activity against Carbapenem- resistant Acinetobacter baumannii 17-5 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID396033	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pBGS18 plasmid by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID205911	In vitro minimum inhibitory concentration for Staphylococcus epidermidis (ATCC-12228) by agar dilution method	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.
AID495683	Antimicrobial activity against Pseudomonas aeruginosa OC 4083 expressing beta-lactamase OXA-10 and containing Oxacillinase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID534906	Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID554391	Antimicrobial activity against Pseudomonas aeruginosa isolate 615R obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID561321	Antimicrobial activity against Escherichia coli isolate 48 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID1373281	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTXM-3 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID545621	Antimicrobial activity against Pseudomonas aeruginosa PS44 with PFGE phenotype 13 expressing beta-lactamase IMP-18 obtained from blood of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID556646	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 1 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID524713	Antibacterial activity against Burkholderia cepacia clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID245351	Minimum inhibitory concentration of compound against Citrobacter freundii derepressed 91/98-2 in presence of compound 14	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID495718	Activity of Escherichia coli CTX-M-15 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID584526	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3667 harboring mutation in putative cysteine sulfinate desulfinase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID585182	Ratio of Kcat to Km for Beta-lactamase GES-7 K104, G170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID555220	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 103 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID573116	Antibacterial activity against methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID531783	Antibacterial activity against Stenotrophomonas maltophilia obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID567282	Ratio of Kcat to Km for Acinetobacter baumannii ADC-11 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID1757500	Antibacterial activity against Escherichia coli 15-3 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285650	Antimicrobial activity against Pseudomonas aeruginosa 19C2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1516029	Antibacterial activity against Staphylococcus aureus 11011 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID583093	Antimicrobial activity against Escherichia coli XL1-Blue harboring pBC-SK plasmid by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID368954	%fT>MIC in human at 38.9 mg/kg administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID532102	Antimicrobial against Pseudomonas aeruginosa 8666 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID368751	Antimicrobial activity against Klebsiella pneumoniae Kp3 expressing SHV-2a TEM-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID373039	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ32 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID533530	Antimicrobial activity against Pseudomonas aeruginosa PA552 expressing IMP-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID565520	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-15 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID528599	Antimicrobial activity against blaKPC-2 and blaTEM-1 producing Escherichia coli 2138 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID1757724	Bactericidal activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-4 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID405825	Antimicrobial activity against Acinetobacter baumannii 694 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID573400	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1373319	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-48 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID519810	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by CLSI protocol based broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID567325	Antimicrobial activity against Escherichia coli ML4909 by broth dilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID535145	Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID556699	Antimicrobial activity against multidrug resistant Escherichia coli ATCC 35218 harboring pDrive plasmid by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID559069	Antibacterial activity against Acinetobacter baumannii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID508488	Antimicrobial activity against Pseudomonas aeruginosa isolate OS-210 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID516144	Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 10 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID285663	Antimicrobial activity against Pseudomonas aeruginosa 22D6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID531576	Antibacterial activity against Gemella morbillorum obtained from complicated skin and skin structure infections by RapID ANA system	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID498832	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae CY1 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID498808	Antimicrobial activity against Klebsiella pneumoniae ZJ99 expressing KPC-2, CTX-M-3, qnrS1, ompK35 DE by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID535723	Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase AmpC-A S287N mutant	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID1373320	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-51 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID582980	Antimicrobial activity against ampC::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID368510	Activity of Serratia marcescens SME3 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID524568	Antimicrobial activity against Shigella sonnei isolate AM22451 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID529865	Ratio of MIC for Pseudomonas aeruginosa N092 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID559072	Antibacterial activity against Citrobacter freundii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID279183	Antibacterial activity against Escherichia coli DH10B expressing recombinant beta lactamase LAP1	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.
AID535721	Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase AmpC-A	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID495752	Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow and treated with Cefixime by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID1757864	Ratio of MBC to MIC for Enterobacter cloacae 17-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID374365	Antimicrobial activity against Escherichia coli DH5alpha expressing pIP19 containing Aeromonas caviae A324R metallo-beta-lactamase blaIMP-19 gene by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID567458	Antimicrobial activity against Salmonella enterica serovar Typhi isolate 080048Ty by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.
AID394694	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing MexAB-OprM pump, MexXY-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID674596	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853	2012	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16	Design, synthesis and antibacterial activities of a series of new 2-oxaisocephems.
AID156122	Affinity for penicillin binding protein 3 of Escherichia coli UB1005 (DC0) was evaluated.	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.
AID524259	Ratio of Kcat to Km in Escherichia coli beta-lactamase SHV-84	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.
AID368548	Activity of Pseudomonas aeruginosa MK-1184 AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID495661	Activity at Pseudomonas aeruginosa 531 beta-lactamase BEL-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID521286	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype J by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID1808860	Antipseudomonal activity against pseudomonas aeruginosa PAOdeltaC AmpC RNA level assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID517954	Antimicrobial activity against Klebsiella oxytoca by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID563591	Inhibition of Pseudomonas aeruginosa PAO1 PBP2 by SDS-PAGE	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID518729	Ratio of Kcat to Km for Pseudomonas stutzeri beta-lactamase DIM-1by UV-spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
AID532407	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-20 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1757560	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-8 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID511398	Antibacterial activity against Pseudomonas aeruginosa by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID529581	Ratio of Kcat to Km for Janthinobacterium lividum THIN-B	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID373056	Antimicrobial activity against Bacillus clausii NR expressing beta-lactamase BCL1 by agar-dilution technique in presence of beta-lactamase inhibitor clavulanic acid	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID556688	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 15 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID532895	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID565713	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-18 harboring A residue at 105 position in PDC- 3 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID531580	Antibacterial activity against Citrobacter braakii obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID532104	Antimicrobial against Pseudomonas aeruginosa 312 harboring PBPP allele by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID67999	In vivo activity in murine against Enterobacter cloacae 5699 infection after sc administration.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID1586251	Antibacterial activity against Acinetobacter baumannii ATCC 19606-1 expressing LpxC after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID495635	Activity of Pseudomonas luteola LAM Beta-lactamase LUT-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID19543	Plasma half-life in monkey after intravenous administration	1993	Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22	Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.
AID584493	Antibacterial activity against porin deficient OmpA positive extended-spectrum beta-lactamase producing Klebsiella pneumoniae KPBj1 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID531650	Antimicrobial activity against CTX-M-15,OXA-30 beta-lactamase producing Escherichia coli isolate CUMC245 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID562331	Antimicrobial activity against Escherichia coli DH5alpha harboring metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID66228	Compound was tested for antimicrobial activity against Enterobacter cloacae constitutive derepressed type I beta-lactamase producer (P99+) strain	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID1757831	Bactericidal activity against carbapenem-sensitive Pseudomonas aeruginosa 17-10 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID565200	Antimicrobial activity against Klebsiella pneumoniae isolate A-1760 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID1757553	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-1 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID529864	Ratio of MIC for Pseudomonas aeruginosa COR6 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID278596	Inhibitory activity against Klebsiella pneumoniae 12-1183	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID519006	Antimicrobial activity against Escherichia coli HB101 harboring empty vector pBK-SK by broth macrodilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID584495	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae KPBj3 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID522573	Antimicrobial activity against Escherichia coli isolate 8009162 with AmpC beta-lactamase A292V mutation	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID1757805	Bactericidal activity against Carbapenem- resistant Pseudomonas aeruginosa 17-1 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID373025	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU73 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID531075	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC190 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID545405	Antimicrobial activity against Pseudomonas aeruginosa PS12 with PFGE phenotype 7B obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID565544	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-08 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID285599	Antimicrobial activity against Pseudomonas aeruginosa 2A2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID555208	Antibacterial activity against Acinetobacter genomosp. 3 isolate 69 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID562949	Antimicrobial activity against Klebsiella pneumoniae PFGE clone F expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID573349	Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID517953	Antimicrobial activity against Escherichia coli by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID544442	Antimicrobial activity against mreB-deficient Escherichia coli YLS-3 harboring empty plasmid by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID573337	Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID543423	Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID567463	Antimicrobial activity against Escherichia coli W3110 transformant harboring bla CTX-M-15 gene by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.
AID583097	Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 A64W mutant beta-lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID498872	Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
AID534174	Antimicrobial activity against armA positive Enterobacter cloacae BEH producing beta lactamase CTX-M-3 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID584694	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4946 harboring mutL mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID575322	Antimicrobial activity against Escherichia coli 06-6550TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID368321	Antibacterial activity against Klebsiella pneumoniae 4238 producing beta lactamase SHV1 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID510510	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-18 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID574427	Antimicrobial activity against Escherichia coli isolate 360 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from urine of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID573131	Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1757616	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-9 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID531587	Antibacterial activity against Proteus mirabilis obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID559899	Antimicrobial activity against Klebsiella pneumoniae 101A harboring beta-lactamase CMY-2 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID563592	Inhibition of Pseudomonas aeruginosa PAO1 PBP3 by SDS-PAGE	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID559822	Antimicrobial activity against Pseudomonas aeruginosa PU21 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID561441	Antibacterial activity against Escherichia coli 1285 harboring beta-lactamase CMY-33 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID1373289	Antimicrobial activity against Escherichia coli expressing beta-lactamase NMC-A by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID584709	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0764 harboring mucB mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID535756	Antimicrobial activity against hospital-acquired Escherichia coli obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID322319	Antibacterial activity against Escherichia coli DH5 alpha isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID520809	Antimicrobial activity against CTX-M-59 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype C by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID519798	Inhibition of Bocillin FL binding to PBP2 in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID1827144	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA100 assessed as inhibition of bacterial growth after 18 hrs in presence of oxacillin by CLSI protocol based broth microdilution assay	2022	ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3	Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID1592958	Antibacterial activity against multi-drug resistant Escherichia coli NMI 3898/15 assessed as reduction in microbial growth incubated for 20 hrs	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID1757558	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-6 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID575321	Antimicrobial activity against Salmonella Typhimurium 06-6550 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID567729	Antimicrobial activity against wild type Pseudomonas aeruginosa	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID562758	Antimicrobial activity against Klebsiella pneumoniae PFGE clone A expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID325449	Antibacterial activity against Staphylococcus aureus ATCC 3556 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID1808864	Antipseudomonal activity against pseudomonas aeruginosa Pseudomonas aeruginosa 13/09-018 (ST-175) assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID285255	Antimicrobial activity against Escherichia coli DH5-alpha CF1179 isolate expressing CMT and TEM1 by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID582978	Antimicrobial activity against ampD::lox, ampDh2::lox,ampDh3::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID573115	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID585451	Antimicrobial activity against ampD, ampDh2, ampDh3 and ampGh1 deficient Pseudomonas aeruginosa PAO1 after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID534529	Antimicrobial activity against Listeria monocytogenes KCTC 19111 after 18 hrs by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID562221	Antimicrobial activity against Desulfovibrio fairfieldensis by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Susceptibilities of 23 Desulfovibrio isolates from humans.
AID209100	In vivo activity in murine against Streptococcus pyogenes 4 infection after sc administration.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID587978	Antibacterial activity against Escherichia coli AS226 carrying pBSDN104A mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID530322	Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SL2 harboring blaVIM-13 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID368512	Ratio of Kcat to Km of Serratia marcescens SME3 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1757648	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-2 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID373762	Antibacterial activity against imipenem-resistant Acinetobacter baumannii ab1266 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID563972	Activity of Klebsiella pneumoniae 05-560 beta-lactamase NDM-1 by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID394689	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing PSE-1, MexXY-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID534623	Antimicrobial activity against ESBL producing Escherichia coli by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID495806	Antimicrobial activity against Providencia stuartii 6858 strain expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID529483	Antimicrobial activity against Enterobacter cloacae isolate 151 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID511408	Total clearance in healthy human subjects at 2 gram, iv administered in 5 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID368308	Ratio of Kcat to Km of Escherichia coli TEM1 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID546427	Activity at Pseudomonas aeruginosa PDC-2 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID565526	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-09 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1752463	Antibacterial activity against Enterobacter cloacae SR36276 producing class C beta-lactamase, AmpC assessed as reduction in microbial growth incubated for 16 to 20 hrs by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID1757857	Ratio of MBC to MIC for ESBLs negative carbapenem-negative Escherichia coli 17-7 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID283111	Antibacterial activity against ciprofloxacin-resistant Pseudomonas aeruginosa	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID583191	Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 5 mM NagZ inhibitor PUGNAc	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID573138	Antibacterial activity against erythromycin-susceptible Streptococcus agalactiae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID520807	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype A by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID535897	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JS33 harboring GyrA T83I mutant, wild-type ParC, GyrB, qnrA and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID534632	Antimicrobial activity against ESBL producing Escherichia coli assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573344	Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1757513	Antibacterial activity against Enterococcus faecalis ATCC 51299 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID498817	Antimicrobial activity against Klebsiella pneumoniae FZ49T expressing IMP-8, TEM-1, CTX-M-14, qnrB2, aac(6')-Ib by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID571231	Antimicrobial activity against Pseudomonas aeruginosa isolate TX292 harboring beta-lactamase AmpD1 11-nt deletion at nt 5064907 and frameshift mutation obtained from patient with non-cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID285580	Antimicrobial activity against Pseudomonas aeruginosa IC7 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID556649	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 4 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID559090	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii isolate A2 by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.
AID1442095	Antibacterial activity against Pseudomonas aeruginosa 26305 clinical isolate after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID533760	Antibacterial activity against OXA-30, PSE-1, VIM-2 and PER-1 producing Pseudomonas aeruginosa isolate P19 exhibiting PFGE F pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID546420	Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-5 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID499046	Antimicrobial activity against Klebsiella pneumoniae ZJ68T expressing CTX-M-15 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID558783	Antimicrobial activity against Enterobacter aerogenes assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID576289	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 16855 harboring porin OmpK36 and OmpK35 genes by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID535716	Activity of Escherichia coli TOP10 beta-lactamase AmpC-B2	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID546431	Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-2 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID245219	Minimum inhibitory concentration of compound against Escherichia coli K12AmpC-Ent in presence of compound 14	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID523969	Antibacterial activity against Burkholderia pseudomallei 1026b infected in mouse AMJ.2 cells assessed as decrease in intracellular bacterial growth at 1 ug/ml after 24 hrs by serial dilution plating technique in presence of 100 U/ml murine recombinant IFN	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1757762	Bactericidal activity against Klebsiella pneumoniae ATCC BAA-1705 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID519639	Antimicrobial activity against ceftazidime-resistant Escherichia coli Irk2322 harboring beta-lactamase CTX-M-42 Pro167Thr mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID564526	Antimicrobial activity against Acinetobacter baumannii AYE expressing VEB-1 gene by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID559586	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutM::Gm mutant gene by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID498804	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ70 deficient in KPC-2, SHV-11, CTX-M-14, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID405807	Inhibition of bocillin FL binding to penicillin-susceptible Streptococcus pneumoniae OC 8865 penicillin-binding protein 3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID529649	Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-16 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID556686	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 13 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID68541	In vitro minimum inhibitory concentration for Enterobacter cloacae (ATCC-27508) by agar dilution method	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.
AID1318931	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 92014	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID495688	Activity of Escherichia coli CTX-M-15	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID532410	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate CR-04X-14 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID562809	Antimicrobial activity against Escherichia coli J53	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID70416	In vitro antimicrobial activity against Escherichia coli TEM	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID445446	Oral bioavailability in human	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID531068	Antimicrobial activity against CTX-M-14, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC244 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID68010	Antibacterial activity against Enterobacter cloacae 265A	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID535163	Antimicrobial activity against imipenem susceptible Acinetobacter by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID585197	Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-13 K104, N170 mutant by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID529857	Antibacterial activity against Pseudomonas aeruginosa N092 expressing MexE-MexD-OprN gene and OprD mutant gene and harboring nfxC mutant gene by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID283132	Antibacterial activity against Pseudomonas aeruginosa PAO4069 expressing inducible AmpC	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID567736	Antimicrobial activity against Pseudomonas aeruginosa OC 12261 by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID511427	Total clearance in cystic fibrosis patient	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID555638	Antimicrobial activity against ampDDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID584554	Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID583020	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Enterobacter asburiae CIP 105006 plasmid carrying ACT-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID516143	Antibacterial activity against Pulsotype B Acinetobacter genomosp. 3 isolate 8 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID584698	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5003 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID535144	Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID545611	Antimicrobial activity against Pseudomonas aeruginosa PS31 with PFGE phenotype 11B obtained from skin of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID373042	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ49 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID544955	Antimicrobial activity against Klebsiella pneumoniae extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID534344	Antimicrobial activity against Burkholderia pseudomallei Bp174 harboring mini-Tn7T-bpeR+ after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID1757593	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-19 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID542773	Antimicrobial activity against Escherichia coli J53 transformed with pHNPA1 carrying qnrB6 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID584722	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3262 harboring fklB mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID372615	Activity of Escherichia coli DH5alpha beta-lactamase TEM-12 by microacidimetric method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID522568	Antimicrobial activity against Escherichia coli isolate 4009273 with AmpC beta-lactamase S287N mutation	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID571034	Antimicrobial activity against Pseudomonas aeruginosa isolate PA22 obtained from patient with cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID545452	Antimicrobial activity against extended-spectrum beta-lactamase-positive Proteus mirabilis assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID571904	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 16 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID584566	Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID559594	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutM mutant gene selected in presence of Ceftazidime by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID495734	Kcat/Km ratio of Klebsiella oxytoca Beta-lactamase K1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID530601	Antibacterial activity against Escherichia coli J53 harboring plasmid pAM carrying beta-lactamase PER-1 by Etest	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Expanded-spectrum beta-lactamase PER-1 in an environmental Aeromonas media isolate from Switzerland.
AID535063	Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-6 plasmid by agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID498835	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU4 deficient in SHV-1, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID555635	Antimicrobial activity against ampDDh2 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID529162	FIC index, ratio of MIC for Pseudomonas aeruginosa 25619 in presence of 250 ug/ml polyethylenimine to MIC for Pseudomonas aeruginosa 25619	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID562474	Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase SHV-12 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID285646	Antimicrobial activity against Pseudomonas aeruginosa 16D5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID405796	Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 2	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID546412	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-29 with PDC-8 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID495912	Hydrolytic activity of beta-lactamase VIM-19 expressed in Escherichia coli TOP10 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID584497	Antibacterial activity against porin deficient OmpA positive Klebsiella pneumoniae KPBj3 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID396026	Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID584691	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4527 harboring pilC mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID584728	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4005 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID394688	Antibacterial activity against beta-lactams resistant OprD-deficient Pseudomonas aeruginosa isolate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID1757732	Bactericidal activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-2 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID498830	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae WH103 deficient in IMP-4, TEM-1, CTX-M-3, qnrS1, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID205884	Minimal inhibitory activity against the Staphylococcus epidermidis (222)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID533534	Antimicrobial activity against Pseudomonas aeruginosa PA399 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID573342	Antibacterial activity against ceftazidime-susceptible Citrobacter freundii assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID587523	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 2 ug/ml NXL104 beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID542769	Antimicrobial activity against Escherichia coli J53 transformed with pHND1 carrying DHA-1 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID584520	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3145 harboring wbpL mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID584563	Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID546621	Antimicrobial activity against Escherichia coli harboring plasmid pPCRScript by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID1757505	Antibacterial activity against Multidrug resistant Klebsiella pneumoniae KR 15-1 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757751	Bactericidal activity against Enterobacter aerogenes 15-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1209734	Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID1757683	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-4 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID422288	Antimicrobial activity against Pseudomonas aeruginosa by almar blue assay	2009	Journal of natural products, Feb-27, Volume: 72, Issue:2	Polyoxygenated methyl cyclohexanoids from a terrestrial ampelomyces fungus.
AID556678	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 5 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1649586	Antimicrobial activity against Pseudomonas aeruginosa PAO1 in presence of 0.1 ug/ml iron by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID546413	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-30 with PDC-8 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID1407935	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 24 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID559595	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutT mutant gene selected in presence of Ceftazidime by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID285655	Antimicrobial activity against Pseudomonas aeruginosa 19D10 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID373212	Activity of Bacillus anthracis beta-lactamase Bla1	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID577650	Antimicrobial activity against Escherichia coli isolate 329T expressing beta-lactamase KPC2 and PFGE cluster 2 isolated from blood of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID368506	Activity of Escherichia coli KPC2 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID531085	Antimicrobial activity against CTX-M-14-like, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC192 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID374113	Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID523971	Antibacterial activity against Burkholderia pseudomallei 1026b infected in BALB/c mouse assessed as decrease in bacterial burden in lung at 25 mg/kg, ip administered 6 hrs postinfection at 12 hrs interval for 3 days measured after 48 hrs of bacterial infe	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID511426	Renal clearance in healthy human subjects	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID531583	Antibacterial activity against Enterobacter cloacae obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID495717	Activity of Klebsiella pneumoniae SHV-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1586257	Antibacterial activity against Haemophilus influenzae H128 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID531062	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC243 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID285680	Antimicrobial activity against Pseudomonas aeruginosa 29G8 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID544957	Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID532099	Antimicrobial against Pseudomonas aeruginosa 40198 harboring nirJ allele by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1373308	Antimicrobial activity against Escherichia coli expressing beta-lactamase SPM-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID587733	Ratio of Kcat to Km for Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-1 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID209297	In vitro antimicrobial activity against Streptococcus pyogenes SG 511	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID499045	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ68T deficient in CTX-M-15, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID508301	Inhibition of PBP6 in penicillin-resistant Enterococcus faecium D63r membranes assessed as inhibition of fluorescent ampicillin binding after 20 mins at 37 degC	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.
AID1553790	Bactericidal activity against Escherichia coli K99 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID508478	Antimicrobial activity against Pseudomonas aeruginosa isolate U9-19005 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID326201	Ratio of MIC for Pseudomonas aeruginosa PAO1 ampD-deffective mutant to MIC for Pseudomonas aeruginosa PAO1	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure.
AID285578	Antimicrobial activity against Pseudomonas aeruginosa P21.23 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1757535	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-9 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID516140	Antibacterial activity against Pulsotype M Acinetobacter genomosp. 3 isolate 5 containing IMP-1, OXA-58, ADC-43, ISAba2, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID573134	Antibacterial activity against erythromycin-nonsusceptible Streptococcus pyogenes by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524567	Antimicrobial activity against Shigella isolate DH-20369 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID584846	Activity at Aeromonas allosaccharophila AL-1 beta-lactamase PER6	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID341127	Increase in ampD gene expression in Pseudomonas aeruginosa 164M1-84C overexpressing mexCD-oprJ genes by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID1442090	Antibacterial activity against ciprofloxacin-resistant Pseudomonas aeruginosa 11411 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID1757868	Ratio of MBC to MIC for Enterobacter aerogenes 17-1 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID368310	Activity of Escherichia coli TEM1 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID544954	Antimicrobial activity against Escherichia coli extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID556698	Antimicrobial activity against multidrug resistant Escherichia coli ATCC 35218 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID524701	Antibacterial activity against Escherichia coli clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID368324	Antibacterial activity against Serratia marcescens 7554 producing beta lactamase SME3 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID546163	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-03 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID429079	Antibacterial activity against Klebsiella pneumoniae Greece producing KPC-2 beta-lactamase by E test method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID405821	Antimicrobial activity against Acinetobacter baumannii 695 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID208140	Minimum inhibitory concentration for antibacterial activity against Streptococcus pneumoniae Q19 (pen s)	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID545655	Antimicrobial activity against Stenotrophomonas maltophilia assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID560590	Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056852	Antibacterial activity against CTX-15 expressing Stenotrophomonas maltophilia isolate 125 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID1757834	Bactericidal activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID518728	Activity of Pseudomonas stutzeri beta-lactamase DIM-1 by UV-spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
AID1586254	Antibacterial activity against TolC deficient Escherichia coli 7623 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID523517	Antimicrobial activity against Pseudomonas aeruginosa isolate 1665 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1808840	Antibacterial activity against Pseudomonas aeruginosa PAO1 36/14-210 (ST-235) by broth microdilution method
AID285257	Antimicrobial activity against recombinant Escherichia coli DH5-alpha CL1295 isolate expressing pBK-TEM-151 and CMT by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID535841	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP4 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID1757806	Bactericidal activity against Carbapenem- resistant Pseudomonas aeruginosa 17-5 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID584938	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_23430 harboring mutation in putative heparinase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID499050	Antimicrobial activity against Klebsiella pneumoniae PU104T expressing TEM-1, CTX-M-15 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1757551	Antibacterial activity against Carbapenem- resistant Pseudomonas aeruginosa 17-5 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535172	Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID529495	Antimicrobial activity against Enterobacter cloacae isolate 4469 containing PFGE genetic clone C expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID584318	Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID373752	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab3 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID556674	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 1 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID535852	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ67T harboring qnrS gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID544432	Antimicrobial activity against Escherichia coli MC4100A harboring beta-lactamase AmpC by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID96430	In vitro synergistic activity against Klebsiella pneumoniae KC2 (TEM-10)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID531976	Antibacterial activity against Escherichia coli DH10B expressing KPC-2 CTX-M-2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID1516085	Antibacterial activity against ciprofloxacin-resistant Escherichia coli ATCC 25922 incubated for 18 to 24 hrs	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID562738	Antimicrobial activity against Escherichia coli K-12 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID1757498	Antibacterial activity against Escherichia coli ATCC 35218 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID558047	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S10 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID584511	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_23420 harboring mutation in putative zinc-binding dehydrogenase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID517960	Antimicrobial activity against Burkholderia sp. by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID544434	Antimicrobial activity against translocase tatC-deficient Escherichia coli B1LK0A harboring beta-lactamase AmpC by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID1757577	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-6 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID373041	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ36 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID519650	Antimicrobial activity against Escherichia coli EPI300 harboring plasmid pCC1 by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID542043	Antibacterial activity against Escherichia coli TrC B expressing Klebsiella pneumoniae B blaCTX-M beta-lactamase by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID559920	Antibacterial activity against Escherichia coli TOP10 harboring recombinant plasmid RTG4-S69 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID565722	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-27 harboring A residue at 105 position in PDC- 7 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID757554	Antibacterial activity against Enterobacter spp. assessed as growth inhibition after 18 to 22 hrs by broth microdilution method	2013	European journal of medicinal chemistry, Jul, Volume: 65	Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID495904	Antimicrobial activity in Klebsiella pneumoniae DIH-2 clinical isolate expressing beta-lactamase VIM-19 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID521992	Antimicrobial activity against Escherichia coli isolate J53 harboring pA-1 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID1447447	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis isolate CAN-ICU 61589 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID499048	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ83 deficient in SHV-11, CTX-M-14, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID535140	Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID561319	Antimicrobial activity against Escherichia coli isolate 17 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID95902	In vivo activity in murine against Klebsiella pneumoniae A infection after sc administration.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID373765	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh13 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID555681	Antimicrobial activity against Escherichia coli DH10B by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID583014	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli ECB2 plasmid carrying CMY-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID563155	Antibacterial activity against Pseudomonas aeruginosa isolate 9BR by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
AID585177	Activity of Beta-lactamase GES-2 E104, N170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID368734	Antimicrobial activity against Enterobacter aerogenes Ea1 expressing TEM-24b gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID533764	Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P11 exhibiting PFGE A pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID495667	Antimicrobial activity against wild type Klebsiella pneumoniae OC 15263 expressing beta-lactamase SHV-1 assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID535900	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JS33T harboring qnrA gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID545613	Antimicrobial activity against Pseudomonas aeruginosa PS34 with PFGE phenotype 4A obtained from blood of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID567461	Antimicrobial activity against Salmonella enterica serovar Typhi isolate 080049Ty by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.
AID528791	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 and other bla gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID325205	Antibacterial activity in CAZ-susceptible Pseudomonas aeruginosa SR24 infected ICR mouse after 7 days	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID1757761	Bactericidal activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535838	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP20 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID511390	Antibacterial activity against Proteus mirabilis by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID1447482	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P262-101856 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID429078	Antibacterial activity against Escherichia coli J53 expressing Klebsiella pneumoniae Greece blaKPC-2 gene by E test method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID518193	Antimicrobial activity against mexAB-oprM protein and mexCD-oprJ deficient Pseudomonas aeruginosa PAO253 overexpressing MexEF-OprN gene by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID369641	Antibacterial activity against Acinetobacter baumannii B clone by Etest method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
AID1668278	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 incubated for 24 hrs by photometry
AID495669	Antimicrobial activity against Escherichia coli OC 11732 expressing extended-spectrum beta-lactamase CTX-M-15 assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1757521	Antibacterial activity against Klebsiella pneumoniae ATCC BAA-1705 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID559091	Antimicrobial activity against bla OXA-66 gene-deficient Acinetobacter baumannii isolate A2 by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.
AID509865	Antibacterial activity against Acinetobacter baumannii ATCC 17978 isolated from human CSF	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID1554004	Antibacterial activity against Pseudomonas aeruginosa UFR49 measured after 16 to 20 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID555216	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 20 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID571236	Antimicrobial activity against Pseudomonas aeruginosa isolate PA367 obtained from patient with cystic fibrosis harboring beta-lactamase AmpDh3 Asp137Gly, Ala219Thr mutant by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID530348	Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID283137	Antibacterial activity against Pseudomonas aeruginosa PAO1	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID534643	Antimicrobial activity against ESBL producing Klebsiella pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573379	Antibacterial activity against beta lactamase-negative Haemophilus influenzae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1757550	Antibacterial activity against Carbapenem- resistant Pseudomonas aeruginosa 17-1 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID546416	Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-1b by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID405824	Antimicrobial activity against Acinetobacter baumannii 696 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID531592	Antibacterial activity against Serratia marcescens obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID341124	Increase in ampDh2 gene expression in Pseudomonas aeruginosa 164M1-94C overexpressing mexCD-oprJ genes by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID521297	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype A by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID544958	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID565515	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-20 harboring A residue at 105 position in PDC- 4 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1553820	Antibacterial activity against Staphylococcus aureus ATCC 29213 measured after 18 to 24 hrs in presence of NaCl	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID422499	Activity of Carnobacterium divergens BM4489 penicillinase Cad-1 at 1 uM enzyme concentration assessed as initial rate of hydrolysis by spectrophotometer	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID576311	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 29830 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID1757770	Ratio of MBC to MIC for ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-16 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID373759	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1316 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID520811	Antimicrobial activity against CTX-M-59 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype E by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID529582	Ratio of Kcat to Km for Bradyrhizobium japonicum beta-Lactamase BJP-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID584555	Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID560703	Ratio of Kcat to Km for Escherichia coli MC4100 Beta-Lactamase CMY-2	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID576271	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18567 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID521836	Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID200880	In vitro minimum inhibitory concentration for Salmonella Typhimurium (ATCC-14028) by agar dilution method	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.
AID563977	Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase VIM2	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID560593	Antimicrobial activity against rifampin-resistant Pseudomonas aeruginosa ATCC 27853 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID587730	Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID523491	Antimicrobial activity against Pseudomonas aeruginosa Z799/61 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID523964	Antibacterial activity against Burkholderia pseudomallei 1026b infected in mouse AMJ.2 cells assessed as intracellular bacterial count at 10 ug/ml after 24 hrs by serial dilution plating technique in presence of 100 U/ml murine recombinant IFN-gamma (Rvb	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID534663	Antimicrobial activity against ESBL producing Proteus mirabilis by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID561932	Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate N50 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID283129	Antibacterial activity against Pseudomonas aeruginosa 22029 expressing metallo beta lactamase	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID1335734	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 16 to 20 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids.
AID511289	Antibacterial activity against Escherichia coli DH5alpha pB-ges-1	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID521300	Antimicrobial activity against SHV-5 producing Klebsiella pneumoniae with PFGE pulsotype D by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID1808870	Antipseudomonal activity against pseudomonas aeruginosa Pseudomonas aeruginosa PAHUAC-27(ST-22) assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID529585	Antibacterial activity against Escherichia coli TP1 harboring pBR322 carrying TEM-10 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Fitness trade-offs in blaTEM evolution.
AID531766	Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4677 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID495903	Antimicrobial activity in Escherichia coli DIH-1 expressing beta-lactamase VIM-19 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID529656	Ratio of Kcat to Km for Pseudomonas aeruginosa 9551 beta-lactamase VIM-15	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID374361	Antimicrobial activity against Escherichia coli DH5alpha expressing pJDB2 containing Aeromonas caviae A324R metallo-beta-lactamase gene by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID520883	Activity of Achromobacter xylosoxidans CIP69598 beta-lactamase OXA-114a expressed in Escherichia coli TOP10 assessed as compound hydrolysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID524715	Antibacterial activity against Stenotrophomonas maltophilia clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID532163	Antimicrobial activity against aac(6')-Ib-cr-negative Escherichia coli PU12T harboring wild-type GyrA, GyrB, ParC and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID587529	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 2 ug/ml NXL104 beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID530347	Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID529491	Antimicrobial activity against Enterobacter cloacae isolate 649 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID534919	Antimicrobial activity against Ceftazidime susceptible Serratia marcescens by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1171223	Ratio of MIC for wild-type Escherichia coli to MIC for tolC-deficient Escherichia coli	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID1752484	Antibacterial activity against Klebsiella pneumoniae JMI:211 producing class A beta lactamase, KPC-2 assessed as reduction in microbial, growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID583084	Activity of Escherichia coli BL21(DE3) VIM-2 W87F mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID524710	Antibacterial activity against Salmonella sp. by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID495822	Antimicrobial activity against Klebsiella pneumoniae 6828 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID555650	Ratio of MIC for ampD gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method presence of 0.5 mM nagZ inhibitor EtBuPUG to MIC for ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 in absence of nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID583017	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli ECB-1 plasmid carrying ACC-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID573122	Antibacterial activity against coagulase-negative and oxacillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1757752	Bactericidal activity against Enterobacter aerogenes 15-4 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1553781	Antifungal activity against Candida albicans cgmcc2.2086 measured after 48 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID534112	Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm1980	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID545464	Antimicrobial activity against Pseudomonas fluorescens assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID368480	Antibacterial activity against Enterobacter cloacae 908R producing beta lactamase AmpC by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID529856	Antibacterial activity against Pseudomonas aeruginosa N091 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID523890	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID544539	Antimicrobial activity against Escherichia coli DH5[alpha] by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID542771	Antimicrobial activity against Escherichia coli J53 transformed with pHND3 carrying qnrB6 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID546425	Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-5 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID1373283	Antimicrobial activity against Escherichia coli expressing beta-lactamase GES-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID519747	Activity of Klebsiella pneumoniae Beta-Lactamase SHV-72	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID573350	Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID368309	Activity of Escherichia coli TEM1 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID559825	Antimicrobial activity against Escherichia coli J53 harboring pCHE-B plasmid expressing blaSHV-5 gene by agar dilution in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID528608	Ratio of Kcat to Km for Escherichia coli 2138 beta-lactamase KPC-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID531077	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC214 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID1752461	Antibacterial activity against Escherichia coli NIHJ JC-2 assessed as reduction in microbial growth incubated for 16 to 20 hrs by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID495662	Ratio of Kcat to Km for Pseudomonas aeruginosa 531 beta-lactamase BEL-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID498822	Antimicrobial activity against Klebsiella pneumoniae WH77 expressing IMP-4, TEM-1, SHV-14, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID555662	Antimicrobial activity against Salmonella enterica serotype Westhampton isolate 04CEB8273SAL expressing CTX-M-53 gene by disk diffusion method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID325196	Antibacterial activity against Haemophilus influenzae ATCC 49766 by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID1209735	Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID564686	Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID285601	Antimicrobial activity against Pseudomonas aeruginosa 2A3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID555228	Ratio of Kcat to Km for Acinetobacter genomosp. 3 isolate 195 ADC-18	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1309045	Antifungal activity against clinical isolates of Candida albicans SC5314 after 48 hrs by broth microdilution method	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	Synthesis of riccardin D derivatives as potent antimicrobial agents.
AID422494	Antimicrobial activity against Escherichia coli BL21 (DE3) by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID531579	Antibacterial activity against Micrococcus spp. obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID1757829	Bactericidal activity against carbapenem-sensitive Pseudomonas aeruginosa 17-7 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757628	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-8 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID528792	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 and other bla gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID585436	Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID682281	TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.02 uM, Ceftazidime: 2500 uM) in OCTN2-expressing HeLa cells	2000	The Journal of biological chemistry, Jan-21, Volume: 275, Issue:3	beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
AID511407	Mean residence time in cystic fibrosis patient at 2 gram, iv administered in 5 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID530340	Activity of Pseudomonas aeruginosa VIM-1 beta-lactamase	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID522005	Antimicrobial activity against Klebsiella pneumoniae isolate KpI-1 expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID562813	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID585198	Antimicrobial activity against Escherichia coli DH5[alpha] by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID499047	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ69 deficient in SHV-28, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID522000	Antimicrobial activity against Escherichia coli isolate J53 harboring p4A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID524700	Antibacterial activity against Enterobacter cloacae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID554399	Antimicrobial activity against Pseudomonas aeruginosa isolate 2858 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID285258	Antimicrobial activity against recombinant Escherichia coli DH5-alpha CL1179 isolate expressing pBK-TEM-152 and CMT by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID285689	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4012 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID531314	Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID562766	Antimicrobial activity against Escherichia coli DH10B transformant harboring blaTEM-168 gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID563590	Inhibition of Pseudomonas aeruginosa PAO1 PBP1c by SDS-PAGE	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID544441	Antimicrobial activity against mreB-deficient Escherichia coli YLS-3 harboring beta-lactamase AmpC by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID425865	Antimicrobial activity against Carnobacterium divergens BM4489 expressing beta-lactamase CAD1 at 0.5 McFarland inoculum size by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID495914	Hydrolytic activity of beta-lactamase VIM-1 expressed in Escherichia coli TOP10 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID523976	Antibacterial activity against Burkholderia pseudomallei 1026b infected in BALB/c mouse assessed as increase in survival rate at 25 mg/kg, ip administered 6 hrs postinfection at 12 hrs interval for 3 days measured on day 60 in presence of murine recombina	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID534297	Antimicrobial activity against Pseudomonas aeruginosa isolate PA481 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID540948	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c2 plasmid expressing cephalosporinase CMY-2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID368945	Elimination rate constant in mouse	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID520696	Antimicrobial activity against Escherichia coli DH10B harboring p041060 carrying qepA gene by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID508730	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C9 GM1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID571914	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 21 expressing ampC, ompA, adeB, adeM, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID565525	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-10 harboring A residue at 105 position in PDC- 2 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID519658	Antimicrobial activity against Escherichia coli EPI300 Irk1224 type 2 mutant harboring beta-lactamase CTX-M-3 Ser167 mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID575330	Antimicrobial activity against Salmonella Typhimurium 08-2211 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID285606	Antimicrobial activity against Pseudomonas aeruginosa 2A7 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID520778	Antibacterial activity against beta-lactamase KPC-2 producing Escherichia coli isolate E1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID372344	Antibacterial activity against Pseudomonas aeruginosa PAO1 in in vitro PK/PD model assessed as AAC (0 to 24 hrs) at 2 g infused thrice daily at 8 hrs interval	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID532392	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-21 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID368483	Antibacterial activity against Pseudomonas aeruginosa 4352 producing beta lactamase AmpC by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID529601	Antibacterial activity against Escherichia coli TP1 harboring pBR322 carrying TEM-10 assessed as inhibition of bacterial growth at >64 ug/ml after 18 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Fitness trade-offs in blaTEM evolution.
AID584556	Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID608253	Antibacterial activity against 1 x 10'4 cfu/mL Escherichia coli ATCC 11303 after 24 hrs by NCCLS M7-A6 microtiter broth dilution method	2011	European journal of medicinal chemistry, Aug, Volume: 46, Issue:8	Synthesis and antimicrobial evaluation of new benzofuran derivatives.
AID1757840	Ratio of MBC to MIC for Carbapenem- resistant Acinetobacter baumannii 17-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID70637	In vitro minimum inhibitory concentration against Escherichia coli (DC0 parent organism).	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID368736	Antimicrobial activity against Enterobacter aerogenes Ea2 expressing TEM-3 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID529163	Antibacterial activity against Pseudomonas aeruginosa 100609 assessed as reduction in bacterial count at 0.25 times MIC after 9 hrs by time-kill assay in presence of 250 ug/ml polyethylenimine relative to control	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID535882	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN132T harboring qnrB gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID545606	Antimicrobial activity against Pseudomonas aeruginosa PS25 with PFGE phenotype 1A obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID585439	Antimicrobial activity against ampGh1 deficient Pseudomonas aeruginosa PAO1 after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID613258	Antibacterial activity against Bacillus subtilis ATCC 33712 after 24 hrs by NCCLS M7-A6 broth dilution method	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.
AID285631	Antimicrobial activity against Pseudomonas aeruginosa 10A6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID495808	Antimicrobial activity against Escherichia coli DH5alpha 2878 transformant expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID535139	Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID422882	Antimicrobial activity against Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis by broth microdilution assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
AID518817	Antibacterial activity against Acinetobacter genomosp. 3 isolates assessed as percent of resistance isolates by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID405643	Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 2	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID585450	Antimicrobial activity against ampD, ampDh2, ampDh3 and ampG deficient Pseudomonas aeruginosa PAO1 harboring pUCP24 conferring resistance to gentamycin after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID373061	Antimicrobial activity against Escherichia coli BL21(DE3) by agar-dilution technique in presence of beta-lactamase inhibitor clavulanic acid	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID1379935	Antibacterial activity against Klebsiella oxytoca assessed as inhibition of microbial growth incubated for 18 to 22 hrs by broth microdilution method	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID1757549	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-13 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID373210	Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID534927	Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1757504	Antibacterial activity against Klebsiella pneumoniae ATCC BAA-1705 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1300873	Antibacterial activity against Streptococcus alpha-hemolyticus clinical isolate after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID301093	Antibacterial activity against CAZ susceptible Pseudomonas aeruginosa SR24 infected in mouse after 7 days	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID405818	Antimicrobial activity against Acinetobacter sp. 5248 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID583083	Activity of Escherichia coli BL21(DE3) VIM-2 W87A mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID511292	Ratio of Kcat/Km for Pseudomonas aeruginosa GES-13 beta lactamase assessed as hydrolysis by spectrometry	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID1586265	Antibacterial activity against Staphylococcus aureus WCUH29 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID554991	Antibacterial activity against Acinetobacter genomosp. 3 isolate 67 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID285681	Antimicrobial activity against Pseudomonas aeruginosa 29H1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID531080	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC225 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID532397	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D isolate VA-06X-69 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID559900	Antimicrobial activity against Klebsiella pneumoniae 278 harboring beta-lactamase OXY-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID524712	Antibacterial activity against Pseudomonas aeruginosa clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID573203	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID532898	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID584560	Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1757650	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-4 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID571228	Antimicrobial activity against Pseudomonas aeruginosa isolate GB57 harboring beta-lactamase AmpD1 Val10Ile mutant obtained from patient with non-cystic fibrosis by Etest	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID524703	Antibacterial activity against Klebsiella pneumoniae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID554388	Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY F29S mutant by twofold macrodilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID562570	Antimicrobial activity against SHV-5 ESBL producing Escherichia coli clinical isolate by CLSI disk diffusion assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania.
AID499063	Antimicrobial activity against Escherichia coli HX74T expressing CTX-M-3 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID583186	Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 0.5 mM NagZ inhibitor PUGNAc	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID584734	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4745 harboring nusA mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1757807	Bactericidal activity against Carbapenem- resistant Pseudomonas aeruginosa 17-8 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757634	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-4 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID323041	Antimicrobial activity against extended-spectrum-beta-lactamase producing Proteus mirabilis isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID1757654	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-8 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534534	Antimicrobial activity against Salmonella enterica KCTC 2930 after 18 hrs by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID368745	Antimicrobial activity against Escherichia coli Ec8 expressing TEM-21 AmpC gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID529481	Antimicrobial activity against Enterobacter cloacae isolate 18 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID559260	Antibacterial activity against non-ciprofloxacin-susceptible Pseudomonas aeruginosa by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID529499	Antimicrobial activity against Escherichia coli GeneHogs by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID324361	Activity of Acinetobacter johnsonii SCO1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID368729	Activity of Pseudomonas aeruginosa AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID586057	Antimicrobial activity against Acinetobacter baumannii clinical isolate harboring plasmid encoded ISAba1-blaOXA-51-like gene with nuc upstream sequence by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
AID546429	Activity at Pseudomonas aeruginosa PDC-5 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID1330474	Ratio of AUC in mouse epithelial lining fluid to AUC in mouse serum	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.
AID558046	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S9 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID283135	Antibacterial activity against Pseudomonas aeruginosa KG4545 producing MexXY efflux pump	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID585396	Ratio of Kcat to Km for Bradyrhizobium japonicum metallo-beta-lactamase BJP-1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID301089	Antibacterial activity against penicillin resistant Streptococcus pneumoniae SR-16675 after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID373050	Antimicrobial activity against Bacillus clausii NR expressing beta-lactamase BCL1 by agar-dilution technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID422286	Antimicrobial activity against Escherichia coli by almar blue assay	2009	Journal of natural products, Feb-27, Volume: 72, Issue:2	Polyoxygenated methyl cyclohexanoids from a terrestrial ampelomyces fungus.
AID394492	Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc4 plasmid by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID532389	Antibacterial activity against VIM-1 producing Enterobacter cloacae isolate TO-16X-51 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID571924	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 26 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID534650	Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1407928	Antibacterial activity against Haemophilus influenzae ATCC 49247 after 24 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID586086	Antimicrobial activity against verocytotoxin-producing Escherichia coli isolate O157 obtained from animals and food assessed as percentage of resistant isolates by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
AID283109	Antibacterial activity against ceftazidime-resistant Pseudomonas aeruginosa	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID567731	Antimicrobial activity against Pseudomonas aeruginosa OC 4351 by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID341112	Antibacterial activity against Pseudomonas aeruginosa 164M1	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID517958	Antimicrobial activity against Serratia marcescens by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID554439	Ratio of MIC for Pseudomonas aeruginosa 2858 to MIC for Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID529575	Activity of Erwinia carotovora subsp. atroseptica DSM 30184 beta-lactamase CAR-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID565769	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 151 fold elevated mexX expression and 127 fold elevated mexY expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID1757866	Ratio of MBC to MIC for Enterobacter cloacae 17-9 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID374364	Antimicrobial activity against Aeromonas caviae A324R expressing metallo-beta-lactamase IMP-19 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID565532	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-03 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID341110	Increase in ampC gene expression in mexCD-oprJ overexpressing Pseudomonas aeruginosa 164M1-94C harboring p26PAD1 plasmid containing ampD gene by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID532912	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID285679	Antimicrobial activity against Pseudomonas aeruginosa 29G7 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID368543	Activity of Pseudomonas aeruginosa 18SH AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID404965	Activity of OXA58 from Acinetobacter baumannii 193 isolate carrying two bla-OXA58 gene copy assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID564451	Antimicrobial activity against Pseudomonas aeruginosa isolate 1036 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID555646	Antimicrobial activity against ampDDh2 and ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs using 30 ug/ml by agar diffusion method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID577004	Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as viable bacterial count by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID285671	Antimicrobial activity against Pseudomonas aeruginosa 24E2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID757557	Antibacterial activity against Staphylococcus faecalis assessed as growth inhibition after 18 to 22 hrs by broth microdilution method	2013	European journal of medicinal chemistry, Jul, Volume: 65	Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID1808813	Antibacterial activity against Pseudomonas aeruginosa PAO1 deltaDdeltsDh2deltaDh3 by broth microdilution method
AID558802	Antimicrobial activity against extended spectrum beta-lactamase-deficient Klebsiella oxytoca assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID573388	Antibacterial activity against Pasteurella multocida by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID517959	Antimicrobial activity against Acinetobacter sp. by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID571939	Antimicrobial activity against Escherichia coli MC4100 expressing promoterless beta-lactamase GES-1 by Etest	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID573399	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1553774	Antibacterial activity against Escherichia coli K99 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID495514	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4668 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID533563	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA758 isolated from patient with cystic fibrosis	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID584519	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3141 harboring wbpM mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID571935	Antimicrobial activity against Escherichia coli MC4100 harboring promoter hybrid 2 in beta-lactamase GES-1 by Etest	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID1757846	Ratio of MBC to MIC for Carbapenem-resistant Klebsiella pneumoniae KR 15-6 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID394488	Activity of Hafnia alvei beta-lactamase ACC-1 assessed as nmol of compound hydrolysis per ug of protein	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID556672	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 27 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID585397	Activity at Stenotrophomonas maltophilia 1SML metallo-beta-lactamase L1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID520879	Antibacterial activity against Achromobacter xylosoxidans DUC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID1887539	Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 16 to 18 hrs by broth microdilution method	2022	Journal of natural products, 10-28, Volume: 85, Issue:10	Developing the Natural Prenylflavone Artocarpin from
AID1757791	Ratio of MBC to MIC for carbapenem-sensitive Pseudomonas aeruginosa 17-29 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757721	Bactericidal activity against Carbapenem- resistant Acinetobacter baumannii 17-5 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID584708	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0503 harboring mutation in Putative biotin synthesis protein BioC by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID342024	Antibacterial activity against Klebsiella pneumoniae NK29 assessed as inhibition zone diameter by CLSI disk diffusion confirmatory test	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID511405	Cmax in cystic fibrosis patient at 2 gram, iv administered in 5 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID573199	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T380C mutant gene selected at 0.5 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1757881	Ratio of MBC to MIC for Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1808867	Antipseudomonal activity against pseudomonas aeruginosa Pseudomonas aeruginosa 53/22-113 (ST-244) assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID543412	Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID531565	Antibacterial activity against Enterococcus faecalis obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID496009	Antimicrobial activity against tobramycin resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID207123	In vitro synergistic activity against Stenotrophomonas maltophilia 1712(L1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID368536	Activity of Providencia stuartii AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID511586	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant and deficient in ampD gene by selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution metho	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID531313	Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID574436	Antimicrobial activity against Escherichia coli isolate 547T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from blood of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1442096	Cytotoxicity in mouse RAW264.7 cells after 24 hrs by MTT assay	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID523498	Antimicrobial activity against Pseudomonas aeruginosa isolate 14169c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID535720	Activity of Escherichia coli TOP10 beta-lactamase AmpC-A	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID562473	Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase KPC-2/TEM-1 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID351197	Antimicrobial activity against drug-resistant Acinetobacter baumannii producing PER1 beta-lactamase	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Global challenge of multidrug-resistant Acinetobacter baumannii.
AID534526	Antimicrobial activity against Bacillus subtilis KCTC 2213 after 18 hrs by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID1649584	Antimicrobial activity against Escherichia coli clinical isolates by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID250296	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH21; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID530813	Antibacterial activity against Escherichia coli J53 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID561446	Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK carrying beta-lactamase CMY-2 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID582973	Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID66222	Minimum inhibitory concentration in Enterobacter cloacae, DR 401108 constitutive depressed type 1 lactamase producer	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID546167	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-07 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID584914	Activity of Beta-lactamase in Pseudomonas aeruginosa PA14 PA3047 harboring complemented dacB mutant gene assessed as nitrocefin hydrolysis per mg of protein by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID330962	Antimicrobial activity against wild type Escherichia coli in medium containing EtbuPUG by serial dilution method	2007	The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29	Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID559526	Antibacterial activity against Acinetobacter lwoffii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1757734	Bactericidal activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-12 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535832	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP61 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID534168	Antimicrobial activity against Escherichia coli TOP10 harboring plasmid VOG2 expressing CTX-M-14 and AAC(6 )-Ib gene by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID558039	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S2 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID511409	Volume of distribution at steady state in healthy human subjects at 2 gram, iv administered in 5 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID565766	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 7 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID587629	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=512:128 mg/kg, sc compound to NXL1	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID285604	Antimicrobial activity against Pseudomonas aeruginosa 2A6 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID283118	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM5	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID510513	Antibacterial activity against Escherichia coli ATCC 25922 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID1553821	Antibacterial activity against Staphylococcus aureus ATCC 29213 measured after 18 to 24 hrs in presence of KCl	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID573123	Antibacterial activity against coagulase-negative and oxacillin-resistant Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID613260	Antifungal activity against Candida albicans ATCC 10231 after 24 hrs by NCCLS M38-P broth dilution method	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.
AID530339	Activity of Pseudomonas aeruginosa VIM-13 beta-lactamase	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID301085	Antibacterial activity against AmpC hyperproducing Pseudomonas aeruginosa SR24-12 after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID529498	Antimicrobial activity against Escherichia coli T-781 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID571036	Antimicrobial activity against Pseudomonas aeruginosa isolate PA367 obtained from patient with cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID757552	Antibacterial activity against Klebsiella oxytoca assessed as growth inhibition after 18 to 22 hrs by broth microdilution method	2013	European journal of medicinal chemistry, Jul, Volume: 65	Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID1757572	Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-19 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534109	Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm0527	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID543416	Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID549352	Antimicrobial activity against Escherichia coli isolate 49 harboring bla CTX-M-3a gene by broth microdilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID561657	Antimicrobial activity against Pseudomonas aeruginosa isolate OC14805 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID164246	Antibacterial activity against Pseudomonas aeruginosa X528	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID524435	Antimicrobial activity against Shigella isolate DH-13291 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID1757675	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-12 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID549350	Antimicrobial activity against Escherichia coli isolate 100 harboring bla CTX-M-3a gene by broth microdilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID559086	Antibacterial activity against ciprofloxacin-susceptible Pseudomonas aeruginosa by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID325195	Antibacterial activity against imipenem-resistant Pseudomonas aeruginosa SR-6554 by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID518192	Antimicrobial activity against mexAB-oprM protein and mexCD-oprJ deficient Pseudomonas aeruginosa PAO238 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID559597	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene selected in presence of tobramycin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID517950	Antimicrobial activity against Proteus vulgaris by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1300871	Antibacterial activity against Staphylococcus warneri clinical isolate after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID301082	Antibacterial activity against Enterobacter cloacae ATCC 13047 after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID535864	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ47T harboring qnrB gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID495816	Antimicrobial activity against Escherichia coli 2603 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID325189	Antibacterial activity against Toho 2 producing Escherichia coli by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID559821	Antimicrobial activity against Pseudomonas aeruginosa PU21 harboring pCHE-A plasmid expressing blaGES-5 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID573385	Antibacterial activity against beta lactamase-positive Moraxella catarrhalis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID565199	Antimicrobial activity against Klebsiella pneumoniae isolate T-1780 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID545437	Antimicrobial activity against extended-spectrum beta-lactamase-negative Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID495828	Antimicrobial activity against Escherichia coli C600 2878 transconjugate expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID534299	Antimicrobial activity against Pseudomonas aeruginosa isolate PA510 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1752475	Antimicrobial activity against Enterobacterales producing KPC assessed as reduction in microbial growth measured after 16 to 20 hrs in presence of avibactam by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID285619	Antimicrobial activity against Pseudomonas aeruginosa 5G3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID340887	Antimicrobial activity against Escherichia coli JM83 harboring pACYC184-ATEM by serial dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cytoplasmic-membrane anchoring of a class A beta-lactamase and its capacity in manifesting antibiotic resistance.
AID324856	Antimicrobial activity against Acinetobacter baumannii A24 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID559602	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutM mutant gene selected in presence of ciprofloxacin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1056842	Antibacterial activity against TEM-1/SHV-12/CTX-15 expressing Enterobacter intermedius isolate 243 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID394494	Antimicrobial activity against Escherichia coli MC4100 harboring pACYC184 plasmid by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID574428	Antimicrobial activity against Escherichia coli isolate 360T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from urine of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID567310	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2201 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID250295	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH20; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID1757681	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-22 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID583189	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 5 mM NagZ inhibitor PUGNAc	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID1752480	Antibacterial activity against Escherichia coli SR34100 producing class A beta lactamase, CTX-M-15 assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID555671	Antimicrobial activity against Escherichia coli DH5[alpha] harboring recombinant plasmid carrying CTX-M-53 gene by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID544433	Antimicrobial activity against Escherichia coli CU164A harboring beta-lactamase AmpC by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID95717	In vitro antimicrobial activity against Klebsiella aerogenes 1522 E	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID511578	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID573212	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB C25T mutant gene selected at 1 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1516019	Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID545394	Antimicrobial activity against OprD overproducing Pseudomonas aeruginosa PAO1 expressing mexA and oprD by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1757597	Antibacterial activity against Enterobacter cloacae 17-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID544959	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID573209	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB G539A mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID529304	Antimicrobial activity against Acinetobacter baumannii isolate Ac058 expressing beta-lactamase Oxa-58 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
AID564457	Antimicrobial activity against Pseudomonas aeruginosa isolate 878 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID1757787	Ratio of MBC to MIC for carbapenem-sensitive Pseudomonas aeruginosa 17-7 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID529161	FIC index, ratio of MIC for Pseudomonas aeruginosa 100609 in presence of 250 ug/ml polyethylenimine to MIC for Pseudomonas aeruginosa 100609	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID532098	Antimicrobial against Pseudomonas aeruginosa 1494 harboring phnA allele by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID322324	Antibacterial activity against Escherichia coli INSRA5924 isolates expressing CTX-M-32 and TEM-1B enzymes by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID567747	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 9 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID324854	Antimicrobial activity against Acinetobacter baumannii A24 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID1757750	Bactericidal activity against Enterobacter aerogenes 17-4 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534867	Antimicrobial activity against ESBL producing Proteus mirabilis assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID531591	Antibacterial activity against Salmonella spp. obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID156120	Affinity for penicillin binding protein 2 of Escherichia coli UB1005 (DC0) was evaluated.	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.
AID528602	Antimicrobial activity against blaKPC-2, blaKLUC-2 and blaTEM-1 producing Enterobacter cloacae 7506 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID544438	Antimicrobial activity against Escherichia coli MC4100A expressing beta-lactamase TEM-1 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID565506	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-24 harboring A residue at 105 position in PDC- 5 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID534527	Antimicrobial activity against Micrococcus luteus KCTC 9341 after 18 hrs by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID530326	Antimicrobial activity against Escherichia coli XL1-Blue harboring pUCP carrying VIM-1 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID1752456	Antibacterial activity against Escherichia coli BL21(DE3) transfected with pET9a vector harboring class A beta lactamase, CTX-M-15 incubated for 16 to 20 hrs by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID368489	Activity of Klebsiella pneumoniae SHV1 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID520882	Antibacterial activity against Escherichia coli TOP10 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID535753	Antimicrobial activity against community-acquired Klebsiella pneumoniae expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID542523	Antimicrobial activity against Pseudomonas aeruginosa PAO1 infected in in vitro pharmacodynamic model assessed as bacterial killing at 4 mg/L after 8 hrs using 10'6 CFU/ml inoculum by time kill study	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.
AID283136	Antibacterial activity against Pseudomonas aeruginosa KG4001 producing MexEF-OprN efflux pump	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID1757812	Bactericidal activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-17 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID330966	Antimicrobial activity against ampD deficient Escherichia coli in medium containing EtbuPUG by serial dilution method	2007	The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29	Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID558786	Antimicrobial activity against Citrobacter freundii assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID1442087	Antibacterial activity against Pseudomonas aeruginosa CICC 10419 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID534648	Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584501	Antibacterial activity against porin deficient OmpA positive Klebsiella pneumoniae KPBj5 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID1757653	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-7 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID529586	Antibacterial activity against Escherichia coli TP1 harboring pBR322 carrying TEM-12 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Fitness trade-offs in blaTEM evolution.
AID529645	Antimicrobial activity against Pseudomonas aeruginosa 166301 expressing beta-lactamase VIM-16 obtained from urine of patient by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID546176	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-16 with PDC-3 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID373038	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate NJ59 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID562816	Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID565517	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-18 harboring A residue at 105 position in PDC- 3 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID285443	Ratio of kcat to Km of Citrobacter gillenii CIP 106783 Beta-lactamase GIL1 expressed in Escherichia coli DH10B relative to benzyl-penicillin	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID535754	Antimicrobial activity against hospital-acquired Klebsiella pneumoniae expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID531081	Antimicrobial activity against CTX-M-15,OXA-30 beta-lactamase producing Escherichia coli isolate CUMC245 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID564211	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring cloned pUCPOXA-2 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID1757594	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-20 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID429077	Antibacterial activity against Escherichia coli J53 by E test method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID559070	Antibacterial activity against Acinetobacter calcoaceticus by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573120	Antibacterial activity against coagulase-negative and oxacillin-susceptible Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1757809	Bactericidal activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-6 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID545422	Antimicrobial activity against Citrobacter freundii obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID69808	In vitro minimum inhibitory concentration for Escherichia coli (ATCC-10536) by agar dilution method	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.
AID372358	%T>MIC against Pseudomonas aeruginosa PAO1 in in vitro PK/PD model at 2 g infused thrice daily at 8 hrs interval	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID518522	Antimicrobial activity against Capnocytophaga sputigena CIP 104301T after 2 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID555667	Antimicrobial activity against Escherichia coli DH10B harboring natural plasmid pWES-1 carrying CTX-M-53 gene by disk diffusion method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID495656	Antimicrobial activity against Escherichia coli TOP10 expressing recombinant beta-lactamase BEL-2 by solid agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID52958	In vitro minimum inhibitory concentration required to produce antibacterial activity against Citrobacter freundii 902	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID522023	Antimicrobial activity against Citrobacter freundii isolate expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID573206	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T562C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID523967	Antibacterial activity against Burkholderia pseudomallei 1026b infected in mouse AMJ.2 cells assessed as intracellular bacterial load at 10 ug/ml after 24 hrs by serial dilution plating technique in presence of 1000 U/ml murine recombinant IFN-gamma (Rvb	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID279814	Antimicrobial activity against Escherichia coli DH5-alpha with pYW2 expressing KPC2 and TEM1 gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID533558	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA381	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1808854	Antipseudomonal activity against pseudomonas aeruginosa PAO deltadacBdeltaampD assessed as AmpC RNA expression by RT-PCR analysis Pseudomonas aeruginosa PAO1
AID519647	Antimicrobial activity against Escherichia coli AB14156 harboring beta-lactamase CTX-M-42 Pro167Thr mutant gene by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID164081	In vivo activity in murine against Pseudomonas aeruginosa 5712 infection after sc administration.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID2914	The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID495813	Antimicrobial activity against Escherichia coli 138 expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID585193	Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-1 E104, G170 mutant by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID68870	In vitro synergistic activity against Escherichia coli 300 (no beta-lactamase, imp mutant)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID532398	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D1 isolate VA-06X-63 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID555203	Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID649219	Antibacterial activity against Pseudomonas aeruginosa clinical isolates after 16 to 20 hrs by broth microdilution method	2012	Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2	Potent inhibitors of LpxC for the treatment of Gram-negative infections.
AID24087	The half life period was tested	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID368492	Activity of Escherichia coli CTX-M-15 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID372323	Antibacterial activity against hypermutable Pseudomonas aeruginosa isolate 12-09-15 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID374026	Ratio of Kcat to Km for Klebsiella pneumoniae KPC-1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID559819	Antimicrobial activity against Escherichia coli J53 harboring pCHE-B plasmid expressing blaSHV-5 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID587637	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=32:8 mg/kg, sc compound to NXL104	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID1757576	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-5 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID528921	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-14 and CTX-M-27 gene and other bla gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID495695	Activity of Klebsiella pneumoniae KPC-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID531780	Antibacterial activity against Pseudomonas aeruginosa obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID533536	Antimicrobial activity against Pseudomonas aeruginosa PA554 expressing GIM-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID565519	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-16 harboring A residue at 105 position in PDC- 3 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID283130	Antibacterial activity against Pseudomonas aeruginosa FP1380 expressing constitutive AmpC	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID323037	Antimicrobial activity against extended-spectrum-beta-lactamase producing Escherichia coli isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID559272	Antimicrobial activity against Proteus vulgaris Pv9 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID511388	Antibacterial activity against Klebsiella pneumoniae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID554398	Antimicrobial activity against Pseudomonas aeruginosa isolate 2804 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1373305	Antimicrobial activity against Escherichia coli expressing beta-lactamase IMP-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID498802	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ18 deficient in KPC-2, SHV-28, DHA-1, ompK35 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID573205	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1757689	Antibacterial activity against Enterobacter cloacae 17-1 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID544961	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID50561	Minimum inhibitory concentration in Citrobacter freundii, I+382010 inducible type 1 lactamase producer	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID559897	Antimicrobial activity against Klebsiella oxytoca KO280 harboring beta-lactamase OXY-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID543424	Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID563583	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID520803	Antimicrobial activity against Escherichia coli str. K-12 substr. DH10B harboring plasmid CTX-M-2	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID564685	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID534175	Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid BEH by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID561328	Antimicrobial activity against Klebsiella pneumoniae isolate 202 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID564466	Antimicrobial activity against Pseudomonas aeruginosa isolate 821 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID1757811	Bactericidal activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-16 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID573383	Antibacterial activity against beta lactamase-positive Haemophilus influenzae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID520776	Antibacterial activity against beta-lactamase KPC-2 producing Serratia marcescens isolate S1 to S21 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID1757662	Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 15-2 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID394683	Antibacterial activity against Pseudomonas aeruginosa clinical isolate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID563967	Antibacterial activity against Escherichia coli TOP10 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID250259	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH03; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID373770	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh26 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID533758	Antibacterial activity against PER-1 producing Pseudomonas aeruginosa isolate P170 exhibiting PFGE G pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID245354	Minimum inhibitory concentration of compound against Pseudomonas aeruginosa derepressed 88/98 in presence of compound 12	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID511669	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID565283	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring plasmid pA1 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID529492	Antimicrobial activity against Enterobacter cloacae isolate 658 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID531675	Antimicrobial activity against Escherichia coli DH5alpha by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID533548	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA356	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID279186	Activity of Enterobacter cloacae S3 isolate beta lactamase LAP1 expressed in Escherichia coli DH10B	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.
AID373757	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1308 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID543432	Inhibition of Shigella sonnei UIH-1 beta-lactamase CTX-M-64 by spectrophotometry in presence of 100 uM nitrocefin	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1757677	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-15 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1586253	Antibacterial activity against Escherichia coli 7623 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID325444	Antibacterial activity against Escherichia coli K12 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID584745	Activity of Beta-lactamase in Pseudomonas aeruginosa PAO1 PA3047 harboring dacB mutant gene assessed as nitrocefin hydrolysis per mg of protein by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID585400	Ratio of Kcat to Km for Fluoribacter gormanii 1K07 metallo-beta-lactamase FEZ-1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID524702	Antibacterial activity against Klebsiella oxytoca clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID511290	Antibacterial activity against Escherichia coli DH5alpha	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID524931	Antimicrobial activity against Escherichia coli MI1443 harboring P167S and D240G mutations in beta lactamase CTX-M-10 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID519800	Inhibition of Bocillin FL binding to PBP4 in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID567326	Antimicrobial activity against Escherichia coli ML4901 by broth dilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID372605	Antibacterial activity against Escherichia coli BER1 producing beta-lactamase pI 5.2 and pI 5.4 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID404967	Activity of OXA58 from Acinetobacter baumannii 186 isolate carrying three bla-OXA58 gene copy assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID285634	Antimicrobial activity against Pseudomonas aeruginosa 10B3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID529827	Antimicrobial activity against Acinetobacter baumannii by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID558042	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S5 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID1757763	Ratio of MBC to MIC for Carbapenem- resistant Klebsiella pneumoniae KR 15-6 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID164557	In vitro antimicrobial activity against Pseudomonas aeruginosa 1771	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID510503	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M2AC9-31 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID544496	Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-4 to MIC for Escherichia coli TOP10	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID68508	Minimal inhibitory activity against the Enterobacter cloacae (EB5)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID1757802	Bactericidal activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-6 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID374141	Antimicrobial activity against non-CTX-M ESBL producing isolate of Escherichia coli by double-disk diffusion method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
AID529458	Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, CTX-M-15 and Oxa-1 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID585441	Antimicrobial activity against ampG deficient Pseudomonas aeruginosa PAK after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID531647	Antimicrobial activity against CTX-M-14, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC180 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID586085	Antimicrobial activity against verocytotoxin-producing Escherichia coli isolate O157 obtained from human assessed as percentage of resistant isolates by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
AID535844	Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTS harboring mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID374021	Ratio of Kcat to Km for Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID1407930	Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID572124	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 29 expressing ampC, ompA, adeM, aadB, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID521305	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype I by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID404961	Activity of Acinetobacter baumannii BM547 OXA58 assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID495703	Kcat/Km ratio of Escherichia coli CTX-M-15	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID556689	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 16 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID405800	Inhibition of bocillin FL binding to methicillin-resistant Staphylococcus aureus OC 3726 penicillin-binding protein 2a	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID571698	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 6 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID278602	Inhibitory activity against Klebsiella pneumoniae 03-222	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID518200	Antimicrobial activity against Pseudomonas aeruginosa BA(C1-106) selected after 25 ug/ml of compound exposure by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID524929	Antimicrobial activity against Escherichia coli MI1443 harboring N106S and P167S mutations in beta lactamase CTX-M-10 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID531588	Antibacterial activity against Proteus penneri obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID1757556	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-4 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID544531	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 7668 expressing bla SHV-48 gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID404958	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii T193 isolate carrying two bla-OXA58 gene copies by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID559545	Antibacterial activity against levofloxacin-susceptible Stenotrophomonas maltophilia by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID555193	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox deltaampDh3::lox deltanagZ::Gm after 18 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID498803	Antimicrobial activity against Klebsiella pneumoniae ZJ18T expressing KPC-2, DHA-1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID324311	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
AID495791	Antimicrobial activity against Pseudomonas fluorescens isolate PF-1 expressing beta-lactamase BIC-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID519802	Inhibition of Bocillin FL binding to PBP6 in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID405084	Activity of Citrobacter freundii PER2 beta lactamase	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID509866	Antibacterial activity against Acinetobacter baumannii isolate 510 isolated from human sputum	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID373024	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU4A1 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID534662	Antimicrobial activity against Non-ESBL Proteus mirabilis by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584721	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3050 harboring pyrD mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID495681	Antimicrobial activity against Pseudomonas aeruginosa OC 7052 expressing beta-lactamase VIM-2 and containing Carbapenemase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID532418	Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C3 isolate PG-12X-03 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID68878	In vitro synergistic activity against Escherichia coli C600N + (IRT-2)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID529851	Antibacterial activity against MexA-MexB-OprM-overproducing Pseudomonas aeruginosa OCR1 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID1649582	Antimicrobial activity against Pseudomonas aeruginosa clinical isolates by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID575325	Antimicrobial activity against Salmonella Typhimurium 08-843 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID529578	Ratio of Kcat to Km for Chryseobacterium meningosepticum beta-Lactamase GOB-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID561384	Antibacterial activity against Escherichia coli isolate ARL05-909 harboring beta-lactamase CMY 29 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID533544	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA349	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID546162	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-02 with PDC-1 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID561660	Antimicrobial activity against Pseudomonas aeruginosa isolate OC16830 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID495513	Antibacterial activity against Acinetobacter baumannii BM4467 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID495797	Activity at Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B carrying pSau1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID583192	Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by broth microdilution method in presence of 5 mM NagZ inhibitor PUGNAc	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID323042	Antimicrobial activity against extended-spectrum-beta-lactamase producing Proteus mirabilis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID1757496	Antibacterial activity against Enterococcus faecalis ATCC 51299 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285652	Antimicrobial activity against Pseudomonas aeruginosa 19C7 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID368737	Antimicrobial activity against Escherichia coli Ec1 containing pEc1-A plasmid expressing CTX-M-15 TEM-1 OXA-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID530345	Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID584723	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3433 harboring mutation in putative transcriptional regulator, LysR family by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523975	Antibacterial activity against Burkholderia pseudomallei 1026b infected in BALB/c mouse assessed as increase survival rate at 25 mg/kg, ip administered 6 hrs postinfection at 12 hrs interval for 3 days measured on day 20	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID667376	Antibacterial activity against Escherichia coli ATCC 11303 after 24 hrs by microtiter broth dilution method	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.
AID554401	Antimicrobial activity against Pseudomonas aeruginosa isolate 2998 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID531084	Antimicrobial activity against CTX-M-14, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC180 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID567749	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 31 fold elevated mexX expression and 17 fold elevated mexY expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID531083	Antimicrobial activity against CTX-M-14, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC176 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID583182	Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID1757879	Ratio of MBC to MIC for Escherichia coli NCTC 13353 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID546620	Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-2 by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID520390	Activity at Escherichia coli DH5alpha metallo-beta-lactamase VIM-11 assessed as compound hydrolysis per mg of total periplasmic protein by spectrometry	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID283131	Antibacterial activity against Pseudomonas aeruginosa PAO1456 expressing constitutive AmpC	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID285264	Antimicrobial activity against Escherichia coli DH5-alpha TC1179 isolate expressing TEM-1 by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID405641	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 1b	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID573382	Antibacterial activity against beta lactamase-positive Haemophilus influenzae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID534340	Antimicrobial activity against Burkholderia pseudomallei Bp50 harboring deleted (amrRAB-oprA)::FRT gene after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID1757746	Bactericidal activity against Enterobacter cloacae 17-9 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534926	Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID495802	Antimicrobial activity against Escherichia coli 138 expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID532897	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 ST 340 expressing beta-lactamase TEM-1, SHV-11 and OXA-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID544427	Antimicrobial activity against Escherichia coli CU164A harboring beta-lactamase L1 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID556676	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 3 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1373303	Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-121 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID522566	Antimicrobial activity against Escherichia coli isolate 7008153 with AmpC beta-lactamase H296P mutation	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID524706	Antibacterial activity against Proteus mirabilis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID1808865	Antipseudomonal activity against pseudomonas aeruginosa Pseudomonas aeruginosa 17/14-017 (ST-235) assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID1335736	Antibacterial activity against Acinetobacter baumannii ATCC 19606 after 16 to 20 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids.
AID546182	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-22 with PDC-4 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID584729	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4007 harboring proA mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID546179	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-19 with PDC-3 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID531646	Antimicrobial activity against CTX-M-14-like, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC192 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID564461	Antimicrobial activity against Pseudomonas aeruginosa isolate 856 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID285365	Susceptibility of qnr positive Enterobacter cloacae producing IMP8 and/or SHV2 assessed as percentage nonsusceptible isolates	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital.
AID368953	%fT>MIC in mouse at 129.7 mg/kg administered every 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID542759	Antimicrobial activity against Escherichia coli Du19 expressing qnrB6 and CTX-M-9G genes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID585447	Antimicrobial activity against ampG deficient Pseudomonas aeruginosa PAK harboring pZY0901 conferring resistance to gentamycin after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID665125	Antibacterial activity against Staphylococcus aureus after 18 to 22 hrs by EUCAST broth microdilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID524927	Antimicrobial activity against Escherichia coli MI1443 harboring A77V and D240G mutations in beta lactamase CTX-M-10 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID556682	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 9 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1592960	Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 3081/09 assessed as reduction in microbial growth incubated for 20 hrs	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID228704	In vitro dose required for anticholinergic activity in isolated guinea pig trachea	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID1056843	Antibacterial activity against CTX-15 expressing Enterobacter cloacae isolate 51 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID1757720	Bactericidal activity against Carbapenem- resistant Acinetobacter baumannii 17-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID373207	Antimicrobial activity against Bacillus clausii ATCC 21536 by agar-dilution technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID534627	Antimicrobial activity against Non-ESBL Escherichia coli assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID556654	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 9 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID508728	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C1 VAL6 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID544443	Antimicrobial activity against mreB-deficient Escherichia coli YLS-3 harboring beta-lactamase L2 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID584525	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3620 harboring mutS mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1475190	Antibacterial activity against Pseudomonas aeruginosa clinical isolate after 18 to 24 hrs	2017	Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12	Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
AID163930	Compound was tested for antimicrobial activity against Pseudomonas aeruginosa constitutive derepressed type I beta-lactamase producer (18SH) strain	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID495732	Kcat/Km ratio of Klebsiella pneumoniae SHV-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID330961	Antimicrobial activity against wild type Escherichia coli by serial dilution method	2007	The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29	Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID585181	Ratio of Kcat to Km for Beta-lactamase GES-1 E104, G170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID278604	Inhibitory activity against azide-resistant Escherichia coli J53 T12-1502	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID557795	Antimicrobial activity against Proteus mirabilis 06-489 isolated from infected human urinary tract by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.
AID1808850	Antibacterial activity against Pseudomonas aeruginosa PAO1 PAHUAC-27(ST-22) by broth microdilution method
AID1580092	Antibacterial activity against novobiocin and test compound-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages in presence of novobiocin by checkerboard assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID368750	Antimicrobial activity against Klebsiella pneumoniae Kp2 expressing TEM-15 TEM-17 TEM-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID373028	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU86 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID556687	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 14 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID285579	Antimicrobial activity against Pseudomonas aeruginosa IA5 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID546177	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-17 with PDC-3 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID534533	Antimicrobial activity against Citrobacter freundii KCTC 2359 after 18 hrs by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID285602	Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID534388	Antibacterial activity against Escherichia coli JM109 harboring recombinant pKHM-1 by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID544497	Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-5 to MIC for Escherichia coli TOP10	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID1757852	Ratio of MBC to MIC for ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-2 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID561672	Antimicrobial activity against Pseudomonas aeruginosa isolate OC16830 harboring plasmid MexZ expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID574429	Antimicrobial activity against Escherichia coli isolate 386 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from wound of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID545395	Antimicrobial activity against Pseudomonas aeruginosa PS1 with PFGE phenotype 9C expressing beta-lactamase IMP-18 and OXA-2 obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID499056	Antimicrobial activity against carbapenem-resistant Escherichia coli PU102 deficient in TEM-1, CTX-M-14, CMY-2, aac(6')-Ib, ompC DEc, ompF by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524714	Antibacterial activity against Acinetobacter sp. by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID534303	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA483	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID519740	Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-72 by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID252618	Mean lysis diameter of wild type Enterobacter aerogenes EA289 with OmpF by standard disk diffusion method on MH agar	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	Beta-lactam screening by specific residues of the OmpF eyelet.
AID372367	Antibacterial activity against Pseudomonas aeruginosa PAO1 at 30 ug/disk in presence of cephalosporinase inhibitor cloxacillin by disk diffusion test	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID1257069	Antibacterial activity against Staphylococcus aureus ATCC 29213 after 20 hrs by CLSI broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities.
AID529848	Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID373029	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA7 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1553824	Antibacterial activity against Staphylococcus aureus ATCC 29213 measured after 18 to 24 hrs in presence of ZnCl2	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID1757723	Bactericidal activity against Carbapenem- resistant Acinetobacter baumannii 17-11 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID573334	Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1056839	Antibacterial activity against TEM-1/CTX-M-15 expressing Aeromonas caviae isolate 260 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID245221	Minimum inhibitory concentration of compound against Escherichia coli derepressed in presence of compound 14	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID559524	Antibacterial activity against Acinetobacter baumannii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID534343	Antimicrobial activity against Burkholderia pseudomallei Bp173 harboring mini-Tn7T after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID523511	Antimicrobial activity against Pseudomonas aeruginosa isolate 13167 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID530341	Ratio of Kcat to Km for Pseudomonas aeruginosa VIM-1 beta-lactamase	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID69004	In vitro synergistic activity against Escherichia coli C600N + (OXA-10) {PSE-2}	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID565548	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-12 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID583030	Antimicrobial activity against Escherichia coli TOP10 transformed with Enterobacter asburiae CIP 105006 plasmid carrying ACT-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1553819	Antibacterial activity against Escherichia coli ATCC 25922 measured after 18 to 24 hrs in presence of NH4Cl	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID563585	Bactericidal activity against Pseudomonas aeruginosa PAO1 assessed as reduction in viable bacterial count at 2 X MIC after 8 hrs by time-kill analysis	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID570782	Antimicrobial activity against multidrug-resistant Acinetobacter baumannii assessed as resistant isolates by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.
AID534649	Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID574425	Antimicrobial activity against Escherichia coli isolate 339 expressing beta-lactamase KPC2, TEM and PFGE cluster 5 isolated from peritoneal fluid of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID424862	Antimicrobial activity against carbapenem-susceptible Pseudomonas aeruginosa clinical isolate assessed as resistant isolates	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID562815	Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID572126	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 30 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID285442	Activity of Citrobacter gillenii CIP 106783 Beta-lactamase GIL1 expressed in Escherichia coli DH10B	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID567315	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2206 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID1757883	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-30 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID575319	Antimicrobial activity against Salmonella Llandoff 06CEB6542SAL by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID542056	Antibacterial activity against Klebsiella pneumoniae expressing CTX-M group 1 beta-lactamase by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID373774	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh39 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID567753	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 8 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID95913	Antibacterial activity against Klebsiella pneumoniae 1082E	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID564228	Activity of Escherichia coli TOP10 beta-lactamase OXA-143	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID584565	Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID285260	Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-28 and ESBL by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID1373292	Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-4 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1757837	Bactericidal activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID511417	fT>MIC in cystic fibrosis patient at 6 gram/70kg, iv administered as 6 mg/l infusion every 6 hrs	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID524743	Antimicrobial activity against Escherichia coli GB20 harboring D240G mutation in beta lactamase CTX-M-10 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID1373294	Antimicrobial activity against Escherichia coli expressing beta-lactamase SME-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID368948	%fT>MIC in human at 20.2 mg/kg administered every 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID554395	Antimicrobial activity against Pseudomonas aeruginosa isolate 2716 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID584489	Antibacterial activity against porin deficient OmpA positive Klebsiella pneumoniae KPBj1 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID301081	Antibacterial activity against Toho 2 (ESBL) producing Escherichia coli SR-21003 after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID534300	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA459	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID546178	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-18 with PDC-3 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID564467	Antimicrobial activity against Pseudomonas aeruginosa isolate 1080 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID324360	Antibacterial activity against Acinetobacter johnsonii 7037 expressing SCO1 by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID372340	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as maximum bactericidal effect in in vitro PK/PD model by measuring change in bacterial count at 2 g infused every 8 hrs interval measured 17.5 hrs after third dose relative to initial in	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1373299	Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-10 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID608254	Antibacterial activity against 1 x 10'4 cfu/mL Staphylococcus aureus ATCC 29213 after 24 hrs by NCCLS M7-A6 microtiter broth dilution method	2011	European journal of medicinal chemistry, Aug, Volume: 46, Issue:8	Synthesis and antimicrobial evaluation of new benzofuran derivatives.
AID529604	Antibacterial activity against Escherichia coli TP1 harboring pBR322 carrying TEM-12 assessed as inhibition of bacterial growth at 64 ug/ml after 18 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Fitness trade-offs in blaTEM evolution.
AID520709	Antibacterial activity against Acinetobacter baumannii MAD by disk diffusion method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID368504	Ratio of Kcat to Km of Klebsiella pneumoniae TEM26 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID584562	Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1757728	Bactericidal activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-8 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID556677	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 4 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID68060	Antibacterial activity against Enterococcus faecium	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID495913	Ratio of Kcat to Km for beta-lactamase VIM-19 expressed in Escherichia coli TOP10 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID519009	Ratio of Kcat to Km for Beta-lactamase TEM-149 expressed in Escherichia coli HB101	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID1757590	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-7 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID519741	Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-72 by agar dilution method in presence of 2 ug/ml clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID495805	Antimicrobial activity against Klebsiella pneumoniae 6828 strain expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID571226	Antimicrobial activity against Pseudomonas aeruginosa isolate PA24 obtained from patient with cystic fibrosis harboring beta-lactamase AmpD1 12-nt deletion at nucleotide 5064908 and deletion of codons 144-147 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID495915	Ratio of Kcat to Km for beta-lactamase VIM-1 expressed in Escherichia coli TOP10 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID1553783	Antifungal activity against Candida tropicalis cgmcc2.1975 measured after 48 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID534296	Antimicrobial activity against Pseudomonas aeruginosa isolate PA477 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID562817	Antimicrobial activity against Escherichia coli DH5[alpha] in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID519648	Antimicrobial activity against Escherichia coli EPI300 harboring pCC1 carrying beta-lactamase CTX-M-3 by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID531581	Antibacterial activity against Citrobacter freundii obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID546418	Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-3 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID285268	Activity of Escherichia coli BL21(DE3) beta-lactamase TEM152	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID584915	Activity of Beta-lactamase in Pseudomonas aeruginosa PA14 PA3047 harboring complemented dacB mutant gene relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID521834	Antibacterial activity against Klebsiella pneumoniae isolate VA367 with blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, blaSHV-12, aac(6')-1b genes by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID1757580	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-11 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID422493	Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 3 McFarland inoculum size by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID1553782	Antifungal activity against Candida parapsilosis cgmcc2.3989 measured after 48 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID499070	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ84 deficient in SHV-11, aac(6')-Ib-cr, ompK35 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID521294	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype H by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID534385	Antibacterial activity against Escherichia coli K-12 W1895 by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID519638	Antimicrobial activity against ceftazidime-resistant Escherichia coli Irk2320 harboring beta-lactamase CTX-M-42 Pro167Thr mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID368477	Antibacterial activity against Enterobacter cloacae 4092 producing beta lactamase AmpC (E2) by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID584517	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2621 harboring clpS mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID151629	The compound was tested for minimum inhibitory concentration in Staphylococcus aureus Oxford penicillin sensitive Staphylococcus aureus	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID531332	Antibacterial activity against Pseudomonas aeruginosa PAO4290 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID373754	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab8 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID1757514	Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID374368	Ratio of Kcat to Km of Acinetobacter baumannii AC-54/97 metallo-beta-lactamase IMP-2 expressed in Escherichia coli DH5alpha	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID285669	Antimicrobial activity against Pseudomonas aeruginosa 24D5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID545402	Antimicrobial activity against Pseudomonas aeruginosa PS9 with PFGE phenotype 3B obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1757527	Antibacterial activity against Multidrug resistant Acinetobacter baumannii AR 15-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID405081	Antimicrobial activity against Escherichia coli CAG12177 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID285668	Antimicrobial activity against Pseudomonas aeruginosa 24D1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1757619	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-21 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1649587	Antimicrobial activity against Pseudomonas aeruginosa PAO1 in presence of 1 ug/ml iron by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID1649588	Antimicrobial activity against Pseudomonas aeruginosa PAO1 in presence of 10 ug/ml iron by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID285603	Antimicrobial activity against Pseudomonas aeruginosa 2B5 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID508479	Antimicrobial activity against Pseudomonas aeruginosa isolate PA66 producing metallo-beta-lactamase VIM4 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID394697	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC, MexAB-OprM pump, MexXY-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID68853	In vitro minimum inhibitory concentration required to produce antibacterial activity against Escherichia coli 25922	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID368522	Ratio of Kcat to Km of Enterobacter cloacae 4092 AmpC (E2) assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID155840	The compound was evaluated for the inhibition of [14C]- Pen G binding to Escherichia coli UB1005 PBP3 60 kDa.	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.
AID531969	Antibacterial activity against Klebsiella pneumoniae blood isolate A28008 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID1757722	Bactericidal activity against Carbapenem- resistant Acinetobacter baumannii 17-6 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495690	Activity of Klebsiella pneumoniae Beta-lactamase TEM-26	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID522002	Antimicrobial activity against Escherichia coli isolate J53 harboring p6A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID585443	Antimicrobial activity against ampG, ampGh1 deficient Pseudomonas aeruginosa PAK after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID1752478	Antimicrobial activity against Enterobacterales producing OXA-48 assessed as reduction in microbial growth measured after 16 to 20 hrs in presence of avibactam by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID554989	Antibacterial activity against Acinetobacter genomosp. 3 isolate 60 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID524707	Antibacterial activity against Proteus vulgaris clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
AID495810	Antimicrobial activity against Escherichia coli harbouring plasmid BK-CMV expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID559546	Antibacterial activity against levofloxacin-susceptible Stenotrophomonas maltophilia assessed as assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1553815	Antibacterial activity against Escherichia coli ATCC 25922 measured after 18 to 24 hrs in presence of CaCl2	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID529665	Activity of Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2 relative to cephaloridine	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID542060	Antibacterial activity against Klebsiella pneumoniae expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID1757725	Bactericidal activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-5 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID564208	Antibacterial activity against Pseudomonas aeruginosa PAO1 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID521296	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype J by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID324858	Antimicrobial activity against Acinetobacter baumannii A24A after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID1757737	Bactericidal activity against ESBLs negative Carbapenem--sensitive Escherichia coli 17-7 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID587731	Ratio of Kcat to Km for Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID368518	Ratio of Kcat to Km of Pseudomonas aeruginosa VIM2 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1447481	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P259-96918 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID283114	Antibacterial activity against Escherichia coli C600 expressing SHV1	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID529573	Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid pLBII carrying beta-lactamase CAR-1 gene after 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID565710	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-15 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID405805	Inhibition of bocillin FL binding to penicillin-susceptible Streptococcus pneumoniae OC 8865 penicillin-binding protein 2a	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID518190	Antimicrobial activity against oprD protein deficient Pseudomonas aeruginosa C2 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID520794	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype B by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID374363	Activity of Aeromonas caviae A324R metallo-beta-lactamase IMP-19 expressed in Escherichia coli DH5alpha by computerized microacidimetric method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID584920	Activity of Beta-lactamase in Pseudomonas aeruginosa PA14 PA4020 harboring complemented mpl mutant gene assessed as nitrocefin hydrolysis per mg of protein by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID285678	Antimicrobial activity against Pseudomonas aeruginosa 29G6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID368756	Antimicrobial activity against Enterobacter cloacae Ecl1 expressing TEM-24b AmpC TEM-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID285583	Antimicrobial activity against Pseudomonas aeruginosa 65.33-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID394687	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC, MexXY-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID564222	Antimicrobial activity against Escherichia coli TOP10 harboring plasmid PH1 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID567745	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 29 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID368520	Activity of Enterobacter cloacae 4092 AmpC (E2) assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID209568	In vitro antimicrobial activity against Streptococcus faecium MD 8b	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID535660	Antimicrobial activity against aac(6')-Ib-cr-positive Enterobacter cloacae FJ63 harboring GyrA S83I, GyrA D87A, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1808853	Antipseudomonal activity against Pseudomonas aeruginosa PAO1 deltadacB assessed as AmpC RNA expression by RT-PCR analysis relative to Pseudomonas aeruginosa PAO1
AID373059	Antimicrobial activity against Escherichia coli DH10B by agar-dilution technique in presence of beta-lactamase inhibitor clavulanic acid	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID68012	Antibacterial activity against Enterobacter cloacae EB5	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID521295	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype I by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID531582	Antibacterial activity against Enterobacter amnigenus obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID543415	Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID573143	Antibacterial activity against penicillin-susceptible Streptococcus viridans by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID163551	In vitro minimum inhibitory concentration for Proteus vulgaris (ATCC-6059) by agar dilution method	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.
AID522569	Antimicrobial activity against Escherichia coli isolate 5000869 with AmpC beta-lactamase H296P mutation	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID524247	Antimicrobial activity against Escherichia coli INSRA4590 expressing SHV-84	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.
AID1757871	Ratio of MBC to MIC for Enterobacter aerogenes 15-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID341593	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 469 isolate producing KPC2, OXA4 and CTX-M-10 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID495633	Antimicrobial activity against Escherichia coli DH10B transfected with pBK-L3 expressing blaLUT-1 by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID519738	Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-1 by agar dilution method in presence of 2 ug/ml clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID523516	Antimicrobial activity against Pseudomonas aeruginosa isolate 13120 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID535876	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JN1T by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1757780	Ratio of MBC to MIC for Enterobacter cloacae 17-8 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID524593	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolate Kpn-DK2 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
AID534100	Antibacterial activity against Acinetobacter baumannii PFGE type A isolate assessed as reduction of MIC by microdilution method in presence of 200 mM NaCl	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
AID560706	Inhibition of Escherichia coli MC4100 Beta-Lactamase CMY-2 using cephalothin as reporter substrate	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID587531	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 4 ug/ml Tazobactam beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID1553830	Antifungal activity against Candida albicans cgmcc2.2086 measured after 48 hrs in presence of MgCl by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID577222	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring phoU::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID567741	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 30 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID497693	Antimicrobial activity against colistin-susceptible Klebsiella pneumoniae isolated from bacteremia patient assessed as percentage of resistant isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.
AID571894	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 11 expressing ompA, adeB, adeM, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID584732	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4269 harboring rpoC mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID424863	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa clinical isolate assessed as resistant isolates	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID540942	Antimicrobial activity against Salmonella enterica serotype Newport AM17274 expressing CMY-31 cephalosporinase by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID1757719	Bactericidal activity against Carbapenem- resistant Acinetobacter baumannii 17-2 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495804	Antimicrobial activity against Klebsiella pneumoniae 2878 strain expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID285589	Antimicrobial activity against Pseudomonas aeruginosa 65.36-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID534107	Antibacterial activity against TolC deficient Pasteurella multocida pm0527 after 24 hrs by broth dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1335732	Antibacterial activity against Enterococcus faecalis after 16 to 20 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids.
AID531676	Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid containing OXA-58-3 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID530346	Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID531315	Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID564452	Antimicrobial activity against Pseudomonas aeruginosa isolate 944 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID583085	Activity of Escherichia coli BL21(DE3) wild-type VIM-2 beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID96428	In vitro synergistic activity against Klebsiella pneumoniae (ACT-1 + 3 blas, IPM=S)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID498806	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ71 deficient in KPC-2, TEM-1, SHV-11, CTX-M-14, ompK35 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID573364	Antibacterial activity against ceftazidime-susceptible Morganella morganii by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID545408	Antimicrobial activity against Pseudomonas aeruginosa PS15A with PFGE phenotype 10A obtained from blood of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID571933	Antimicrobial activity against Escherichia coli MC4100 harboring strong promoter in beta-lactamase GES-1 by Etest	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID372366	Antibacterial activity against Pseudomonas aeruginosa PAO1/CAZ mutant at 30 ug/disk in absence of cephalosporinase inhibitor cloxacillin by disk diffusion test	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID508482	Antimicrobial activity against Pseudomonas aeruginosa isolate K34-73 producing metallo-beta-lactamase VIM4 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID520968	Antibacterial activity against Escherichia coli harboring pRYC plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID557797	Antimicrobial activity against Escherichia coli J53 transconjugated with Proteus mirabilis pHS10 carrying qnrC gene by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.
AID372322	Antibacterial activity against Pseudomonas aeruginosa PAO1 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID535707	Antibacterial activity against Escherichia coli TOP10 expressing AmpC-B2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID495686	Activity of Escherichia coli TEM-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1808838	Antibacterial activity against Pseudomonas aeruginosa PAO1 17/14-017 (ST-235) by broth microdilution method
AID156119	Affinity for penicillin binding protein 1b of Escherichia coli UB1005 (DC0) was evaluated.	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.
AID521291	Antimicrobial activity against CTX-M-59 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype E by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID519737	Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID1757603	Antibacterial activity against Enterobacter cloacae 17-9 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID322316	Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID498841	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae SX67 deficient in SHV-2, CTX-M-14, DHA-1, qnrB6/S1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524572	Antimicrobial activity against Shigella flexneri isolate AM26336 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID531768	Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4696 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID532175	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae SH39T harboring qnrA gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID534866	Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID519804	Inhibition of Bocillin FL binding to PBP1A in Pseudomonas aeruginosa PAO1 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID532409	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-38 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID545425	Antimicrobial activity against Enterobacter aerogenes obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID555557	Antimicrobial activity against Pseudomonas aeruginosa isolate 27135 expressing VIM-2 beta lactamase gene by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID562757	Ratio of Kcat to Km for Klebsiella pneumoniae AH27 CTX-M-15 beta-lactamase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID585178	Activity of Beta-lactamase GES-5 E104, S170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID372510	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as reduction of bacterial count in in vitro PK/PD model at 2 g infused every 8 hrs interval measured after first dose relative to initial inoculum	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID1757605	Antibacterial activity against Enterobacter aerogenes 17-1 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID573343	Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1757709	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-7 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1265632	Antibacterial activity against Staphylococcus aureus after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID585186	Ratio of Kcat to Km for Beta-lactamase GES-13 K104, N170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID582969	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID516141	Antibacterial activity against Pulsotype K Acinetobacter genomosp. 3 isolate 6 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID678865	TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 25 uM, Ceftazidime: 2500uM) in PEPT2-expressing HeLa cells	2000	The Journal of biological chemistry, Jan-21, Volume: 275, Issue:3	beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
AID495720	Activity of Klebsiella pneumoniae Beta-lactamase TEM-26 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID519646	Antimicrobial activity against ceftazidime-resistant Escherichia coli Irk2322 harboring beta-lactamase CTX-M-42 Pro167Thr mutant gene by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID518226	Antimicrobial activity against Pseudomonas aeruginosa BA by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID558045	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S8 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID562578	Antimicrobial activity against Escherichia coli NO8-1503 harboring blaTEM-168 gene by Etest in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID587977	Antibacterial activity against Escherichia coli AS226 carrying pBSD-H2 after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID561676	Antimicrobial activity against Pseudomonas aeruginosa isolate OC17355 harboring plasmid MexZ expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID564691	Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID576267	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18918 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID562341	Ratio of Kcat to Km for Chryseobacterium meningosepticum CCUG 4310 beta-lactamase BlaB1 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID1373296	Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-4 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID562568	Antimicrobial activity against CTX-M ESBL producing Escherichia coli clinical isolate by CLSI disk diffusion assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania.
AID326272	Activity of Escherichia coli K12 beta-lactamase TEM1 relative to penicillin G	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID571234	Antimicrobial activity against Pseudomonas aeruginosa PAO1 expressing beta-lactamase AmpDh3 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID209892	Antibacterial activity against Streptococcus pneumoniae	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID520806	Antimicrobial activity against Escherichia coli str. K-12 substr. DH10B harboring plasmid CTX-M-59 in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID567739	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 34 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID1757512	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID532166	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii PU55 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB, qnrA genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID394497	Antimicrobial activity against Escherichia coli MC4100 harboring pBCSK plasmid by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID498821	Antimicrobial activity against Klebsiella pneumoniae WH76T expressing IMP-4, TEM-1, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID68374	In vitro synergistic activity against Enterobacter cloacae (Imi-1+AmpC)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID1757743	Bactericidal activity against Enterobacter cloacae 17-2 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID531775	Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4659 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID534101	Antibacterial activity against Acinetobacter baumannii PFGE type A isolate assessed as reduction of MIC by microdilution method in presence of 200 mg/liter cloxacillin	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
AID554384	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by twofold macrodilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID519663	Antimicrobial activity against Escherichia coli Irk1224 harboring beta-lactamase CTX-M-3 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID283147	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM7	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID573113	Antibacterial activity against methicillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID543420	Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID524935	Antimicrobial activity against Escherichia coli MI1443 harboring V27A, Q38R, N106S mutations in beta lactamase CTX-M-3 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID325194	Antibacterial activity against Pseudomonas aeruginosa SR-5393 by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID68170	In vitro antimicrobial activity against Enterobacter cloacae P99	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID562328	Antimicrobial activity against Chryseobacterium indologenes 597 expressing metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID608336	Antibacterial activity against 1 x 10'4 cfu/mL methicillin-resistant Staphylococcus aureus ATCC 700699 after 24 hrs by NCCLS M7-A6 microtiter broth dilution method	2011	European journal of medicinal chemistry, Aug, Volume: 46, Issue:8	Synthesis and antimicrobial evaluation of new benzofuran derivatives.
AID341117	Antibacterial activity against mexCD-oprJ overexpressing Pseudomonas aeruginosa 164M1-84C harboring p26PAD1 plasmid containing ampD gene	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID567320	Antimicrobial activity against Escherichia coli ML4909 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID25254	Pseudo-first-order Rate constant for hydrolysis at pH 10	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	The acylating potential of gamma-lactam antibacterials: base hydrolysis of bicyclic pyrazolidinones.
AID368947	Elimination rate constant in human	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID559073	Antibacterial activity against Citrobacter koseri by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID495699	Activity of Pseudomonas aeruginosa SPM-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID585446	Antimicrobial activity against ampG deficient Pseudomonas aeruginosa PAK harboring pUCP24 conferring resistance to gentamycin after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID1516025	Antibacterial activity against Escherichia coli 20411 clinical isolate incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID340730	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase TEM-ES by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID1808862	Antipseudomonal activity against pseudomonas aeruginosa PAOdeltaC+pUCP-(PDC-5) assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID565282	Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A3 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID545398	Antimicrobial activity against Pseudomonas aeruginosa PS4 with PFGE phenotype 9B expressing beta-lactamase IMP-18 obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID285625	Antimicrobial activity against Pseudomonas aeruginosa 9A1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID554389	Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY F1018L mutant by twofold macrodilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID68873	In vitro synergistic activity against Escherichia coli 4100 (no beta-lactamase)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID245353	Minimum inhibitory concentration of compound against Escherichia cloacae derepressed 12991 ED in presence of compound 14	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID1586248	Antibacterial activity against Acinetobacter baumannii 1484749 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID556696	Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] harboring pDrive plasmid expressing ampC gene by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1752455	Antibacterial activity against Escherichia coli BL21(DE3) transfected with pET9a empty vector incubated for 16 to 20 hrs by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID584848	Ratio of Kcat to Km for Aeromonas allosaccharophila AL-1 beta-lactamase PER2	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID394692	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC, MexAB-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID67861	In vitro minimum inhibitory concentration for Enterobacter aerogenes (ATCC-29751) by agar dilution method	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.
AID394685	Antibacterial activity against wild type Pseudomonas aeruginosa isolate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID524573	Antimicrobial activity against Shigella isolate DH-26336 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID368529	Ratio of Kcat to Km of Enterobacter cloacae 908R AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID584720	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2970 harboring rpmF mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID373060	Antimicrobial activity against Escherichia coli BL21(DE3) carrying pET9a expressing Bacillus clausii beta-lactamase BCL1 by agar-dilution technique in presence of beta-lactamase inhibitor clavulanic acid	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID1553789	Bactericidal activity against Escherichia coli K88 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID396030	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP2 plasmid containing Enterobacter cloacae acrA gene by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID394493	Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc1 plasmid by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID1596894	Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 18 hrs by broth microdilution assay
AID560489	Antibacterial activity against 5 x 10'5 CFU/ml CMY-2 producing Escherichia coli MC4100 harboring plasmid AC-cmy2 by microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID559261	Antimicrobial activity against Proteus vulgaris Pv8 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID534531	Antimicrobial activity against Escherichia coli KCTC 1039 after 18 hrs by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID567744	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 32 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID587985	Antibacterial activity against Escherichia coli AS226 carrying pBSD6 mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID559264	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv5 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID1171215	Antibacterial activity against wild-type Escherichia coli	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID283134	Antibacterial activity against Pseudomonas aeruginosa KG3056 producing MexCD-OprJ efflux pump	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID556685	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 12 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1757599	Antibacterial activity against Enterobacter cloacae 17-5 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495679	Antimicrobial activity against Pseudomonas aeruginosa OC 4352 overexpressing beta-lactamase AmpC assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID531073	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC243 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID1757635	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-5 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID519981	Ratio of Kcat to Km for Klebsiella pneumoniae Beta-Lactamase SHV-1	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae.
AID571218	Antimicrobial activity against Pseudomonas aeruginosa isolate TX292 obtained from patient with non-cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID583027	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli ECB-1 plasmid carrying ACC-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID531567	Antibacterial activity against Streptococcus agalactiae obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID285661	Antimicrobial activity against Pseudomonas aeruginosa 19F2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID517957	Antimicrobial activity against Proteus mirabilis by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID521840	Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID524433	Antimicrobial activity against Shigella isolate DH10B by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID587727	Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-18-pLBII after 18 hrs by microdilution broth method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID572138	Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 36 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID545443	Antimicrobial activity against extended-spectrum beta-lactamase-positive Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID554385	Antimicrobial activity against Pseudomonas aeruginosa mutGR1 overexpressing mexXY mutant by twofold macrodilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID531682	Antimicrobial activity against Acinetobacter baumannii Ab290 containing plasmid harboring OXA-58-4 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID559592	Antimicrobial activity against Pseudomonas aeruginosa PAO1 selected in presence of Ceftazidime by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID511291	Activity of Pseudomonas aeruginosa GES-13 beta lactamase assessed as hydrolysis by spectrometry	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID68877	In vitro synergistic activity against Escherichia coli C600N (no beta-lactamase)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID542525	Antimicrobial activity against Pseudomonas aeruginosa PAO1 infected in in vitro pharmacodynamic model assessed as bacterial killing up to 64 mg/L after 48 hrs using 10'7 CFU/ml inoculum by time kill study	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.
AID565530	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-05 harboring A residue at 105 position in PDC- 2 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID567321	Antimicrobial activity against Escherichia coli ML4901 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID583652	Antibacterial activity against Escherichia coli TOP10 expressing metallo-beta-lactamase NDM-1	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
AID322323	Antibacterial activity against Escherichia coli DH5 alpha-URA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID373986	Antimicrobial activity against azide-resistant aac(6')-Ib-cr expressing Escherichia coli J53 qnrA1 bearing pHS3 transconjugant from Citrobacter freundii 64 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID520775	Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K1 to K9 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID1757748	Bactericidal activity against Enterobacter aerogenes 17-1 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535129	Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID394490	Ratio of Vmax to Km for Hafnia alvei beta-lactamase ACC-1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID523514	Antimicrobial activity against Pseudomonas aeruginosa isolate 12102 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID534909	Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID322313	Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID559537	Antibacterial activity against Morganella morganii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1553817	Antibacterial activity against Escherichia coli ATCC 25922 measured after 18 to 24 hrs in presence of ZnCl2	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID325203	Antibacterial activity against Pseudomonas aeruginosa SR-24797 isolate by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID373756	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab20 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID498813	Antimicrobial activity against Escherichia coli ZJ87T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1757872	Ratio of MBC to MIC for Enterobacter aerogenes 15-4 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID519735	Antibacterial activity against Escherichia coli DH5alpha with deltaampC by agar dilution method in presence of 2 ug/ml clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID523489	Antimicrobial activity against Pseudomonas aeruginosa R20 Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID511294	Antibacterial activity against Pseudomonas aeruginosa NL68 expressing GES-13 beta lactamase in presence of 2 ug/ml clavulanic acid	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID1757657	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-11 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID555645	Antimicrobial activity against ampDh2 gene-deficient Pseudomonas aeruginosa PAO1 using 30 ug/disk by agar diffusion method in presence of 0.5 mM nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID325199	Antibacterial activity against Pseudomonas aeruginosa SR-24722 isolate by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID531064	Antimicrobial activity against CTX-M-14-like, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC203 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID523490	Antimicrobial activity against Pseudomonas aeruginosa AHP Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID373760	Antibacterial activity against imipenem-intermediate Acinetobacter baumannii ab1297 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID532412	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-07 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID573355	Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1757853	Ratio of MBC to MIC for ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-6 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1447478	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID531589	Antibacterial activity against Proteus vulgaris obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID523510	Antimicrobial activity against Pseudomonas aeruginosa isolate 16008 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID533550	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA361	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1808866	Antipseudomonal activity against pseudomonas aeruginosa Pseudomonas aeruginosa 36/14-210 (ST-235) assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID283110	Antibacterial activity against imipenem-resistant Pseudomonas aeruginosa	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID508486	Antimicrobial activity against Pseudomonas aeruginosa isolate BU-36178 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID531684	Antimicrobial activity against Acinetobacter baumannii ATCC 15151T containing plasmid harboring OXA-58-3 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID405799	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by CLSI method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID1752477	Antimicrobial activity against Enterobacterales producing VIM assessed as reduction in microbial growth measured after 16 to 20 hrs in presence of avibactam by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID565512	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-30 harboring A residue at 105 position in PDC- 8 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID556759	Antimicrobial activity against extended spectrum beta-lactamase CTX-M-2-producing Pseudomonas aeruginosa isolate P6208 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa.
AID571886	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 7 expressing ampC, ompA, adeB, adeM, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID532417	Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-12 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID545616	Antimicrobial activity against Pseudomonas aeruginosa PS37 with PFGE phenotype 11D obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID301094	Antibacterial activity against CAZ resistant Pseudomonas aeruginosa SR24-12 infected in mouse after 7 days	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID520966	Antibacterial activity against Klebsiella pneumoniae YC by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID576062	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 71697 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID522022	Antimicrobial activity against Escherichia coli isolate J53 harboring pEnc2 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID508741	Antibacterial activity against Pseudomonas aeruginosa assessed as percent nonsusceptible isolates by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID561443	Antibacterial activity against Escherichia coli 34943 harboring beta-lactamase CMY-44 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID521842	Antibacterial activity against Escherichia coli J53 by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID532169	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii PU55T harboring wild-type GyrA, ParC, GyrB and qnrA genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID564464	Antimicrobial activity against Pseudomonas aeruginosa isolate 968 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID373026	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA1 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID546175	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-15 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID562769	Antimicrobial activity against Escherichia coli DH10B transformant harboring blaTEM-168 gene by Etest in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID559599	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutT mutant gene selected in presence of tobramycin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1757530	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-2 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID545605	Antimicrobial activity against Pseudomonas aeruginosa PS23 with PFGE phenotype 4A expressing beta-lactamase KPC-2 obtained from blood of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID577225	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring yaaA::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID498837	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU8 deficient in SHV-11, DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID660265	Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump	2012	European journal of medicinal chemistry, Jun, Volume: 52	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID520805	Antimicrobial activity against Escherichia coli str. K-12 substr. DH10B harboring plasmid CTX-M-59	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID571898	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 13 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID544440	Antimicrobial activity against mreB-deficient Escherichia coli YLS-3 harboring beta-lactamase L1 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID1752482	Antibacterial activity against Enterobacter cloacae SR36276 producing class C beta lactamase, AmpC assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID285510	Antibacterial activity against Acinetobacter baumannii after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID495701	Kcat/Km ratio of Escherichia coli TEM-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1757636	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-6 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID522001	Antimicrobial activity against Escherichia coli isolate J53 harboring p5A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID522581	Antimicrobial activity against AmpC producing Escherichia coli Top10 isolate 25922	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID405813	Inhibition of bocillin FL binding to penicillin-resistant Streptococcus pneumoniae OC 8819 penicillin-binding protein 2b	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID535722	Activity of Escherichia coli TOP10 beta-lactamase AmpC-A S287N mutant	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID535842	Antimicrobial activity against Pseudomonas aeruginosa PAO1 SO20 harboring mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID565773	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 65 fold elevated mexX expression and 106 fold elevated mexY expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID1373300	Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-16 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1752473	Antibacterial activity against Klebsiella pneumonia ATCC 13883 infected in cyclophosphamide-induced neutropenic Jcl:ICR mouse model assessed as log10 reduction in CFU at 10 mg/kg, sc administered at 2, 5 and 8 hrs after infection and measured at 10 hrs af	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID79506	In vitro relative anticholinergic activity in isolated guinea pig trachea	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID529463	Antimicrobial activity against Klebsiella pneumoniae isolate 21 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-9 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID573366	Antibacterial activity against ceftazidime-susceptible Morganella morganii assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID531584	Antibacterial activity against Escherichia coli obtained from complicated skin and skin structure infections by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
AID546430	Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-1 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID250292	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH17; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID508481	Antimicrobial activity against Pseudomonas aeruginosa isolate B4-25753 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID564533	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID1757630	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-10 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757645	Antibacterial activity against Carbapenem- resistant Pseudomonas aeruginosa 17-5 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID509868	Antibacterial activity against Acinetobacter baumannii isolate 2898 isolated from human ankle	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID529830	Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolates by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID532400	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-17 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID562753	Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID283140	Reduction in susceptibility against Pseudomonas aeruginosa PAO1 after single passage	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID521303	Antimicrobial activity against CTX-M-59 producing Klebsiella pneumoniae with PFGE pulsotype G by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID549349	Antimicrobial activity against Escherichia coli isolate 36 harboring bla CTX-M-3a gene by broth microdilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID509869	Antibacterial activity against Acinetobacter baumannii isolate 4860 isolated from human urine	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID535370	Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID546422	Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-2 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID522758	Antimicrobial activity against AmpC producing Escherichia coli Top10 isolate 7014517	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID1757670	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-5 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID509870	Antibacterial activity against Acinetobacter baumannii isolate 5191 isolated from human urine	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID519655	Antimicrobial activity against Escherichia coli GM2995 harboring plasmid pCC1 carrying beta-lactamase CTX-M-3 Ser167 mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID1553829	Antifungal activity against Candida albicans cgmcc2.2086 measured after 48 hrs in presence of CaCl by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID499069	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ91 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID534607	Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID508489	Antimicrobial activity against Pseudomonas aeruginosa isolate K44-24 producing metallo-beta-lactamase IMP14 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID559820	Antimicrobial activity against Escherichia coli J53 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID340728	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-9 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID523959	Antibacterial activity against Burkholderia pseudomallei 1026b infected in BALB/c mouse assessed as cure rate at 25 mg/kg, ip administered 6 hrs postinfection at 12 hrs interval for 3 days measured on day 3 in presence of IFN-gamma-harboring cationic lipo	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID1373310	Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID405427	Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID535367	Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient by broth microdilution method in presence of Tazobactam	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID559896	Antimicrobial activity against Klebsiella oxytoca KO279 harboring beta-lactamase OXY-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID324359	Antibacterial activity against Escherichia coli DH10B by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID95734	In vitro antimicrobial activity against Klebsiella oxytoca 1082	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID495911	Antimicrobial activity in Escherichia coli J53 strain	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID530342	Ratio of Kcat to Km for Pseudomonas aeruginosa VIM-13 beta-lactamase	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID1757573	Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-20 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID374367	Activity of Acinetobacter baumannii AC-54/97 metallo-beta-lactamase IMP-2 expressed in Escherichia coli DH5alpha	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID1757678	Antibacterial activity against ESBLs positive Carbapenem- sensitive Escherichia coli 17-17 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1808816	Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method
AID535848	Antimicrobial activity against Pseudomonas aeruginosa GP61KT51 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID572140	Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 37 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID368942	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as bacterial growth rate by time-kill study	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID533546	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA352	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID555661	Antimicrobial activity against Salmonella enterica serotype Westhampton isolate 04CEB8273SAL expressing CTX-M-53 gene by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID532092	Antimicrobial against Pseudomonas aeruginosa 33410 harboring phoU allele by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID545612	Antimicrobial activity against Pseudomonas aeruginosa PS33 with PFGE phenotype 9A obtained from blood of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID531652	Antimicrobial activity against CMY-2,TEM-2-like beta-lactamase producing Escherichia coli isolate CUMC224 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID1757667	Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-20 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID524258	Activity at Escherichia coli beta-lactamase SHV-84	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.
AID584925	Activity of Beta-lactamase in Pseudomonas aeruginosa PAO1 PA4109 harboring ampR mutant gene relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1553786	Bactericidal activity against Salmonella typhimurium ATCC 14028 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID373055	Antimicrobial activity against Escherichia coli BL21(DE3) by agar-dilution technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID534110	Antibacterial activity against TolC deficient Pasteurella multocida pm1980 after 24 hrs by broth dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID584703	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0011 harboring mutation in putative 2-OH-lauroyltransferase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID546165	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-05 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID66239	Minimum inhibitory concentration in Enterobacter cloacae, I+401029 inducible type 1 lactamase producer	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID559543	Antibacterial activity against levofloxacin susceptible Serratia marcescens assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID495736	Kcat/Km ratio of Escherichia coli CMY-2 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1757824	Bactericidal activity against Enterobacter aerogenes 17-1 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID565709	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-14 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID571240	Antimicrobial activity against Pseudomonas aeruginosa isolate 164CD harboring beta-lactamase AmpDh3 Ile67Thr mutant obtained from patient with non-cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID587630	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=512:128 mg/kg, sc compound to NXL1	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID1586260	Antibacterial activity against Klebsiella pneumoniae 1161486 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID424857	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pV2GY3 with blaVIM-2 and aac(6)'-32 by E-test	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID565533	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-02 harboring T residue at 105 position in PDC- 1 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1757674	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-11 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID587620	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse septicemia infection model at 4:1 compound to NXL104 beta-lactamase inhibitor ratio by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID564690	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID1318901	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86052	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID250293	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH18; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID520979	Antibacterial activity against Pseudomonas aeruginosa KG2505 by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID155833	The compound was evaluated for the inhibition of [14C]- Pen G binding to Escherichia coli UB1005 PBP2 66 kDa.	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.
AID585179	Activity of Beta-lactamase GES-6 K104, S170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID508483	Antimicrobial activity against Pseudomonas aeruginosa isolate K34-7 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID532178	Antimicrobial activity against aac(6')-Ib-cr-negative Klebsiella pneumoniae SY22 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1757820	Bactericidal activity against Enterobacter cloacae 17-3 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757844	Ratio of MBC to MIC for Carbapenem- resistant Klebsiella pneumoniae KR 15-4 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID522018	Antimicrobial activity against Escherichia coli isolate TOP10 harboring pPR containing beta-lactamase and TEM-101 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID565528	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-07 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID535758	Antimicrobial activity against hospital-acquired Escherichia coli expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID534608	Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID301080	Antibacterial activity against Escherichia coli NIHJJC2 after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID559082	Antibacterial activity against Morganella morganii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID369573	Antibacterial activity against multidrug-resistant Acinetobacter baumannii 06-74 isolate assessed as reduction in bacterial load at 50 ug/ml administered as continuous infusion in vitro pharmacodynamic model after 3 to 4 hrs by time kill experiment	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
AID564020	Antibacterial activity against Pseudomonas aeruginosa isolated from wound infection of patient by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID544585	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8133 expressing bla TEM-55 gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID546168	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-08 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID584558	Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1553785	Bactericidal activity against Escherichia coli UB1005 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID560554	Antimicrobial activity against Proteus vulgaris Pv5 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID1553773	Antibacterial activity against Escherichia coli K88 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID1757647	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-1 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID565768	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 10 fold elevated mexX expression and 23 fold elevated mexY expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID562768	Antimicrobial activity against Escherichia coli DH10B transformant harboring blaTEM-168 gene by Etest	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID562739	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBC-CTX-M-71 plasmid by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID584492	Antibacterial activity against porin, OmpA positive extended-spectrum beta-lactamase producing Klebsiella pneumoniae KPBj1 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID583194	Antimicrobial activity against nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 at 1 ug/ml	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID374139	Antimicrobial activity against CTX-M ESBL producing isolate of Klebsiella pneumoniae at 30 ug by double-disk diffusion method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID521991	Antimicrobial activity against Klebsiella pneumoniae isolate Kp11978 expressing beta-lactamase OXA-48, SHV-2a and TEM-1 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID555225	Activity of Acinetobacter genomosp. 3 isolate 103 ADC-16	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID534905	Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID519799	Inhibition of Bocillin FL binding to PBP3 in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID1318936	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 84745	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID404964	Activity of OXA58 from Acinetobacter baumannii T183 isolate carrying one bla-OXA58 gene copy assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID540943	Antimicrobial activity against Klebsiella pneumoniae HP205 expressing CMY-36 cephalosporinase by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID326268	Antibacterial activity against Escherichia coli DH5-alpha by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID524744	Antimicrobial activity against Escherichia coli GB20 harboring V27A, Q38R mutations in beta lactamase CTX-3 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID560591	Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID584499	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae KPBj5 expressing efflux system by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID373987	Antimicrobial activity against azide-resistant aac(6')-Ib-cr deficient Escherichia coli J53 qnrA1 bearing pHS4 transconjugant from Enterobacter cloacae 91 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID1757543	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-7 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID549336	Antimicrobial activity against Escherichia coli isolate 49 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID325197	Antibacterial activity against beta-lactamase negative ampicillin-resistant Haemophilus influenzae SR-11435 by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID545461	Antimicrobial activity against Pasteurella sp. assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID567279	Activity of Acinetobacter baumannii ADC-33 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID372608	Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-12 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID374135	Antimicrobial activity Enterobacter cloacae 63 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID571888	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 8 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID534178	Antimicrobial activity against Escherichia coli TOP10 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID1757618	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-11 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID157424	In vitro minimum inhibitory concentration for Pseudomonas aeruginosa (ATCC-27853) by agar dilution method	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.
AID583183	Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID373209	Activity of Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID584707	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0427 harboring oprM mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID368475	Antibacterial activity against Pseudomonas aeruginosa HPA101-1477 producing beta lactamase IMP1 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID519642	Antimicrobial activity against Escherichia coli EPI300 harboring pCC1 carrying beta-lactamase CTX-M-42 Pro167Thr mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID1373290	Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID532913	Antimicrobial activity against Escherichia coli Genehogs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID573118	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID511428	Total clearance in juveline to adult cystic fibrosis patient	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID495706	Kcat/Km ratio of Escherichia coli CMY-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID372349	Antibacterial activity against Pseudomonas aeruginosa PAO1/CAZ mutant by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID520877	Antibacterial activity against Achromobacter xylosoxidans MER by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID533001	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa isolate P67 exhibiting PFGE J pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID542768	Antimicrobial activity against Escherichia coli J53 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID519982	Activity of Klebsiella pneumoniae Beta-Lactamase SHV-55	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae.
AID1318932	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 108590	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1757830	Bactericidal activity against carbapenem-sensitive Pseudomonas aeruginosa 17-9 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534171	Antimicrobial activity against beta lactamase CTX-M-14 producing Escherichia coli TOP10 harboring plasmid COP2 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID544490	Antibacterial activity against Pseudomonas aeruginosa PR280 harboring beta-lactamase KPC-5 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID372360	Ratio of Cmax in in vitro PK/PD model at 2 g infused at every 8 hrs intervals to MIC for Pseudomonas aeruginosa PAO1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID394487	Activity of Escherichia coli beta-lactamase ACC4 by UV spectrophotometry	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID520972	Antibacterial activity against Escherichia coli harboring pBC633 plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID368313	Activity of Staphylococcus aureus betalactamase PC1 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID372635	Activity of Escherichia coli TO799 beta-lactamase TEM-125 by microacidimetric method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID571232	Antimicrobial activity against Pseudomonas aeruginosa isolate 164CD harboring beta-lactamase AmpD1 Leu32Pro, Gly46Ser, Gly148Ala mutant obtained from patient with non-cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID545403	Antimicrobial activity against Pseudomonas aeruginosa PS10 with PFGE phenotype 1A expressing beta-lactamase KPC-2 obtained from blood of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID510505	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-4 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID1666866	Inhibition of swarming motility of Pseudomonas aeruginosa clinical isolates incubated for 16 to 20 hrs	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	Optimized plant compound with potent anti-biofilm activity across gram-negative species.
AID495900	Activity of Pseudomonas aeruginosa VIM-2 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID558813	Antimicrobial activity against Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID405804	Inhibition of bocillin FL binding to penicillin-susceptible Streptococcus pneumoniae OC 8865 penicillin-binding protein 2x	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID285595	Antimicrobial activity against Pseudomonas aeruginosa 1B9 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID535663	Antimicrobial activity against aac(6')-Ib-cr-positive Enterobacter cloacae FJ63T harboring qnrS gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID324310	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolate	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
AID1757502	Antibacterial activity against Escherichia coli 15-5 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID511397	Antibacterial activity against Acinetobacter baumannii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID322314	Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID533561	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA734 isolated from patient with cystic fibrosis	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID532405	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone G isolate NA-14X-13 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1757665	Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-18 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID301084	Antibacterial activity against Pseudomonas aeruginosa SR24 after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID1757639	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-9 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID576280	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17830 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID544489	Antibacterial activity against Enterobacter cancerogenus E624 harboring beta-lactamase KPC-4 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID576302	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 26077 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID584725	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3800 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID245002	Minimum inhibitory concentration of compound against Escherichia cloacae derepressed 12991 ED	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID556663	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 18 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1757539	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-13 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID556340	Activity of Salmonella enterica serotype Westhampton beta-lactamase CTX-M-53	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID582974	Antimicrobial activity against dacB::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID495744	Kcat/Km ratio of Pseudomonas aeruginosa SPM-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID405085	Ratio of Kcat to Km of Citrobacter freundii PER2 beta lactamase	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID1265634	Antibacterial activity against Staphylococcus faecalis after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID38399	Binding affinity towards AmpC beta-lactamase binding site from Escherichia coli; NA means not applicable	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Structure-based approach for binding site identification on AmpC beta-lactamase.
AID1757703	Antibacterial activity against Enterobacter aerogenes 17-5 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535847	Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID585440	Antimicrobial activity against ampG, ampGh1 deficient Pseudomonas aeruginosa PAO1 after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID1757773	Ratio of MBC to MIC for ESBLs negative Carbapenem-sensitive Escherichia coli 17-9 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID524245	Antimicrobial activity against Escherichia coli DH5alpha expressing SHV-1	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.
AID544564	Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID206176	In vitro minimum inhibitory concentration for Staphylococcus aureus (ATCC 6538p) by agar dilution method	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.
AID1757873	Ratio of MBC to MIC for carbapenem-sensitive Pseudomonas aeruginosa 17-7 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757863	Ratio of MBC to MIC for Enterobacter cloacae 17-2 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1827146	Antibacterial activity against methicillin-resistant Staphylococcus aureus COL assessed as inhibition of bacterial growth after 18 hrs in presence of oxacillin by CLSI protocol based broth microdilution assay	2022	ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3	Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID285439	Antimicrobial activity against Citrobacter gillenii CIP 106783 after 18 hrs by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID545413	Antimicrobial activity against Pseudomonas aeruginosa PS21 with PFGE phenotype 11F obtained from skin of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID534173	Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid MEZ by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID583188	Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by broth microdilution method in presence of 0.5 mM NagZ inhibitor PUGNAc	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID322318	Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID368315	Antibacterial activity against Klebsiella pneumoniae 4094 producing beta lactamase TEM26 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID520711	Antibacterial activity against Escherichia coli TOP10 harboring pOXA-58	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID285624	Antimicrobial activity against Pseudomonas aeruginosa 8B11 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID50542	In vitro minimum inhibitory concentration for Citrobacter freundii (ATCC-8090) by agar dilution method	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.
AID556656	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 11 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID373767	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh17 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID528788	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID285647	Antimicrobial activity against Pseudomonas aeruginosa 19B1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID508299	Inhibition of PBP5 in penicillin-resistant Enterococcus faecium D63r membranes assessed as inhibition of fluorescent ampicillin binding after 20 mins at 37 degC	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.
AID511404	Volume of distribution at steady state in cystic fibrosis patient at 2 gram, iv administered in 5 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID95552	Minimal inhibitory activity against the Klebsiella (X26)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID559590	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutM::Gm mutant gene assessed as doubling time	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID587613	Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 infected in sc dosed CD-1 mouse septicemia infection model by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID524570	Antimicrobial activity against Shigella sonnei isolate AM22855 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID554386	Antimicrobial activity against mexXY deficient ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant by twofold macrodilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID405636	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 6	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID554394	Antimicrobial activity against Pseudomonas aeruginosa isolate 2715 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID560122	Antimicrobial activity against Acinetobacter baumannii CIP70.10 harboring beta-lactamase RTG4 gene by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID587522	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 1 ug/ml NXL104 beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID394714	Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as susceptible rate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID528604	Antimicrobial activity against Escherichia coli J53 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID559267	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv9 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1824273	Antimicrobial activity against Escherichia coli clinical isolate T2228 expressing VIM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID582977	Antimicrobial activity against ampD::lox, ampDh2::lox and ampDh3::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID573354	Antibacterial activity against ceftazidime-susceptible Escherichia coli assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID556346	Ratio of Kcat/Km for Escherichia coli beta-lactamase CTX-M-16	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID524930	Antimicrobial activity against Escherichia coli MI1443 harboring N106S and D240G mutations in beta lactamase CTX-M-10 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID529859	Ratio of MIC for Pseudomonas aeruginosa MR08 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID535840	Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID511582	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID567750	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 71 fold elevated mexX expression and 43 fold elevated mexY expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID564465	Antimicrobial activity against Pseudomonas aeruginosa isolate 971 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID283143	Efficacy against Pseudomonas aeruginosa 93 pulmonary infection in mouse assessed as reduction in bacterial counts at 10 mg/kg, sc	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID560119	Antimicrobial activity against Acinetobacter baumannii by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID533567	Antimicrobial activity against Pseudomonas aeruginosa isolate PA465 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID573351	Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID660261	Ratio of MIC for wild type Escherichia coli JC7623 to MIC for acrAB-deficient Escherichia coli JZM120	2012	European journal of medicinal chemistry, Jun, Volume: 52	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID534530	Antimicrobial activity against multidrug-resistant Pseudomonas aeruginosa CCARM 2161 after 18 hrs by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID544428	Antimicrobial activity against translocase tatC-deficient Escherichia coli B1LK0A harboring beta-lactamase L1 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID587729	Antimicrobial activity against Escherichia coli DH5alpha carrying empty pBC-SK after 18 hrs by microdilution broth method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID1435415	Anti-bacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 measured after 24 hrs by microtiter broth dilution method	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.
AID279816	Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID535062	Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-5 plasmid by agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID1757571	Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-18 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID279813	Antimicrobial activity against Escherichia coli DH5-alpha pYW1 transformants expressing KPC2 gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID543419	Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1757587	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-22 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757606	Antibacterial activity against Enterobacter aerogenes 17-2 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID555209	Antibacterial activity against Acinetobacter genomosp. 3 isolate 90 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID587633	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=128:32 mg/kg, sc compound to NXL10	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID555197	Antimicrobial activity against nagZ gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID1757528	Antibacterial activity against Multidrug resistant Acinetobacter baumannii AR 15-4 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID373764	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh11 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID425867	Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 0.5 McFarland inoculum size by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID530815	Antibacterial activity against human urinary Klebsiella pneumoniae UCL-1 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID278595	Inhibitory activity against Escherichia coli 12-1502	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID562575	Antimicrobial activity against Escherichia coli NO8-1503 harboring blaTEM-168 gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID405430	fAUC (0 to 24 hrs)/MIC ratio in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 70 mg/kg, ip administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID1887586	Synergistic antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 24 hrs in presence of artocarpin by checkerboard method	2022	Journal of natural products, 10-28, Volume: 85, Issue:10	Developing the Natural Prenylflavone Artocarpin from
AID368502	Activity of Klebsiella pneumoniae TEM26 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID564525	Antimicrobial activity against Acinetobacter baumannii CIP70.10 by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID583082	Ratio of Kcat to Km for Escherichia coli BL21(DE3) wild-type VIM-2 beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID285600	Antimicrobial activity against Pseudomonas aeruginosa 2C2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID531606	Ratio of Kcat to Km for Escherichia coli Inhibitor-resistant beta-lactamase SHV-56	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID565514	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-21 harboring A residue at 105 position in PDC- 4 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID522386	Antimicrobial activity against Escherichia coli NI540 carrying cloned class C beta-lactamase TRU-1 gene	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID571225	Antimicrobial activity against Pseudomonas aeruginosa isolate PA367 obtained from patient with cystic fibrosis harboring beta-lactamase AmpD1 Gly148ala and Asp183Tyr mutant by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID565716	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-21 harboring A residue at 105 position in PDC- 4 and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID519008	Activity of Beta-lactamase TEM-149 expressed in Escherichia coli HB101	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID498827	Antimicrobial activity against Citrobacter freundii SZ63T expressing IMP-4, qnrS1by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID559898	Antimicrobial activity against Klebsiella oxytoca KO281 harboring beta-lactamase OXY-1 and CMY-2 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID541004	Antimicrobial activity against Burkholderia cenocepacia 07-34 expressing beta-lactamase PenB1	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID1553818	Antibacterial activity against Escherichia coli ATCC 25922 measured after 18 to 24 hrs in presence of FeCl3	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID1757717	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-29 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID372625	Ratio of Kcat for Escherichia coli DH5alpha beta-lactamase TEM-12 to Kcat for Escherichia coli CF0042 producing beta-lactamase TEM-35	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID511424	Terminal half life in healthy human subjects at 50 gram, iv administered 20 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID1757592	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-16 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID519654	Antimicrobial activity against Escherichia coli GM2995 harboring plasmid pCC1 carrying beta-lactamase CTX-M-3 from by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID368322	Antibacterial activity against Escherichia coli 11732 producing beta lactamase CTX-M-15 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID520387	Ratio of Kcat to Km for Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-11	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID562754	Activity of Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID532904	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID511403	Total clearance in cystic fibrosis patient at 2 gram, iv administered in 5 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID341969	Antimicrobial activity against Escherichia coli AJE0508 isolate carrying ISCR1 element related blaCTX-M-14 gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Novel complex class 1 integron bearing an ISCR1 element in an Escherichia coli isolate carrying the blaCTX-M-14 gene.
AID562337	Activity at Chryseobacterium indologenes 597 metallo-beta-lactamase IND-6 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID322321	Antibacterial activity against Escherichia coli DH5 alpha-URA5776 isolates expressing CTX-M-14 enzyme by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID567307	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2205 isolated from burn patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID373030	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU78 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID510506	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-6 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID523970	Antibacterial activity against Burkholderia pseudomallei 1026b infected in mouse AMJ.2 cells assessed as intracellular bacterial count at 10 ug/ml measured on 24 hrs postinfection by serial dilution plating technique (Rvb = 2 X 10'4 CFU/ml)	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID495672	Antimicrobial activity against Klebsiella pneumoniae OC 4094 expressing extended-spectrum Beta-lactamase TEM-26 assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1447484	Antibacterial activity against multidrug/extremely drug-resistant/colistin-resistant Pseudomonas aeruginosa isolate 91433 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID546417	Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-2 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID584746	Activity of Beta-lactamase in Pseudomonas aeruginosa PAO1 PA3047 harboring dacB mutant gene relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID405433	fAUC (0 to 24 hrs)/MIC ratio in Pseudomonas aeruginosa PAOdeltamutS infected C57BL/6J mouse at 70 mg/kg, ip administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID495739	Kcat/Km ratio of Pseudomonas aeruginosa OXA-10 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID19127	Terminal half life in Rhesus monkeys urine at the dose of 30 mg/kg.	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID374023	Activity of Enterobacter cloacae IMI1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID534106	Antibacterial activity against Pasteurella multocida AL435 after 24 hrs by broth dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID325192	Antibacterial activity against Pseudomonas aeruginosa SR24 by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID372609	Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-35 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID564532	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid with entire blaAmpC gene with alanine residue deletion at 215 position by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID545615	Antimicrobial activity against Pseudomonas aeruginosa PS36 with PFGE phenotype 11B obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID369576	Antibacterial activity against multidrug-resistant Acinetobacter baumannii 06-74 isolate by CLSI microdilution test	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
AID422285	Antimicrobial activity against Staphylococcus aureus by almar blue assay	2009	Journal of natural products, Feb-27, Volume: 72, Issue:2	Polyoxygenated methyl cyclohexanoids from a terrestrial ampelomyces fungus.
AID556694	Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID545399	Antimicrobial activity against Pseudomonas aeruginosa PS5 with PFGE phenotype 7A expressing beta-lactamase KPC-2 obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID405795	Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 1	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID325204	Antibacterial activity against Pseudomonas aeruginosa SR-24816 isolate by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID495834	Antimicrobial activity against Escherichia coli DH5alpha harbouring plasmid BK-VIM-19 expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID583651	Antibacterial activity against Escherichia coli isolate 271	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
AID534394	Activity of Beta-lactamase KHM-1 in Escherichia coli JM109 harboring recombinant pKHM-1 assessed as compound hydrolysis by UV-visible spectrophotometry	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID531974	Antibacterial activity against Escherichia coli DH10B by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID576068	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 69036 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID1757640	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-10 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757813	Bactericidal activity against ESBLs negative carbapenem-sensitive Escherichia coli 17-7 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495841	Ratio of Kcat to Km for beta-lactamase VIM-1 in Escherichia coli DH5alpha expressing pBCLL/39H by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID519645	Antimicrobial activity against ceftazidime-resistant Escherichia coli Irk2320 harboring beta-lactamase CTX-M-42 Pro167Thr mutant gene by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID405452	Antibacterial activity against Pseudomonas aeruginosa PAOdeltamutS infected in C57BL/6J mouse assessed as lung bacterial count at 70 mg/kg, ip administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID534631	Antimicrobial activity against ESBL producing Escherichia coli assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID546415	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-32 with PDC-10 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID576314	Antimicrobial activity against ESBL-negative Klebsiella pneumoniae 299332 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID1257070	Antibacterial activity against methicillin-resistant Staphylococcus aureus XJ 75302 after 20 hrs by CLSI broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities.
AID405808	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae OC 8865 by CLSI method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID543431	Activity at Shigella sonnei UIH-1 beta-lactamase CTX-M-64 by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID546410	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-27 with PDC-7 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID495511	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4665 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID583092	Activity of Escherichia coli XL1-Blue VIM-2 A64W mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID573192	Antimicrobial activity against mexD::lox-deficient Pseudomonas aeruginosa PAOMxD biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID544967	Antimicrobial activity against Proteus mirabilis expressing beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID561662	Antimicrobial activity against Pseudomonas aeruginosa isolate OC17355 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID520977	Antibacterial activity against Escherichia coli DH10B expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID285622	Antimicrobial activity against Pseudomonas aeruginosa 8A12 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID511415	fT>MIC in healthy human subjects at 6 gram/70kg, iv administered as 4 mg/l infusion every 6 hrs	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID1516086	Resistance index, ratio of MIC for antibacterial activity against ciprofloxacin-resistant Escherichia coli to MIC for Escherichia coli ATCC 25922 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID1757540	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-4 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID554393	Antimicrobial activity against Pseudomonas aeruginosa isolate 3020R obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID565534	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-01 harboring T residue at 105 position in PDC- 1 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID562223	Antimicrobial activity against Desulfovibrio desulfuricans MB by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Susceptibilities of 23 Desulfovibrio isolates from humans.
AID562574	Antimicrobial activity against Escherichia coli NO8-1503 harboring blaTEM-168 gene by disk diffusion method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID285660	Antimicrobial activity against Pseudomonas aeruginosa 19F1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID531087	Antimicrobial activity against CTX-M-14-like, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC204 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID584736	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5130 harboring mutation in putative rhodanese-like domain protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID69605	Antibacterial activity against Escherichia coli EC14	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID368311	Ratio of Kcat to Km of Staphylococcus aureus betalactamase PC1 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1757782	Ratio of MBC to MIC for Enterobacter cloacae 17-10 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID516146	Antibacterial activity against Pulsotype J Acinetobacter genomosp. 3 isolate 15 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID557799	Antimicrobial activity against Escherichia coli J53 by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.
AID1757753	Bactericidal activity against carbapenem-sensitive Pseudomonas aeruginosa 17-7 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534630	Antimicrobial activity against ESBL producing Escherichia coli assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573190	Antimicrobial activity against nfxB gene-deficient Pseudomonas aeruginosa PAONB biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID533553	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA368	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1752467	Antibacterial activity against Klebsiella pneumoniae ATCC13883 assessed as reduction in microbial growth incubated for 16 to 20 hrs by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID563973	Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase NDM-1	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID563593	Inhibition of Pseudomonas aeruginosa PAO1 PBP4 by SDS-PAGE	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID573386	Antibacterial activity against beta lactamase-positive Moraxella catarrhalis assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID534341	Antimicrobial activity against Burkholderia pseudomallei Bp227 harboring deleted (bpeAB-oprA)::FRT gene after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID584504	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0479 harboring mutation in putative transcriptional regulator, LysR family by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID65230	Minimum inhibitory concentration for inhibition of [14C]- Pen G binding to Escherichia coli UB1005.	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.
AID511420	fT>MIC in healthy human subjects at 6 gram/70kg, iv administered as 8 mg/l infusion every 8 hrs	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID584500	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae KPBj5 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID529603	Antibacterial activity against Escherichia coli TP1 harboring pBR322 carrying TEM-12 assessed as inhibition of bacterial growth at <=16 ug/ml after 18 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Fitness trade-offs in blaTEM evolution.
AID531061	Antimicrobial activity against CMY-2,CTX-M-14,TEM-2-like beta-lactamase producing Klebsiella pneumoniae isolate CUMCK2 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID565725	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-30 harboring A residue at 105 position in PDC- 8 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID495709	Kcat/Km ratio of Pseudomonas aeruginosa OXA-10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID562948	Antimicrobial activity against Klebsiella pneumoniae PFGE clone E expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID571688	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 1 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID285259	Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-29 and ESBL by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID368544	Activity of Pseudomonas aeruginosa 18SH AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID285642	Antimicrobial activity against Pseudomonas aeruginosa 15G2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID372606	Antibacterial activity against rifampin-resistant Escherichia coli C600 transconjugant producing beta-lactamase of pI 5.2 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID68872	In vitro synergistic activity against Escherichia coli 300 + (ampR ampC)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID516139	Antibacterial activity against Pulsotype F Acinetobacter genomosp. 3 isolate 4 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS18, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID584561	Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID208139	In vitro minimum inhibitory concentration required to produce antibacterial activity against Streptococcus pneumoniae 1/37(pen r)	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID1757845	Ratio of MBC to MIC for Carbapenem-resistant Klebsiella pneumoniae KR 15-5 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID341597	Antibacterial activity against sEscherichia coli GeneHogs harboring blaKPC-encoding plasmids	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID559826	Antimicrobial activity against Escherichia coli J53 by agar dilution in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID534305	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA507	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID495708	Kcat/Km ratio of Enterobacter cloacae AmpC	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID523499	Antimicrobial activity against Pseudomonas aeruginosa isolate 1247c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID522004	Antimicrobial activity against Escherichia coli isolate J53 harboring p7A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID583091	Activity of Escherichia coli XL1-Blue wild-type IMP-1 beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID283117	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM4	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID667373	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 after 24 hrs by microtiter broth dilution method	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.
AID575332	Antimicrobial activity against Escherichia coli 08-2712TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID1056850	Antibacterial activity against TEM-1/SHV-12 expressing Klebsiella pneumoniae isolate 303 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID522567	Antimicrobial activity against Escherichia coli isolate 7001178 with AmpC beta-lactamase S287N mutation	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID285636	Antimicrobial activity against Pseudomonas aeruginosa 12A7 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID285638	Antimicrobial activity against Pseudomonas aeruginosa 13D3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID565538	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-02 harboring T residue at 105 position in PDC- 1, and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID559901	Antimicrobial activity against Klebsiella pneumoniae 278sp by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID529462	Antimicrobial activity against Klebsiella pneumoniae isolate 11 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-1 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID1757615	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-7 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID583019	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli DH10B plasmid carrying DHA-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID524745	Antimicrobial activity against Escherichia coli GB20 harboring V27A, Q38R, P167S mutation in beta lactamase CTX-M-3 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID245003	Minimum inhibitory concentration of compound against Pseudomonas aeruginosa derepressed 88/98	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID565338	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-23 harboring A residue at 105 position in PDC- 5 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1379932	Antibacterial activity against Escherichia coli assessed as inhibition of microbial growth incubated for 18 to 22 hrs by broth microdilution method	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID1056845	Antibacterial activity against TEM-1/SHV-12 expressing Enterobacter cloacae isolate 306 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID520638	Antimicrobial activity against Escherichia coli MRY04-1060 expressing qepA gene by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID341113	Antibacterial activity against Pseudomonas aeruginosa 164M1-94C overexpressing mexCD-oprJ genes	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID1318928	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86067	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID519660	Antimicrobial activity against Escherichia coli EPI300 harboring GM2995 pCC1 carrying beta-lactamase CTX-M-3 gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID559818	Antimicrobial activity against Escherichia coli J53 harboring pCHE-A plasmid expressing blaGES-5 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID542047	Antibacterial activity against Escherichia coli TrC A expressing Klebsiella pneumoniae A blaCTX-M beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID1373284	Antimicrobial activity against Escherichia coli expressing beta-lactamase IMI-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID522021	Antimicrobial activity against Enterobacter cloacae isolate 2 expressing beta-lactamase OXA-48 and SHV-5 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID330967	Antimicrobial activity against ampD deficient Escherichia coli transfected with pCF1 by serial dilution method	2007	The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29	Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID584491	Antibacterial activity against porin, OmpA positive extended-spectrum beta-lactamase producing Klebsiella pneumoniae KPBj1 by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID584741	Activity of wild type Pseudomonas aeruginosa PA14 Beta-lactamase assessed as nitrocefin hydrolysis per mg of protein by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID567459	Antimicrobial activity against Escherichia coli W3110 transformant harboring bla CTX-M-15 gene by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.
AID499073	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae SZ93 deficient in ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1553772	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID495723	Activity of Enterobacter cloacae AmpC relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID520386	Activity at Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2 by spectrometry	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID520721	Antibacterial activity against Escherichia coli DH10B harboring pOXA-97	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID508724	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E2 PpA1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID521304	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype H by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID341123	Increase in ampD gene expression in Pseudomonas aeruginosa 164M1-94C overexpressing mexCD-oprJ genes by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID285576	Antimicrobial activity against Pseudomonas aeruginosa 65.18-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID495906	Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-4 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID532029	Antimicrobial activity against Escherichia coli TOP10F' transformant harboring beta-lactamase CTX-M-78 by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Novel chromosome-encoded CTX-M-78 beta-lactamase from a Kluyvera georgiana clinical isolate as a putative origin of CTX-M-25 subgroup.
AID523495	Antimicrobial activity against Pseudomonas aeruginosa isolate 1693c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1757755	Bactericidal activity against carbapenem-sensitive Pseudomonas aeruginosa 17-10 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID571044	Antimicrobial activity against Pseudomonas aeruginosa isolate GB57 obtained from patient with non-cystic fibrosis by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID279182	Antibacterial activity against Enterobacter cloacae S3 isolate by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.
AID544420	Antimicrobial activity against mreB-deficient Escherichia coli YLS-3 expressing beta-lactamase TEM-1 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID1757771	Ratio of MBC to MIC for ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-17 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID499051	Antimicrobial activity against carbapenem-resistant Escherichia coli PU60 deficient in TEM-1, CMY-2, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1757792	Ratio of MBC to MIC for Escherichia coli ATCC 25922 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285672	Antimicrobial activity against Pseudomonas aeruginosa 24E5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID535727	Antibacterial activity against Klebsiella pneumoniae urine isolate A28011 PFGE pattern A expressing KPC-2 CTX-M-2 beta-lactamase by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID520978	Antibacterial activity against Escherichia coli harboring pCOL plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID523888	Antimicrobial activity against Acinetobacter baumannii 6AB11 harboring ISAba1-blaOXA-66 gene by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID341128	Increase in ampDh2 gene expression in Pseudomonas aeruginosa 164M1-84C overexpressing mexCD-oprJ genes by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID405445	Antibacterial activity against Pseudomonas aeruginosa PAO1 infected in C57BL/6J mouse assessed as mortality at 70 mg/kg, ip administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID534629	Antimicrobial activity against Non-ESBL Escherichia coli assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID523504	Antimicrobial activity against Pseudomonas aeruginosa isolate 15110c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID565717	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-22 harboring A residue at 105 position in PDC- 4 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID283123	Antibacterial activity against Escherichia coli C600 expressing ESBL SHV3	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID520729	Activity of Acinetobacter baumannii CIP7010 beta-lactamase OXA-97 assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID757559	Antibacterial activity against Staphylococcus aureus assessed as growth inhibition after 18 to 22 hrs by broth microdilution method	2013	European journal of medicinal chemistry, Jul, Volume: 65	Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID205371	In vivo activity in murine against Serratia marcescens SM infection after sc administration.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID546432	Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-3 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID1757552	Antibacterial activity against Carbapenem- resistant Pseudomonas aeruginosa 17-8 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535751	Antimicrobial activity against community-acquired Klebsiella pneumoniae obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID373985	Antimicrobial activity Citrobacter freundii 64 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID613255	Antibacterial activity against Escherichia coli ATCC 11303 after 24 hrs by NCCLS M7-A6 broth dilution method	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.
AID374140	Antimicrobial activity against CTX-M ESBL producing isolate of Klebsiella oxytoca at 30 ug by double-disk diffusion method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
AID585402	Ratio of Kcat to Km for Chryseobacterium meningosepticum NCTC 10585 metallo-beta-lactamase GOB-1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID364442	Induction of convulsion in intracerebroventricular dosed mouse	2008	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17	Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.
AID368728	Ratio of Kcat to Km of Serratia marcescens AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID533541	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA341	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID405080	Antimicrobial activity against Citrobacter freundii 33587 isolate by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID518724	Antimicrobial activity against Escherichia coli TOP10 harboring beta-lactamase DIM-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
AID532181	Antimicrobial activity against aac(6')-Ib-cr-negative Klebsiella pneumoniae SY22T harboring qnrS gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID368943	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as maximum bacterial kill rate by time-kill study	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID583184	Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID1407929	Antibacterial activity against Enterobacter cloacae ARC3528 after 24 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID497694	Antimicrobial activity against colistin-resistant Klebsiella pneumoniae isolated from bacteremia patient assessed as percentage of resistant isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.
AID531776	Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4680 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID544569	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 7668 expressing bla SHV-48 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID285271	Activity of Escherichia coli BL21(DE3) beta-lactamase TEM1	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID573213	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB T544C mutant gene selected at 4 ug/ml of azithromycin after 1 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID326265	Antibacterial activity against Escherichia coli 3521r carrying pR352 encoding SCO1 by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID545607	Antimicrobial activity against Pseudomonas aeruginosa PS26 with PFGE phenotype 3A expressing beta-lactamase OXA-2 obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID368478	Antibacterial activity against Enterobacter cloacae 4081 producing beta lactamase AmpC (E2) by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID535836	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP37 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID1782792	Antibacterial activity against 98 member subset of carbapenem resistant Acinetobacter baumannii assessed as assessed as inhibition of bacterial growth by microdilution method	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID1757851	Ratio of MBC to MIC for Carbapenem-resistant Pseudomonas aeruginosa 17-8 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495702	Kcat/Km ratio of Klebsiella pneumoniae SHV-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID529850	Antibacterial activity against OprD-deficient Pseudomonas aeruginosa MR08 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID561385	Antibacterial activity against Escherichia coli isolate ARL06-39 harboring beta-lactamase CMY 30 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID1757712	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-11 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID372610	Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-1 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID529489	Antimicrobial activity against Enterobacter cloacae isolate 656 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID534887	Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID577648	Antimicrobial activity against Escherichia coli isolate 157T expressing beta-lactamase KPC2 and PFGE cluster 3 isolated from urine of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID499058	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae GX24 deficient in TEM-1, DHA-1, aac(6')-Ib, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID508721	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1C2 PTOL1 harboring beta-lactamase OXA-17 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID499067	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ89 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID529658	Ratio of Kcat to Km for Pseudomonas aeruginosa 166301 beta-lactamase VIM-16	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID521285	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype I by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID1649585	Antimicrobial activity against Pseudomonas aeruginosa PAO1 in absence of iron by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID325446	Antibacterial activity against Salmonella enterica serovar Typhimurium LT2 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID405639	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID559528	Antibacterial activity against Citrobacter koseri assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1373298	Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID285654	Antimicrobial activity against Pseudomonas aeruginosa 19D9 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID559273	Antimicrobial activity against Providencia stuartii Ps5 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID531317	Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID559525	Antibacterial activity against Acinetobacter calcoaceticus assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID511418	fT>MIC in cystic fibrosis patient at 6 gram/70kg, iv administered as 6 mg/l infusion every 4 hrs	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID405634	Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1a	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID1757738	Bactericidal activity against ESBLs negative Carbapenem--sensitive Escherichia coli 17-9 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID200339	Minimal inhibitory activity against the Salmonella (X514)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID565711	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-16 harboring A residue at 105 position in PDC- 3 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID562573	Antimicrobial activity against Escherichia coli NO8-1503 harboring blaTEM-168 gene by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID535855	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae GZ40 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID529517	Antibacterial activity against Pseudomonas aeruginosa isolates by Etest	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
AID565507	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-25 harboring T residue at 105 position in PDC- 6 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID534868	Antimicrobial activity against ESBL producing Proteus mirabilis assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584924	Activity of Beta-lactamase in Pseudomonas aeruginosa PAO1 PA4109 harboring ampR mutant gene assessed as nitrocefin hydrolysis per mg of protein by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID571920	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 24 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID516147	Antibacterial activity against Pulsotype D Acinetobacter genomosp. 3 isolate 18 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, repAcil, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID556665	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 20 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1300876	Antibacterial activity against Enterobacter spp. clinical isolate after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID529862	Ratio of MIC for Pseudomonas aeruginosa N045 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID585194	Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-7 K104, G170 mutant by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID544488	Antibacterial activity against Pseudomonas aeruginosa PR100 harboring beta-lactamase KPC-2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID521290	Antimicrobial activity against SHV-5 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype D by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID341594	Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 469 transformants producing KPC2, OXA4 and CTX-M-10 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID576065	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 69928 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID368539	Activity of Pseudomonas aeruginosa 4352 AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID559687	Antibacterial activity against ESBL-positive Escherichia coli Top10 harboring plasmid AT517	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID285441	Antimicrobial activity against Escherichia coli DH10B after 18 hrs by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID1553833	Antifungal activity against Candida albicans cgmcc2.2086 measured after 48 hrs in presence of NH4Cl by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID543428	Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID495510	Antibacterial activity against Acinetobacter baumannii BM4454 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID368754	Antimicrobial activity against Proteus mirabilis Pm1-Pm3 expressing TEM-24b gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID520880	Antibacterial activity against Achromobacter xylosoxidans TB1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID278601	Inhibitory activity against azide-resistant Escherichia coli J53 T07-006	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID576265	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 19039 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID519813	Inhibition of Bocillin FL binding to PBP2 in Pseudomonas aeruginosa 27853 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID571896	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 12 expressing ompA, adeB, adeM, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID540235	Phospholipidosis-negative literature compound
AID535061	Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pYMAb3 plasmid by agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID163919	In vitro minimum inhibitory concentration required to produce antibacterial activity against Pseudomonas aeruginosa ATCC 27853	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID495700	Activity of Acinetobacter baumannii OXA-23	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID522574	Antimicrobial activity against Escherichia coli isolate 8009389 with AmpC beta-lactamase H296P mutation	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID533761	Antibacterial activity against OXA-28 producing Pseudomonas aeruginosa isolate P174 exhibiting PFGE E pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID364439	Antipseudomonal activity against Pseudomonas aeruginosa class C AmpC(1d) beta-lactamase-induced clinical isolate FP1380 by CLSI method	2008	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17	Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.
AID245350	Minimum inhibitory concentration of compound against Citrobacter freundii derepressed 91/98-2 in presence of compound 12	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID563587	Induction of ampC mRNA expression in Pseudomonas aeruginosa PAO1 at 0.25 X MIC relative to untreated control	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID532899	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 ST 340 expressing beta-lactamase TEM-1 and SHV-11 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID562950	Antimicrobial activity against Klebsiella oxytoca expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID534652	Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID560117	Antibacterial activity against Escherichia coli TOP10 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID396027	Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID559544	Antibacterial activity against non-levofloxacin susceptible Stenotrophomonas maltophilia assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID520881	Antibacterial activity against Escherichia coli TOP10 harboring recombinant p6S3 expressing beta lactamase OXA-114a by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID554987	Antibacterial activity against Acinetobacter genomosp. 3 isolate 52 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID516142	Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 7 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID524748	Antimicrobial activity against Escherichia coli GB20 harboring V27A, Q38R, A77V, N114D, A140S, P167S, D288N mutations in beta lactamase CTX-M-1 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID556691	Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 harboring pDrive plasmid by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID546421	Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-1 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID555227	Activity of Acinetobacter genomosp. 3 isolate 195 ADC-18	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID523891	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring plasmid AT801 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID368735	Antimicrobial activity against Enterobacter aerogenes Ea2 expressing TEM-3 AmpC gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID495670	Antimicrobial activity against Escherichia coli DH5-alpha expressing beta-lactamase TEM-1 assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID499053	Antimicrobial activity against carbapenem-resistant Escherichia coli PU96 deficient in TEM-1, CTX-M-14, CMY-2, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID584509	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1348 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID495687	Activity of Klebsiella pneumoniae SHV-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID544584	Antimicrobial activity against Escherichia coli ATCC 25922 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID1757754	Bactericidal activity against carbapenem-sensitive Pseudomonas aeruginosa 17-9 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID565508	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-26 harboring T residue at 105 position in PDC- 6 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID534612	Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID555672	Antimicrobial activity against Escherichia coli DH5[alpha] harboring recombinant plasmid carrying CTX-M-53 gene by disk diffusion method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID533000	Antibacterial activity against IMP-18 producing Pseudomonas aeruginosa isolate P85 exhibiting PFGE K pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID567580	Antimicrobial activity against Acinetobacter baumannii assessed as resistant isolate by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID571936	Antimicrobial activity against Escherichia coli MC4100 harboring weak promoter and active promoter P2 in beta-lactamase GES-1 by Etest	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID529647	Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-15 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID559278	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Providencia stuartii Ps5 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID373204	Antimicrobial activity against Bacillus clausii SIN by agar-dilution technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID559684	Antibacterial activity against Acinetobacter baumannii BM4652	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID508296	Inhibition of PBP2 in penicillin-resistant Enterococcus faecium D63r membranes assessed as inhibition of fluorescent ampicillin binding after 20 mins at 37 degC	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.
AID534647	Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1757835	Bactericidal activity against Escherichia coli NCTC 13353 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID567733	Antimicrobial activity against Pseudomonas aeruginosa OC 11492 by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID499066	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ88 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID564527	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID613256	Antibacterial activity against Staphylococcus aureus ATCC 10832 after 24 hrs by NCCLS M7-A6 broth dilution method	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.
AID519743	Antibacterial activity against Klebsiella pneumoniae INSRA1229 harboring SHV-72 Ile8Phe, Ala146Val, and Lys234Arg mutations by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID573378	Antibacterial activity against imipenem-susceptible Acinetobacter assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID545410	Antimicrobial activity against Pseudomonas aeruginosa PS18A with PFGE phenotype 11D obtained from CSF of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID495730	Activity of Acinetobacter baumannii OXA-23 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID519651	Antimicrobial activity against Escherichia coli Irk1224 type 2 mutant harboring beta-lactamase CTX-M-3 Ser167 mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID368545	Ratio of Kcat to Km of Pseudomonas aeruginosa 18SH AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID519661	Antimicrobial activity against Escherichia coli EPI300 harboring GM2995 pCC1 carrying beta-lactamase CTX-M-3 Ser167 mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID577226	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring gabD::ISlacZ/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID567283	Ratio of Kcat to Km for Acinetobacter baumannii ADC-33 beta-lactamase to Kcat to Km for Acinetobacter baumannii ADC-11 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID585183	Ratio of Kcat to Km for Beta-lactamase GES-2 E104, N170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID559588	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutY::Gm mutant gene assessed as doubling time	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID558043	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S6 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID520796	Antimicrobial activity against SHV-5 producing Klebsiella pneumoniae with PFGE pulsotype D by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID531773	Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4688 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID1592959	Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 2697/14 assessed as reduction in microbial growth incubated for 20 hrs	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID1056844	Antibacterial activity against TEM-1/CTX-M-15 expressing Enterobacter cloacae isolate 62 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID1757730	Bactericidal activity against Carbapenem- resistant Pseudomonas aeruginosa 17-5 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757525	Antibacterial activity against Acinetobacter baumannii NCTC 13304 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID250284	Susceptibility testing against Pseudomonas aeruginosa ATCC 27853; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID534301	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA460	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID522013	Antimicrobial activity against Klebsiella pneumoniae isolate KpBEL expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID523977	Antibacterial activity against Burkholderia pseudomallei 1026b infected in BALB/c mouse assessed as decrease in bacterial count in spleen at 25 mg/kg, ip administered 6 hrs postinfection at 12 hrs interval for 3 days measured on day 65 in presence of muri	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID69007	In vitro synergistic activity against Escherichia coli C600N + (SHV-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID535138	Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584521	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3247 harboring mutation in putative aspartyl aminopeptidase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1335731	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 16 to 20 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids.
AID245220	Minimum inhibitory concentration of compound against Escherichia coli derepressed in presence of compound 12	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID585196	Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-6 K104, S170 mutant by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID541007	Antimicrobial activity against Burkholderia cenocepacia 09-54 expressing beta-lactamase PenB2	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID1827138	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as inhibition of bacterial growth after 18 hrs by CLSI protocol based broth microdilution assay	2022	ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3	Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.
AID519809	Inhibition of Bocillin FL binding to PBP5/6 in Pseudomonas aeruginosa PAO1 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID1373314	Antimicrobial activity against Escherichia coli expressing beta-lactamase P99 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID587614	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse septicemia infection model by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID521288	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype B by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID555632	Antimicrobial activity against ampDh2 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID573348	Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID561670	Antimicrobial activity against Pseudomonas aeruginosa isolate OC16827 harboring plasmid MexZ expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID535873	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JN1 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB and qnrA genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID524747	Antimicrobial activity against Escherichia coli GB20 harboring V27A, Q38R, A77V, N114D, A140S, D288N mutations in beta lactamase CTX-M-1 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID545618	Antimicrobial activity against Pseudomonas aeruginosa PS40 with PFGE phenotype 5 expressing beta-lactamase KPC-2, OXA-2 obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1553770	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID245352	Minimum inhibitory concentration of compound against Escherichia cloacae derepressed 12991 ED in presence of compound 12	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID561665	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring plasmid JAK16 expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID495729	Activity of Pseudomonas aeruginosa SPM-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID374022	Activity of Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID405806	Inhibition of bocillin FL binding to penicillin-susceptible Streptococcus pneumoniae OC 8865 penicillin-binding protein 2b	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID519012	Activity of Beta-lactamase TEM-10	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID322322	Antibacterial activity against Escherichia coli INSRA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID368521	Ratio of Kcat to Km of Enterobacter cloacae 4092 AmpC (E2) assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID545609	Antimicrobial activity against Pseudomonas aeruginosa PS29 with PFGE phenotype 11D obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID495838	Hydrolytic activity of Escherichia coli BL21 DE3 beta-lactamase VIM-19 by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID535846	Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID1666869	Inhibition of swarming motility of Salmonella enterica clinical isolates incubated for 16 to 20 hrs	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	Optimized plant compound with potent anti-biofilm activity across gram-negative species.
AID368484	Antibacterial activity against Pseudomonas aeruginosa 18SH producing beta lactamase AmpC by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID559918	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase RTG4 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID520810	Antimicrobial activity against SHV-5 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype D by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID283320	Antimicrobial activity against Klebsiella pneumoniae KPN15-NL	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.
AID495631	Antimicrobial activity against Pseudomonas luteola LAM expressing blaLUT-1 by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID529666	Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2 relative to cephaloridine	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID531683	Antimicrobial activity against Acinetobacter baumannii ATCC 15151T by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID1757726	Bactericidal activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-6 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID374112	Antimicrobial activity against azide-resistant aac(6')-Ib-cr expressing Escherichia coli J53 qnrA1 bearing pHS6 transconjugant from Escherichia coli 650 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID545440	Antimicrobial activity against Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID325186	Antibacterial activity against Staphylococcus aureus Smith by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID368955	%fT>MIC in human at 59.8 mg/kg administered every 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID511668	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID285670	Antimicrobial activity against Pseudomonas aeruginosa 24E1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID368487	Antibacterial activity against Pseudomonas aeruginosa 4083 producing beta lactamase OXA10 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID368526	Ratio of Kcat to Km of Enterobacter cloacae 4080 AmpC (P99) assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID495737	Kcat/Km ratio of Pseudomonas aeruginosa AmpC relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID567323	Antimicrobial activity against Escherichia coli TUM4670 by broth dilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID559276	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv8 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID529599	Antibacterial activity against Escherichia coli TP1 harboring pBR322 carrying TEM-1 assessed as inhibition of bacterial growth at 2 ug/ml after 18 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Fitness trade-offs in blaTEM evolution.
AID368949	%fT>MIC in mouse at 2.12 mg/kg administered every 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID587625	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse septicemia infection model at 16:1 compound to NXL104 beta-lactamase inhibitor ratio by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID497692	Antimicrobial activity against Klebsiella pneumoniae isolated from bacteremia patient assessed as percentage of resistant isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.
AID1757656	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-10 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID372604	Antibacterial activity against Escherichia coli BER1 producing TEM-158 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID522007	Antimicrobial activity against Escherichia coli isolate J53 harboring pI-1 containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID573189	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1808835	Antibacterial activity against Pseudomonas aeruginosa PAO1 13/09-018 (ST-175) by broth microdilution method
AID545406	Antimicrobial activity against Pseudomonas aeruginosa PS13 with PFGE phenotype 11E obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID555205	Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID559542	Antibacterial activity against non-ciprofloxacin-susceptible Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID574426	Antimicrobial activity against Escherichia coli isolate 339T expressing beta-lactamase KPC2 and PFGE cluster 5 isolated from peritoneal fluid of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1757776	Ratio of MBC to MIC for ESBLs positive Carbapenem-sensitive Escherichia coli 17-10 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID583094	Activity of Escherichia coli XL1-Blue wild-type VIM-2 beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID681115	TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells	2005	European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID1586264	Antibacterial activity against Pseudomonas aeruginosa PAO322 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID545455	Antimicrobial activity against Pseudomonas aeruginosa assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID530324	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pUCP carrying VIM-13 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID577649	Antimicrobial activity against Escherichia coli isolate 329 expressing beta-lactamase KPC2, CTX-M-2, TEM and PFGE cluster 2 isolated from blood of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID565522	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-13 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID368507	Ratio of Kcat to Km of Escherichia coli KPC2 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID531091	Antimicrobial activity against CTX-M-14, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC248 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID522570	Antimicrobial activity against Escherichia coli isolate 7008710 with AmpC beta-lactamase S287N mutation	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID533555	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA376	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID572142	Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 38 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID560701	Ratio of Kcat to Km for Escherichia coli MC4100 Beta-Lactamase CMY-30 harboring Val211?Gly211 mutation	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID534864	Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573202	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring deletion od C534 in nfxB mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID563595	Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as appearance of long filaments at 0.5 X MIC after 2 hrs by Live/dead cell viability assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID1171218	Antibacterial activity against MeXABCDXY-deficient Pseudomonas aeruginosa	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID555219	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 69 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID531078	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC223 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID495673	Antimicrobial activity against Klebsiella pneumoniae OC 5367 expressing beta-lactamase KPC-2 and containing Carbapenemase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1586262	Antibacterial activity against Pseudomonas aeruginosa 394303 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID584697	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5002 harboring mutation in hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID368323	Antibacterial activity against Klebsiella oxytoca 4076 producing beta lactamase K1 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID573371	Antibacterial activity against ceftazidime-susceptible Serratia marcescens assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID70951	Antibacterial activity against Escherichia coli TEM	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID495840	Hydrolytic activity of beta-lactamase VIM-1 in Escherichia coli DH5alpha expressing pBCLL/39H by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID499071	Antimicrobial activity against Klebsiella pneumoniae WH97 expressing SHV-33, aac(6')-Ib, ompK35 DE by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID555682	Antimicrobial activity against Escherichia coli DH10B by disk diffusion method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID567319	Antimicrobial activity against Escherichia coli TUM4672 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID532395	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate NA-14X-34 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID545619	Antimicrobial activity against Pseudomonas aeruginosa PS41 with PFGE phenotype 11D obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID575324	Antimicrobial activity against Escherichia coli 07-819TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID279187	Ratio of kcat to Km of Enterobacter cloacae S3 isolate beta lactamase LAP1 expressed in Escherichia coli DH10B	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.
AID521299	Antimicrobial activity against CTX-M-59 producing Klebsiella pneumoniae with PFGE pulsotype C by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID520717	Antibacterial activity against Acinetobacter baumannii CIP7010 harboring pOXA-97 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID1757795	Bactericidal activity against Carbapenem- resistant Acinetobacter baumannii 17-2 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID325207	Stability in presence of AmpC beta-lactamase	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID341595	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID405638	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 4	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID511577	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID571230	Antimicrobial activity against Pseudomonas aeruginosa isolate TX291 harboring beta-lactamase AmpD1 11-nt deletion at nt 5064907 and frameshift mutation obtained from patient with non-cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID534169	Antimicrobial activity against armB positive Escherichia coli COP producing beta lactamase CTX-M-14 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID544491	Antibacterial activity against Escherichia coli TOP10 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID1649589	Antimicrobial activity against Klebsiella pneumoniae clinical isolates in absence of iron by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID498824	Antimicrobial activity against Citrobacter freundii SZ62 expressing IMP-4, TEM-1, CMY-2, qnrS1, aac(6')-Ib-cr by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID535372	Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID498839	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ66 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID583193	Antimicrobial activity against Pseudomonas aeruginosa PAO1 at 1 ug/ml	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID565511	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-29 harboring A residue at 105 position in PDC- 8 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID587525	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 4 ug/ml Tazobactam beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID520728	Activity of Acinetobacter baumannii CIP7010 beta-lactamase assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID1808810	Antibacterial activity against Pseudomonas aeruginosa PAO1 deltadacBdeltapbpGdeltadacC by broth microdilution method
AID283121	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM9	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID495743	Kcat/Km ratio of Pseudomonas aeruginosa IMP-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID583015	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID584522	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3259 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID584731	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4088 harboring mutation in putative aminotransferase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID205379	Antibacterial activity against Serratia marcescens SE3	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID584704	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0401 harboring mutation in Noncatalytic dihydroorotase-like protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID561325	Antimicrobial activity against Klebsiella pneumoniae isolate 135 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID283142	Efficacy against Pseudomonas aeruginosa 93 pulmonary infection in mouse assessed as reduction in bacterial counts at 2 mg/kg, sc	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID1757736	Bactericidal activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-17 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID533535	Antimicrobial activity against Pseudomonas aeruginosa PA430 expressing VIM-4 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID544556	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8128 expressing bla SHV-105 gene by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID561671	Antimicrobial activity against Pseudomonas aeruginosa isolate OC16830 harboring plasmid JAK16 expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID561934	Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate RUH134 harboring plasmid ABVA01 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID529854	Antibacterial activity against MexA-MexB-OprM-overproducing and OprD-deficient Pseudomonas aeruginosa N041 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID522016	Antimicrobial activity against Escherichia coli isolate J53 harboring pL containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID534925	Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID524934	Antimicrobial activity against Escherichia coli MI1443 harboring V27A, Q38R, A77V and D240G mutations in beta lactamase CTX-M-3 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID518726	Antimicrobial activity against Escherichia coli TOP10 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
AID563600	Antimicrobial activity against Klebsiella pneumoniae isolate 048 expressing beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID1757814	Bactericidal activity against ESBLs negative carbapenem-sensitive Escherichia coli 17-9 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID573336	Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID529457	Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID559817	Antimicrobial activity against Enterobacter cloacae CHE-2 harboring blaGES-5 and blaSHV-5 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID573186	Antimicrobial activity against Pseudomonas aeruginosa PAO1 biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID564524	Antimicrobial activity against Acinetobacter baumannii KI by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID1757515	Antibacterial activity against Escherichia coli ATCC 35218 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID533557	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA380	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID584738	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5288 harboring glnK mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID554392	Antimicrobial activity against Pseudomonas aeruginosa isolate 3020S obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID405088	Activity of Alcaligenes faecalis PER2 beta lactamase	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID1442091	Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa 11421 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID368497	Activity of Klebsiella oxytoca beta-lactamase K1assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID545431	Antimicrobial activity against Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID495665	Ratio of Km for Pseudomonas aeruginosa 51170 beta-lactamase BEL-1 to Km for Pseudomonas aeruginosa 531 beta-lactamase BEL-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID563966	Antibacterial activity against Klebsiella pneumoniae 05-560 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID545412	Antimicrobial activity against Pseudomonas aeruginosa PS20A with PFGE phenotype 11D obtained from skin of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID665128	Antibacterial activity against Enterococcus faecalis after 18 to 22 hrs by EUCAST broth microdilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID518191	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1808859	Antipseudomonal activity against pseudomonas aeruginosa PAOdeltaampD AmpC RNA level assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID573341	Antibacterial activity against ceftazidime-susceptible Citrobacter freundii assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID520976	Antibacterial activity against Pseudomonas aeruginosa KG2505 harboring pCOL plasmid by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID531090	Antimicrobial activity against CTX-M-14, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC244 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID565524	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-11 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID70636	Compound was tested for antimicrobial activity against Escherichia coli DC0 strain (parent organism)	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID522580	Antimicrobial activity against wild-type AmpC producing Escherichia coli ATCC 25922	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID571229	Antimicrobial activity against Pseudomonas aeruginosa isolate GB61 harboring beta-lactamase AmpD1 Gly148Ala mutant obtained from patient with non-cystic fibrosis by Etest	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID760042	Antibacterial activity against Burkholderia pseudomallei assessed as bacterial growth inhibition	2013	ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8	Discovery of Inhibitors of
AID528603	Antimicrobial activity against Escherichia coli J53 harboring blaKPC-2 and blaTEM-1 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID250298	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH23; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID1757517	Antibacterial activity against Escherichia coli 15-3 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285667	Antimicrobial activity against Pseudomonas aeruginosa 22C5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID584926	Activity of Beta-lactamase in Pseudomonas aeruginosa PA14 PA4522 harboring ampD mutant gene assessed as nitrocefin hydrolysis per mg of protein by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID549348	Antimicrobial activity against Escherichia coli isolate 86 harboring bla CTX-M-3a gene by broth microdilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID1757765	Ratio of MBC to MIC for Carbapenem- resistant Pseudomonas aeruginosa 17-5 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID405091	Antimicrobial activity against non-integron carrying Enterobacteriaceae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
AID534628	Antimicrobial activity against Non-ESBL Escherichia coli assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID561387	Antibacterial activity against Escherichia coli isolate ARL05-705 harboring beta-lactamase CMY 7 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID368944	Volume of distribution in mouse	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID587530	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 4 ug/ml NXL104 beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID573114	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID540946	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c31 plasmid expressing cephalosporinase CMY-31 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID567304	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2202 isolated from burn patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID561313	Antimicrobial activity against Enterobacter cloacae isolate 37 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID394682	Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant rate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID532399	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-16 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1757548	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-12 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID163932	Minimum inhibitory concentration in Pseudomonas aeruginosa, 18SH constitutive depressed type 1 lactamase producer	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID535845	Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL1 harboring oprD, mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID559584	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutY::Gm mutant gene by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1757629	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-9 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID522009	Antimicrobial activity against Klebsiella pneumoniae isolate KpBIC expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID405815	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae OC 8819 by CLSI method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID534342	Antimicrobial activity against Burkholderia pseudomallei Bp58 harboring deleted bpeR::FRT gene after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID585401	Activity at Chryseobacterium meningosepticum NCTC 10585 metallo-beta-lactamase GOB-1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID252616	Mean lysis diameter of porin deficient Enterobacter aerogenes EA289 by standard disk diffusion method on MH agar	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	Beta-lactam screening by specific residues of the OmpF eyelet.
AID1757588	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-1 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID520777	Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K10 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID555218	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 65 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID285664	Antimicrobial activity against Pseudomonas aeruginosa 22D9 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID571906	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 17 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID583025	Antimicrobial activity against Escherichia coli TOP10 transformed by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID531777	Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4663 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID1447485	Antibacterial activity against multidrug/extremely drug-resistant/colistin-resistant Pseudomonas aeruginosa isolate 101243 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID511666	Antimicrobial activity against beta-lactam resistant beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant and deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID495515	Antibacterial activity against Acinetobacter baumannii CIP70-10 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID1757607	Antibacterial activity against Enterobacter aerogenes 17-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757536	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-10 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID565775	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 27 fold elevated mexX expression and 49 fold elevated mexY expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID368476	Antibacterial activity against Pseudomonas aeruginosa 7052 producing beta lactamase VIM2 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID535657	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ61T harboring qnrS gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID405089	Antibacterial activity against blaVIM2-harboring integrons containing Pseudomonas aeruginosa 42 isolate from ventilator-associated pneumonia patient	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence.
AID1757563	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-11 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID544495	Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-2 to MIC for Escherichia coli TOP10	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID340733	Antimicrobial activity against Chryseobacterium indologenes NF16 isolate assessed as drug level at which microbial resistance was observed by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID518194	Antimicrobial activity against mexAB-oprM protein and mexZ deficient Pseudomonas aeruginosa PAO267 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID561661	Antimicrobial activity against Pseudomonas aeruginosa isolate OC17349 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID1757614	Antibacterial activity against Enterobacter aerogenes 15-7 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757554	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-2 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID555206	Antimicrobial activity against ampD gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID1649609	Stabilization of Pseudomonas aeruginosa PBP3 assessed as melting temperature at 0.2 mM by DSF thermal shift assay (Rvb = 44.1 +/- 0.14 degC)	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID324362	Ratio of kcat to Km for Acinetobacter johnsonii SCO1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID499059	Antimicrobial activity against carbapenem-resistant Enterobacter aerogenes PU41 deficient in CTX-M-14, DHA-1, qnrS1, ompC DEc, ompF by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID574433	Antimicrobial activity against Escherichia coli isolate 543T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID665127	Antibacterial activity against Streptococcus pyogenes after 18 to 22 hrs by EUCAST broth microdilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID285659	Antimicrobial activity against Pseudomonas aeruginosa 19E9 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID404963	Activity of OXA58 from Acinetobacter baumannii 183 isolate carrying one bla-OXA58 gene copy assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID405798	Inhibition of bocillin FL binding to methicillin-susceptible Staphylococcus aureus ATCC 29213 penicillin-binding protein 4	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID1752454	Antibacterial activity against Escherichia coli BL21(DE3) transfected with pET9a vector harboring class D beta lactamase, OXA-48 incubated for 16 to 20 hrs by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID285666	Antimicrobial activity against Pseudomonas aeruginosa 22E3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID373049	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate JN45 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID565719	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-24 harboring A residue at 105 position in PDC- 5 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID405819	Antimicrobial activity against Acinetobacter sp. 5227 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID532893	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID546174	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-14 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID583653	Antibacterial activity against Escherichia coli TOP10	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
AID584705	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0402 harboring pyrB mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID521301	Antimicrobial activity against CTX-M-59 producing Klebsiella pneumoniae with PFGE pulsotype E by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID532903	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 ST 376 expressing beta-lactamase SHV-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID562338	Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-6 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID1335733	Antibacterial activity against vancomycin-resistant Enterococcus faecalis after 16 to 20 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids.
AID555642	Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by using 30 ug/disk by agar diffusion method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID559922	Antibacterial activity against Escherichia coli TOP10 harboring recombinant plasmid RTG4-V49 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID562751	Antimicrobial activity against Escherichia coli DH5alpha harboring pBC-CTX-M-71 plasmid by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID1435414	Anti-bacterial activity against Staphylococcus aureus ATCC 10832 measured after 24 hrs by microtiter broth dilution method	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.
AID330965	Antimicrobial activity against ampD deficient Escherichia coli by serial dilution method	2007	The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29	Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID564455	Antimicrobial activity against Pseudomonas aeruginosa isolate 1095 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID587623	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse septicemia infection model at 8:1 compound to NXL104 beta-lactamase inhibitor ratio by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID373027	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA6 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID545428	Antimicrobial activity against Enterobacter cloacae obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID584713	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1195 harboring mutation in putative dimethylarginine dimethylaminohydrolase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID285593	Antimicrobial activity against Pseudomonas aeruginosa 65.38-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID519803	Antimicrobial activity against Escherichia coli MC4100 by CLSI protocol based broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID524926	Antimicrobial activity against Escherichia coli MI1443 harboring A77V and P167S mutations in beta lactamase CTX-M-10 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID1427880	Antibacterial activity against wild type Escherichia coli AG100 after 18 hrs by broth dilution method	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E. aerogenes Gram-negative bacteria.
AID325202	Antibacterial activity against Pseudomonas aeruginosa SR-24770 isolate by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID564212	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring cloned pUCPOXA-161 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID368748	Antimicrobial activity against Klebsiella pneumoniae Kp1 expressing SHV-4 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID1373315	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-10 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID549353	Antimicrobial activity against Escherichia coli ATCC 25922 harboring bla CTX-M-3a gene by broth microdilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID1442092	Antibacterial activity against ceftazidime-resistant Pseudomonas aeruginosa 11431 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID518195	Antimicrobial activity against mexAB-oprM, mexCD-oprJ, mexEF-oprN, mexJK, mexXY, opmH and pscC gene deficient Pseudomonas aeruginosa PAO750 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID540944	Antimicrobial activity against Escherichia coli DH5[alpha] transformant harboring pA172 plasmid expressing cephalosporinase CMY-31 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID583029	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli DH10B plasmid carrying DHA-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID495905	Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-19 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID498809	Antimicrobial activity against Klebsiella pneumoniae ZJ99T expressing KPC-2, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID559683	Antibacterial activity against Acinetobacter baumannii BM4674 isolated from the tibia fracture of a patient by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID523502	Antimicrobial activity against Pseudomonas aeruginosa isolate 1333c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID200860	In vitro antimicrobial activity against Salmonella Typhimurium	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID1757644	Antibacterial activity against Carbapenem- resistant Pseudomonas aeruginosa 17-1 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1808844	Antibacterial activity against Pseudomonas aeruginosa PAO1 6/04-224 (ST-175) by broth microdilution method
AID584743	Activity of Beta-lactamase in Pseudomonas aeruginosa PA14 PA3047 harboring dacB mutant gene assessed as nitrocefin hydrolysis per mg of protein by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1553769	Antibacterial activity against Salmonella typhimurium ATCC 14028 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID520384	Antimicrobial activity Escherichia coli DH5alpha expressing beta lactamase VIM-2 by agar macrodilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID519811	Inhibition of Bocillin FL binding to PBP1A in Pseudomonas aeruginosa 27853 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID573210	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T77C mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1757875	Ratio of MBC to MIC for carbapenem-sensitive Pseudomonas aeruginosa 17-10 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID561327	Antimicrobial activity against Klebsiella pneumoniae isolate 202 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID405823	Antimicrobial activity against Acinetobacter baumannii 9043 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID555212	Antibacterial activity against Acinetobacter genomosp. 3 isolate 128 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID535861	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ47 harboring qnrB and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID757555	Antibacterial activity against Escherichia coli assessed as growth inhibition after 18 to 22 hrs by broth microdilution method	2013	European journal of medicinal chemistry, Jul, Volume: 65	Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID585199	Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-5 E104, S170 mutant by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID1553788	Bactericidal activity against Pseudomonas aeruginosa ATCC 27853 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID1757524	Antibacterial activity against Multidrug resistant Klebsiella pneumoniae KR 15-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID560128	Antimicrobial activity against Acinetobacter baumannii CIP70.10 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID1335737	Antibacterial activity against ESBL-producing Klebsiella pneumoniae ATCC 27736 after 16 to 20 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids.
AID1757783	Ratio of MBC to MIC for Enterobacter aerogenes 17-1 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID372353	Antibacterial activity against Pseudomonas aeruginosa PAO1/CAZ mutant at 30 ug/disk in presence of cephalosporinase inhibitor cloxacillin by disk diffusion test	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID495658	Antimicrobial activity against Escherichia coli TOP10 by solid agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID1757516	Antibacterial activity against Escherichia coli NCTC 13353 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495831	Antimicrobial activity against Escherichia coli DH5alpha 2878 transformant expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID583190	Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 5 mM NagZ inhibitor PUGNAc	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID1407931	Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs in presence of 2% human albumin by broth microdilution method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID535858	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae GZ40T harboring qnrB gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID584836	Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER6 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID532396	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate FG-17X-08 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID563601	Antimicrobial activity against Escherichia coli isolate CKP048 transconjugant harboring beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID573369	Antibacterial activity against ceftazidime-susceptible Proteus mirabilis assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID565536	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-32 harboring A residue at 105 position in PDC- 10 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID498825	Antimicrobial activity against Citrobacter freundii SZ62T expressing IMP-4, qnrS1by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID545409	Antimicrobial activity against Pseudomonas aeruginosa PS17B with PFGE phenotype 11D expressing beta-lactamase KPC-2 obtained from blood of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID522024	Antimicrobial activity against Escherichia coli isolate J53 harboring pCF containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID519010	Activity of Beta-lactamase TEM-149 T182M mutant expressed in Escherichia coli HB101	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID324862	Antimicrobial activity against Acinetobacter baumannii A24C after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID155829	The compound was evaluated for the inhibition of [14C]- Pen G binding to Escherichia coli UB1005 PBP1a 90 kDa.	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.
AID511423	Terminal half life in cystic fibrosis patient at 50 gram, iv administered 20 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID533537	Antimicrobial activity against Acinetobacter baumannii AB551 expressing SIM-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID68874	In vitro synergistic activity against Escherichia coli 4100 + (CCRA)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID322315	Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID571239	Antimicrobial activity against Pseudomonas aeruginosa isolate TX291 harboring beta-lactamase AmpDh3 Ala208Val mutant obtained from patient with non-cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID587532	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 4 ug/ml cavulanate beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID369640	Antibacterial activity against Acinetobacter baumannii A clone expressing carbapenemase-encoding blaOXA-40 gene by Etest method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
AID405453	Antibacterial activity against Pseudomonas aeruginosa PAOdeltamutS by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID1757713	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-21 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757870	Ratio of MBC to MIC for Enterobacter aerogenes 17-4 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID529600	Antibacterial activity against Escherichia coli TP1 harboring pBR322 carrying TEM-10 assessed as bacterial density up to 64 ug/ml after 18 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Fitness trade-offs in blaTEM evolution.
AID558807	Antimicrobial activity against extended spectrum beta-lactamase-deficient Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID520725	Activity of Acinetobacter baumannii MAD beta-lactamase assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID405420	fCmax in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 70 mg/kg, ip administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID565523	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-12 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1757843	Ratio of MBC to MIC for Carbapenem- resistant Acinetobacter baumannii 17-11 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID523974	Antibacterial activity against Burkholderia pseudomallei 1026b infected in BALB/c mouse assessed as survival rate at 25 mg/kg, ip administered 6 hrs postinfection at 12 hrs interval for 3 days measured on day 20 in presence of murine recombinant IFN-gamma	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID1554003	Antibacterial activity against Escherichia coli UFR39 measured after 16 to 20 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
AID546407	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-24 with PDC-5 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID1757701	Antibacterial activity against Enterobacter aerogenes 17-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757862	Ratio of MBC to MIC for ESBLs positive carbapenem-negative Escherichia coli 17-18 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285592	Antimicrobial activity against Pseudomonas aeruginosa 65.38-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID368508	Ratio of Kcat to Km of Escherichia coli KPC2 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID544494	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-5 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID561317	Antimicrobial activity against Enterobacter cloacae isolate 153 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID531336	Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID576277	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17834 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID495749	Antimicrobial activity against Salmonella enterica serotype Virchow 3464b by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID325447	Antibacterial activity against Staphylococcus aureus N315 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID583187	Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 0.5 mM NagZ inhibitor PUGNAc	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID565770	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 12 fold elevated mexX expression and 25 fold elevated mexY expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID285261	Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-36 and IRT by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID285610	Antimicrobial activity against Pseudomonas aeruginosa 65.68-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID530350	Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID283119	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM6	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID573339	Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID285608	Antimicrobial activity against Pseudomonas aeruginosa 3B1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID574432	Antimicrobial activity against Escherichia coli isolate 543 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID575317	Antimicrobial activity against Salmonella Typhimurium 05-9280 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID520391	Activity at Escherichia coli DH5alpha metallo-beta-lactamase VIM-2 assessed as compound hydrolysis per mg of total periplasmic protein by spectrometry	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID495728	Activity of Pseudomonas aeruginosa IMP-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID545411	Antimicrobial activity against Pseudomonas aeruginosa PS19A with PFGE phenotype 11C obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID532907	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 ST 376 expressing beta-lactamase SHV-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID565721	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-26 harboring T residue at 105 position in PDC- 6 and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID546619	Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-18 by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID564529	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID572122	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 28 expressing ampC, ompA, adeM, aadB, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID497691	Antimicrobial activity against colistin-resistant Klebsiella pneumoniae isolated from bacteremia patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.
AID562577	Antimicrobial activity against Escherichia coli NO8-1503 harboring blaTEM-168 gene by Etest	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID1757555	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-3 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID508480	Antimicrobial activity against Pseudomonas aeruginosa isolate AK5493 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID519471	Antimicrobial activity against Stenotrophomonas maltophilia K279a expressing beta-lactamase L1 and L2 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
AID535702	Antibacterial activity against Escherichia coli TOP10 expressing AmpC-A by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID535757	Antimicrobial activity against community-acquired Escherichia coli expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID1442089	Antibacterial activity against Pseudomonas aeruginosa CICC 21630 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID546414	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-31 with PDC-9 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID534172	Antimicrobial activity against armA positive Escherichia coli MEZ producing beta lactamase CTX-M-3 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID535835	Antimicrobial activity against Pseudomonas aeruginosa GP37KT31 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID571902	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 15 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID583087	Ratio of Kcat to Km for Escherichia coli XL1-Blue VIM-2 A64W mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID584714	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_07490/07510 harboring mutation in intergenic region by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID522565	Antimicrobial activity against Escherichia coli isolate 7008211 with AmpC beta-lactamase H296P mutation	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID532415	Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-10 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID340888	Antimicrobial activity against Escherichia coli JM83 harboring pACYC184-TEM by serial dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cytoplasmic-membrane anchoring of a class A beta-lactamase and its capacity in manifesting antibiotic resistance.
AID535137	Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID530349	Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID555214	Antibacterial activity against Acinetobacter genomosp. 3 isolate 243 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID528920	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-14 and CTX-M-27 and other bla gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID278599	Inhibitory activity against azide-resistant Escherichia coli J53 T35	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID368540	Activity of Pseudomonas aeruginosa 4352 AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID535168	Antimicrobial activity against imipenem susceptible Acinetobacter assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID511416	fT>MIC in healthy human subjects at 6 gram/70kg, iv administered as 3 mg/l infusion every 8 hrs	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID542770	Antimicrobial activity against Escherichia coli J53 transformed with pHND2 carrying qnrB6 and CTX-M-9G genes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID69005	In vitro synergistic activity against Escherichia coli C600N + (P99)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID368752	Antimicrobial activity against Klebsiella pneumoniae Kp4 expressing SHV-12 SHV-1 and plasmid-mediated cephalosporinase CMY-4	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID1757696	Antibacterial activity against Enterobacter cloacae 17-8 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID567460	Antimicrobial activity against Salmonella enterica serovar Typhi isolate 080048Ty transconjugant harboring bla CTX-M-15 gene by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.
AID1757632	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-12 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID531065	Antimicrobial activity against CTX-M-14-like, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC204 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID495907	Antimicrobial activity in Escherichia coli TOP10 strain harbouring recombinant plasmid VIM-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID534111	Antibacterial activity against Pasteurella multocida pm1980 after 24 hrs by broth dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID564468	Antimicrobial activity against Pseudomonas aeruginosa isolate 1093 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID573207	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB G461A mutant gene selected at 4 ug/ml of azithromycin after 5 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID340889	Antimicrobial activity against Escherichia coli JM83 by serial dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Cytoplasmic-membrane anchoring of a class A beta-lactamase and its capacity in manifesting antibiotic resistance.
AID587528	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 1 ug/ml NXL104 beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID1757688	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-20 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495843	Ratio of Kcat to Km for Escherichia coli DH10B beta-lactamase VIM-2 by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID532172	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae SH39 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrA genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID495678	Antimicrobial activity against wild type Pseudomonas aeruginosa ATCC 27853 expressing beta-lactamase AmpC assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID495842	Hydrolytic activity of Escherichia coli DH10B beta-lactamase VIM-2 by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID573363	Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1757749	Bactericidal activity against Enterobacter aerogenes 17-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534108	Antibacterial activity against Pasteurella multocida pm0527 after 24 hrs by broth dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID587632	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=256:64 mg/kg, sc compound to NXL10	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID1265636	Antibacterial activity against Escherichia coli at after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID545397	Antimicrobial activity against Pseudomonas aeruginosa PS3 with PFGE phenotype 12 obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID567309	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2207 isolated from burn patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID519629	Antimicrobial activity against Escherichia coli JM83 without producing beta-lactamase OXA-63 after 3 days by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID522017	Antimicrobial activity against Providencia rettgeri isolate expressing beta-lactamase OXA-48 and TEM-101 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID325191	Antibacterial activity against AmpC producing Enterobacter cloacae SR-4321 by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID573380	Antibacterial activity against beta lactamase-negative Haemophilus influenzae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID301087	Antibacterial activity against Imipenem resistant Pseudomonas aeruginosa SR-6554 after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID405082	Antimicrobial activity against Escherichia coli 33587-TC9 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID423775	Antibacterial activity against ESBL-negative Klebsiella pneumoniae isolate 113 at 1 ug/ml by Etest	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Selection of SHV extended-spectrum-beta-lactamase-dependent cefotaxime and ceftazidime resistance in Klebsiella pneumoniae requires a plasmid-borne blaSHV gene.
AID1586266	Antibacterial activity against Streptococcus pneumoniae ERY2 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID584733	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4393 harboring mutation in putative permease by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID560490	Antibacterial activity against 5 x 10'5 CFU/ml Escherichia coli MC4100 harboring plasmid ACYC184 by microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID1056836	Antibacterial activity against CTX-15 expressing Escherichia coli isolate 235 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID555648	Ratio of MIC for ampDh2 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG to MIC for ampDh2 gene-deficient Pseudomonas aeruginosa PAO1 in absence of nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID534346	Antimicrobial activity against Burkholderia pseudomallei Bp207 harboring deleted (bpeAB-oprA)::FRT gene after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID576320	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 31750 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID564528	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-50 plasmid by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID571693	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 2 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID559593	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene selected in presence of Ceftazidime by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID373040	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ58 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID521289	Antimicrobial activity against CTX-M-59 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype C by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID555639	Antimicrobial activity against ampDh2 and ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID1757718	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-30 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID510509	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC4AC9-30 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID519013	Ratio of Kcat to Km for Beta-lactamase TEM-10	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID584715	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_59780 harboring rcsC mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1757617	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-10 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757729	Bactericidal activity against Carbapenem- resistant Pseudomonas aeruginosa 17-1 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495685	Antimicrobial activity against Acinetobacter baumannii OC 11738 expressing beta-lactamase OXA-23 and containing Carbapenemase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID584737	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5174 harboring mutation in putative beta-ketoacyl synthase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1586259	Antibacterial activity against Klebsiella pneumoniae 1511191 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID535059	Antimicrobial activity against Acinetobacter genomic species 13TU by agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID283219	Antimicrobial susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patient assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
AID573362	Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID532096	Antimicrobial against Pseudomonas aeruginosa 3434 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID560702	Activity of Escherichia coli MC4100 Beta-Lactamase CMY-2	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID573401	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB T77C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID519640	Antimicrobial activity against Escherichia coli AB14156 harboring beta-lactamase CTX-M-42 Pro167Thr mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID510507	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-7 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID565201	Antimicrobial activity against Klebsiella pneumoniae isolate T-1504 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID519815	Inhibition of Bocillin FL binding to PBP4 in Pseudomonas aeruginosa 27853 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID584564	Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID368730	Activity of Pseudomonas aeruginosa AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID528601	Antimicrobial activity against Escherichia coli TOP10 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID534928	Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID542044	Antibacterial activity against Escherichia coli TrC B expressing Klebsiella pneumoniae B blaCTX-M beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID534167	Antimicrobial activity against Escherichia coli TOP10 harboring plasmid VOG1 expressing RmtB, TEM-1, and QepA gene by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID544516	Metabolic stability in Escherichia coli TOP10 harboring beta-lactamase KPC-4 assessed as hydrolysis rate per mg of extracts at 50 uM after 5 mins by spectrophotometric analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID1757610	Antibacterial activity against Enterobacter aerogenes 15-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID283126	Antibacterial activity against Escherichia coli C600 expressing ESBL CTX-M3	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID373206	Antimicrobial activity against Bacillus clausii OC by agar-dilution technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID86133	Minimal inhibitory activity against the Haemophilus influenzae (C.L)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID1407933	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA100 after 24 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID1757529	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID508729	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C8 GM1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID498816	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae FZ49 deficient in IMP-8, TEM-1, SHV-11, CTX-M-14, qnrB2, aac(6')-Ib, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID529486	Antimicrobial activity against Enterobacter cloacae isolate 533 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID587527	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID559598	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutM mutant gene selected in presence of tobramycin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID532414	Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-02 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID532190	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii TJ15 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB, qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1757817	Bactericidal activity against ESBLs positive carbapenem-sensitive Escherichia coli 17-10 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID373034	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ3-9 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID519657	Antimicrobial activity against Escherichia coli EPI300 Irk1224 type 1 mutant harboring beta-lactamase CTX-M-3 gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID1209733	Binding affinity to mouse OAT3 expressed in CHO cells at 10 to 1000 uM measured over 20 mins	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID562778	Antimicrobial activity against Escherichia coli DH10B by Etest in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID757553	Antibacterial activity against Proteus mirabilis assessed as growth inhibition after 18 to 22 hrs by broth microdilution method	2013	European journal of medicinal chemistry, Jul, Volume: 65	Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID567316	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2207 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID498814	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae FZ47 deficient in IMP-8, TEM-1, SHV-11, CTX-M-14, qnrB2, aac(6')-Ib, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID285262	Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-1 and TEM1 by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID533562	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA736 isolated from patient with cystic fibrosis	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID563596	Antimicrobial activity against Pseudomonas aeruginosa PAO1 at 4 X MIC after 8 hrs by Live/dead cell viability assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID1757522	Antibacterial activity against Multidrug resistant Klebsiella pneumoniae KR 15-1 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID555556	Antimicrobial activity against Pseudomonas aeruginosa isolate 22843 expressing VIM-2 beta lactamase gene by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID556679	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 6 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1757541	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-5 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID531066	Antimicrobial activity against CTX-M-14-like, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC233 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID1757861	Ratio of MBC to MIC for ESBLs positive carbapenem-negative Escherichia coli 17-10 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID583018	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli pGLK-1 plasmid carrying FOX-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1407932	Antibacterial activity against methicillin-resistant Staphylococcus aureus FQ-R after 24 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID1757839	Ratio of MBC to MIC for Carbapenem- resistant Acinetobacter baumannii 17-2 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1808824	Antibacterial activity against Pseudomonas aeruginosa PAO1 deltaC+pUCP-(PDC-1) by broth microdilution method
AID495682	Antimicrobial activity against Pseudomonas aeruginosa OC 12115 expressing beta-lactamase SPM-1 and containing Carbapenemase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID499049	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU104 deficient in TEM-1, SHV-11, CTX-M-15, qnrS1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID546409	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-26 with PDC-6 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID535368	Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient by broth microdilution method in presence of Tazobactam	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID563975	Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase IMP1	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID495745	Kcat/Km ratio of Acinetobacter baumannii OXA-23 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID571934	Antimicrobial activity against Escherichia coli MC4100 harboring promoter hybrid 1 in beta-lactamase GES-1 by Etest	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID571910	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 19 expressing ampC, ompA, adeB, adeM, aacC2 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID529456	Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID554390	Antimicrobial activity against Pseudomonas aeruginosa isolate 615S obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID564460	Antimicrobial activity against Pseudomonas aeruginosa isolate 1006 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID405426	fAUC (0 to 24 hrs) in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 70 mg/kg, ip administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID1757622	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-26 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757526	Antibacterial activity against Multidrug resistant Acinetobacter baumannii AR 15-2 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID531069	Antimicrobial activity against CTX-M-14, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC248 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID283116	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM3	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID372361	Ratio of Cmax in in vitro PK/PD model at 2 g infused at every 8 hrs intervals to MIC for hypermutable Pseudomonas aeruginosa isolate 12-09-15	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID373044	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate CY6 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID522025	Antimicrobial activity against Escherichia coli isolate A expressing beta-lactamase OXA-48 and TEM-150 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID532199	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae WH42T harboring qnrA gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID584505	Antimicrobial activity against wild type Pseudomonas aeruginosa PA14 by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID584689	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4402 harboring argJ mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1435411	Anti-fungal activity against Candida albicans ATCC 10231 measured after 24 hrs by microtiter broth dilution method	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.
AID1553827	Antifungal activity against Candida albicans cgmcc2.2086 measured after 48 hrs in presence of NaCl by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID163938	Minimum inhibitory concentration in Pseudomonas aeruginosa,799/61 permeability mutant	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID1757757	Bactericidal activity against carbapenem-sensitive Pseudomonas aeruginosa 17-29 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID567742	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 40 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID1435413	Anti-bacterial activity against Escherichia coli ATCC 11303 measured after 24 hrs by microtiter broth dilution method	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.
AID368482	Antibacterial activity against Providencia stuartii 2772 producing beta lactamase AmpC by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID559585	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutT::Gm mutant gene by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1757666	Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-19 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID564459	Antimicrobial activity against Pseudomonas aeruginosa isolate 988 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID325201	Antibacterial activity against Pseudomonas aeruginosa SR-24765 isolate by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID520973	Antibacterial activity against Klebsiella pneumoniae KN2303 by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID1757651	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-5 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID425863	Antimicrobial activity against Carnobacterium divergens CIP101029 at 0.5 McFarland inoculum size by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID1318930	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86141	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID285605	Antimicrobial activity against Pseudomonas aeruginosa 2F6 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID511584	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID523488	Antimicrobial activity against Pseudomonas aeruginosa R70 Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID549346	Antimicrobial activity against Escherichia coli isolate 16 harboring bla CTX-M-3a gene by broth microdilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID558048	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S11 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID1808842	Antibacterial activity against Pseudomonas aeruginosa PAO1 53/22-113 (ST-244) by broth microdilution method
AID1757508	Antibacterial activity against Acinetobacter baumannii NCTC 13304 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID529494	Antimicrobial activity against Enterobacter cloacae isolate 837 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID573403	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB C89T mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID530814	Antibacterial activity against Klebsiella pneumoniae 11978 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID533547	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA355	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID498831	Antimicrobial activity against Escherichia coli C600 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID520801	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype I by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID530327	Antimicrobial activity against Escherichia coli XL1-Blue harboring pUCP carrying VIM-13 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID565513	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-22 harboring A residue at 105 position in PDC- 4 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID582975	Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID559902	Antimicrobial activity against Escherichia coli TF-KO279 harboring beta-lactamase OXY-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID396029	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID69001	In vitro synergistic activity against Escherichia coli C600N + (Imi-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID585435	Antimicrobial activity against Pseudomonas aeruginosa PA14 mutS gene hypermutant by EUCAST method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.
AID341126	Increase in ampC gene expression in Pseudomonas aeruginosa 164M1-84C overexpressing mexCD-oprJ genes by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID368740	Antimicrobial activity against Escherichia coli Ec2 containing pEc1-D plasmid expressing CTX-M-15 TEM-1 OXA-1gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID524571	Antimicrobial activity against Shigella isolate DH-22855 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID561318	Antimicrobial activity against Enterobacter cloacae isolate 153 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID529577	Ratio of Kcat to Km for Pseudomonas maltophilia ULA-511 beta-Lactamase L-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID372341	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as bacterial count in in vitro PK/PD model at 2 g infused every 8 hrs interval measured 40 hrs after first dose relative to initial inoculum	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID556352	Antimicrobial activity against Salmonella enterica serotype concord expressing extended-spectrum beta-lactamase SHV-12 by Etest	2009	Antimicrobial agents and chemotherapy, 05, Volume: 53, Issue:5	Chromosomal integration of the extended-spectrum beta-lactamase gene blaCTX-M-15 in Salmonella enterica serotype Concord isolates from internationally adopted children.
AID1757832	Bactericidal activity against carbapenem-sensitive Pseudomonas aeruginosa 17-26 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID396028	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID209295	In vitro antimicrobial activity against Streptococcus pyogenes 77A	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID1757796	Bactericidal activity against Carbapenem- resistant Acinetobacter baumannii 17-3 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757542	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-6 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535867	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ51 harboring qnrA gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID323689	Antibacterial activity against Acinetobacter baumannii by CLSI method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.
AID368725	Activity of Serratia marcescens AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID372634	Activity of Escherichia coli DH5alpha CL1179 clone beta-lactamase TEM-152 by microacidimetric method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID1757710	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-9 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID584699	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5005 harboring mutation in putative carbamoyltransferase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID520797	Antimicrobial activity against CTX-M-59 producing Klebsiella pneumoniae with PFGE pulsotype E by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID405439	fCmax/MIC ratio in Pseudomonas aeruginosa PAOdeltamutS infected C57BL/6J mouse at 70 mg/kg, ip administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID529459	Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase Oxa-48 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID556670	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 25 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID554397	Antimicrobial activity against Pseudomonas aeruginosa isolate 2729 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID544562	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8130 expressing bla SHV-1 gene by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID528605	Antimicrobial activity against blaKPC-2 producing Escherichia coli DH5alpha by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID532202	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae WH99 harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID561444	Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK carrying beta-lactamase CMY-33 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID564219	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID529303	Antimicrobial activity against Acinetobacter genospecies 3 isolate Ac057 expressing beta-lactamase Oxa-58 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
AID368753	Antimicrobial activity against Klebsiella pneumoniae Kp5 expressing plasmid-mediated cephalosporinase ACC-1 and TEM-1	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID250257	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH01; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID556683	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 10 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID405635	Antibacterial activity against Escherichia coli MC4100 by CLSI method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID565542	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-06 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID394686	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID583096	Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87F mutant beta-lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID542720	Antimicrobial activity against ESBL-producing Klebsiella pneumoniae clinical isolate assessed as susceptible isolates	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases.
AID565421	Antimicrobial activity against ESBL- and MBL-producing Pseudomonas aeruginosa isolated from patients with bloodstream infection assessed as resistant isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.
AID584523	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3520 harboring mutation in putative periplasmic metal-binding protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID531067	Antimicrobial activity against CTX-M-14, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC241 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID584744	Activity of Beta-lactamase in Pseudomonas aeruginosa PA14 PA3047 harboring dacB mutant gene relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID585395	Activity at Bradyrhizobium japonicum metallo-beta-lactamase BJP-1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID545400	Antimicrobial activity against Pseudomonas aeruginosa PS6A with PFGE phenotype 11A obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID544950	Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1757760	Bactericidal activity against Acinetobacter baumannii NCTC 13304 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495716	Activity of Escherichia coli TEM-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID556684	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 11 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID681787	TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Ceftazidime: 2000 uM) in Xenopus laevis oocytes	1999	The Journal of pharmacology and experimental therapeutics, Aug, Volume: 290, Issue:2	The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID155941	Concentration required for 90% inhibition of [14C]-pen G binding	1994	Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3	Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.
AID532905	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 ST 376 expressing beta-lactamase SHV-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID1586252	Antibacterial activity against Escherichia coli 1162222 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID66233	Compound was tested for antimicrobial activity against Enterobacter cloacae inducible type I beta-lactamase producer (P99-) strain	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID285263	Antimicrobial activity against Escherichia coli DH5-alpha TC1295 isolate expressing TEM-1 by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID541016	Antimicrobial activity against Escherichia coli TOP10 harboring beta-lactamase PenB1	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID373054	Antimicrobial activity against Escherichia coli BL21(DE3) carrying pET9a expressing Bacillus clausii beta-lactamase BCL1 by agar-dilution technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID674594	Antibacterial activity against Staphylococcus epidermidis	2012	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16	Design, synthesis and antibacterial activities of a series of new 2-oxaisocephems.
AID1757566	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-14 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID162788	In vitro synergistic activity against Pseudomonas aeruginosa Ps505A1 (AmpC derepressed)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID571912	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 20 expressing ampC, ompA, adeB, adeM, aacC2 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID511296	Antibacterial activity against Escherichia coli DH5alpha pB-ges-1in presence of 2 ug/ml clavulanic acid	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID523500	Antimicrobial activity against Pseudomonas aeruginosa isolate 1681c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID498845	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU105 deficient TEM-1, SHV-12, CTX-M-14, DHA-1, qnrB10/B4-like, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID585453	Antimicrobial activity against ampD, ampDh2, ampDh3 and ampG deficient Pseudomonas aeruginosa PAO1 harboring pZY0901 conferring resistance to gentamycin after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID574437	Antimicrobial activity against Escherichia coli isolate 1679 expressing beta-lactamase KPC2, SHV-12, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1373302	Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-47 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID535369	Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534886	Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1757739	Bactericidal activity against ESBLs negative Carbapenem--sensitive Escherichia coli 17-20 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID341118	Increase in ampC gene expression in Pseudomonas aeruginosa 164M1 by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID555226	Ratio of Kcat to Km for Acinetobacter genomosp. 3 isolate 103 ADC-16	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID533763	Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P122 exhibiting PFGE A pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID543433	Ratio of Kcat to km for Shigella sonnei UIH-1 CTX-M-64	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID546181	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-21 with PDC-4 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID529493	Antimicrobial activity against Enterobacter cloacae isolate 781 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID549351	Antimicrobial activity against Escherichia coli isolate Z1 harboring bla CTX-M-3a gene by broth microdilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID524750	Antimicrobial activity against Escherichia coli MI1443 harboring V27A, Q38R, D240G mutations in beta lactamase CTX-M-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID519627	Antimicrobial activity against Brachyspira pilosicoli 80.10 without producing beta-lactamase OXA-63 by disc diffusion method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID495803	Antimicrobial activity against Escherichia coli 2603 strain expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID533551	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA362	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID584510	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_15600 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID404956	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii T183 isolate carrying one bla-OXA58 gene copy by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID522578	Antimicrobial activity against Escherichia coli isolate 8009162 AmpC with A292V mutation	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID584518	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2797 harboring mutation in putative anti-anti-sigma factor by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID528917	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-14 and CTX-M-27 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID394695	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC, MexXY-OprM pump, TEM-2 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID1757700	Antibacterial activity against Enterobacter aerogenes 17-2 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID546428	Activity at Pseudomonas aeruginosa PDC-3 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID584502	Antibacterial activity against porin deficient OmpA positive Klebsiella pneumoniae KPBj5 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID562777	Antimicrobial activity against Escherichia coli DH10B by Etest	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID529860	Ratio of MIC for Pseudomonas aeruginosa OCR1 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID555633	Antimicrobial activity against ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID524257	Ratio of Kcat to Km in Escherichia coli beta-lactamase SHV-1	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.
AID563602	Antimicrobial activity against lacZ-negative, Nalidixic acid-, rifampicin-resistant Escherichia coli EC600 by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID571235	Antimicrobial activity against Pseudomonas aeruginosa isolate PA22 obtained from patient with cystic fibrosis harboring beta-lactamase AmpDh3 Asp137Gly, Ala219Thr mutant by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID577221	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring gatA::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID584695	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5000 harboring wapR mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID563156	Antibacterial activity against Pseudomonas aeruginosa isolate 19BR by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
AID545404	Antimicrobial activity against Pseudomonas aeruginosa PS11A with PFGE phenotype 7A obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID404960	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii T186 isolate carrying three bla-OXA58 gene copies by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID1752485	Antibacterial activity against Enterobacter cloacae 1,261,347 producing class A beta lactamase, PER-2 assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID283128	Antibacterial activity against Escherichia coli C600	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID559823	Antimicrobial activity against Enterobacter cloacae CHE-2 harboring blaGES-5 and blaSHV-5 gene by agar dilution in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID587619	Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 infected in sc dosed CD-1 mouse septicemia infection model at 4:1 compound to NXL104 beta-lactamase inhibitor ratio by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID495750	Antimicrobial activity against Escherichia coli J5 by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID341106	Antibacterial activity against metallo-beta-lactamase VIM12 expressing Escherichia coli 28 isolate from decubitus ulcer infection patient by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
AID285626	Antimicrobial activity against Pseudomonas aeruginosa 9A3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID495655	Antimicrobial activity against Pseudomonas aeruginosa 51170 expressing beta-lactamase BEL-1 by solid agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID558799	Antimicrobial activity against extended spectrum beta-lactamase-expressing Klebsiella oxytoca assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID519004	Antimicrobial activity against Serratia marcescens isolate CT-118 by broth macrodilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID535837	Antimicrobial activity against Pseudomonas aeruginosa GP20KT21 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID556652	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 7 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID576317	Antimicrobial activity against ESBL-negative Klebsiella pneumoniae 30018 harboring porin OmpK35 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID495677	Antimicrobial activity against Enterobacter cloacae OC 4080 overexpressing beta-lactamase AmpC assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID585176	Activity of Beta-lactamase GES-7 K104, G170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID584919	Activity of Beta-lactamase in Pseudomonas aeruginosa PAO1 PA4020 harboring mpl mutant gene relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID373057	Antimicrobial activity against Bacillus clausii ATCC 21537 by agar-dilution technique in presence of beta-lactamase inhibitor clavulanic acid	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID1757621	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-24 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1373301	Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-24 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID508725	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E3 PpA2 harboring acquired beta-lactamase OXA-101 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID1300874	Antibacterial activity against Escherichia coli after clinical isolate 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID520719	Antibacterial activity against Escherichia coli DH10B	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID1209736	Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID564216	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 harboring plasmid PH98 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID1757788	Ratio of MBC to MIC for carbapenem-sensitive Pseudomonas aeruginosa 17-9 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID571890	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 9 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID368755	Antimicrobial activity against Proteus mirabilis Pm4 expressing TEM-21 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID1757579	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-10 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757633	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-13 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495715	Kcat/Km ratio of Acinetobacter baumannii OXA-23	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID674597	Antibacterial activity against Klebsiella pneumoniae	2012	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16	Design, synthesis and antibacterial activities of a series of new 2-oxaisocephems.
AID285644	Antimicrobial activity against Pseudomonas aeruginosa 15H5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID368501	Activity of Klebsiella pneumoniae TEM26 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID372621	Ratio of Kcat for Escherichia coli DH5alpha beta-lactamase TEM-12 to Kcat for Escherichia coli DH5alpha beta-lactamase TEM-158	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID368533	Ratio of Kcat to Km of Morganella morganii AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID757558	Antibacterial activity against Staphylococcus warneri assessed as growth inhibition after 18 to 22 hrs by broth microdilution method	2013	European journal of medicinal chemistry, Jul, Volume: 65	Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID519649	Antimicrobial activity against Escherichia coli EPI300 harboring pCC1 carrying beta-lactamase CTX-M-42 Pro167Thr mutant gene by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID519797	Inhibition of Bocillin FL binding to PBP1B in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID52929	In vivo activity in murine against Citrobacter freundii BS#16 infection after sc administration.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID531772	Antimicrobial activity against Pseudomonas aeruginosa pleural fluid isolate 4679 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID534382	Antibacterial activity against Escherichia coli K-12 W1895 transconjugant harboring pCF243 by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID565726	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-31 harboring A residue at 105 position in PDC- 9 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID326266	Antibacterial activity against Escherichia coli K12 carrying pR3521 encoding SCO1 by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID534339	Antimicrobial activity against Burkholderia pseudomallei 1026b after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID372359	%T>MIC against hypermutable Pseudomonas aeruginosa 12-09-15 isolate in in vitro PK/PD model at 2 g infused thrice daily at 8 hrs interval	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID562774	Antimicrobial activity against Escherichia coli DH10B by disk diffusion method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID511581	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD and dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID546169	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-09 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID583024	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli ECB2 plasmid carrying CMY-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1309044	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate SDSM1503 after 24 hrs by broth microdilution method	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	Synthesis of riccardin D derivatives as potent antimicrobial agents.
AID533539	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA339	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID285640	Antimicrobial activity against Pseudomonas aeruginosa 13D11 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID543427	Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1516020	Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID529643	Antimicrobial activity against Pseudomonas aeruginosa 9551 expressing beta-lactamase VIM-15 obtained from urine of patient by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID278603	Inhibitory activity against azide-resistant Escherichia coli J53 T03-222	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID533549	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA360	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1300872	Antibacterial activity against Streptococcus faecalis clinical isolate after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID565529	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-06 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID283122	Antibacterial activity against Escherichia coli C600 expressing ESBL SHV2	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID1757501	Antibacterial activity against Escherichia coli 15-4 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID341114	Antibacterial activity against Pseudomonas aeruginosa 164M1-84C overexpressing mexCD-oprJ genes	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID368481	Antibacterial activity against Morganella morganii 2574 producing beta lactamase AmpC by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID495676	Antimicrobial activity against wild type Serratia marcescens OC 7554 expressing beta-lactamase SME-3 and containing Carbapenemase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID573357	Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522008	Antimicrobial activity against Escherichia coli isolate J53 harboring pI-2 containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID522391	Inhibition of Aeromonas enteropelogenes Beta-lactamase TRU1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID285620	Antimicrobial activity against Pseudomonas aeruginosa 5H6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID279815	Antimicrobial activity against Escherichia coli DH5-alpha with pGEM-T EASY expressing TEM1 gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID587634	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=128:32 mg/kg, sc compound to NXL10	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID1757534	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-8 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID573375	Antibacterial activity against multidrug-resistant Acinetobacter assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID587676	Antibacterial activity against Pseudomonas aeruginosa as growth inhibition by liquid microdilution assay	2011	Journal of natural products, Feb-25, Volume: 74, Issue:2	Triterpenoid saponins from Symplocos lancifolia.
AID405810	Inhibition of bocillin FL binding to penicillin-resistant Streptococcus pneumoniae OC 8819 penicillin-binding protein 1b	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID544583	Antimicrobial activity against Escherichia coli DH5[alpha] by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID561931	Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate VA-566/00 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID495645	Antimicrobial activity against Pseudomonas luteola LAM expressing blaLUT-1 by Etest method in presence of 4 ug/ml clavulanic acid	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID519983	Activity of Klebsiella pneumoniae Beta-Lactamase SHV-1	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae.
AID584508	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0958 harboring oprD mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID495798	Ratio of Kcat to Km of Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B using nitrocefin hydrolysis	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID495684	Antimicrobial activity against wild type Acinetobacter baumannii OC 16708 deficient in beta-lactamase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID341125	Increase in ampDh3 gene expression in Pseudomonas aeruginosa 164M1-94C overexpressing mexCD-oprJ genes by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID341596	Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID495725	Activity of Klebsiella pneumoniae KPC-2 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID524742	Antimicrobial activity against Escherichia coli GB20 harboring P167S mutation in beta lactamase CTX-M-10 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID368499	Ratio of Kcat to Km of Klebsiella oxytoca beta-lactamase K1 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID368541	Ratio of Kcat to Km of Pseudomonas aeruginosa 4352 AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID368537	Ratio of Kcat to Km of Providencia stuartii AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID562740	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBC-CTX-M-15 plasmid by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID584918	Activity of Beta-lactamase in Pseudomonas aeruginosa PAO1 PA4020 harboring mpl mutant gene assessed as nitrocefin hydrolysis per mg of protein by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID534869	Antimicrobial activity against ESBL producing Proteus mirabilis assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID68507	Minimal inhibitory activity against the Enterobacter cloacae (265A beta lactamase containing)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID1757882	Ratio of MBC to MIC for Klebsiella pneumoniae ATCC BAA-1705 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID325200	Antibacterial activity against Pseudomonas aeruginosa SR-24736 isolate by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID1757682	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-1 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757772	Ratio of MBC to MIC for ESBLs negative Carbapenem-sensitive Escherichia coli 17-7 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID545608	Antimicrobial activity against Pseudomonas aeruginosa PS28 with PFGE phenotype 6 expressing beta-lactamase KPC-5 obtained from skin of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID559685	Antibacterial activity against Acinetobacter baumannii BM4652 harboring plasmid IP847	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID545620	Antimicrobial activity against Pseudomonas aeruginosa PS43 with PFGE phenotype 2 expressing beta-lactamase KPC-2, OXA-2 obtained from skin of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID252635	Bacterial susceptibility induced by D121 mutation in Escherichia coli OmpF	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	Beta-lactam screening by specific residues of the OmpF eyelet.
AID323040	Antimicrobial activity against extended-spectrum-beta-lactamase producing Klebsiella pneumoniae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID368952	%fT>MIC in mouse at 35.6 mg/kg administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID531063	Antimicrobial activity against CMY-2,CTX-M-14,TEM-2-like beta-lactamase producing Escherichia coli isolate CUMC215 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID577223	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring gabD::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID207945	In vitro antimicrobial activity against Methicillin resistant Staphylococcus aureus (MRSA)	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID529661	Activity of Pseudomonas aeruginosa 9551 beta-lactamase VIM-15 relative to cephaloridine	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID585399	Activity at Fluoribacter gormanii 1K07 metallo-beta-lactamase FEZ-1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID522020	Antimicrobial activity against Escherichia coli isolate J53 harboring pEnc1 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID522028	Antimicrobial activity against Escherichia coli isolate TOP10 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID575340	Antimicrobial activity against Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.
AID535717	Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase AmpC-B2	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID562222	Antimicrobial activity against Desulfovibrio desulfuricans Essex 6 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Susceptibilities of 23 Desulfovibrio isolates from humans.
AID1757545	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-9 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757509	Antibacterial activity against Multidrug resistant Acinetobacter baumannii AR 15-2 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495646	Antimicrobial activity against Pseudomonas luteola expressing blaLUT-2 to blaLUT-6 by Etest method in presence of 4 ug/ml clavulanic acid	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID207361	In vitro minimum inhibitory concentration required to produce antibacterial activity against Staphylococcus aureus 743 MRSA	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID523501	Antimicrobial activity against Pseudomonas aeruginosa isolate 1352c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID561664	Antimicrobial activity against Pseudomonas aeruginosa isolate OC14551 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID544570	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8130 expressing bla SHV-1 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID584692	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4550 harboring fimU mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID210248	Antibacterial activity against Streptococcus pyogenes	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID584739	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5366 harboring pstB mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID567313	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2204 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID368741	Antimicrobial activity against Escherichia coli Ec3 expressing CTX-M-15 TEM-1 OXA-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID584527	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3704 harboring wspE mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID372352	Antibacterial activity against Pseudomonas aeruginosa PAO1 at 30 ug/disk in absence of cephalosporinase inhibitor cloxacillin by disk diffusion test	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID1781724	Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID571937	Antimicrobial activity against Escherichia coli MC4100 harboring strong promoter and active promoter P2 in beta-lactamase GES-1 by Etest	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID560555	Antimicrobial activity against Proteus vulgaris Pv7 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID571233	Antimicrobial activity against Pseudomonas aeruginosa PAO1 expressing beta-lactamase AmpDh2 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID555666	Antimicrobial activity against Escherichia coli DH10B harboring natural plasmid pWES-1 carrying CTX-M-53 gene by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID558040	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S3 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID544492	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID1757854	Ratio of MBC to MIC for ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-12 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID519806	Inhibition of Bocillin FL binding to PBP2 in Pseudomonas aeruginosa PAO1 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID532390	Antibacterial activity against VIM-1 producing Pseudomonas putida isolate RM-11X-11 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID529487	Antimicrobial activity against Enterobacter cloacae isolate 622 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID529576	Ratio of Kcat to Km for Erwinia carotovora subsp. atroseptica DSM 30184 beta-Lactamase CAR-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID518520	Antimicrobial activity against Escherichia coli TOP10(pNOR-1) expressing CSP-1 gene after 2 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.
AID499062	Antimicrobial activity against carbapenem-resistant Escherichia coli HX74 deficient in TEM-1, CTX-M-14, CTX-M-3, aac(6')-Ibcr, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID534651	Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1757789	Ratio of MBC to MIC for carbapenem-sensitive Pseudomonas aeruginosa 17-10 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID510504	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-2 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID555213	Antibacterial activity against Acinetobacter genomosp. 3 isolate 195 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID565539	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-03 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID405637	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 5	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID495509	Antibacterial activity against Acinetobacter baumannii BM4587 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID1757842	Ratio of MBC to MIC for Carbapenem- resistant Acinetobacter baumannii 17-6 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID559688	Antibacterial activity against ESBL-positive and OmpF and OmpC porin-deficient Escherichia coli HB4	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID520799	Antimicrobial activity against CTX-M-59 producing Klebsiella pneumoniae with PFGE pulsotype G by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID534609	Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID518521	Antimicrobial activity against Capnocytophaga sputigena CRBIP 17.39 after 2 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.
AID498818	Antimicrobial activity against Klebsiella pneumoniae GZ64 expressing IMP-4, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID549337	Antimicrobial activity against Escherichia coli ATCC 25922 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID571038	Antimicrobial activity against Pseudomonas aeruginosa isolate PA24 obtained from patient with cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID1553778	Antibacterial activity against Staphylococcus aureus ATCC 25923 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID534908	Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID520726	Activity of Escherichia coli TOP10 beta-lactamase OXA-58 assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID559269	Antimicrobial activity against Proteus vulgaris Pv5 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID396032	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP3 plasmid containing Enterobacter aerogenes acrR gene by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID1516023	Antibacterial activity against Escherichia coli ATCC 25922 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID1757684	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-7 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495675	Antimicrobial activity against wild type Serratia marcescens OC 7555 deficient in beta-lactamase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID542526	Antimicrobial activity against Pseudomonas aeruginosa PAO1 infected in in vitro pharmacodynamic model assessed as bacterial killing at 0 to 128 mg/L using 10'8 CFU/ml inoculum by time kill study	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.
AID584507	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0908 harboring mutation in hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID531089	Antimicrobial activity against CTX-M-14, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC241 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID495666	Antimicrobial activity against Klebsiella pneumoniae OC 4238 overexpressing beta-lactamase SHV-1 assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID285621	Antimicrobial activity against Pseudomonas aeruginosa 8A2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID555677	Antimicrobial activity against Escherichia coli DH5[alpha] harboring phagemid pBK-CMV by disk diffusion method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID1808856	Antipseudomonal activity against pseudomonas aeruginosa PAO deltadacBdeltapbpGdeltadacC assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID1757687	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-19 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID567738	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 33 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID1757707	Antibacterial activity against Enterobacter aerogenes 15-6 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID531765	Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4667 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID665126	Antibacterial activity against Staphylococcus warneri after 18 to 22 hrs by EUCAST broth microdilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID368525	Ratio of Kcat to Km of Enterobacter cloacae 4080 AmpC (P99) assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID498805	Antimicrobial activity against Klebsiella pneumoniae ZJ70T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID325188	Antibacterial activity against Escherichia coli SR-21003 by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID523509	Antimicrobial activity against Pseudomonas aeruginosa isolate 15107 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID499055	Antimicrobial activity against Escherichia coli PU101T expressing CMY-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID522387	Antimicrobial activity against Escherichia coli TOP10	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID559265	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv7 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID532391	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A1 isolate FG-17X-14 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID567324	Antimicrobial activity against Escherichia coli TUM4672 by broth dilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID1757838	Bactericidal activity against Klebsiella pneumoniae ATCC BAA-1705 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757609	Antibacterial activity against Enterobacter aerogenes 17-5 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID523507	Antimicrobial activity against Pseudomonas aeruginosa isolate 1495c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID561666	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring plasmid MexXY expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID1553776	Antibacterial activity against Salmonella typhimurium C7731 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID520876	Antibacterial activity against Achromobacter xylosoxidans CIP69598 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID667374	Antibacterial activity against Pseudomonas aeruginosa ATCC 49189 after 24 hrs by microtiter broth dilution method	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.
AID405792	Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 5/6	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID565516	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-19 harboring A residue at 105 position in PDC- 3 wild-type OprD porin gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID534929	Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1407927	Antibacterial activity against Klebsiella pneumoniae ARC1865 after 24 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
AID1592957	Antibacterial activity against multi-drug resistant Escherichia coli NMI 3548/14 assessed as reduction in microbial growth incubated for 20 hrs	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID330963	Antimicrobial activity against wild type Escherichia coli transfected with pCF1 by serial dilution method	2007	The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29	Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID584719	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2963 harboring mutation in putative aminodeoxychorismate lyase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID531966	Antibacterial activity against Klebsiella pneumoniae urine isolate A28009 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID572146	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii unique clonal group isolate 40 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID285366	Susceptibility of metallo beta lactamase and extended spectrum beta lactamase deficient qnr positive Enterobacter cloacae assessed as percentage nonsusceptible isolates	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital.
AID250297	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH22; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID342020	Antibacterial activity against Escherichia coli J53 by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID565772	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 36 fold elevated mexX expression and 39 fold elevated mexY expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID573208	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB C116T mutant gene selected at 4 ug/ml of azithromycin after 5 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID584916	Activity of Beta-lactamase in Pseudomonas aeruginosa PA14 PA4020 harboring mpl mutant gene assessed as nitrocefin hydrolysis per mg of protein by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1808868	Antipseudomonal activity against pseudomonas aeruginosa Pseudomonas aeruginosa 6/04-224 (ST-175) assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID1757727	Bactericidal activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-7 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495632	Antimicrobial activity against Pseudomonas luteola expressing blaLUT-2 to blaLUT-6 by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID546423	Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-3 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID567314	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2205 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID559274	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv5 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID587983	Antibacterial activity against Escherichia coli AS226 carrying pBSDC69A mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1373293	Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV-12 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID567743	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 expressing 36 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID1757768	Ratio of MBC to MIC for ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-6 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID559600	Antimicrobial activity against Pseudomonas aeruginosa PAO1 selected in presence of ciprofloxacin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1373313	Antimicrobial activity against Escherichia coli expressing beta-lactamase MIR-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID535064	Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-7 plasmid by agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID531767	Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4682-1 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID1580096	Antibacterial activity against wild type Acinetobacter baumannii ATCC 17978 by checkerboard assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID519744	Antibacterial activity against Klebsiella pneumoniae INSRA1229 harboring SHV-72 Ile8Phe, Ala146Val, and Lys234Arg mutations by agar dilution method in presence of 2 ug/ml clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID368941	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID495634	Antimicrobial activity against Escherichia coli DH10B by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID373761	Antibacterial activity against imipenem-resistant Acinetobacter baumannii ab1265 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID519628	Antimicrobial activity against beta-lactamase OXA-63 producing Brachyspira pilosicoli isolate BM4442 isolated from feces of patient with diarrhea by disc diffusion method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID556662	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 17 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID535885	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN41 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID285615	Antimicrobial activity against Pseudomonas aeruginosa 3D10 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID285656	Antimicrobial activity against Pseudomonas aeruginosa 19E1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID203148	In vivo synergistic activity against Serratia marcescens GC 4132 (Amp C)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID571938	Antimicrobial activity against Escherichia coli MC4100 harboring promoter hybrid 1 and active promoter P2 in beta-lactamase GES-1 by Etest	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID565537	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-01 harboring T residue at 105 position in PDC- 1 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID531972	Antibacterial activity against Klebsiella pneumoniae blood isolate A28006 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID1373306	Antimicrobial activity against Escherichia coli expressing beta-lactamase NDM-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID555636	Antimicrobial activity against ampDDh2 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID518196	Antimicrobial activity against fpvA, fpvB, fptA and pirA gene deficient Pseudomonas aeruginosa 860 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534337	Antimicrobial activity against Burkholderia pseudomallei Bp216 harboring mini-Tn7T after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID556700	Antimicrobial activity against multidrug resistant Escherichia coli ATCC 35218 harboring pDrive plasmid expressing ampC gene by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID567737	Antimicrobial activity against wild type Pseudomonas aeruginosa ATCC 27853 by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID1177408	Antibacterial activity against Staphylococcus aureus ATCC 6538 after 7 hrs by Alamar Blue assay	2014	Journal of natural products, Aug-22, Volume: 77, Issue:8	Cytotoxic and Antibacterial Quinone Sesquiterpenes from a Myrothecium Fungus.
AID583016	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli EC-6 plasmid carrying AmpC-B2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID96429	In vitro synergistic activity against Klebsiella pneumoniae GC 6269 clinical isolate	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID394696	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing OXA2 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID561668	Antimicrobial activity against Pseudomonas aeruginosa isolate OC16827 harboring plasmid JAK16 expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID495837	Antimicrobial activity against Escherichia coli harbouring plasmidBK-CMV expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID1757511	Antibacterial activity against Multidrug resistant Acinetobacter baumannii AR 15-4 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID587638	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=32:8 mg/kg, sc compound to NXL104	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID523512	Antimicrobial activity against Pseudomonas aeruginosa isolate 1240 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID555450	Antibacterial activity against Escherichia coli DH5alpha by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1553822	Antibacterial activity against Staphylococcus aureus ATCC 29213 measured after 18 to 24 hrs in presence of CaCl2	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID285651	Antimicrobial activity against Pseudomonas aeruginosa 19C5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID326198	Antibacterial activity against Pseudomonas aeruginosa FP1380 after 18 hrs by agar dilution method	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure.
AID524746	Antimicrobial activity against Escherichia coli GB20 harboring V27A, Q38R, A77V, P167S mutation in beta lactamase CTX-M-3 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID522384	Antimicrobial activity against Aeromonas enteropelogenes ATCC 49803 producing endogenous class C beta-lactamase TRU-1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID535141	Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535879	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN132 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID528916	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-14 and CTX-M-27 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID529855	Antibacterial activity against Pseudomonas aeruginosa COR6 expressing MexC-MexD-OprJ gene by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID556681	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 8 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID368515	Ratio of Kcat to Km of Pseudomonas aeruginosa IMP1 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID368723	Ratio of Kcat to Km of Pseudomonas aeruginosa MK-1184 AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID544560	Antimicrobial activity against Escherichia coli DH5[alpha] by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID572134	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 34 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID68375	In vitro synergistic activity against Enterobacter cloacae SC12629 (AmpC inducible)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID522012	Antimicrobial activity against Escherichia coli isolate J53 harboring pE containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID565279	Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A1 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID573392	Antibacterial activity against ceftazidime-susceptible Providencia sp. assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID587675	Antibacterial activity against Escherichia coli assessed as growth inhibition by liquid microdilution assay	2011	Journal of natural products, Feb-25, Volume: 74, Issue:2	Triterpenoid saponins from Symplocos lancifolia.
AID534391	Antibacterial activity against Escherichia coli JM109 by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID531079	Antimicrobial activity against CMY-2,TEM-2-like beta-lactamase producing Escherichia coli isolate CUMC224 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID70415	In vitro antimicrobial activity against Escherichia coli DC 2	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID516145	Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 11 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID95918	Antibacterial activity against Klebsiella pneumoniae X26	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID1373287	Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-4 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID510508	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC1AC9-26 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID495697	Activity of Pseudomonas aeruginosa VIM-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID520715	Antibacterial activity against Acinetobacter baumannii CIP7010 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID533762	Antibacterial activity against OXA-2 and OXA-19 producing Pseudomonas aeruginosa isolate P66 exhibiting PFGE C pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID534176	Antimicrobial activity against armA positive Klebsiella pneumoniae DU producing beta lactamase CTX-M-3 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID531318	Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID523492	Antimicrobial activity against Pseudomonas aeruginosa 2779-con by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1757661	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-15 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID560705	Inhibition of Escherichia coli MC4100 Beta-Lactamase CMY-30 using cephalothin as reporter substrate	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID574434	Antimicrobial activity against Escherichia coli isolate 544 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from abscess of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1757686	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-16 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID584847	Ratio of Kcat to Km for Aeromonas allosaccharophila AL-1 beta-lactamase PER6	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID587979	Antibacterial activity against Escherichia coli AS226 carrying pBSDN104D mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID523889	Antimicrobial activity against Acinetobacter baumannii 6AB15 harboring ISAba1-blaOXA-23 and blaOXA-66 gene by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID1757565	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-13 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID587984	Antibacterial activity against Escherichia coli AS226 carrying pBSDF160T mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID126324	Percent of dose in Rhesus monkeys urine at the dose of 30 mg/kg.	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.
AID564463	Antimicrobial activity against Pseudomonas aeruginosa isolate 927 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID1649592	Antimicrobial activity against Klebsiella pneumoniae clinical isolates in presence of 10 ug/ml iron by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID499068	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ90 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID508727	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1D5 SA1 harboring acquired beta-lactamase VIM-2 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID1335735	Antibacterial activity against Escherichia coli ATCC 25925 after 16 to 20 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids.
AID531337	Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 selected after 1.0 ug/ml of azithromycin by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID584524	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3589 harboring mutation in acetyl-coenzyme A (CoA) acetyltransferase (thiolase) by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID584929	Activity of Beta-lactamase in Pseudomonas aeruginosa PAO1 PA4522 harboring ampD mutant gene relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID373058	Antimicrobial activity against Escherichia coli DH10B carrying pJIM2246 expressing Bacillus clausii NR beta-lactamase BCL1 by agar-dilution technique in presence of beta-lactamase inhibitor clavulanic acid	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID564531	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid with entire blaAmpC gene by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID368727	Ratio of Kcat to Km of Serratia marcescens AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID535666	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ67 harboring wild-type GyrA S83I and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID495910	Antimicrobial activity in Escherichia coli TOP10 strain	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID565509	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-27 harboring A residue at 105 position in PDC- 7 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1553826	Antibacterial activity against Staphylococcus aureus ATCC 29213 measured after 18 to 24 hrs in presence of NH4Cl	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID250261	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH05; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID519630	Antimicrobial activity against Escherichia coli JM83 harboring beta-lactamase OXA-63 after 3 days by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID518197	Antimicrobial activity against fpvA deficient Pseudomonas aeruginosa (560546)9 M.P. by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID562224	Antimicrobial activity against Desulfovibrio piger by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Susceptibilities of 23 Desulfovibrio isolates from humans.
AID583028	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli pGLK-1 plasmid carrying FOX-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1757608	Antibacterial activity against Enterobacter aerogenes 17-4 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID424858	Antimicrobial activity against Pseudomonas aeruginosa GY3 producing blaVIM-2 by E-test	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID495809	Antimicrobial activity against Escherichia coli DH5alpha harbouring plasmid BK-VIM-19 expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID529580	Ratio of Kcat to Km for Caulobacter crescentus beta-Lactamase CAU-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID587628	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=1024:256 mg/kg, sc compound to NXL	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID495636	Ratio of kcat/Km for Pseudomonas luteola LAM Beta-lactamase LUT-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID1427882	Antibacterial activity against multidrug resistant Enterobacter aerogenes EA289 over-expressing AcrAB-TolC after 18 hrs by broth dilution method	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E. aerogenes Gram-negative bacteria.
AID1442085	Antibacterial activity against Staphylococcus aureus ATCC 29213 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID556354	Antimicrobial activity against Salmonella enterica serotype concord expressing extended-spectrum beta-lactamase CTX-M-15 by Etest	2009	Antimicrobial agents and chemotherapy, 05, Volume: 53, Issue:5	Chromosomal integration of the extended-spectrum beta-lactamase gene blaCTX-M-15 in Salmonella enterica serotype Concord isolates from internationally adopted children.
AID561323	Antimicrobial activity against Klebsiella pneumoniae isolate 132 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID573204	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T41C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID373983	Antimicrobial activity Escherichia coli 633 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID1553795	Bactericidal activity against Staphylococcus aureus ATCC 25923 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID285590	Antimicrobial activity against Pseudomonas aeruginosa 65.38-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID546618	Antimicrobial activity against Pseudomonas aeruginosa isolate 243-31C expressing beta-lactamase VIM-18 isolated from sputum of patient by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID69009	In vitro synergistic activity against Escherichia coli C600N + (Sme-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID495704	Kcat/Km ratio of Klebsiella oxytoca Beta-lactamase K1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID534192	Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
AID523966	Antibacterial activity against Burkholderia pseudomallei 1026b infected in mouse AMJ.2 cells assessed as intracellular bacterial load at 10 ug/ml after 24 hrs by serial dilution plating technique in presence of IFN-gamma-harboring cationic liposome-DNA co	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID368316	Antibacterial activity against Escherichia coli 6226 producing beta lactamase KPC2 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID325448	Antibacterial activity against Staphylococcus aureus Mu50 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID533002	Antibacterial activity against VEB-1a and OXA-10 producing Pseudomonas aeruginosa isolate P151 exhibiting PFGE I pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID521997	Antimicrobial activity against Klebsiella pneumoniae isolate Kp4A expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID285632	Antimicrobial activity against Pseudomonas aeruginosa 10A9 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1757818	Bactericidal activity against ESBLs positive carbapenem-sensitive Escherichia coli 17-18 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID252617	Mean lysis diameter of Enterobacter aerogenes EA289 with D113A mutation by standard disk diffusion method on MH agar	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	Beta-lactam screening by specific residues of the OmpF eyelet.
AID1757694	Antibacterial activity against Enterobacter cloacae 17-6 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID524937	Antimicrobial activity against Escherichia coli MI1443 harboring V27A, Q38R, N106S and D240G mutations in beta lactamase CTX-M-3 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID532902	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID285587	Antimicrobial activity against Pseudomonas aeruginosa 65.36-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID585445	Antimicrobial activity against ampG deficient Pseudomonas aeruginosa PAO1 harboring pZY0908 conferring resistance to gentamycin after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID66240	Minimum inhibitory concentration in Enterobacter cloacae, P99- inducible type 1 lactamase producer	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID1757669	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-3 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535752	Antimicrobial activity against hospital-acquired Klebsiella pneumoniae obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID562775	Antimicrobial activity against Escherichia coli DH10B by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID368491	Ratio of Kcat to Km of Klebsiella pneumoniae SHV1 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1757745	Bactericidal activity against Enterobacter cloacae 17-8 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID529853	Antibacterial activity against beta-lactamase and MexA-MexB-OprM-overproducing Pseudomonas aeruginosa N045 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID285688	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA2404 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID556657	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 12 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID565535	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-31 harboring A residue at 105 position in PDC- 9 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID422883	Antimicrobial activity against 8 ug/ml colistin-subcultured Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis and bacteremia by broth microdilution assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
AID498812	Antimicrobial activity against Escherichia coli ZJ87 expressing KPC-2, TEM-1, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID575320	Antimicrobial activity against Escherichia coli 06CEB6542SALTC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID555649	Ratio of MIC for ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method presence of 0.5 mM nagZ inhibitor EtBuPUG to MIC for ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 in absence of nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID585442	Antimicrobial activity against ampGh1 deficient Pseudomonas aeruginosa PAK after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID1808869	Antipseudomonal activity against pseudomonas aeruginosa Pseudomonas aeruginosa PAHUAC-14 (ST-966) assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID567306	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2204 isolated from burn patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID531656	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC190 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID535171	Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID559527	Antibacterial activity against Citrobacter freundii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID585434	Antimicrobial activity against Pseudomonas aeruginosa PA14 by EUCAST method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.
AID69003	In vitro synergistic activity against Escherichia coli C600N + (MIR-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID572120	Antimicrobial activity against Acinetobacter baumannii lambda clonal group isolate 27 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID285657	Antimicrobial activity against Pseudomonas aeruginosa 19E2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID69034	Minimal inhibitory activity against the E. coli(TEM beta lactamase containing)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID573345	Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID33217	In vitro synergistic activity against Aeromonas sobria (Asb A, OXA-12, Asb M)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID521292	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype F by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID1757671	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-6 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534532	Antimicrobial activity against Klebsiella oxytoca KCTC 1686 after 18 hrs by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID520802	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype J by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID546161	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-01 with PDC-1 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID533759	Antibacterial activity against OXA-10, PSE-1, VIM-2 and PER-1 producing Pseudomonas aeruginosa isolate P22 exhibiting PFGE F pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID573201	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T533C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1757794	Ratio of MBC to MIC for Klebsiella pneumoniae ATCC BAA-1705 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID341129	Increase in ampDh3 gene expression in Pseudomonas aeruginosa 164M1-84C overexpressing mexCD-oprJ genes by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID529484	Antimicrobial activity against Enterobacter cloacae isolate 185 containing PFGE genetic clone A expressing qnrB2 aac(6')-Ib-cr and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID573335	Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID533569	Antimicrobial activity against Pseudomonas aeruginosa isolate PA475 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID373035	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ55 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID543411	Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID70805	In vitro minimum inhibitory concentration against Escherichia coli (DC2 permeability mutant).	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID544426	Antimicrobial activity against Escherichia coli MC4100A harboring beta-lactamase L1 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID340731	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase SHV-ES by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID571237	Antimicrobial activity against Pseudomonas aeruginosa isolate PA24 obtained from patient with cystic fibrosis harboring beta-lactamase AmpDh3 Ala219Thr mutant by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID511287	Antibacterial activity against Pseudomonas aeruginosa NL68 expressing GES-13 beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID522582	Antimicrobial activity against Escherichia coli Top10	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID531071	Antimicrobial activity against CMY-2,CTX-M-14,TEM-2-like beta-lactamase producing Klebsiella pneumoniae isolate CUMCK2 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID495722	Activity of Pseudomonas aeruginosa AmpC relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID532403	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone E isolate VA-06X-29 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID667372	Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by microtiter broth dilution method	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.
AID535719	Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase AmpC-B2 S287N mutant	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID567734	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID571918	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 23 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, aphA6 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID571227	Antimicrobial activity against Pseudomonas aeruginosa isolate PA113 harboring beta-lactamase AmpD1 Gly148Ala, Asp183Tyr mutant obtained from patient with cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID554984	Antibacterial activity against Acinetobacter genomosp. 3 isolate 14 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID394496	Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc1 plasmid by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID535648	Antimicrobial activity against aac(6')-Ib-cr-positive Escherichia coli FJ3 harboring GyrA S83L, ParC S80R mutant, wild-type GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1757880	Ratio of MBC to MIC for Acinetobacter baumannii NCTC 13304 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID555191	Ratio of MIC for Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox deltaampDh3::lox deltanagZ::Gm to MIC for nagZ gene-deficient Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID1757562	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-10 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID163939	Minimum inhibitory concentration in Pseudomonas aeruginosa,799WT parent organism	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID511579	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD and ampDh3 gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID575329	Antimicrobial activity against Salmonella Typhimurium 08-1745 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID585184	Ratio of Kcat to Km for Beta-lactamase GES-5 E104, S170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID368547	Activity of Pseudomonas aeruginosa MK-1184 AmpC assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1757800	Bactericidal activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-4 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID524928	Antimicrobial activity against Escherichia coli MI1443 harboring N106S mutation in beta lactamase CTX-M-10 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID534528	Antimicrobial activity against vancomycin-resistant Enterococcus faecium CCARM 5028 after 18 hrs by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.
AID587624	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse septicemia infection model at 8:1 compound to NXL104 beta-lactamase inhibitor ratio by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID562741	Antimicrobial activity against Escherichia coli DH5[alpha] by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID1757544	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-8 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID563970	Antibacterial activity against Escherichia coli J53 harboring beta-lactamase NDM-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID1668276	Antibacterial activity against Staphylococcus aureus subsp. aureus ATCC 29213 incubated for 24 hrs by photometry
AID542585	Antimicrobial activity against plasmid encoded beta-lactamase OXA-58 deficient Acinetobacter radioresistens by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
AID583026	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli EC-6 plasmid carrying AmpC-B2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1757877	Ratio of MBC to MIC for carbapenem-sensitive Pseudomonas aeruginosa 17-29 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757570	Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-17 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID373032	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FW-F1 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1757663	Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-16 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID665123	Antibacterial activity against Enterobacter aerogenes after 18 to 22 hrs by EUCAST broth microdilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1757786	Ratio of MBC to MIC for Enterobacter aerogenes 15-4 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID559686	Antibacterial activity against Escherichia coli Top10	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID285674	Antimicrobial activity against Pseudomonas aeruginosa 23C5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID207948	In vitro antimicrobial activity against Staphylococcus aureus 503	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.
AID582763	Antimicrobial activity against eaeA positive verocytotoxin-producing non-O157 Escherichia coli isolates obtained from human assessed as percentage of resistant isolates	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
AID1757659	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-13 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535698	Antimicrobial activity against Azide-resistant Escherichia coli J53 by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID544439	Antimicrobial activity against mreB-deficient Escherichia coli YLS-3 harboring beta-lactamase CTX-M-14 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID1666868	Inhibition of swarming motility of Burkholderia cepacia clinical isolates incubated for 16 to 20 hrs	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	Optimized plant compound with potent anti-biofilm activity across gram-negative species.
AID373036	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ52 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1757804	Bactericidal activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-8 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285265	Antimicrobial activity against Escherichia coli DH5-alpha isolate expressing pBK-CMV by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID369643	Antibacterial activity against Acinetobacter haemolyticus expressing carbapenemase-encoding blaOXA-40 gene by Etest method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
AID555403	Antimicrobial activity against ampDh2 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID586058	Antimicrobial activity against Acinetobacter baumannii clinical isolate harboring chromosomally encoded ISAba1-blaOXA-51-like gene with fxsA upstream sequence by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
AID1586263	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID208150	Minimal inhibitory activity against the Streptococcus pneumoniae (PARK)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID573193	Antimicrobial activity against mutS::lox,mexD::lox-deficient Pseudomonas aeruginosa PAOMSMxD biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID520383	Antimicrobial activity Escherichia coli DH5alpha expressing metallo-beta-lactamase VIM-11 by agar macrodilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID555634	Antimicrobial activity against ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID561933	Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate RUH134 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID531657	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC181 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID524436	Antimicrobial activity against Shigella flexneri isolate AM19035 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID582924	Ratio of Kcat to Km for Escherichia coli BL21(DE3) VIM-2 W87A mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID162918	Minimal inhibitory activity against the Proteus morganii (PR15)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID535894	Antimicrobial activity against aac(6')-Ib-cr-negative Citrobacter freundii JN64T harboring qnrA gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID546419	Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-4 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID1056840	Antibacterial activity against CTX-15 expressing Aeromonas caviae isolate 258 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID341116	Antibacterial activity against mexCD-oprJ overexpressing Pseudomonas aeruginosa 164M1-94C harboring p26PAD1 plasmid containing ampD gene	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID1171224	Ratio of MIC for wild-type Pseudomonas aeruginosa to MIC for MeXABCDXY-deficient Pseudomonas aeruginosa	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID285675	Antimicrobial activity against Pseudomonas aeruginosa 24F4 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID520808	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype B by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID340738	Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis relative to control	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID511667	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID368538	Ratio of Kcat to Km of Providencia stuartii AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID572144	Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 39 expressing ampC, ompA, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID542046	Antibacterial activity against Escherichia coli TrC A expressing Klebsiella pneumoniae A blaCTX-M beta-lactamase by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID1752474	Antibacterial activity against Klebsiella pneumonia ATCC 13883 infected in cyclophosphamide-induced neutropenic Jcl:ICR mouse model assessed as log10 reduction in CFU at 3 mg/kg, sc administered at 2, 5 and 8 hrs after infection and measured at 10 hrs aft	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID556660	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 15 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID584496	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae KPBj3 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID324868	Antimicrobial activity against Acinetobacter baumannii B46 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID518523	Antimicrobial activity against Escherichia coli TOP10 after 2 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.
AID573365	Antibacterial activity against ceftazidime-susceptible Morganella morganii assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1757584	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-17 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID531681	Antimicrobial activity against Acinetobacter baumannii Ab290 containing plasmid harboring OXA-58-3 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID576299	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 25008 by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID559689	Antibacterial activity against ESBL-positive and OmpF and OmpC porin-deficient Escherichia coli HB4 harboring plasmid AT517	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID368490	Ratio of Kcat to Km of Klebsiella pneumoniae SHV1 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID369642	Antibacterial activity against Acinetobacter baumannii C clone by Etest method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
AID1757523	Antibacterial activity against Multidrug resistant Klebsiella pneumoniae KR 15-2 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID368319	Antibacterial activity against Staphylococcus aureus 4116 producing betalactamase PC1 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1757680	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-21 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID372618	Ratio of Kcat to Km for Escherichia coli CF0042 beta-lactamase TEM-35	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID519662	Antimicrobial activity against Escherichia coli EPI300 harboring GM2995 pCC1-1224 carrying CTX-M-3 beta-lactamase gene from by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID587616	Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 infected in sc dosed CD-1 mouse septicemia infection model at 2:1 compound to NXL104 beta-lactamase inhibitor ratio by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID587982	Antibacterial activity against Escherichia coli AS226 carrying pBSDD240A mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID575316	Antimicrobial activity against Escherichia coli 03-8748TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID23804	Half-life was evaluated for pharmacokinetic data in rats	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID573374	Antibacterial activity against multidrug-resistant Acinetobacter assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID324870	Antimicrobial activity against Acinetobacter baumannii B46 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID519801	Inhibition of Bocillin FL binding to PBP5 in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID554986	Antibacterial activity against Acinetobacter genomosp. 3 isolate 21 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID326271	Activity of Escherichia coli K12 beta-lactamase CARB1 relative to penicillin G	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID555686	Antimicrobial activity against Escherichia coli ATCC 25922 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID368493	Activity of Escherichia coli CTX-M-15 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID285574	Antimicrobial activity against Pseudomonas aeruginosa 65.18-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID285339	Antimicrobial activity against streptomycin-resistant Escherichia coli J53 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
AID523973	Antibacterial activity against Burkholderia pseudomallei 1026b infected in BALB/c mouse assessed as decrease in bacterial burden in liver at 25 mg/kg, ip administered 6 hrs postinfection at 12 hrs interval for 3 days measured after 48 hrs of bacterial inf	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID495751	Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID373753	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab4 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID511295	Antibacterial activity against Escherichia coli DH5alpha pB-ges-13 plasmid in presence of 2 ug/ml clavulanic acid	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID511414	fT>MIC in cystic fibrosis patient at 6 gram/70kg, iv administered as 1 mg/l infusion every 8 hrs	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID405820	Antimicrobial activity against Acinetobacter baumannii 501 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID542766	Antimicrobial activity against Escherichia coli PA11 expressing aac(6')-Ib-cr, qnrS1 and qepA genes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID556692	Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 harboring pACM204 plasmid by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID498828	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae SZ92 deficient in IMP-4, TEM-1, CTX-M-14, DHA-1, qnrB10/B4-like, aac(6')-Ib, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524434	Antimicrobial activity against Shigella flexneri isolate AM13291 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID372325	Cmax in PK/PD in vitro model infused with 2g at 8hr intervals	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID498844	Antimicrobial activity against Klebsiella pneumoniae XJ81T expressing TEM-1, SHV-12, aac(6')-Ib by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1757520	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1427881	Antibacterial activity against AcrAB deficient Escherichia coli AG100A after 18 hrs by broth dilution method	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E. aerogenes Gram-negative bacteria.
AID511410	Cmax in healthy human subjects at 2 gram, iv administered in 5 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID546408	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-25 with PDC-6 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID535891	Antimicrobial activity against aac(6')-Ib-cr-negative Citrobacter freundii JN64 harboring GyrA T83I, wild-type ParC, GyrB and qnrA genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1757658	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-12 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID523968	Antibacterial activity against Burkholderia pseudomallei 1026b infected in mouse AMJ.2 cells assessed as decrease in intracellular bacterial growth at 10 ug/ml after 24 hrs by serial dilution plating technique in presence of 1 U/ml murine recombinant IFN-	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID559803	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutT mutant gene selected in presence of ciprofloxacin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1752457	Antibacterial activity against Escherichia coli BL21(DE3) transfected with pET9a vector harboring class B beta lactamase, NDM-1 incubated for 16 to 20 hrs by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID562756	Ratio of Kcat to Km for Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID324852	Antimicrobial activity against Acinetobacter baumannii D54 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID368950	%fT>MIC in mouse at 4.60 mg/kg administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
AID495654	Antimicrobial activity against Pseudomonas aeruginosa 531 expressing beta-lactamase BEL-2 by solid agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID534396	Ratio of Kcat to Km for Escherichia coli JM109 harboring recombinant pKHM-1 Beta-lactamase KHM-1 assessed as compound hydrolysis by UV-visible spectrophotometry	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID68876	In vitro synergistic activity against Escherichia coli ATCC 35218 (TEM-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID535692	Antimicrobial activity against beta-lactamase CTX-M-15-producing fluoroquinolone-resistant Escherichia coli FMV5825 expressing qnrB2 and aac(6')-Ib-cr and harboring gyrA Ser83Ile and Asp87Asn mutant gene and ParC Ser80Ile and Glu84Val mutant gene obtained	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID567735	Antimicrobial activity against Pseudomonas aeruginosa OC 11678 by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID571694	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 3 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1257071	Antibacterial activity against methicillin-resistant Staphylococcus aureus Mu50 ATCC 700699 after 20 hrs by CLSI broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities.
AID285630	Antimicrobial activity against Pseudomonas aeruginosa 9B5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID576283	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17829 by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID562773	Antimicrobial activity against Escherichia coli DH10B by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID520779	Antibacterial activity against Escherichia coli EC600 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID531648	Antimicrobial activity against CTX-M-14, TEM-1-like beta-lactamase producing Escherichia coli isolate CUMC176 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID325445	Antibacterial activity against Escherichia coli C921-61 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID1752458	Antibacterial activity against Escherichia coli BL21(DE3) transfected with pET9a vector harboring class C beta lactamase, AmpC incubated for 16 to 20 hrs by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID561322	Antimicrobial activity against Escherichia coli isolate 48 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID561445	Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK carrying beta-lactamase CMY-44 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID555199	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox delta ampDh3::lox after 18 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID495738	Kcat/Km ratio of Enterobacter cloacae AmpC relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID561669	Antimicrobial activity against Pseudomonas aeruginosa isolate OC16827 harboring plasmid MexXY expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID368479	Antibacterial activity against Enterobacter cloacae 4080 producing beta lactamase AmpC (P99) by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID534345	Antimicrobial activity against Burkholderia pseudomallei Bp175 harboring mini-Tn7T-P1-bpeR+ after 24 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID495693	Activity of Enterobacter cloacae AmpC	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID519659	Antimicrobial activity against Escherichia coli EPI300 Irk1224 type 3 mutant harboring CTX-M-3 beta-lactamase Lys136 mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.
AID529159	Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID203166	In vitro minimum inhibitory concentration for Serratia marcescens (ATCC-27117) by agar dilution method	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.
AID556673	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae ATCC 11296 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID374138	Antimicrobial activity against CTX-M ESBL producing isolate of Escherichia coli at 30 ug by double-disk diffusion method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
AID545610	Antimicrobial activity against Pseudomonas aeruginosa PS30 with PFGE phenotype 11D obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID495707	Kcat/Km ratio of Pseudomonas aeruginosa AmpC	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID542584	Antimicrobial activity against Acinetobacter radioresistens 251-39C expressing beta-lactamase OXA-133 by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
AID14931	The compound was evaluated for area under the curve	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.
AID542050	Antibacterial activity against rifampicin resistant Escherichia coli J53-2 by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID571916	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 22 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID530816	Antibacterial activity against Escherichia coli J53 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID95551	Minimal inhibitory activity against the Klebsiella(KAE beta lactamase containing)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID1757822	Bactericidal activity against Enterobacter cloacae 17-9 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID563588	Induction of ampC mRNA expression in Pseudomonas aeruginosa PAO1 at 0.5 X MIC relative to untreated control	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID584727	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3978 harboring mutation in hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID530330	Antimicrobial activity against Escherichia coli XL1-Blue by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1757601	Antibacterial activity against Enterobacter cloacae 17-7 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID283218	Antimicrobial susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patient assessed as percent susceptible isolates	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
AID368743	Antimicrobial activity against Escherichia coli Ec5 expressing CTX-M-2 TEM-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID532184	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae SY26 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID325206	Antibacterial activity in CAZ-resistant Pseudomonas aeruginosa SR24-12 infected ICR mouse after 7 days	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID1442094	Antibacterial activity against Pseudomonas aeruginosa 25349 clinical isolate after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID519807	Inhibition of Bocillin FL binding to PBP3 in Pseudomonas aeruginosa PAO1 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID372327	Half life in in vitro PK/PD model at 2 g infused thrice daily at 8 hrs interval	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID534888	Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID495668	Antimicrobial activity against Escherichia coli OC 6697 expressing beta-lactamase CMY-2 and containing plasmid AmpC assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID301091	Antibacterial activity against beta-lactamase negative ampicillin resistant Haemophilus influenzae SR-11435 after 20 hrs by agar dilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.
AID519014	Antimicrobial activity against Enterobacter aerogenes isolate SS-13 by broth macrodilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID373047	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FZ4A18 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID535136	Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID565714	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-19 harboring A residue at 105 position in PDC- 3 and wild type OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID529651	Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-2 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID69012	In vitro synergistic activity against Escherichia coli C600N + (ampR ampC)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID571040	Antimicrobial activity against Pseudomonas aeruginosa isolate PA113 obtained from patient with cystic fibrosis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
AID495517	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4675 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID245001	Minimum inhibitory concentration of compound against Citrobacter freundii derepressed 91/98-2	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID518730	Antimicrobial activity against Pseudomonas stutzeri clinical isolate expressing beta-lactamase DIM-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
AID519980	Ratio of Kcat to Km for Klebsiella pneumoniae Beta-Lactamase SHV-55	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae.
AID587631	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in CD-1 mouse thigh infection model assessed as change in log10 CFU reduction per thigh treated 1.5 hr post infection at >=256:64 mg/kg, sc compound to NXL10	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID545446	Antimicrobial activity against extended-spectrum beta-lactamase-negative Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID373763	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh9 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID1757833	Bactericidal activity against carbapenem-sensitive Pseudomonas aeruginosa 17-29 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID555637	Antimicrobial activity against ampDDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID534865	Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID555640	Antimicrobial activity against ampDh2 and ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID405090	Antimicrobial activity against integron carrying Enterobacteriaceae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
AID330968	Antimicrobial activity against ampD deficient Escherichia coli transfected with pCF1 in medium containing EtbuPUG by serial dilution method	2007	The Journal of biological chemistry, Jul-20, Volume: 282, Issue:29	Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
AID573198	Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMAA biofilm harboring nfxB C25T mutant gene selected at 1 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1668277	Antibacterial activity against Salmonella enterica subsp. enterica ATCC 14028 incubated for 24 hrs by photometry
AID368496	Activity of Klebsiella oxytoca beta-lactamase K1 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID68875	In vitro synergistic activity against Escherichia coli ATCC 25922 (no beta-lactamase)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID405451	Antibacterial activity against Pseudomonas aeruginosa PAO1 infected in C57BL/6J mouse assessed as lung bacterial count at 70 mg/kg, ip administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID521838	Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID564213	Antimicrobial activity against Acinetobacter baumannii ATCC 135040 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID535173	Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID567730	Antimicrobial activity against wild type Pseudomonas aeruginosa PAO1 by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID1373317	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-23 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID541023	Ratio of Kcat to Km for Burkholderia cenocepacia 07-34 beta-lactamase PenB1 expressed in Escherichia coli Top10	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID285618	Antimicrobial activity against Pseudomonas aeruginosa 5F8 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID544568	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8128 expressing bla SHV-105 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID285582	Antimicrobial activity against Pseudomonas aeruginosa 65.33-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID285639	Antimicrobial activity against Pseudomonas aeruginosa 13D6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID564210	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA lung biopsy specimen of patient by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID1318927	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86053	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID555217	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 56 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID341122	Increase in ampC gene expression in Pseudomonas aeruginosa 164M1-94C overexpressing mexCD-oprJ genes by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID519814	Inhibition of Bocillin FL binding to PBP3 in Pseudomonas aeruginosa 27853 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID1586255	Antibacterial activity against Escherichia coli Top 10 expressing TolC-parent after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID573347	Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID559905	Antimicrobial activity against Escherichia coli DH5alpha by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID1561472	Antibacterial activity against wild type Escherichia coli TG1 in Mueller-Hinton broth by CLSI protocol based method
AID1757790	Ratio of MBC to MIC for carbapenem-sensitive Pseudomonas aeruginosa 17-26 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID372626	Ratio of Kcat/Km for Escherichia coli DH5alpha beta-lactamase TEM-12 to Kcat/Km for Escherichia coli DH5alpha beta-lactamase TEM-158	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID1553814	Antibacterial activity against Escherichia coli ATCC 25922 measured after 18 to 24 hrs in presence of KCl	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID520798	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype F by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID511406	Terminal half life in cystic fibrosis patient at 2 gram, iv administered in 5 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID576296	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 16830 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID285633	Antimicrobial activity against Pseudomonas aeruginosa 10B1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID326200	Antibacterial activity against Pseudomonas aeruginosa PAO1 ampD-deffective mutant after 18 hrs by agar dilution method	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure.
AID278594	Inhibitory activity against azide-resistant Escherichia coli J53	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID532208	Antimicrobial activity against Escherichia coli J53 harboring wild-type GyrA, ParC, GyrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID520967	Antibacterial activity against Escherichia coli harboring pNYC plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID582976	Antimicrobial activity against ampD::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID1757589	Antibacterial activity against ESBLs negative Carbapenem-sensitive Escherichia coli 17-4 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID584498	Antibacterial activity against porin deficient OmpA positive Klebsiella pneumoniae KPBj3 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID1300877	Antibacterial activity against Klebsiella oxytoca clinical isolate after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID495648	Antimicrobial activity against Escherichia coli DH10B by Etest method in presence of 4 ug/ml clavulanic acid	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID1752464	Antibacterial activity against Klebsiella pneumoniae PLE producing class D beta-lactamase, OXA-48 assessed as reduction in microbial growth incubated for 16 to 20 hrs by broth microdilution method	2021	Bioorganic & medicinal chemistry, 09-15, Volume: 46	A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.
AID368757	Antimicrobial activity against Morganella morganii expressing TEM-24b AmpC gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID575328	Antimicrobial activity against Escherichia coli 08-1537TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID1757582	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-14 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1586267	Antibacterial activity against Streptococcus pyogenes 1308007P after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID1757581	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-12 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495741	Kcat/Km ratio of Serratia marcescens SME-3 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID521993	Antimicrobial activity against Klebsiella pneumoniae isolate KpB expressing OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID564456	Antimicrobial activity against Pseudomonas aeruginosa isolate 22 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID1373288	Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-8 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID373773	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh37 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID405438	fCmax/MIC ratio in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 70 mg/kg, ip administered every 3 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID508485	Antimicrobial activity against Pseudomonas aeruginosa isolate BU-43038 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID574431	Antimicrobial activity against Escherichia coli isolate 540 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID523962	Antibacterial activity against Burkholderia pseudomallei 1026b infected in BALB/c mouse assessed as survival rate at 25 mg/kg, ip administered 6 hrs postinfection at 12 hrs interval for 3 days measured on day 20	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID558049	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S12 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID560113	Antibacterial activity against Escherichia coli TOP10 harboring recombinant plasmid RTG4-S69-V49 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID583089	Ratio of Kcat to Km for Escherichia coli XL1-Blue wild-type VIM-2 beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID326267	Antibacterial activity against Escherichia coli DH5-alpha carrying pSCO1 encoding SCO1 by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID404954	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii BM4547 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID587617	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse septicemia infection model at 2:1 compound to NXL104 beta-lactamase inhibitor ratio by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID325443	Antibacterial activity against Escherichia coli K10 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID368314	Activity of Staphylococcus aureus betalactamase PC1 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID532908	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID544537	Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID565510	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-28 harboring A residue at 105 position in PDC- 7 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1757767	Ratio of MBC to MIC for ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-2 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757602	Antibacterial activity against Enterobacter cloacae 17-8 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID368485	Antibacterial activity against Pseudomonas aeruginosa MK-1184 producing beta lactamase AmpC by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID544566	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8133 expressing bla TEM-55 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID1757557	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-5 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID498811	Antimicrobial activity against Escherichia coli ZJ86T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID573194	Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring duplication mutation at nucleotide 333 in nfxB gene selected at 0.5 ug/ml of azithromycin by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID520795	Antimicrobial activity against CTX-M-59 producing Klebsiella pneumoniae with PFGE pulsotype C by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID562576	Antimicrobial activity against Escherichia coli NO8-1503 harboring blaTEM-168 gene by broth microdilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID518199	Antimicrobial activity against Pseudomonas aeruginosa BA(C2-107) selected after 25 ug/ml of compound exposure by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID1757547	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-11 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID285577	Antimicrobial activity against Pseudomonas aeruginosa 65.18-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID510514	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID1316797	Inhibition of wild type His-tagged translin/trax E126A mutant (unknown origin) coexpressed in Escherichia coli BL21 cells using RNase Alert as substrate at 30 uM incubated for 10 mins prior to substrate addition monitored over 60 mins by fluorescence assa	2016	Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20	A druggable target for rescuing microRNA defects.
AID558792	Antimicrobial activity against extended spectrum beta-lactamase-expressing Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID584718	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2615 harboring ftsK mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1757631	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-11 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757708	Antibacterial activity against Enterobacter aerogenes 15-7 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID534889	Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID559904	Antimicrobial activity against Escherichia coli TF-KP278 harboring beta-lactamase OXY-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID549330	Antimicrobial activity against Escherichia coli isolate 16 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID394698	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, TEM-2 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID520780	Antibacterial activity against Escherichia coli EC600 transconjugant harboring beta-lactamase KPC-2 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID518824	Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 2 containing IMP-8, OXA-58, ADC-43, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID368530	Ratio of Kcat to Km of Enterobacter cloacae 908R AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1317870	Substrate activity at Enterobacter cloacae beta lactamase P99 expressed in Escherichia coli AS226-51 cells by UV spectrophotometric method	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	β-Lactamases: Why and How.
AID495692	Activity of Pseudomonas aeruginosa AmpC	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID521302	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype F by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID567457	Antimicrobial activity against Salmonella enterica serovar Typhi isolate 080049Ty by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.
AID576293	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 11932 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID1373282	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTXM-15 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID285627	Antimicrobial activity against Pseudomonas aeruginosa 9A7 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID394684	Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID368312	Ratio of Kcat to Km of Staphylococcus aureus betalactamase PC1 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID187595	Urinary recovery was evaluated for pharmacokinetic data in rats	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID1553825	Antibacterial activity against Staphylococcus aureus ATCC 29213 measured after 18 to 24 hrs in presence of FeCl3	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID555641	Antimicrobial activity against ampDDh2 and ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID587615	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse septicemia infection model by acute lethal septicemia analysis	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID1442086	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID522385	Antimicrobial activity against Aeromonas enteropelogenes M1 hyperproducing beta-lactamase AmpC	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID368528	Activity of Enterobacter cloacae 908R AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID531074	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC181 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID1691822	Antibacterial activity against Pseudomonas aeruginosa PAO1 biofilm cells assessed as reduction in bacterial growth after 2 days by resazurin dye based assay	2020	European journal of medicinal chemistry, May-15, Volume: 194	Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1.
AID524932	Antimicrobial activity against Escherichia coli MI1443 harboring V27A and Q38R mutations in beta lactamase CTX-M-10 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID1757595	Antibacterial activity against Enterobacter cloacae 17-1 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID559530	Antibacterial activity against Enterobacter cloacae assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID584717	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2128 harboring cupA1 mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID498815	Antimicrobial activity against Klebsiella pneumoniae FZ47T expressing IMP-8, TEM-1, CTX-M-14, qnrB2, aac(6')-Ib by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID342025	Antibacterial activity against plasmid pK29 transconjugant Escherichia coli J53 assessed as inhibition zone diameter by CLSI disk diffusion confirmatory test	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID1757531	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID544421	Antimicrobial activity against Escherichia coli CU164A expressing beta-lactamase TEM-1 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID285641	Antimicrobial activity against Pseudomonas aeruginosa 13E1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID520697	Antimicrobial activity against Escherichia coli DH10B harboring p05283 carrying qepA and rmtB gene by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID559275	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv7 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID546164	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-04 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID523513	Antimicrobial activity against Pseudomonas aeruginosa isolate 3149 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID531607	Ratio of Kcat to Km for Escherichia coli beta-lactamase SHV-11	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID584515	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2023 harboring galU mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID425864	Antimicrobial activity against Carnobacterium divergens CIP101029 at 3 McFarland inoculum size by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID556697	Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] harboring pACM204 plasmid by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID665124	Antibacterial activity against Klebsiella pneumoniae after 18 to 22 hrs by EUCAST broth microdilution method	2012	European journal of medicinal chemistry, Jul, Volume: 53	Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1265638	Antibacterial activity against Enterobacter sp. after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID556675	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 2 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID340735	Antimicrobial activity against Escherichia coli HB101 harboring pBC-IND-5 plasmid containing metallo-beta-lactamase IND5 assessed as drug level at which microbial resistance was observed by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID576305	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 287942 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID1649590	Antimicrobial activity against Klebsiella pneumoniae clinical isolates in presence of 0.1 ug/ml iron by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID1379930	Antibacterial activity against Streptococcus faecalis assessed as inhibition of microbial growth incubated for 18 to 22 hrs by broth microdilution method	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID511301	Antibacterial activity against Escherichia coli DH5alpha in presence of 4 ug/ml Tazobactam	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID530602	Antibacterial activity against Escherichia coli J53 by Etest	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Expanded-spectrum beta-lactamase PER-1 in an environmental Aeromonas media isolate from Switzerland.
AID532413	Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C1 isolate AV-13X-28 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID757556	Antibacterial activity against Staphylococcus haemolyticus assessed as growth inhibition after 18 to 22 hrs by broth microdilution method	2013	European journal of medicinal chemistry, Jul, Volume: 65	Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID584838	Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID521995	Antimicrobial activity against Klebsiella pneumoniae isolate Kp3A expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID584513	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_06490 harboring mutation in hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1553777	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 measured after 24 hrs	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID495740	Kcat/Km ratio of Klebsiella pneumoniae KPC-2 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID556667	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 22 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID394713	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID323038	Antimicrobial activity against extended-spectrum-beta-lactamase producing Escherichia coli assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID394495	Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc4 plasmid by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID1757793	Ratio of MBC to MIC for Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495909	Antimicrobial activity in Escherichia coli J53 transconjugate with Escherichia coli DIH-1 expressing natural plasmid containing beta-lactamase VIM-19	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID373755	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab12 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID565527	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-08 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1757841	Ratio of MBC to MIC for Carbapenem- resistant Acinetobacter baumannii 17-5 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757815	Bactericidal activity against ESBLs negative carbapenem-sensitive Escherichia coli 17-20 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID252634	Bacterial susceptibility induced by D113 mutation in Escherichia coli OmpF	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	Beta-lactam screening by specific residues of the OmpF eyelet.
AID285662	Antimicrobial activity against Pseudomonas aeruginosa 22D2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID495712	Kcat/Km ratio of Pseudomonas aeruginosa VIM-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID555222	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 195 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID519808	Inhibition of Bocillin FL binding to PBP4 in Pseudomonas aeruginosa PAO1 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID533756	Antibacterial activity against SHV-2a producing Pseudomonas aeruginosa isolate P102 exhibiting PFGE H pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID562339	Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-5 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID534924	Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID567311	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2202 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID532101	Antimicrobial against Pseudomonas aeruginosa 9256 harboring ybhO allele by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID558044	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S7 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID285665	Antimicrobial activity against Pseudomonas aeruginosa 22E1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID529490	Antimicrobial activity against Enterobacter cloacae isolate 354 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID1553828	Antifungal activity against Candida albicans cgmcc2.2086 measured after 48 hrs in presence of KCl by broth microdilution method	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID405809	Inhibition of bocillin FL binding to penicillin-resistant Streptococcus pneumoniae OC 8819 penicillin-binding protein 1a	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID561316	Antimicrobial activity against Enterobacter cloacae isolate 101 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID368495	Ratio of Kcat to Km of Escherichia coli CTX-M-15 assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID535843	Antimicrobial activity against Pseudomonas aeruginosa PAO1 IPM46 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID498810	Antimicrobial activity against carbapenem-resistant Escherichia coli ZJ86 deficient in KPC-2, TEM-1, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID531655	Antimicrobial activity against CMY-2 beta-lactamase producing Escherichia coli isolate CUMC201 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID556659	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 14 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID524938	Antimicrobial activity against Escherichia coli MI1443 harboring V27A, Q38R, P167S and D240G mutations in beta lactamase CTX-M-3 by E-test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.
AID533532	Antimicrobial activity against Pseudomonas aeruginosa PA550 expressing VIM-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID565767	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 5 fold elevated AmpC expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID522187	Antimicrobial activity against Klebsiella pneumoniae isolate KpL expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID523494	Antimicrobial activity against Pseudomonas aeruginosa isolate 1530c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1379933	Antibacterial activity against Proteus mirabilis assessed as inhibition of microbial growth incubated for 18 to 22 hrs by broth microdilution method	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID531072	Antimicrobial activity against CMY-2,CTX-M-14,TEM-2-like beta-lactamase producing Escherichia coli isolate CUMC215 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID368494	Ratio of Kcat to Km of Escherichia coli CTX-M-15 assessed as drug hydrolysis by spectrophotometry	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID1808863	Antipseudomonal activity against pseudomonas aeruginosa Pseudomonas aeruginosa 23/14-053 (ST-309) assessed as AmpC RNA level relative to Pseudomonas aeruginosa PAO1
AID535697	Antimicrobial activity against Azide-resistant Escherichia coli J53 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID1757733	Bactericidal activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-6 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID565724	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-29 harboring A residue at 105 position in PDC- 8 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID511300	Antibacterial activity against Escherichia coli DH5alpha pB-ges-1in presence of 4 ug/ml Tazobactam	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID1553823	Antibacterial activity against Staphylococcus aureus ATCC 29213 measured after 18 to 24 hrs in presence of MgCl2	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID532205	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae WH99T harboring qnrB gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID544425	Antimicrobial activity against translocase tatC-deficient Escherichia coli B1LK0A harboring beta-lactamase CTX-M-14 by liquid microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.
AID559271	Antimicrobial activity against Proteus vulgaris Pv8 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID584742	Activity of wild type Pseudomonas aeruginosa PAO1 Beta-lactamase assessed as nitrocefin hydrolysis per mg of protein by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID495710	Kcat/Km ratio of Klebsiella pneumoniae KPC-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID531771	Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4658 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID368738	Antimicrobial activity against Escherichia coli Ec2 containing pEc1-B plasmid expressing CTX-M-15 TEM-1 OXA-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID1757742	Bactericidal activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-18 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID565198	Antimicrobial activity against Klebsiella pneumoniae isolate A-1797 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID565727	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-32 harboring A residue at 105 position in PDC- 10 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID495748	Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID1379934	Antibacterial activity against Enterobacter spp. assessed as inhibition of microbial growth incubated for 18 to 22 hrs by broth microdilution method	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
AID283138	Antibacterial activity against Pseudomonas aeruginosa PAO4222	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID285690	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4036 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID520969	Antibacterial activity against Klebsiella pneumoniae GR by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID325190	Antibacterial activity against Enterobacter cloacae ATCC 13047 by standard serial agar dilution method	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.
AID373768	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh18 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID1373295	Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1757668	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-2 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID67568	In vitro minimum inhibitory concentration required to produce antibacterial activity against Enterococcus faecalis ATCC 29212	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID1757740	Bactericidal activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID368546	Ratio of Kcat to Km of Pseudomonas aeruginosa 18SH AmpC assessed as drug hydrolysis by spectrophotometry relative to cephaloridine	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
AID583095	Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87A mutant beta-lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID498843	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae XJ81 deficient in TEM-1, SHV-12, DHA-1, aac(6')-Ib, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID584488	Antibacterial activity against porin, OmpA positive Klebsiella pneumoniae KPBj1 revertant by disk agar diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.
AID1757624	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-2 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID495735	Kcat/Km ratio of Klebsiella pneumoniae Beta-lactamase TEM-26 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID404955	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii 183 isolate carrying one bla-OXA58 gene copy by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID520382	Antimicrobial activity Escherichia coli DH5alpha harboring bacteriophage T4 plasmid alpha omega by agar macrodilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID373771	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh29 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID541010	Antimicrobial activity against Burkholderia cenocepacia 212 expressing beta-lactamase PenB3	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID521306	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype J by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID535134	Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534907	Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID521996	Antimicrobial activity against Escherichia coli isolate J53 harboring p3A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID545458	Antimicrobial activity against Serratia marcescens assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID529858	Ratio of MIC for Pseudomonas aeruginosa N043 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID511425	Renal clearance in cystic fibrosis patient	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID1442088	Antibacterial activity against Pseudomonas aeruginosa CICC 21625 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
AID285364	Susceptibility of qnr positive Enterobacter cloacae assessed as percentage nonsusceptible isolates	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital.
AID368742	Antimicrobial activity against Escherichia coli Ec4 expressing CTX-M-1 AmpC gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID1586249	Antibacterial activity against Acinetobacter baumannii BM4454 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID1757775	Ratio of MBC to MIC for ESBLs positive Carbapenem-sensitive Escherichia coli 17-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757646	Antibacterial activity against Carbapenem- resistant Pseudomonas aeruginosa 17-8 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID368739	Antimicrobial activity against Escherichia coli Ec2-a containing pEc1-C plasmid expressing CTX-M-15 OXA-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID584700	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5038 harboring aroB mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1553816	Antibacterial activity against Escherichia coli ATCC 25922 measured after 18 to 24 hrs in presence of MgCl2	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID531092	Antimicrobial activity against SHV-12-like, SHV-1-like beta-lactamase producing Klebsiella pneumoniae isolate CUMCK9 by disk diffusion method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.
AID1757546	Antibacterial activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-10 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID405793	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 1.5 hrs by CLSI method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID574430	Antimicrobial activity against Escherichia coli isolate 386T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from wound of patient by vitek-2 method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID1757693	Antibacterial activity against Enterobacter cloacae 17-5 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757672	Antibacterial activity against ESBLs positive Carbapenem-sensitive Escherichia coli 17-8 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID520731	Activity of Escherichia coli DH10B beta-lactamase OXA-97 assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID1580090	Antibacterial activity against novobiocin-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages by checkerboard assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1757849	Ratio of MBC to MIC for Carbapenem-resistant Pseudomonas aeruginosa 17-1 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535142	Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID250294	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH19; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID368747	Antimicrobial activity against Escherichia coli Ec10 expressing TEM-24b gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID562569	Antimicrobial activity against CTX-M-15 ESBL producing Escherichia coli clinical isolate by CLSI disk diffusion assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania.
AID373046	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZS5 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID585195	Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-2 E104, N170 mutant by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID567332	Antimicrobial activity against Proteus mirabilis TUM4660 by disk diffusion method in presence of 300 ug 3-aminophenyl-boronic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID1300870	Antibacterial activity against Staphylococcus aureus clinical isolate after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
AID573372	Antibacterial activity against ceftazidime-susceptible Serratia marcescens assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID250262	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH06; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID207368	In vitro synergistic activity against Staphylococcus aureus (PC1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID529852	Antibacterial activity against beta-lactamase-overproducing and OprD-deficient Pseudomonas aeruginosa N044 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID1757567	Antibacterial activity against Carbapenem- sensitive Klebsiella pneumoniae 17-15 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID524566	Antimicrobial activity against Shigella sonnei isolate AM20369 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID559824	Antimicrobial activity against Escherichia coli J53 harboring pCHE-A plasmid expressing blaGES-5 gene by agar dilution in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID1808804	Antibacterial activity against Pseudomonas aeruginosa PAO1 deltadacBdeltaampD by broth microdilution method
AID368749	Antimicrobial activity against Klebsiella pneumoniae Kp2 expressing TEM-15 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID556669	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 24 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1757569	Antibacterial activity against ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-16 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID324866	Antimicrobial activity against Acinetobacter baumannii A24D after 4 days in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID584688	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4109 harboring ampR mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID530321	Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SD2 harboring blaVIM-1 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID567318	Antimicrobial activity against Escherichia coli TUM4670 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID584837	Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID495516	Antibacterial activity against multidrug-resistant Acinetobacter baumannii AYE by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID532401	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D3 isolate VA-06X-65 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1373316	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-18 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID522575	Antimicrobial activity against Escherichia coli isolate 8009989 with AmpC beta-lactamase H296P mutation	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID1757519	Antibacterial activity against Escherichia coli 15-5 overexpressing extended spectrum beta-lactamases assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID511421	Total clearance in cystic fibrosis patient at 50 gram, iv administered 20 mins infusion	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
AID531535	Antibacterial activity against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Extended-spectrum beta-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in Klebsiella pneumoniae.
AID560497	Activity of Escherichia coli MC4100 Beta-Lactamase CMY-30 harboring Val211?Gly211 mutation	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID565197	Antimicrobial activity against Klebsiella pneumoniae isolate H-1406 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID532393	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-26 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID565549	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-13 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID558050	Antimicrobial activity against blaKPC-positive Klebsiella oxytoca S13 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID529160	Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay in presence of 250 ug/ml polyethylenimine	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID394691	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing PSE-1 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID544586	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8128 expressing bla SHV-105 gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID522576	Antimicrobial activity against Escherichia coli isolate 7014517 AmpC with LAA insertion at position 295	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID613257	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 after 24 hrs by NCCLS M7-A6 broth dilution method	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.
AID1265635	Antibacterial activity against Staphylococcus haemolyticus after 18 to 22 hrs by broth microdilution method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
AID322317	Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID532406	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B1 isolate SS-09X-45 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID533542	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA342	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID278598	Inhibitory activity against Klebsiella pneumoniae 35	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID283322	Antimicrobial activity against Escherichia coli XL10/pSHV-31	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.
AID522010	Antimicrobial activity against Escherichia coli isolate TOP10 harboring pBIC containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID429062	Antimicrobial activity against Proteus mirabilis JIE273 expressing 16S rRNA methyltransferase RmtC	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	RmtC 16S rRNA methyltransferase in Australia.
AID508734	Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID519796	Inhibition of Bocillin FL binding to PBP1A in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID322325	Antibacterial activity against Escherichia coli DH5 alpha-URA5924 isolates expressing CTX-M-32 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID498833	Antimicrobial activity against Klebsiella pneumoniae CY1T expressing SHV-11, DHA-1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID554387	Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY operon by twofold macrodilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID163049	Minimal inhibitory activity against the Proteus rettgeri (C24)	1989	Journal of medicinal chemistry, Nov, Volume: 32, Issue:11	3-Quaternary ammonium 1-carba-1-dethiacephems.
AID250304	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH07; I=Intermediate	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID529662	Ratio of Kcat to Km for Pseudomonas aeruginosa 9551 beta-lactamase VIM-15 relative to cephaloridine	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1373324	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-225 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID250260	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH04; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID560115	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase RTG3 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID495839	Ratio of Kcat to Km for Escherichia coli BL21 DE3 beta-lactamase VIM-19 by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID523505	Antimicrobial activity against Pseudomonas aeruginosa isolate 12142c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1586256	Antibacterial activity against Enterobacter cloacae X4422 after 6 days by resazurin dye-based fluorescence assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
AID498829	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae RJ94 deficient in IMP-4, TEM-1, CTX-M-3, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID558810	Antimicrobial activity against Proteus mirabilis assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID523487	Antimicrobial activity against Pseudomonas aeruginosa M1251 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID561659	Antimicrobial activity against Pseudomonas aeruginosa isolate OC16827 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID1757538	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-12 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID522392	Ratio of Kcat Km for Aeromonas enteropelogenes Beta-lactamase TRU1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID341119	Increase in ampD gene expression in Pseudomonas aeruginosa 164M1 by RT-PCR relative to wild-type	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.
AID584316	Antimicrobial activity against beta-lactamase AmpC producing meropenem-resistant Serratia marcescens by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID535870	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ51T harboring qnrA gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID565541	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-05 harboring A residue at 105 position in PDC- 2 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID556664	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 19 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID364438	Antipseudomonal activity against Pseudomonas aeruginosa class A TEM beta-lactamase-induced clinical isolate FP2056 by CLSI method	2008	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17	Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.
AID495908	Antimicrobial activity in Escherichia coli TOP10 harbouring recombinant plasmid VIM-1-N215K by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID519812	Inhibition of Bocillin FL binding to PBP1B in Pseudomonas aeruginosa 27853 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID521284	Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype H by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID531769	Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4698 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID560592	Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolate IMCJ2S1 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID1757626	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-5 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID499052	Antimicrobial activity against Escherichia coli PU60T expressing CMY-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1757623	Antibacterial activity against Carbapenem- sensitive Pseudomonas aeruginosa 17-29 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757652	Antibacterial activity against ESBLs positive Carbapenem-sensitive Klebsiella pneumoniae 17-6 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID528607	Activity of Escherichia coli DH5alpha beta-lactamase KPC-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID559596	Antimicrobial activity against Pseudomonas aeruginosa PAO1 selected in presence of tobramycin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID564462	Antimicrobial activity against Pseudomonas aeruginosa isolate 913 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID542106	Antibacterial activity against Escherichia coli TrC C expressing Klebsiella pneumoniae C blaCTX-M beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID495689	Activity of Klebsiella oxytoca Beta-lactamase K1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID565531	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-04 harboring A residue at 105 position in PDC- 2 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1373323	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-181 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID523497	Antimicrobial activity against Pseudomonas aeruginosa isolate 1529c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID532187	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae SY26T harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID499061	Antimicrobial activity against carbapenem-resistant Escherichia coli PU43 deficient in TEM-1, CTX-M-14, aac(6')-Ib, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID521293	Antimicrobial activity against CTX-M-59 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype G by Etest in presence of clavulanic acid	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID535834	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP62 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID544558	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 7668 expressing bla SHV-48 gene by Etest method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID556650	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 5 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID531678	Antimicrobial activity against Acinetobacter baumannii TVICU53 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID373205	Antimicrobial activity against Bacillus clausii T by agar-dilution technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID1516028	Antibacterial activity against Pseudomonas aeruginosa 25349 clinical isolate incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID555207	Antimicrobial activity against ampD gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID283120	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM8	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID405087	Ratio of Kcat to Km of Alcaligenes faecalis PER2 beta lactamase	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID565771	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 107 fold elevated mexX expression and 155 fold elevated mexY expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID532901	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 ST 376 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID544964	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase DHA by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1808801	Antibacterial activity against Pseudomonas aeruginosa PAO1 deltadacB by broth microdilution method
AID522579	Antimicrobial activity against AmpC producing Escherichia coli Top10 isolate 8009162	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.
AID562571	Antimicrobial activity against SHV-7 ESBL producing Escherichia coli clinical isolate by CLSI disk diffusion assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania.
AID573195	Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring deletion mutation at nucleotide 231-244 in nfxB gene selected at 1 ug/ml of azithromycin after 4 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID283141	Antibacterial activity against Pseudomonas aeruginosa 93	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID250300	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH25; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID1757499	Antibacterial activity against Escherichia coli NCTC 13353 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757596	Antibacterial activity against Enterobacter cloacae 17-2 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID373772	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh36 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID498807	Antimicrobial activity against Klebsiella pneumoniae ZJ71T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID522026	Antimicrobial activity against Escherichia coli isolate J53 harboring pEcA containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID206553	In vivo activity in murine against Staphylococcus aureus Smith (MS) infection after sc administration.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
AID532100	Antimicrobial against Pseudomonas aeruginosa 8564 harboring pyrX allele by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID584839	Antimicrobial activity against Escherichia coli DH10B by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID26428	Serum T1/2 in marmosets (IV dose)	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID561663	Antimicrobial activity against Pseudomonas aeruginosa isolate OC14552 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID520327	Antimicrobial activity against Acinetobacter baumannii isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests.
AID374111	Antimicrobial activity against azide-resistant aac(6')-Ib-cr deficient Escherichia coli J53 qnrA1 bearing pHS5 transconjugant from Enterobacter cloacae 641 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID529574	Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid BC-SK after 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID1757874	Ratio of MBC to MIC for carbapenem-sensitive Pseudomonas aeruginosa 17-9 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID584917	Activity of Beta-lactamase in Pseudomonas aeruginosa PA14 PA4020 harboring mpl mutant gene relative to wild type	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID562334	Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid pBC-SK after 18 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID555687	Antimicrobial activity against Escherichia coli ATCC 25922 by disk diffusion method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID1757878	Ratio of MBC to MIC for Escherichia coli ATCC 25922 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID564530	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid with entire blaAmpC gene by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID68366	In vitro minimum inhibitory concentration required to produce antibacterial activity against Enterobacter cloacae 908SSI	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID394690	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC, PSE-1, MexXY-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID563969	Antibacterial activity against Escherichia coli J53 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID499060	Antimicrobial activity against Enterobacter aerogenes PU41T expressing CTX-M-14, DHA-1, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID207713	Compound was tested for antimicrobial activity against Staphylococcus aureus Oxford strain	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID423774	Antibacterial activity against ESBL-negative Klebsiella pneumoniae isolate 106 at 1 ug/ml by Etest	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Selection of SHV extended-spectrum-beta-lactamase-dependent cefotaxime and ceftazidime resistance in Klebsiella pneumoniae requires a plasmid-borne blaSHV gene.
AID1447479	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 100036 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID559262	Antimicrobial activity against Proteus vulgaris Pv9 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID285612	Antimicrobial activity against Pseudomonas aeruginosa 65.68-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID535135	Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID529579	Ratio of Kcat to Km for Legionella gormanii ATCC 33297T beta-Lactamase FEZ-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID544519	Metabolic stability in Escherichia coli TOP10 harboring beta-lactamase KPC-5 assessed as hydrolysis rate per mg of extracts at 50 uM after 5 mins by spectrophotometric analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID572128	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 31 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID285440	Antimicrobial activity against Escherichia coli DH10B expressing GIL1 after 18 hrs by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID585444	Antimicrobial activity against ampG deficient Pseudomonas aeruginosa PAO1 harboring pUCP24 conferring resistance to gentamycin after 16 to 20 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression.
AID1757803	Bactericidal activity against Carbapenem- resistant Klebsiella pneumoniae KR 15-7 assessed as reduction in bacterial growth in the presence of avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757497	Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID1757855	Ratio of MBC to MIC for ESBLs negative Carbapenem-sensitive Klebsiella pneumoniae 17-16 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID511680	Antimicrobial activity against Pseudomonas aeruginosa clinical isolate assessed as resistant isolates selected in vitro after antipseudomonal treatment of intensive care unit patient by by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID405801	Antibacterial activity against methicillin-resistant Staphylococcus aureus OC 3726 by CLSI method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID561678	Antimicrobial activity against Pseudomonas aeruginosa isolate OC14551 harboring plasmid MexZ expressing mexXY gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
AID372620	Ratio of Kcat to Km for Escherichia coli DH5alpha beta-lactamase TEM-1	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID556648	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 3 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID573196	Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring nfxB T248C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1309043	Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolate SDS15016 after 24 hrs by broth microdilution method	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	Synthesis of riccardin D derivatives as potent antimicrobial agents.
AID245355	Minimum inhibitory concentration of compound against Pseudomonas aeruginosa derepressed 88/98 in presence of compound 14	2004	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID404957	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii 193 isolate carrying two bla-OXA58 gene copies by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID520793	Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype A by Etest	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
AID575318	Antimicrobial activity against Escherichia coli 05-9280TC1 transconjugant expressing IncI1 plasmid-encoded beta lactamase CTX-M-1 by Etest	2010	Antimicrobial agents and chemotherapy, 10, Volume: 54, Issue:10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.
AID583185	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 0.5 mM NagZ inhibitor PUGNAc	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID531333	Antibacterial activity against Pseudomonas aeruginosa PAO4290 selected after 1.0 ug/ml of azithromycin by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID523506	Antimicrobial activity against Pseudomonas aeruginosa isolate 1712c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID562765	Antimicrobial activity against Escherichia coli DH10B transformant harboring blaTEM-168 gene by disk diffusion method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
AID584730	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4069 harboring mutation in putative dTDP-4-rhamnose reductase-related protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1373280	Antimicrobial activity against wild type Escherichia coli by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1757510	Antibacterial activity against Multidrug resistant Acinetobacter baumannii AR 15-3 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID567582	Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolate by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID562475	Antimicrobial activity against rifampicin-resistant Escherichia coli A15 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID285585	Antimicrobial activity against Pseudomonas aeruginosa 65.33-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1516021	Antibacterial activity against Salmonella enterica serovar typhimurium C77-31 incubated for 18 to 24 hrs by broth microdilution method	2019	Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15	Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
AID523965	Antibacterial activity against Burkholderia pseudomallei 1026b infected in mouse AMJ.2 cells assessed as inhibition of bacterial replication at <= 10 ug/ml after 24 hrs by serial dilution plating technique	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
AID1553791	Bactericidal activity against Escherichia coli 078 incubated for 24 hrs followed by replating on agar plate and measured after overnight incubation	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens.
AID340727	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-2 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID533565	Antimicrobial activity against Pseudomonas aeruginosa isolate PA399 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID532416	Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-11 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID369574	Antibacterial activity against multidrug-resistant Acinetobacter baumannii 06-74 isolate assessed as regrowth bacterial load at 50 ug/ml administered as continuous infusion in vitro pharmacodynamic model after 3 to 4 hrs by time kill experiment	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
AID405814	Inhibition of bocillin FL binding to penicillin-resistant Streptococcus pneumoniae OC 8819 penicillin-binding protein 3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID524437	Antimicrobial activity against Shigella isolate DH-19035 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Identification and characterization of CTX-M-producing Shigella isolates in the United States.
AID555184	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox delta ampDh3::lox and plasmid pUCP27 after 18 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID532105	Antimicrobial against Pseudomonas aeruginosa 46396 harboring katA allele by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID564534	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid carrying entire blaAmpC gene with alanine residue deletion at 215 position and R210P substitution by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID561447	Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
AID519472	Antimicrobial activity against Stenotrophomonas maltophilia K279a harboring -121 frameshift mutation in ampR gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
AID555215	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 14 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID535833	Antimicrobial activity against Pseudomonas aeruginosa GP62KT41 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID559263	Antimicrobial activity against Providencia stuartii Ps5 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID584928	Activity of Beta-lactamase in Pseudomonas aeruginosa PAO1 PA4522 harboring ampD mutant gene assessed as nitrocefin hydrolysis per mg of protein by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID520723	Activity of Acinetobacter baumannii phenotype 1 beta-lactamase assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID534166	Antimicrobial activity against rmtB positive Escherichia coli VOG producing beta lactamase CTX-M-14 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID1757533	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-6 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID563971	Antibacterial activity against Escherichia coli NF-NDM-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID529516	Antibacterial activity against Pseudomonas aeruginosa 1750J expressing beta-lactamase IMP-15 by Etest	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
AID511580	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD, ampDh3 and ampDh3 gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID285628	Antimicrobial activity against Pseudomonas aeruginosa 9A10 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID565715	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-20 harboring A residue at 105 position in PDC- 4 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID405811	Inhibition of bocillin FL binding to penicillin-resistant Streptococcus pneumoniae OC 8819 penicillin-binding protein 2x	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID283220	Antimicrobial activity against Pseudomonas aeruginosa PA0905	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.
AID529497	Antimicrobial activity against Escherichia coli T-625 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID565774	Antimicrobial activity against Pseudomonas aeruginosa OC 12070 expressing 11 fold elevated mexX expression and 10 fold elevated mexY expression by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
AID534610	Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID555211	Antibacterial activity against Acinetobacter genomosp. 3 isolate 109 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID545396	Antimicrobial activity against Pseudomonas aeruginosa PS2 with PFGE phenotype 10B obtained from urine of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID533765	Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P9 exhibiting PFGE A pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID567464	Antimicrobial activity against Salmonella enterica serovar Typhi isolate 080048Ty transconjugant harboring bla CTX-M-15 gene by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.
AID532097	Antimicrobial against Pseudomonas aeruginosa 3894 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID567305	Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2203 isolated from burn patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.
AID573393	Antibacterial activity against ceftazidime-susceptible Providencia sp. assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID565546	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-10 harboring A residue at 105 position in PDC- 2 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1757702	Antibacterial activity against Enterobacter aerogenes 17-4 assessed as reduction in bacterial growth in the presence of Avibactam	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID133821	Compound was evaluated in vivo for antibacterial activity against Pseudomonas aeruginosa (strain 101010) in mice; range 1.0-6.0 mg/Kg	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.
AID285617	Antimicrobial activity against Pseudomonas aeruginosa 5F2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1757537	Antibacterial activity against Carbapenem- resistant Acinetobacter baumannii 17-11 assessed as reduction in bacterial growth	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	Synthesis and in vitro antibacterial activity of new aminothiazole-oximepiperidone cephalosporins.
AID535654	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ61 harboring GyrA S83I, GyrA D87A, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (0.57)	18.7374
1990's	11 (3.13)	18.2507
2000's	204 (57.95)	29.6817
2010's	121 (34.38)	24.3611
2020's	14 (3.98)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (0.56%)	5.53%
Reviews	5 (1.41%)	6.00%
Case Studies	9 (2.54%)	4.05%
Observational	0 (0.00%)	0.25%
Other	338 (95.48%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (75)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of a Single Dose of Intravenous Ceftazidime NXL104 (3000/2000 mg) or Ceftaroline Fosamil NXL104 (1500/2000 mg), Co [NCT01290900]	Phase 1	54 participants (Actual)	Interventional	2011-02-28	Completed
Population Pharmacokinetics of Anti-infective Drugs in Children in Anti-infectious Therapies [NCT03113344]		800 participants (Anticipated)	Observational [Patient Registry]	2017-06-21	Recruiting
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified [NCT02526004]		223 participants (Actual)	Interventional	2013-10-01	Completed
Retrospective Analysis to Characterize the Real World Use Patterns, Efficacy and Safety of Ceftazidime-avibactam in the Management of Gram Negative Infections. [NCT04628572]		204 participants (Actual)	Observational	2021-01-29	Completed
What Duration of Intravenous Antibiotic Therapy Should be Used in the Treatment of Infective Exacerbations of Cystic Fibrosis Chronically Colonised With Pseudomonas Aeruginosa [NCT01044719]	Phase 4	240 participants (Anticipated)	Interventional	2010-01-31	Not yet recruiting
Optimisation, Valorisation and Application of UPLC-MS/MS Based Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients - Part 3: Non-blank Sputum Samples for Method Optimisation and Validation [NCT02840136]		40 participants (Actual)	Interventional	2016-02-29	Terminated(stopped due to Lack of staff)
Single- Versus Multiple-dose Antimicrobial Prophylaxis for The Prevention of Infectious Complications Associated With Peroral Endoscopic Myotomy(POEM) for Achalasia: A Triple-Blind, Randomized Controlled, Non-Inferiority Trial [NCT03404739]	Phase 2/Phase 3	666 participants (Anticipated)	Interventional	2017-10-01	Active, not recruiting
Is Combination Antibiotic Therapy Superior to Monotherapy in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease [NCT04879030]	Phase 2/Phase 3	170 participants (Actual)	Interventional	2020-01-01	Completed
A Phase 3 Randomized Double-Blind Study Of Ceftobiprole Medocaril Versus Linezolid Plus Ceftazidime In The Treatment Of Nosocomial Pneumonia [NCT00229008]	Phase 3	106 participants (Actual)	Interventional	2005-11-30	Completed
Population Pharmacokinetics Of Ceftazidime, Ciprofloxacin And Voriconazole In Paediatric Young Patients (< 12 Years Old) [NCT01344512]		214 participants (Actual)	Interventional	2011-06-30	Completed
A Study the Population Pharmacokinetics of Children Receiving the Anti-infective Drugs for Treatment of Infectious Disease in Central Nervous System [NCT03960905]		800 participants (Anticipated)	Observational	2019-01-01	Recruiting
Mutil-institutions Comparing Antibiotic Therapy With Laparscopic Appendectomy in Pediatric Chronic Appendicitis [NCT03754387]		200 participants (Anticipated)	Interventional	2019-01-01	Enrolling by invitation
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]	Phase 4	135 participants (Anticipated)	Interventional	2023-08-04	Enrolling by invitation
A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Assess the Efficacy, Safety and Tolerability of Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Intensive Phase Therapy of Melioidosis in Hospitalized Pa [NCT05105035]	Phase 2	100 participants (Anticipated)	Interventional	2022-06-14	Recruiting
Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia [NCT02463747]	Phase 4	110 participants (Anticipated)	Interventional	2015-06-30	Not yet recruiting
Pharmacokinetics and Pharmacodynamics of Ceftazidime Avitbatan Sodium in Children With Severe Infection [NCT04961580]		30 participants (Anticipated)	Observational	2022-10-01	Recruiting
A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Thera [NCT01595438]	Phase 3	598 participants (Actual)	Interventional	2012-10-31	Completed
AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED STUDY TO ESTIMATE THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) VERSUS BEST AVAILABLE TREATMENT (BAT) IN THE TREATMENT OF INFECTIONS DUE TO CARBAPENEM-RESISTANT GRAM-NEGATIVE PATHOGEN [NCT04882085]	Phase 4	59 participants (Actual)	Interventional	2021-08-26	Completed
Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia [NCT04948463]	Phase 4	312 participants (Anticipated)	Interventional	2021-11-15	Recruiting
Assessment of Efficiency of Nebulized Ceftazidime and Amikacin in Treatment of Ventilator Associated Pneumonia Caused by Pseudomonas Aeruginosa [NCT00786305]	Phase 2	40 participants (Actual)	Interventional	2004-10-31	Completed
A Phase 1, Open-Label Study in Healthy Adults to Evaluate the Safety and Pharmacokinetics of AVYCAZ(R) in Combination With Aztreonam (COMBINE) [NCT03978091]	Phase 1/Phase 2	48 participants (Actual)	Interventional	2019-07-09	Completed
Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria [NCT04167228]		348 participants (Actual)	Observational	2019-10-01	Completed
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404]		5,000 participants (Anticipated)	Observational	2020-03-05	Recruiting
Dose Optimization by PK/PD of Antibiotics to Improve Clinical Outcome of CRKP Bloodstream Infections in Critically Ill Patients and in Vitro Study of Monotherapy, Combination Therapy and Molecular Biology of Drug Resistance at Phramongkutklao Hospital: Pr [NCT05862402]	Phase 4	76 participants (Anticipated)	Interventional	2023-05-07	Recruiting
Prospective, Multicenter, Investigator-blinded, Randomized, Comparative Study Estimate Safety, Tolerability, Efficacy of NXL104/Ceftazidime vs. Comparator Followed Appropriate Oral Therapy Treatment Complicated UTI Hosp Adults [NCT00690378]	Phase 2	137 participants (Actual)	Interventional	2008-11-30	Completed
A Multicenter, Randomized, Controlled Trial Comparing Cefepime Monotherapy Versus Combination of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-associated Peritonitis [NCT02872038]	Phase 4	154 participants (Actual)	Interventional	2015-08-31	Completed
A Phase I Open-Label, 2-Part, 3-Cohort, Single-Centre Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid (ELF) and Plasma Using at Least Two Different Dosing Regimens in Healthy Volunteers [NCT01395420]	Phase 1	45 participants (Actual)	Interventional	2011-08-31	Completed
A Multicenter, Double-blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA-101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelonephritis [NCT00921024]	Phase 2	129 participants (Actual)	Interventional	2009-06-30	Completed
Comparison of Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration [NCT00752882]	Phase 2	24 participants (Anticipated)	Interventional		Not yet recruiting
Randomized, Multicenter, Phase III, Controlled Clinical Trial, to Demonstrate the no Inferiority of Reduced Antibiotic Treatment vs a Broad Spectrum Betalactam Antipseudomonal Treatment in Patients With Bacteremia by Enterobacteriaceae [NCT02795949]	Phase 3	344 participants (Actual)	Interventional	2016-10-31	Completed
[NCT02593201]	Phase 4	358 participants (Actual)	Interventional	2016-02-26	Completed
A Prospective, Multicenter, Double-blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-abdominal Infections in Hospitalized Adu [NCT00752219]	Phase 2	204 participants (Actual)	Interventional	2009-03-31	Completed
Adverse Drug Reactions of Different Brands of Ceftazidime Injection [NCT00173901]	Phase 4	536 participants	Interventional	2001-03-31	Active, not recruiting
Comparison of Antibiotics for Pseudomonas in Early CF [NCT00823238]	Phase 1	21 participants (Actual)	Interventional	2004-07-31	Completed
A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections [NCT00210899]	Phase 3	828 participants (Actual)	Interventional	2005-09-30	Completed
Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients [NCT05413343]		30 participants (Anticipated)	Observational [Patient Registry]	2022-01-01	Recruiting
Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever in Pediatric Acute Leukemia: Review of Temperature and Absolute Neutrophil [NCT04187755]	Phase 4	72 participants (Actual)	Interventional	2019-03-01	Completed
A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis [NCT00579956]		750 participants (Anticipated)	Interventional	2007-12-31	Recruiting
A Phase I, 2-Part, Open-Label, Pharmacokinetic and Drug-Drug Interaction Study of CAZ104 (Avibactam and Ceftazidime in Healthy Subjects) [NCT01430910]	Phase 1	43 participants (Actual)	Interventional	2011-09-30	Completed
Comparison of Lung Concentrations of Ceftazidime Administered by Continuous Versus Intermittent Infusion in Patients With Ventilator-associated Pneumonia [NCT02837835]	Phase 3	34 participants (Actual)	Interventional	2005-03-31	Completed
Real-World Study of Ceftazidime-Avibactam to Characterize the Usage in Clinical Practice [NCT05487586]		450 participants (Anticipated)	Observational	2022-10-20	Recruiting
Pharmacokinetic Evaluation of Cefazolin, Ceftazidime, and Ciprofloxacin in Chronic Hemodialysis Patients [NCT04319328]		60 participants (Anticipated)	Observational	2019-10-18	Recruiting
Antibiotic Concentrations in Serum and Epithelial Lining Fluid Under Continous Infusion [NCT00435305]		40 participants (Anticipated)	Observational	2006-11-30	Terminated(stopped due to difficulties by enrolling patients fundings consumed, no staff could be recruited and payed to continue enrolling patients,)
Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®) [NCT04033029]		20 participants (Actual)	Observational	2021-01-01	Completed
A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) IN CHILDREN FROM 3 MONTHS TO LESS THAN 18 YEARS OF AGE WHO ARE HOSPITALIZED AND RECEIVING SYSTEMIC ANTIBIOTIC THERAPY FOR S [NCT04040621]	Phase 1	4 participants (Actual)	Interventional	2020-06-15	Terminated(stopped due to Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.)
[NCT00333385]	Phase 4	120 participants	Interventional	2001-10-31	Terminated
Prospective Randomized Evaluation of Antibiotic Regimen Following Appendectomy for Perforated Appendicitis [NCT00195923]		100 participants	Observational	2005-04-30	Completed
Standard vs. Biofilm Susceptibility Testing in CF [NCT00153634]		75 participants (Actual)	Interventional	2004-03-31	Completed
A SINGLE ARM, OPEN-LABEL, MULTI-CENTER, INTERVENTIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) IN CHINESE ADULTS WITH HAP (INCLUDING VAP) [NCT04774094]	Phase 4	235 participants (Actual)	Interventional	2021-05-21	Completed
Continuous-infusion Anti-pseudomonal β-lactams for the Treatment of Acute, Infective Pulmonary Exacerbations in Cystic Fibrosis [NCT01667094]	Phase 4	50 participants (Actual)	Interventional	2012-09-30	Active, not recruiting
Nosocomial Infections in Patients With Acute Respiratory Distress Syndrome Treated With Extracorporeal Membrane Oxygenation [NCT05566665]		200 participants (Anticipated)	Observational	2023-01-01	Recruiting
Diclophenac Potassium Versus Ceftazidime for Reduction of Post ERCP Pancreatitis in Average Risk Patients-double Blind, Randomised Controlled Trial [NCT01784445]	Phase 4	124 participants (Actual)	Interventional	2013-06-30	Completed
Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients [NCT01785641]		300 participants (Anticipated)	Interventional	2012-12-31	Recruiting
A Randomized Controlled Trial to Evaluate Fibrin Glue Application in the Treatment of Low-Output Enterocutaneous Fistulas [NCT01828892]		30 participants (Anticipated)	Interventional	2014-03-31	Recruiting
Intraperitoneal (IP) Vancomycin Plus Oral Moxifloxacin Versus IP Vancomycin Plus IP Ceftazidime for the Treatment of Peritoneal Dialysis-related Peritonitis: a Pilot Randomized Controlled Study [NCT02787057]		80 participants (Actual)	Interventional	2012-11-30	Completed
Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving Continuous Venovenous Hemodiafiltration [NCT04358991]		20 participants (Actual)	Observational	2017-01-01	Completed
A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients [NCT02822950]	Phase 1	10 participants (Actual)	Interventional	2017-01-31	Completed
Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis: an Open, Randomized, Controlled Clinical Trial [NCT01455246]	Phase 2/Phase 3	32 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group.)
Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance [NCT04771884]		300 participants (Anticipated)	Observational	2020-10-01	Recruiting
Steady-state Pharmacokinetics of Ceftazidime/Avibactam in CF [NCT02504827]	Phase 4	12 participants (Actual)	Interventional	2015-09-30	Completed
A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam When Given In Combination With Metronidazole, Compared With Meropenem, In Children From 3 Month [NCT02475733]	Phase 2	83 participants (Actual)	Interventional	2015-08-01	Completed
A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam Compared With Cefepime In Children From 3 Months To Less Than 18 Years Of Age With Complicated [NCT02497781]	Phase 2	97 participants (Actual)	Interventional	2015-09-24	Completed
A Randomized, Open Label, Multicentre Phase Iv Study To Evaluate The Efficacy And Safety Of Magnex (Cefoperazone-Sulbactam) In Comparison With Ceftazidime Plus Amikacin And Metronidazole In The Treatment Of Intra-Abdominal Infections [NCT00360607]	Phase 4	307 participants (Actual)	Interventional	2004-07-31	Completed
Evaluation of Antibiogram Results and Clinical Response to Prescribed Antimicrobials in Microbial Keratitis Patients [NCT05655689]		123 participants (Actual)	Observational	2021-12-31	Completed
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdo [NCT01726023]	Phase 3	486 participants (Actual)	Interventional	2013-01-31	Completed
A Phase III Randomized Double-Blind Study Of Ceftobiprole Versus Linezolid Plus Ceftazidime In The Treatment Of Nosocomial Pneumonia [NCT00210964]	Phase 3	781 participants (Actual)	Interventional	2005-04-30	Completed
Comparative Study Between Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in the Treatment of ARDS Induced by Both Lung Trauma and VAP [NCT04402359]		200 participants (Actual)	Observational [Patient Registry]	2018-07-05	Completed
Ceftazidime-Avibactam Versus Colistin in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections (AVI-ICU): A Non-Inferiority Randomized Clinical Trial [NCT05258851]	Phase 3	168 participants (Anticipated)	Interventional	2022-06-01	Recruiting
: Pharmacokinetics of Ceftazidime-Avibactam in Critically Ill Patients With Renal Failure Requiring Continuous Venovenous Hemodiafiltration [NCT03243864]		10 participants (Anticipated)	Observational	2017-03-13	Recruiting
A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANTS FROM BIRTH TO LESS THAN 3 MONTHS OF AGE WITH SUSPECTED O [NCT04126031]	Phase 2	48 participants (Actual)	Interventional	2020-01-14	Terminated(stopped due to Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.)
A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers [NCT03376529]	Phase 1	27 participants (Actual)	Interventional	2017-11-10	Completed
An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens [NCT01644643]	Phase 3	345 participants (Actual)	Interventional	2013-01-31	Completed
A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-A [NCT01808092]	Phase 3	969 participants (Actual)	Interventional	2013-04-30	Completed
A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Thera [NCT01599806]	Phase 3	641 participants (Actual)	Interventional	2012-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the LFU Visit
NCT00690378 (20) [back to overview]	Clinical Outcome in CE Patients at the Late Follow-up (LFU) Visit
NCT00690378 (20) [back to overview]	Clinical Outcome in CE Patients at the TOC Visit
NCT00690378 (20) [back to overview]	Clinical Outcome in Clinically Evaluable (CE) Patients at the End of Intravenous (IV) Therapy Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the End of IV Therapy Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the LFU Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the TOC Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the End of IV Therapy Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the TOC Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the End of IV Therapy Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the LFU Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the TOC Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the End of IV Therapy Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the TOC Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the End of IV Therapy Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the LFU Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the TOC Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome in ME Patients at the End of IV Therapy Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome in ME Patients at the LFU Visit
NCT00690378 (20) [back to overview]	Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit
NCT00752219 (10) [back to overview]	Number of Participants With Clinical Response at the Test of Cure (TOC) Visit
NCT00752219 (10) [back to overview]	Number of Participants With Clinical Response in CE Participants at the End of IV Therapy
NCT00752219 (10) [back to overview]	Number of Participants With Clinical Response in CE Participants at the Late Follow-up Visit
NCT00752219 (10) [back to overview]	Number of Participants With Clinical Response in Clinically Evaluable (CE) Participants at the Test of Cure Visit
NCT00752219 (10) [back to overview]	Number of Participants With Microbiological Response at the End of IV Therapy
NCT00752219 (10) [back to overview]	Number of Participants With Microbiological Response at the Late Follow-up Visit
NCT00752219 (10) [back to overview]	Number of Participants With Microbiological Response at the Test of Cure Visit
NCT00752219 (10) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00752219 (10) [back to overview]	Number of Participants With Clinical Response at the End of Intravenous (IV) Therapy
NCT00752219 (10) [back to overview]	Number of Participants With Clinical Response at the Late Follow-up Visit
NCT00921024 (2) [back to overview]	Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population
NCT00921024 (2) [back to overview]	Microbiological Response at the TOC Visit in the Microbiologically Evaluable (ME) Population.
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at LFU (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)
NCT01595438 (63) [back to overview]	Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at LFU (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at LFU (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)
NCT01599806 (63) [back to overview]	Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at LFU (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at FU2 in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at FU2 in EME at FU2 Analysis Set
NCT01644643 (38) [back to overview]	Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set
NCT01644643 (38) [back to overview]	Clinical Response at FU2 in EME at FU2 Analysis Set
NCT01644643 (38) [back to overview]	Clinical Response at FU1 in EME at FU1 Analysis Set.
NCT01644643 (38) [back to overview]	Clinical Response at Follow-up 2 (FU2) in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Clinical Response at Follow-up 1 (FU1) in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Clinical Response at EOT in Extended Microbiologically Evaluable (EME) at EOT Analysis Set.
NCT01644643 (38) [back to overview]	Clinical Response at End of Treatment (EOT) in mMITT Analysis Set.
NCT01644643 (38) [back to overview]	The 28 Days All Cause Mortality Rate in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Clinical Cure at TOC by Previously Failed Treatment Class in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Clinical Cure at TOC by Previously Failed Treatment Class in EME at TOC Analysis Set
NCT01644643 (38) [back to overview]	Clinical Cure at TOC by Baseline Gram-negative Pathogen in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Clinical Cure at TOC by Baseline Gram-negative Pathogen in EME at TOC Analysis Set
NCT01644643 (38) [back to overview]	Clinical Cure at FU2 by Previously Failed Treatment Class in EME at FU2 Analysis Set
NCT01644643 (38) [back to overview]	Clinical Cure at FU1 by Previously Failed Treatment Class in EME at FU1 Analysis Set
NCT01644643 (38) [back to overview]	Clinical Cure at EOT by Previously Failed Treatment Class in EME at EOT Analysis Set
NCT01644643 (38) [back to overview]	The Reason for Treatment Change/Discontinuation in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Plasma Concentrations for Ceftazidime and Avibactam - cUTI in PK Analysis Set
NCT01644643 (38) [back to overview]	The 28 Days All Cause Mortality Rate in EME at TOC Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at TOC in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at TOC in EME at TOC Analysis Set
NCT01644643 (38) [back to overview]	Clinical Response at TOC in EME at TOC Analysis Set.
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at EOT in EME at EOT Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at EOT in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at FU1 in EME at FU1 Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at FU1 in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at FU2 in EME at FU2 Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at FU2 in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Plasma Concentrations for Ceftazidime and Avibactam - cIAI in PK Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC by CAZ-AVI MIC in EME at TOC Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC by CAZ-AVI MIC in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC in EME at TOC Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at EOT in EME at EOT Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at EOT in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at FU1 in EME at FU1 Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at FU1 in mMITT Analysis Set
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable(ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	Safety and Tolerability:ECG , QTcB and QTcF Intervals
NCT01726023 (41) [back to overview]	Safety and Tolerability: Clinical Laboratory Evaluation Hematology.
NCT01726023 (41) [back to overview]	Safety and Tolerability: Clinical Laboratory Evaluation Clinical Chemistry.
NCT01726023 (41) [back to overview]	Safety and Tolerability by Incidence: Extent of Exposure.
NCT01726023 (41) [back to overview]	Safety and Tolerability by Incidence and Severity of Adverse Events and Serious Adverse Events and Mortality.
NCT01726023 (41) [back to overview]	The Time to First Defervescence in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set for Patients Who Have Fever at Study Entry.
NCT01726023 (41) [back to overview]	The Time to First Defervescence in the Clinically Evaluable (CE) Analysis Set for Patients Who Have Fever at Study Entry.
NCT01726023 (41) [back to overview]	Plasma Concentrations for Ceftazidime and Avibactam
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Clinically Evaluable (CE) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Clinically Evaluable (CE) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]	The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in the Clinically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Clinically Evaluable Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Clinically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Microbiologically Evaluable Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Evaluable at TOC Analysis Set (Co-primary Analyses)
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set (Co-primary Analyses)
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Extended Microbiologically Evaluable Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Microbiologically Evaluable Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Clinically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Clinically Modified Intent-to-treat Analysis Set at End of Treatment Visit
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Clinically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Clinically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in Clinically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]	The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]	The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in the Clinically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Death Due to Any Cause (All-cause Mortality) in Clinically Modified Intent-to-treat Analysis Set at Day 28
NCT01808092 (49) [back to overview]	The Number of Patients With Death Due to Any Cause (All-cause Mortality) in Microbiologically Modified Intent-to-treat Analysis Set at Day 28
NCT01808092 (49) [back to overview]	The Number of Patients With Death Due to Any Cause (All-cause Mortality) in the Clinically Evaluable at Test-of-cure Analysis Set at Day 28
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit
NCT01808092 (49) [back to overview]	Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Clinical Response (CR) at End of Treatment (EOT) Visit: Intent-to-treat (ITT) Analysis Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)
NCT02475733 (26) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at Day 7
NCT02475733 (26) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at Late Follow-up (LFU) Visit
NCT02475733 (26) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit
NCT02475733 (26) [back to overview]	Percentage of Participants With Electrocardiogram (ECG) Parameter QTcF: > 450, >480 and >500 Millisecond (ms)
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Clinical Response (CR): Clinically Evaluable (CE) Analysis Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Microbiological Response: Microbiologically Evaluable (ME) Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters
NCT02475733 (26) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02475733 (26) [back to overview]	Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Population
NCT02475733 (26) [back to overview]	Plasma Concentrations of Ceftazidime and Avibactam
NCT02475733 (26) [back to overview]	Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Emergent Infections at Test of Cure (TOC) Visit: Microbiologically Evaluable Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Clinical Response (CR) at End of 72 Hours Treatment: Intent-to-treat (ITT) Analysis Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Clinical Response (CR) at End of Intravenous Therapy (EOIV) Visit: Intent-to-treat (ITT) Analysis Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Clinical Response (CR) at Test of Cure (TOC) Visit: Intent-to-treat (ITT) Analysis Population
NCT02475733 (26) [back to overview]	Change From Baseline in Body Temperature at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]	Change From Baseline in Body Weight at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]	Change From Baseline in Pulse Rate at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]	Change From Baseline in Respiratory Rate at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]	Percentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Therapy (EOIV) Visit
NCT02497781 (29) [back to overview]	Change From Baseline in Body Weight at End of Intravenous Treatment (EOIV) Visit
NCT02497781 (29) [back to overview]	Change From Baseline in Body Temperature at End of Intravenous Treatment (EOIV) Visit
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR) at TOC: Clinically Evaluable (CE) Analysis Set at TOC
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR) at End of Treatment (EOT) Visit: Clinically Evaluable (CE) Analysis Set at EOT
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR) at End of Intravenous Treatment (EOIV) Visit: Clinically Evaluable (CE) Analysis Set at EOIV
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR) at End of 72 Hours Treatment: Clinically Evaluable (CE) Analysis Set at 72 Hours
NCT02497781 (29) [back to overview]	Percentage of Participants With Emergent Infections: Microbiologically Evaluable (ME) Analysis Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Analysis Set at LFU
NCT02497781 (29) [back to overview]	Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Analysis Set at LFU
NCT02497781 (29) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Treatment (EOIV) Visit
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR): Microbiologically Evaluable (ME) Analysis Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Combined Response: Microbiological Intent-to-treat (Micro-ITT) Population
NCT02497781 (29) [back to overview]	Change From Baseline in Pulse Rate at End of Intravenous Treatment (EOIV) Visit
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR): Microbiological ITT (Micro-ITT) Analysis Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Microbiological Response: Microbiologically Evaluable (ME) Analysis Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR): Intent-to-treat (ITT) Analysis Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters
NCT02497781 (29) [back to overview]	Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters
NCT02497781 (29) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02497781 (29) [back to overview]	Plasma Concentrations of Ceftazidime and Avibactam
NCT02497781 (29) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Treatment (EOIV) Visit
NCT02497781 (29) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at Day 7
NCT02497781 (29) [back to overview]	Percentage of Participants With Combined Response: Microbiologically Evaluable (ME) Analysis Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)
NCT02497781 (29) [back to overview]	Percentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Treatment (EOIV) Visit
NCT02497781 (29) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit
NCT02497781 (29) [back to overview]	Change From Baseline in Respiratory Rate at End of Intravenous Treatment (EOIV) Visit
NCT02504827 (2) [back to overview]	Peak Sputum Concentration
NCT02504827 (2) [back to overview]	Peak Plasma Concentration (Cmax)
NCT02787057 (4) [back to overview]	Secondary Treatment Failure Rate
NCT02787057 (4) [back to overview]	Primary Treatment Failure Rate
NCT02787057 (4) [back to overview]	Primary Response Rate
NCT02787057 (4) [back to overview]	Complete Cure Rate
NCT02822950 (5) [back to overview]	Mean (SD) Ceftazadime/Avibactam Pharmacokinetic Half Life Parameter in Intensive Care Patients
NCT02822950 (5) [back to overview]	Mean (SD) Ceftazadime/Avibactam Pharmacokinetic Clearance of Drug Parameter in Intensive Care Patients
NCT02822950 (5) [back to overview]	Mean (SD) Ceftazadime/Avibactam Pharmacokinetic Area Under Serum Curve (mg*h/L) Parameter in Intensive Care Patients
NCT02822950 (5) [back to overview]	Mean (SD) Ceftazadime/Avibactam Pharmacokinetic (PK) Volume of Distribution Parameter in Intensive Care Patients
NCT02822950 (5) [back to overview]	Mean (SD) Ceftazadime/Avibactam Pharmacokinetic (PK) Maximum Serum Concentration in Intensive Care Patients
NCT03978091 (40) [back to overview]	Concentration of Study Drug at Steady State After Continuous Infusion (Css)
NCT03978091 (40) [back to overview]	Volume of Distribution of Study Drug at Steady-state Based on the Last Observed Concentration (Vss)
NCT03978091 (40) [back to overview]	Volume of Distribution of Study Drug at Steady-state Based on the Last Observed Concentration (Vss)
NCT03978091 (40) [back to overview]	Total Body Plasma Clearance of Study Drug (CL)
NCT03978091 (40) [back to overview]	Total Body Plasma Clearance of Study Drug (CL)
NCT03978091 (40) [back to overview]	Total Body Plasma Clearance of Study Drug (CL)
NCT03978091 (40) [back to overview]	Time to Cmax (Maximum Plasma Concentration) of Study Drug Following Multiple Daily Dosing (Tmax)
NCT03978091 (40) [back to overview]	Time to Cmax (Maximum Plasma Concentration) of Study Drug Following Multiple Daily Dosing (Tmax)
NCT03978091 (40) [back to overview]	Time to Cmax (Maximum Plasma Concentration) of Study Drug Following Multiple Daily Dosing (Tmax)
NCT03978091 (40) [back to overview]	Time of Cmax (Maximum Plasma Concentration) of Study Drug After the First Dose (Tmax)
NCT03978091 (40) [back to overview]	Time of Cmax (Maximum Plasma Concentration) of Study Drug After the First Dose (Tmax)
NCT03978091 (40) [back to overview]	Accumulation Ratio for AUC (Area Under the Plasma Concentration-time Curve of Study Drug) [RAUC]
NCT03978091 (40) [back to overview]	Renal Clearance of Study Drug (CLR)
NCT03978091 (40) [back to overview]	Renal Clearance of Study Drug (CLR)
NCT03978091 (40) [back to overview]	Renal Clearance of Study Drug (CLR)
NCT03978091 (40) [back to overview]	Area Under the Plasma Concentration-time Curve Data of Study Drug During the Dosing Interval on Day 1 [AUC(0-Tau)]
NCT03978091 (40) [back to overview]	Minimum Plasma Concentration of Study Drug Following Multiple Daily Dosing on Day 1 (Cmin)
NCT03978091 (40) [back to overview]	Minimum Plasma Concentration of Study Drug Following Multiple Daily Dosing on Day 1 (Cmin)
NCT03978091 (40) [back to overview]	Minimum Plasma Concentration of Study Drug Following Multiple Daily Dosing on Day 1 (Cmin)
NCT03978091 (40) [back to overview]	Maximum Plasma Concentration of Study Drug Following Multiple Daily Dosing (Cmax)
NCT03978091 (40) [back to overview]	Time of Cmax (Maximum Plasma Concentration) of Study Drug After the First Dose (Tmax)
NCT03978091 (40) [back to overview]	Maximum Plasma Concentration of Study Drug Following Multiple Daily Dosing (Cmax)
NCT03978091 (40) [back to overview]	Maximum Plasma Concentration of Study Drug Following Multiple Daily Dosing (Cmax)
NCT03978091 (40) [back to overview]	Maximum Plasma Concentration of Study Drug After the First Dose (Cmax)
NCT03978091 (40) [back to overview]	Maximum Plasma Concentration of Study Drug After the First Dose (Cmax)
NCT03978091 (40) [back to overview]	Maximum Plasma Concentration of Study Drug After the First Dose (Cmax)
NCT03978091 (40) [back to overview]	Volume of Distribution of Study Drug at Steady-state Based on the Last Observed Concentration (Vss)
NCT03978091 (40) [back to overview]	Concentration of Study Drug at Steady State After Continuous Infusion (Css)
NCT03978091 (40) [back to overview]	Accumulation Ratio for AUC (Area Under the Plasma Concentration-time Curve of Study Drug) [RAUC]
NCT03978091 (40) [back to overview]	Accumulation Ratio for AUC (Area Under the Plasma Concentration-time Curve of Study Drug) [RAUC]
NCT03978091 (40) [back to overview]	Accumulation Ratio for Cmax (Maximum Plasma Concentration) (RCmax)
NCT03978091 (40) [back to overview]	Accumulation Ratio for Cmax (Maximum Plasma Concentration) (RCmax)
NCT03978091 (40) [back to overview]	Accumulation Ratio for Cmax (Maximum Plasma Concentration) (RCmax)
NCT03978091 (40) [back to overview]	Area Under the Plasma Concentration-time Curve Data of Study Drug During the Dosing Interval on Day 1 [AUC(0-Tau)]
NCT03978091 (40) [back to overview]	Number of Participants With at Least One Grade 2 (Moderate) or Higher Treatment-emergent Adverse Event
NCT03978091 (40) [back to overview]	Area Under the Plasma Concentration-time Curve Data of Study Drug During the Dosing Interval on Day 1 [AUC(0-Tau)]
NCT03978091 (40) [back to overview]	Area Under the Plasma Concentration-time Curve of Study Drug From Time of Dosing Extrapolated to Infinity [AUC(0-Inf)]
NCT03978091 (40) [back to overview]	Area Under the Plasma Concentration-time Curve of Study Drug From Time of Dosing Extrapolated to Infinity [AUC(0-Inf)]
NCT03978091 (40) [back to overview]	Area Under the Plasma Concentration-time Curve of Study Drug From Time of Dosing Extrapolated to Infinity [AUC(0-Inf)]
NCT03978091 (40) [back to overview]	Incidence of Treatment-emergent Adverse Events, by System Organ Class (SOC) and Maximum Severity Level
NCT04358991 (1) [back to overview]	Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients

Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the LFU Visit

Sustained eradication: a uropathogen found at entry at >10^5 CFU/mL remained <10^4 CFU/mL (NCT00690378)
Timeframe: 4 to 6 weeks post-therapy

Intervention	Participants (Number)
NXL104/CAZ	0
Imipenem Cilastatin	0

[back to top]

Clinical Outcome in CE Patients at the Late Follow-up (LFU) Visit

Cure: all or most pre-therapy signs and symptoms of the index infection showed no evidence of resurgence and no additional antibiotic was required (NCT00690378)
Timeframe: 4 to 6 weeks post-therapy

Intervention	Participants (Number)
NXL104/CAZ	20
Imipenem Cilastatin	24

[back to top]

Clinical Outcome in CE Patients at the TOC Visit

Cure: all or most pre-therapy signs and symptoms of the index infection had resolved and no additional antibiotic was required (NCT00690378)
Timeframe: 5 to 9 days post-therapy

Intervention	Participants (Number)
NXL104/CAZ	24
Imipenem Cilastatin	29

[back to top]

Clinical Outcome in Clinically Evaluable (CE) Patients at the End of Intravenous (IV) Therapy Visit

Cure: all or most pre-therapy signs and symptoms of the index infection had resolved and no additional antibiotic was required (NCT00690378)
Timeframe: End of IV therapy (4 to 14 days)

Intervention	Participants (Number)
NXL104/CAZ	28
Imipenem Cilastatin	36

[back to top]

Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the End of IV Therapy Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: End of IV therapy (4 to 14 days)

Intervention	Participants (Number)
NXL104/CAZ	1
Imipenem Cilastatin	0

[back to top]

Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the LFU Visit

Sustained eradication: a uropathogen found at entry at >10^5 CFU/mL remained <10^4 CFU/mL (NCT00690378)
Timeframe: 4 to 6 weeks post-therapy

Intervention	Participants (Number)
NXL104/CAZ	1
Imipenem Cilastatin	0

[back to top]

Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the TOC Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: 5 to 9 days post-therapy

Intervention	Participants (Number)
NXL104/CAZ	1
Imipenem Cilastatin	0

[back to top]

Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the End of IV Therapy Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: End of IV therapy (4 to 14 days)

Intervention	Participants (Number)
NXL104/CAZ	0
Imipenem Cilastatin	1

[back to top]

Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the TOC Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: 5 to 9 days post-therapy

Intervention	Participants (Number)
NXL104/CAZ	0
Imipenem Cilastatin	1

[back to top]

Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the End of IV Therapy Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: End of IV therapy (4 to 14 days)

Intervention	Participants (Number)
NXL104/CAZ	24
Imipenem Cilastatin	32

[back to top]

Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the LFU Visit

Sustained eradication: a uropathogen found at entry at >10^5 CFU/mL remained <10^4 CFU/mL (NCT00690378)
Timeframe: 4 to 6 weeks post-therapy

Intervention	Participants (Number)
NXL104/CAZ	15
Imipenem Cilastatin	17

[back to top]

Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the TOC Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: 5 to 9 days post-therapy

Intervention	Participants (Number)
NXL104/CAZ	19
Imipenem Cilastatin	23

[back to top]

Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the End of IV Therapy Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: End of IV therapy (4 to 14 days)

Intervention	Participants (Number)
NXL104/CAZ	1
Imipenem Cilastatin	0

[back to top]

Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the TOC Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: 5 to 9 days post-therapy

Intervention	Participants (Number)
NXL104/CAZ	0
Imipenem Cilastatin	0

[back to top]

Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the End of IV Therapy Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: End of IV therapy (4 to 14 days)

Intervention	Participants (Number)
NXL104/CAZ	0
Imipenem Cilastatin	1

[back to top]

Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the LFU Visit

Sustained eradication: a uropathogen found at entry at >10^5 CFU/mL remained <10^4 CFU/mL (NCT00690378)
Timeframe: 4 to 6 weeks post-therapy

Intervention	Participants (Number)
NXL104/CAZ	0
Imipenem Cilastatin	1

[back to top]

Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the TOC Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: 5 to 9 days post-therapy

Intervention	Participants (Number)
NXL104/CAZ	0
Imipenem Cilastatin	1

[back to top]

Microbiological Outcome in ME Patients at the End of IV Therapy Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: End of IV therapy (4 to 14 days)

Intervention	Participants (Number)
NXL104/CAZ	25
Imipenem Cilastatin	34

[back to top]

Microbiological Outcome in ME Patients at the LFU Visit

Sustained eradication: a uropathogen found at entry at >10^5 CFU/mL remained <10^4 CFU/mL (NCT00690378)
Timeframe: 4 to 6 weeks post-therapy

Intervention	Participants (Number)
NXL104/CAZ	15
Imipenem Cilastatin	18

[back to top]

Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: 5 to 9 days post-therapy

Intervention	Participants (Number)
NXL104/CAZ	19
Imipenem Cilastatin	25

[back to top]

Number of Participants With Clinical Response at the Test of Cure (TOC) Visit

Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were microbiologically evaluable (ME) at baseline. (NCT00752219)
Timeframe: Test of cure visit: 2 weeks post-therapy (Day 28)

Intervention	participants (Number)
NXL104/Ceftazidime + Metronidazole	62
Meropenem	71

[back to top]

Number of Participants With Clinical Response in CE Participants at the End of IV Therapy

Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. (NCT00752219)
Timeframe: End of IV therapy: From Day 5 to Day 14

Intervention	participants (Number)
NXL104/Ceftazidime + Metronidazole	84
Meropenem	87

[back to top]

Number of Participants With Clinical Response in CE Participants at the Late Follow-up Visit

Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. (NCT00752219)
Timeframe: Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)

Intervention	participants (Number)
NXL104/Ceftazidime + Metronidazole	79
Meropenem	84

[back to top]

Number of Participants With Clinical Response in Clinically Evaluable (CE) Participants at the Test of Cure Visit

Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. (NCT00752219)
Timeframe: Test of cure visit: 2 weeks post-therapy (Day 28)

Intervention	participants (Number)
NXL104/Ceftazidime + Metronidazole	80
Meropenem	85

[back to top]

Number of Participants With Microbiological Response at the End of IV Therapy

Microbiological response was defined as eradication of pathogen identified (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication of pathogens (absence of material to culture in a participant who had responded clinically to treatment). This clinical response was measured in participants who were ME at baseline. (NCT00752219)
Timeframe: End of IV therapy: From Day 5 to Day 14

Intervention	participants (Number)
NXL104/Ceftazidime + Metronidazole	66
Meropenem	74

[back to top]

Number of Participants With Microbiological Response at the Late Follow-up Visit

Favorable: eradication (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication (absence of material to culture in a patient who had responded clinically to treatment) (NCT00752219)
Timeframe: Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)

Intervention	participants (Number)
NXL104/Ceftazidime + Metronidazole	62
Meropenem	71

[back to top]

Number of Participants With Microbiological Response at the Test of Cure Visit

Intervention	participants (Number)
NXL104/Ceftazidime + Metronidazole	62
Meropenem	71

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 6 weeks after last dose of study treatment that were absent before treatment or that worsened relative to pretreatment state. (NCT00752219)
Timeframe: Baseline up to 6 weeks after last dose of study treatment (up to a maximum of 8 weeks)

Intervention	participants (Number)
	AEs	SAEs
Meropenem	59	11
NXL104/Ceftazidime + Metronidazole	65	9

[back to top]

Number of Participants With Clinical Response at the End of Intravenous (IV) Therapy

Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were ME at baseline. (NCT00752219)
Timeframe: End of IV therapy: From Day 5 to Day 14

Intervention	participants (Number)
NXL104/Ceftazidime + Metronidazole	66
Meropenem	74

[back to top]

Number of Participants With Clinical Response at the Late Follow-up Visit

Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were ME at baseline. (NCT00752219)
Timeframe: Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)

Intervention	participants (Number)
NXL104/Ceftazidime + Metronidazole	62
Meropenem	71

[back to top]

Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population

Microbiological response is eradication for each baseline pathogen (NCT00921024)
Timeframe: TOC; 6-9 days after last study drug administration

Intervention	percentage of patients (Number)
CXA-101	83.1
Ceftazidime	76.3

[back to top]

Microbiological Response at the TOC Visit in the Microbiologically Evaluable (ME) Population.

Microbiological response is eradication for each baseline pathogen (NCT00921024)
Timeframe: TOC; 6-9 days after last study drug administration

Intervention	percentage of patients (Number)
CXA-101	85.5
Ceftazidime	92.6

[back to top]

Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)

Number of favorable per-pathogen microbiological responses at the LFU visit in the Extended ME at LFU analysis set for blood only (NCT01595438)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=19, 18)	Klebsiella pneumoniae - Favorable (n=2, 1)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=0, 1)
CAZ-AVI	19	2	1	0
Doripenem	17	1	0	1

[back to top]

Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)

Number of favorable per-pathogen microbiological responses at the LFU visit in the ME at LFU analysis set for blood only (NCT01595438)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=19, 18)	Klebsiella pneumoniae - Favorable (n=2, 1)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=0, 1)
CAZ-AVI	19	2	1	0
Doripenem	17	1	0	1

[back to top]

Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)

Number of favorable per-pathogen microbiological responses at the LFU visit in the mMITT analysis set for blood only (NCT01595438)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=32, 28)	Klebsiella pneumoniae - Favorable (n=4, 2)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=1, 2)
CAZ-AVI	29	3	1	1
Doripenem	27	2	0	2

[back to top]

Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)

Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the Extended ME at TOC analysis set (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=4,4)	E. coli (MIC: 0.015) - Favorable (n=5, 6)	E. coli (MIC: 0.03) - Favorable (n=18, 21)	E. coli (MIC: 0.06) - Favorable (n=95, 111)	E. coli (MIC: 0.12) - Favorable (n=68, 54)	E. coli (MIC: 0.25) - Favorable (n=19, 18)	E. coli (MIC: 0.5) - Favorable (n=2, 5)	E. coli (MIC: 1) - Favorable (n=2, 0)	E. coli (MIC: 2) - Favorable (n=1, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: 32) - Favorable (n=0, 0)	E. coli (MIC: >32) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 0.03) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=5, 7)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=8, 9)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=3, 7)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=6, 11)	Kleb. pneumoniae (MIC: 1) - Favorable (n=6, 4)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 2, 1)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 32) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >32) - Favorable (n=0, 1)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=1,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=9, 2)	Proteus mirabilis (MIC: 0.06)- Favorable (n=4,5)	Proteus mirabilis (MIC: 0.12)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.25)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 0.5)- Favorable (n=0,0)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 32)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >32)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,0)	Entero. cloacae (MIC: 0.06)- Favorable (n= 0, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 1,2)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,3)	Entero. cloacae (MIC: 0.5)- Favorable (n= 1,1)	Entero. cloacae (MIC: 1)- Favorable (n= 1,4)	Entero. cloacae (MIC: 2)- Favorable (n= 1,0)	Entero. cloacae (MIC: 4)- Favorable (n= 2,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: 32)- Favorable (n= 0,0)	Entero. cloacae (MIC: >32)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.12) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.25) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.5) - Favorable (n=0,0)	P.aeruginosa (MIC: 1) - Favorable (n=1,4)	P.aeruginosa (MIC: 2) - Favorable (n=4,5)	P.aeruginosa (MIC: 4) - Favorable (n=5,6)	P.aeruginosa (MIC: 8) - Favorable (n=2,2)	P.aeruginosa (MIC: 16) - Favorable (n=0,1)	P.aeruginosa (MIC: 32) - Favorable (n=0,0)	P.aeruginosa (MIC: >32) - Favorable (n=1,0)
CAZ-AVI	2	5	17	83	56	13	2	1	1	0	0	0	0	0	0	1	1	4	7	1	4	6	2	0	0	0	0	0	0	1	9	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	1	4	1	1	0	0	1
Doripenem	4	5	17	94	40	8	2	0	0	0	0	0	0	0	0	0	2	7	6	2	8	3	0	0	0	0	0	1	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2	5	4	1	1	0	0

[back to top]

Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)

Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the ME at TOC analysis set (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=4,4)	E. coli (MIC: 0.015) - Favorable (n=5, 6)	E. coli (MIC: 0.03) - Favorable (n=18, 21)	E. coli (MIC: 0.06) - Favorable (n=95, 111)	E. coli (MIC: 0.12) - Favorable (n=68, 54)	E. coli (MIC: 0.25) - Favorable (n=19, 18)	E. coli (MIC: 0.5) - Favorable (n=2, 5)	E. coli (MIC: 1) - Favorable (n=2, 0)	E. coli (MIC: 2) - Favorable (n=1, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: 32) - Favorable (n=0, 0)	E. coli (MIC: >32) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 0.03) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=5, 7)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=8, 9)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=3, 7)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=6, 11)	Kleb. pneumoniae (MIC: 1) - Favorable (n=5, 4)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 2, 1)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 32) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >32) - Favorable (n=0, 0)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=1,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=9, 2)	Proteus mirabilis (MIC: 0.06)- Favorable (n=4,5)	Proteus mirabilis (MIC: 0.12)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.25)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 0.5)- Favorable (n=0,0)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 32)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >32)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,0)	Entero. cloacae (MIC: 0.06)- Favorable (n= 0, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 1,2)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,3)	Entero. cloacae (MIC: 0.5)- Favorable (n= 1,1)	Entero. cloacae (MIC: 1)- Favorable (n= 1,4)	Entero. cloacae (MIC: 2)- Favorable (n= 1,0)	Entero. cloacae (MIC: 4)- Favorable (n= 2,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: 32)- Favorable (n= 0,0)	Entero. cloacae (MIC: >32)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.12) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.25) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.5) - Favorable (n=0,0)	P.aeruginosa (MIC: 1) - Favorable (n=1,4)	P.aeruginosa (MIC: 2) - Favorable (n=4,4)	P.aeruginosa (MIC: 4) - Favorable (n=3,4)	P.aeruginosa (MIC: 8) - Favorable (n=1,1)	P.aeruginosa (MIC: 16) - Favorable (n=0,0)	P.aeruginosa (MIC: 32) - Favorable (n=0,0)	P.aeruginosa (MIC: >32) - Favorable (n=0,0)
CAZ-AVI	2	5	17	83	56	13	2	1	1	0	0	0	0	0	0	1	1	4	7	1	4	5	2	0	0	0	0	0	0	1	9	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	1	4	1	1	0	0	0
Doripenem	4	5	17	94	40	8	2	0	0	0	0	0	0	0	0	0	2	7	6	2	8	3	0	0	0	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2	4	3	0	0	0	0

[back to top]

Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)

Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the mMITT analysis set (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=5, 6)	E. coli (MIC: 0.015) - Favorable (n=8, 7)	E. coli (MIC: 0.03) - Favorable (n=28, 35)	E. coli (MIC: 0.06) - Favorable (n=123, 139)	E. coli (MIC: 0.12) - Favorable (n=90, 81)	E. coli (MIC: 0.25) - Favorable (n=28, 25)	E. coli (MIC: 0.5) - Favorable (n=5, 6)	E. coli (MIC: 1) - Favorable (n=3, 0)	E. coli (MIC: 2) - Favorable (n=1, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: 32) - Favorable (n=0, 0)	E. coli (MIC: >32) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 0.03) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=9, 8)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=11, 10)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=4, 10)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=8, 16)	Kleb. pneumoniae (MIC: 1) - Favorable (n=8, 5)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 2, 4)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 32) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >32) - Favorable (n=0, 1)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=1,1)	Proteus mirabilis (MIC: 0.03)- Favorable (n=10, 5)	Proteus mirabilis (MIC: 0.06)- Favorable (n=6,6)	Proteus mirabilis (MIC: 0.12)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.25)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 0.5)- Favorable (n=0,1)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 32)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >32)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,0)	Entero. cloacae (MIC: 0.06)- Favorable (n= 0, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 3,2)	Entero. cloacae (MIC: 0.25)- Favorable (n= 1,4)	Entero. cloacae (MIC: 0.5)- Favorable (n= 1,1)	Entero. cloacae (MIC: 1)- Favorable (n= 2,5)	Entero. cloacae (MIC: 2)- Favorable (n= 1,0)	Entero. cloacae (MIC: 4)- Favorable (n= 2,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: 32)- Favorable (n= 0,0)	Entero. cloacae (MIC: >32)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.12) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.25) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.5) - Favorable (n=0,2)	P.aeruginosa (MIC: 1) - Favorable (n=1,4)	P.aeruginosa (MIC: 2) - Favorable (n=5,5)	P.aeruginosa (MIC: 4) - Favorable (n=7,6)	P.aeruginosa (MIC: 8) - Favorable (n=2,2)	P.aeruginosa (MIC: 16) - Favorable (n=1,1)	P.aeruginosa (MIC: 32) - Favorable (n=0,0)	P.aeruginosa (MIC: >32) - Favorable (n=2,0)
CAZ-AVI	3	8	24	103	67	18	4	1	1	0	0	0	0	0	0	1	1	7	9	1	6	6	2	0	0	0	0	0	0	1	10	5	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	1	5	3	1	0	0	2
Doripenem	5	6	23	111	54	13	2	0	0	0	0	0	0	0	0	0	2	8	7	3	11	3	0	0	0	0	0	1	0	0	3	5	0	0	1	0	0	0	0	0	0	0	0	0	0	1	2	1	1	4	0	0	0	0	0	0	0	0	0	0	0	0	2	2	5	4	1	1	0	0

[back to top]

Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)

Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the Extended ME at TOC analysis set (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=1,1)	E. coli (MIC: 0.015) - Favorable (n=122, 119)	E. coli (MIC: 0.03) - Favorable (n=79, 89)	E. coli (MIC: 0.06) - Favorable (n=10, 8)	E. coli (MIC: 0.12) - Favorable (n=1, 2)	E. coli (MIC: 0.25) - Favorable (n=1, 0)	E. coli (MIC: 0.5) - Favorable (n=0, 0)	E. coli (MIC: 1) - Favorable (n=0, 0)	E. coli (MIC: 2) - Favorable (n=0, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: >16) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC:0.03) - Favorable (n=15, 23)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=8, 12)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=3, 2)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=2, 2)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 1) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 0,0)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 1)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >16) - Favorable (n=1, 0)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=1,0)	Proteus mirabilis (MIC: 0.06)- Favorable (n=2,2)	Proteus mirabilis (MIC: 0.12)- Favorable (n=4,2)	Proteus mirabilis (MIC: 0.25)- Favorable (n=6, 3)	Proteus mirabilis (MIC: 0.5)- Favorable (n=1,0)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >16)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 1,1)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,4)	Entero. cloacae (MIC: 0.06)- Favorable (n= 2, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 0,4)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.5)- Favorable (n= 3,0)	Entero. cloacae (MIC: 1)- Favorable (n= 0,1)	Entero. cloacae (MIC: 2)- Favorable (n= 0,0)	Entero. cloacae (MIC: 4)- Favorable (n= 0,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: >16)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=2,3)	P.aeruginosa (MIC: 0.12) - Favorable (n=1,2)	P.aeruginosa (MIC: 0.25) - Favorable (n=2,4)	P.aeruginosa (MIC: 0.5) - Favorable (n=2,1)	P.aeruginosa (MIC: 1) - Favorable (n=1,3)	P.aeruginosa (MIC: 2) - Favorable (n=1,0)	P.aeruginosa (MIC: 4) - Favorable (n=0,2)	P.aeruginosa (MIC: 8) - Favorable (n=1,1)	P.aeruginosa (MIC: 16) - Favorable (n=2,1)	P.aeruginosa (MIC: >16) - Favorable (n=1,1)
CAZ-AVI	1	106	64	7	1	1	0	0	0	0	0	0	0	0	1	12	7	2	1	1	1	0	0	0	0	1	0	0	1	2	4	6	1	0	0	0	0	0	0	0	1	1	1	0	0	2	0	0	0	0	0	0	0	0	0	2	0	2	2	0	1	0	0	0	1
Doripenem	1	95	70	3	1	0	0	0	0	0	0	0	0	0	1	18	6	2	1	0	0	0	0	1	0	0	0	0	0	1	2	1	0	0	0	0	0	0	0	0	1	1	1	4	0	0	1	0	0	0	0	0	0	0	0	3	2	1	1	2	0	1	1	1	1

[back to top]

Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)

Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the ME at TOC analysis set (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=1,1)	E. coli (MIC: 0.015) - Favorable (n=122, 119)	E. coli (MIC: 0.03) - Favorable (n=79, 89)	E. coli (MIC: 0.06) - Favorable (n=10, 8)	E. coli (MIC: 0.12) - Favorable (n=1,2)	E. coli (MIC: 0.25) - Favorable (n=1,0)	E. coli (MIC: 0.5) - Favorable (n=0,0)	E. coli (MIC: 1) - Favorable (n=0, 0)	E. coli (MIC: 2) - Favorable (n=0, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: >16) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC:0.03) - Favorable (n=15, 23)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=8, 12)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=3,2)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=2, 2)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=1,0)	Kleb. pneumoniae (MIC: 1) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 0,0)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >16) - Favorable (n=0, 0)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=1, 0)	Proteus mirabilis (MIC: 0.06)- Favorable (n=2,2)	Proteus mirabilis (MIC: 0.12)- Favorable (n=4,2)	Proteus mirabilis (MIC: 0.25)- Favorable (n=6, 3)	Proteus mirabilis (MIC: 0.5)- Favorable (n=1,0)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >16)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 1,1)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,4)	Entero. cloacae (MIC: 0.06)- Favorable (n= 2, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 0,4)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.5)- Favorable (n= 3,0)	Entero. cloacae (MIC: 1)- Favorable (n= 0,1)	Entero. cloacae (MIC: 2)- Favorable (n= 0,0)	Entero. cloacae (MIC: 4)- Favorable (n= 0,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: >16)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=2,3)	P.aeruginosa (MIC: 0.12) - Favorable (n=1,2)	P.aeruginosa (MIC: 0.25) - Favorable (n=2,4)	P.aeruginosa (MIC: 0.5) - Favorable (n=2,1)	P.aeruginosa (MIC: 1) - Favorable (n=1,3)	P.aeruginosa (MIC: 2) - Favorable (n=1,0)	P.aeruginosa (MIC: 4) - Favorable (n=0,0)	P.aeruginosa (MIC: 8) - Favorable (n=0,0)	P.aeruginosa (MIC: 16) - Favorable (n=0,0)	P.aeruginosa (MIC: >16) - Favorable (n=0,0)
CAZ-AVI	1	106	64	7	1	1	0	0	0	0	0	0	0	0	1	12	7	2	1	1	1	0	0	0	0	0	0	0	1	2	4	6	1	0	0	0	0	0	0	0	1	1	1	0	0	2	0	0	0	0	0	0	0	0	0	2	0	2	2	0	1	0	0	0	0
Doripenem	1	95	70	3	1	0	0	0	0	0	0	0	0	0	1	18	6	2	1	0	0	0	0	0	0	0	0	0	0	1	2	1	0	0	0	0	0	0	0	0	1	1	1	4	0	0	1	0	0	0	0	0	0	0	0	3	2	1	1	2	0	0	0	0	0

[back to top]

Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)

Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the mMITT analysis set (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=1, 3)	E. coli (MIC: 0.015) - Favorable (n=160, 160)	E. coli (MIC: 0.03) - Favorable (n=112, 123)	E. coli (MIC: 0.06) - Favorable (n=14, 10)	E. coli (MIC: 0.12) - Favorable (n=3, 3)	E. coli (MIC: 0.25) - Favorable (n=1, 0)	E. coli (MIC: 0.5) - Favorable (n=0,0)	E. coli (MIC: 1) - Favorable (n=0, 0)	E. coli (MIC: 2) - Favorable (n=0, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: >16) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 3)	Kleb. pneumoniae (MIC: 0.03)-Favorable (n=22, 27)	Kleb. pneumoniae (MIC: 0.06)- Favorable (n=11, 16)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=4,4)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=2,3)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=2, 1)	Kleb. pneumoniae (MIC: 1) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 0, 0)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 1)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 1)	Kleb. pneumoniae (MIC: >16) - Favorable (n=1, 0)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=1, 0)	Proteus mirabilis (MIC: 0.06)- Favorable (n=2,2)	Proteus mirabilis (MIC: 0.12)- Favorable (n=6,5)	Proteus mirabilis (MIC: 0.25)- Favorable (n=6, 4)	Proteus mirabilis (MIC: 0.5)- Favorable (n=2,2)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >16)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 3,1)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,5)	Entero. cloacae (MIC: 0.06)- Favorable (n= 3, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 0, 4)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,1)	Entero. cloacae (MIC: 0.5)- Favorable (n= 4,0)	Entero. cloacae (MIC: 1)- Favorable (n= 0,1)	Entero. cloacae (MIC: 2)- Favorable (n= 0,0)	Entero. cloacae (MIC: 4)- Favorable (n= 0,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: >16)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=2,3)	P.aeruginosa (MIC: 0.12) - Favorable (n=2,2)	P.aeruginosa (MIC: 0.25) - Favorable (n=2,5)	P.aeruginosa (MIC: 0.5) - Favorable (n=2,1)	P.aeruginosa (MIC: 1) - Favorable (n=1,4)	P.aeruginosa (MIC: 2) - Favorable (n=1,0)	P.aeruginosa (MIC: 4) - Favorable (n=2,2)	P.aeruginosa (MIC: 8) - Favorable (n=2,1)	P.aeruginosa (MIC: 16) - Favorable (n=2,1)	P.aeruginosa (MIC: >16) - Favorable (n=2,1)
CAZ-AVI	1	127	89	10	1	1	0	0	0	0	0	0	0	0	1	16	10	2	1	1	1	0	0	0	0	1	0	0	1	2	5	6	2	0	0	0	0	0	0	0	2	1	1	0	0	2	0	0	0	0	0	0	0	0	0	2	1	2	2	0	1	1	1	0	2
Doripenem	3	119	86	4	2	0	0	0	0	0	0	0	0	0	2	21	7	2	2	0	0	0	0	1	0	0	0	0	0	1	4	2	2	0	0	0	0	0	0	0	1	2	1	4	0	0	1	0	0	0	0	0	0	0	0	3	2	2	1	3	0	1	1	1	1

[back to top]

Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)

Number of favorable per-pathogen microbiological responses at the TOC visit in the Extended ME at TOC analysis set (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=214, 226)	Klebsiella pneumoniae - Favorable (n=32, 42)	Proteus mirabilis - Favorable (n=14, 7)	Enterobacter cloacae - Favorable (n= 7, 11)	Pseudomonas aeruginosa - Favorable (n=13, 18)
CAZ-AVI	180	26	14	5	8
Doripenem	176	29	4	8	13

[back to top]

Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)

Number of favorable per-pathogen microbiological responses at the TOC visit in the ME at TOC analysis set (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=214, 221)	Klebsiella pneumoniae - Favorable (n=31, 41)	Proteus mirabilis - Favorable (n=14, 7)	Enterobacter cloacae - Favorable (n= 7, 11)	Pseudomonas aeruginosa - Favorable (n=9, 13)
CAZ-AVI	180	25	14	5	7
Doripenem	171	28	4	8	9

[back to top]

Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)

Number of favorable per-pathogen microbiological responses at the TOC visit in the mMITT analysis set (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=292, 306)	Klebsiella pneumoniae - Favorable (n=44, 56)	Proteus mirabilis - Favorable (n=17, 13)	Enterobacter cloacae - Favorable (n= 11,13)	Pseudomonas aeruginosa - Favorable (n=18, 20)
CAZ-AVI	229	33	16	6	12
Doripenem	220	35	9	9	15

[back to top]

Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)

Number of favorable per-pathogen microbiological responses at the TOC visit in the Extended ME at TOC analysis set for blood only (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=22, 20)	Klebsiella pneumoniae - Favorable (n=2, 2)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=0, 1)
CAZ-AVI	22	2	1	0
Doripenem	20	2	0	1

[back to top]

Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)

Number of favorable per-pathogen microbiological responses at the TOC visit in the ME at TOC analysis set for blood only (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=22, 20)	Klebsiella pneumoniae - Favorable (n=2, 2)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=0, 1)
CAZ-AVI	22	2	1	0
Doripenem	20	2	0	1

[back to top]

Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)

Number of favorable per-pathogen microbiological responses at the TOC visit in the mMITT analysis set for blood only (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=32, 28)	Klebsiella pneumoniae - Favorable (n=4, 2)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=1, 2)
CAZ-AVI	31	3	1	1
Doripenem	28	2	0	2

[back to top]

Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)

Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01595438)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participants (Number)
	Clinical cure	Clinical failure
CAZ-AVI	235	19
Doripenem	254	33

[back to top]

Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)

Number of patients with a favorable per-patient microbiological response at EOT (IV) (NCT01595438)
Timeframe: At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	324	1
Doripenem	359	2

[back to top]

Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)

Intervention	Participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	374	1	18
Doripenem	395	3	19

[back to top]

Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)

Number of patients with a favorable per patient microbiological response at LFU (NCT01595438)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	184	67
Doripenem	173	99

[back to top]

Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)

Number of patients with a favorable per patient microbiological response at LFU (NCT01595438)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	182	63
Doripenem	166	96

[back to top]

Per-patient Microbiological Response at LFU (mMITT Analysis Set)

Number of patients with a favorable per patient microbiological response at LFU (NCT01595438)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	268	83	42
Doripenem	254	125	38

[back to top]

Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)

Number of patients with a favorable per patient microbiological response at TOC (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	243	49
Doripenem	236	75

[back to top]

Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)

Number of patients with a favorable per patient microbiological response at TOC (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	241	45
Doripenem	225	73

[back to top]

Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test

Number of patients with a favorable per patient microbiological response at TOC. The primary efficacy outcome variable for ROW is the proportion of patients with a favorable per-patient microbiological response at the TOC visit in the mMITT analysis set. (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	304	58	31
Doripenem	296	83	38

[back to top]

Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)

Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the Extended ME at TOC analysis set. (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	37	14
Doripenem	41	22

[back to top]

Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)

Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the ME at TOC analysis set. (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	35	13
Doripenem	37	20

[back to top]

Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)

Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the mMITT analysis set. (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	47	19	9
Doripenem	51	27	6

[back to top]

Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)

Time to first defervescence while on IV study therapy in patients in the CE at TOC analysis set who have fever at study entry. (NCT01595438)
Timeframe: Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.

Intervention	Participants (Number)
	Number of patients with fever (>38°C) at baseline	Number afebrile at the time of the last obs	Number censored at the time of the last obs
CAZ-AVI	123	122	1
Doripenem	118	113	5

[back to top]

Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)

Time to first defervescence while on IV study therapy in patients in the Extended ME at TOC analysis set who have fever at study entry. (NCT01595438)
Timeframe: Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.

Intervention	Participants (Number)
	Number of patients with fever (>38°C) at baseline	Number afebrile at the time of the last obs	Number censored at the time of the last obs
CAZ-AVI	124	124	0
Doripenem	111	108	3

[back to top]

Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)

Time to first defervescence while on IV study therapy in patients in the ME at TOC analysis set who have fever at study entry. (NCT01595438)
Timeframe: Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.

Intervention	Participants (Number)
	Number of patients with fever (>38°C) at baseline	Number afebrile at the time of the last obs	Number censored at the time of the last obs
CAZ-AVI	124	124	0
Doripenem	108	105	3

[back to top]

Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)

Time to first defervescence while on IV study therapy in patients in the mMITT analysis set who have fever at study entry. (NCT01595438)
Timeframe: Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.

Intervention	Participants (Number)
	Number of patients with fever (>38°C) at baseline	Number afebrile at the time of the last obs	Number censored at the time of the last obs
CAZ-AVI	157	155	2
Doripenem	150	143	7

[back to top]

Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)

Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration. (NCT01595438)
Timeframe: Between 30 to 90 minutes after dose

Intervention	NG/ML (Geometric Mean)
CAZ-AVI	6587.2

[back to top]

Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)

Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration. (NCT01595438)
Timeframe: Between 300 to 360 minutes after dose

Intervention	NG/ML (Geometric Mean)
CAZ-AVI	1883.2

[back to top]

Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)

Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration. (NCT01595438)
Timeframe: within 15 minutes before/after dose

Intervention	NG/ML (Geometric Mean)
CAZ-AVI	9307.3

[back to top]

Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)

Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration. (NCT01595438)
Timeframe: Between 30 to 90 minutes after dose

Intervention	NG/ML (Geometric Mean)
CAZ-AVI	47575.1

[back to top]

Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)

Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration. (NCT01595438)
Timeframe: Between 300 to 360 minutes after dose

Intervention	NG/ML (Geometric Mean)
CAZ-AVI	16959.6

[back to top]

Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)

Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration. (NCT01595438)
Timeframe: within 15 minutes before/after dose

Intervention	NG/ML (Geometric Mean)
CAZ-AVI	65481.2

[back to top]

Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test

Number of patients with both a favorable per patient microbiological response and symptomatic resolution (or return to premorbid state) of all UTI-specific symptoms (frequency/urgency/dysuria/suprapubic pain/flank pain) based on the patient-reported symptom assessment response at the TOC visit in the mMITT analysis set. The sponsor will conclude noninferiority if the lower limit of the 95% CI of difference (corresponding to a 97.5% 1-sided lower bound) is greater than -12.5% for both FDA coprimary outcome variables (symptomatic resolution at day 5 or favorable combined response at test of cure (TOC)). (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	280	81	32
Doripenem	269	109	39

[back to top]

Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)

Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01595438)
Timeframe: At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participants (Number)
	Clinical cure	Clinical failure
CAZ-AVI	346	4
Doripenem	387	4

[back to top]

Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	327	4	5
Doripenem	368	2	1

[back to top]

Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	318	4	3
Doripenem	358	2	1

[back to top]

Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	378	5	10
Doripenem	407	5	5

[back to top]

Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	232	15	4
Doripenem	246	24	2

[back to top]

Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	226	15	4
Doripenem	236	24	2

[back to top]

Investigator Determined Clinical Response at LFU (mMITT Analysis Set)

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	335	23	35
Doripenem	350	39	28

[back to top]

Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)

Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Clinical cure	Clinical failure
CAZ-AVI	289	8
Doripenem	309	21

[back to top]

Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	283	4	5
Doripenem	298	13	0

[back to top]

Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	277	4	5
Doripenem	285	13	0

[back to top]

Investigator Determined Clinical Response at TOC (mMITT Analysis Set)

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	355	11	27
Doripenem	377	24	16

[back to top]

Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)

Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the Extended ME at TOC analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen. (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	All patients - Clinical cure (n=51, 63)	Escherichia coli patients - Clin cure (n=23, 27)	Klebsiella pneumoniae patients-Clin cure(n=15, 23)	Pseudomonas aeruginosa patients-Clin cure(n=3,6)	Enterobacter cloacae patients-Clin cure(n=5,5)	Proteus mirabilis patients - Clin cure (n=0, 2)
CAZ-AVI	50	22	15	3	5	0
Doripenem	61	25	23	6	5	2

[back to top]

Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)

Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the ME at TOC analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen. (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	All patients - Clinical cure (n=48, 57)	Escherichia coli patients-Clin cure (n=23,27)	Klebsiella pneumoniae patients-Clin cure(n=14, 22)	Pseudomonas aeruginosa patients-Clin cure(n=1, 2)	Enterobacter cloacae patients-Clin cure(n=5,5)	Proteus mirabilis patients - Clin cure (n=0, 2)
CAZ-AVI	47	22	14	1	5	0
Doripenem	55	25	22	2	5	2

[back to top]

Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	335	1
Doripenem	369	2

[back to top]

Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)

Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the mMITT analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen. (NCT01595438)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	All patients - Clinical cure (n=75, 84)	Escherichia coli patients - Clin cure (n=36, 37)	Klebsiella pneumoniae patients-Clin cure(n=18,30)	Pseudomonas aeruginosa patients- Clin cure(n=7,6)	Enterobacter cloacae patients-Clin cure(n=7,6)	Proteus mirabilis patients - Clin cure (n=2, 5)
CAZ-AVI	67	33	17	5	5	2
Doripenem	75	31	28	6	5	5

[back to top]

Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test

Number of patients with symptomatic resolution (or return to premorbid state) of UTI-specific symptoms except flank pain (frequency/urgency/dysuria/suprapubic pain) with resolution of or improvement in flank pain based on the patient-reported symptom assessment response at the Day 5 visit in the mMITT analysis set. The sponsor will conclude noninferiority if the lower limit of the 95% CI of difference (corresponding to a 97.5% 1-sided lower bound) is greater than -12.5% for both FDA coprimary outcome variables (symptomatic resolution at day 5 or favorable combined response at test of cure (TOC)). (NCT01595438)
Timeframe: At Day 5 visit. Day 5 visit is based on 24 hour periods from the first dose date and time.

Intervention	Participants (Number)
	Symptomatic resolution	Symptom persistence	Indeterminate
CAZ-AVI	276	103	14
Doripenem	276	124	17

[back to top]

Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)

Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the Extended ME at EOT (IV) analysis set (NCT01595438)
Timeframe: At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=250, 274)	Klebsiella pneumoniae - Favorable (n=34, 49)	Proteus mirabilis - Favorable (n=13, 11)	Enterobacter cloacae - Favorable (n= 9, 12)	Pseudomonas aeruginosa - Favorable (n=18, 18)
CAZ-AVI	250	34	13	9	17
Doripenem	274	48	11	12	17

[back to top]

Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)

Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the ME at EOT (IV) analysis set (NCT01595438)
Timeframe: At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=249, 270)	Klebsiella pneumoniae - Favorable (n=33, 48)	Proteus mirabilis - Favorable (n=13,11)	Enterobacter cloacae - Favorable (n= 9, 12)	Pseudomonas aeruginosa - Favorable (n=10, 15)
CAZ-AVI	249	33	13	9	9
Doripenem	270	47	11	12	14

[back to top]

Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)

Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the mMITT analysis set (NCT01595438)
Timeframe: At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=292, 306)	Klebsiella pneumoniae - Favorable (n=44, 56)	Proteus mirabilis - Favorable (n=17, 13)	Enterobacter cloacae - Favorable (n= 11,13)	Pseudomonas aeruginosa - Favorable (n=18, 20)
CAZ-AVI	280	41	16	9	17
Doripenem	293	51	11	13	18

[back to top]

Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)

Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the Extended ME at EOT (IV) analysis set for blood only (NCT01595438)
Timeframe: At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=26, 24)	Klebsiella pneumoniae - Favorable (n=2, 1)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=1, 2)
CAZ-AVI	26	1	1	1
Doripenem	24	1	0	2

[back to top]

Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)

Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the ME at EOT (IV) analysis set for blood only (NCT01595438)
Timeframe: At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=26, 24)	Klebsiella pneumoniae - Favorable (n=2, 1)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=1, 2)
CAZ-AVI	26	1	1	1
Doripenem	24	1	0	2

[back to top]

Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)

Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the mMITT analysis set for blood only (NCT01595438)
Timeframe: At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=32, 28)	Klebsiella pneumoniae - Favorable (n=4, 2)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=1, 2)
CAZ-AVI	31	2	1	1
Doripenem	28	2	0	2

[back to top]

Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)

Number of favorable per-pathogen microbiological responses at the LFU visit in the Extended ME at LFU analysis set (NCT01595438)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=179, 198)	Klebsiella pneumoniae - Favorable (n=31, 36)	Proteus mirabilis - Favorable (n=11,5)	Enterobacter cloacae - Favorable (n= 7, 11)	Pseudomonas aeruginosa - Favorable (n=12, 16)
CAZ-AVI	129	24	11	5	7
Doripenem	131	19	1	8	9

[back to top]

Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)

Number of favorable per-pathogen microbiological responses at the LFU visit in the ME at LFU analysis set (NCT01595438)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=179, 194)	Klebsiella pneumoniae - Favorable (n=30, 35)	Proteus mirabilis - Favorable (n=11,5)	Enterobacter cloacae - Favorable (n= 7, 11)	Pseudomonas aeruginosa - Favorable (n=8, 13)
CAZ-AVI	129	23	11	5	6
Doripenem	127	18	1	8	8

[back to top]

Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)

Number of favorable per-pathogen microbiological responses at the LFU visit in the mMITT analysis set (NCT01595438)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=292, 306)	Klebsiella pneumoniae - Favorable (n=44, 56)	Proteus mirabilis - Favorable (n=17, 13)	Enterobacter cloacae - Favorable (n= 11,13)	Pseudomonas aeruginosa - Favorable (n=18, 20)
CAZ-AVI	198	32	16	6	9
Doripenem	189	30	6	9	13

[back to top]

Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)

Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the ME at EOT (IV) analysis set (NCT01599806)
Timeframe: At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=249, 270)	Klebsiella pneumoniae - Favorable (n=33, 48)	Proteus mirabilis - Favorable (n=13,11)	Enterobacter cloacae - Favorable (n= 9, 12)	Pseudomonas aeruginosa - Favorable (n=10, 15)
CAZ-AVI	249	33	13	9	9
Doripenem	270	47	11	12	14

[back to top]

Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)

Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the mMITT analysis set (NCT01599806)
Timeframe: At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=292, 306)	Klebsiella pneumoniae - Favorable (n=44, 56)	Proteus mirabilis - Favorable (n=17, 13)	Enterobacter cloacae - Favorable (n= 11,13)	Pseudomonas aeruginosa - Favorable (n=18, 20)
CAZ-AVI	280	41	16	9	17
Doripenem	293	51	11	13	18

[back to top]

Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)

Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the Extended ME at EOT (IV) analysis set for blood only (NCT01599806)
Timeframe: At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=26, 24)	Klebsiella pneumoniae - Favorable (n=2, 1)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=1, 2)
CAZ-AVI	26	1	1	1
Doripenem	24	1	0	2

[back to top]

Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)

Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the ME at EOT (IV) analysis set for blood only (NCT01599806)
Timeframe: At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=26, 24)	Klebsiella pneumoniae - Favorable (n=2, 1)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=1, 2)
CAZ-AVI	26	1	1	1
Doripenem	24	1	0	2

[back to top]

Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)

Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the mMITT analysis set for blood only (NCT01599806)
Timeframe: At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=32, 28)	Klebsiella pneumoniae - Favorable (n=4, 2)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=1, 2)
CAZ-AVI	31	2	1	1
Doripenem	28	2	0	2

[back to top]

Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)

Number of favorable per-pathogen microbiological responses at the LFU visit in the Extended ME at LFU analysis set (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=179, 198)	Klebsiella pneumoniae - Favorable (n=31, 36)	Proteus mirabilis - Favorable (n=11,5)	Enterobacter cloacae - Favorable (n= 7, 11)	Pseudomonas aeruginosa - Favorable (n=12, 16)
CAZ-AVI	129	24	11	5	7
Doripenem	131	19	1	8	9

[back to top]

Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)

Number of favorable per-pathogen microbiological responses at the LFU visit in the ME at LFU analysis set (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=179, 194)	Klebsiella pneumoniae - Favorable (n=30, 35)	Proteus mirabilis - Favorable (n=11,5)	Enterobacter cloacae - Favorable (n= 7, 11)	Pseudomonas aeruginosa - Favorable (n=8, 13)
CAZ-AVI	129	23	11	5	6
Doripenem	127	18	1	8	8

[back to top]

Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)

Number of favorable per-pathogen microbiological responses at the LFU visit in the mMITT analysis set (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=292, 306)	Klebsiella pneumoniae - Favorable (n=44, 56)	Proteus mirabilis - Favorable (n=17, 13)	Enterobacter cloacae - Favorable (n= 11,13)	Pseudomonas aeruginosa - Favorable (n=18, 20)
CAZ-AVI	198	32	16	6	9
Doripenem	189	30	6	9	13

[back to top]

Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)

Number of favorable per-pathogen microbiological responses at the LFU visit in the Extended ME at LFU analysis set for blood only (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=19, 18)	Klebsiella pneumoniae - Favorable (n=2, 1)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=0, 1)
CAZ-AVI	19	2	1	0
Doripenem	17	1	0	1

[back to top]

Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)

Number of favorable per-pathogen microbiological responses at the LFU visit in the ME at LFU analysis set for blood only (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=19, 18)	Klebsiella pneumoniae - Favorable (n=2, 1)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=0, 1)
CAZ-AVI	19	2	1	0
Doripenem	17	1	0	1

[back to top]

Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)

Number of favorable per-pathogen microbiological responses at the LFU visit in the mMITT analysis set for blood only (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=32, 28)	Klebsiella pneumoniae - Favorable (n=4, 2)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=1, 2)
CAZ-AVI	29	3	1	1
Doripenem	27	2	0	2

[back to top]

Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)

Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the Extended ME at TOC analysis set (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=4,4)	E. coli (MIC: 0.015) - Favorable (n=5, 6)	E. coli (MIC: 0.03) - Favorable (n=18, 21)	E. coli (MIC: 0.06) - Favorable (n=95, 111)	E. coli (MIC: 0.12) - Favorable (n=68, 54)	E. coli (MIC: 0.25) - Favorable (n=19, 18)	E. coli (MIC: 0.5) - Favorable (n=2, 5)	E. coli (MIC: 1) - Favorable (n=2, 0)	E. coli (MIC: 2) - Favorable (n=1, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: 32) - Favorable (n=0, 0)	E. coli (MIC: >32) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 0.03) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=5, 7)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=8, 9)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=3, 7)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=6, 11)	Kleb. pneumoniae (MIC: 1) - Favorable (n=6, 4)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 2, 1)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 32) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >32) - Favorable (n=0, 1)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=1,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=9, 2)	Proteus mirabilis (MIC: 0.06)- Favorable (n=4,5)	Proteus mirabilis (MIC: 0.12)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.25)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 0.5)- Favorable (n=0,0)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 32)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >32)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,0)	Entero. cloacae (MIC: 0.06)- Favorable (n= 0, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 1,2)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,3)	Entero. cloacae (MIC: 0.5)- Favorable (n= 1,1)	Entero. cloacae (MIC: 1)- Favorable (n= 1,4)	Entero. cloacae (MIC: 2)- Favorable (n= 1,0)	Entero. cloacae (MIC: 4)- Favorable (n= 2,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: 32)- Favorable (n= 0,0)	Entero. cloacae (MIC: >32)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.12) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.25) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.5) - Favorable (n=0,0)	P.aeruginosa (MIC: 1) - Favorable (n=1,4)	P.aeruginosa (MIC: 2) - Favorable (n=4,5)	P.aeruginosa (MIC: 4) - Favorable (n=5,6)	P.aeruginosa (MIC: 8) - Favorable (n=2,2)	P.aeruginosa (MIC: 16) - Favorable (n=0,1)	P.aeruginosa (MIC: 32) - Favorable (n=0,0)	P.aeruginosa (MIC: >32) - Favorable (n=1,0)
CAZ-AVI	2	5	17	83	56	13	2	1	1	0	0	0	0	0	0	1	1	4	7	1	4	6	2	0	0	0	0	0	0	1	9	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	1	4	1	1	0	0	1
Doripenem	4	5	17	94	40	8	2	0	0	0	0	0	0	0	0	0	2	7	6	2	8	3	0	0	0	0	0	1	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2	5	4	1	1	0	0

[back to top]

Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)

Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the ME at TOC analysis set (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=4,4)	E. coli (MIC: 0.015) - Favorable (n=5, 6)	E. coli (MIC: 0.03) - Favorable (n=18, 21)	E. coli (MIC: 0.06) - Favorable (n=95, 111)	E. coli (MIC: 0.12) - Favorable (n=68, 54)	E. coli (MIC: 0.25) - Favorable (n=19, 18)	E. coli (MIC: 0.5) - Favorable (n=2, 5)	E. coli (MIC: 1) - Favorable (n=2, 0)	E. coli (MIC: 2) - Favorable (n=1, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: 32) - Favorable (n=0, 0)	E. coli (MIC: >32) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 0.03) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=5, 7)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=8, 9)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=3, 7)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=6, 11)	Kleb. pneumoniae (MIC: 1) - Favorable (n=5, 4)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 2, 1)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 32) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >32) - Favorable (n=0, 0)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=1,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=9, 2)	Proteus mirabilis (MIC: 0.06)- Favorable (n=4,5)	Proteus mirabilis (MIC: 0.12)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.25)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 0.5)- Favorable (n=0,0)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 32)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >32)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,0)	Entero. cloacae (MIC: 0.06)- Favorable (n= 0, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 1,2)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,3)	Entero. cloacae (MIC: 0.5)- Favorable (n= 1,1)	Entero. cloacae (MIC: 1)- Favorable (n= 1,4)	Entero. cloacae (MIC: 2)- Favorable (n= 1,0)	Entero. cloacae (MIC: 4)- Favorable (n= 2,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: 32)- Favorable (n= 0,0)	Entero. cloacae (MIC: >32)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.12) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.25) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.5) - Favorable (n=0,0)	P.aeruginosa (MIC: 1) - Favorable (n=1,4)	P.aeruginosa (MIC: 2) - Favorable (n=4,4)	P.aeruginosa (MIC: 4) - Favorable (n=3,4)	P.aeruginosa (MIC: 8) - Favorable (n=1,1)	P.aeruginosa (MIC: 16) - Favorable (n=0,0)	P.aeruginosa (MIC: 32) - Favorable (n=0,0)	P.aeruginosa (MIC: >32) - Favorable (n=0,0)
CAZ-AVI	2	5	17	83	56	13	2	1	1	0	0	0	0	0	0	1	1	4	7	1	4	5	2	0	0	0	0	0	0	1	9	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	1	4	1	1	0	0	0
Doripenem	4	5	17	94	40	8	2	0	0	0	0	0	0	0	0	0	2	7	6	2	8	3	0	0	0	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2	4	3	0	0	0	0

[back to top]

Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)

Per pathogen microbiological response at TOC by CAZ-AVI MIC for baseline pathogen in the mMITT analysis set (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=5, 6)	E. coli (MIC: 0.015) - Favorable (n=8, 7)	E. coli (MIC: 0.03) - Favorable (n=28, 35)	E. coli (MIC: 0.06) - Favorable (n=123, 139)	E. coli (MIC: 0.12) - Favorable (n=90, 81)	E. coli (MIC: 0.25) - Favorable (n=28, 25)	E. coli (MIC: 0.5) - Favorable (n=5, 6)	E. coli (MIC: 1) - Favorable (n=3, 0)	E. coli (MIC: 2) - Favorable (n=1, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: 32) - Favorable (n=0, 0)	E. coli (MIC: >32) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 0.03) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=9, 8)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=11, 10)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=4, 10)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=8, 16)	Kleb. pneumoniae (MIC: 1) - Favorable (n=8, 5)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 2, 4)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 32) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >32) - Favorable (n=0, 1)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=1,1)	Proteus mirabilis (MIC: 0.03)- Favorable (n=10, 5)	Proteus mirabilis (MIC: 0.06)- Favorable (n=6,6)	Proteus mirabilis (MIC: 0.12)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.25)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 0.5)- Favorable (n=0,1)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 32)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >32)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,0)	Entero. cloacae (MIC: 0.06)- Favorable (n= 0, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 3,2)	Entero. cloacae (MIC: 0.25)- Favorable (n= 1,4)	Entero. cloacae (MIC: 0.5)- Favorable (n= 1,1)	Entero. cloacae (MIC: 1)- Favorable (n= 2,5)	Entero. cloacae (MIC: 2)- Favorable (n= 1,0)	Entero. cloacae (MIC: 4)- Favorable (n= 2,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: 32)- Favorable (n= 0,0)	Entero. cloacae (MIC: >32)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.12) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.25) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.5) - Favorable (n=0,2)	P.aeruginosa (MIC: 1) - Favorable (n=1,4)	P.aeruginosa (MIC: 2) - Favorable (n=5,5)	P.aeruginosa (MIC: 4) - Favorable (n=7,6)	P.aeruginosa (MIC: 8) - Favorable (n=2,2)	P.aeruginosa (MIC: 16) - Favorable (n=1,1)	P.aeruginosa (MIC: 32) - Favorable (n=0,0)	P.aeruginosa (MIC: >32) - Favorable (n=2,0)
CAZ-AVI	3	8	24	103	67	18	4	1	1	0	0	0	0	0	0	1	1	7	9	1	6	6	2	0	0	0	0	0	0	1	10	5	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	1	5	3	1	0	0	2
Doripenem	5	6	23	111	54	13	2	0	0	0	0	0	0	0	0	0	2	8	7	3	11	3	0	0	0	0	0	1	0	0	3	5	0	0	1	0	0	0	0	0	0	0	0	0	0	1	2	1	1	4	0	0	0	0	0	0	0	0	0	0	0	0	2	2	5	4	1	1	0	0

[back to top]

Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)

Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the Extended ME at TOC analysis set (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=1,1)	E. coli (MIC: 0.015) - Favorable (n=122, 119)	E. coli (MIC: 0.03) - Favorable (n=79, 89)	E. coli (MIC: 0.06) - Favorable (n=10, 8)	E. coli (MIC: 0.12) - Favorable (n=1, 2)	E. coli (MIC: 0.25) - Favorable (n=1, 0)	E. coli (MIC: 0.5) - Favorable (n=0, 0)	E. coli (MIC: 1) - Favorable (n=0, 0)	E. coli (MIC: 2) - Favorable (n=0, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: >16) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC:0.03) - Favorable (n=15, 23)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=8, 12)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=3, 2)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=2, 2)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 1) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 0,0)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 1)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >16) - Favorable (n=1, 0)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=1,0)	Proteus mirabilis (MIC: 0.06)- Favorable (n=2,2)	Proteus mirabilis (MIC: 0.12)- Favorable (n=4,2)	Proteus mirabilis (MIC: 0.25)- Favorable (n=6, 3)	Proteus mirabilis (MIC: 0.5)- Favorable (n=1,0)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >16)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 1,1)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,4)	Entero. cloacae (MIC: 0.06)- Favorable (n= 2, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 0,4)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.5)- Favorable (n= 3,0)	Entero. cloacae (MIC: 1)- Favorable (n= 0,1)	Entero. cloacae (MIC: 2)- Favorable (n= 0,0)	Entero. cloacae (MIC: 4)- Favorable (n= 0,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: >16)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=2,3)	P.aeruginosa (MIC: 0.12) - Favorable (n=1,2)	P.aeruginosa (MIC: 0.25) - Favorable (n=2,4)	P.aeruginosa (MIC: 0.5) - Favorable (n=2,1)	P.aeruginosa (MIC: 1) - Favorable (n=1,3)	P.aeruginosa (MIC: 2) - Favorable (n=1,0)	P.aeruginosa (MIC: 4) - Favorable (n=0,2)	P.aeruginosa (MIC: 8) - Favorable (n=1,1)	P.aeruginosa (MIC: 16) - Favorable (n=2,1)	P.aeruginosa (MIC: >16) - Favorable (n=1,1)
CAZ-AVI	1	106	64	7	1	1	0	0	0	0	0	0	0	0	1	12	7	2	1	1	1	0	0	0	0	1	0	0	1	2	4	6	1	0	0	0	0	0	0	0	1	1	1	0	0	2	0	0	0	0	0	0	0	0	0	2	0	2	2	0	1	0	0	0	1
Doripenem	1	95	70	3	1	0	0	0	0	0	0	0	0	0	1	18	6	2	1	0	0	0	0	1	0	0	0	0	0	1	2	1	0	0	0	0	0	0	0	0	1	1	1	4	0	0	1	0	0	0	0	0	0	0	0	3	2	1	1	2	0	1	1	1	1

[back to top]

Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)

Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the ME at TOC analysis set (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=1,1)	E. coli (MIC: 0.015) - Favorable (n=122, 119)	E. coli (MIC: 0.03) - Favorable (n=79, 89)	E. coli (MIC: 0.06) - Favorable (n=10, 8)	E. coli (MIC: 0.12) - Favorable (n=1,2)	E. coli (MIC: 0.25) - Favorable (n=1,0)	E. coli (MIC: 0.5) - Favorable (n=0,0)	E. coli (MIC: 1) - Favorable (n=0, 0)	E. coli (MIC: 2) - Favorable (n=0, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: >16) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC:0.03) - Favorable (n=15, 23)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=8, 12)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=3,2)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=2, 2)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=1,0)	Kleb. pneumoniae (MIC: 1) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 0,0)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >16) - Favorable (n=0, 0)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=1, 0)	Proteus mirabilis (MIC: 0.06)- Favorable (n=2,2)	Proteus mirabilis (MIC: 0.12)- Favorable (n=4,2)	Proteus mirabilis (MIC: 0.25)- Favorable (n=6, 3)	Proteus mirabilis (MIC: 0.5)- Favorable (n=1,0)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >16)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 1,1)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,4)	Entero. cloacae (MIC: 0.06)- Favorable (n= 2, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 0,4)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.5)- Favorable (n= 3,0)	Entero. cloacae (MIC: 1)- Favorable (n= 0,1)	Entero. cloacae (MIC: 2)- Favorable (n= 0,0)	Entero. cloacae (MIC: 4)- Favorable (n= 0,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: >16)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=2,3)	P.aeruginosa (MIC: 0.12) - Favorable (n=1,2)	P.aeruginosa (MIC: 0.25) - Favorable (n=2,4)	P.aeruginosa (MIC: 0.5) - Favorable (n=2,1)	P.aeruginosa (MIC: 1) - Favorable (n=1,3)	P.aeruginosa (MIC: 2) - Favorable (n=1,0)	P.aeruginosa (MIC: 4) - Favorable (n=0,0)	P.aeruginosa (MIC: 8) - Favorable (n=0,0)	P.aeruginosa (MIC: 16) - Favorable (n=0,0)	P.aeruginosa (MIC: >16) - Favorable (n=0,0)
CAZ-AVI	1	106	64	7	1	1	0	0	0	0	0	0	0	0	1	12	7	2	1	1	1	0	0	0	0	0	0	0	1	2	4	6	1	0	0	0	0	0	0	0	1	1	1	0	0	2	0	0	0	0	0	0	0	0	0	2	0	2	2	0	1	0	0	0	0
Doripenem	1	95	70	3	1	0	0	0	0	0	0	0	0	0	1	18	6	2	1	0	0	0	0	0	0	0	0	0	0	1	2	1	0	0	0	0	0	0	0	0	1	1	1	4	0	0	1	0	0	0	0	0	0	0	0	3	2	1	1	2	0	0	0	0	0

[back to top]

Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)

Per pathogen microbiological response at TOC by Doripenem MIC for baseline pathogen in the mMITT analysis set (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=1, 3)	E. coli (MIC: 0.015) - Favorable (n=160, 160)	E. coli (MIC: 0.03) - Favorable (n=112, 123)	E. coli (MIC: 0.06) - Favorable (n=14, 10)	E. coli (MIC: 0.12) - Favorable (n=3, 3)	E. coli (MIC: 0.25) - Favorable (n=1, 0)	E. coli (MIC: 0.5) - Favorable (n=0,0)	E. coli (MIC: 1) - Favorable (n=0, 0)	E. coli (MIC: 2) - Favorable (n=0, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: >16) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 3)	Kleb. pneumoniae (MIC: 0.03)-Favorable (n=22, 27)	Kleb. pneumoniae (MIC: 0.06)- Favorable (n=11, 16)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=4,4)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=2,3)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=2, 1)	Kleb. pneumoniae (MIC: 1) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 0, 0)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 1)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 1)	Kleb. pneumoniae (MIC: >16) - Favorable (n=1, 0)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=1, 0)	Proteus mirabilis (MIC: 0.06)- Favorable (n=2,2)	Proteus mirabilis (MIC: 0.12)- Favorable (n=6,5)	Proteus mirabilis (MIC: 0.25)- Favorable (n=6, 4)	Proteus mirabilis (MIC: 0.5)- Favorable (n=2,2)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >16)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 3,1)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,5)	Entero. cloacae (MIC: 0.06)- Favorable (n= 3, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 0, 4)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,1)	Entero. cloacae (MIC: 0.5)- Favorable (n= 4,0)	Entero. cloacae (MIC: 1)- Favorable (n= 0,1)	Entero. cloacae (MIC: 2)- Favorable (n= 0,0)	Entero. cloacae (MIC: 4)- Favorable (n= 0,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: >16)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=2,3)	P.aeruginosa (MIC: 0.12) - Favorable (n=2,2)	P.aeruginosa (MIC: 0.25) - Favorable (n=2,5)	P.aeruginosa (MIC: 0.5) - Favorable (n=2,1)	P.aeruginosa (MIC: 1) - Favorable (n=1,4)	P.aeruginosa (MIC: 2) - Favorable (n=1,0)	P.aeruginosa (MIC: 4) - Favorable (n=2,2)	P.aeruginosa (MIC: 8) - Favorable (n=2,1)	P.aeruginosa (MIC: 16) - Favorable (n=2,1)	P.aeruginosa (MIC: >16) - Favorable (n=2,1)
CAZ-AVI	1	127	89	10	1	1	0	0	0	0	0	0	0	0	1	16	10	2	1	1	1	0	0	0	0	1	0	0	1	2	5	6	2	0	0	0	0	0	0	0	2	1	1	0	0	2	0	0	0	0	0	0	0	0	0	2	1	2	2	0	1	1	1	0	2
Doripenem	3	119	86	4	2	0	0	0	0	0	0	0	0	0	2	21	7	2	2	0	0	0	0	1	0	0	0	0	0	1	4	2	2	0	0	0	0	0	0	0	1	2	1	4	0	0	1	0	0	0	0	0	0	0	0	3	2	2	1	3	0	1	1	1	1

[back to top]

Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)

Number of favorable per-pathogen microbiological responses at the TOC visit in the Extended ME at TOC analysis set (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=214, 226)	Klebsiella pneumoniae - Favorable (n=32, 42)	Proteus mirabilis - Favorable (n=14, 7)	Enterobacter cloacae - Favorable (n= 7, 11)	Pseudomonas aeruginosa - Favorable (n=13, 18)
CAZ-AVI	180	26	14	5	8
Doripenem	176	29	4	8	13

[back to top]

Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)

Number of favorable per-pathogen microbiological responses at the TOC visit in the ME at TOC analysis set (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=214, 221)	Klebsiella pneumoniae - Favorable (n=31, 41)	Proteus mirabilis - Favorable (n=14, 7)	Enterobacter cloacae - Favorable (n= 7, 11)	Pseudomonas aeruginosa - Favorable (n=9, 13)
CAZ-AVI	180	25	14	5	7
Doripenem	171	28	4	8	9

[back to top]

Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)

Number of favorable per-pathogen microbiological responses at the TOC visit in the mMITT analysis set (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=292, 306)	Klebsiella pneumoniae - Favorable (n=44, 56)	Proteus mirabilis - Favorable (n=17, 13)	Enterobacter cloacae - Favorable (n= 11,13)	Pseudomonas aeruginosa - Favorable (n=18, 20)
CAZ-AVI	229	33	16	6	12
Doripenem	220	35	9	9	15

[back to top]

Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)

Number of favorable per-pathogen microbiological responses at the TOC visit in the Extended ME at TOC analysis set for blood only (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=22, 20)	Klebsiella pneumoniae - Favorable (n=2, 2)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=0, 1)
CAZ-AVI	22	2	1	0
Doripenem	20	2	0	1

[back to top]

Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)

Number of favorable per-pathogen microbiological responses at the TOC visit in the ME at TOC analysis set for blood only (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=22, 20)	Klebsiella pneumoniae - Favorable (n=2, 2)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=0, 1)
CAZ-AVI	22	2	1	0
Doripenem	20	2	0	1

[back to top]

Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)

Number of favorable per-pathogen microbiological responses at the TOC visit in the mMITT analysis set for blood only (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=32, 28)	Klebsiella pneumoniae - Favorable (n=4, 2)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=1, 2)
CAZ-AVI	31	3	1	1
Doripenem	28	2	0	2

[back to top]

Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)

Number of patients with a favorable per-patient microbiological response at EOT (IV) (NCT01599806)
Timeframe: At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	335	1
Doripenem	369	2

[back to top]

Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	324	1
Doripenem	359	2

[back to top]

Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)

Intervention	Participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	374	1	18
Doripenem	395	3	19

[back to top]

Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)

Number of patients with a favorable per patient microbiological response at LFU (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	184	67
Doripenem	173	99

[back to top]

Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)

Number of patients with a favorable per patient microbiological response at LFU (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	182	63
Doripenem	166	96

[back to top]

Per-patient Microbiological Response at LFU (mMITT Analysis Set)

Number of patients with a favorable per patient microbiological response at LFU (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	268	83	42
Doripenem	254	125	38

[back to top]

Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)

Number of patients with a favorable per patient microbiological response at TOC (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	243	49
Doripenem	236	75

[back to top]

Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)

Number of patients with a favorable per patient microbiological response at TOC (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	241	45
Doripenem	225	73

[back to top]

Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test

Number of patients with a favorable per patient microbiological response at TOC. The primary efficacy outcome variable for ROW is the proportion of patients with a favorable per-patient microbiological response at the TOC visit in the mMITT analysis set. (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	304	58	31
Doripenem	296	83	38

[back to top]

Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)

Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the Extended ME at TOC analysis set. (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	37	14
Doripenem	41	22

[back to top]

Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)

Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the ME at TOC analysis set. (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable
CAZ-AVI	35	13
Doripenem	37	20

[back to top]

Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)

Favorable per-patient microbiological response at the TOC visit for patients infected with a ceftazidime resistant pathogen in the mMITT analysis set. (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	47	19	9
Doripenem	51	27	6

[back to top]

Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)

Time to first defervescence while on IV study therapy in patients in the CE at TOC analysis set who have fever at study entry. (NCT01599806)
Timeframe: Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.

Intervention	Participants (Number)
	Number of patients with fever (>38°C) at baseline	Number afebrile at the time of the last obs	Number censored at the time of the last obs
CAZ-AVI	123	122	1
Doripenem	118	113	5

[back to top]

Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)

Time to first defervescence while on IV study therapy in patients in the Extended ME at TOC analysis set who have fever at study entry. (NCT01599806)
Timeframe: Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.

Intervention	Participants (Number)
	Number of patients with fever (>38°C) at baseline	Number afebrile at the time of the last obs	Number censored at the time of the last obs
CAZ-AVI	124	124	0
Doripenem	111	108	3

[back to top]

Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)

Time to first defervescence while on IV study therapy in patients in the ME at TOC analysis set who have fever at study entry. (NCT01599806)
Timeframe: Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.

Intervention	Participants (Number)
	Number of patients with fever (>38°C) at baseline	Number afebrile at the time of the last obs	Number censored at the time of the last obs
CAZ-AVI	124	124	0
Doripenem	108	105	3

[back to top]

Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)

Time to first defervescence while on IV study therapy in patients in the mMITT analysis set who have fever at study entry. (NCT01599806)
Timeframe: Time to first defervescence is defined as the time (in days) from the first dose of IV study therapy to first absence of fever, which is temperature ≤ 37.8 C in a 24-hour period.

Intervention	Participants (Number)
	Number of patients with fever (>38°C) at baseline	Number afebrile at the time of the last obs	Number censored at the time of the last obs
CAZ-AVI	157	155	2
Doripenem	150	143	7

[back to top]

Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)

Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	226	15	4
Doripenem	236	24	2

[back to top]

Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)

Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration. (NCT01599806)
Timeframe: Between 30 to 90 minutes after dose

Intervention	NG/ML (Geometric Mean)
CAZ-AVI	6587.2

[back to top]

Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)

Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration. (NCT01599806)
Timeframe: Between 300 to 360 minutes after dose

Intervention	NG/ML (Geometric Mean)
CAZ-AVI	1883.2

[back to top]

Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)

Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration. (NCT01599806)
Timeframe: within 15 minutes before/after dose

Intervention	NG/ML (Geometric Mean)
CAZ-AVI	9307.3

[back to top]

Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)

Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration. (NCT01599806)
Timeframe: Between 30 to 90 minutes after dose

Intervention	NG/ML (Geometric Mean)
CAZ-AVI	47575.1

[back to top]

Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)

Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration. (NCT01599806)
Timeframe: Between 300 to 360 minutes after dose

Intervention	NG/ML (Geometric Mean)
CAZ-AVI	16959.6

[back to top]

Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)

Blood samples were taken on Day 3 for ceftazidime (CAZ) and avibactam (AVI) plasma concentration. (NCT01599806)
Timeframe: within 15 minutes before/after dose

Intervention	NG/ML (Geometric Mean)
CAZ-AVI	65481.2

[back to top]

Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test

Number of patients with both a favorable per patient microbiological response and symptomatic resolution (or return to premorbid state) of all UTI-specific symptoms (frequency/urgency/dysuria/suprapubic pain/flank pain) based on the patient-reported symptom assessment response at the TOC visit in the mMITT analysis set. The sponsor will conclude noninferiority if the lower limit of the 95% CI of difference (corresponding to a 97.5% 1-sided lower bound) is greater than -12.5% for both FDA coprimary outcome variables (symptomatic resolution at day 5 or favorable combined response at test of cure (TOC)). (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	280	81	32
Doripenem	269	109	39

[back to top]

Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)

Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01599806)
Timeframe: At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participants (Number)
	Clinical cure	Clinical failure
CAZ-AVI	346	4
Doripenem	387	4

[back to top]

Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)

Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01599806)
Timeframe: At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	327	4	5
Doripenem	368	2	1

[back to top]

Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)

Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01599806)
Timeframe: At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	318	4	3
Doripenem	358	2	1

[back to top]

Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)

Number of patients with a clinical cure at EOT (IV). The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01599806)
Timeframe: At EOT (IV) visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	378	5	10
Doripenem	407	5	5

[back to top]

Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)

Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participants (Number)
	Clinical cure	Clinical failure
CAZ-AVI	235	19
Doripenem	254	33

[back to top]

Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)

Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	232	15	4
Doripenem	246	24	2

[back to top]

Investigator Determined Clinical Response at LFU (mMITT Analysis Set)

Number of patients with a clinical cure at LFU. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01599806)
Timeframe: At LFU visit. LFU visit is 45 to 52 days from Randomization.

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	335	23	35
Doripenem	350	39	28

[back to top]

Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)

Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Clinical cure	Clinical failure
CAZ-AVI	289	8
Doripenem	309	21

[back to top]

Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)

Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	283	4	5
Doripenem	298	13	0

[back to top]

Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)

Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	277	4	5
Doripenem	285	13	0

[back to top]

Investigator Determined Clinical Response at TOC (mMITT Analysis Set)

Number of patients with a clinical cure at TOC. The investigator should consider the entirety of the patient's clinical course and current status, including an evaluation of signs and symptoms (eg, fever, dysuria, costovertebral angle tenderness) and physical examination in order to classify the patient's clinical response. (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	355	11	27
Doripenem	377	24	16

[back to top]

Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)

Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the Extended ME at TOC analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen. (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	All patients - Clinical cure (n=51, 63)	Escherichia coli patients - Clin cure (n=23, 27)	Klebsiella pneumoniae patients-Clin cure(n=15, 23)	Pseudomonas aeruginosa patients-Clin cure(n=3,6)	Enterobacter cloacae patients-Clin cure(n=5,5)	Proteus mirabilis patients - Clin cure (n=0, 2)
CAZ-AVI	50	22	15	3	5	0
Doripenem	61	25	23	6	5	2

[back to top]

Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)

Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the ME at TOC analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen. (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	All patients - Clinical cure (n=48, 57)	Escherichia coli patients-Clin cure (n=23,27)	Klebsiella pneumoniae patients-Clin cure(n=14, 22)	Pseudomonas aeruginosa patients-Clin cure(n=1, 2)	Enterobacter cloacae patients-Clin cure(n=5,5)	Proteus mirabilis patients - Clin cure (n=0, 2)
CAZ-AVI	47	22	14	1	5	0
Doripenem	55	25	22	2	5	2

[back to top]

Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)

Clinical cure at the TOC visit for patients infected with a ceftazidime resistant pathogen in the mMITT analysis set. Includes patients infected by at least one ceftazidime-resistant Gram-negative pathogen. (NCT01599806)
Timeframe: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Intervention	Participants (Number)
	All patients - Clinical cure (n=75, 84)	Escherichia coli patients - Clin cure (n=36, 37)	Klebsiella pneumoniae patients-Clin cure(n=18,30)	Pseudomonas aeruginosa patients- Clin cure(n=7,6)	Enterobacter cloacae patients-Clin cure(n=7,6)	Proteus mirabilis patients - Clin cure (n=2, 5)
CAZ-AVI	67	33	17	5	5	2
Doripenem	75	31	28	6	5	5

[back to top]

Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test

Number of patients with symptomatic resolution (or return to premorbid state) of UTI-specific symptoms except flank pain (frequency/urgency/dysuria/suprapubic pain) with resolution of or improvement in flank pain based on the patient-reported symptom assessment response at the Day 5 visit in the mMITT analysis set. The sponsor will conclude noninferiority if the lower limit of the 95% CI of difference (corresponding to a 97.5% 1-sided lower bound) is greater than -12.5% for both FDA coprimary outcome variables (symptomatic resolution at day 5 or favorable combined response at test of cure (TOC)). (NCT01599806)
Timeframe: At Day 5 visit. Day 5 visit is based on 24 hour periods from the first dose date and time.

Intervention	Participants (Number)
	Symptomatic resolution	Symptom persistence	Indeterminate
CAZ-AVI	276	103	14
Doripenem	276	124	17

[back to top]

Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)

Number of favorable per-pathogen microbiological responses at the EOT (IV) visit in the Extended ME at EOT (IV) analysis set (NCT01599806)
Timeframe: At EOT IV visit. EOT (IV) visit is Within 24 hours after completion of the last infusion of IV study therapy and on/before the first dose for oral study therapy

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=250, 274)	Klebsiella pneumoniae - Favorable (n=34, 49)	Proteus mirabilis - Favorable (n=13, 11)	Enterobacter cloacae - Favorable (n= 9, 12)	Pseudomonas aeruginosa - Favorable (n=18, 18)
CAZ-AVI	250	34	13	9	17
Doripenem	274	48	11	12	17

[back to top]

Per-patient Microbiological Response at FU2 in mMITT Analysis Set

"Microbiological responses as per the protocoled criteria: responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cIAI patients where the clinical response was changed to indeterminate due to a Surgical Review Panel assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01644643)
Timeframe: At FU2, data was only collected for the cUTI Arms: 28-34 calendar days from randomization

Intervention	Participant (Number)
	Favorable	Unfavorable	Indeterminate
cUTI:Best Available Therapy	73	54	10
cUTI:CAZ-AVI	99	35	10

[back to top]

Per-patient Microbiological Response at FU2 in EME at FU2 Analysis Set

Intervention	Participant (Number)
	Favorable	Unfavorable
cUTI:Best Available Therapy	68	47
cUTI:CAZ-AVI	85	32

[back to top]

Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set

Proportion of patients with clinical cure at the TOC visit in the mMITT analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: 6-12 days after last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Clinical cure	Clinical failure	Indeterminate
cIAI:Best Available Therapy	6	0	5
cIAI:CAZ-AVI + Metronidazole	8	0	2
cUTI:Best Available Therapy	129	2	6
cUTI:CAZ-AVI	132	2	10

[back to top]

Clinical Response at FU2 in EME at FU2 Analysis Set

Proportion of patients with clinical cure at the FU2 visit in EME at FU2 analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary. (NCT01644643)
Timeframe: At FU2, data was only collected for the cUTI Arms: 28-34 calendar days from randomization

Intervention	Participant (Number)
	Clinical cure	Clinical failure
cUTI:Best Available Therapy	102	12
cUTI:CAZ-AVI	106	10

[back to top]

Clinical Response at FU1 in EME at FU1 Analysis Set.

Proportion of patients with clinical cure at the FU1 visit in EME at FU1 analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: cIAI: 27-37 calendar days from randomization/cUTI: 20-27 calendar days from randomization

,,,

Intervention	Participant (Number)
	Clinical cure	Clinical failure
cIAI:Best Available Therapy	5	0
cIAI:CAZ-AVI + Metronidazole	7	0
cUTI:Best Available Therapy	110	8
cUTI:CAZ-AVI	120	4

[back to top]

Clinical Response at Follow-up 2 (FU2) in mMITT Analysis Set

Proportion of patients with clinical cure at the FU2 visit in the mMITT analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: At FU2, data was only collected for the cUTI Arms: 28-34 calendar days from randomization

Intervention	Participant (Number)
	Clinical cure	Clinical failure	Indeterminate
cUTI:Best Available Therapy	118	13	6
cUTI:CAZ-AVI	123	11	10

[back to top]

Clinical Response at Follow-up 1 (FU1) in mMITT Analysis Set

Proportion of patients with clinical cure at the FU1 visit in the mMITT analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: cIAI: 27-37 calendar days from randomization/cUTI: 20-27 calendar days from randomization

,,,

Intervention	Participant (Number)
	Clinical cure	Clinical failure	Indeterminate
cIAI:Best Available Therapy	6	0	5
cIAI:CAZ-AVI + Metronidazole	8	0	2
cUTI:Best Available Therapy	121	8	8
cUTI:CAZ-AVI	127	5	12

[back to top]

Clinical Response at EOT in Extended Microbiologically Evaluable (EME) at EOT Analysis Set.

Proportion of patients with clinical cure at the EOT visit in the EME at EOT analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: 28 hours after completion of last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Clinical cure	Clinical failure
cIAI:Best Available Therapy	5	0
cIAI:CAZ-AVI + Metronidazole	9	0
cUTI:Best Available Therapy	127	0
cUTI:CAZ-AVI	134	0

[back to top]

Clinical Response at End of Treatment (EOT) in mMITT Analysis Set.

Proportion of patients with clinical cure at the EOT visit in the mMITT analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: 28 hours after completion of last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Clinical cure	Clinical failure	Indeterminate
cIAI:Best Available Therapy	6	0	5
cIAI:CAZ-AVI + Metronidazole	9	0	1
cUTI:Best Available Therapy	136	0	1
cUTI:CAZ-AVI	142	0	2

[back to top]

The 28 Days All Cause Mortality Rate in mMITT Analysis Set

Proportion of patients with Day 28 all-cause mortality in mMITT analysis set. The death in the cIAI patient were reviewed independently by the SRP Chair. (NCT01644643)
Timeframe: From first infusion to Day 28

,,,

Intervention	Participant (Number)
	All cause mortality	Deaths due to disease progression	Number of patients with any AE with outcome=death
cIAI:Best Available Therapy	1	0	1
cIAI:CAZ-AVI + Metronidazole	0	0	0
cUTI:Best Available Therapy	3	0	3
cUTI:CAZ-AVI	3	0	3

[back to top]

Clinical Cure at TOC by Previously Failed Treatment Class in mMITT Analysis Set

Proportion of patients with clinical cure at TOC visit by previously failed treatment class in the mMITT analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: 6-12 days after last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	At least 1 failed - Clin. cure (n=4,7,12,7)	Antibiotics - Clin. cure (n=0,1,0,0)	Carbapenems - Clin. cure (n=1,0,1,2)	Comb of Sulf/Trime inc Deriv-Clin. cure(n=0,0,2,0)	Combs Of Peni. Inc B-Lact. Inhib.-Cure(n=1,3,0,2)	Cortico,Po. Comb W/Antibio.-Clin. cure(n=0,0,1,0)	First-Gen. Cephalosporins-Clin. cure (n=0,0,2,0)	Fluoroquinolones - Clin. cure (n=1,2,7,1)	Glycopeptide Antibacterials-Clin. cure (n=1,0,0,0)	Imidazole Derivatives - Clin. cure (n=2,3,0,0)	Other Aminoglycosides-Clin. cure (n=0,0,1,1)	Other Antibacterials-Clin. cure (n=0,1,1,0)	Other Antibio. F. Topic. Use-Clin. cure(n=0,0,1,0)	Penici. With Ext. Spectrum-Clin. cure(n=0,1,0,0)	Third-Gen.Cephalosporins -Clin. cure(n=2,4,3,2)
cIAI:Best Available Therapy	3	0	0	0	1	0	0	0	0	1	0	0	0	0	2
cIAI:CAZ-AVI + Metronidazole	7	1	0	0	3	0	0	2	0	3	0	1	0	1	4
cUTI:Best Available Therapy	12	0	1	2	0	1	2	7	0	0	1	1	1	0	3
cUTI:CAZ-AVI	6	0	1	0	2	0	0	1	0	0	1	0	0	0	2

[back to top]

Clinical Cure at TOC by Previously Failed Treatment Class in EME at TOC Analysis Set

Proportion of patients with clinical cure at TOC visit by previously failed treatment class in EME at TOC analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: 6-12 days after last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Antibiotics - Clin. cure (n=0,1,0,0)	Carbapenems - Clin. cure (n=0,0,1,1)	Comb of Sulf/Trime inc Deriv-Clin. cure(n=0,0,2,0)	Combs Of Peni. Inc B-Lact. Inhib.-Cure(n=1,3,0,2)	Cortico,Po. Comb W/Antibio.-Clin. cure(n=0,0,1,0)	First-Gen. Cephalosporins-Clin. cure (n=0,0,2,0)	Fluoroquinolones - Clin. cure (n=0,2,5,1)	Imidazole Derivatives - Clin. cure (n=1,3,0,0)	Other Aminoglycosides-Clin. cure (n=0,0,0,1)	Other Antibacterials-Clin. cure (n=0,1,1,0)	Other Antibio. F. Topic. Use-Clin. cure(n=0,0,1,0)	Penici. With Ext. Spectrum-Clin. cure(n=0,1,0,0)	Third-Gen.Cephalosporins -Clin. cure(n=2,4,2,2)
cIAI:Best Available Therapy	0	0	0	1	0	0	0	1	0	0	0	0	2
cIAI:CAZ-AVI + Metronidazole	1	0	0	3	0	0	2	3	0	1	0	1	4
cUTI:Best Available Therapy	0	1	2	0	1	2	5	0	0	1	1	0	2
cUTI:CAZ-AVI	0	1	0	2	0	0	1	0	1	0	0	0	2

[back to top]

Clinical Cure at TOC by Baseline Gram-negative Pathogen in mMITT Analysis Set

Proportion of patients with clinical cure at TOC visit by baseline pathogen (>=10% of frequency in the combined cIAI and cUTI patients) in the mMITT analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: 6-12 days after last infusion of study therapy.Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	E. coli - Clinical cure (n=6, 4, 57, 59)	K. pneumoniae - Clinical cure (n=3, 5, 65, 55)	P. aeruginosa - clinical cure (n=1, 1, 5, 14)
cIAI:Best Available Therapy	2	2	1
cIAI:CAZ-AVI + Metronidazole	3	3	1
cUTI:Best Available Therapy	54	61	5
cUTI:CAZ-AVI	53	54	12

[back to top]

Clinical Cure at TOC by Baseline Gram-negative Pathogen in EME at TOC Analysis Set

Proportion of patients with clinical cure at TOC visit by baseline Gram-negative pathogen (>=10% of frequency in the combined cIAI and cUTI patients) in EME at TOC analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: 6-12 days after last infusion of study therapy.Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	E. coli - Clinical cure (n=2, 3, 48, 52)	K. pneumoniae - Clinical cure (n=2, 3, 59, 53)	P. aeruginosa - Clinical cure (n=1, 1, 5, 12)
cIAI:Best Available Therapy	2	2	1
cIAI:CAZ-AVI + Metronidazole	3	3	1
cUTI:Best Available Therapy	47	59	5
cUTI:CAZ-AVI	51	53	12

[back to top]

Clinical Cure at FU2 by Previously Failed Treatment Class in EME at FU2 Analysis Set

Proportion of patients with clinical cure at FU2 visit by previously failed treatment class in EME at FU2 analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary. (NCT01644643)
Timeframe: At FU2, data was only collected for the cUTI Arms: 28-34 calendar days from randomization

Intervention	Participant (Number)
	Carbapenems - Clin. cure (n=1,0)	Comb of Sulf/Trime inc Deriv-Clin. cure(n=1,0)	Combs Of Peni. Inc B-Lact. Inhib.-Cure(n=0,2)	Cortico,Po. Comb W/Antibio.-Clin. cure(n=1,0)	First-Gen. Cephalosporins-Clin. cure (n=2,0)	Fluoroquinolones - Clin. cure (n=5,0)	Other Aminoglycosides-Clin. cure (n=0,1)	Other Antibacterials-Clin. cure (n=1,0)	Other Antibio. F. Topic. Use-Clin. cure(n=1,0)	Third-Gen.Cephalosporins -Clin. cure(n=1,1)
cUTI:Best Available Therapy	0	0	0	0	2	4	0	0	1	0
cUTI:CAZ-AVI	0	0	2	0	0	0	1	0	0	1

[back to top]

Clinical Cure at FU1 by Previously Failed Treatment Class in EME at FU1 Analysis Set

Proportion of patients with clinical cure at FU1 visit by previously failed treatment class in EME at FU1 analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: cIAI: 27-37 calendar days from randomization/cUTI: 20-27 calendar days from randomization

,,,

Intervention	Participant (Number)
	Antibiotics - Clin. cure (n=0,1,0,0)	Carbapenems - Clin. cure (n=0,0,1,1)	Comb of Sulf/Trime inc Deriv-Clin. cure(n=0,0,1,0)	Combs Of Peni. Inc B-Lact. Inhib.-Cure(n=1,3,0,2)	Cortico,Po. Comb W/Antibio.-Clin. cure(n=0,0,1,0)	First-Gen. Cephalosporins-Clin. cure (n=0,0,2,0)	Fluoroquinolones - Clin. cure (n=0,2,5,1)	Imidazole Derivatives - Clin. cure (n=1,3,0,0)	Other Aminoglycosides-Clin. cure (n=0,0,0,1)	Other Antibacterials-Clin. cure (n=0,1,1,0)	Other Antibio. F. Topic. Use-Clin. cure(n=0,0,1,0)	Penici. With Ext. Spectrum-Clin. cure(n=0,1,0,0)	Third-Gen.Cephalosporins -Clin. cure(n=2,4,1,2)
cIAI:Best Available Therapy	0	0	0	1	0	0	0	1	0	0	0	0	2
cIAI:CAZ-AVI + Metronidazole	1	0	0	3	0	0	2	3	0	1	0	1	4
cUTI:Best Available Therapy	0	1	1	0	0	2	4	0	0	1	1	0	0
cUTI:CAZ-AVI	0	1	0	2	0	0	1	0	1	0	0	0	2

[back to top]

Clinical Cure at EOT by Previously Failed Treatment Class in EME at EOT Analysis Set

Proportion of patients with clinical cure at EOT visit by previously failed treatment class in EME at EOT analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: 28 hours after completion of last infusion of study therapy.Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Antibiotics - Clin. cure (n=0,1,0,0)	Carbapenems - Clin. cure (n=0,0,1,1)	Comb of Sulf/Trime inc Deriv-Clin. cure(n=0,0,2,0)	Combs Of Peni. Inc B-Lact. Inhib.-Cure(n=1,3,0,2)	Cortico,Po. Comb W/Antibio.-Clin. cure(n=0,0,1,0)	First-Gen. Cephalosporins-Clin. cure (n=0,0,2,0)	Fluoroquinolones - Clin. cure (n=0,2,5,1)	Imidazole Derivatives - Clin. cure (n=1,3,0,0)	Other Aminoglycosides-Clin. cure (n=0,0,1,1)	Other Antibacterials-Clin. cure (n=0,1,1,0)	Other Antibio. F. Topic. Use-Clin. cure(n=0,0,1,0)	Penici. With Ext. Spectrum-Clin. cure(n=0,1,0,0)	Third-Gen.Cephalosporins -Clin. cure(n=2,4,2,2)
cIAI:Best Available Therapy	0	0	0	1	0	0	0	1	0	0	0	0	2
cIAI:CAZ-AVI + Metronidazole	1	0	0	3	0	0	2	3	0	1	0	1	4
cUTI:Best Available Therapy	0	1	2	0	1	2	5	0	1	1	1	0	2
cUTI:CAZ-AVI	0	1	0	2	0	0	1	0	1	0	0	0	2

[back to top]

The Reason for Treatment Change/Discontinuation in mMITT Analysis Set

Proportion of patients in the mMITT analysis set for whom the assigned study treatment was changed, discontinued, or interrupted. Creatinine clearance (CrCl) (NCT01644643)
Timeframe: From first infusion to last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Treatment Change	Treatment Change - Crcl change	Treatment Change - Other	Treatment discontinuation	Treatment discontinuation - AE	Treatment discontinuation - Other	Treatment interrupted	Treatment interrupted - Change of infusion site
cIAI:Best Available Therapy	1	1	0	4	1	3	0	0
cIAI:CAZ-AVI + Metronidazole	0	0	0	0	0	0	0	0
cUTI:Best Available Therapy	8	5	3	3	1	2	0	0
cUTI:CAZ-AVI	11	10	1	1	1	0	1	1

[back to top]

Plasma Concentrations for Ceftazidime and Avibactam - cUTI in PK Analysis Set

Blood samples were taken on Day 3 for ceftazidime and avibactam plasma concentration. (NCT01644643)
Timeframe: Anytime within 15 minutes prior to or after stopping study drug, anytime between 30 to 90 minutes after stopping study drug, anytime between 300 to 360 minutes after stopping study drug

Intervention	NG/ML (Geometric Mean)
CAZ (1)	74260.2
AVI (1)	10103.8
CAZ (2)	56905.9
AVI (2)	8141.2
CAZ (3)	21442.0
AVI (3)	2425.0

[back to top]

The 28 Days All Cause Mortality Rate in EME at TOC Analysis Set

Proportion of patients with Day 28 all-cause mortality in EME at TOC analysis set. The death in the cIAI patient were reviewed independently by the SRP Chair. (NCT01644643)
Timeframe: From first infusion to Day 28

,,,

Intervention	Participant (Number)
	All cause mortality	Deaths due to disease progression	Number of patients with any AE withoutcome=death
cIAI:Best Available Therapy	0	0	0
cIAI:CAZ-AVI + Metronidazole	0	0	0
cUTI:Best Available Therapy	1	0	1
cUTI:CAZ-AVI	1	0	1

[back to top]

Per-patient Microbiological Response at TOC in mMITT Analysis Set

"Microbiological responses as per the protocoled criteria: responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cIAI patients where the clinical response was changed to indeterminate due to a Surgical Review Panel assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01644643)
Timeframe: 6-12 days after last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Favorable	Unfavorable	Indeterminate
cIAI:Best Available Therapy	6	0	5
cIAI:CAZ-AVI + Metronidazole	8	0	2
cUTI:Best Available Therapy	88	42	7
cUTI:CAZ-AVI	118	17	9

[back to top]

Per-patient Microbiological Response at TOC in EME at TOC Analysis Set

"Microbiological responses as per the protocoled criteria: responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cIAI patients where the clinical response was changed to indeterminate due to a Surgical Review Panel assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01644643)
Timeframe: 6-12 days after last infusion of study therapy.Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Favorable	Unfavorable
cIAI:Best Available Therapy	5	0
cIAI:CAZ-AVI + Metronidazole	8	0
cUTI:Best Available Therapy	84	40
cUTI:CAZ-AVI	114	17

[back to top]

Clinical Response at TOC in EME at TOC Analysis Set.

Proportion of patients with clinical cure at the TOC visit in the EME at TOC analysis set. Clinical cure: Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy (other than those allowed per protocol) is necessary; for cIAI patients no drainage or surgical intervention after 96 hours from randomization is necessary (ie. drainage or surgical intervention up to 96 hours from randomization is permissible). (NCT01644643)
Timeframe: 6-12 days after last infusion of study therapy.Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Clinical cure	Clinical failure
cIAI:Best Available Therapy	5	0
cIAI:CAZ-AVI + Metronidazole	8	0
cUTI:Best Available Therapy	120	2
cUTI:CAZ-AVI	126	2

[back to top]

Per-pathogen Microbiological Response of Gram-negative Pathogen at EOT in EME at EOT Analysis Set

Proportion of patients with a favorable per-pathogen microbiological response for pathogens (>=10% of frequncy in the combined cIAI and cUTI patients): favourable microbiological response includes: Eradication Absence (or urine quantification less than 10^4 CFU/ml for cUTI patients) of causative pathogen from an appropriately obtained specimen at the site of infection. If the patient was bacteremic at Screening, the bacteremia has also resolved. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure (specific to cIAI population). (NCT01644643)
Timeframe: 28 hours after completion of last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=2, 3, 51, 55)	Escherichia coli - Unfavorable (n=2, 3, 51, 55)	Kleb. pneumoniae - Favorable (n=2, 4, 60, 52)	Kleb. pneumoniae - Unfavorable (n=2, 4, 60, 52)	Pseudo. aeruginosa - Favorable (n=1, 1, 5, 14)	Pseudo. aeruginosa - Unfavorable (n=1, 1, 5, 14)
cIAI:Best Available Therapy	2	0	2	0	1	0
cIAI:CAZ-AVI + Metronidazole	3	0	4	0	1	0
cUTI:Best Available Therapy	51	0	60	0	5	0
cUTI:CAZ-AVI	55	0	52	0	14	0

[back to top]

Per-pathogen Microbiological Response of Gram-negative Pathogen at EOT in mMITT Analysis Set

Proportion of patients with a favorable per-pathogen microbiological response for pathogens (>=10% of frequency in the combined cIAI and cUTI patients): favourable microbiological response includes: Eradication Absence (or urine quantification less than 10^4 CFU/ml for cUTI patients) of causative pathogen from an appropriately obtained specimen at the site of infection. If the patient was bacteremic at Screening, the bacteremia has also resolved. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure (specific to cIAI population). (NCT01644643)
Timeframe: 28 hours after completion of last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=6, 4, 57, 59)	Escherichia coli - Unfavorable (n=6, 4, 57, 59)	Escherichia coli - Indeterminate (n=6, 4, 57, 59)	Kleb. pneumoniae - Favorable (n=3, 5, 65, 55)	Kleb. pneumoniae - Unfavorable (n=3, 5, 65, 55)	Kleb. pneumoniae - Indeterminate (n=3, 5, 65, 55)	Pseudo. aeruginosa - Favorable (n=1, 1, 5, 14)	Pseudo. aeruginosa - Unfavorable (n=1, 1, 5, 14)	Pseudo. aeruginosa - Indeterminate (n=1, 1, 5, 14)
cIAI:Best Available Therapy	2	0	4	2	0	1	1	0	0
cIAI:CAZ-AVI + Metronidazole	3	0	1	4	0	1	1	0	0
cUTI:Best Available Therapy	53	0	4	61	1	3	5	0	0
cUTI:CAZ-AVI	57	0	2	52	0	3	14	0	0

[back to top]

Per-pathogen Microbiological Response of Gram-negative Pathogen at FU1 in EME at FU1 Analysis Set

Proportion of patients with a favorable per-pathogen microbiological response for pathogens (>=10% of frequncy in the combined cIAI and cUTI patients): favourable microbiological response includes: Eradication Absence (or urine quantification less than 10^4 CFU/ml for cUTI patients) of causative pathogen from an appropriately obtained specimen at the site of infection. If the patient was bacteremic at Screening, the bacteremia has also resolved. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure (specific to cIAI population). (NCT01644643)
Timeframe: cIAI: 27-37 calendar days from randomization/cUTI: 20-27 calendar days from randomization

,,,

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=2, 3, 46, 54)	Escherichia coli - Unfavorable (n=2, 3, 46, 54)	Kleb. pneumoniae - Favorable (n=2, 2, 59, 50)	Kleb. pneumoniae - Unfavorable (n=2, 2, 59, 50)	Pseudo. aeruginosa - Favorable (n=1, 1, 5, 10)	Pseudo. aeruginosa - Unfavorable (n=1, 1, 5, 10)
cIAI:Best Available Therapy	2	0	2	0	1	0
cIAI:CAZ-AVI + Metronidazole	3	0	2	0	1	0
cUTI:Best Available Therapy	30	16	38	21	3	2
cUTI:CAZ-AVI	43	11	40	10	8	2

[back to top]

Per-pathogen Microbiological Response of Gram-negative Pathogen at FU1 in mMITT Analysis Set

Proportion of patients with a favorable per-pathogen microbiological response for pathogens (>=10% of frequency in the combined cIAI and cUTI patients): favourable microbiological response includes: Eradication Absence (or urine quantification less than 10^4 CFU/ml for cUTI patients) of causative pathogen from an appropriately obtained specimen at the site of infection. If the patient was bacteremic at Screening, the bacteremia has also resolved. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure (specific to cIAI population). (NCT01644643)
Timeframe: cIAI: 27-37 calendar days from randomization/cUTI: 20-27 calendar days from randomization

,,,

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=6, 4, 57, 59)	Escherichia coli - Unfavorable (n=6, 4, 57, 59)	Escherichia coli - Indeterminate (n=6, 4, 57, 59)	Kleb. pneumoniae - Favorable (n=3, 5, 65, 55)	Kleb. pneumoniae - Unfavorable (n=3, 5, 65, 55)	Kleb. pneumoniae - Indeterminate (n=3, 5, 65, 55)	Pseudo. aeruginosa - Favorable (n=1, 1, 5, 14)	Pseudo. aeruginosa - Unfavorable (n=1, 1, 5, 14)	Pseudo. aeruginosa - Indeterminate (n=1, 1, 5, 14)
cIAI:Best Available Therapy	2	0	4	2	0	1	1	0	0
cIAI:CAZ-AVI + Metronidazole	3	0	1	3	0	2	1	0	0
cUTI:Best Available Therapy	33	18	6	39	23	3	3	2	0
cUTI:CAZ-AVI	45	12	2	42	10	3	8	2	4

[back to top]

Per-pathogen Microbiological Response of Gram-negative Pathogen at FU2 in EME at FU2 Analysis Set

Proportion of patients with a favorable per-pathogen microbiological response for pathogens (>=10% of frequncy in the combined cIAI and cUTI patients): favourable microbiological response includes: Eradication Absence (or urine quantification less than 10^4 CFU/ml for cUTI patients) of causative pathogen from an appropriately obtained specimen at the site of infection. If the patient was bacteremic at Screening, the bacteremia has also resolved. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure (specific to cIAI population). (NCT01644643)
Timeframe: At FU2, data was only collected for the cUTI Arms: 28-34 calendar days from randomization

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=44, 50)	Escherichia coli - Unfavorable (n=44, 50)	Kleb. pneumoniae - Favorable (n= 56, 46)	Kleb. pneumoniae - Unfavorable (n=56, 46)	Pseudo. aeruginosa - Favorable (n=4, 11)	Pseudo. aeruginosa - Unfavorable (n=4, 11)
cUTI:Best Available Therapy	28	16	33	23	2	2
cUTI:CAZ-AVI	39	11	32	14	9	2

[back to top]

Per-pathogen Microbiological Response of Gram-negative Pathogen at FU2 in mMITT Analysis Set

Proportion of patients with a favorable per-pathogen microbiological response for pathogens (>=10% of frequncy in the combined cIAI and cUTI patients): favourable microbiological response includes: Eradication Absence (or urine quantification less than 10^4 CFU/ml for cUTI patients) of causative pathogen from an appropriately obtained specimen at the site of infection. If the patient was bacteremic at Screening, the bacteremia has also resolved. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure (specific to cIAI population). (NCT01644643)
Timeframe: At FU2, data was only collected for the cUTI Arms: 28-34 calendar days from randomization

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=0, 0, 57, 59)	Escherichia coli - Unfavorable (n=0, 0, 57, 59)	Escherichia coli - Indeterminate (n=0, 0, 57, 59)	Kleb. pneumoniae - Favorable (n=0, 0, 65, 55)	Kleb. pneumoniae - Unfavorable (n=0, 0, 65, 55)	Kleb. pneumoniae - Indeterminate (n=0, 0, 65, 55)	Pseudo. aeruginosa - Favorable (n=0, 0, 5, 14)	Pseudo. aeruginosa - Unfavorable (n=0, 0, 5, 14)	Pseudo. aeruginosa - Indeterminate (n=0, 0, 5, 14)
cUTI:Best Available Therapy	32	19	6	35	26	4	2	3	0
cUTI:CAZ-AVI	43	14	2	39	14	2	10	2	2

[back to top]

Plasma Concentrations for Ceftazidime and Avibactam - cIAI in PK Analysis Set

Intervention	NG/ML (Geometric Mean)
CAZ (1)	23880.3
AVI (1)	3061.3
CAZ (2)	39465.3
AVI (2)	6304.1
CAZ (3)	14904.8
AVI (3)	1769.3

[back to top]

Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC by CAZ-AVI MIC in EME at TOC Analysis Set

Proportion of patients with a favorable per-pathogen microbiological response for pathogens (>=10% of frequncy in the combined cIAI and cUTI patients): favourable microbiological response includes: Eradication Absence (or urine quantification less than 10^4 CFU/ml for cUTI patients) of causative pathogen from an appropriately obtained specimen at the site of infection. If the patient was bacteremic at Screening, the bacteremia has also resolved. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure (specific to cIAI population). For E.coli, MIC available values are: <=0.008, 0.03, 0.06, 0.12, 0.25, 0.5, 1, 2, 8. For K. pneumoniae, MIC available values are: 0.06, 0.12, 0.25, 0.5, 1, 2, 4, >32. For P. aeruginosa, MIC available values are: 2, 4, 8, 16, 32, >32. (NCT01644643)
Timeframe: 6-12 days after last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=0, 0, 1, 1)	E. coli (MIC: 0.03) - Favorable (n=0, 0, 0, 2)	E. coli (MIC: 0.06) - Favorable (n=0, 0, 3, 1)	E. coli (MIC: 0.12) - Favorable (n=2, 1, 18, 18)	E. coli (MIC: 0.25) - Favorable (n=0, 0, 13, 15)	E. coli (MIC: 0.5) - Favorable (n=0, 1, 6, 9)	E. coli (MIC: 1) - Favorable (n=0, 0, 2, 2)	E. coli (MIC: 2) - Favorable (n=0, 0, 2, 1)	E. coli (MIC: 8) - Favorable (n=0, 0, 2, 4)	K. pneumoniae (MIC: 0.06) - Favorable (n=0,0,1,0)	K. pneumoniae (MIC: 0.12) - Favorable (n=0,0,8,5)	K. pneumoniae (MIC: 0.25) - Favorable (n=0,2,11,6)	K. pneumoniae (MIC: 0.5) - Favorable (n=1,0,23,21)	K. pneumoniae (MIC: 1) - Favorable (n=0,0,15,17)	K. pneumoniae (MIC: 2) - Favorable (n=1, 1, 1, 2)	K. pneumoniae (MIC: 4) - Favorable (n=0, 0, 1, 1)	K. pneumoniae (MIC: >32) - Favorable (n=0,0,0,1)	P. aeruginosa (MIC: 2) - Favorable (n=1, 0, 0, 1)	P. aeruginosa (MIC: 4) - Favorable (n=0, 0, 3, 2)	P. aeruginosa (MIC: 8) - Favorable (n=0, 0, 0, 2)	P. aeruginosa (MIC: 16) - Favorable (n=0, 1, 0, 1)	P. aeruginosa (MIC: 32) - Favorable (n=0, 0, 1, 3)	P. aeruginosa (MIC: >32) - Favorable (n=0,0,1,4)
cIAI:Best Available Therapy	0	0	0	2	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	0	0	0
cIAI:CAZ-AVI + Metronidazole	0	0	0	1	0	1	0	0	0	0	0	2	0	0	1	0	0	0	0	0	1	0	0
cUTI:Best Available Therapy	1	0	3	10	9	4	1	2	2	0	6	7	16	11	1	1	0	0	1	0	0	1	1
cUTI:CAZ-AVI	1	1	1	16	15	9	2	1	4	0	4	5	19	15	2	0	0	1	1	2	0	3	4

[back to top]

Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC by CAZ-AVI MIC in mMITT Analysis Set

Proportion of patients with a favorable per-pathogen microbiological response for pathogens (>=10% of frequncy in the combined cIAI and cUTI patients): favourable microbiological response includes: Eradication Absence (or urine quantification less than 10^4 CFU/ml for cUTI patients) of causative pathogen from an appropriately obtained specimen at the site of infection. If the patient was bacteremic at Screening, the bacteremia has also resolved. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure (specific to cIAI population). For E.coli, MIC available values are: <=0.008, 0.03, 0.06, 0.12, 0.25, 0.5, 1, 2, 8. For K. pneumoniae, MIC available values are: 0.06, 0.12, 0.25, 0.5, 1, 2, 4, 32, >32. For P. aeruginosa, MIC available values are: 2, 4, 8, 16, 32, >32. (NCT01644643)
Timeframe: 6-12 days after last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=0, 0, 1, 1)	E. coli (MIC: 0.03) - Favorable (n=0, 0, 0, 2)	E. coli (MIC: 0.06) - Favorable (n=1, 0, 3, 2)	E. coli (MIC: 0.12) - Favorable (n=4, 2, 20, 20)	E. coli (MIC: 0.25) - Favorable (n=0, 0, 15, 16)	E. coli (MIC: 0.5) - Favorable (n=0, 1, 8, 11)	E. coli (MIC: 1) - Favorable (n=0, 0, 2, 2)	E. coli (MIC: 2) - Favorable (n=0, 0, 2, 1)	E. coli (MIC: 8) - Favorable (n=0, 0, 2, 4)	K. pneumoniae (MIC: 0.06) - Favorable (n=0,0,2,0)	K. pneumoniae (MIC: 0.12) - Favorable (n=0,1,8,5)	K. pneumoniae (MIC: 0.25) - Favorable (n=0,3,12,6)	K. pneumoniae (MIC: 0.5) - Favorable (n=2,0,24,22)	K. pneumoniae (MIC: 1) - Favorable (n=0,0,16,18)	K. pneumoniae (MIC: 2) - Favorable (n=1, 1, 1, 2)	K. pneumoniae (MIC: 4) - Favorable (n=0, 0, 1, 1)	K. pneumoniae (MIC: 32) - Favorable (n=0, 0, 1, 0)	K. pneumoniae (MIC: >32) - Favorable (n=0,0,0,1)	P. aeruginosa (MIC: 2) - Favorable (n=1, 0, 0, 1)	P. aeruginosa (MIC: 4) - Favorable (n=0, 0, 3, 2)	P. aeruginosa (MIC: 8) - Favorable (n=0, 0, 0, 2)	P. aeruginosa (MIC: 16) - Favorable (n=0, 1, 0, 1)	P. aeruginosa (MIC: 32) - Favorable (n=0, 0, 1, 3)	P. aeruginosa (MIC: >32) - Favorable (n=0,0,1,5)
cIAI:Best Available Therapy	0	0	0	2	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	0	0	0	0	0
cIAI:CAZ-AVI + Metronidazole	0	0	0	1	0	1	0	0	0	0	0	2	0	0	1	0	0	0	0	0	0	1	0	0
cUTI:Best Available Therapy	1	0	3	12	10	5	1	2	2	1	6	7	16	11	1	1	0	0	0	1	0	0	1	1
cUTI:CAZ-AVI	1	1	2	16	15	10	2	1	4	0	4	5	19	16	1	0	0	0	1	1	2	0	3	4

[back to top]

Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC in EME at TOC Analysis Set

Proportion of patients with a favorable per-pathogen microbiological response for pathogens (>=10% of frequncy in the combined cIAI and cUTI patients): favourable microbiological response includes: Eradication Absence (or urine quantification less than 10^4 CFU/ml for cUTI patients) of causative pathogen from an appropriately obtained specimen at the site of infection. If the patient was bacteremic at Screening, the bacteremia has also resolved. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure (specific to cIAI population). (NCT01644643)
Timeframe: 6-12 days after last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=2, 3, 49, 53)	Escherichia coli - Unfavorable (n=2, 3, 49, 53)	Kleb. pneumoniae - Favorable (n=2, 3, 60, 53)	Kleb. pneumoniae - Unfavorable (n=2, 3, 60, 53)	Pseudo. aeruginosa - Favorable (n=1, 1, 5, 13)	Pseudo. aeruginosa - Unfavorable (n=1, 1, 5, 13)
cIAI:Best Available Therapy	2	0	2	0	1	0
cIAI:CAZ-AVI + Metronidazole	3	0	3	0	1	0
cUTI:Best Available Therapy	34	15	42	18	3	2
cUTI:CAZ-AVI	50	3	45	8	11	2

[back to top]

Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC in mMITT Analysis Set

Proportion of patients with a favorable per-pathogen microbiological response for pathogens (>=10% of frequency in the combined cIAI and cUTI patients): favourable microbiological response includes: Eradication Absence (or urine quantification less than 10^4 CFU/ml for cUTI patients) of causative pathogen from an appropriately obtained specimen at the site of infection. If the patient was bacteremic at Screening, the bacteremia has also resolved. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure (specific to cIAI population). (NCT01644643)
Timeframe: 6-12 days after last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=6, 4, 57, 59)	Escherichia coli - Unfavorable (n=6, 4, 57, 59)	Escherichia coli - Indeterminate (n=6, 4, 57, 59)	Kleb. pneumoniae - Favorable (n=3, 5, 65, 55)	Kleb. pneumoniae - Unfavorable (n=3, 5, 65, 55)	Kleb. pneumoniae - Indeterminate (n=3, 5, 65, 55)	Pseudo. aeruginosa - Favorable (n=1, 1, 5, 14)	Pseudo. aeruginosa - Unfavorable (n=1, 1, 5, 14)	Pseudo. aeruginosa - Indeterminate (n=1, 1, 5, 14)
cIAI:Best Available Therapy	2	0	4	2	0	1	1	0	0
cIAI:CAZ-AVI + Metronidazole	3	0	1	3	0	2	1	0	0
cUTI:Best Available Therapy	38	16	3	43	19	3	3	2	0
cUTI:CAZ-AVI	52	3	4	46	8	1	11	2	1

[back to top]

Per-patient Microbiological Response at EOT in EME at EOT Analysis Set

"Microbiological responses as per the protocoled criteria: responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cIAI patients where the clinical response was changed to indeterminate due to a Surgical Review Panel assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01644643)
Timeframe: 28 hours after completion of last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Favorable	Unfavorable
cIAI:Best Available Therapy	5	0
cIAI:CAZ-AVI + Metronidazole	9	0
cUTI:Best Available Therapy	127	0
cUTI:CAZ-AVI	133	1

[back to top]

Per-patient Microbiological Response at EOT in mMITT Analysis Set

"Microbiological responses as per the protocoled criteria: responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cIAI patients where the clinical response was changed to indeterminate due to a Surgical Review Panel assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01644643)
Timeframe: 28 hours after completion of last infusion of study therapy. Duration of study therapy was 5 to 21 days.

,,,

Intervention	Participant (Number)
	Favorable	Unfavorable	Indeterminate
cIAI:Best Available Therapy	6	0	5
cIAI:CAZ-AVI + Metronidazole	9	0	1
cUTI:Best Available Therapy	130	1	6
cUTI:CAZ-AVI	136	1	7

[back to top]

Per-patient Microbiological Response at FU1 in EME at FU1 Analysis Set

"Microbiological responses as per the protocoled criteria: responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cIAI patients where the clinical response was changed to indeterminate due to a Surgical Review Panel assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01644643)
Timeframe: cUTI: 20-27 calendar days from randomization/cIAI: 27-37 calendar days from randomization

,,,

Intervention	Participant (Number)
	Favorable	Unfavorable
cIAI:Best Available Therapy	5	0
cIAI:CAZ-AVI + Metronidazole	7	0
cUTI:Best Available Therapy	75	45
cUTI:CAZ-AVI	98	28

[back to top]

Per-patient Microbiological Response at FU1 in mMITT Analysis Set

"Microbiological responses as per the protocoled criteria: responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cIAI patients where the clinical response was changed to indeterminate due to a Surgical Review Panel assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01644643)
Timeframe: cUTI: 20-27 calendar days from randomization/cIAI: 27-37 calendar days from randomization

,,,

Intervention	Participant (Number)
	Favorable	Unfavorable	Indeterminate
cIAI:Best Available Therapy	6	0	5
cIAI:CAZ-AVI + Metronidazole	8	0	2
cUTI:Best Available Therapy	78	50	9
cUTI:CAZ-AVI	103	29	12

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure. (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

Intervention	Participants with favorable responses (Number)
	Escherichia coli (n=69, 77)	Klebsiella oxytoca (n=5, 5)	Klebsiella pneumoniae (n=22, 29)	Pseudomonas aeruginosa (n=14, 16)
Ceftazidime-Avibactam Plus Metronidazole	64	5	21	13
Meropenem	74	5	28	14

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable(ME) Analysis Set.

Intervention	Participants with favorable responses (Number)
	Escherichia coli (n=70, 80)	Klebsiella oxytoca (n=5, 5)	Klebsiella pneumoniae (n=22, 30)	Pseudomonas aeruginosa (n=14, 18)
Ceftazidime-Avibactam Plus Metronidazole	65	5	21	13
Meropenem	77	5	29	16

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.

Intervention	Participants with favorable responses (Number)
	Escherichia coli (n=69, 77)	Klebsiella oxytoca (n=5, 5)	Klebsiella pneumoniae (n=22, 29)	Pseudomonas aeruginosa (n=14, 16)
Ceftazidime-Avibactam Plus Metronidazole	63	4	21	13
Meropenem	72	5	27	14

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

Intervention	Participants with favorable responses (Number)
	Escherichia coli (n=70, 80)	Klebsiella oxytoca (n=5, 5)	Klebsiella pneumoniae (n=22, 30)	Pseudomonas aeruginosa (n=14, 18)
Ceftazidime-Avibactam Plus Metronidazole	64	4	21	13
Meropenem	75	5	28	16

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.

Intervention	Participants with favorable responses (Number)
	Escherichia coli (n=69, 77)	Klebsiella oxytoca (n=5, 5)	Klebsiella pneumoniae (n=22, 29)	Pseudomonas aeruginosa (n=14, 16)
Ceftazidime-Avibactam Plus Metronidazole	68	5	21	14
Meropenem	75	5	28	14

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

Intervention	Participants with favorable responses (Number)
	Escherichia coli (n=84, 89)	Klebsiella oxytoca (n=5, 5)	Klebsiella pneumoniae (n=28,35)	Pseudomonas aeruginosa (n=17, 20)	Streptococcus anginosus grou (n=8, 7)	Streptococcus mitis group (n=6, 5)	Enterococcus faecalis (n=6, 6)	Enterococcus faecium (n=4, 7)
Ceftazidime-Avibactam Plus Metronidazole	77	5	22	15	7	6	5	4
Meropenem	86	5	32	17	6	5	5	5

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

Intervention	Participants with favorable responses (Number)
	Escherichia coli (n=70, 80)	Klebsiella oxytoca (n=5, 5)	Klebsiella pneumoniae (n=22, 30)	Pseudomonas aeruginosa (n=14, 18)
Ceftazidime-Avibactam Plus Metronidazole	69	5	21	14
Meropenem	78	5	29	16

[back to top]

Safety and Tolerability:ECG , QTcB and QTcF Intervals

Shifts in ECG interpretation and changes in QT, QTcB, and QTcF intervals , from baseline to post baseline. (NCT01726023)
Timeframe: EOT visit/any observation on treatment

Intervention	Number of patients (Number)
	Normal to Abnormal: EOT	Normal to Abnormal: Anytime up to EOT	Reaching a value in QT: ≥450 (ms)	Reaching a value in QT: ≥480 (ms)	Reaching a value in QT: ≥500 (ms)	QT: ≥500 and increase from Baseline ≥60(ms)	Increase in QT: ≥30 (ms)	Increase in QT: ≥60 (ms)	Decrease in QT: ≥30 (ms)	Decrease in QT: ≥60 (ms)	Reaching a value in QTcB: ≥450(ms)	Reaching a value in QTcB: ≥480(ms)	Reaching a value in QTcB: ≥500 (ms)	QTcB: ≥500 and increase from Baseline ≥60(ms)	Increase in QTcB: ≥30 (ms)	Increase in QTcB: ≥60 (ms)	Decrease in QTcB: ≥30 (ms)	Decrease in QTcB: ≥60 (ms)	Reaching a value in QTcF: ≥450 (ms)	Reaching a value in QTcF: ≥480 (ms)	Reaching a value in QTcF: ≥500 (ms)	QTcF: ≥500 and increase from Baseline ≥60 (ms)	Increase in QTcF: ≥30 (ms)	Increase in QTcF: ≥60 (ms)	Decrease QTcF: ≥30 (ms)	Decrease QTcF: ≥60 (ms)
Ceftazidime-Avibactam Plus Metronidazole	17	34	9	2	0	0	115	50	24	12	57	13	4	2	21	2	42	6	19	4	1	0	42	4	21	7
Meropenem	14	30	10	1	0	0	114	44	24	4	63	8	2	1	27	1	26	4	18	0	0	0	41	3	19	1

[back to top]

Safety and Tolerability: Clinical Laboratory Evaluation Hematology.

Potentially clinically significant (PCS) post Baseline hematology values up to LFU (Safety analysis set) (NCT01726023)
Timeframe: study duration (from screening to Day 49 LFU visit)

Intervention	Number of patients (Number)
	Platelet count: PCS (Low)	Platelet count: PCS (High)	Red blood cell count: PCS (Low)	Red blood cell count: PCS (High)	White blood cell: PCS (Low)	White blood cell: PCS (High)	Hemoglobin: PCS (Low)	Hemoglobin: PCS (High)	Lymphocytes: PCS (Low)	Lymphocytes: PCS (High)	Neutrophils: PCS (Low)	Neutrophils: PCS (High)	Eosinophils: PCS (High)	Monocytes: PCS (High)	Basophils: PCS (High)	Direct Coombs test:- at Baseline, + post-Baseline	Hematocrit (ratio): PCS (Low)	Hematocrit (ratio): PCS (High)
Ceftazidime-Avibactam Plus Metronidazole	1	5	7	0	1	4	7	0	1	0	4	9	0	0	0	15	5	0
Meropenem	1	4	13	0	1	5	14	0	1	1	2	8	0	0	0	2	8	0

[back to top]

Safety and Tolerability: Clinical Laboratory Evaluation Clinical Chemistry.

Potentially clinically significant (PCS) post Baseline clinical chemistry values up to LFU (Safety analysis set) (NCT01726023)
Timeframe: study duration (from screening to Day 49 LFU visit)

Intervention	Number of patients (Number)
	Alanine aminotransferase (μkat/L): PCS (High)	Alkaline phosphatase (μkat/L): PCS (Low)	Alkaline phosphatase (μkat/L): PCS (High)	Aspartate aminotransferase (μkat/L): PCS (High)	Bicarbonate (mmol/L) PCS (Low)	Bicarbonate (mmol/L): PCS (High)	Creatinine (μmol/L): PCS (High)	Glucose (non-fasting) (mmol/L): PCS (Low)	Glucose (non-fasting) (mmol/L): PCS (High)	Gamma-glutamyl transferase (μkat/L):PCS (High)	Inorganic phosphorus (mmol/L): PCS (Low)	Inorganic phosphorus (mmol/L): PCS (High)	Potassium (mmol/L): PCS (Low)	Potassium (mmol/L): PCS (High)	Total bilirubin (μmol/L): PCS (High)	Direct bilirubin (μmol/L): PCS (High)
Ceftazidime-Avibactam Plus Metronidazole	3	0	2	4	1	0	0	0	1	2	3	0	9	3	0	1
Meropenem	8	0	3	4	0	0	1	0	1	4	7	0	5	1	1	1

[back to top]

Safety and Tolerability by Incidence: Extent of Exposure.

Duration of exposure is calculated as the difference between the last study therapy date and the first study therapy date converted to days plus 1 day. Actual calculated duration could be shorter or longer than a full day. (NCT01726023)
Timeframe: study duration (from screening to Day 49 LFU visit)

Intervention	Number of patients (Number)
	1 - 2 days	3 - 4 days	5 -10 days	11 - 14 days	>14 days
Ceftazidime-Avibactam Plus Metronidazole	10	6	175	24	0
Meropenem	5	5	181	26	0

[back to top]

Safety and Tolerability by Incidence and Severity of Adverse Events and Serious Adverse Events and Mortality.

Adverse event data were collected from the screening/consent visit until the late follow-up visit (i.e. Day -1/0 to Day 42). (NCT01726023)
Timeframe: study duration (from screening to Day 49 LFU visit)

Intervention	Number of patients (Number)
	Any AE	Any SAE	Any AE leading to discontinuation of IP	Any AE of severe intensity	Total number of deaths	Deaths due to disease progression	Any AE with outcome=death
Ceftazidime-Avibactam Plus Metronidazole	82	9	7	5	2	2	0
Meropenem	83	11	3	5	1	0	1

[back to top]

The Time to First Defervescence in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set for Patients Who Have Fever at Study Entry.

Time to first defervescence was calculated for patients with a fever (>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. Time to first defervescence while on IV study therapy in the CE analysis set at TOC for patients who had fever at study entry is defined as time (in days) from the first dose of IV study therapy to first absence of fever. (NCT01726023)
Timeframe: while on study therapy (from Day 1 to Day 14)

Intervention	Days (Median)
Ceftazidime-Avibactam Plus Metronidazole	1
Meropenem	2

[back to top]

The Time to First Defervescence in the Clinically Evaluable (CE) Analysis Set for Patients Who Have Fever at Study Entry.

Intervention	Days (Median)
Ceftazidime-Avibactam Plus Metronidazole	1
Meropenem	1.5

[back to top]

Plasma Concentrations for Ceftazidime and Avibactam

Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations (NCT01726023)
Timeframe: At Day 3: Anytime within 15 minutes prior to or after stopping study drug, anytime between 30 and 90 minutes after stopping study drug, anytime between 300 minutes and 360 minutes after stopping study drug.

Intervention	ng/mL (Geometric Mean)
Ceftazidime(1)	60300.4
Avibactam(1)	10126.9
Ceftazidime(2)	46473.9
Avibactam(2)	7289.3
Ceftazidime(3)	9555.0
Avibactam(3)	1207.2

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

Intervention	Participants with favorable responses (Number)
	Escherichia coli (n=84, 89)	Klebsiella pneumoniae (n=28, 35)	Pseudomonas aeruginosa (n=17, 20)	Klebsiella oxytoca (n=5, 5)	Enterococcus faecalis (n=6, 6)	Enterococcus faecium (n=4, 7)	Streptococcus anginosus group (n=8, 7)	Streptococcus mitis group (n=6, 5)
Ceftazidime-Avibactam Plus Metronidazole	70	22	14	4	4	3	7	6
Meropenem	82	31	17	5	4	5	5	5

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

Intervention	Number of patients (Number)
	Favorable	Unfavorable
Ceftazidime-Avibactam Plus Metronidazole	92	7
Meropenem	107	6

[back to top]

The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.

The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

Intervention	Number of patients (Number)
	Clinical cure	Clinical failure
Ceftazidime-Avibactam Plus Metronidazole	92	7
Meropenem	107	6

[back to top]

The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

Intervention	Number of patients (Number)
	Clinical cure	Clinical failure	Indeterminate
Ceftazidime-Avibactam Plus Metronidazole	119	10	14
Meropenem	135	9	8

[back to top]

The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

Intervention	Number of patients (Number)
	Clinical cure	Clinical failure
Ceftazidime-Avibactam Plus Metronidazole	93	7
Meropenem	113	6

[back to top]

The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) Analysis Set.

Intervention	Number of patients (Number)
	Clinical cure	Clinical failure
Ceftazidime-Avibactam Plus Metronidazole	166	11
Meropenem	173	11

[back to top]

The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.

Intervention	Number of patients (Number)
	Clinical cure	Clinical failure
Ceftazidime-Avibactam Plus Metronidazole	89	7
Meropenem	100	6

[back to top]

The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

Intervention	Number of patients (Number)
	Clinical cure	Clinical failure	Indeterminate
Ceftazidime-Avibactam Plus Metronidazole	116	10	17
Meropenem	132	9	11

[back to top]

The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

Intervention	Number of patients (Number)
	Clinical cure	Clinical failure
Ceftazidime-Avibactam Plus Metronidazole	90	7
Meropenem	106	6

[back to top]

The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Clinically Evaluable (CE) Analysis Set.

Intervention	Number of patients (Number)
	Clinical cure	Clinical failure
Ceftazidime-Avibactam Plus Metronidazole	157	11
Meropenem	168	11

[back to top]

The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.

Intervention	Number of patients (Number)
	Clinical cure	Clinical failure
Ceftazidime-Avibactam Plus Metronidazole	103	3
Meropenem	113	5

[back to top]

The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

Intervention	Number of patients (Number)
	Clinical cure	Clinical failure	Indeterminate
Ceftazidime-Avibactam Plus Metronidazole	126	6	11
Meropenem	140	7	5

[back to top]

The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

Intervention	Number of patients (Number)
	Clinical cure	Clinical failure
Ceftazidime-Avibactam Plus Metronidazole	104	3
Meropenem	120	5

[back to top]

The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Clinically Evaluable (CE) Analysis Set.

Intervention	Number of patients (Number)
	Clinical cure	Clinical failure
Ceftazidime-Avibactam Plus Metronidazole	183	7
Meropenem	187	9

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

Intervention	Number of patients (Number)
	Favorable	Unfavorable	Indeterminate
Ceftazidime-Avibactam Plus Metronidazole	119	10	14
Meropenem	135	9	8

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

Intervention	Number of patients (Number)
	Favorable	Unfavorable
Ceftazidime-Avibactam Plus Metronidazole	93	7
Meropenem	113	6

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the late follow up (LFU) (Day 42 to 49)

Intervention	Number of patients (Number)
	Favorable	Unfavorable
Ceftazidime-Avibactam Plus Metronidazole	89	7
Meropenem	100	6

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the late follow up (LFU) (Day 42 to 49)

Intervention	Number of patients (Number)
	Favorable	Unfavorable	Indeterminate
Ceftazidime-Avibactam Plus Metronidazole	116	10	17
Meropenem	132	9	11

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the late follow up (LFU) (Day 42 to 49)

Intervention	Number of patients (Number)
	Favorable	Unfavorable
Ceftazidime-Avibactam Plus Metronidazole	90	7
Meropenem	106	6

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated." (NCT01726023)
Timeframe: At the end of treatment (EOT) (within 24 hours after last IV dose)

Intervention	Number of patients (Number)
	Favorable	Unfavorable
Ceftazidime-Avibactam Plus Metronidazole	103	3
Meropenem	113	5

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

Intervention	Number of patients (Number)
	Favorable	Unfavorable	Indeterminate
Ceftazidime-Avibactam Plus Metronidazole	126	6	11
Meropenem	140	7	5

[back to top]

The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.

Intervention	Number of patients (Number)
	Favorable	Unfavorable
Ceftazidime-Avibactam Plus Metronidazole	104	3
Meropenem	120	5

[back to top]

The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiologically Evaluable (ME) Analysis Set.

"The microbiological responses as per the protocoled criteria: responses other than indeterminate were classified as favorable or unfavorable. Favorable microbiological response assessments included eradication and presumed eradication. Unfavorable microbiological response assessments included persistence, persistence with increasing minimum inhibitory concentration (MIC), and presumed persistence. Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence)." (NCT01726023)
Timeframe: At the test of cure (TOC) (Day 28 to 35)

Intervention	Number of patients (Number)
	Favorable	Unfavorable
Ceftazidime-Avibactam Plus Metronidazole	22	1
Meropenem	23	1

[back to top]

The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

Intervention	Number of patients (Number)
	Favorable	Unfavorable	Indeterminate
Ceftazidime-Avibactam Plus Metronidazole	24	1	4
Meropenem	27	1	1

[back to top]

The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Extended Microbiologically Evaluable (ME) Analysis Set.

Intervention	Number of patients (Number)
	Favorable	Unfavorable
Ceftazidime-Avibactam Plus Metronidazole	22	1
Meropenem	25	1

[back to top]

The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.

Intervention	Participants with favorable responses (Number)
	Escherichia coli (n=84, 89)	Klebsiella oxytoca (n=5, 5)	Klebsiella pneumoniae (n=28,35)	Pseudomonas aeruginosa (n=17, 20)	Streptococcus anginosus group (n=8, 7)	Streptococcus mitis group (n=6, 5)	Enterococcus faecalis (n=6, 6)	Enterococcus faecium (n=4, 7)
Ceftazidime-Avibactam Plus Metronidazole	70	5	23	14	7	6	6	4
Meropenem	84	5	31	17	5	5	4	5

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set

The number of patients with a favorable per-pathogen microbiological response: favorable microbiological response includes: Eradication where, source specimen demonstrates absence of the original baseline pathogen. Presumed eradication where, source specimen was not available to culture and the patient was assessed as a clinical cure. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

Intervention	participants with favorable responses (Number)
	Enterobacter aerogenes (n=6, 5)	Enterobacter cloacae (n=21, 11)	Escherichia coli (n=10, 18)	Klebsiella pneumoniae (n=37, 47)	Proteus mirabilis (n=11, 8)	Serratia marcescens (n=12, 8)	Haemophilus influenzae (n=9, 12)	Pseudomonas aeruginosa (n=31, 28)	Staphylococcus aureus (n=13, 19)
CAZ-AVI	5	18	10	29	9	9	9	13	4
Meropenem	3	7	16	38	6	5	11	12	15

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit

Intervention	participants with favorable responses (Number)
	Enterobacter aerogenes (n=8, 8)	Enterobacter cloacae (n=26, 22)	Escherichia coli (n=17, 20)	Klebsiella pneumoniae (n=59, 71)	Proteus mirabilis (n=14, 12)	Serratia marcescens (n=15, 13)	Haemophilus influenzae (n=16, 25)	Pseudomonas aeruginosa (n=58, 47)	Staphylococcus aureus (n=24, 34)
CAZ-AVI	5	21	13	37	11	10	14	22	11
Meropenem	5	13	16	53	8	8	23	18	25

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set

Intervention	participants with favorable responses (Number)
	Enterobacter aerogenes (n=4, 2)	Enterobacter cloacae (n=6, 5)	Escherichia coli (n=6, 4)	Klebsiella pneumoniae (n=16, 28)	Pseudomonas aeruginosa (n=10, 13)
CAZ-AVI	3	6	5	14	8
Meropenem	2	5	4	25	6

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit

Intervention	participants with favorable responses (Number)
	Enterobacter aerogenes (n=4, 2)	Enterobacter cloacae (n=6, 6)	Escherichia coli (n=6, 5)	Klebsiella pneumoniae (n=20, 30)	Pseudomonas aeruginosa (n=11, 15)
CAZ-AVI	3	6	5	18	8
Meropenem	2	6	4	26	7

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set

Intervention	participants with favorable responses (Number)
	Enterobacter cloacae (n=5, 5)	Escherichia coli (n=5, 4)	Klebsiella pneumoniae (n=14, 22)	Pseudomonas aeruginosa (n=9, 13)
CAZ-AVI	4	4	11	3
Meropenem	4	4	14	3

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set

Intervention	participants with favorable responses (Number)
	Enterobacter cloacae (n=5, 5)	Escherichia coli (n=4, 4)	Klebsiella pneumoniae (n=14, 20)	Pseudomonas aeruginosa (n=3, 6)
CAZ-AVI	4	4	11	1
Meropenem	4	4	13	1

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit

Intervention	participants with favorable responses (Number)
	Enterobacter aerogenes (n=4, 2)	Enterobacter cloacae (n=6, 6)	Escherichia coli (n=6, 5)	Klebsiella pneumoniae (n=20, 30)	Pseudomonas aeruginosa (n=11, 15)
CAZ-AVI	3	5	4	15	4
Meropenem	2	5	4	18	4

[back to top]

The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set

The number of patients discharged from hospital in microbiologically modified intent-to-treat analysis set. (NCT01808092)
Timeframe: up to 25 days from randomization

Intervention	participants (Number)
	Number of patients with admission date	Number of patients with at least one discharge	1 discharge	2 discharges	>2 discharges
CAZ-AVI	170	71	71	0	0
Meropenem	182	75	74	1	0

[back to top]

The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in the Clinically Evaluable at Test-of-cure Analysis Set

The number of patients discharged from hospital in the clinically evaluable at test-of-cure analysis set. (NCT01808092)
Timeframe: up to 25 days from randomization

Intervention	participants (Number)
	Number of patients with admission date	Number of patients with at least one discharge	1 discharge	2 discharges	>2 discharges
CAZ-AVI	256	148	144	4	0
Meropenem	266	155	151	3	1

[back to top]

The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set

The number of patients discharged from hospital in the clinically modified intent-to-treat analysis set. (NCT01808092)
Timeframe: up to 25 days from randomization

Intervention	participants (Number)
	Number of patients with admission date	Number of patients with at least one discharge	1 discharge	2 discharges	>2 discharges
CAZ-AVI	355	206	201	5	0
Meropenem	366	206	200	4	2

[back to top]

The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set

"Per-patient favorable response indicates that all of the patient's baseline pathogens are eradicated or presumed eradicated. Eradication is defined as: source specimen demonstrates absence of the original baseline pathogen. Presumed eradication is defined as: source specimen was not available to culture and the patient was assessed as a clinical cure." (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

Intervention	participants (Number)
	Favorable	Unfavorable
CAZ-AVI	112	31
Meropenem	123	28

[back to top]

The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set

Intervention	participants (Number)
	Favorable	Unfavorable
CAZ-AVI	96	26
Meropenem	112	26

[back to top]

The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set

Intervention	participants (Number)
	Favorable	Unfavorable
CAZ-AVI	80	45
Meropenem	89	42

[back to top]

The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set

Intervention	participants (Number)
	Favorable	Unfavorable
CAZ-AVI	70	37
Meropenem	83	35

[back to top]

The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set

Intervention	participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	95	64	12
Meropenem	118	54	12

[back to top]

The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Clinically Evaluable Analysis Set

The number of patients meeting the cure criteria: the patient is alive and all signs and symptoms of pneumonia have resolved or improved such that all antibacterial therapies for Nosocomial Pneumonia are stopped. No antibacterial therapy other than those outlined by the protocol has been administered for Nosocomial Pneumonia prior to end of treatment. (NCT01808092)
Timeframe: Patients were followed after the last IV dose but no later than 24 hours after the last IV dose.

Intervention	participants (Number)
	Clinical cure	Clinical failure
CAZ-AVI	253	38
Meropenem	268	38

[back to top]

The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Clinically Modified Intent-to-treat Analysis Set

Intervention	participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	292	50	14
Meropenem	309	45	16

[back to top]

The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable Analysis Set

Intervention	participants (Number)
	Clinical cure	Clinical failure
CAZ-AVI	125	18
Meropenem	135	16

[back to top]

The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Microbiologically Evaluable Analysis Set

Intervention	participants (Number)
	Clinical cure	Clinical failure
CAZ-AVI	110	12
Meropenem	126	12

[back to top]

The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set

Intervention	participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	143	23	5
Meropenem	161	18	5

[back to top]

The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Evaluable at TOC Analysis Set (Co-primary Analyses)

The number of patients meeting the cure criteria: the patient was not a clinical failure at end of treatment and the patient is alive and all signs and symptoms of pneumonia have resolved or improved to an extent that no antibacterial therapy for Nosocomial Pneumonia was taken between end of treatment and test-of-cure inclusive. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

Intervention	participants (Number)
	Clinical cure	Clinical failure
CAZ-AVI	199	58
Meropenem	211	59

[back to top]

The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set (Co-primary Analyses)

Intervention	participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	245	79	32
Meropenem	270	70	30

[back to top]

The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Extended Microbiologically Evaluable Analysis Set

Intervention	participants (Number)
	Clinical cure	Clinical failure
CAZ-AVI	96	29
Meropenem	103	28

[back to top]

The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Microbiologically Evaluable Analysis Set

Intervention	participants (Number)
	Clinical cure	Clinical failure
CAZ-AVI	85	22
Meropenem	94	24

[back to top]

The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Microbiologically Modified Intent-to-treat Analysis Set

Intervention	participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	120	37	14
Meropenem	138	34	12

[back to top]

The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Clinically Evaluable at End of Treatment Analysis Set

Intervention	participants (Number)
	All (n=39, 49)	Enterobacteriaceae (n=29, 37)	Enterobacter aerogenes (n=4, 2)	Enterobacter cloacae (n=6, 5)	Escherichia coli (n=6, 4)	Klebsiella pneumoniae (n=16, 28)	Gram- pathogens not Enterobacteriaceae (n=10,14)	Pseudomonas aeruginosa (n=10, 13)
CAZ-AVI	35	27	3	6	5	16	8	8
Meropenem	42	31	2	3	3	25	13	12

[back to top]

The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Clinically Modified Intent-to-treat Analysis Set at End of Treatment Visit

Intervention	participants (Number)
	All (n=45, 54)	Enterobacteriaceae (n=34, 41)	Enterobacter aerogenes (n=4, 2)	Enterobacter cloacae (n=6, 6)	Escherichia coli (n=6, 5)	Klebsiella pneumoniae (n=20, 30)	Gram- pathogens not Enterobacteriaceae (n=11,16)	Pseudomonas aeruginosa (n=11, 15)
CAZ-AVI	40	32	3	6	5	20	8	8
Meropenem	45	33	2	4	3	26	14	13

[back to top]

The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set

Intervention	participants (Number)
	All (n=32, 40)	Enterobacteriaceae (n=28, 35)	Enterobacter aerogenes (n=4, 2)	Enterobacter cloacae (n=6, 5)	Escherichia coli (n=5, 4)	Klebsiella pneumoniae (n=16, 26)	Gram- pathogens not Enterobacteriaceae (n=4,7)	Pseudomonas aeruginosa (n=4, 6)
CAZ-AVI	31	27	3	6	5	16	4	4
Meropenem	36	31	2	3	3	25	7	6

[back to top]

The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Clinically Evaluable at Test-of-cure Analysis Set

Intervention	participants (Number)
	All (n=36, 41)	Enterobacteriaceae (n=27, 30)	Enterobacter cloacae (n=5, 5)	Escherichia coli (n=5, 4)	Klebsiella pneumoniae (n=14, 22)	Gram- pathogens not Enterobacteriaceae (n=9,13)	Pseudomonas aeruginosa (n=9, 13)
CAZ-AVI	29	23	5	4	12	6	6
Meropenem	32	22	3	3	17	12	12

[back to top]

The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Clinically Modified Intent-to-treat Analysis Set at Test-of-cure Visit

Intervention	participants (Number)
	All (n=45, 54)	Enterobacteriaceae (n=34, 41)	Enterobacter aerogenes (n=4, 2)	Enterobacter cloacae (n=6, 6)	Escherichia coli (n=6, 5)	Klebsiella pneumoniae (n=20, 30)	Gram- pathogens not Enterobacteriaceae (n=11,16)	Pseudomonas aeruginosa (n=11, 15)
CAZ-AVI	35	28	3	6	4	16	7	7
Meropenem	40	29	2	4	3	22	13	13

[back to top]

The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set

Intervention	participants (Number)
	All (n=29, 32)	Enterobacteriaceae (n=26, 28)	Enterobacter cloacae (n=5, 5)	Escherichia coli (n=4, 4)	Klebsiella pneumoniae (n=14, 20)	Gram- pathogens not Enterobacteriaceae (n=3,6)	Pseudomonas aeruginosa (n=3, 6)
CAZ-AVI	25	23	5	4	12	2	2
Meropenem	26	22	3	3	17	6	6

[back to top]

The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in Clinically Modified Intent-to-treat Analysis Set at Test-of-cure Visit

The number of patients with death due to any cause (all-cause mortality) in clinically modified intent-to-treat analysis set at test-of-cure visit. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

Intervention	participants (Number)
	Number of patients who died (all cause mortality)	Deaths due to disease progression	Number of patients with any AE with outcome=death	Number of patients alive	Number of patients with unknown survival status
CAZ-AVI	29	10	19	316	11
Meropenem	25	6	19	341	4

[back to top]

The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit

The number of patients with death due to any cause (all-cause mortality) in microbiologically modified intent-to-treat analysis set at test-of-cure visit. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

Intervention	participants (Number)
	Number of patients who died (all cause mortality)	Deaths due to disease progression	Number of patients with any AE with outcome=death	Number of patients alive	Number of patients with unknown survival status
CAZ-AVI	16	6	10	153	2
Meropenem	14	5	9	170	0

[back to top]

The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in the Clinically Evaluable at Test-of-cure Analysis Set

The number of patients with death due to any cause (all-cause mortality) in the clinically evaluable at test-of-cure analysis set. (NCT01808092)
Timeframe: At the test-of-cure (TOC) visit (Day 21 to 25)

Intervention	participants (Number)
	Number of patients who died (all cause mortality)	Deaths due to disease progression	Number of patients with any AE with outcome=death	Number of patients alive	Number of patients with unknown survival status
CAZ-AVI	11	5	6	245	1
Meropenem	8	4	4	262	0

[back to top]

The Number of Patients With Death Due to Any Cause (All-cause Mortality) in Clinically Modified Intent-to-treat Analysis Set at Day 28

The number of patients with death due to any cause (all-cause mortality) in clinically modified intent-to-treat analysis set at day 28. (NCT01808092)
Timeframe: at Day 28 from randomization

Intervention	participants (Number)
	Number of patients who died (all cause mortality)	Deaths due to disease progression	Number of patients with any AE with outcome=death	Number of patients alive	Number of patients with unknown survival status
CAZ-AVI	30	10	20	315	11
Meropenem	27	6	21	339	4

[back to top]

The Number of Patients With Death Due to Any Cause (All-cause Mortality) in Microbiologically Modified Intent-to-treat Analysis Set at Day 28

The number of patients with death due to any cause (all-cause mortality) in microbiologically modified intent-to-treat analysis set at day 28. (NCT01808092)
Timeframe: at Day 28 from randomization

Intervention	participants (Number)
	Number of patients who died (all cause mortality)	Deaths due to disease progression	Number of patients with any AE with outcome=death	Number of patients alive	Number of patients with unknown survival status
CAZ-AVI	17	6	11	152	2
Meropenem	16	5	11	168	0

[back to top]

The Number of Patients With Death Due to Any Cause (All-cause Mortality) in the Clinically Evaluable at Test-of-cure Analysis Set at Day 28

The number of patients with death due to any cause (all-cause mortality) in the clinically evaluable at test-of-cure analysis set at day 28. (NCT01808092)
Timeframe: at Day 28 from randomization

Intervention	participants (Number)
	Number of patients who died (all cause mortality)	Deaths due to disease progression	Number of patients with any AE with outcome=death	Number of patients alive	Number of patients with unknown survival status
CAZ-AVI	12	5	7	244	1
Meropenem	9	4	5	261	0

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set

Intervention	participants with favorable responses (Number)
	Enterobacter aerogenes (n=4, 2)	Enterobacter cloacae (n=6, 5)	Escherichia coli (n=5, 4)	Klebsiella pneumoniae (n=16, 26)	Pseudomonas aeruginosa (n=4, 6)
CAZ-AVI	3	6	5	14	3
Meropenem	2	5	4	23	1

[back to top]

The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set

Intervention	participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	128	38	5
Meropenem	148	31	5

[back to top]

Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set

Intervention	participants (Number)
	Favorable	Unfavorable
CAZ-AVI	31	9
Meropenem	36	13

[back to top]

Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set

Intervention	participants (Number)
	Favorable	Unfavorable
CAZ-AVI	26	7
Meropenem	29	11

[back to top]

Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit

Intervention	participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	35	10	1
Meropenem	39	13	2

[back to top]

Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set

Intervention	participants (Number)
	Favorable	Unfavorable
CAZ-AVI	23	14
Meropenem	21	20

[back to top]

Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set

Intervention	participants (Number)
	Favorable	Unfavorable
CAZ-AVI	21	9
Meropenem	18	14

[back to top]

Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit

Intervention	participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	27	16	3
Meropenem	27	23	4

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set

Intervention	participants with favorable responses (Number)
	Enterobacter aerogenes (n=6, 7)	Enterobacter cloacae (n=22, 17)	Escherichia coli (n=14, 18)	Klebsiella pneumoniae (n=46, 57)	Proteus mirabilis (n=9, 8)	Serratia marcescens (n=13, 10)	Haemophilus influenzae (n=14, 16)	Pseudomonas aeruginosa (n=50, 41)	Staphylococcus aureus (n=18, 26)
CAZ-AVI	4	22	13	39	8	12	14	30	16
Meropenem	5	17	17	53	6	8	16	24	25

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set

Intervention	participants with favorable responses (Number)
	Enterobacter aerogenes (n=6, 7)	Enterobacter cloacae (n=22, 17)	Escherichia coli (n=13, 18)	Klebsiella pneumoniae (n=45, 55)	Proteus mirabilis (n=9, 8)	Serratia marcescens (n=13, 10)	Haemophilus influenzae (n=12, 15)	Pseudomonas aeruginosa (n=38, 34)	Staphylococcus aureus (n=16, 23)
CAZ-AVI	4	22	13	38	8	12	12	22	14
Meropenem	5	17	17	51	6	8	15	19	22

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit

Intervention	participants with favorable responses (Number)
	Enterobacter aerogenes (n=8, 8)	Enterobacter cloacae (n=26, 22)	Escherichia coli (n=17, 20)	Klebsiella pneumoniae (n=59, 71)	Proteus mirabilis (n=14, 12)	Serratia marcescens (n=15, 13)	Haemophilus influenzae (n=16, 25)	Pseudomonas aeruginosa (n=58, 47)	Staphylococcus aureus (n=24, 34)
CAZ-AVI	6	25	15	49	12	12	15	33	21
Meropenem	5	20	18	65	10	11	25	27	32

[back to top]

The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set

Intervention	participants with favorable responses (Number)
	Enterobacter aerogenes (n=6, 5)	Enterobacter cloacae (n=21, 11)	Escherichia coli (n=11, 18)	Klebsiella pneumoniae (n=37, 49)	Proteus mirabilis (n=11, 8)	Serratia marcescens (n=12, 8)	Haemophilus influenzae (n=11, 13)	Pseudomonas aeruginosa (n=42, 35)	Staphylococcus aureus (n=14, 22)
CAZ-AVI	5	18	10	29	9	9	11	18	5
Meropenem	3	7	16	39	6	5	12	14	17

[back to top]

Percentage of Participants With Favorable Clinical Response (CR) at End of Treatment (EOT) Visit: Intent-to-treat (ITT) Analysis Population

Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required. EOT visit occurred within 48 hours after completion of the last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study (if on oral switch therapy). (NCT02475733)
Timeframe: EOT visit (up to Day 17)

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	91.8
Meropenem	100

[back to top]

Percentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)

Percentage of participants with Cephalosporin class effects (defined as adverse event of special interest (AEoSI) within the safety topics (ST) of hypersensitivity/anaphylaxis) and additional AEs (which included AEs of seizures, diarrhea, renal disorder, and liver disorder relevant to the cephalosporin class within the ST and AEs with preferred term in the system organ class of nervous system disorder system organ class based on MedDRA 20.0) were reported in this outcome measure. (NCT02475733)
Timeframe: Baseline until the LFU visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	AE in the ST of Diarrhea	AEoSI in the ST of Hypersensitivity/Anaphylaxis	AE in the ST of Liver Disorder	AE in the ST of Renal Disorder	AEs with PTs in the Nervous System Disorder SOC	AE of seizure
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	1.6	4.9	0	0	1.6	0
Meropenem	0	13.6	0	0	4.5	0

[back to top]

Percentage of Participants With Creatinine Clearance (CrCl) at Day 7

CrCl is a measure of glomerular filtration rate (GMFR), an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: <30 mL/min/1.73 m^2, >=30 to <50 mL/min/1.73 m^2, >=50 mL/min/1.73 m^2 to <80 mL/min/1.73 m^2, and >=80 mL/min/1.73 m^2. (NCT02475733)
Timeframe: Day 7

Intervention	percentage of participants (Number)
	CrCl: <30mL/min/1.73 m^2	CrCl: >=30 to <50mL/min/1.73 m^2	CrCl: >=50 to <80mL/min/1.73 m^2	CrCl: >=80mL/min/1.73 m^2
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	0	0	0	50.8
Meropenem	0	0	0	59.1

[back to top]

Percentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Therapy (EOIV) Visit

CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: <30 mL/min/1.73 m^2, >=30 to <50 mL/min/1.73 m^2, >=50 mL/min/1.73 m^2 to <80 mL/min/1.73 m^2, and >=80 mL/min/1.73 m^2. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: EOIV visit (anytime from Day 4 up to 16)

Intervention	percentage of participants (Number)
	CrCl: <30mL/min/1.73 m^2	CrCl: >=30 to <50mL/min/1.73 m^2	CrCl: >=50 to <80mL/min/1.73 m^2	CrCl: >=80mL/min/1.73 m^2
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	0	0	0	82.0
Meropenem	0	0	0	81.8

[back to top]

Percentage of Participants With Creatinine Clearance (CrCl) at Late Follow-up (LFU) Visit

CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: <30 mL/min/1.73 m^2, >=30 to <50 mL/min/1.73 m^2, >=50 mL/min/1.73 m^2 to <80 mL/min/1.73 m^2, and >=80 mL/min/1.73 m^2. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral). (NCT02475733)
Timeframe: LFU visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	CrCl: <30mL/min/1.73 m^2	CrCl: >=30 to <50mL/min/1.73 m^2	CrCl: >=50 to <80mL/min/1.73 m^2	CrCl: >=80mL/min/1.73 m^2
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	0	0	1.6	6.6
Meropenem	0	0	0	9.1

[back to top]

Percentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit

CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: <30 mL/min/1.73 m^2, >=30 to <50 mL/min/1.73 m^2, >=50 mL/min/1.73 m^2 to <80 mL/min/1.73 m^2, and >=80 mL/min/1.73 m^2. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). (NCT02475733)
Timeframe: TOC visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	CrCl: <30mL/min/1.73 m^2	CrCl: >=30 to <50mL/min/1.73 m^2	CrCl: >=50 to <80mL/min/1.73 m^2	CrCl: >=80mL/min/1.73 m^2
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	0	0	3.3	42.6
Meropenem	0	0	0	59.1

[back to top]

Percentage of Participants With Electrocardiogram (ECG) Parameter QTcF: > 450, >480 and >500 Millisecond (ms)

ECG parameters included maximum QT intervals using Fridericia's correction (QTcF). Maximum QTcF >450 millisecond (ms); maximum QTcF >480 ms; and maximum QTcF >500 ms. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: Baseline until the EOIV visit (anytime from Day 4 to 16)

Intervention	percentage of participants (Number)
	Maximum QTcF Interval : >450 ms	Maximum QTcF Interval : >480 ms	Maximum QTcF Interval : >500 ms
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	1.6	1.6	0
Meropenem	4.5	4.5	4.5

[back to top]

Percentage of Participants With Favorable Clinical Response (CR): Clinically Evaluable (CE) Analysis Population

Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required, or improvement in participants who had switch to oral therapy and met the following criterion: afebrile (temperature <=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reative-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study (if on oral switch therapy). TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). (NCT02475733)
Timeframe: End of 72 hours study drug treatment on Day 1, EOIV (anytime from Day 4 up to 16), EOT visit (up to Day 17) and TOC visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	End 72 hours study medication	EOIV	EOT	TOC
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	98.0	98.1	94.2	92.9
Meropenem	95.0	100	100	95.0

[back to top]

Percentage of Participants With Favorable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population

Favorable microbiological response was achieved when all baseline pathogens were eradicated or presumed eradicated based on investigator's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 15 days). EOIV visit occurred within 24 hours after completion of last infusion of the study drug. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral). (NCT02475733)
Timeframe: EOIV visit (Day 4 up to 16), EOT visit (up to Day 17), TOC visit (up to a maximum study duration of 50 days) and LFU visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	EOIV	EOT	TOC	LFU
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	96.0	90.0	90.0	90.0
Meropenem	100	100	94.7	94.7

[back to top]

Percentage of Participants With Favorable Microbiological Response: Microbiologically Evaluable (ME) Population

Favorable microbiological response was achieved when all baseline pathogens were eradicated or presumed eradicated based on investigator's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 15 days). TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral). (NCT02475733)
Timeframe: EOIV visit (Day 4 up to 16), EOT visit (up to Day 17), TOC visit (up to a maximum study duration of 50 days) and LFU visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	EOIV	EOT	TOC	LFU
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	97.5	91.7	90.0	89.2
Meropenem	100	100	93.3	92.9

[back to top]

Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters

Criteria for potentially clinically significant laboratory abnormalities: Chemistry (calcium: <0.7*lower limit of normal range [LLN] and >30 percent decrease from baseline [DFB]; alanine aminotransferase [ALT]: >3*upper limit of normal range [ULN] and >300 percent IFB; alanine aminotransferase [AST]: >3*ULN and >300 percent IFB) and hematology (platelets: >2*ULN and >100 percent IFB). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral). (NCT02475733)
Timeframe: Baseline until the LFU visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	Chemistry: Calcium	Chemistry: ALT	Chemistry: AST	Hematology: Platelets
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	1.9	1.7	1.8	3.3
Meropenem	0	0	0	0

[back to top]

Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to late follow-up (LFU) visit (20 to 35 days after last dose of study treatment [IV or oral]) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE. (NCT02475733)
Timeframe: Baseline until the LFU visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	AEs	SAEs
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	52.5	8.2
Meropenem	59.1	4.5

[back to top]

Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Population

A participant was said to have clinical relapse if met either 1 of the following criteria: reappearance or worsening of signs and symptoms of cIAI that required further antimicrobial therapy and/or surgery, or death after TOC in which cIAI was contributory. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral). (NCT02475733)
Timeframe: LFU visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	0
Meropenem	0

[back to top]

Plasma Concentrations of Ceftazidime and Avibactam

(NCT02475733)
Timeframe: 15, 30-90, 300-360 minutes post-dose on Day 3

Intervention	nanogram per milliliter (Geometric Mean)
	Ceftazidime: 15 minute post-dose on Day 3	Ceftazidime: 30-90 minute post-dose on Day 3	Ceftazidime:300-360minute post-dose on Day 3	Avibactam: 15 minute post-dose on Day 3	Avibactam: 30-90 minute post-dose on Day 3	Avibactam: 300-360 minute post-dose on Day 3
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	63565.5	38048.0	4603.0	12186.2	6548.6	821.5

[back to top]

Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Population

A participant was said to have clinical relapse if me either 1 of the following criteria: reappearance or worsening of signs and symptoms of cIAI that required further antimicrobial therapy and/or surgery, or death after TOC in which cIAI was contributory. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral). (NCT02475733)
Timeframe: LFU visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	0
Meropenem	0

[back to top]

Percentage of Participants With Emergent Infections at Test of Cure (TOC) Visit: Microbiologically Evaluable Population

Emergent Infections was an intra-abdominal culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy, new infection was an intra-abdominal culture identified pathogen other than a baseline pathogen at any time after study treatment has finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). Participants with any (super infections or new infections) of the infections were reported. (NCT02475733)
Timeframe: TOC visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	0
Meropenem	0

[back to top]

Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population

Emergent infections were categorized as super infections and new infections. Superinfection: An intra-abdominal culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. New infection: An intra-abdominal culture identified pathogen other than a baseline pathogen at any time after study treatment had finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. Participants with any (super infections or new infections) of the infections were reported. (NCT02475733)
Timeframe: Baseline up to 50 days

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	0
Meropenem	0

[back to top]

Percentage of Participants With Favorable Clinical Response (CR) at End of 72 Hours Treatment: Intent-to-treat (ITT) Analysis Population

Favorable CR was defined as resolution of all acute signs and symptoms of complicated intra- abdominal infection (cIAIs), or improvement to such an extent that no further antimicrobial therapy was required, or improvement but not enough to switch to oral therapy and still on IV study drug at end of 72 hours and had met following criterion: absence of new signs and symptoms, improvement in at least 1 symptom/sign (fever, pain, tenderness, elevated White Blood Cells [WBCs], elevated c-reactive protein) from baseline and no worsening symptom/sign. (NCT02475733)
Timeframe: End of 72 hours study drug treatment on Day 1

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	93.4
Meropenem	90.9

[back to top]

Percentage of Participants With Favorable Clinical Response (CR) at End of Intravenous Therapy (EOIV) Visit: Intent-to-treat (ITT) Analysis Population

Favorable CR was resolution of all acute signs and symptoms of cIAI or improvement to such an extent that no further antimicrobial therapy was required, or improvement in participants who had switch to oral therapy and met the following criterion: afebrile (temperature <=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reative-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: EOIV visit (anytime from Day 4 up to 16)

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	96.7
Meropenem	100

[back to top]

Percentage of Participants With Favorable Clinical Response (CR) at Test of Cure (TOC) Visit: Intent-to-treat (ITT) Analysis Population

Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). (NCT02475733)
Timeframe: TOC visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	91.8
Meropenem	95.5

[back to top]

Change From Baseline in Body Temperature at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: Baseline, EOIV visit (anytime from Day 4 up to 16)

Intervention	degree Celsius (Mean)
	Baseline	Change at EOIV
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	37.35	-0.78
Meropenem	37.16	-0.60

[back to top]

Change From Baseline in Body Weight at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: Baseline, EOIV visit (anytime from Day 4 up to 16)

Intervention	kilograms (Mean)
	Baseline	Change at EOIV
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	40.58	-0.38
Meropenem	38.35	-1.06

[back to top]

Change From Baseline in Pulse Rate at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: Baseline, EOIV visit (anytime from Day 4 up to 16)

Intervention	beats per minute (Mean)
	Baseline	Change at EOIV
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	102.1	-15.2
Meropenem	103.0	-15.4

[back to top]

Change From Baseline in Respiratory Rate at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: Baseline, EOIV visit (anytime from Day 4 up to 16)

Intervention	breaths per minute (Mean)
	Baseline	Change at EOIV
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	22.4	-1.3
Meropenem	22.9	-1.3

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: Baseline, EOIV visit (anytime from Day 4 up to 16)

Intervention	millimeter of mercury (mmHg) (Mean)
	SBP: Baseline	SBP: Change at EOIV	DBP: Baseline	DBP: Change at EOIV
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	109.7	-4.0	63.5	1.3
Meropenem	111.6	-6.0	63.1	-2.8

[back to top]

Percentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Therapy (EOIV) Visit

Physical examination included an assessment of the following: general appearance, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, respiratory system, cardiovascular system, abdomen, musculoskeletal system (including spine and extremities), and neurological system. Participants with new or aggravated abnormal physical examination findings with regard to baseline findings were reported. Abnormality in physical examinations were based on blinded observer's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02475733)
Timeframe: EOIV visit (anytime from Day 4 up to 16)

Intervention	percentage of participants (Number)
	Abdomen	Cardiovascular System	General Appearance	Head and Neck	Lymph Nodes	Musculoskeletal System	Neurological System	Respiratory System	Skin	Thyroid
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole	6.6	0	1.6	0	0	0	0	3.3	1.6	0
Meropenem	18.2	0	0	0	0	0	0	0	0	0

[back to top]

Change From Baseline in Body Weight at End of Intravenous Treatment (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02497781)
Timeframe: Baseline, EOIV visit (anytime from Day 4 to 15)

Intervention	kilogram (Mean)
	Baseline	Change at EOIV
Cefepime	25.24	0.14
Ceftazidime- Avibactam (CAZ-AVI)	24.55	-0.08

[back to top]

Change From Baseline in Body Temperature at End of Intravenous Treatment (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02497781)
Timeframe: Baseline, EOIV visit (anytime from Day 4 to 15)

Intervention	degree Celsius (Mean)
	Baseline	Change at EOIV
Cefepime	37.49	-0.90
Ceftazidime- Avibactam (CAZ-AVI)	37.67	-1.15

[back to top]

Percentage of Participants With Favourable Clinical Response (CR) at TOC: Clinically Evaluable (CE) Analysis Set at TOC

Favourable clinical response was defined as resolution of all acute signs/symptoms of cUTIs or improvement to such an extent that no further antimicrobial therapy was needed. Participants who met the following criterion: Incomplete resolution or worsening of cUTI signs or symptoms or development of new signs or symptoms requiring alternative non-study antimicrobial therapy or death in which cUTI was contributory. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). (NCT02497781)
Timeframe: TOC visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI)	93.9
Cefepime	85.0

[back to top]

Percentage of Participants With Favourable Clinical Response (CR) at End of Treatment (EOT) Visit: Clinically Evaluable (CE) Analysis Set at EOT

Favourable clinical response was defined as a CR cure. Cure was defined as resolution of all acute signs and symptoms of complicated urinary tract infections (cUTIs) or improvement to such an extent that no further antimicrobial therapy was required. EOT visit occurred within 48hr after completion of the last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study(if on oral switch therapy). (NCT02497781)
Timeframe: EOT visit (up to Day 16)

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI)	98.0
Cefepime	94.7

[back to top]

Percentage of Participants With Favourable Clinical Response (CR) at End of Intravenous Treatment (EOIV) Visit: Clinically Evaluable (CE) Analysis Set at EOIV

Favourable clinical response was defined as a CR of improvement and cure. Cure was defined as resolution of all acute signs and symptoms of complicated urinary tract infections (cUTIs) or improvement to such an extent that no further antimicrobial therapy was required. Clinical Improvement included all the participants who had switched to oral therapy and had meet the following criterion: afebrile (temperature <=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reactive-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02497781)
Timeframe: EOIV visit (anytime from Day 4 to 15)

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI)	98.1
Cefepime	95.5

[back to top]

Percentage of Participants With Favourable Clinical Response (CR) at End of 72 Hours Treatment: Clinically Evaluable (CE) Analysis Set at 72 Hours

Favourable clinical response was defined as a CR of improvement and cure. Cure was defined as resolution of all acute signs and symptoms of complicated urinary tract infections (cUTIs) or improvement to such an extent that no further antimicrobial therapy was required. Clinical Improvement included all the participants who had improvement but not enough to switch to oral therapy and were still on IV study drug at End of 72 hours and had meet the following criterion: absence of new signs and symptoms, and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated CRP) from baseline, and with no worsening of any symptom or sign. (NCT02497781)
Timeframe: End of 72 hours study drug treatment on Day 1

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI)	100
Cefepime	95.2

[back to top]

Percentage of Participants With Emergent Infections: Microbiologically Evaluable (ME) Analysis Population

Emergent infections were categorized as super-infection and new infections. Superinfection: A urine culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. New infection: A urine culture identified pathogen other than a baseline pathogen at any time after study treatment had finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. Percentage of participants with any (super infections or new infections) of the infections were reported. (NCT02497781)
Timeframe: Baseline up to 50 days

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI)	7.3
Cefepime	0

[back to top]

Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI)	5.6
Cefepime	0

[back to top]

Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Analysis Set at LFU

A participant was said to have clinical relapse if met either 1 of the following criteria: reappearance or worsening of signs and symptoms of cUTI that required further antimicrobial therapy and/or surgery, or death after TOC in which cUTI was contributory. LFU visit occurred within 20 to 36 days after last dose of study treatment (IV or oral). (NCT02497781)
Timeframe: LFU visit (anytime up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI)	12.5
Cefepime	0

[back to top]

Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Analysis Set at LFU

A participant was said to have clinical relapse if met either 1 of the following criteria: reappearance or worsening of signs and symptoms of cUTI that required further antimicrobial therapy and/or surgery or death after TOC in which cUTI was contributory. LFU visit occurred within 20 to 36 days after last dose of study treatment (IV or oral). (NCT02497781)
Timeframe: LFU visit (anytime up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
Ceftazidime- Avibactam (CAZ-AVI)	6.8
Cefepime	0

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Treatment (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02497781)
Timeframe: Baseline, EOIV visit (anytime from Day 4 to 15)

Intervention	millimeter of mercury (mmHg) (Mean)
	SBP: Baseline	SBP: Change at EOIV	DBP: Baseline	DBP: Change at EOIV
Cefepime	111.9	-5.4	69.1	-5.0
Ceftazidime- Avibactam (CAZ-AVI)	105.6	-1.0	62.6	0.9

[back to top]

Percentage of Participants With Favourable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population

Favourable microbiological response was achieved when all baseline pathogens were eradicated. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of the last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 14 days). (NCT02497781)
Timeframe: EOIV visit (Day 4 to 15), EOT visit(up to Day 16)

Intervention	percentage of participants (Number)
	EOIV	EOT
Cefepime	78.3	73.9
Ceftazidime- Avibactam (CAZ-AVI)	81.5	83.3

[back to top]

Percentage of Participants With Favourable Clinical Response (CR): Microbiologically Evaluable (ME) Analysis Population

Favorable CR was defined as a CR of improvement and cure(at end of 72 hours(hr) and EOIV) and a CR of cure(at EOT and TOC).Cure is resolution of all acute signs/symptoms of cUTI/improvement to such an extent that no further antimicrobial therapy required.Improvement is:1)at end of 72hr study drug treatment: improvement but not enough to switch to oral therapy and still on IV study drug at end of 72hr and meet following criterion: Absence of new signs/symptoms, and improvement in at least 1 symptom/sign(ie, fever,pain,tenderness,elevated WBCs,elevated CRP) from Baseline,and with no worsening of any symptom/sign. 2) at EOIV: participants who switched to oral therapy and had afebrile(temperature<=38.0°C) for >=24hr;absence of new and improvement in at least 1 symptom/sign from Baseline and worsening of none.EOT visit occurred within 48hr after completion of the last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study(if on oral switch therapy). (NCT02497781)
Timeframe: EOIV visit (anytime from Day 4 to 15), EOT visit (up to Day 16), TOC visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	EOIV	EOT	TOC
Cefepime	100	100	87.5
Ceftazidime- Avibactam (CAZ-AVI)	100	100	92.7

[back to top]

Percentage of Participants With Favourable Combined Response: Microbiological Intent-to-treat (Micro-ITT) Population

Combined response was the combined assessment of clinical response and microbiological response. Favorable clinical response was defined as a clinical response of improvement and cure (at EOIV) and a clinical response of cure (at TOC). Cure defined as: resolution of all acute signs/symptoms of cUTI/improvement to such an extent that no further antimicrobial therapy required. Improvement defined as: participants who switched to oral therapy and had afebrile (temperature<=38.0°C) for >=24 hr; absence of new and improvement in at least 1 symptom or sign (ie, fever, pain, tenderness, elevated WBCs, elevated CRP) from Baseline and worsening of none. Favourable microbiological response was absence of the original baseline pathogen in source specimen. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). (NCT02497781)
Timeframe: EOIV visit (Day 4 to 15), TOC visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	Favourable at EOIV	Favourable at TOC
Cefepime	78.3	60.9
Ceftazidime- Avibactam (CAZ-AVI)	79.6	72.2

[back to top]

Change From Baseline in Pulse Rate at End of Intravenous Treatment (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02497781)
Timeframe: Baseline, EOIV visit (anytime from Day 4 to 15)

Intervention	beats per minute (Mean)
	Baseline	Change at EOIV
Cefepime	119.1	-17.1
Ceftazidime- Avibactam (CAZ-AVI)	111.5	-11.9

[back to top]

Percentage of Participants With Favourable Clinical Response (CR): Microbiological ITT (Micro-ITT) Analysis Population

Favorable CR was defined as a CR of improvement and cure(at end of 72 hours(hr) and EOIV) and a CR of cure(at EOT and TOC).Cure is resolution of all acute signs/symptoms of cUTI/improvement to such an extent that no further antimicrobial therapy required.Improvement is:1)at end of 72hr study drug treatment: improvement but not enough to switch to oral therapy and still on IV study drug at end of 72hr and meet following criterion: Absence of new signs/symptoms, and improvement in at least 1 symptom/sign(ie, fever,pain,tenderness,elevated WBCs,elevated CRP) from Baseline,and with no worsening of any symptom/sign. 2) at EOIV: participants who switched to oral therapy and had afebrile(temperature<=38.0°C) for >=24hr;absence of new and improvement in at least 1 symptom/sign from Baseline and worsening of none.EOT visit occurred within 48hr after completion of the last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study(if on oral switch therapy). (NCT02497781)
Timeframe: End of 72 hours study drug treatment, EOIV visit (anytime from Day 4 to 15), EOT visit (up to Day 16), TOC visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	End of 72 hours	EOIV	EOT	TOC
Cefepime	95.7	95.7	95.7	82.6
Ceftazidime- Avibactam (CAZ-AVI)	90.7	96.3	90.7	88.9

[back to top]

Percentage of Participants With Favourable Microbiological Response: Microbiologically Evaluable (ME) Analysis Population

Intervention	percentage of participants (Number)
	EOIV	EOT
Cefepime	100	100
Ceftazidime- Avibactam (CAZ-AVI)	97.1	97.4

[back to top]

Percentage of Participants With Favourable Clinical Response (CR): Intent-to-treat (ITT) Analysis Population

Favorable CR was defined as a CR of improvement and cure(at end of 72 hours(hr) and EOIV) and a CR of cure(at EOT and TOC).Cure is resolution of all acute signs/symptoms of cUTI/improvement to such an extent that no further antimicrobial therapy required.Improvement is:1)at end of 72hr study drug treatment: improvement but not enough to switch to oral therapy and still on IV study drug at end of 72hr and meet following criterion: Absence of new signs/symptoms, and improvement in at least 1 symptom/sign(ie, fever,pain,tenderness,elevated WBCs,elevated CRP) from Baseline,and with no worsening of any symptom/sign. 2) at EOIV: participants who switched to oral therapy and had afebrile(temperature<=38.0°C) for >=24hr;absence of new and improvement in at least 1 symptom/sign from Baseline and worsening of none.EOT visit occurred within 48hr after completion of the last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study(if on oral switch therapy). (NCT02497781)
Timeframe: End of 72 hours study drug treatment, EOIV visit (anytime from Day 4 to 15), EOT visit (up to Day 16), TOC visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	End of 72 hours	EOIV	EOT	TOC
Cefepime	86.2	89.7	89.7	82.8
Ceftazidime- Avibactam (CAZ-AVI)	88.2	91.2	88.2	86.8

[back to top]

Percentage of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters

PCS criteria for abnormal value of ECG parameters: QT interval >=450 milliseconds (msec); 480 msec; >=500 msec; Increase from baseline (IFB) of >=30 msec; >=60 msec and >90 msec; Decrease from baseline (DFB) of >=30 msec; >=60 msec and >90 msec. QT interval using Bazett's correction (QTcB): >=450 milliseconds (msec); 480 msec; >=500 msec; Increase from baseline (IFB) of >=30 msec; >=60 msec and >90 msec; DFB of >=30 msec; >=60 msec and >90 msec. QT interval using Fridericia's correction (QTcF): >=450 msec; 480 msec; >=500 msec; IFB of >=30 msec; >=60 msec and >90 msec; DFB of >=30 msec; >=60 msec and >90 msec. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02497781)
Timeframe: Baseline until the EOIV visit (anytime from Day 4 to 15)

Intervention	percentage of participants (Number)
	QT Interval : >450 msec	QT Interval : >480 msec	QT Interval : >500 msec	Maximum IFB QT Interval : > 30 msec	Maximum IFB QT Interval : > 60 msec	Maximum IFB QT Interval : >90 msec	Maximum DFB QT Interval : > 30 msec	Maximum DFB QT Interval : > 60 msec	Maximum DFB QT Interval : > 90 msec	QTcB Interval : >450 msec	QTcB Interval : >480 msec	QTcB Interval : >500 msec	Maximum IFB QTcB Interval : > 30 msec	Maximum IFB QTcB Interval : > 60 msec	Maximum IFB QTcB Interval : > 90 msec	Maximum DFB QTcB Interval : > 30 msec	Maximum DFB QTcB Interval : > 60 msec	Maximum DFB QTcB Interval : > 90 msec	QTcF Interval : >450 msec	QTcF Interval : >480 msec	QTcF Interval : >500 msec	Maximum IFB QTcF Interval : > 30 msec	Maximum IFB QTcF Interval : > 60 msec	Maximum IFB QTcF Interval : > 90 msec	Maximum DFB QTcF Interval : > 30 msec	Maximum DFB QTcF Interval : > 60 msec	Maximum DFB QTcF Interval : > 90 msec
Cefepime	0	0	0	14.3	3.6	0	17.9	0	0	3.6	0	0	14.3	3.6	0	7.1	3.6	3.6	0	0	0	14.3	3.6	0	10.7	3.6	0
Ceftazidime- Avibactam (CAZ-AVI)	0	0	0	19.4	7.5	3.0	9.0	4.5	1.5	16.4	11.9	7.5	17.9	7.5	3.0	10.4	6.0	1.5	6.0	6.0	6.0	17.9	3.0	3.0	9.0	3.0	1.5

[back to top]

Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters

Criteria for potentially clinically significant laboratory abnormalities: hematology (platelets: <0.4*lower limit of normal [LLN], >2*upper limit of normal [ULN], >40% decrease from baseline [DFB],>100% Increase from baseline [IFB]; Chemistry (Bicarbonate: <0.7*LLN, >1.3*ULN, >50% DFB, >30% IFB). (NCT02497781)
Timeframe: Baseline until the LFU visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	Chemistry: Bicarbonate	Hematology: Platelets
Cefepime	0	0
Ceftazidime- Avibactam (CAZ-AVI)	2.0	1.6

[back to top]

Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to late follow-up (LFU) visit (20 to 36 days after last dose of study treatment [IV or oral]) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE. (NCT02497781)
Timeframe: Baseline until the LFU visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	AEs	SAEs
Cefepime	53.6	7.1
Ceftazidime- Avibactam (CAZ-AVI)	53.7	11.9

[back to top]

Plasma Concentrations of Ceftazidime and Avibactam

(NCT02497781)
Timeframe: 15, 30-90, 300-360 minutes post-dose on Day 3

Intervention	nanogram per milliliter (Geometric Mean)
	Ceftazidime: 15 minute post-dose on Day 3	Ceftazidime: 30-90 minute post-dose on Day 3	Ceftazidime:300-360minute post-dose on Day 3	Avibactam: 15 minute post-dose on Day 3	Avibactam: 30-90 minute post-dose on Day 3	Avibactam: 300-360 minute post-dose on Day 3
Ceftazidime- Avibactam (CAZ-AVI)	61411.2	47638.5	7285.7	9577.4	7046.4	936.3

[back to top]

Percentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Treatment (EOIV) Visit

Intervention	percentage of participants (Number)
	CrCl: <30mL/min/1.73 m^2	CrCl: >=30 to <50mL/min/1.73 m^2	CrCl: >=50 to <80mL/min/1.73 m^2	CrCl: >=80mL/min/1.73 m^2
Cefepime	0	0	13.6	86.4
Ceftazidime- Avibactam (CAZ-AVI)	0	0	20.0	80.0

[back to top]

Percentage of Participants With Creatinine Clearance (CrCl) at Day 7

Intervention	percentage of participants (Number)
	CrCl: <30mL/min/1.73 m^2	CrCl: >=30 to <50mL/min/1.73 m^2	CrCl: >=50 to <80mL/min/1.73 m^2	CrCl: >=80mL/min/1.73 m^2
Cefepime	0	0	0	100
Ceftazidime- Avibactam (CAZ-AVI)	0	0	11.1	88.9

[back to top]

Percentage of Participants With Combined Response: Microbiologically Evaluable (ME) Analysis Population

Intervention	percentage of participants (Number)
	Favourable at EOIV	Favourable at TOC
Cefepime	100	68.8
Ceftazidime- Avibactam (CAZ-AVI)	97.1	80.5

[back to top]

Percentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)

Percentage of participants with Cephalosporin class effects (defined as adverse event of special interest (AEoSI) within the safety topics (ST) of hypersensitivity/anaphylaxis) and additional AEs (which included AEs of diarrhea, renal disorder, hematological disorder and liver disorder relevant to the cephalosporin class within the safety topics (ST) based on MedDRA 20.0) were reported in this outcome measure. (NCT02497781)
Timeframe: Baseline until the LFU visit (up to a maximum study duration of 50 days)

Intervention	percentage of participants (Number)
	AE in the ST of Diarrhea	AE in the ST of Hematological Disorders	AEoSI in the ST of Hypersensitivity/Anaphylaxis	AE in the ST of Liver Disorder	AE in the ST of Renal Disorder
Cefepime	10.7	0	7.1	0	0
Ceftazidime- Avibactam (CAZ-AVI)	7.5	0	7.5	1.5	0

[back to top]

Percentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Treatment (EOIV) Visit

Physical examination included an assessment of the following: general appearance, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, respiratory system, cardiovascular system, abdomen, musculoskeletal system (including spine and extremities), and neurological system. Participants with new or aggravated abnormal physical examination findings with regard to baseline findings were reported. Abnormality in physical examinations were based on blinded observer's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02497781)
Timeframe: EOIV visit (anytime from Day 4 to 15)

Intervention	percentage of participants (Number)
	Abdomen	Cardiovascular System	General Appearance	Head and Neck	Lymph Nodes	Musculoskeletal System	Neurological System	Respiratory System	Skin	Thyroid
Cefepime	3.6	0	0	3.6	3.6	0	0	0	7.1	0
Ceftazidime- Avibactam (CAZ-AVI)	0	1.5	0	1.5	0	0	0	3.0	3.0	0

[back to top]

Percentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit

Intervention	percentage of participants (Number)
	CrCl: <30mL/min/1.73 m^2	CrCl: >=30 to <50mL/min/1.73 m^2	CrCl: >=50 to <80mL/min/1.73 m^2	CrCl: >=80mL/min/1.73 m^2
Cefepime	0	0	41.7	58.3
Ceftazidime- Avibactam (CAZ-AVI)	0	0	25.0	75.0

[back to top]

Change From Baseline in Respiratory Rate at End of Intravenous Treatment (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug. (NCT02497781)
Timeframe: Baseline, EOIV visit (anytime from Day 4 to 15)

Intervention	breaths per minute (Mean)
	Baseline	Change at EOIV
Cefepime	27.0	-2.6
Ceftazidime- Avibactam (CAZ-AVI)	25.8	-2.5

[back to top]

Peak Sputum Concentration

(NCT02504827)
Timeframe: 8 hours

Intervention	mg/L (Mean)
IV Ceftazidime/Avibactam	2.5

[back to top]

Peak Plasma Concentration (Cmax)

(NCT02504827)
Timeframe: 8 hours

Intervention	mg/L (Mean)
IV Ceftazidime/Avibactam	85.87

[back to top]

Secondary Treatment Failure Rate

Secondary treatment failure was defined as treatment failure despite adjustment of antibiotics or changing to second line antibiotics for 3 to 5 days in patients with primary treatment failure (NCT02787057)
Timeframe: after 6 to 8 days of treatment

Intervention	Participants (Count of Participants)
Control Group	5
Study Group	4

[back to top]

Primary Treatment Failure Rate

Primary treatment failure was defined as the presence of fever, abdominal pain, and turbid peritoneal dialysate, and if the total peritoneal WBC counts is >50% of the pretreatment values after 3 days of treatment by the assigned antibiotics (NCT02787057)
Timeframe: after 3 days of treatment by the assigned antibiotics

Intervention	Participants (Count of Participants)
Control Group	8
Study Group	13

[back to top]

Primary Response Rate

Primary response was defined as resolution of peritonitis (normalization of body temperature, resolution of abdominal pain, clearing of dialysate, and PD effluent neutrophil count less than 100 cells/mL and proportion of polynuclear cell less than 50%) on day 10 by using antibiotics alone (NCT02787057)
Timeframe: on day 10 by using antibiotics alone

Intervention	Participants (Count of Participants)
Control Group	32
Study Group	27

[back to top]

Complete Cure Rate

complete cure was defined as complete resolution of peritonitis (normalization of body temperature, resolution of abdominal pain, clearing of dialysate, and PD effluent neutrophil count less than 100 cells/mL and proportion of polynuclear cell less than 50%) by using antibiotics alone without relapse within 4 weeks of completion of therapy (NCT02787057)
Timeframe: within 4 weeks of completion of therapy

Intervention	Participants (Count of Participants)
Control Group	32
Study Group	31

[back to top]

Mean (SD) Ceftazadime/Avibactam Pharmacokinetic Half Life Parameter in Intensive Care Patients

(NCT02822950)
Timeframe: 2,4,6, 8 hours after receiving the drug

Intervention	Hours (Mean)
Ceftazadime/Avibactam	4.3

[back to top]

Mean (SD) Ceftazadime/Avibactam Pharmacokinetic Clearance of Drug Parameter in Intensive Care Patients

(NCT02822950)
Timeframe: 2,4,6, 8 hours after receiving the drug

Intervention	Liters/hour (Mean)
Ceftazadime/Avibactam	6.4

[back to top]

Mean (SD) Ceftazadime/Avibactam Pharmacokinetic Area Under Serum Curve (mg*h/L) Parameter in Intensive Care Patients

(NCT02822950)
Timeframe: 2,4,6, 8 hours after receiving the drug

Intervention	mg*hour/liters (Mean)
Ceftazadime/Avibactam	343

[back to top]

Mean (SD) Ceftazadime/Avibactam Pharmacokinetic (PK) Volume of Distribution Parameter in Intensive Care Patients

(NCT02822950)
Timeframe: 2,4,6, 8 hours after receiving the drug

Intervention	Liter (Mean)
Ceftazadime/Avibactam	34

[back to top]

Mean (SD) Ceftazadime/Avibactam Pharmacokinetic (PK) Maximum Serum Concentration in Intensive Care Patients

(NCT02822950)
Timeframe: 2,4,6, 8 hours after receiving the drug

Intervention	mg/liter (Mean)
Ceftazadime/Avibactam	48

[back to top]

Concentration of Study Drug at Steady State After Continuous Infusion (Css)

Mean and standard deviation (SD) of the Css (ug/mL) PK parameter were estimated from the Day 1 ceftazidime, avibactam, and/or aztreonam plasma concentration-time data for AVYCAZ CI and ATM CI. (NCT03978091)
Timeframe: Day 1

Intervention	ug/mL (Mean)
	Aztreonam
ATM CI	58.80

[back to top]

Volume of Distribution of Study Drug at Steady-state Based on the Last Observed Concentration (Vss)

Mean and standard deviation (SD) of the Vss (L) PK parameter were estimated from the Day 7 ceftazidime, avibactam, and/or aztreonam plasma concentration-time data using Non-compartmental analysis. (NCT03978091)
Timeframe: Day 7

Intervention	L (Mean)
	Avibactam	Ceftazidime
AVYCAZ CI	17.40	12.60
AVYCAZ IV	25.90	19.90

[back to top]

Volume of Distribution of Study Drug at Steady-state Based on the Last Observed Concentration (Vss)

Intervention	L (Mean)
	Aztreonam
ATM IV	14.30

[back to top]

Total Body Plasma Clearance of Study Drug (CL)

Mean and standard deviation (SD) of the CL (L/h) PK parameter were estimated from the Day 7 ceftazidime, avibactam, and/or aztreonam plasma concentration-time data using Non-compartmental analysis. (NCT03978091)
Timeframe: Day 7

Intervention	L/h (Mean)
	Avibactam	Ceftazidime	Aztreonam
AVYCAZ + ATM 1.5	12.90	7.26	6.18
AVYCAZ + ATM 2.0	14.30	8.13	6.47

[back to top]

Total Body Plasma Clearance of Study Drug (CL)

Intervention	L/h (Mean)
	Avibactam	Ceftazidime
AVYCAZ CI	12.20	6.80
AVYCAZ IV	15.80	8.59

[back to top]

Total Body Plasma Clearance of Study Drug (CL)

Intervention	L/h (Mean)
	Aztreonam
ATM IV	7.74

[back to top]

Time to Cmax (Maximum Plasma Concentration) of Study Drug Following Multiple Daily Dosing (Tmax)

Mean and standard deviation (SD) of the Tmax (h) PK parameter following multiple daily dosing were estimated from the Day 7 ceftazidime, avibactam, and/or aztreonam plasma concentration-time data using Non-compartmental analysis. (NCT03978091)
Timeframe: Day 7

Intervention	h (Mean)
	Avibactam	Ceftazidime	Aztreonam
AVYCAZ + ATM 1.5	1.99	1.86	1.99
AVYCAZ + ATM 2.0	1.88	1.88	2.00

[back to top]

Time to Cmax (Maximum Plasma Concentration) of Study Drug Following Multiple Daily Dosing (Tmax)

Intervention	h (Mean)
	Avibactam	Ceftazidime
AVYCAZ CI	2.85	2.25
AVYCAZ IV	1.82	2.14

[back to top]

Time to Cmax (Maximum Plasma Concentration) of Study Drug Following Multiple Daily Dosing (Tmax)

Intervention	h (Mean)
	Aztreonam
ATM IV	2.00

[back to top]

Time of Cmax (Maximum Plasma Concentration) of Study Drug After the First Dose (Tmax)

Mean and standard deviation (SD) of the Tmax (h) PK parameter after the first dose were estimated from the Day 1 ceftazidime, avibactam, and/or aztreonam plasma concentration-time data using Non-compartmental analysis. (NCT03978091)
Timeframe: Day 1

Intervention	h (Mean)
	Avibactam	Ceftazidime
AVYCAZ CI	2.00	2.06
AVYCAZ IV	1.89	2.06

[back to top]

Time of Cmax (Maximum Plasma Concentration) of Study Drug After the First Dose (Tmax)

Intervention	h (Mean)
	Aztreonam
ATM CI	2.00
ATM IV	1.94

[back to top]

Accumulation Ratio for AUC (Area Under the Plasma Concentration-time Curve of Study Drug) [RAUC]

Mean and standard deviation (SD) of the RAUC PK parameter were estimated for ceftazidime, avibactam, and/or aztreonam by dividing the AUC(0-8) (avibactam and ceftazidime) or AUC(0-6) (aztreonam) on Day 7 by the AUC(0-Tau) on Day 1. AUC(0-8) and AUC(0-6) (µg*hr/mL) on Day 7 and AUC(0-Tau) (µg*hr/mL) on Day 1 were estimated from plasma concentration-time data using Non-compartmental analysis with the linear trapezoidal linear interpolation method for AVYCAZ IV, ATM IV, AVYCAZ + ATM 1.5, and AVYCAZ + ATM 2.0. (NCT03978091)
Timeframe: Day 1 and Day 7

Intervention	Accumulation ratio (Mean)
	Aztreonam
ATM IV	0.90

[back to top]

Renal Clearance of Study Drug (CLR)

Mean and standard deviation (SD) of the CLR (L/h) PK parameter were estimated from the Day 1 ceftazidime, avibactam, and/or aztreonam plasma and urine concentration-time data using Non-compartmental analysis. Renal clearance was calculated as Ae(0-8)/AUC(0-8) for ceftazidime and avibactam and as AE(0-4)/AUC(0-4) for aztreonam where Ae(0-8) and Ae(0-4) are the amounts of study drug excreted into the urine from time of dosing to 8 or 4 h post-dose, respectively, and AUC(0-8) and AUC(0-4) are the areas under the plasma concentration-time curve from time of dosing to 8 or 4 h post-dose, respectively. (NCT03978091)
Timeframe: Day 1

Intervention	L/h (Mean)
	Avibactam	Ceftazidime	Aztreonam
AVYCAZ + ATM 1.5	11.40	7.10	4.61
AVYCAZ + ATM 2.0	14.70	9.42	4.50

[back to top]

Renal Clearance of Study Drug (CLR)

Intervention	L/h (Mean)
	Avibactam	Ceftazidime
AVYCAZ CI	11.70	6.92
AVYCAZ IV	11.10	5.70

[back to top]

Renal Clearance of Study Drug (CLR)

Intervention	L/h (Mean)
	Aztreonam
ATM CI	3.90
ATM IV	4.25

[back to top]

Area Under the Plasma Concentration-time Curve Data of Study Drug During the Dosing Interval on Day 1 [AUC(0-Tau)]

Mean and standard deviation (SD) of the AUC(0-Tau) (µg*hr/mL) PK parameter were estimated from the Day 1 ceftazidime, avibactam, and/or aztreonam plasma concentration-time data using Non-compartmental analysis using linear trapezoidal linear interpolation method for AVYCAZ IV, ATM IV, AVYCAZ + ATM 1.5, and AVYCAZ + ATM 2.0. AVYCAZ CI and ATM CI were not reported. (NCT03978091)
Timeframe: Day 1

Intervention	µg*hr/mL (Mean)
	Avibactam	Ceftazidime
AVYCAZ IV	35.80	223.00

[back to top]

Minimum Plasma Concentration of Study Drug Following Multiple Daily Dosing on Day 1 (Cmin)

Mean and standard deviation (SD) of the Cmin (ug/mL) PK parameter were estimated from the Day 7 ceftazidime, avibactam, and/or aztreonam plasma concentration-time data using Non-compartmental analysis for AVYCAZ IV, ATM IV, AVYCAZ + ATM 1.5, and AVYCAZ + ATM 2.0. (NCT03978091)
Timeframe: Day 1

Intervention	ug/mL (Mean)
	Avibactam	Ceftazidime	Aztreonam
AVYCAZ + ATM 1.5	0.74	6.29	13.30
AVYCAZ + ATM 2.0	0.72	6.28	18.90

[back to top]

Minimum Plasma Concentration of Study Drug Following Multiple Daily Dosing on Day 1 (Cmin)

Intervention	ug/mL (Mean)
	Avibactam	Ceftazidime
AVYCAZ IV	0.52	5.52

[back to top]

Minimum Plasma Concentration of Study Drug Following Multiple Daily Dosing on Day 1 (Cmin)

Intervention	ug/mL (Mean)
	Aztreonam
ATM IV	13.90

[back to top]

Maximum Plasma Concentration of Study Drug Following Multiple Daily Dosing (Cmax)

Mean and standard deviation (SD) of the Cmax (ug/mL) PK parameter following multiple daily dosing were estimated from the Day 7 ceftazidime, avibactam, and/or aztreonam plasma concentration-time data using Non-compartmental analysis. (NCT03978091)
Timeframe: Day 7

Intervention	ug/mL (Mean)
	Avibactam	Ceftazidime	Aztreonam
AVYCAZ + ATM 1.5	14.20	88.20	74.40
AVYCAZ + ATM 2.0	12.80	69.80	90.30

[back to top]

Time of Cmax (Maximum Plasma Concentration) of Study Drug After the First Dose (Tmax)

Intervention	h (Mean)
	Avibactam	Ceftazidime	Aztreonam
AVYCAZ + ATM 1.5	1.81	1.93	1.99
AVYCAZ + ATM 2.0	1.99	1.93	2.06

[back to top]

Maximum Plasma Concentration of Study Drug Following Multiple Daily Dosing (Cmax)

Intervention	ug/mL (Mean)
	Avibactam	Ceftazidime
AVYCAZ CI	4.58	31.80
AVYCAZ IV	10.70	63.60

[back to top]

Maximum Plasma Concentration of Study Drug Following Multiple Daily Dosing (Cmax)

Intervention	ug/mL (Mean)
	Aztreonam
ATM IV	78.40

[back to top]

Maximum Plasma Concentration of Study Drug After the First Dose (Cmax)

Mean and standard deviation (SD) of the Cmax (ug/mL) PK parameter after the first dose were estimated from the Day 1 ceftazidime, avibactam, and/or aztreonam plasma concentration-time data using Non-compartmental analysis. (NCT03978091)
Timeframe: Day 1

Intervention	ug/mL (Mean)
	Avibactam	Ceftazidime	Aztreonam
AVYCAZ + ATM 1.5	15.80	82.70	71.20
AVYCAZ + ATM 2.0	14.30	70.30	93.20

[back to top]

Maximum Plasma Concentration of Study Drug After the First Dose (Cmax)

Intervention	ug/mL (Mean)
	Avibactam	Ceftazidime
AVYCAZ CI	13.10	71.20
AVYCAZ IV	12.40	67.90

[back to top]

Maximum Plasma Concentration of Study Drug After the First Dose (Cmax)

Intervention	ug/mL (Mean)
	Aztreonam
ATM CI	93.80
ATM IV	89.10

[back to top]

Volume of Distribution of Study Drug at Steady-state Based on the Last Observed Concentration (Vss)

Intervention	L (Mean)
	Avibactam	Ceftazidime	Aztreonam
AVYCAZ + ATM 1.5	18.50	14.50	11.50
AVYCAZ + ATM 2.0	24.30	19.20	13.80

[back to top]

Concentration of Study Drug at Steady State After Continuous Infusion (Css)

Intervention	ug/mL (Mean)
	Avibactam	Ceftazidime
AVYCAZ CI	4.34	27.60

[back to top]

Accumulation Ratio for AUC (Area Under the Plasma Concentration-time Curve of Study Drug) [RAUC]

Intervention	Accumulation ratio (Mean)
	Avibactam	Ceftazidime
AVYCAZ IV	0.87	0.98

[back to top]

Accumulation Ratio for AUC (Area Under the Plasma Concentration-time Curve of Study Drug) [RAUC]

Intervention	Accumulation ratio (Mean)
	Avibactam	Ceftazidime	Aztreonam
AVYCAZ + ATM 1.5	0.80	0.95	0.91
AVYCAZ + ATM 2.0	0.82	0.95	0.94

[back to top]

Accumulation Ratio for Cmax (Maximum Plasma Concentration) (RCmax)

Mean and standard deviation (SD) of the RCmax PK parameter were estimated for ceftazidime, avibactam, and/or aztreonam by dividing the Cmax on Day 7 by the Cmax on Day 1. Cmax (ug/mL) was estimated from plasma concentration-time data using Non-compartmental analysis for AVYCAZ IV, ATM IV, AVYCAZ + ATM 1.5, and AVYCAZ + ATM 2.0. (NCT03978091)
Timeframe: Day 1 and Day 7

Intervention	Accumulation ratio (Mean)
	Aztreonam
ATM IV	0.88

[back to top]

Accumulation Ratio for Cmax (Maximum Plasma Concentration) (RCmax)

Intervention	Accumulation ratio (Mean)
	Avibactam	Ceftazidime
AVYCAZ IV	0.88	0.96

[back to top]

Accumulation Ratio for Cmax (Maximum Plasma Concentration) (RCmax)

Intervention	Accumulation ratio (Mean)
	Avibactam	Ceftazidime	Aztreonam
AVYCAZ + ATM 1.5	0.83	0.96	0.95
AVYCAZ + ATM 2.0	0.91	1.01	0.97

[back to top]

Area Under the Plasma Concentration-time Curve Data of Study Drug During the Dosing Interval on Day 1 [AUC(0-Tau)]

Intervention	µg*hr/mL (Mean)
	Aztreonam
ATM IV	266.00

[back to top]

Number of Participants With at Least One Grade 2 (Moderate) or Higher Treatment-emergent Adverse Event

Adverse events include local and systemic reactions. All Grade 2 (moderate) adverse events were reported, regardless of relationship to study product. Number of participants with an AE are summarized by MedDRA system organ class (SOC). Each participant is only counted once per SOC. (NCT03978091)
Timeframe: Day 1 through Day 11

,,,,,

Intervention	Participants (Count of Participants)
	Cardiac Disorders	Eye disorders	General disorders and administration site conditions	Infections and infestations	Injury, poisoning and procedural complications	Investigations	Nervous system disorders	Respiratory, thoracic and mediastinal disorders
ATM CI	1	1	0	0	0	5	1	0
ATM IV	0	0	1	1	0	3	1	0
AVYCAZ + ATM 1.5	1	0	0	0	0	4	0	1
AVYCAZ + ATM 2.0	0	0	0	0	1	4	0	0
AVYCAZ CI	0	0	0	0	0	1	0	0
AVYCAZ IV	1	0	0	0	0	3	0	0

[back to top]

Area Under the Plasma Concentration-time Curve Data of Study Drug During the Dosing Interval on Day 1 [AUC(0-Tau)]

Intervention	µg*hr/mL (Mean)
	Avibactam	Ceftazidime	Aztreonam
AVYCAZ + ATM 1.5	44.00	255.00	221.00
AVYCAZ + ATM 2.0	42.40	241.00	295.00

[back to top]

Area Under the Plasma Concentration-time Curve of Study Drug From Time of Dosing Extrapolated to Infinity [AUC(0-Inf)]

Mean and standard deviation (SD) of the AUC(0-inf) (µg*hr/mL) PK parameter were estimated from the Day 7 ceftazidime, avibactam, and/or aztreonam plasma concentration-time data using Non-compartmental analysis. (NCT03978091)
Timeframe: Day 7

Intervention	µg*hr/mL (Mean)
	Aztreonam
ATM IV	263.00

[back to top]

Area Under the Plasma Concentration-time Curve of Study Drug From Time of Dosing Extrapolated to Infinity [AUC(0-Inf)]

Intervention	µg*hr/mL (Mean)
	Avibactam	Ceftazidime
AVYCAZ CI	42.40	308.00
AVYCAZ IV	32.10	235.00

[back to top]

Area Under the Plasma Concentration-time Curve of Study Drug From Time of Dosing Extrapolated to Infinity [AUC(0-Inf)]

Intervention	µg*hr/mL (Mean)
	Avibactam	Ceftazidime	Aztreonam
AVYCAZ + ATM 1.5	39.10	277.00	245.00
AVYCAZ + ATM 2.0	36.10	249.00	317.00

[back to top]

Incidence of Treatment-emergent Adverse Events, by System Organ Class (SOC) and Maximum Severity Level

Number of participants with an AE are summarized by MedDRA system organ class (SOC) and severity. Each participant is only counted once at the highest severity recorded. For clinical laboratory tests, mild abnormal laboratory values that were not, in the investigator's opinion, medically significant were not reported as adverse events. (NCT03978091)
Timeframe: Day 1 through Day 14

Intervention	Participants (Count of Participants)
	Cardiac Disorders72375878				Cardiac Disorders72375879	Cardiac Disorders72375880	Cardiac Disorders72375881	Cardiac Disorders72375882	Cardiac Disorders72375883	Eye disorders72375879	Eye disorders72375880	Eye disorders72375881	Eye disorders72375882	Eye disorders72375883	Eye disorders72375878	Gastrointestinal Disorders72375878	Gastrointestinal Disorders72375879	Gastrointestinal Disorders72375880	Gastrointestinal Disorders72375881	Gastrointestinal Disorders72375882	Gastrointestinal Disorders72375883	General disorders and administration site conditions72375878	General disorders and administration site conditions72375879	General disorders and administration site conditions72375880	General disorders and administration site conditions72375881	General disorders and administration site conditions72375882	General disorders and administration site conditions72375883	Infections and infestations72375878	Infections and infestations72375879	Infections and infestations72375880	Infections and infestations72375881	Infections and infestations72375882	Infections and infestations72375883	Injury, poisoning and procedural complications72375878	Injury, poisoning and procedural complications72375879	Injury, poisoning and procedural complications72375880	Injury, poisoning and procedural complications72375881	Injury, poisoning and procedural complications72375882	Injury, poisoning and procedural complications72375883	Investigations72375878	Investigations72375879	Investigations72375880	Investigations72375881	Investigations72375882	Investigations72375883	Musculoskeletal and connective tissue disorders72375878	Musculoskeletal and connective tissue disorders72375879	Musculoskeletal and connective tissue disorders72375880	Musculoskeletal and connective tissue disorders72375881	Musculoskeletal and connective tissue disorders72375882	Musculoskeletal and connective tissue disorders72375883	Nervous system disorders72375878	Nervous system disorders72375879	Nervous system disorders72375880	Nervous system disorders72375881	Nervous system disorders72375882	Nervous system disorders72375883	Renal and urinary disorders72375878	Renal and urinary disorders72375879	Renal and urinary disorders72375880	Renal and urinary disorders72375881	Renal and urinary disorders72375882	Renal and urinary disorders72375883	Respiratory, thoracic and mediastinal disorders72375878	Respiratory, thoracic and mediastinal disorders72375879	Respiratory, thoracic and mediastinal disorders72375880	Respiratory, thoracic and mediastinal disorders72375881	Respiratory, thoracic and mediastinal disorders72375882	Respiratory, thoracic and mediastinal disorders72375883	Skin and subcutaneous tissue disorders72375878	Skin and subcutaneous tissue disorders72375879	Skin and subcutaneous tissue disorders72375880	Skin and subcutaneous tissue disorders72375881	Skin and subcutaneous tissue disorders72375882	Skin and subcutaneous tissue disorders72375883	Vascular disorders72375878	Vascular disorders72375879	Vascular disorders72375880	Vascular disorders72375881	Vascular disorders72375882	Vascular disorders72375883
	Mild	Severe	None	Moderate
AVYCAZ IV	2
AVYCAZ CI	2
ATM IV	4
ATM CI	1
AVYCAZ + ATM 1.5	3
AVYCAZ + ATM 2.0	2
AVYCAZ IV	1
AVYCAZ CI	0
ATM IV	0
ATM CI	0
AVYCAZ + ATM 1.5	1
AVYCAZ + ATM 2.0	0
AVYCAZ + ATM 1.5	0
AVYCAZ IV	5
AVYCAZ CI	6
ATM CI	6
AVYCAZ + ATM 1.5	4
AVYCAZ IV	0
AVYCAZ IV	8
AVYCAZ CI	8
ATM IV	8
ATM CI	7
AVYCAZ + ATM 1.5	8
AVYCAZ + ATM 2.0	8
AVYCAZ IV	3
AVYCAZ CI	1
ATM IV	2
AVYCAZ + ATM 1.5	5
AVYCAZ + ATM 2.0	3
AVYCAZ CI	7
ATM IV	6
ATM CI	8
AVYCAZ + ATM 2.0	5
ATM IV	3
ATM CI	2
AVYCAZ + ATM 2.0	4
ATM IV	1
AVYCAZ IV	6
ATM IV	7
AVYCAZ + ATM 1.5	7
AVYCAZ + ATM 2.0	1
AVYCAZ + ATM 2.0	7
AVYCAZ CI	4
ATM CI	3
AVYCAZ IV	4
AVYCAZ CI	3
AVYCAZ IV	7
AVYCAZ + ATM 1.5	2
AVYCAZ + ATM 1.5	6
ATM IV	5
AVYCAZ + ATM 2.0	6

[back to top]

Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients

PK samples obtained around standard of care dosing regimens immediately before and at 1, 2, 4, 6, and 8 hours after administration (NCT04358991)
Timeframe: 8 hours

Intervention	mcg/mL (Median)
	Ceftazidime Cmax	Avibactam Cmax
Subjects Included	80.6	15.9

[back to top]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
ethylene dichloride ethylene dichloride: RN given refers to 1,2-isomer; structure given in first source. 1,2-dichloroethane : A member of the class of chloroethanes substituted by two chloro groups at positions 1 and 2.	2.46	2	0	chloroethanes	hepatotoxic agent; mutagen; non-polar solvent
ethylene glycol Ethylene Glycol: A colorless, odorless, viscous dihydroxy alcohol. It has a sweet taste, but is poisonous if ingested. Ethylene glycol is the most important glycol commercially available and is manufactured on a large scale in the United States. It is used as an antifreeze and coolant, in hydraulic fluids, and in the manufacture of low-freezing dynamites and resins.. ethanediol : Any diol that is ethane or substituted ethane carrying two hydroxy groups.. ethylene glycol : A 1,2-glycol compound produced via reaction of ethylene oxide with water.	2.46	2	0	ethanediol; glycol	metabolite; mouse metabolite; solvent; toxin
adenine [no description available]	2.04	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	2.96	4	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
benzyl alcohol Benzyl Alcohol: A colorless liquid with a sharp burning taste and slight odor. It is used as a local anesthetic and to reduce pain associated with LIDOCAINE injection. Also, it is used in the manufacture of other benzyl compounds, as a pharmaceutic aid, and in perfumery and flavoring.. hydroxytoluene : Any member of the class of toluenes carrying one or more hydroxy substituents.. benzyl alcohol : An aromatic alcohol that consists of benzene bearing a single hydroxymethyl substituent.. aromatic alcohol : Any alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.. aromatic primary alcohol : Any primary alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.	2.04	1	0	benzyl alcohols	antioxidant; fragrance; metabolite; solvent
betaine glycine betaine : The amino acid betaine derived from glycine.	3.58	2	0	amino-acid betaine; glycine derivative	fundamental metabolite
chlordecone [no description available]	2.04	1	0	cyclic ketone; organochlorine compound	insecticide; persistent organic pollutant
coumarin 2H-chromen-2-one: coumarin derivative	2.07	1	0	coumarins	fluorescent dye; human metabolite; plant metabolite
4-aminophenol 4-aminophenol: RN given refers to parent cpd. 4-aminophenol : An amino phenol (one of the three possible isomers) which has the single amino substituent located para to the phenolic -OH group.	2.05	1	0	aminophenol	allergen; metabolite
bupropion Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.	3.85	3	0	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	4.4	6	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.04	1	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
5,6-dimethylbenzimidazole 5,6-dimethylbenzimidazole: RN given refers to parent cpd. 5,6-dimethylbenzimidazole : A dimethylbenzimidazole carrying methyl substituents at positions 5 and 6.	2.04	1	0	dimethylbenzimidazole	Escherichia coli metabolite; human metabolite
hexachlorocyclohexane Lindane: An organochlorine insecticide made up of greater than 99% gamma-Hexachlorocyclohexane. It has been used as a pediculicide and scabicide, and shown to cause cancer.. beta-hexachlorocyclohexane : The beta-isomer of hexachlorocyclohexane.	2.74	3	0	chlorocyclohexane
glycine [no description available]	2.46	2	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	2.04	1	0	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
alpha-glycerophosphoric acid [no description available]	2.04	1	0	glycerol monophosphate	algal metabolite; human metabolite
histamine [no description available]	2.04	1	0	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	2.74	3	0	cyclitol; hexol
melatonin [no description available]	2.46	2	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
niacin Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.	4.26	5	0	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent
parathion [no description available]	2.04	1	0	C-nitro compound; organic thiophosphate; organothiophosphate insecticide	acaricide; agrochemical; avicide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; mouse metabolite
pentachlorophenol PENTA: structure given in first source	2.04	1	0	aromatic fungicide; chlorophenol; organochlorine pesticide; pentachlorobenzenes	human xenobiotic metabolite
pyrazinamide pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.	4.26	5	0	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
pyridoxine 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).	3.86	3	0	hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
spermidine [no description available]	2.03	1	0	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
spermine [no description available]	2.03	1	0	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
succinic acid Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851). succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.	2.04	1	0	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent
thiamine thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.	3.86	3	0	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
1,10-phenanthroline 1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases	2.77	3	0	phenanthroline	EC 2.7.1.1 (hexokinase) inhibitor; EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor
1-(3-chlorophenyl)piperazine 1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.	2.04	1	0	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic
2,4-dinitrophenol 2,4-Dinitrophenol: A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed). dinitrophenol : Members of the class of nitrophenol carrying two nitro substituents.. 2,4-dinitrophenol : A dinitrophenol having the nitro groups at the 2- and 4-positions.	2.46	2	0	dinitrophenol	allergen; antiseptic drug; bacterial xenobiotic metabolite; geroprotector; oxidative phosphorylation inhibitor
amitrole Amitrole: A non-selective post-emergence, translocated herbicide. According to the Seventh Annual Report on Carcinogens (PB95-109781, 1994) this substance may reasonably be anticipated to be a carcinogen. (From Merck Index, 12th ed) It is an irreversible inhibitor of CATALASE, and thus impairs activity of peroxisomes.. amitrole : A member of the class of triazoles that is 1H-1,2,4-triazole substituted by an amino group at position 3. Used to control annual grasses and aquatic weeds (but not on food crops because it causes cancer in laboratory animals). Its use within the EU was banned from September 2017 on the grounds of potential groundwater contamination and risks to aquatic life; there have also been concerns about its endocrine-disrupting properties.	2.04	1	0	aromatic amine; triazoles	carotenoid biosynthesis inhibitor; EC 1.11.1.6 (catalase) inhibitor; herbicide
3-methylcholanthrene Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.	2.46	2	0	ortho- and peri-fused polycyclic arene	aryl hydrocarbon receptor agonist; carcinogenic agent
enprofylline enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.	2.45	2	0	oxopurine	anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug
3-nitrobenzeneboronic acid [no description available]	2.01	1	0
phenytoin [no description available]	4.41	6	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
oxyquinoline Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.	2.08	1	0	monohydroxyquinoline	antibacterial agent; antifungal agrochemical; antiseptic drug; iron chelator
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	3.43	7	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
acebutolol Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.	4.24	5	0	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	4.85	10	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	4.41	6	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohexamide Acetohexamide: A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide.. acetohexamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is replaced by a p-acetylphenylsulfonyl group, while a hydrogen attached to the other nitrogen is replaced by a cyclohexyl group.	2.74	3	0	acetophenones; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
acetohydroxamic acid acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.	3.56	2	0	acetohydroxamic acids; carbohydroximic acid	algal metabolite; EC 3.5.1.5 (urease) inhibitor
methacholine methacholine : A quaternary ammonium ion in which the nitrogen is substituted with three methyl groups and a 2-acetoxypropyl group. Parasympathomimetic bronchoconstrictor drug used in clinical diagnosis.	2.04	1	0	acetate ester; quaternary ammonium ion	bronchoconstrictor agent; cholinergic agonist; epitope; muscarinic agonist; vasodilator agent
alaproclate alaproclate: specific 5-hydroxytryptamine uptake inhibitors; RN given refers to (DL)-isomer	3.23	1	0	alpha-amino acid ester
albendazole [no description available]	4.08	4	0	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	4.24	5	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	3.56	2	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alfuzosin alfuzosin: structure given in first source	3.58	2	0	monocarboxylic acid amide; quinazolines; tetrahydrofuranol	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
alosetron alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.	3.58	2	0	imidazoles; pyridoindole	antiemetic; gastrointestinal drug; serotonergic antagonist
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	4.06	4	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
alprenolol Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.	2.45	2	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.	3.84	3	0	triamino-1,3,5-triazine
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	4.53	7	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
ambenonium ambenonium : A symmetrical oxalamide-based bis-quaternary ammonium ion having ethyl and 2-chlorobenzyl groups attached to the nitrogens.	3.23	1	0	quaternary ammonium ion	EC 3.1.1.8 (cholinesterase) inhibitor
ambroxol Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.	2.45	2	0	aromatic amine
ametantrone ametantrone: RN given refers to parent cpd; structure	2.04	1	0
diatrizoic acid Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.	3.58	2	0	acetamides; benzoic acids; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
amifostine anhydrous Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.	3.56	2	0	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent
aminoglutethimide Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.	3.14	5	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	3.23	1	0	N-acylglycine	Daphnia magna metabolite
theophylline [no description available]	4.65	8	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
2-aminothiazole 2-aminothiazole: RN given refers to parent cpd; structure. 1,3-thiazol-2-amine : A primary amino compound that is 1,3-thiazole substituted by an amino group at position 2.	2.04	1	0	1,3-thiazoles; primary amino compound
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	4.76	9	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
dan 2163 [no description available]	2.05	1	0	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	4.54	7	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amlexanox amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.	2.02	1	0	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	4.4	6	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
amoxapine Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.	4.07	4	0	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	2.46	2	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole [no description available]	3.56	2	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
antazoline Antazoline: An antagonist of histamine H1 receptors.. antazoline : A member of the class of imidazolines that is 2-aminomethyl-2-imidazoline in which the exocyclic amino hydrogens are replaced by benzyl and phenyl groups. Antazoline is only found in individuals that have taken the drug.	2.04	1	0	aromatic amine; imidazolines; tertiary amino compound	cholinergic antagonist; H1-receptor antagonist; xenobiotic
antipyrine Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.	2.45	2	0	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
apraclonidine apraclonidine: relieves postoperative intraocular pressure following trabeculoplasty; RN given refers to parent cpd. apraclonidine : An imidazoline that is 2-amino 4,5-dihydro-1H-imidazoline in which one of the exocyclic amino hydrogens has been replaced by a 4-amino-2,6-dichlorophenyl group.	2.02	1	0	dichlorobenzene; guanidines; imidazolines	alpha-adrenergic agonist; antiglaucoma drug; beta-adrenergic agonist; diagnostic agent; ophthalmology drug
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	4.65	8	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	2.73	3	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	4.53	7	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	4.41	6	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
azelaic acid nonanedioic acid : An alpha,omega-dicarboxylic acid that is heptane substituted at positions 1 and 7 by carboxy groups.	2.02	1	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	antibacterial agent; antineoplastic agent; dermatologic drug; plant metabolite
azelastine azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia. azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.	2.73	3	0	monochlorobenzenes; phthalazines; tertiary amino compound	anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor
azinphosmethyl Azinphosmethyl: An organothiophosphorus cholinesterase inhibitor. It has been used as an acaricide and as an insecticide.. azinphos-methyl : A member of the class of benzotriazines that is 1,2,3-benzotriazine substituted by an oxo group at position 4 and a [(dimethoxyphosphorothioyl)sulfanyl]methyl group at position 3.	2.04	1	0	benzotriazines; organic thiophosphate; organothiophosphate insecticide	agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor
baclofen [no description available]	3.56	2	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
barbital 5,5-diethylbarbituric acid : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by two ethyl groups. Formerly used as a hypnotic (sleeping aid).	2.04	1	0	barbiturates	drug allergen
bendazac bendazac : A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts.	3.23	1	0	indazoles; monocarboxylic acid	non-steroidal anti-inflammatory drug; radical scavenger
bendroflumethiazide Bendroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810). bendroflumethiazide : A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.	3.58	2	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
benzamide benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.	2.45	2	0	benzamides
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	4.09	4	0	1-benzofurans; aromatic ketone	uricosuric drug
benzquinamide [no description available]	2.04	1	0	monocarboxylic acid amide	antiemetic; antipsychotic agent; H1-receptor antagonist; muscarinic antagonist; sedative
bepridil Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.. bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.	2.43	2	0	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
benzo(b)thiophene-2-boronic acid benzo(b)thiophene-2-boronic acid: inhibits AmpC beta-lactamase; structure in first source	2.01	1	0
bethanidine Bethanidine: A guanidinium antihypertensive agent that acts by blocking adrenergic transmission. The precise mode of action is not clear.	2.04	1	0	guanidines	adrenergic antagonist; antihypertensive agent
betaxolol [no description available]	4.4	6	0	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bethanechol Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.. bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.	3.23	1	0	carbamate ester; quaternary ammonium ion	muscarinic agonist
bevantolol bevantolol: structure given in first source. bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.	2.45	2	0	propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; calcium channel blocker
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	4.25	5	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
biperiden Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.. biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.	3.58	2	0	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
bisacodyl Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)	3.58	2	0	diarylmethane
bisoprolol Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.	4.24	5	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bithionol Bithionol: Halogenated anti-infective agent that is used against trematode and cestode infestations.. bithionol : An aryl sulfide that is diphenyl sulfide in which each phenyl group is substituted at position 2 by hydroxy and at positions 3 and 5 by chlorine. A fungicide and anthelmintic, it was used in various topical drug products for the treatment of liver flukes, but withdrawn after being shown to be a potent photosensitizer with the potential to cause serious skin disorders.	2.46	2	0	aryl sulfide; bridged diphenyl antifungal drug; bridged diphenyl fungicide; dichlorobenzene; organochlorine pesticide; polyphenol	antifungal agrochemical; antiplatyhelmintic drug
brimonidine [no description available]	2.02	1	0	imidazoles; quinoxaline derivative; secondary amine	adrenergic agonist; alpha-adrenergic agonist; antihypertensive agent
bromazepam Bromazepam: One of the BENZODIAZEPINES that is used in the treatment of ANXIETY DISORDERS.	2.45	2	0	organic molecular entity
bromhexine Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).	2.74	3	0	organobromine compound; substituted aniline; tertiary amino compound	mucolytic
bromopride bromopride: RN given refers to parent cpd; structure	2.45	2	0	benzamides
brotizolam brotizolam: structure	2.04	1	0	organic molecular entity
buflomedil buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure	2.45	2	0	aromatic ketone
bumetanide [no description available]	4.53	7	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bunazosin bunazosin: structure	2.04	1	0	quinazolines
bunitrolol bunitrolol: was heading 1975-94 (see under PROPANOLAMINES 1975-90); KO 1366 was see BUNITROLOL 1975-94; use PROPANOLAMINES to search BUNITROLOL 1975-94; a beta-adrenergic receptor antagonist with weak antiarrhythmic activity and minor ability to decrease the heart rate	2.04	1	0	aromatic ether
bupivacaine Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.	3.14	5	0	aromatic amide; piperidinecarboxamide; tertiary amino compound
bupranolol Bupranolol: An adrenergic-beta-2 antagonist that has been used for cardiac arrhythmia, angina pectoris, hypertension, glaucoma, and as an antithrombotic.	2.04	1	0	aromatic ether
buspirone Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.	4.54	7	0	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
busulfan [no description available]	4.65	8	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
secbutabarbital secbutabarbital: Butabarbital (a synonym for Secbutabarbital) should be distinguished from Butobarbital	3.23	1	0	barbiturates
butalbital butalbital: management of butalbital withdrawal can be simplified by using a phenobarbital-loading protocol; RN given refers to parent cpd. butalbital : A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. Frequently combined with other medicines, such as aspirin, paracetamol and codeine, it is used for treatment of pain and headache.	2.04	1	0	barbiturates	analgesic; sedative
butenafine butenafine: studied on experimental dermatophytosis. butenafine : Trimethylamine in which hydrogen atoms attached to different methyl groups are substituted by 1-naphthyl and 4-tert-butylphenyl groups. It is an inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes, and is used as its hydrochloride salt for treatment of dermatological fungal infections.	2.02	1	0	naphthalenes; tertiary amine	antifungal drug; EC 1.14.13.132 (squalene monooxygenase) inhibitor
caffeine [no description available]	4.76	9	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	4.06	4	0	aromatic ether; nitrile; polyether; tertiary amino compound
metrizoate Metrizoic Acid: A diagnostic radiopaque that usually occurs as the sodium salt.	2.73	3	0	monocarboxylic acid	radioopaque medium
candesartan candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.	3.86	3	0	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	4.54	7	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carbazochrome carbazochrome: a hemostatic which increases capillary resistance & activates platelet factors, Note: Adona is a multimeaning tradename	2.04	1	0
carbinoxamine carbinoxamine: Note: tradenames that start with Histex refer to more than one drug. carbinoxamine : An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease.	3.58	2	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist
carbazilquinone Carbazilquinone: An alkylating agent structurally similar to MITOMYCIN and found to be effective in the treatment of leukemia and various other neoplasms in mice. It causes leukemia and thrombocytopenia in almost all human patients.	2.04	1	0	organic molecular entity
carisoprodol Carisoprodol: A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202). carisoprodol : A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.	3.23	1	0	carbamate ester	muscle relaxant
carmofur [no description available]	2.04	1	0	organohalogen compound; pyrimidines
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	3.14	5	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
carprofen carprofen: RN given refers to cpd without isomeric designation. carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.	2.41	1	0	carbazoles; organochlorine compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug; photosensitizing agent
carteolol Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.	2.43	2	0	quinolone; secondary alcohol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
carvedilol [no description available]	4.06	4	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
carbonyl cyanide m-chlorophenyl hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.	3.16	5	0	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
celecoxib [no description available]	3.59	2	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
celiprolol Celiprolol: A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.	2.04	1	0	aromatic ketone
cetirizine Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.	3.85	3	0	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
chloral hydrate [no description available]	2.04	1	0	aldehyde hydrate; ethanediol; organochlorine compound	general anaesthetic; mouse metabolite; sedative; xenobiotic
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	4.07	4	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlorcyclizine chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness	3.86	3	0	diarylmethane
chlordiazepoxide Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.	3.85	3	0	benzodiazepine
chlormezanone Chlormezanone: A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.. chlormezanone : A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.	3.56	2	0	1,3-thiazine; lactam; monochlorobenzenes; sulfone	antipsychotic agent; anxiolytic drug; muscle relaxant
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	4.54	7	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorothiazide Chlorothiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812). thiazide : Heterocyclic compound with sulfur and nitrogen in the ring.. chlorothiazide : 4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.	3.85	3	0	benzothiadiazine	antihypertensive agent; diuretic
chloroxine chloroxine : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 have been substituted by chlorine. A synthetic antibacterial prepared by chlorination of quinolin-8-ol, it is used for the treatment of dandruff and seborrhoeic dermatitis of the scalp.	2.52	2	0	monohydroxyquinoline; organochlorine compound	antibacterial agent; antifungal drug; antiseborrheic
chlorpheniramine Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.	3.85	3	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	4.66	8	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.	4.66	8	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorthalidone Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.	4.07	4	0	isoindoles; monochlorobenzenes; sulfonamide
chlorzoxazone Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.	3.86	3	0	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
cifenline [no description available]	2.45	2	0	diarylmethane
ciclopirox [no description available]	2.73	3	0	cyclic hydroxamic acid; hydroxypyridone antifungal drug; pyridone	antibacterial agent; antiseborrheic
ciglitazone ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.	2.46	2	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
cilostazol [no description available]	3.6	2	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	4.76	9	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
cinoxacin Cinoxacin: Synthetic antimicrobial related to OXOLINIC ACID and NALIDIXIC ACID and used in URINARY TRACT INFECTIONS.. cinoxacin : A member of the class of cinnolines that is 6,7-methylenedioxycinnolin-4(1H)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections.	2.41	2	0	cinnolines; oxacycle; oxo carboxylic acid	antibacterial drug; antiinfective agent
ciprofibrate [no description available]	2.97	4	0	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	10.55	148	1	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
cisapride Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed). cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.	2.96	4	0	benzamides
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	4.54	7	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clenbuterol Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.. clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.	2.04	1	0	amino alcohol; dichlorobenzene; ethanolamines; primary arylamine; secondary amino compound; substituted aniline	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
clioquinol Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.	2.44	2	0	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
clofazimine Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.	2.43	2	0	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	4.27	5	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clomiphene [no description available]	3.59	2	0	tertiary amine	estrogen antagonist; estrogen receptor modulator
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	4.53	7	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clonazepam Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.	3.85	3	0	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	4.24	5	0	clonidine; imidazoline
chlorazepate clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.	3.84	3	0	1,4-benzodiazepinone	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
clotrimazole [no description available]	4.8	9	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
cloxyquin cloxyquin: has antitubercular activity; structure in first source	2.57	2	0	organochlorine compound; quinolines
cromolyn cromoglycic acid : A dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer.	2.75	3	0	chromones; dicarboxylic acid	anti-asthmatic drug; calcium channel blocker
cyclandelate Cyclandelate: A direct-acting SMOOTH MUSCLE relaxant used to dilate BLOOD VESSELS.. cyclandelate : The ester obtained by formal condensation of mandelic acid and 3,3,5-tricyclohexanol. It is a direct-acting smooth muscle relaxant used to dilate blood vessels.	2.04	1	0	carboxylic ester; secondary alcohol	vasodilator agent
cyclobenzaprine cyclobenzaprine: RN given refers to parent cpd; Lisseril is synonymous for HCl; structure. cyclobenzaprine : 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm.	3.56	2	0	carbotricyclic compound	antidepressant; muscle relaxant; tranquilizing drug
cyclofenil Cyclofenil: A gonadal stimulant and inducer of ovulation. It is used in the treatment of infertility and amenorrhea, but is thought to be less effective than CLOMIPHENE.	3.58	2	0	organic molecular entity
cycloleucine Cycloleucine: An amino acid formed by cyclization of leucine. It has cytostatic, immunosuppressive and antineoplastic activities.. 1-aminocyclopentanecarboxylic acid : A non-proteinogenic alpha-amino acid that is cyclopentane substituted at position 1 by amino and carboxy groups.	2.04	1	0	non-proteinogenic alpha-amino acid	EC 2.5.1.6 (methionine adenosyltransferase) inhibitor
cyproheptadine Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.	3.23	1	0	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist
dapi DAPI: RN given refers to parent cpd.	2.05	1	0	indoles	fluorochrome
dapsone [no description available]	4.54	7	0	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
debrisoquin Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.	2.44	2	0	carboxamidine; isoquinolines	adrenergic agent; antihypertensive agent; human metabolite; sympatholytic agent
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	3.59	2	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	4.54	7	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
nordazepam Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.. nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.	2.04	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	3.85	3	0	primary amine
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	4.4	6	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.	4.07	4	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
dicamba Dicamba: A chlorinated organic herbicide.. dicamba : A methoxybenzoic acid that is O-methylsalicylic acid substituted by chloro groups at positions 3 and 6.	2.04	1	0	dichlorobenzene; methoxybenzoic acid	agrochemical; environmental contaminant; herbicide; synthetic auxin; xenobiotic
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	4.66	8	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
dichlorphenamide Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.	3.85	3	0	dichlorobenzene; sulfonamide	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor; ophthalmology drug
dicyclomine Dicyclomine: A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.. dicyclomine : The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.	3.58	2	0	carboxylic ester; tertiary amine	antispasmodic drug; muscarinic antagonist; parasympatholytic
diethylcarbamazine Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.	2.74	3	0	N-carbamoylpiperazine; N-methylpiperazine
pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.	3.23	1	0	pentacarboxylic acid	copper chelator
diphenidol diphenidol: shows anti-arrhythmic activity; RN given refers to unlabeled parent cpd. diphenidol : A tertiary alcohol that is butan-1-ol substituted by two phenyl groups at position 1 and a piperidin-1-yl group at position 4.	2.04	1	0	benzenes; piperidines; tertiary alcohol	antiemetic
diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.	4.53	7	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
dimercaprol Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.	4.08	4	0	dithiol; primary alcohol	chelator
dinitolmide Dinitolmide: A coccidiostat for poultry.	2.04	1	0	dinitrotoluene
diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.	4.08	4	0	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
dipivefrin dipivefrin: used in treatment of both primary & open angle glaucoma; RN given refers to (+-)-isomer. dipivefrin : The dipivalate ester of (+-)-epinephrine (racepinephrine). A pro-drug of epinephrine, the hydrochloride is used topically as eye drops to reduce intra-ocular pressure in the treatment of open-angle glaucoma or ocular hypertension.	2.02	1	0	ethanolamines; pivalate ester	adrenergic agonist; antiglaucoma drug; ophthalmology drug; prodrug; sympathomimetic agent
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	4.08	4	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
dipyrone metamizole : A pyrazole that is antiipyrine substituted at C-4 by a methyl(sulfomethyl)amino group, the sodium salt of which, metamizole sodium, was widely used as a powerful analgesic and antipyretic, but withdrawn from many markets from the 1970s due to a risk of causing risk of causing agranulocytosis.	2.04	1	0	amino sulfonic acid; pyrazoles	anti-inflammatory agent; antipyretic; antirheumatic drug; cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug; prodrug
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	4.4	6	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
disulfiram [no description available]	4.25	5	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	4.85	10	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.73	3	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
donepezil Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.	4.27	5	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
doxapram Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225). doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.	3.86	3	0	morpholines; pyrrolidin-2-ones	central nervous system stimulant
doxazosin Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.	3.84	3	0	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent
doxepin Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.	4.06	4	0	dibenzooxepine; tertiary amino compound	antidepressant
doxylamine Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.	3.58	2	0	pyridines; tertiary amine	anti-allergic agent; antiemetic; antitussive; cholinergic antagonist; H1-receptor antagonist; histamine antagonist; sedative
droperidol Droperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593). droperidol : An organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon.	3.56	2	0	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic
dyphylline Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.	3.85	3	0	oxopurine; propane-1,2-diols	bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent
econazole Econazole: An imidazole derivative that is commonly used as a topical antifungal agent.. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.. 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group.	2.02	1	0	dichlorobenzene; ether; imidazoles; monochlorobenzenes
edrophonium Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.. edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.	3.23	1	0	phenols; quaternary ammonium ion	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor
enflurane Enflurane: An extremely stable inhalation anesthetic that allows rapid adjustments of anesthesia depth with little change in pulse or respiratory rate.. enflurane : An ether in which the oxygen atom is connected to 2-chloro-1,1,2-trifluoroethyl and difluoromethyl groups.	2.02	1	0	ether; organochlorine compound; organofluorine compound	anaesthetic
enoxacin Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.	2.73	3	0	1,8-naphthyridine derivative; amino acid; fluoroquinolone antibiotic; monocarboxylic acid; N-arylpiperazine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor
estazolam Estazolam: A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than DIAZEPAM or NITRAZEPAM.. estazolam : A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia.	3.56	2	0	triazoles; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA modulator
ethacrynic acid Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.	3.58	2	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
ethinamate ethinamate: short duration hypnotic with fast onset & relatively low toxicity; may cause dependence; minor descriptor (76-85); on-line & Index Medicus search CARBAMATES (76-85). ethinamate : A carbamate ester that is the 1-vinylcyclohexyl ester of carbamic acid. A short-acting sedative-hypnotic, it was formerly used to treat insomnia.	2.04	1	0	carbamate ester; terminal acetylenic compound	sedative
profenamine profenamine: was heading 1972-94 (see under PHENOTHIAZINES 1972-90); use PHENOTHIAZINES to search ETHOPROPAZINE 1972-94. profenamine : A member of the class of phenothiazines that is phenothiazine in which the hydrogen attached to the nitrogen is substituted by a 2-(diethylamino)propyl group. An antimuscarinic, it is used as the hydrochloride for the symptomatic treatment of Parkinson's disease.	2.04	1	0	phenothiazines; tertiary amino compound	adrenergic antagonist; antidyskinesia agent; antiparkinson drug; histamine antagonist; muscarinic antagonist
ethosuximide Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.	4.08	4	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
ethotoin ethotoin: was heading 1966-94 (see under HYDANTOINS 1966-90); use HYDANTOINS to search ETHOTOIN 1966-94. ethotoin : An imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective.	3.23	1	0	imidazolidine-2,4-dione	anticonvulsant
ethyl loflazepate ethyl loflazepate: structure given in first source	2.45	2	0	organic molecular entity
etidronate Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.	3.85	3	0	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator
etilefrine Etilefrine: A phenylephrine-related beta-1 adrenergic and alpha adrenergic agonist used as a cardiotonic and antihypotensive agent.	2.45	2	0	phenols
etizolam etizolam: structure given in first source	2.04	1	0	organic molecular entity
etodolac Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).. etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.	3.56	2	0	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
brl 42810 [no description available]	3.84	3	0	2-aminopurines; acetate ester	antiviral drug; prodrug
carbonyl cyanide p-trifluoromethoxyphenylhydrazone Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.	2.46	2	0	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore
felbamate Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.	4.41	6	0	carbamate ester	anticonvulsant; neuroprotective agent
felodipine Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.	4.24	5	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
fenfluramine Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.. fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.	2.73	3	0	(trifluoromethyl)benzenes; secondary amino compound	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE	4.27	5	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
fenoldopam Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.	3.23	1	0	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent
fenoprofen Fenoprofen: A propionic acid derivative that is used as a non-steroidal anti-inflammatory agent.. fenoprofen : A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.	3.58	2	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.96	4	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
fenspiride fenspiride: was heading 1975-94 (see under SPIRO COMPOUNDS 1975-90); use SPIRO COMPOUNDS to search FENSPIRIDE 1975-94; bronchodilator agent used in asthma	2.04	1	0	azaspiro compound
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.73	3	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
fexofenadine fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.	4.25	5	0	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
fipexide fipexide: regulates dopaminergic systems at macromolecular level	3.86	3	0	benzodioxoles
flavoxate Flavoxate: A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.. flavoxate : A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.	3.58	2	0	carboxylic ester; flavones; piperidines; tertiary amino compound	antispasmodic drug; muscarinic antagonist; parasympatholytic
flecainide Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	4.53	7	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
fleroxacin Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.	2.94	4	0	difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines	antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	5.12	13	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.	4.65	8	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
flufenamic acid Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16). flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.	2.74	3	0	aromatic amino acid; organofluorine compound	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
fluphenazine [no description available]	3.84	3	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.	4.4	6	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
flunitrazepam Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.	2.04	1	0	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative
fluorescite fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.	3.58	2	0	benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye	fluorescent dye; radioopaque medium
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	4.65	8	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	4.54	7	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
fluphenazine depot fluphenazine decanoate : The prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia.	2.43	2	0	decanoate ester; N-alkylpiperazine; organofluorine compound; phenothiazines	dopaminergic antagonist; phenothiazine antipsychotic drug; prodrug
fluphenazine enanthate [no description available]	2.43	2	0	phenothiazines
flurazepam Flurazepam: A benzodiazepine derivative used mainly as a hypnotic.. flurazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia.	3.58	2	0	1,4-benzodiazepinone; monofluorobenzenes; organochlorine compound; tertiary amino compound	anticonvulsant; anxiolytic drug; GABAA receptor agonist; sedative
flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.	4.07	4	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
fluspirilene Fluspirilene: A long-acting injectable antipsychotic agent used for chronic schizophrenia.	2.46	2	0	diarylmethane
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	4.54	7	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
flutazolam flutazolam: structure	2.04	1	0	hemiaminal ether; organic molecular entity
fomepizole Fomepizole: A pyrazole and competitive inhibitor of ALCOHOL DEHYDROGENASE that is used for the treatment of poisoning by ETHYLENE GLYCOL or METHANOL.. fomepizole : A member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4.	3.23	1	0	pyrazoles	antidote; EC 1.1.1.1 (alcohol dehydrogenase) inhibitor; protective agent
foscarnet Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	4.4	6	0	carboxylic acid; one-carbon compound; phosphonic acids	antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	4.85	10	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
fusaric acid Fusaric Acid: A picolinic acid derivative isolated from various Fusarium species. It has been proposed for a variety of therapeutic applications but is primarily used as a research tool. Its mechanisms of action are poorly understood. It probably inhibits DOPAMINE BETA-HYDROXYLASE, the enzyme that converts dopamine to norepinephrine. It may also have other actions, including the inhibition of cell proliferation and DNA synthesis.	2.04	1	0	aromatic carboxylic acid; pyridines
gabapentin Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.	4.4	6	0	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
gemfibrozil [no description available]	4.53	7	0	aromatic ether	antilipemic drug
glafenine Glafenine: An anthranilic acid derivative with analgesic properties used for the relief of all types of pain.. glafenine : A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market.	4.09	4	0	aminoquinoline; carboxylic ester; glycol; organochlorine compound; secondary amino compound	inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
gliclazide Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.	2.74	3	0	N-sulfonylurea	hypoglycemic agent; insulin secretagogue; radical scavenger
glimepiride glimepiride: structure given in first source	4.4	6	0	sulfonamide
glipizide Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.	4.06	4	0	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glutethimide Glutethimide: A hypnotic and sedative. Its use has been largely superseded by other drugs.	2.74	3	0	piperidines
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	4.24	5	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester [no description available]	3.23	1	0	benzenes
granisetron [no description available]	4.06	4	0	aromatic amide; indazoles
guaifenesin Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.	3.6	2	0	methoxybenzenes
guanethidine Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.	3.85	3	0	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
guanfacine Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.	4.06	4	0	acetamides
guanidine Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.	3.23	1	0	carboxamidine; guanidines; one-carbon compound
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	4.4	6	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
halothane [no description available]	2.43	2	0	haloalkane; organobromine compound; organochlorine compound; organofluorine compound	inhalation anaesthetic
hexachlorophene Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.	2.77	3	0	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug
hexobarbital Hexobarbital: A barbiturate that is effective as a hypnotic and sedative.. hexobarbital : A member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups.	2.45	2	0	barbiturates
hexylresorcinol [no description available]	2.04	1	0	resorcinols
homochlorocyclizine homochlorocyclizine: RN given refers to parent cpd	2.45	2	0	diarylmethane
hycanthone Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.	2.75	3	0	thioxanthenes	mutagen; schistosomicide drug
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	4.41	6	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	4.25	5	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroflumethiazide Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.	3.85	3	0	benzothiadiazine; thiazide	antihypertensive agent; diuretic
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	3.58	2	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
hydroxyurea [no description available]	4.65	8	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	4.25	5	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
hypericin [no description available]	2.04	1	0
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	4.65	8	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
phenelzine Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.	4.41	6	0	primary amine
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	4.66	8	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifosfamide [no description available]	4.4	6	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	4.41	6	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.	4.65	8	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indapamide Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.	3.84	3	0	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	4.54	7	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iodamide Iodamide: An ionic monomeric contrast medium. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706). iodamide : A benzoic acid compound having iodo substituents at the 2-, 4- and 6-positions, an acetamido substituent at the 3-position and an acetamidomethyl substituent at the 5-position.	2.04	1	0	benzoic acids; organoiodine compound	radioopaque medium
iodixanol iodixanol: dimeric contrast media; structure given in first source. iodixanol : A dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography.	2.02	1	0	organoiodine compound	radioopaque medium
iohexol Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.	2.43	2	0	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
iopromide iopromide: structure given in first source. iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.	2.73	3	0	dicarboxylic acid diamide; organoiodine compound	environmental contaminant; nephrotoxic agent; radioopaque medium; xenobiotic
iothalamic acid Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.	2.44	2	0	organic molecular entity
iodipamide Iodipamide: A water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.. adipiodone : An organoiodine compound that is 3-amino-2,4,6-triiodobenzoic acid in which one of the amino hydrogens is substituted by a 6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl group. It is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.	2.04	1	0	benzoic acids; organoiodine compound; secondary carboxamide	radioopaque medium
ioversol [no description available]	3.56	2	0	amidobenzoic acid
iproniazid [no description available]	4.26	5	0	carbohydrazide; pyridines
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	4.08	4	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
isocarboxazid Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)	3.86	3	0	benzenes
isoflurane Isoflurane: A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.	2.02	1	0	organofluorine compound	inhalation anaesthetic
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	4.77	9	0	carbohydrazide	antitubercular agent; drug allergen
isopropamide iodide [no description available]	2.04	1	0	diarylmethane
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	3.85	3	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
isoxsuprine Isoxsuprine: A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.	3.58	2	0	alkylbenzene
isradipine Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.	4.06	4	0	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
itraconazole [no description available]	4.06	4	0	piperazines
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	3.58	2	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.45	2	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	5.04	12	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	4.4	6	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
ketorolac Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.	4.06	4	0	amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
ketotifen Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.	2.74	3	0	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
labetalol Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.	4.85	10	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
lamotrigine [no description available]	3.85	3	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.	4.06	4	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	4.08	4	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
letrozole [no description available]	3.85	3	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lomefloxacin lomefloxacin: structure given in first source. lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.	3.85	3	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antimicrobial agent; antitubercular agent; photosensitizing agent
lomustine [no description available]	3.58	2	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
loperamide Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.	3.23	1	0	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.	4.06	4	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
lorazepam Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.	4.07	4	0	benzodiazepine
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	4.54	7	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
loxapine Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.	3.84	3	0	dibenzooxazepine	antipsychotic agent; dopaminergic antagonist
maprotiline Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.	4.65	8	0	anthracenes
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	4.4	6	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
mecamylamine Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.	3.6	2	0	primary aliphatic amine
mechlorethamine nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.	3.58	2	0	nitrogen mustard; organochlorine compound	alkylating agent
meclizine Meclizine: A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.	3.87	3	0	diarylmethane
meclofenamic acid Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.	3.56	2	0	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
meclofenamate sodium anhydrous [no description available]	2.46	2	0	organic sodium salt
mefenamic acid Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.	4.25	5	0	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
mefloquine hydrochloride [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.	2.02	1	0	organofluorine compound; piperidines; quinolines; secondary alcohol
memantine [no description available]	4.26	5	0	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
vitamin k 3 Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.	2.97	4	0	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
mepenzolate mepenzolic acid: anticholinergic, antispasmodic agent; RN given refers to parent cpd; structure	3.23	1	0	diarylmethane
meperidine Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.	4.08	4	0	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
mephenytoin Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.	3.58	2	0	imidazolidine-2,4-dione	anticonvulsant
mepivacaine Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.	4.08	4	0	piperidinecarboxamide	drug allergen; local anaesthetic
meprobamate Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)	4.25	5	0	organic molecular entity
mesalamine Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.	4.06	4	0	amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols	non-steroidal anti-inflammatory drug
mesoridazine Mesoridazine: A phenothiazine antipsychotic with effects similar to CHLORPROMAZINE.. mesoridazine : A phenothiazine substituted at position 2 (para to the S atom) by a methylsulfinyl group, and on the nitrogen by a 2-(1-methylpiperidin-2-yl)ethyl group.	3.86	3	0	phenothiazines; sulfoxide; tertiary amino compound	dopaminergic antagonist; first generation antipsychotic
metaproterenol Metaproterenol: A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.. orciprenaline : A racemate composed of equimolar amounts of (R)- and (S)-orciprenaline. Used (as its sulfate salt) to relax the airway muscles and improve breathing for patients suffering from asthma or bronchitis.. 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol : A member of the class of resorcinols bearing an additional 1-hydroxy-2-(isopropanylamino)ethyl substituent at position 5 of resorcinol itself.	3.23	1	0	aralkylamino compound; phenylethanolamines; resorcinols; secondary alcohol; secondary amino compound
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	4.65	8	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methadone Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.	4.08	4	0	benzenes; diarylmethane; ketone; tertiary amino compound
methapyrilene Methapyrilene: Histamine H1 antagonist with sedative action used as a hypnotic and in allergies.. methapyrilene : A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group.	3.15	5	0	ethylenediamine derivative	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative
methazolamide Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.	3.23	1	0	sulfonamide; thiadiazoles
methocarbamol Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.	3.86	3	0	aromatic ether; carbamate ester; secondary alcohol
methoxsalen Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.	3.23	1	0	aromatic ether; psoralens	antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite
methoxyflurane Methoxyflurane: An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with NITROUS OXIDE to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180). methoxyflurane : An ether in which the two groups attached to the central oxygen atom are methyl and 2,2-dichloro-1,1-difluoroethyl.	2.04	1	0	ether; organochlorine compound; organofluorine compound	hepatotoxic agent; inhalation anaesthetic; nephrotoxic agent; non-narcotic analgesic
methyclothiazide Methyclothiazide: A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)	3.58	2	0	benzothiadiazine
nocodazole [no description available]	2.46	2	0	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
methyl salicylate methyl salicylate: used in over-the-counter liniments, ointments, lotions for relief of musculoskeletal aches and pains; has hemolytic effect on human & sheep erythrocytes; RN given refers to parent cpd; structure in Merck Index, 9th ed, #5990. methyl salicylate : A benzoate ester that is the methyl ester of salicylic acid.	2.04	1	0	benzoate ester; methyl ester; salicylates	flavouring agent; insect attractant; metabolite
methylphenidate Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.	4.41	6	0	beta-amino acid ester; methyl ester; piperidines
methyprylon methyprylon: was heading 1973-94 (see under HYPNOTICS AND SEDATIVES 1963-72); use PIPERIDONES to search METHYPRYLON 1973-94	2.04	1	0	organic molecular entity
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	4.24	5	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metolazone Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.	4.26	5	0	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor
metoprolol Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.	4.24	5	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	6.4	12	1	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
metyrapone Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.	3.58	2	0	aromatic ketone	antimetabolite; diagnostic agent; EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	4.24	5	0	aromatic ether; primary amino compound	anti-arrhythmia drug
mianserin Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.	2.97	4	0	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
miconazole Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	3.19	5	0	dichlorobenzene; ether; imidazoles
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	4.24	5	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
midodrine Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.. midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.	3.85	3	0	amino acid amide; aromatic ether; secondary alcohol	alpha-adrenergic agonist; prodrug; sympathomimetic agent; vasoconstrictor agent
milrinone [no description available]	3.85	3	0	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	4.07	4	0	dialkylarylamine; tertiary amino compound
mirtazapine Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.	4.06	4	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
mitotane Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.	3.23	1	0	diarylmethane
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	4.24	5	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
moclobemide Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.	2.73	3	0	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic
modafinil Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.. modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.. 2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.	3.86	3	0	monocarboxylic acid amide; sulfoxide
moxisylyte Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)	3.58	2	0	monoterpenoid
acecainide Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.	2.45	2	0	acetamides; benzamides	anti-arrhythmia drug
clorgyline Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.. clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.	2.04	1	0	aromatic ether; dichlorobenzene; terminal acetylenic compound; tertiary amino compound	antidepressant; EC 1.4.3.4 (monoamine oxidase) inhibitor
nabumetone Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.	3.56	2	0	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
nadolol [no description available]	3.23	1	0	tetralins
nalidixic acid [no description available]	5.85	29	0	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
naratriptan naratriptan: structure given in first source	3.85	3	0	heteroarylpiperidine; sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
nefazodone nefazodone: may be useful as an opiate adjunct	4.65	8	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nefopam Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.	2.04	1	0	benzoxazocine; tertiary amino compound
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	4.25	5	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nialamide Nialamide: An MAO inhibitor that is used as an antidepressive agent.	3.23	1	0	organonitrogen compound; organooxygen compound
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	4.06	4	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	4.65	8	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nilutamide [no description available]	3.85	3	0	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	4.09	4	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nimetazepam nimetazepam : A nitrazepam which is substituted at positions 1 by a methyl group. It is used as an anticonvulsant and as a hypnotic for the short-term management of insomnia.	2.04	1	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; GABA modulator; sedative
nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.	4.65	8	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nisoldipine Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.	4.54	7	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
nitrazepam Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).	2.73	3	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	2.96	4	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	3.58	2	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
nizatidine [no description available]	4.06	4	0	1,3-thiazoles; C-nitro compound; carboxamidine; organic sulfide; tertiary amino compound	anti-ulcer drug; cholinergic drug; H2-receptor antagonist
nomifensine Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.	4.41	6	0	isoquinolines	dopamine uptake inhibitor
masoprocol nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)	2.02	1	0	catechols; lignan; tetrol	antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	5.54	21	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	4.4	6	0	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
nylidrin Nylidrin: A beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor.	2.04	1	0	alkylbenzene
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	5.54	21	0	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	4.4	6	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	3.84	3	0	carbazoles
orphenadrine Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.. orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.	3.6	2	0	ether; tertiary amino compound	antidyskinesia agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
oxamniquine Oxamniquine: An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martindale, The Extra Pharmacopoeia, 31st ed, p121). oxamniquine : A racemate comprising equimolar amounts of (R)- and (S)-oxamniquine. An anthelmintic, it is administered orally for the treatment of schistomiasis caused by Schistosoma mansoni (but not by other Schistosoma species); intramuscular administration is no longer used as it causes severe pain at the injection site.. {2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol : A member of the class of quinolines that is 1,2,3,4-tetrahydroquinoline which is substituted at positions 2, 6, and 7 by (isopropylamino)methyl, hydroxymethyl, and nitro groups, respectively.	2.04	1	0	aromatic primary alcohol; C-nitro compound; quinolines; secondary amino compound
oxaprozin Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.	4.07	4	0	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug
oxazepam Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.	3.85	3	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
oxibendazole oxibendazole: structure	2.46	2	0	benzimidazoles; carbamate ester
oxidopamine Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).	2.05	1	0	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
oxiracetam oxiracetam: structure in first source	2.04	1	0	organonitrogen compound; organooxygen compound
oxolinic acid quinolone antibiotic : An organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.	2.44	2	0	aromatic carboxylic acid; organic heterotricyclic compound; oxacycle; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; antifungal agent; antiinfective agent; antimicrobial agent; enzyme inhibitor
oxprenolol Oxprenolol: A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.	2.04	1	0	aromatic ether
oxybutynin oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.	3.86	3	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
oxyphenbutazone Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27). oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.	2.07	1	0	phenols; pyrazolidines	antimicrobial agent; antineoplastic agent; antipyretic; drug metabolite; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic metabolite
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	4.09	4	0	aminobenzoic acid; phenols	antitubercular agent
pamidronate [no description available]	4.41	6	0	phosphonoacetic acid
pantoprazole Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.	3.85	3	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	3.85	3	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
4-dichlorobenzene dichlorobenzene : Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.. 1,4-dichlorobenzene : A dichlorobenzene carrying chloro groups at positions 1 and 4.	2.74	3	0	dichlorobenzene	insecticide
pargyline Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.	2.74	3	0	aromatic amine
pemoline Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.. pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.	4.07	4	0	1,3-oxazoles	central nervous system stimulant
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	4.06	4	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	3.85	3	0	barbiturates	GABAA receptor agonist
pentoxifylline [no description available]	4.06	4	0	oxopurine
perhexiline Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.	4.41	6	0	piperidines	cardiovascular drug
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	4.4	6	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacemide phenacemide: anti-epileptic drug; structure	2.44	2	0	acetamides
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	3.3	6	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
phenazopyridine Phenazopyridine: A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.. phenazopyridine : A diaminopyridine that is 2,6-diaminopyridine substituted at position 3 by a phenylazo group. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.	2.44	2	0	diaminopyridine; monoazo compound	anticoronaviral agent; carcinogenic agent; local anaesthetic; non-narcotic analgesic
phenindione Phenindione: An indandione that has been used as an anticoagulant. Phenindione has actions similar to WARFARIN, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)	2.04	1	0	aromatic ketone; beta-diketone	anticoagulant
pheniramine Pheniramine: One of the HISTAMINE H1 ANTAGONISTS with little sedative action. It is used in treatment of hay fever, rhinitis, allergic dermatoses, and pruritus.	2.04	1	0	pyridines; tertiary amino compound
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	4.54	7	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
phenolphthalein Phenolphthalein: An acid-base indicator which is colorless in acid solution, but turns pink to red as the solution becomes alkaline. It is used medicinally as a cathartic.	2.04	1	0	phenols
phenoxybenzamine Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.	3.6	2	0	aromatic amine
phentermine Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.	4.26	5	0	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent
4-phenylbutyric acid 4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.	3.23	1	0	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug
phenylbutazone Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.	2.75	3	0	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
moxonidine moxonidine: structure given in first source	2.45	2	0	organohalogen compound; pyrimidines
pimobendan pimobendan: produces arterial & venous dilatation in dogs; structure given in first source	2.04	1	0	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
pinacidil Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)	2.46	2	0	pyridines
pindolol Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.	4.53	7	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	4.09	4	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
pipobroman Pipobroman: An antineoplastic agent that acts by alkylation.. pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.	2.04	1	0	N-acylpiperazine; organobromine compound; tertiary carboxamide	alkylating agent; antineoplastic agent
pirbuterol pirbuterol: structure	2.02	1	0	pyridines
piretanide piretanide: potent inhibitor of chloride transport; structure	2.45	2	0	aromatic ether
polythiazide [no description available]	3.58	2	0	benzothiadiazine
practolol Practolol: A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS.. practolol : N-(4-Hydroxyphenyl)acetamide in which the hydrogen of the phenolic hydroxy group is substituted by a 3-(isopropylaminoamino)-2-hydroxypropyl group. A selective beta blocker, it has been used in the emergency treatment of cardiac arrhythmias.	2.05	1	0	acetamides; ethanolamines; propanolamine; secondary alcohol; secondary amino compound	anti-arrhythmia drug; beta-adrenergic antagonist
duodote duodote: consists of atropine and pralidoxime chloride; for treating those exposed to organophosphorus-containing nerve agents	3.23	1	0	pyridinium ion	antidote to organophosphate poisoning; antidote to sarin poisoning; cholinergic drug; cholinesterase reactivator
pyranoprofen pyranoprofen: RN given refers to unlabled parent cpd; structure given in first source	2.04	1	0	pyridochromene
prazepam Prazepam: A benzodiazepine that is used in the treatment of ANXIETY DISORDERS.	2.02	1	0	benzodiazepine
praziquantel azinox: Russian drug	4.07	4	0	isoquinolines
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	4.06	4	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine Prilocaine: A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.. prilocaine : An amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic.	2.44	2	0	amino acid amide; monocarboxylic acid amide	anticonvulsant; local anaesthetic
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	3.85	3	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
primidone Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.	4.25	5	0	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	4.76	9	0	benzoic acids; sulfonamide	uricosuric drug
probucol Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.	2.74	3	0	dithioketal; polyphenol	anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	4.53	7	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
procaine Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).. procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.	2.45	2	0	benzoate ester; substituted aniline; tertiary amino compound	central nervous system depressant; drug allergen; local anaesthetic; peripheral nervous system drug
procarbazine Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	3.84	3	0	benzamides; hydrazines	antineoplastic agent
prochlorperazine Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.	3.86	3	0	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
procyclidine Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.	3.58	2	0	pyrrolidines; tertiary alcohol	antidyskinesia agent; antiparkinson drug; muscarinic antagonist
proglumide Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.. proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.. N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.	2.04	1	0	benzamides; dicarboxylic acid monoamide; glutamine derivative; racemate	anti-ulcer drug; cholecystokinin antagonist; cholinergic antagonist; delta-opioid receptor agonist; drug metabolite; gastrointestinal drug; opioid analgesic; xenobiotic metabolite
promazine Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.	2.74	3	0	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	4.25	5	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	3.84	3	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propantheline Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.	3.23	1	0	xanthenes
propiomazine propiomazine: was heading 1966-94 (prov 1966-72); use PHENOTHIAZINES to search PROPIOMAZINE 1966-94; phenothiazine derivative used for sedation and as an antiemetic during labor. propiomazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 2-(dimethylamino)propyl group at nitrogen atom and a propanoyl group at position 2.	2.04	1	0	aromatic ketone; phenothiazines; tertiary amino compound	dopaminergic antagonist; histamine antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; sedative; serotonergic antagonist
propofol Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.	4.25	5	0	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	4.66	8	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
protriptyline Protriptyline: Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.	3.58	2	0	carbotricyclic compound	antidepressant
proxyphylline [no description available]	2.04	1	0	oxopurine
pyridostigmine [no description available]	4.08	4	0	pyridinium ion
pyrilamine Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.. mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.	2.07	1	0	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
pyrimethamine Maloprim: contains above 2 cpds	4.08	4	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
sch 16134 quazepam: structure given in first source	3.56	2	0	benzodiazepine
quetiapine [no description available]	3.23	1	0	dibenzothiazepine; N-alkylpiperazine; N-arylpiperazine	adrenergic antagonist; dopaminergic antagonist; histamine antagonist; second generation antipsychotic; serotonergic antagonist
rabeprazole Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.	3.85	3	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
raloxifene raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.	4.09	4	0	1-benzothiophenes; aromatic ketone; N-oxyethylpiperidine; phenols	bone density conservation agent; estrogen antagonist; estrogen receptor modulator
ranitidine [no description available]	3.43	7	0	aralkylamine
resorcinol resorcinol: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7951. resorcinol : A benzenediol that is benzene dihydroxylated at positions 1 and 3.	2.04	1	0	benzenediol; phenolic donor; resorcinols	erythropoietin inhibitor; sensitiser
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	4.07	4	0	benzothiazoles
rimantadine Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.	3.56	2	0	alkylamine
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	4.4	6	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
rizatriptan rizatriptan: structure given in first source; RN given refers to benzoate	4.07	4	0	tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rofecoxib [no description available]	2.04	1	0	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
ropinirole [no description available]	3.23	1	0	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist
salmeterol xinafoate salmeterol : A racemate consisting of equal parts of (R)- and (S)-salmeterol. It is a potent and selective beta2-adrenoceptor agonist (EC50 = 5.3 nM). Unlike other beta2 agonists, it binds to the exo-site domain of beta2 receptors, producing a slow onset of action and prolonged activation.. 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol : A phenol having a hydroxymethyl group at C-2 and a 1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl group at C-4; derivative of phenylethanolamine.	2.02	1	0	ether; phenols; primary alcohol; secondary alcohol; secondary amino compound
salicylsalicylic acid salicylsalicylic acid: structure. salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.	3.58	2	0	benzoate ester; benzoic acids; phenols; salicylates	antineoplastic agent; antirheumatic drug; EC 3.5.2.6 (beta-lactamase) inhibitor; hypoglycemic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
secobarbital Secobarbital: A barbiturate that is used as a sedative. Secobarbital is reported to have no anti-anxiety activity.. secobarbital : A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by prop-2-en-1-yl and pentan-2-yl groups.	3.58	2	0	barbiturates	anaesthesia adjuvant; GABA modulator; sedative
semustine Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.. semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group.	2.04	1	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent
sevoflurane Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.. sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.	2.02	1	0	ether; organofluorine compound	central nervous system depressant; inhalation anaesthetic; platelet aggregation inhibitor
sibutramine sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride	3.23	1	0	organochlorine compound; tertiary amino compound	anti-obesity agent; serotonin uptake inhibitor
sulfadiazine Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.	4.4	6	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
ipodate Ipodate: Ionic monomeric contrast media. Usually the sodium or calcium salts are used for examination of the gall bladder and biliary tract. (From Martindale, The Extra Pharmacopoeia, 30th ed, p704)	2.04	1	0
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	4.08	4	0	pyridines
sotalol Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.	4.54	7	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
imatinib [no description available]	3.85	3	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
streptonigrin [no description available]	2.04	1	0	pyridines; quinolone	antimicrobial agent; antineoplastic agent
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.58	2	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
succinylcholine Succinylcholine: A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.. succinylcholine : A quaternary ammonium ion that is the bis-choline ester of succinic acid.	3.58	2	0	quaternary ammonium ion; succinate ester	drug allergen; muscle relaxant; neuromuscular agent
sulconazole sulconazole: RN given refers to cpd with unspecified isomeric designation; structure given in first source. sulconazole : A racemate comprising equimolar amounts of (R)- and (S)-sulconazole. An antifungal agent with activity against Candida species, it is used (generally as the nitrate salt) for the topical treatment of fungal skin infections.. 1-{2-[(4-chlorobenzyl)sulfanyl]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole : A member of the class of imidazoles that is 1-ethyl-1H-imidazole in which one of the hydrogens of the methyl group is replaced by a (4-chlorobenzyl)sulfanediyl group while a second is replaced by a 2,4-dichlorophenyl group.	2.02	1	0	dichlorobenzene; imidazoles; monochlorobenzenes; organic sulfide
sulfabenzamide sulfabenzamide : A sulfonamide containing a benzamido substituent on nitrogen. An antibacterial/antimicrobial, it is often used in conjunction with sulfathiazole and sulfacetamide as a topical, intravaginal antibacterial preparation.	2.46	2	0	benzenes; sulfonamide antibiotic; sulfonamide	antibacterial drug; antimicrobial drug
sulfacetamide Sulfacetamide: An anti-bacterial agent that is used topically to treat skin infections and orally for urinary tract infections.. sulfacetamide : A sulfonamide that is sulfanilamide acylated on the sulfonamide nitrogen.	2.46	2	0	N-sulfonylcarboxamide; substituted aniline	antibacterial drug; antiinfective agent; antimicrobial agent; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfadimethoxine Sulfadimethoxine: A sulfanilamide that is used as an anti-infective agent.. sulfadimethoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position.	2.04	1	0	aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic
sulfaguanidine Sulfaguanidine: A sulfanilamide antimicrobial agent that is used to treat enteric infections.. sulfaguanidine : A sulfonamide incorporating a guanidine moiety used to block the synthesis of folic acid; mostly used in veterinary medicine	2.04	1	0	sulfonamide antibiotic	antiinfective agent
sulfamethazine Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.. sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position.	2.04	1	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antibacterial drug; antiinfective agent; antimicrobial agent; carcinogenic agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; ligand; xenobiotic
sulfamethizole Sulfamethizole: A sulfathiazole antibacterial agent.. sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.	3.86	3	0	sulfonamide antibiotic; sulfonamide; thiadiazoles	antiinfective agent; antimicrobial agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.	4.06	14	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
sulfamethoxypyridazine Sulfamethoxypyridazine: A sulfanilamide antibacterial agent.. sulfamethoxypyridazine : A sulfonamide consisting of pyridazine having a methoxy substituent at the 6-position and a 4-aminobenzenesulfonamido group at the 3-position.	2.04	1	0	pyridazines; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfanilamide [no description available]	2.74	3	0	substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; drug allergen; EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfaphenazole Sulfaphenazole: A sulfonilamide anti-infective agent.. sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.	2.07	1	0	primary amino compound; pyrazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial drug; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor; P450 inhibitor
sulfapyridine Sulfapyridine: Antibacterial, potentially toxic, used to treat certain skin diseases.. sulfapyridine : A sulfonamide consisting of pyridine with a 4-aminobenzenesulfonamido group at the 2-position.	2.04	1	0	pyridines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; dermatologic drug; drug allergen; environmental contaminant; xenobiotic
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	4.41	6	0
sulfathiazole Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.	3.85	3	0	1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
sulfinpyrazone Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.	2.96	4	0	pyrazolidines; sulfoxide	uricosuric drug
sulfisoxazole Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.	2.73	3	0	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
sulfobromophthalein Sulfobromophthalein: A phenolphthalein that is used as a diagnostic aid in hepatic function determination.	2.45	2	0	2-benzofurans; organobromine compound; organosulfonic acid; phenols	dye
sulfoxone sulfoxone: RN given refers to parent cpd	2.04	1	0	sulfonamide
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol [no description available]	3.23	1	0	alkylbenzene
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	2.46	2	0	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
sumatriptan Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.	4.65	8	0	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
suprofen Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.	2.73	3	0	aromatic ketone; monocarboxylic acid; thiophenes	antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	2.96	4	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	3.75	10	0	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tazarotene tazarotene: a topical acetylenic retinoid; a topical kerytolytic. tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.	2.02	1	0	acetylenic compound; ethyl ester; pyridines; retinoid; thiochromane	keratolytic drug; prodrug; teratogenic agent
tegafur [no description available]	2.04	1	0	organohalogen compound; pyrimidines
telenzepine telenzepine: structure given in first source	2.05	1	0	benzodiazepine
temazepam Temazepam: A benzodiazepine that acts as a GAMMA-AMINOBUTYRIC ACID modulator and anti-anxiety agent.	3.56	2	0	benzodiazepine
temozolomide [no description available]	4.08	4	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
terazosin Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia	4.4	6	0	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
terbutaline Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.	4.4	6	0	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.73	3	0	diarylmethane
tetracaine Tetracaine: A potent local anesthetic of the ester type used for surface and spinal anesthesia.. tetracaine : A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia.	2.04	1	0	benzoate ester; tertiary amino compound	local anaesthetic
tetrahydroxy-1,4-quinone tetrahydroxy-1,4-quinone: structure. tetrahydroxy-1,4-benzoquinone : A hydroxybenzoquinone in which all four protons of the benzoquinone structure are substituted by hydroxy groups. A systemic keratolytic, it is normally supplied as its hydrate (CHEBI:137471).	2.13	1	0	hydroxybenzoquinone	keratolytic drug
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	3.85	3	0	phthalimides; piperidones
thiabendazole Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate	3.58	2	0	1,3-thiazoles; benzimidazole fungicide; benzimidazoles	antifungal agrochemical; antinematodal drug
2,2'-thiodiethanol 2,2'-thiodiethanol: product of yperite hydrolysis; a hydrolysis product opf mustard gas; strongly stimulates differentiation of chick embryo myogenic cells. thiodiglycol : A diol that is pentane-1,5-diol in which the methylene group at position 3 is replaced by a sulfur atom	2.04	1	0	aliphatic sulfide; diol	antineoplastic agent; antioxidant; metabolite; solvent
thioridazine Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.	4.06	4	0	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	4.24	5	0	aziridines
tiaramide tiaramide: NTA-194, solantal, FK 1160 refer to mono-HCl salt; RN given refers to parent cpd; structure	2.04	1	0	benzothiazoles
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	4.41	6	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
tilorone Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.	2.45	2	0	aromatic ether; diether; fluoren-9-ones; tertiary amino compound	anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist
tinidazole Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.	3.85	3	0	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug
tioconazole tioconazole : A racemate comprising equimolar amounts of (R)- and (S)-tioconazole.. 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that comprises 2-(2,4-dichlorophenyl)ethylimidazole carrying an additional (2-chloro-3-thienyl)methoxy substituent at position 2.	3	4	0	dichlorobenzene; ether; imidazoles; thiophenes
tiopronin Tiopronin: Sulfhydryl acylated derivative of GLYCINE.	3.84	3	0	N-acyl-amino acid
tizanidine tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.	4.24	5	0	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant
tolazamide Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.. tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.	4.08	4	0	N-sulfonylurea	hypoglycemic agent; potassium channel blocker
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	4.41	6	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
tolmetin Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.. tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.	3.86	3	0	aromatic ketone; monocarboxylic acid; pyrroles	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
tolperisone Tolperisone: A centrally acting muscle relaxant that has been used for the symptomatic treatment of spasticity and muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1211)	2.04	1	0	aromatic ketone
ultram 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.	4.24	5	0	aromatic ether; tertiary alcohol; tertiary amino compound
tranexamic acid Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.	3.58	2	0	amino acid
trazodone Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.	3.84	3	0	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine	adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	4.07	4	0	pteridines	diuretic; sodium channel blocker
triazolam Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.	4.06	4	0	triazolobenzodiazepine	sedative
trichlormethiazide Trichlormethiazide: A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830). trichlormethiazide : A benzothiadiazine, hydrogenated at positions 2, 3 and 4 and substituted with an aminosulfonyl group at C-7, a chloro substituent at C-6 and a dichloromethyl group at C-3 and with S-1 as an S,S-dioxide. A sulfonamide antibiotic, it is used as a diuretic to treat oedema (including that associated with heart failure) and hypertension.	2.44	2	0	benzothiadiazine; sulfonamide antibiotic	antihypertensive agent; diuretic
2,2',2''-trichlorotriethylamine 2,2',2''-trichlorotriethylamine: RN given refers to parent cpd; structure	2.04	1	0
trientine Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.. TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.. 2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.	2.02	1	0	polyazaalkane; tetramine	copper chelator
trifluoperazine [no description available]	4.07	4	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trifluperidol Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)	2.04	1	0	aromatic ketone
trihexyphenidyl Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.	3.23	1	0	amine
trimebutine Trimebutine: Proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.	2.04	1	0	trihydroxybenzoic acid
trimethadione Trimethadione: An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378). trimethadione : An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.	4.4	6	0	oxazolidinone	anticonvulsant; geroprotector
trimethobenzamide trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd. trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.	3.23	1	0	benzamides; tertiary amino compound	antiemetic
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	5.67	24	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
trimetrexate Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.	4.24	5	0
trimipramine Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.. trimipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.	4.24	5	0	dibenzoazepine; tertiary amino compound	antidepressant; environmental contaminant; xenobiotic
tripelennamine Tripelennamine: A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat ASTHMA; HAY FEVER; URTICARIA; and RHINITIS; and also in veterinary applications. Tripelennamine is administered by various routes, including topically.	2.45	2	0	aromatic amine
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	4.26	5	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
tyramine [no description available]	3.23	1	0	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	3.58	2	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
urapidil [no description available]	2.04	1	0	piperazines
urethane [no description available]	2.04	1	0	carbamate ester	fungal metabolite; mutagen
venlafaxine venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.	4.4	6	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
vesamicol vesamicol: RN given refers to parent cpd; structure	2.04	1	0	piperidines
vigabatrin [no description available]	3.23	1	0	gamma-amino acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
viloxazine Viloxazine: A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.	2.04	1	0	aromatic ether
pirinixic acid pirinixic acid: structure	2.46	2	0	aryl sulfide; organochlorine compound; pyrimidines
ici 204,219 zafirlukast: a leukotriene D4 receptor antagonist	4.25	5	0	carbamate ester; indoles; N-sulfonylcarboxamide	anti-asthmatic agent; leukotriene antagonist
zaleplon zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.	3.85	3	0	nitrile; pyrazolopyrimidine	anticonvulsant; anxiolytic drug; central nervous system depressant; sedative
zolpidem Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.	4.54	7	0	imidazopyridine	central nervous system depressant; GABA agonist; sedative
zomepirac zomepirac: RN given refers to parent cpd; structure	2.96	4	0	aromatic ketone; monocarboxylic acid; monochlorobenzenes; pyrroles	cardiovascular drug; non-steroidal anti-inflammatory drug
zonisamide Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.	3.23	1	0	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
zopiclone zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.	2.45	2	0	monochloropyridine; pyrrolopyrazine	central nervous system depressant; sedative
cortisone acetate Cortisone Acetate: The acetate ester of cortisone that is used mainly for replacement therapy in adrenocortical insufficiency and in the treatment of many allergic and inflammatory disorders.	3.23	1	0	corticosteroid hormone
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	3.6	2	0	mitomycin	alkylating agent; antineoplastic agent
oxyphenonium Oxyphenonium: A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of ATROPINE. It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect.	2.46	2	0	acylcholine
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	3.85	3	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
estriol hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.	2.07	1	0	16alpha-hydroxy steroid; 17beta-hydroxy steroid; 3-hydroxy steroid	estrogen; human metabolite; human xenobiotic metabolite; mouse metabolite
lysergic acid diethylamide Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.. lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.	2.45	2	0	ergoline alkaloid; monocarboxylic acid amide; organic heterotetracyclic compound	dopamine agonist; hallucinogen; serotonergic agonist
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	3.58	2	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
cephaloridine Cephaloridine: A cephalosporin antibiotic.. cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.	4.68	27	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
phentolamine Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.	3.58	2	0	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
sorbitol D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).	4.08	4	0	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.	3.3	6	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent
triethylenemelamine Triethylenemelamine: Toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers.	2.04	1	0	1,3,5-triazines	alkylating agent; insect sterilant
isoproterenol hydrochloride [no description available]	2.46	2	0	catechols
thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.	3.23	1	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
dextroamphetamine Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.	3.23	1	0	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent
norethindrone acetate norethisterone acetate : A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.	2.04	1	0	3-oxo-Delta(4) steroid; acetate ester; terminal acetylenic compound	progestin; synthetic oral contraceptive
spironolactone Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.	4.07	4	0	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
cyclobarbital cyclobarbital: was heading 1977-94 (see under BARBITURATES 1977-90); CYCLOBARBITONE, HEXEMAL, & TETRAHYDROPHENOBARBITAL were see CYCLOBARBITAL 1977-94; use BARBITURATES to search CYCLOBARBITAL 1977-94; short to intermediate duration barbiturate used as hypnotic and sedative	2.04	1	0	barbiturates
allobarbital allobarbital: was heading 1976-94 (see under BARBITURATES 1976-90); ALLOBARBITONE, DIALLYLBARBITAL, DIALLYLBARBITURIC ACID, & DIALLYLMAL were see ALLOBARBITAL 1976-94; use BARBITURATES to search ALLOBARBITAL 1976-94; a barbiturate derivative with effects of intermediate duration; at lower doses, it is used as a sedative; at higher doses, it displays hypnotic effects	2.04	1	0	barbiturates
penicillamine Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.	3.84	3	0	non-proteinogenic alpha-amino acid; penicillamine	antirheumatic drug; chelator; copper chelator; drug allergen
norethandrolone Norethandrolone: A synthetic hormone with anabolic and androgenic properties and moderate progestational activity.	2.04	1	0	corticosteroid hormone
cysteine [no description available]	3.23	1	0	cysteine zwitterion; cysteine; L-alpha-amino acid; proteinogenic amino acid; serine family amino acid	EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; flour treatment agent; human metabolite
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	4.54	7	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	3.86	3	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
paramethasone Paramethasone: A glucocorticoid with the general properties of corticosteroids. It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than HYDROCORTISONE with supplementary FLUDROCORTISONE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p737)	2.04	1	0	fluorinated steroid
oxandrolone Oxandrolone: A synthetic hormone with anabolic and androgenic properties.	3.58	2	0	17beta-hydroxy steroid; 3-oxo steroid; anabolic androgenic steroid; oxa-steroid	anabolic agent; androgen
promazine hydrochloride [no description available]	2.46	2	0	hydrochloride
2-acetylaminofluorene 2-Acetylaminofluorene: A hepatic carcinogen whose mechanism of activation involves N-hydroxylation to the aryl hydroxamic acid followed by enzymatic sulfonation to sulfoxyfluorenylacetamide. It is used to study the carcinogenicity and mutagenicity of aromatic amines.	2.05	1	0	2-acetamidofluorenes	antimitotic; carcinogenic agent; epitope; mutagen
azauridine Azauridine: A triazine nucleoside used as an antineoplastic antimetabolite. It interferes with pyrimidine biosynthesis thereby preventing formation of cellular nucleic acids. As the triacetate, it is also effective as an antipsoriatic.	2.04	1	0	N-glycosyl-1,2,4-triazine	antimetabolite; antineoplastic agent; drug metabolite
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	8.06	67	1	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
idoxuridine [no description available]	2.74	3	0	organoiodine compound; pyrimidine 2'-deoxyribonucleoside	antiviral drug; DNA synthesis inhibitor
metaraminol Metaraminol: A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.. metaraminol : A member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension.	2.07	1	0	phenylethanolamines	alpha-adrenergic agonist; sympathomimetic agent; vasoconstrictor agent
pilocarpine Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.	4.25	5	0	pilocarpine	antiglaucoma drug
triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.	4.09	4	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
isonicotinic acid isonicotinic acid : A pyridinemonocarboxylic acid in which the carboxy group is at position 4 of the pyridine ring.	2.05	1	0	pyridinemonocarboxylic acid	algal metabolite; human metabolite
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.75	3	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
desoxycorticosterone acetate Desoxycorticosterone Acetate: The 21-acetate derivative of desoxycorticosterone.	2.04	1	0	corticosteroid hormone
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	6.24	43	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	3.23	1	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.04	1	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
vincristine [no description available]	4.06	4	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
physostigmine Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.	4.26	5	0	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	3.3	6	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
testosterone propionate Testosterone Propionate: An ester of TESTOSTERONE with a propionate substitution at the 17-beta position.. androgen : A sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.	2.02	1	0	steroid ester
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	3.58	2	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
aminopyrine Aminopyrine: A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.. aminophenazone : A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.	2.07	1	0	pyrazolone; tertiary amino compound	antipyretic; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
methyltestosterone Methyltestosterone: A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL).. methyltestosterone : A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.	3.23	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; enone	anabolic agent; androgen; antineoplastic agent
dromostanolone dromostanolone: synthetic anabolic androgenic steroid used to lower plasma cholesterol & as antineoplastic agent in advanced breast neoplasms; major descriptor (66-86); on-line search ANDROSTANOLS (80-86); ANDROSTANES (68-86); INDEX MEDICUS search DROMOSTANOLONE (66-86); RN given refers to (2alpha,5alpha,17beta)-isomer	2.04	1	0	17beta-hydroxy steroid; 3-oxo-5alpha-steroid; anabolic androgenic steroid	anabolic agent; antineoplastic agent
promethazine hydrochloride [no description available]	2.46	2	0	hydrochloride	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; geroprotector; H1-receptor antagonist; local anaesthetic; sedative
tetrabenazine 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one : A benzoquinolizine that is 1,2,3,4,4a,9,10,10a-octahydrophenanthrene in which the carbon at position 10a is replaced by a nitrogen and which is substituted by an isobutyl group at position 2, an oxo group at position 3, and methoxy groups at positions 6 and 7.	3.23	1	0	benzoquinolizine; cyclic ketone; tertiary amino compound
cephalothin Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.	5.72	78	0	azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes	antibacterial drug; antimicrobial agent
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	5.29	16	0	kanamycins	bacterial metabolite
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.04	1	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
thiamine [no description available]	2.04	1	0	organic chloride salt; vitamin B1
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	3.14	5	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	4.43	6	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
cysteamine Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.	3.58	2	0	amine; thiol	geroprotector; human metabolite; mouse metabolite; radiation protective agent
acetylcholine chloride acetylcholine chloride : The chloride salt of acetylcholine, and a parasympatomimetic drug.	3.86	3	0	quaternary ammonium salt
mepazine mepazine: major descriptor (66-85); on-line search PHENOTHIAZINES (66-85); Index Medicus search MEPAZINE (66-85); RN given refers to parent cpd. pacatal : A phenothiazine derivative in which 10H-phenothiazine has an N-methylpiperidin-4-ylmethyl substituent at the N-10 position.	3.23	1	0	phenothiazines
methoxamine hydrochloride [no description available]	2.46	2	0	dimethoxybenzene
methicillin Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.	3.17	5	0	penicillin allergen; penicillin	antibacterial drug
niridazole Niridazole: An antischistosomal agent that has become obsolete.	2.04	1	0	1,3-thiazoles; C-nitro compound
cloxacillin Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.	5.16	14	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial agent; antibacterial drug
bretylium tosylate Bretylium Tosylate: An agent that blocks the release of adrenergic transmitters and may have other actions. It was formerly used as an antihypertensive agent, but is now proposed as an anti-arrhythmic.. bretylium tosylate : The tosylate salt of bretylium. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation.	2.43	2	0	organosulfonate salt; quaternary ammonium salt	adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent
zoxazolamine Zoxazolamine: A uricosuric and muscle relaxant. Zoxazolamine acts centrally as a muscle relaxant, but the mechanism of its action is not understood.	2.46	2	0	benzoxazole
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	2.46	2	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
aniline [no description available]	2.04	1	0	anilines; primary arylamine
calcium acetate calcium acetate: a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer. calcium acetate : The calcium salt of acetic acid. It is used, commonly as a hydrate, to treat hyperphosphataemia (excess phosphate in the blood) in patients with kidney disease: the calcium ion combines with dietary phosphate to form (insoluble) calcium phosphate, which is excreted in the faeces.	3.23	1	0	calcium salt	chelator
dimethylnitrosamine Dimethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. It causes serious liver damage and is a hepatocarcinogen in rodents.	2.46	2	0	nitrosamine	geroprotector; mutagen
lactose Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.. beta-lactose : The beta-anomer of lactose.	2.46	2	0	lactose
primaquine phosphate [no description available]	2.46	2	0
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	3.23	1	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	4.54	7	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
gallamine triethiodide Gallamine Triethiodide: A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of TUBOCURARINE, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)	2.74	3	0
mebanazine mebanazine: RN given refers to parent cpd without isomeric designation; structure	3.23	1	0	benzenes
uracil mustard Uracil Mustard: Nitrogen mustard derivative of URACIL. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage.	2.74	3	0	aminouracil; nitrogen mustard
oxacillin Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.	7.1	25	1	penicillin	antibacterial agent; antibacterial drug
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.44	2	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
chloroform Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.	2.75	3	0	chloromethanes; one-carbon compound	carcinogenic agent; central nervous system drug; inhalation anaesthetic; non-polar solvent; refrigerant
fluocinolone acetonide Fluocinolone Acetonide: A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluocinolone acetonide : A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders.	2.04	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; glucocorticoid; organic heteropentacyclic compound; primary alpha-hydroxy ketone	anti-inflammatory drug; antipruritic drug
dimethylformamide Dimethylformamide: A formamide in which the amino hydrogens are replaced by methyl groups.. N,N-dimethylformamide : A member of the class of formamides that is formamide in which the amino hydrogens are replaced by methyl groups.	2.05	1	0	formamides; volatile organic compound	geroprotector; hepatotoxic agent; polar aprotic solvent
norethindrone Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.	2.46	2	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	progestin; synthetic oral contraceptive
cycloserine Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).	3.23	1	0	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
triaziquone Triaziquone: Alkylating antineoplastic agent used mainly for ovarian tumors. It is toxic to skin, gastrointestinal tract, bone marrow and kidneys.. triaziquone : A member of the class of 1,4-benzoquinones that is 1,4-benzoquinone in which three of the ring hydrogens are replaced by aziridin-1-yl groups.	2.04	1	0	1,4-benzoquinones; aziridines	alkylating agent; antineoplastic agent
benziodarone benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)	3.23	1	0	aromatic ketone
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	7.09	102	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
mannitol [no description available]	3.58	2	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
cytarabine [no description available]	4.25	5	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
trifluridine Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.	2.43	2	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor
4-hydroxypropiophenone [no description available]	2.04	1	0	acetophenones
medroxyprogesterone acetate [no description available]	2.73	3	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
sulfobromophthalein sodium bromosulfophthalein sodium : An organic sodium salt that is the disodium salt of bromosulfophthalein.. bromosulfophthalein : An organosulfonic acid that consists of phthalide bearing four bromo substituents at positions 4, 5, 6 and 7 as well as two 4-hydroxy-3-sulfophenyl groups both located at position 1.	2.04	1	0	organic sodium salt	dye
mestranol [no description available]	2.96	4	0	17beta-hydroxy steroid; aromatic ether; terminal acetylenic compound	prodrug; xenoestrogen
methandrostenolone Methandrostenolone: A synthetic steroid with anabolic properties that are more pronounced than its androgenic effects. It has little progestational activity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1188)	2.04	1	0	organic molecular entity
chlorquinaldol Chlorquinaldol: Local anti-infective agent used for skin, gastrointestinal, and vaginal infections with fungi, protozoa, and certain bacteria. In animals, it causes central nervous system damage and is not administered parenterally. It is also used as antiseptic, fungistat, or deodorant.. chlorquinaldol : A monohydroxyquinoline that is quinolin-8-ol which is substituted by a methyl group at position 2 and by chlorine at positions 5 and 7. An antifungal and antibacterial, it was formerly used for topical treatment of skin conditions and vaginal infections.	2.41	1	0	monohydroxyquinoline; organochlorine compound	antibacterial drug; antiprotozoal drug; antiseptic drug
quinethazone quinethazone: RN given for cpd without isomeric designation. quinethazone : A member of the class of quinazolines that is quinazolin-4-one substituted at positions 2, 6 and 7 by ethyl, sulfamoyl and chloro groups respectively; a thiazide-like diuretic used to treat hypertension.	2.04	1	0	quinazolines	antihypertensive agent; diuretic
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	3.86	3	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
bromoethane bromoethane : A bromoalkane that is ethane carrying a bromo substituent. It is an alkylating agent used as a chemical intermediate in various organic syntheses.	2.05	1	0	bromoalkane; bromohydrocarbon; volatile organic compound	alkylating agent; carcinogenic agent; local anaesthetic; refrigerant; solvent
tribromoethanol tribromoethanol: major descriptor (66-90); on-line search ETHANOL (66-90); INDEX MEDICUS search TRIBROMOETHANOL (66-90)	2.04	1	0	alcohol; organobromine compound
dalapon dalapon: RN given refers to parent cpd; structure	2.04	1	0	carboxylic acid; organohalogen compound
perflutren Definity: a fluorocarbon-filled ultrasonic contrast agent; Definity is tradename. octafluoropropane : A fluorocarbon that is propane in which all of the hydrogens have been replaced by fluorines.	3.23	1	0	fluoroalkane; fluorocarbon
triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.	2.04	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
fluoxymesterone Fluoxymesterone: An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.	3.23	1	0	11beta-hydroxy steroid; 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid; fluorinated steroid	anabolic agent; antineoplastic agent
mepenzolate bromide [no description available]	2.04	1	0	diarylmethane
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	2.45	2	0	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
methsuximide methsuximide: anticonvulsant effective in petit mal & psychomotor epilepsy; has a number of unpleasant & toxic side effects; minor descriptor (75-86); on-line & INDEX MEDICUS search SUCCINIMIDES (75-86); RN given refers to parent cpd without isomeric designation	3.23	1	0	organic molecular entity
carbromal carbromal: was heading 1963-94 (Prov 1963-73); use UREA to search CARBROMAL 1963-94	2.04	1	0	N-acylurea
methylpentynol methylpentynol: structure	2.04	1	0	ynone
tromethamine Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)	3.86	3	0	primary amino compound; triol	buffer
triparanol Triparanol: Antilipemic agent with high ophthalmic toxicity. According to Merck Index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts.	2.45	2	0	stilbenoid	anticoronaviral agent
trichloroethylene Trichloroethylene: A highly volatile inhalation anesthetic used mainly in short surgical procedures where light anesthesia with good analgesia is required. It is also used as an industrial solvent. Prolonged exposure to high concentrations of the vapor can lead to cardiotoxicity and neurological impairment.. triol : A chemical compound containing three hydroxy groups.	2.46	2	0	chloroethenes	inhalation anaesthetic; mouse metabolite
dichloroacetic acid [no description available]	2.04	1	0	monocarboxylic acid; organochlorine compound	astringent; marine metabolite
pantothenic acid Pantothenic Acid: A butyryl-beta-alanine that can also be viewed as pantoic acid complexed with BETA ALANINE. It is incorporated into COENZYME A and protects cells against peroxidative damage by increasing the level of GLUTATHIONE.. pantothenic acid : A member of the class of pantothenic acids that is an amide formed from pantoic acid and beta-alanine.. vitamin B5 : Any member of a group of vitamers that belong to the chemical structural class called pantothenic acids that exhibit biological activity against vitamin B5 deficiency. Deficiency of vitamin B5 is rare due to its widespread distribution in whole grain cereals, legumes and meat. Symptoms associated with vitamin B5 deficiency are difficult to asses since they are subtle and resemble those of other B vitamin deficiencies. The vitamers include (R)-pantothenic acid and its ionized and salt forms.. (R)-pantothenate : A pantothenate that is the conjugate base of (R)-pantothenic acid, obtained by deprotonation of the carboxy group.. (R)-pantothenic acid : A pantothenic acid having R-configuration.	2.04	1	0	pantothenic acid; vitamin B5	antidote to curare poisoning; geroprotector; human blood serum metabolite
taurocholic acid Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.	2.04	1	0	amino sulfonic acid; bile acid taurine conjugate	human metabolite
cyclizine Cyclizine: A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935). cyclizine : An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group.	2.97	4	0	N-alkylpiperazine	antiemetic; central nervous system depressant; cholinergic antagonist; H1-receptor antagonist; local anaesthetic
buclizine buclizine : An N-alkylpiperazine carrying (4-chlorophenyl)(phenyl)methyl and 4-tert-butylbenzyl groups.	2.04	1	0	monochlorobenzenes; N-alkylpiperazine	antiemetic; central nervous system depressant; cholinergic antagonist; histamine antagonist; local anaesthetic
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	4.24	5	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.46	2	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
thiopropazate thiopropazate: minor descriptor (66-72); major descriptor (73-85); on-line search PHENOTHIAZINES (66-85); Index Medicus search PHENOTHIAZINES (66-72); THIOPROPAZATE (73-85); RN given refers to parent cpd. thiopropazate : A phenothiazine derivative in which 10H-phenothiazine has a chloro subsitituent at the 2-position and a 3-[4-(2-acetoxyethyl)piperazin-1-yl]propyl group at N-10.	2.04	1	0	acetate ester; N-alkylpiperazine; organochlorine compound; phenothiazines	dopaminergic antagonist; phenothiazine antipsychotic drug
8-hydroxyquinoline-5-sulfonic acid 8-hydroxyquinoline-5-sulfonic acid: RN given refers to parent cpd	2.57	2	0
diquat Diquat: A contact herbicide used also to produce desiccation and defoliation. (From Merck Index, 11th ed). diquat : The organic cation formed formally by addition of an ethylene bridge between the nitrogen atoms of 2,2'-bipyridine. Most often available as the dibromide.	2.05	1	0	organic cation	defoliant; herbicide
acetrizoic acid Acetrizoic Acid: An iodinated radiographic contrast medium used as acetrizoate sodium in HYSTEROSALPINGOGRAPHY.	2.04	1	0	aminobenzoic acid
brompheniramine Brompheniramine: Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.. brompheniramine : Pheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	3.23	1	0	organobromine compound; pyridines	anti-allergic agent; H1-receptor antagonist
acriflavine chloride 3,6-diamino-10-methylacridinium chloride : The 10-methochloride salt of 3,6-diaminoacridine. Note that a mixture of this compound with 3,6-diaminoacridine (proflavine) is known as acriflavine or neutral acriflavine.	2.74	3	0	organic chloride salt	antibacterial agent; antiseptic drug; carcinogenic agent; histological dye; intercalator
carbazole carbazole: structure in first source	2.41	1	0	carbazole
penicillin v Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.	4.64	8	0	penicillin allergen; penicillin
isosorbide dinitrate Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.	4.25	5	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
hexachlorobutadiene hexachlorobutadiene: a potent nephrotoxicant in rats; structure	2.05	1	0	organochlorine compound
pseudoephedrine Pseudoephedrine: A phenethylamine that is an isomer of EPHEDRINE which has less central nervous system effects and usage is mainly for respiratory tract decongestion.. pseudoephedrine : A member of the class of the class of phenylethanolamines that is (1S)-2-(methylamino)-1-phenylethan-1-ol in which the pro-S hydrogen at position 2 is replaced by a methyl group.	3.85	3	0	phenylethanolamines; secondary alcohol; secondary amino compound	anti-asthmatic drug; bronchodilator agent; central nervous system drug; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
diethylpropion Diethylpropion: A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290). diethylpropion : An aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity.	3.23	1	0	aromatic ketone; tertiary amine	appetite depressant
pyronine Pyronine: Xanthene dye used as a bacterial and biological stain. Synonyms: Pyronin; Pyronine G; Pyronine Y. Use also for Pyronine B. which is diethyl-rather than dimethylamino-.. pyronin Y : An organic chloride salt having 6-(dimethylamino)-N,N-dimethyl-3H-xanthen-3-iminium as the cation. Used with methyl green to selectively demonstrate RNA (red) in contrast to DNA (green) with the Unna-Pappenheim method.	2.05	1	0	iminium salt; organic chloride salt	histological dye
proflavine Proflavine: Topical antiseptic used mainly in wound dressings.. 3,6-diaminoacridine : An aminoacridine that is acridine that is substituted by amino groups at positions 3 and 6. A slow-acting bacteriostat that is effective against many Gram-positive bacteria (but ineffective against spores), its salts were formerly used for treatment of burns and infected wounds.	2.07	1	0	aminoacridines	antibacterial agent; antiseptic drug; carcinogenic agent; chromophore; intercalator
phenothiazine 10H-phenothiazine : The 10H-tautomer of phenothiazine.	2.46	2	0	phenothiazine	ferroptosis inhibitor; plant metabolite; radical scavenger
fenoprop fenoprop: RN given is for parent cpd; structure	2.04	1	0	monocarboxylic acid	phenoxy herbicide
propylparaben Parabens: Methyl, propyl, butyl, and ethyl esters of p-hydroxybenzoic acid. They have been approved by the FDA as antimicrobial agents for foods and pharmaceuticals. (From Hawley's Condensed Chemical Dictionary, 11th ed, p872)	2.04	1	0	benzoate ester; paraben; phenols	antifungal agent; antimicrobial agent
2-methyl-4-chlorophenoxyacetic acid 2-Methyl-4-chlorophenoxyacetic Acid: A powerful herbicide used as a selective weed killer.. (4-chloro-2-methylphenoxy)acetic acid : A chlorophenoxyacetic acid that is (4-chlorophenoxy)acetic acid substituted by a methyl group at position 2.	2.04	1	0	chlorophenoxyacetic acid; monochlorobenzenes	environmental contaminant; phenoxy herbicide; synthetic auxin
2-bromophenol bromophenol : A halophenol that is any phenol containing one or more covalently bonded bromine atoms.	2.46	2	0	bromophenol	marine metabolite
dicloran 2,6-dichloro-4-nitroaniline : A nitroaniline that is 4-nitroaniline in which the hydrogens at positions 2 and 6 are replaced by chlorines. An agricultural fungicide, it is not approved for use in the European Union.	2.04	1	0	aromatic fungicide; dichlorobenzene; nitroaniline	antifungal agrochemical
3-dinitrobenzene dinitrobenzene : Any member of the class of nitrobenzenes that consists of a benzene ring substituted by two nitro groups. A closed class.. 1,3-dinitrobenzene : A dinitrobenzene that is benzene disubstituted at positions 1 and 3 with nitro groups.	2.05	1	0	dinitrobenzene	neurotoxin
methylparaben methylparaben: used as a preservative in cosmetics but potentiates UV-induced damage of skin; RN given refers to parent cpd. methylparaben : A 4-hydroxybenzoate ester resulting from the formal condensation of the carboxy group of 4-hydroxybenzoic acid with methanol. It is the most frequently used antimicrobial preservative in cosmetics. It occurs naturally in several fruits, particularly in blueberries.	2.04	1	0	paraben	antifungal agent; antimicrobial food preservative; neuroprotective agent; plant metabolite
phenylhydrazine [no description available]	2.04	1	0	phenylhydrazines	xenobiotic
dyrene dyrene: structure. anilazine : A member of the class of triazenes that is dichlorotriazene in which the hydrogen is replaced by an o-chloroanilino group. A fungicide formerly used to control leaf spots and downy mildew, it is no longer approved for use within the European Union.	2.04	1	0	monochlorobenzenes; organochlorine pesticide; secondary amino compound; triazines	antifungal agrochemical
pyridostigmine bromide Pyridostigmine Bromide: A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.	2.46	2	0	pyridinium salt
4,4'-diaminodiphenylmethane 4,4'-diaminodiphenylmethane: RN given refers to parent cpd; structure. 4,4'-diaminodiphenylmethane : An aromatic amine that is diphenylmethane substituted at the 4-position of each benzene ring by an amino group.	2.46	2	0	aromatic amine	allergen; carcinogenic agent
phenylisothiocyanate phenylisothiocyanate: structure. phenyl isothiocyanate : An isothiocyanate having a phenyl group attached to the nitrogen; used for amino acid sequencing in the Edman degradation.	2.46	2	0	isothiocyanate	allergen; reagent
benzonatate benzonatate: structure in Merck Index, 9th ed, #1107. benzonatate : The ester obtained by formal condensation of 4-butylaminobenzoic acid with nonaethylene glycol monomethyl ether. Structurally related to procaine and benzocaine, it has an anaesthetic effect on the stretch sensors in the lungs, and is used as a non-narcotic cough suppressant.	3.23	1	0	benzoate ester; secondary amino compound; substituted aniline	anaesthetic; antitussive
4-bromophenol 4-bromophenol : A bromophenol containing only hydroxy and bromo substituents that are para to one another.	2.46	2	0	bromophenol	human urinary metabolite; human xenobiotic metabolite; marine metabolite; mouse metabolite; persistent organic pollutant; rat metabolite
acrolein [no description available]	2.04	1	0	enal	herbicide; human xenobiotic metabolite; toxin
2-bromoethylamine [no description available]	2.46	2	0
allyl alcohol allyl alcohol: structure. allylic alcohol : An alcohol where the hydroxy group is attached to a saturated carbon atom adjacent to a double bond (R groups may be H, organyl, etc.).. allyl alcohol : A propenol in which the C=C bond connects C-2 and C-3. It is has been found in garlic (Allium sativum). Formerly used as a herbicide for the control of various grass and weed seeds.	2.46	2	0	primary allylic alcohol; propenol	antibacterial agent; fungicide; herbicide; insecticide; plant metabolite
bromobenzene [no description available]	2.46	2	0	bromoarene; bromobenzenes; volatile organic compound	hepatotoxic agent; mouse metabolite; non-polar solvent
n-pentanoic acid n-pentanoic acid: RN given refers to unlabeled parent cpd. valeric acid : A straight-chain saturated fatty acid containing five carbon atoms.	2.05	1	0	short-chain fatty acid; straight-chain saturated fatty acid	plant metabolite
tetraethylenepentamine [no description available]	2.04	1	0	polyazaalkane	copper chelator
ergotamine Ergotamine: A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.. ergotamine : A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.	2.44	2	0	peptide ergot alkaloid	alpha-adrenergic agonist; mycotoxin; non-narcotic analgesic; oxytocic; serotonergic agonist; vasoconstrictor agent
estradiol dipropionate estradiol dipropionate: RN given refers to (17beta)-isomer; RN for cpd without isomeric designation not in Chemline 7/83	2.43	2	0	steroid ester
methylergonovine Methylergonovine: A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed)	3.23	1	0	ergoline alkaloid
imipramine hydrochloride [no description available]	2.46	2	0	hydrochloride	antidepressant
neostigmine bromide neostigmine bromide : The bromide salt of neostigmine.	2.46	2	0	bromide salt
mephobarbital Mephobarbital: A barbiturate that is metabolized to PHENOBARBITAL. It has been used for similar purposes, especially in EPILEPSY, but there is no evidence mephobarbital offers any advantage over PHENOBARBITAL.. mephobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups.	2.46	2	0	barbiturates	anticonvulsant
paramethadione paramethadione: structure	2.04	1	0	oxazolidinone	anticonvulsant
edrophonium chloride edrophonium chloride : The chloride salt of edrophonium. A reversible inhibitor of cholinesterase with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes), it is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.	2.46	2	0	chloride salt; quaternary ammonium salt	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor
1-amino-2-naphthol-4-sulfonic acid 4-amino-3-hydroxynaphthalene-1-sulfonic acid: reagent for removal of chromium(VI) from aqueous solution	2.41	1	0	aminonaphthalene; naphthalenesulfonic acid	mutagen
chloranil Chloranil: A quinone fungicide used for treatment of seeds and foliage.. tetrachloro-1,4-benzoquinone : A member of the class of 1,4-benzoquiones that is 1,4-benzoquinone in which all four hydrogens are substituted by chlorines.	2.04	1	0	1,4-benzoquinones; organochlorine compound	EC 2.7.1.33 (pantothenate kinase) inhibitor; metabolite
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	2.96	4	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
di-n-pentyl phthalate dipentyl phthalate : A phthalate ester that is the dipentyl ester of benzene-1,2-dicarboxylic acid.	2.46	2	0	diester; phthalate ester	plasticiser
cinchophen cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94	3.86	3	0	quinolines
amiben Amiben: RN given refers to parent cpd	2.04	1	0	chlorobenzoic acid
phenazopyridine hydrochloride phenazopyridine hydrochloride : A hydrochloride obtained by combining phenazopyridine with one equivalent of hydrochloric acid. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.	2.46	2	0	hydrochloride	carcinogenic agent; local anaesthetic; non-narcotic analgesic
tetrracaine hydrochloride leocaine: a crystal beta-modification of the beta-dimethylaminoethyl ether of n-butylaminobenzoic acid hydrochloride	2.46	2	0	benzoate ester
monuron monuron: minor descriptor (72-83); on-line & Index Medicus search UREA/AA (72-74) & HERBICIDES (72-74) & HERBICIDES UREA (75-83); RN given refers to unlabeled cpd; structure. monuron : A member of the class of 3-(3,4-substituted-phenyl)-1,1-dimethylureas that is urea in which one of the nitrogens is substituted by a p-chlorophenyl group while the other is substituted by two methyl groups.	2.04	1	0	3-(3,4-substituted-phenyl)-1,1-dimethylurea; monochlorobenzenes	environmental contaminant; herbicide; xenobiotic
iminodiacetic acid iminodiacetic acid: used as hepatobiliary imaging agent when labeled with Tc; RN given refers to parent cpd; structure. iminodiacetic acid : An amino dicarboxylic acid that is glycine in which one of the hydrogens attached to the nitrogen is substituted by a carboxymethyl group.	2.04	1	0	amino dicarboxylic acid; glycine derivative; non-proteinogenic alpha-amino acid	chelator
anileridine anileridine: minor descriptor (64-86); on line & INDEX MEDICUS search ISONIPECOTIC ACIDS (68-86); RN given refers to parent cpd. anileridine : A piperidinecarboxylate ester that is the ethyl ester of isonipecotic acid in which the hydrogen alpha- to the carboxyl group is substituted by a phenyl group, and the hydrogen attached to the nitrogen is substituted by a 2-(4-aminophenyl)ethyl group.	2.04	1	0	ethyl ester; piperidinecarboxylate ester; substituted aniline	opioid analgesic; opioid receptor agonist
diphenhydramine hydrochloride Antitussive Agents: Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.. diphenhydramine hydrochloride : The hydrochloride salt of diphenhydramine.	2.46	2	0	hydrochloride; organoammonium salt	anti-allergic agent; antiemetic; antiparkinson drug; antipruritic drug; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; sedative
nafcillin Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.	4.53	7	0	penicillin allergen; penicillin	antibacterial drug
ditiocarb Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.	2.04	1	0	dithiocarbamic acids	chelator; copper chelator
methohexital Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.. methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.	3.84	3	0	acetylenic compound; barbiturates	drug allergen; intravenous anaesthetic
sulfalene Sulfalene: Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.	2.04	1	0	pyrazines; sulfonamide antibiotic; sulfonamide
tripelennamine hydrochloride [no description available]	2.46	2	0
phenetidine Phenetidine: Used in the manufacture of acetophenetidin.. 4-ethoxyaniline : An aromatic ether that is aniline in which the hydrogen at position 4 is replaced by an ethoxy group. It is a hydrolysis metabolite of phenacetin.	2.04	1	0	aromatic ether; primary amino compound; substituted aniline	drug metabolite
diazooxonorleucine Diazooxonorleucine: An amino acid that inhibits phosphate-activated glutaminase and interferes with glutamine metabolism. It is an antineoplastic antibiotic produced by an unidentified species of Streptomyces from Peruvian soil. (From Merck Index, 11th ed). 6-diazo-5-oxo-L-norleucine : A non-proteinogenic L-alpha-amino acid that is L-norleucine which is substituted at position 5 by an oxo group and at position 6 by a diazo group. It is as inhibitor of various glutamine-utilising enzymes.	2.04	1	0	amino acid zwitterion; diazo compound; ketone; non-proteinogenic L-alpha-amino acid	analgesic; antibacterial agent; antimetabolite; antineoplastic agent; antiviral agent; apoptosis inducer; bacterial metabolite; EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitor; EC 3.5.1.2 (glutaminase) inhibitor; EC 6.3.4.2 [CTP synthase (glutamine hydrolyzing)] inhibitor; EC 6.3.5.1 [NAD(+) synthase (glutamine-hydrolysing)] inhibitor; EC 6.3.5.2 [GMP synthase (glutamine-hydrolysing)] inhibitor; EC 6.3.5.3 (phosphoribosylformylglycinamidine synthase) inhibitor; EC 6.3.5.4 [asparagine synthase (glutamine-hydrolysing)] inhibitor; EC 6.3.5.5 [carbamoyl-phosphate synthase (glutamine-hydrolysing)] inhibitor; glutamine antagonist
ethynodiol diacetate Ethynodiol Diacetate: A synthetic progestational hormone used alone or in combination with estrogens as an oral contraceptive (CONTRACEPTIVES, ORAL).	2.46	2	0	steroid ester; terminal acetylenic compound	contraceptive drug; estrogen receptor modulator; synthetic oral contraceptive
propantheline bromide [no description available]	2.04	1	0	xanthenes
ephedrine Ephedrine: A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.. (-)-ephedrine : A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.	3.58	2	0	phenethylamine alkaloid; phenylethanolamines	bacterial metabolite; environmental contaminant; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
hydrazine diamine : Any polyamine that contains two amino groups.	2.75	3	0	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
chlormadinone acetate Chlormadinone Acetate: An orally active synthetic progestational hormone used often in combinations as an oral contraceptive (CONTRACEPTIVES, ORAL).	2.04	1	0	corticosteroid hormone
pirinitramide Pirinitramide: A diphenylpropylamine with intense narcotic analgesic activity of long duration. It is a derivative of MEPERIDINE with similar activity and usage.	2.45	2	0	nitrile
methylpentynol carbamate [no description available]	2.04	1	0
mechlorethamine n-oxide [no description available]	2.04	1	0	nitrogen mustard
edrophonium bromide [no description available]	2.04	1	0
norchlorcyclizine norchlorcyclizine: RN given refers to parent cpd	2.45	2	0
estradiol 17 beta-cypionate [no description available]	2.02	1	0	steroid ester
evans blue Evans Blue: An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly.. Evans blue : An organic sodium salt that is the tetrasodium salt of 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate). It is sometimes used as a counterstain, especially in fluorescent methods to suppress background autofluorescence.	2.04	1	0	organic sodium salt	fluorochrome; histological dye; sodium channel blocker; teratogenic agent
monocrotaline Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.	2.46	2	0	pyrrolizidine alkaloid
testosterone enanthate [no description available]	2.02	1	0	heptanoate ester; sterol ester	androgen
opipramol Opipramol: A tricyclic antidepressant with actions similar to AMITRIPTYLINE.	2.04	1	0	dibenzoazepine
aminophylline Aminophylline: A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.. aminophylline : A mixture comprising of theophylline and ethylenediamine in a 2:1 ratio.	3.23	1	0	mixture	bronchodilator agent; cardiotonic drug
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	4.25	5	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
linuron Linuron: A selective pre- and post-emergence herbicide. (From Merck Index, 11th ed). linuron : A member of the class of phenylureas that is N-methyl urea substituted by a methoxy group at position 1 and a 3,4-dichlorophenyl group at position 3.	2.04	1	0	dichlorobenzene; phenylureas	agrochemical; environmental contaminant; herbicide; xenobiotic
carbutamide Carbutamide: A sulfonylurea antidiabetic agent with similar actions and uses to CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277)	2.44	2	0	benzenes; sulfonamide
glymidine glymidine: was MH 1975-92 (see under SULFONAMIDES 1975-90); GLIDIAZINE & GLYCODIAZINE were see GLYMIDINE 1975-92; use SULFONAMIDES to search GLYMIDINE 1975-92; a sulfonamide hypoglycemic agent which stimulates insulin secretion. glymidine : A sulfonamide that is N-(pyrimidin-2-yl)benzenesulfonamide which is substituted at position 5 of the pyrimidine ring by a 2-methoxyethoxy group. It is a hypoglycemic drug used for the treatment of diabetes mellitus.	2.04	1	0	diether; pyrimidines; sulfonamide	hypoglycemic agent
pseudoephedrine hydrochloride pseudoephedrine hydrochloride : A hydrochloride that is the monohydrochloride salt of pseudoephedrine.	2.46	2	0	hydrochloride	plant metabolite
galantamine Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.	3.85	3	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
nandrolone decanoate Nandrolone Decanoate: Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS.	3.23	1	0	steroid ester
procarbazine hydrochloride procarbazine hydrochloride : A hydrochloride obtained by combining procarbazine with one equivalent of hydrochloric acid. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	2.46	2	0	hydrochloride	antineoplastic agent
N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine [no description available]	2.45	2	0	aromatic amine
betamethasone Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)	3.29	6	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
prenylamine Prenylamine: A drug formerly used in the treatment of angina pectoris but superseded by less hazardous drugs. Prenylamine depletes myocardial catecholamine stores and has some calcium channel blocking activity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1406)	2.45	2	0	diarylmethane
cyproterone acetate [no description available]	2.75	3	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; chlorinated steroid; steroid ester	androgen antagonist; geroprotector; progestin
lithocholic acid Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.. lithocholic acid : A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.. lithocholate : A bile acid anion that is the conjugate base of lithocholic acid.	2.46	2	0	bile acid; C24-steroid; monohydroxy-5beta-cholanic acid	geroprotector; human metabolite; mouse metabolite
nandrolone Nandrolone: C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.. nandrolone : A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.	2.04	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid	human metabolite
thiazolidine-4-carboxylic acid thiazolidine-4-carboxylic acid: active against thimerosal intoxication; acts on cell membranes of tumor cells causing reverse transformation to normal cells; RN given refers to parent cpd	2.04	1	0	alpha-amino acid zwitterion; non-proteinogenic alpha-amino acid; sulfur-containing amino acid; thiazolidinemonocarboxylic acid	antidote; antioxidant; hepatoprotective agent
hydantoins Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.	2.04	1	0	imidazolidine-2,4-dione
chlorphentermine Chlorphentermine: A sympathomimetic agent that was formerly used as an anorectic. It has properties similar to those of DEXTROAMPHETAMINE. It has been implicated in lipid storage disorders and pulmonary hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1223)	2.45	2	0	amphetamines
dextropropoxyphene Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.	3.85	3	0	1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate	mu-opioid receptor agonist; opioid analgesic
ketobemidone ketobemidone: structure	2.04	1	0	piperidines
glycyrrhetinic acid [no description available]	2.07	1	0	cyclic terpene ketone; hydroxy monocarboxylic acid; pentacyclic triterpenoid	immunomodulator; plant metabolite
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	4.07	4	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
lucanthone Lucanthone: One of the SCHISTOSOMICIDES, it has been replaced largely by HYCANTHONE and more recently PRAZIQUANTEL. (From Martindale The Extrapharmacopoeia, 30th ed., p46). lucanthone : A thioxanthen-9-one compound having a methyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. Formerly used for the treatment of schistosomiasis. It is a prodrug, being metabolised to hycanthone.	2.04	1	0	thioxanthenes	adjuvant; antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; mutagen; photosensitizing agent; prodrug; schistosomicide drug
dichloralantipyrine dichloralantipyrine: 1:2 compound of antipyrine with chloral hydrate	2.04	1	0
plumbagin plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.	2.04	1	0	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.74	3	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
dihydralazine Dihydralazine: 1,4-Dihydrazinophthalazine. An antihypertensive agent with actions and uses similar to those of HYDRALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p354)	2.04	1	0	phthalazines
pamaquine pamaquine: structure; RN given refers to parent cpd	2.04	1	0	aminoquinoline
dipicolinic acid dipicolinic acid : A pyridinedicarboxylic acid carrying two carboxy groups at positions 2 and 6.	2.44	2	0	pyridinedicarboxylic acid	bacterial metabolite
4-hydroxybutyric acid 4-hydroxybutyric acid: was an entry term to Sodium Oxybate (74-98). 4-hydroxybutyric acid : A 4-hydroxy monocarboxylic acid that is butyric acid in which one of the hydrogens at position 4 is replaced by a hydroxy group.	3.23	1	0	4-hydroxy monocarboxylic acid; hydroxybutyric acid	general anaesthetic; GHB receptor agonist; neurotoxin; sedative
mustard gas Mustard Gas: Severe irritant and vesicant of skin, eyes, and lungs. It may cause blindness and lethal lung edema and was formerly used as a war gas. The substance has been proposed as a cytostatic and for treatment of psoriasis. It has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP-85-002, 1985) (Merck, 11th ed).. bis(2-chloroethyl) sulfide : An ethyl sulfide that is diethyl sulfide in which a hydrogen from each of the terminal methyl groups is replaced by a chlorine. It is a powerful vesicant regulated under the Chemical Weapons Convention.	2.04	1	0	ethyl sulfide; organochlorine compound	alkylating agent; carcinogenic agent; vesicant
oleanolic acid [no description available]	2.52	2	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
dihydroergotamine Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.	3.23	1	0	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent
methallenestril methallenestril: RN given refers to parent cpd	2.04	1	0	naphthalenes
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	2.02	1	0	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
hesperidin Hesperidin: A flavanone glycoside found in CITRUS fruit peels.. hesperidin : A disaccharide derivative that consists of hesperetin substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.04	1	0	3'-hydroxyflavanones; 4'-methoxyflavanones; dihydroxyflavanone; disaccharide derivative; flavanone glycoside; monomethoxyflavanone; rutinoside	mutagen
medroxyprogesterone [no description available]	3.58	2	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	contraceptive drug; progestin; synthetic oral contraceptive
androstenediol Androstenediol: An intermediate in TESTOSTERONE biosynthesis, found in the TESTIS or the ADRENAL GLANDS. Androstenediol, derived from DEHYDROEPIANDROSTERONE by the reduction of the 17-keto group (17-HYDROXYSTEROID DEHYDROGENASES), is converted to TESTOSTERONE by the oxidation of the 3-beta hydroxyl group to a 3-keto group (3-HYDROXYSTEROID DEHYDROGENASES).. androst-5-ene-3beta,17beta-diol : A 3beta-hydroxy-Delta(5)-steroid that is 3beta-hydroxyandrost-5-ene carrying an additional hydroxy group at position 17beta.	2.04	1	0	17beta-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid	androgen; human metabolite; mouse metabolite; radiation protective agent
dimenhydrinate gravinol: has antioxidant and ant-inflammatory activities; structure in first source	3.23	1	0	diarylmethane
apronalide apronalide: structure	2.04	1	0	N-acylurea
chlormethiazole Chlormethiazole: A sedative and anticonvulsant often used in the treatment of alcohol withdrawal. Chlormethiazole has also been proposed as a neuroprotective agent. The mechanism of its therapeutic activity is not entirely clear, but it does potentiate GAMMA-AMINOBUTYRIC ACID receptors response and it may also affect glycine receptors.	2.45	2	0	thiazoles
4,6-dinitro-o-cresol 4,6-dinitro-o-cresol: RN given refers to parent cpd; structure. 4,6-dinitro-o-cresol : A hydroxytoluene that is o-cresol carrying nitro substituents at positions 4 and 6.	2.04	1	0	dinitrophenol acaricide; hydroxytoluene; nitrotoluene	dinitrophenol insecticide; fungicide; herbicide
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	3.86	3	0	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
levocarnitine (R)-carnitine : The (R)-enantiomer of carnitine.	4.06	4	0	carnitine	antilipemic drug; nootropic agent; nutraceutical; Saccharomyces cerevisiae metabolite; water-soluble vitamin (role)
decamethonium dibromide [no description available]	2.04	1	0
sulfanilylurea sulfanilylurea: antimicrobial agent; structure	3.23	1	0	benzenes; sulfonamide
gentian violet Gentian Violet: A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.. crystal violet : An organic chloride salt that is the monochloride salt of crystal violet cation. It has been used in creams for the topical treatment of bacterial and fungal infections, being effective against some Gram-positive bacteria (notably Staphylococcus species) and some pathogenic fungi (including Candida species) but use declined following reports of animal carcinogenicity. It has also been used for dying wood, silk, and paper, as well as a histological stain.	2.44	2	0	organic chloride salt	anthelminthic drug; antibacterial agent; antifungal agent; antiseptic drug; histological dye
thiphenamil thiphenamil: RN given refers to parent cpd; structure	2.04	1	0	diarylmethane
amitriptyline hydrochloride [no description available]	2.46	2	0	organic tricyclic compound
1-naphthylisothiocyanate 1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.	2.75	3	0	isothiocyanate	insecticide
aminopenicillanic acid aminopenicillanic acid: RN given refers to parent cpd; structure. 6-aminopenicillanic acid : A penicillanic acid compound having a (6R)-amino substituent. The active nucleus common to all penicillins, it may be substituted at the 6-amino position to form the semisynthetic penicillins, resulting in a variety of antibacterial and pharmacologic characteristics.	2.45	2	0	amino acid zwitterion; penicillanic acids	allergen
lithium carbonate Lithium Carbonate: A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.	2.04	1	0	carbonate salt; lithium salt	antimanic drug
metahexamide metahexamide: major descriptor (64-83); on-line search SULFONYLUREA COMPOUNDS (64-83); Index Medicus search METAHEXAMIDE (64-83); RN given refers to parent cpd; structure	2.44	2	0	benzenes; sulfonamide
phenindamine phenindamine: RN given refers to parent cpd; structure	2.04	1	0	indene
lactulose [no description available]	3.23	1	0	glycosylfructose	gastrointestinal drug; laxative
isoxsuprine hydrochloride [no description available]	2.46	2	0	alkylbenzene
betaine hydrochloride [no description available]	2.46	2	0
megestrol acetate [no description available]	2.43	2	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
pamabrom [no description available]	3.23	1	0
2-amino-2-methyl-1-propanol 2-amino-2-methyl-1-propanol: RN given refers to parent cpd	2.04	1	0
toyocamycin Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.. toyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group.	2.04	1	0	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; nitrile; ribonucleoside	antimetabolite; antineoplastic agent; apoptosis inducer; bacterial metabolite
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	4.25	5	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
3-hydroxyacetanilide metacetamol : A derivative of phenol which has an acetamido substituent located meta to the phenolic -OH group. It is a non-toxic regioisomer of paracetamol with analgesic properties, but has never been marketed as a drug.	2.46	2	0	acetamides; phenols	non-narcotic analgesic
methoxyacetic acid methoxyacetic acid: RN given refers to parent cpd. methoxyacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a methoxy group.	2.46	2	0	ether; monocarboxylic acid	antineoplastic agent; apoptosis inducer; human xenobiotic metabolite; mutagen
phendimetrazine phendimetrazine: minor descriptor (66-86); file maintained to MORPHOLINES (66-86); on-line & INDEX MEDICUS search MORPHOLINES (66-86); RN given refers to parent cpd without isomeric designation	2.46	2	0
trimetozine [no description available]	2.04	1	0	morpholines
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	6.98	22	1	cyclic ketone; erythromycin
butaperazine butaperazine: was heading 1964-94 (Prov 1964-73); use PHENOTHIAZINES to search BUTAPERAZINE 1966-94	2.04	1	0	phenothiazines
agaric acid agaric acid: adenine nucleotide translocase antagonist	2.13	1	0
hadacidin hadacidin: inhibitor of AMP synthesis; RN given refers to parent cpd; structure. hadacidin : A monocarboxylic acid that is N-hydroxyglycine in which the hydrogen attached to the nitrogen is replaced by a formyl group. It was originally isolated from cultures of Penicillium frequentans.	2.04	1	0	aldehyde; monocarboxylic acid; N-hydroxy-alpha-amino-acid	antimicrobial agent; antineoplastic agent; Penicillium metabolite; teratogenic agent
carbophenothion carbophenothion: structure	2.04	1	0	organic sulfide
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	3.84	3	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
porfiromycin Porfiromycin: Toxic antibiotic of the mitomycin group, obtained from MITOMYCIN and also from Streptomyces ardus and other species. It is proposed as an antineoplastic agent, with some antibiotic properties.	2.04	1	0
8-hydroxy-2-methylquinoline 8-hydroxy-2-methylquinoline: structure in first source	2.57	2	0	hydroxyquinoline
lormetazepam lormetazepam: RN given refers to cpd with specified locant for methyl group; structure given in first source. lormetazepam : A 1,4-benzodiazepinone compound having a methyl substituent at the 1-position, a hydroxy substituent at the 3-position, a 2-chlorophenyl group at the 5-position and a chloro substituent at the 7-position.	2.45	2	0	1,4-benzodiazepinone; organochlorine compound	sedative
vinblastine [no description available]	3.14	5	0
diphenoxylate Diphenoxylate: A MEPERIDINE congener used as an antidiarrheal, usually in combination with ATROPINE. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity.. diphenoxylate : A piperidinecarboxylate ester that is the ethyl ester of difenoxin.	3.23	1	0	ethyl ester; nitrile; piperidinecarboxylate ester; tertiary amine	antidiarrhoeal drug
deoxyuridine [no description available]	2.04	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
oxolamine oxolamine: RN given refers to parent cpd; structure	2.04	1	0	oxadiazole; ring assembly
ethylestrenol Ethylestrenol: An anabolic steroid with some progestational activity and little androgenic effect.. ethylestrenol : A 17beta-hydroxy steroid that is estrane containing a double bond between positions 4 and 5 and substituted by an ethyl group and a hydroxy group at the 17alpha and 17beta positions, respectively. It is an anabolic steroid that has little androgenic effect and only slight progestational activity. It has been used to promote growth in boys with delayed bone growth.	2.04	1	0	17beta-hydroxy steroid; tertiary alcohol	anabolic agent
testolactone Testolactone: An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.	2.04	1	0	3-oxo-Delta(1),Delta(4)-steroid; seco-androstane
cyproheptadine hydrochloride (anhydrous) cyproheptadine hydrochloride (anhydrous) : The hydrochloride salt of cyproheptadine. Note that the drug named cyproheptadine hydrochloride generally refers to cyproheptadine hydrochloride sesquihydrate.	2.46	2	0	hydrochloride
estradiol valerate [no description available]	2.02	1	0	steroid ester
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	4.24	5	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
pyrithioxin Pyrithioxin: A neurotropic agent which reduces permeability of blood-brain barrier to phosphate. It has no vitamin B6 activity.	2.04	1	0	methylpyridines
dehydroepiandrosterone acetate 3beta-acetoxyandrost-5-en-17-one: structure in first source	2.04	1	0	steroid ester
ethidium bromide [no description available]	2.96	4	0	organic bromide salt	geroprotector; intercalator; trypanocidal drug
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	7.4	20	1	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
nsc 65346 sangivamycin: RN given refers to parent cpd. sangivamycin : A nucleoside analogue that is adenosine in which the nitrogen at position 7 is replaced by a carbamoyl-substituted carbon. It is a potent inhibitor of protein kinase C.	2.04	1	0	nucleoside analogue	protein kinase inhibitor
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	3.23	1	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
pregnenolone carbonitrile Pregnenolone Carbonitrile: A catatoxic steroid and microsomal enzyme inducer having significant effects on the induction of cytochrome P450. It has also demonstrated the potential for protective capability against acetaminophen-induced liver damage.	2.05	1	0	aliphatic nitrile
guanazole Guanazole: A cytostatic triazole derivative which is not to be confused with guanazolo, the generic name for 8-azaguanine.. guanazole : An aromatic amine that is 1,2,4-triazole substituted at positions 3 and 5 by amino groups.	2.04	1	0	aromatic amine; triazoles	antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor
ibufenac ibufenac: used in the treatment of rheumatism; also possesses antipyretic properties; minor descriptor (75-84); on-line & Index Medicus search PHENYLACETATES (75-84); RN given refers to parent cpd. ibufenac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.	3.86	3	0	monocarboxylic acid	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug
metylperon metylperon: RN given refers to parent cpd	2.04	1	0	aromatic ketone
meturedepa meturedepa: structure in Merck Index, 9th ed, #6031	2.04	1	0	phosphoramide
metaxalone [no description available]	3.58	2	0	aromatic ether
ioxynil ioxynil: RN given refers to parent cpd; structure. ioxynil : A nitrile that is benzonitrile substituted by a hydroxy group at position 4 and iodo groups at positions 3 and 5.	2.04	1	0	iodophenol; nitrile	environmental contaminant; herbicide; xenobiotic
bromoxynil bromoxynil: RN given refers to parent cpd; structure. 3,5-dibromo-4-hydroxybenzonitrile : A dibromobenzene that is 2,6-dibromophenol substituted by a cyano group at position 4.	2.04	1	0	dibromobenzene; hydroxynitrile; phenols	environmental contaminant; herbicide; xenobiotic
spectinomycin Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.	4.4	6	0	cyclic acetal; cyclic hemiketal; cyclic ketone; pyranobenzodioxin; secondary alcohol; secondary amino compound	antibacterial drug; antimicrobial agent; bacterial metabolite
2,3,7,8-tetrachlorodibenzodioxine Tetrachlorodibenzodioxin: A mixture of isomers.	2.05	1	0	polychlorinated dibenzodioxine
paraquat Paraquat: A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.. paraquat : An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.	2.97	4	0	organic cation	geroprotector; herbicide
picloram Picloram: A picolinic acid derivative that is used as a herbicide.. picloram : A pyridinemonocarboxylic acid that is pyridine-2-carboxylic acid which is substituted by a chloro group at positions 3,5 and 6, and by an amino group at position 4. It is a systemic herbicide used to control deeply rooted herbaceous weeds and woody plants in rights-of-way, forestry, range lands, pastures, and small grain crops.	2.04	1	0	aminopyridine; chloropyridine; organochlorine pesticide; pyridinemonocarboxylic acid	herbicide; synthetic auxin
ethoglucid Ethoglucid: Alkylating antineoplastic agent used especially in bladder neoplasms. It is toxic to hair follicles, gastro-intestinal tract, and vasculature.	2.04	1	0	epoxide
dronabinol Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.	3.84	3	0	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	3.23	1	0	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
clothiapine clothiapine: was heading 1975-94 (was see under DIBENZOTHIAZEPINES 1975-90); CLOTIAPINE was see CLOTHIAPINE 1978-94; use DIBENZOTHIAZEPINES to search CLOTHIAPINE 1975-94; antipsychotic similar to clozapine	2.04	1	0	dibenzothiazepine
pimozide Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.	4.07	4	0	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
benperidol Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)	2.04	1	0	aromatic ketone
betamethasone valerate Betamethasone Valerate: The 17-valerate derivative of BETAMETHASONE. It has substantial topical anti-inflammatory activity and relatively low systemic anti-inflammatory activity.. betamethasone valerate : A steroid ester that is betamethasone in which the hydroxy group at the 17alpha position has been converted to the corresponding pentanoate ester.	2.02	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; primary alpha-hydroxy ketone; steroid ester	anti-inflammatory drug
azaribine azaribine: pyrimidine analogue; anti-metabolite used in psoriasis & mycosis fungoides;. azaribine : A N-glycosyl-1,2,4-triazine that is 6-azauridine acetylated at positions 2', 3' and 5' on the sugar ring. It is a prodrug for 6-azauridine and is used for treatment of psoriasis.	2.44	2	0	acetate ester; N-glycosyl-1,2,4-triazine	antipsoriatic; prodrug
methylprednisolone hemisuccinate Methylprednisolone Hemisuccinate: A water-soluble ester of METHYLPREDNISOLONE used for cardiac, allergic, and hypoxic emergencies.	2.02	1	0	corticosteroid hormone; hemisuccinate
dexbrompheniramine dexbrompheniramine : The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	3.23	1	0	brompheniramine	anti-allergic agent; H1-receptor antagonist
sulfadoxine Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.	2.46	2	0	pyrimidines; sulfonamide	antibacterial drug; antimalarial
1,3,5-triglycidyl-s-triazinetrione [no description available]	2.04	1	0
acetophenazine acetophenazine: major descriptor (73-85); minor descriptor (64-72); on-line search PHENOTHIAZINES (64-85); Index Medicus search PHENOTHIAZINES (64-72); ACETOPHENAZINE (73-85); RN given refers to parent cpd. acetophenazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the nitogen atom and an acetyl group at position 2.	2.44	2	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; phenothiazines	phenothiazine antipsychotic drug
chlordesmethyldiazepam [no description available]	2.04	1	0	benzodiazepine
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	4.66	8	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.	2.73	3	0	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug
dicloxacillin Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.	4.4	6	0	dichlorobenzene; penicillin	antibacterial drug
improsan improsan: synonyms NSC-102627, alkylating agent 864 & yoshi 864 refer to HCl; RN given refers to parent cpd; structure	2.04	1	0	organosulfonic ester
cyclacillin Cyclacillin: A cyclohexylamido analog of PENICILLANIC ACID.	2.71	3	0	penicillin	antibacterial drug
megestrol Megestrol: A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.. megestrol : A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a methyl group at position 6 and a hydroxy group at position 17.	3.23	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
cephaloglycin Cephaloglycin: A cephalorsporin antibiotic.. cefaloglycin : A cephalosporin antibiotic containing at the 7beta-position of the cephem skeleton an (R)-amino(phenyl)acetamido group.	2.04	1	0	beta-lactam antibiotic allergen; cephalosporin	antimicrobial agent
tranylcypromine Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.	2.02	1	0	2-phenylcyclopropan-1-amine
streptomycin [no description available]	5.16	14	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
piperacetazine piperacetazine: was MH 1975-91 (see under PHENOTHIAZINE TRANQUILIZERS 1975-90)	2.04	1	0	phenothiazines
nitroxoline nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd. nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5.	2.57	2	0	C-nitro compound; monohydroxyquinoline	antifungal agent; antiinfective agent; antimicrobial agent; renal agent
clonidine hydrochloride [no description available]	2.46	2	0	dichlorobenzene
cladribine [no description available]	4.4	6	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
beclomethasone [no description available]	2.73	3	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug
ethylene dimethanesulfonate ethylene dimethanesulfonate: antispermatogenic agent; structure	2.46	2	0
carbenicillin Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.. carbenicillin : A penicillin antibiotic having a 6beta-2-carboxy-2-phenylacetamido side-chain.	5.49	20	0	penicillin allergen; penicillin	antibacterial drug
estradiol enanthate [no description available]	2.02	1	0	steroid ester
noxiptilin noxiptilin: proposed tricyclic antidepressent; minor descriptor (75-86); on line & INDEX MEDICUS search DIBENZOCYCLOHEPTENES (75-86); RN given refers to parent cpd	2.45	2	0	organic tricyclic compound
benorilate benorilate: was heading 1980-94 (see under SALICYLATES 1980-90); was BENORYLATE see under SALICYLATES 1975-79; BENORYLATE was see BENORILATE 1980-94; use SALICYLATES to search BENORILATE 1980-90 & BENORYLATE 1975-79; an ester of aspirin and paracetamol with analgesic, antipyretic, and anti-inflammatory activity used in the treatment of rheumatoid diseases; it has less severe side effects than aspirin	2.04	1	0	carbonyl compound
metocurine metocurine: from Chinese herb Cyclea hainanensis Mrr	2.04	1	0	isoquinolines
floxacillin Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.	2.96	4	0	penicillin allergen; penicillin	antibacterial drug
clomacran clomacran: RN given refers to parent cpd; structure	3.86	3	0	acridines
mexiletine hydrochloride mexiletine hydrochloride : A hydrochloride composed of equimolar amounts of mexiletine and hydrogen chloride.	2.46	2	0	hydrochloride	anti-arrhythmia drug
pentaquine pentaquine: RN given refers to parent cpd	2.04	1	0
beclomethasone dipropionate beclomethasone dipropionate : A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions.	2.74	3	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; enone; glucocorticoid; propanoate ester; steroid ester	anti-arrhythmia drug; anti-asthmatic drug; anti-inflammatory drug; prodrug
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	2.46	2	0	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
iprindole Iprindole: A tricyclic antidepressant that has actions and uses similar to those of AMITRIPTYLINE, but has only weak antimuscarinic and sedative effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p257)	2.45	2	0	indoles
betamethasone-17,21-dipropionate [no description available]	2.02	1	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; propanoate ester; steroid ester	antipsoriatic
methenamine hippurate methenamine hippurate: both parts of molecule contribute to its antibacterial action	3.23	1	0	N-acylglycine
isometheptene isometheptene: RN given refers to cpd without isomeric designation; structure in Merck Index, 9th ed, #5040	2.04	1	0	secondary amino compound
olsalazine olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.	4.06	4	0	azobenzenes; dicarboxylic acid	non-steroidal anti-inflammatory drug; prodrug
terodiline [no description available]	2.45	2	0	diarylmethane
1-(4-carboxyphenyl)-3,3-dimethyltriazene 1-(4-carboxyphenyl)-3,3-dimethyltriazene: RN given refers to parent cpd	2.04	1	0
metoclopramide hydrochloride metoclopramide hydrochloride : A hydrate that is the monohydrate form of metoclopramide monohydrochloride.	2.46	2	0
molindone Molindone: An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of CLOZAPINE. (From AMA Drug Evaluations Annual, 1994, p283)	2.04	1	0	indoles
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	3.14	5	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
hexocyclium hexocyclium: RN given refers to parent cpd; structure	2.04	1	0	amine
metocurine iodide [no description available]	2.45	2	0	aromatic ether
isopentenyladenosine Isopentenyladenosine: N(6)-[delta(3)-isopentenyl]adenosine. Isopentenyl derivative of adenosine which is a member of the cytokinin family of plant growth regulators.. N(6)-(Delta(2)-isopentenyl)adenosine : A nucleoside analogue in which adenosine has been modified by substitution at the 6-amino nitrogen by a Delta(2)-isopentenyl group.	2.04	1	0	N-ribosyl-N(6)-isopentenyladenine; nucleoside analogue	antineoplastic agent; plant growth regulator; plant metabolite
sodium thiosulfate sodium thiosulfate: do not confuse synonym sodium hyposulfite with sodium hyposulfite, synonym for di-Na salt of dithionous acid. sodium thiosulfate : An inorganic sodium salt composed of sodium and thiosulfate ions in a 2:1 ratio.	3.23	1	0	inorganic sodium salt	antidote to cyanide poisoning; antifungal drug; nephroprotective agent
ancitabine Ancitabine: Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.. ancitabine : An organic heterotricyclic compound resulting from the formal condensation of the oxo group of cytidine to the 2' position with loss of water to give the corresponding cyclic ether. A prodrug, it is metabolised to the antineoplastic agent cytarabine, so is used to maintain a more constant antineoplastic action.	2.44	2	0	diol; organic heterotricyclic compound	antimetabolite; antineoplastic agent; prodrug
clortermine [no description available]	2.04	1	0	amphetamines
phenacid phenacid: RN given refers to parent cpd; structure	2.04	1	0
carbendazim carbendazim: carcinogen when combined with sodium nitrite; principle metabolite of thiophanate methyl & benomyl; structure. carbendazim : A member of the class of benzimidazoles that is 2-aminobenzimidazole in which the primary amino group is substituted by a methoxycarbonyl group. A fungicide, carbendazim controls Ascomycetes, Fungi Imperfecti, and Basidiomycetes on a wide variety of crops, including bananas, cereals, cotton, fruits, grapes, mushrooms, ornamentals, peanuts, sugarbeet, soybeans, tobacco, and vegetables.	2.46	2	0	benzimidazole fungicide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	antifungal agrochemical; antinematodal drug; metabolite; microtubule-destabilising agent
nicofuranose nicofuranose: derivative of nicotinic acid that produces fewer side effects than pure nicotinic acid; used in peripheral vascular disease; also proposed as anticholesteremic; minor descriptor (75-84); on-line search NIACIN/AA (75-84); Index Medicus search NIACIN/AA (83-84), NICOTINIC ACIDS (75-82)	2.04	1	0	organooxygen compound
ethionine L-ethionine : An S-ethylhomocysteine that has S-configuration at the chiral centre.	2.75	3	0	S-ethylhomocysteine	antimetabolite; carcinogenic agent
apazone Apazone: An anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also has uricosuric properties and has been used to treat gout.. apazone : A member of the class of benzotriazines that is 1,2-dihydro-1,2,4-benzotriazine bearing a dimethylamino substitutent at position 3 and a methyl substituent at position 7 and in which the nitrogens at positions 1 and 2 are both acylated by a carboxy group of propylmalonic acid.	2.44	2	0	benzotriazines	non-steroidal anti-inflammatory drug; uricosuric drug
cloforex cloforex: carbamic ethyl ester of chlorphentermine; structure in Negwer, 5th ed, #2275	2.45	2	0	amphetamines
xipamide Xipamide: A sulfamoylbenzamide analog of CLOPAMIDE. It is diuretic and saluretic with antihypertensive activity. It is bound to PLASMA PROTEINS, thus has a delayed onset and prolonged action.	2.04	1	0	benzamides
selegiline Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.	4.53	7	0	selegiline; terminal acetylenic compound	geroprotector
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.43	2	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
clobutinol clobutinol: was minor as SILOMAT mapped to AMINO ALCOHOLS (63-79)	2.04	1	0	benzenes; organic amino compound
clemastine Clemastine: A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.. clemastine : 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.	3.6	2	0	monochlorobenzenes; N-alkylpyrrolidine	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
thiamphenicol [no description available]	2.04	1	0	monocarboxylic acid amide; sulfone	antimicrobial agent; immunosuppressive agent
cephalexin Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.	5.07	13	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
isosorbide-5-mononitrate isosorbide-5-mononitrate: for prevention of angina pectoris; structure given in first source; a Russian drug	3.13	5	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
pentamethylmelamine pentamethylmelamine: RN given refers to parent cpd	2.04	1	0
calusterone calusterone: was MH 1975-92 (see under METHYLTESTOSTERONE 1975-90); use METHYLTESTOSTERONE to search CALUSTERONE 1975-92	2.04	1	0	3-hydroxy steroid	androgen
danazol Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	4.41	6	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
fenclozic acid fenclozic acid: an analgesic & antipyretic with anti-inflammatory properties; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZOLES (75-86); RN given refers to parent cpd	3.23	1	0
lisuride Lisuride: An ergot derivative that acts as an agonist at dopamine D2 receptors (DOPAMINE AGONISTS). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (SEROTONIN RECEPTOR AGONISTS).	2.04	1	0	monocarboxylic acid amide	antidyskinesia agent; antiparkinson drug; dopamine agonist; serotonergic agonist
etoprine etoprine: do not confuse with 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine, also called DDEP	2.04	1	0
laxagetten 4,4'-diacetoxydiphenylpyridylemethane [no description available]	3.23	1	0
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	4.06	4	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
razoxane Razoxane: An antimitotic agent with immunosuppressive properties.	2.44	2	0	N-alkylpiperazine
cephapirin Cephapirin: Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms.. cephapirin : A cephalosporin with acetoxymethyl and 2(pyridin-4-ylsulfanyl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. It is used (as its sodium salt) as an antibiotic, being effective against gram-negative and gram-positive organisms.	2.94	4	0	cephalosporin	antibacterial drug
fludarabine phosphate fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.	3.85	3	0	nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate	antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug
disopyramide phosphate [no description available]	2.46	2	0	organoammonium phosphate
alclofenac alclofenac: was heading 1975-94 (was see under PHENYLACETATES 1975-90); use PHENYLACETATES to search ALCLOFENAC 1975-94; an anti-inflammatory agent used in the treatment of rheumatoid arthritis; acts also as an analgesic and an antipyretic. alclofenac : An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash.	3.23	1	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
carbimazole Carbimazole: An imidazole antithyroid agent. Carbimazole is metabolized to METHIMAZOLE, which is responsible for the antithyroid activity.. carbimazole : A member of the class of imidazoles that is methimazole in which the nitrogen bearing a hydrogen is converted into its ethoxycarbonyl derivative. A prodrug for methimazol, carbimazole is used for the treatment of hyperthyroidism.	2.07	1	0	1,3-dihydroimidazole-2-thiones; carbamate ester	antithyroid drug; prodrug
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	3.84	3	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
cetylpyridinium chloride anhydrous tserigel: according to first source contains polyvinylbutyral & cetylpyridinium chloride; UD only lists cetylpyridinium chloride as constituent. cetylpyridinium chloride : A pyridinium salt that has N-hexadecylpyridinium as the cation and chloride as the anion. It has antiseptic properties and is used in solutions or lozenges for the treatment of minor infections of the mouth and throat.	2.13	1	0	chloride salt; organic chloride salt	antiseptic drug; surfactant
triamcinolone Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.	2.46	2	0	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
oxyphenisatin [no description available]	3.23	1	0	indoles
azetepa [no description available]	2.04	1	0	phosphoramide
fludrocortisone Fludrocortisone: A synthetic mineralocorticoid with anti-inflammatory activity.	3.23	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; fluorinated steroid; mineralocorticoid	adrenergic agent; anti-inflammatory drug
ursodeoxycholic acid Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.	4.07	4	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
pregnanolone Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.	2.04	1	0	3-hydroxy-5beta-pregnan-20-one; 3alpha-hydroxy steroid	human metabolite; intravenous anaesthetic; sedative
butylated hydroxytoluene 2,6-di-tert-butyl-4-methylphenol : A member of the class of phenols that is 4-methylphenol substituted by tert-butyl groups at positions 2 and 6.	2.75	3	0	phenols	antioxidant; ferroptosis inhibitor; food additive; geroprotector
metipranolol Metipranolol: A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.. metipranolol : 3-(Propan-2-ylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by a 4-acetoxy-2,3,5-trimethylphenoxy group. A non-cardioselective beta-blocker, it is used to lower intra-ocular pressure in the management of open-angle glaucoma.	2.02	1	0	acetate ester; aromatic ether; propanolamine; secondary amino compound	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
proquazone proquazone: nonsteroid anti-inflammatory agent; structure	2.04	1	0	pyrimidines
halazepam halazepam: structure	2.43	2	0	organic molecular entity
du-21220 Ritodrine: An adrenergic beta-2 agonist used to control PREMATURE LABOR.. 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol : A secondary amino compound that is 4-(2-amino-1-hydroxypropyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 2-(4-hydroxyphenyl)ethyl group.	2.43	2	0	benzyl alcohols; polyphenol; secondary alcohol; secondary amino compound
dexchlorpheniramine dexchlorpheniramine: RN given refers to parent cpd(S)-isomer	3.23	1	0	chlorphenamine
ribostamycin Ribostamycin: A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus.. ribostamycin : An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).	2.04	1	0	amino cyclitol glycoside; aminoglycoside antibiotic	antibacterial drug; antimicrobial agent; metabolite
clometacin clometacin: structure	3.23	1	0	N-acylindole
cefazolin Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.	5.54	21	0	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
ripazepam [no description available]	2.44	2	0	benzenes
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	6.91	86	0	penicillin allergen; penicillin	antibacterial drug
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	4.24	5	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
indoramin Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.	2.74	3	0	tryptamines
oxcarbazepine Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.	3.23	1	0	cyclic ketone; dibenzoazepine	anticonvulsant; drug allergen
carbidopa carbidopa (anhydrous) : 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.	3.23	1	0	catechols; hydrazines; monocarboxylic acid	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
prednimustine Prednimustine: Ester of CHLORAMBUCIL and PREDNISOLONE used as a combination alkylating agent and synthetic steroid to treat various leukemias and other neoplasms. It causes gastrointestinal and bone marrow toxicity.	2.04	1	0	corticosteroid hormone
toloxatone toloxatone: oxazolidinone derivative; psychotropic drug; structure. toloxatone : A racemate consisting of equimolar amounts of (R)- and (S)-toloxatone. It is a reversible monoamine oxidase A inhibitor and antidepressant.. 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one : A member of the class of oxazolidinones that is 5-(hydroxymethyl)-1,3-oxazolidin-2-one substituted by a 3-methylphenyl group at position 3.	2.45	2	0	oxazolidinone; primary alcohol; toluenes
moricizine hydrochloride moricizine hydrochloride : A hydrochloride salt obtained from equimola amounts of moricizine and hydrogen chloride.	2.46	2	0	hydrochloride	anti-arrhythmia drug
moricizine Moricizine: An antiarrhythmia agent used primarily for ventricular rhythm disturbances.. moricizine : A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.	3.84	3	0	carbamate ester; morpholines; phenothiazines	anti-arrhythmia drug
amygdalin [no description available]	2.04	1	0	cyanogenic glycoside; disaccharide derivative; gentiobioside	plant metabolite
amineptin amineptin: used in treatment of neuroses with psychoasthenic, anxio-phobic & depressive manifestations; synonym S 1694 refers to HCl; structure. amineptine : A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.	3.86	3	0	amino acid; carbocyclic fatty acid; carbotricyclic compound; secondary amino compound	antidepressant; dopamine uptake inhibitor
bitolterol bitolterol: RN given refers to parent cpd; structure. bitolterol : The di-4-toluate ester of (+-)-N-tert-butylnoradrenaline (colterol). A pro-drug for colterol, a beta2-adrenergic receptor agonist, bitolterol is used as its methanesulfonate salt for relief of bronchospasm in conditions such as asthma, chronic bronchitis and emphysema.	2.02	1	0	carboxylic ester; diester; ethanolamines; secondary alcohol; secondary amino compound	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; prodrug
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	4.85	10	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
feprazone Feprazone: A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)	2.04	1	0	organic molecular entity
pirprofen pirprofen: anti-inflammatory agent used in therapy of rheumatoid arthritis; prostaglandin synthetase inhibitor; more potent than indomethacin; structure	4.09	4	0	pyrroline
sisomicin Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).	2.96	4	0	amino cyclitol glycoside; aminoglycoside antibiotic; beta-L-arabinoside; monosaccharide derivative
serentil mesoridazine besylate : The benzenesulfonate salt of mesoridazine prepared using equimolar amounts of mesoridazine and benzenesulfonic acid.	2.46	2	0	organosulfonate salt	dopaminergic antagonist; first generation antipsychotic
amdinocillin Amdinocillin: An amidinopenicillanic acid derivative with broad spectrum antibacterial action.. mecillinam : A penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria.	3.14	5	0	penicillin	antibacterial drug; antiinfective agent
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	5.69	75	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	4.53	7	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	4.76	9	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
propafenone hydrochloride propafenone hydrochloride : A hydrochloride that is the monohydrochloride salt of propafenone. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used in the management of supraventricular and ventricular arrhythmias.	2.46	2	0	hydrochloride	anti-arrhythmia drug
dobutamine Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.	3.84	3	0	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
ticarcillin Ticarcillin: An antibiotic derived from penicillin similar to CARBENICILLIN in action.. ticarcillin : A penicillin compound having a 6beta-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.	5.69	76	0	penicillin allergen; penicillin	antibacterial drug
trimazosin trimazosin: RN given refers to parent cpd; structure	2.04	1	0	N-arylpiperazine
halofantrine halofantrine: used in treatment of mild to moderate acute malaria	2.04	1	0	phenanthrenes
penbutolol Penbutolol: A nonselective beta-blocker used as an antihypertensive and an antianginal agent.	3.56	2	0	ethanolamines
etidocaine Etidocaine: A local anesthetic with rapid onset and long action, similar to BUPIVACAINE.. etidocaine : An amino acid amide in which 2-[ethyl(propyl)amino]butanoic acid and 2,6-dimethylaniline have combined to form the amide bond. Used as a local anaesthetic (amide caine), it has rapid onset and long action properties, similar to bupivacaine, and is given by injection during surgical procedures and during labour and delivery.	2.44	2	0	amino acid amide	local anaesthetic
ribavirin Rebetron: Rebetron is tradename	4.53	7	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adinazolam adinazolam: structure in first source. adinazolam : A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position.	2.45	2	0	triazolobenzodiazepine	anticonvulsant; antidepressant; anxiolytic drug; sedative
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	11.23	111	1	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
tolamolol [no description available]	2.04	1	0
carbidopa [no description available]	2.46	2	0	catechols; hydrate; hydrazines; monocarboxylic acid	antidyskinesia agent; antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
cephradine Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.	5.02	12	0	beta-lactam antibiotic allergen; cephalosporin	antibacterial drug
ticrynafen Ticrynafen: A novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent.. tienilic acid : An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis.	4.09	4	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid; thiophenes	antihypertensive agent; hepatotoxic agent; loop diuretic
guanadrel guanadrel: RN given refers to parent cpd; structure. guanadrel : A spiroketal resulting from the formal condensation of the keto group of cyclohexanone with the hydroxy groups of 1-(2,3-dihydroxypropyl)guanidine. A postganglionic adrenergic blocking agent formerly used (generally as the sulfate salt) for the management of hypertension, it has been largely superseded by other drugs less likely to cause orthostatic hypotension (dizzy spells on standing up or stretching).	2.02	1	0	guanidines; spiroketal	adrenergic antagonist; antihypertensive agent
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	4.85	10	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
tocainide Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.	2.95	4	0	monocarboxylic acid amide	anti-arrhythmia drug; local anaesthetic; sodium channel blocker
sulbenicillin Sulbenicillin: Semisynthetic penicillin-type antibiotic.. sulbenicillin : A penicillin antibiotic having a 6beta-[phenyl(sulfo)acetamido] side-chain.	2.74	3	0	penicillin
bezafibrate [no description available]	2.46	2	0	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
sq-11725 Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.	3.29	6	0
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	4.25	5	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
nimustine Nimustine: Antineoplastic agent especially effective against malignant brain tumors. The resistance which brain tumor cells acquire to the initial effectiveness of this drug can be partially overcome by the simultaneous use of membrane-modifying agents such as reserpine, calcium antagonists such as nicardipine or verapamil, or the calmodulin inhibitor, trifluoperazine. The drug has also been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms.. nimustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-amino-2-methylpyrimidin-5-ylmethyl] group. An antineoplastic agent especially effective against malignant brain tumors.	2.04	1	0	aminopyrimidine; N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
levobunolol Levobunolol: The L-Isomer of bunolol.. levobunolol : A cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma.	2.02	1	0	aromatic ether; cyclic ketone; propanolamine	antiglaucoma drug; beta-adrenergic antagonist
nonachlazine Nonachlazine: Coronary vasodilator with a novel mechanism of action; proposed as antianginal agent.	2.46	2	0
vecuronium bromide Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.	2.43	2	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent; nicotinic antagonist
vecuronium vecuronium : A 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidino- and 16beta-N-methylpiperidinium substituents.	3.23	1	0	acetate ester; androstane; quaternary ammonium ion	drug allergen; muscle relaxant; neuromuscular agent; nicotinic antagonist
benoxaprofen benoxaprofen: RN given refers to parent cpd; structure. benoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.	3.86	3	0	1,3-benzoxazoles; monocarboxylic acid; monochlorobenzenes	antipsoriatic; antipyretic; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; hepatotoxic agent; nephrotoxin; non-narcotic analgesic; non-steroidal anti-inflammatory drug; protein kinase C agonist
permethrin hemoglobin Atlanta-Coventry: Leu replaced by Pro at beta75 and Leu deleted at beta141	2.73	3	0	cyclopropanecarboxylate ester; cyclopropanes	agrochemical; ectoparasiticide; pyrethroid ester acaricide; pyrethroid ester insecticide; scabicide
exifone [no description available]	3.23	1	0	benzophenones
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid [no description available]	2.13	1	0	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor
mefloquine (-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.	3.23	1	0	[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol	antimalarial
flecainide acetate flecainide acetate : An acetate salt obtained by combining flecainide with one molar equivalent of acetic acid. An antiarrhythmic agent used to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	2.46	2	0	acetate salt	anti-arrhythmia drug
meptazinol Meptazinol: A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.	2.45	2	0	azepanes
nicardipine hydrochloride [no description available]	2.46	2	0	dihydropyridine	geroprotector
butibufen butibufen: RN given refers to parent cpd	2.04	1	0	monoterpenoid
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	3.23	1	0	benzamides; carboxylic ester
sufentanil Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.	4.06	4	0	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
acarbose [no description available]	3.23	1	0	tetrasaccharide derivative	EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; geroprotector; hypoglycemic agent
torsemide Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.. torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure.	4.4	6	0	aminopyridine; N-sulfonylurea; secondary amino compound	antihypertensive agent; loop diuretic
medroxalol medroxalol: RN given refers to parent cpd without isomeric designation	2.04	1	0	salicylamides
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	4.41	6	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
spiromustine [no description available]	2.04	1	0
cefmetazole Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.	3.55	8	0	cephalosporin	antibacterial drug
desflurane Desflurane: A fluorinated ether that is used as a volatile anesthetic for maintenance of general anesthesia.	2.02	1	0	organofluorine compound	inhalation anaesthetic
indacrinone indacrinone: polyvalent saluretic; RN given refers to parent cpd without isomeric designation; structure	2.46	2	0
prenalterol Prenalterol: A partial adrenergic agonist with functional beta 1-receptor specificity and inotropic effect. It is effective in the treatment of acute CARDIAC FAILURE, postmyocardial infarction low-output syndrome, SHOCK, and reducing ORTHOSTATIC HYPOTENSION in the SHY-RAGER SYNDROME.	2.04	1	0	aromatic ether
diaziquone diaziquone: RN given refers to parent cpd. diaziquone : A 1,4-benzoquinone that is substituted at positions 2 and 5 have been replaced by aziridin-1-yl groups and at positions 3 and 6 by (ethoxycarbonyl)amino groups.	2.04	1	0	1,4-benzoquinones; aziridines; carbamate ester; enamine	alkylating agent; antineoplastic agent
lorcainide [no description available]	2.73	3	0	acetamides
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	4.4	6	0	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
ceforanide ceforanide: RN given refers to (6R-(trans))-isomer. ceforanide : A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many coliforms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.	2.04	1	0	cephalosporin	antibacterial drug
cefonicid Cefonicid: A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.. cefonicid : A cephalosporin bearing {[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and (R)-2-hydroxy-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	2.43	2	0	cephalosporin	antibacterial drug
piperacillin Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.	8.49	167	0	penicillin allergen; penicillin	antibacterial drug
cefotiam Cefotiam: One of the CEPHALOSPORINS that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.. cefotiam : A cephalosporin with ({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl and (2-amino-1,3-thiazol-4-yl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. A third generation beta-lactam cephalosporin antibiotic, it is active against a broad spectrum of both Gram positive and Gram negative bacteria.	2.05	1	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	4.54	7	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
triciribine phosphate [no description available]	2.04	1	0
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	4.53	7	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.	5.39	18	0	cephalosporin	antibacterial drug
lodoxamide [no description available]	2.02	1	0	organonitrogen compound; organooxygen compound
atracurium Atracurium: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.. atracurium : A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.	4.06	4	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
butoconazole nitrate butoconazole nitrate : An organic nitrate salt obtained by reaction of equimolar amounts of butaconazole and nitric acid. An antifungal agent, it is used in gynaecology for treatment of vulvovaginal infections caused by Candida species, particularly Candida albicans.	2.46	2	0	aryl sulfide; conazole antifungal drug; imidazole antifungal drug; imidazoles; organic nitrate salt
butoconazole butoconazole: RN given refers to parent cpd; structure. butoconazole : A member of the class of imidazoles that is 1H-imidazole in which the hydrogen attached to the nitrogen is substituted by a 4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl group. An antifungal agent, it is used as its nitrate salt in gynaecology for treatment of vulvovaginal infections caused by Candida species, particularly Candida albicans.	2.02	1	0	aryl sulfide; conazole antifungal drug; dichlorobenzene; imidazole antifungal drug; imidazoles; monochlorobenzenes
moxalactam Moxalactam: Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.. moxalactam : A broad-spectrum oxacephem antibiotic in which the oxazine ring is substituted with a tetrazolylthiomethyl group and the azetidinone ring carries methoxy and 2-carboxy-2-(4-hydroxyphenyl)acetamido substituents.	4.05	14	0	cephalosporin; oxacephem	antibacterial drug
endralazine BQ 22-708: RN given refers to parent cpd	2.04	1	0	benzamides
naftifine naftifine: allylamine der; RN given refers to unlabeled parent cpd. naftifine : A tertiary amine in which the nitrogen is substituted by methyl, alpha-naphthylmethyl, and (1E)-cinnamyl groups. It is used (usually as its hydrochloride salt) for the treatment of fungal skin infections.	2.02	1	0	allylamine antifungal drug; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; sterol biosynthesis inhibitor
bw-755c 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine: A dual inhibitor of both cyclooxygenase and lipoxygenase pathways. It exerts an anti-inflammatory effect by inhibiting the formation of prostaglandins and leukotrienes. The drug also enhances pulmonary hypoxic vasoconstriction and has a protective effect after myocardial ischemia.	2.04	1	0
pergolide Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.. pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	3.84	3	0	diamine; methyl sulfide; organic heterotetracyclic compound	antiparkinson drug; dopamine agonist
cefadroxil anhydrous Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	4.84	10	0	cephalosporin	antibacterial drug
encainide Encainide: One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.. encainide : 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market.	2.73	3	0	benzamides; piperidines	anti-arrhythmia drug; sodium channel blocker
nedocromil Nedocromil: A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with ASTHMA, including EOSINOPHILS; NEUTROPHILS; MACROPHAGES; MAST CELLS; MONOCYTES; AND PLATELETS.	2.02	1	0	dicarboxylic acid; organic heterotricyclic compound	anti-allergic agent; anti-asthmatic drug; non-steroidal anti-inflammatory drug
fialuridine [no description available]	3.86	3	0
doxofylline doxofylline : An oxopurine that is a derivative of xanthine, methylated at N-1 and N-3 and carrying a 1,3-dioxolan-2-ylmethyl group at N-7, used in the treatment of asthma.	2.04	1	0	oxopurine	anti-asthmatic drug; antitussive; bronchodilator agent
cefaclor [no description available]	1.97	1	0
cefaclor anhydrous Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	4.94	11	0	cephalosporin	antibacterial drug; drug allergen
pefloxacin Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.	3.14	5	0	fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone	antibacterial drug; antiinfective agent; DNA synthesis inhibitor
mitoxantrone hydrochloride [no description available]	2.46	2	0	hydrochloride	antineoplastic agent
alfentanil Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.	4.4	6	0	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
miglustat miglustat: a glucosylceramide synthase inhibitor. miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.	3.23	1	0	piperidines; tertiary amino compound	anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
haloperidol decanoate [no description available]	3.23	1	0	organic molecular entity
cefotetan Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.	4.94	11	0
recainam recainam: structure given in first source	2.45	2	0
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	4.4	6	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
flupirtine flupirtine: RN given refers to parent cpd without isomeric designation	2.45	2	0	aminopyridine
tolrestat tolrestat: RN & structure given in first source	3.59	2	0	naphthalenes	EC 1.1.1.21 (aldehyde reductase) inhibitor
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.45	2	0	aromatic ketone
piritrexim piritrexim: RN given refers to parent cpd; structure given in first source	2.04	1	0
levocabastine levocabastine: for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis	2.02	1	0	piperidines
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	4.07	4	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
idazoxan Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.	2.04	1	0	benzodioxine; imidazolines	alpha-adrenergic antagonist
remoxipride Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.	2.74	3	0	dimethoxybenzene
balsalazide balsalazide: a mesalamine 5-aminosalicylate prodrug; 99% of ingested drug remains intact through the stomach and is delivered to and activated in the colon; used for inflammatory bowel disease, ulcerative colitis and radiation-induced proctosigmoiditis but avoided in patients with known hypersensitivity reaction to salicylates or mesalamine; structure in first source. balsalazide : A monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-beta-alanine via an azo bond.	3.23	1	0
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	4.25	5	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
cabergoline Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.	3.56	2	0	N-acylurea	antineoplastic agent; antiparkinson drug; dopamine agonist
caracemide [no description available]	2.04	1	0
bambuterol bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.	2.96	4	0	carbamate ester; phenylethanolamines	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; prodrug; sympathomimetic agent; tocolytic agent
atomoxetine atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.	4.26	5	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
quinapril Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.	4.4	6	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
alpidem [no description available]	4.09	4	0	imidazoles
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	3.23	1	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
trospectomycin trospectomycin: active against Neisseria gonorrhoeae; RN refers to 2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9beta,9alpha,9aalpha,10abeta)-(9CI)-isomer	2.45	2	0	dioxanes
cilazapril, anhydrous Cilazapril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors) used for hypertension. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat.. cilazapril : A pyridazinodiazepine resulting from the formal condensation of the carboxy group of cilazaprilat with ethanol. It is a drug used in the treatment of hypertension and heart failure.	2.04	1	0	dicarboxylic acid monoester; ethyl ester; pyridazinodiazepine	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
fosphenytoin fosphenytoin: structure given in first & second source	3.56	2	0	imidazolidine-2,4-dione
ranolazine Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.. N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.. ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina.	3.23	1	0	aromatic amide; monocarboxylic acid amide; monomethoxybenzene; N-alkylpiperazine; secondary alcohol
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	4.25	5	0	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
sematilide sematilide: RN refers to HCl; structure given in first source	2.45	2	0
esmolol methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate : A methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group.. esmolol : A racemate comprising equimolar amounts of (R)- and (S)-esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery. While the S enantiomer possesses all of the heart rate control, both enantiomers contribute to lowering blood pressure.	4.06	4	0	aromatic ether; ethanolamines; methyl ester; secondary alcohol; secondary amino compound
temafloxacin temafloxacin: structure given in first source. temafloxacin : A racemate comprising equimolar amounts of (R)- and (S)-temafloxacin. Both enantiomers both exhibit similar pharmacological profiles. Temafloxacin was briefly used (either as the free base or as the hydrochloride salt) as an antibacterial drug but was withdrawn worldwide in 1992 following reports of serious side effects, including severe hypoglycaemia, haemolytic anaemia, liver and kidney dysfunction, anaphylaxis, and death.. 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid : A quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, and 7 by 2,4-difluorophenyl, fluorine, and 3-methylpiperazin-1-yl groups, respectively.	2.46	2	0	amino acid; monocarboxylic acid; N-arylpiperazine; organofluorine compound; quinolone antibiotic; quinolone; secondary amino compound; tertiary amino compound
clinafloxacin clinafloxacin: structure given in first source; RN given is for monoHCl	2.96	4	0	quinolines
adapalene Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.. adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.	2.02	1	0	adamantanes; monocarboxylic acid; naphthoic acid	dermatologic drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; non-steroidal anti-inflammatory drug
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	3.85	3	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
loxiglumide loxiglumide: cholecystokinin receptor antagonist; RN refers to (+-)-isomer; structure in first source	2.04	1	0	organic molecular entity
aromasil [no description available]	3.23	1	0	17-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor; environmental contaminant; xenobiotic
sparfloxacin [no description available]	3.14	5	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone
zileuton [no description available]	4.41	6	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
clopidogrel Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.	3.23	1	0	methyl ester; monochlorobenzenes; thienopyridine	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	4.06	4	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
tiagabine Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.. tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy.	4.07	4	0	beta-amino acid; piperidinemonocarboxylic acid; tertiary amino compound; thiophenes	anticonvulsant; GABA reuptake inhibitor
mibefradil Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.	2.74	3	0	tetralins	T-type calcium channel blocker
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	4.06	4	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
bromfenac bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.	4.41	6	0	aromatic amino acid; benzophenones; organobromine compound; substituted aniline	non-narcotic analgesic; non-steroidal anti-inflammatory drug
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	4.06	4	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
ibutilide ibutilide: RN & structure in first source; RN refers to the fumarate salt	4.06	4	0	benzenes; organic amino compound
aripiprazole Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.	3.58	2	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
remifentanil Remifentanil: A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care.. remifentanil : A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.	4.06	4	0	alpha-amino acid ester; anilide; monocarboxylic acid amide; piperidinecarboxylate ester	intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; sedative
atorvastatin [no description available]	3.85	3	0	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
lamivudine [no description available]	4.53	7	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
duloxetine [no description available]	3.23	1	0	duloxetine
irinotecan [no description available]	4.06	4	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	4.54	7	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	3.58	2	0
ziprasidone ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.	4.07	4	0	1,2-benzisothiazole; indolones; organochlorine compound; piperazines	antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist
zanamivir Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.	2.45	2	0	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.	3.85	3	0	oxazolidinone; tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
emtricitabine Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.	3.23	1	0	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor
tasosartan tasosartan: angiotensin II antagonist; structure given in first source	3.86	3	0	biphenyls
saquinavir monomethanesulfonate [no description available]	2.46	2	0	organic molecular entity
tiludronic acid tiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first source	3.23	1	0	organochlorine compound
tirofiban Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.. tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.	3.85	3	0	L-tyrosine derivative; piperidines; sulfonamide	anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist
capecitabine Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.	3.23	1	0	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	4.25	5	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone 2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone: structure	2.04	1	0	1,4-benzoquinones
allyl formate [no description available]	2.46	2	0
acridine orange Acridine Orange: A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.. acridine orange : Fluorescent dye useful for cell cycle determination. It is cell-permeable, and interacts with DNA and RNA by intercalation or electrostatic attractions respectively.. acridine orange free base : A member of the class of aminoacridines that is acridine carrying two dimethylamino substituents at positions 3 and 6. The hydrochloride salt is the fluorescent dye 'acridine orange', used for cell cycle determination.	2.45	2	0	aminoacridines; aromatic amine; tertiary amino compound	fluorochrome; histological dye
morzid morzid: structure	2.04	1	0	morpholines
desferrioxamine b mesylate desferrioxamine B mesylate : A methanesulfonate salt obtained by reaction of desferrioxamine B with one molar equivalent of methanesulfonic acid. It is an iron-chelating medicine used to remove excess iron from the body. It binds to iron in the blood, which is then passed out in the urine.	2.46	2	0	methanesulfonate salt	antidote; ferroptosis inhibitor; iron chelator
bupropion hydrochloride [no description available]	2.46	2	0	aromatic ketone
cisatracurium cisatracurium: RN refers to (1R-(1alpha,2alpha(1'R,2'R)))-isomer. cisatracurium : A diester that is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium, a quaternary ammonium ion consisting of pentane-1,5-diol with both hydroxy functions bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. The active species in the skeletal muscle relaxant cisatracurium besylate.	2.04	1	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
diltiazem hydrochloride Carex: fluoride (1.8%) containing varnish; no further information available 8/91. diltiazem hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of diltiazem and hydrogen chloride. A calcium-channel blocker and vasodilator, it is used in the management of angina pectoris and hypertension.	2.05	1	0	hydrochloride	antihypertensive agent; calcium channel blocker; vasodilator agent
trazodone hydrochloride Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.	2.46	2	0	hydrochloride	adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor
fosinoprilat fosinoprilat: active phosphinic acid metabolite of prodrug fosenopril, which is activated by esterases in vivo; structure given in first source; binds zinc with phosphinic acid group. fosinoprilat : A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of hypertension and chronic heart failure.	2.04	1	0	L-proline derivative; phosphinic acids	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
trovafloxacin trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.	4.41	6	0
verapamil hydrochloride verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride.	2.46	2	0
cefprozil [no description available]	3.84	3	0	cephalosporin; semisynthetic derivative	antibacterial drug
ciprofloxacin hydrochloride anhydrous [no description available]	2.46	2	0	hydrochloride	antibacterial drug; antiinfective agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
methylprednisolone aceponate methylprednisolone aceponate: RN given for (6alpha,11beta)-isomer	2.02	1	0	corticosteroid hormone
dexamethasone 17-valerate dexamethasone 17-valerate: RN given refers to (11beta,16alpha)-isomer; structure	2.02	1	0	21-hydroxy steroid
dexamethasone dipropionate [no description available]	2.02	1	0	corticosteroid hormone
febrifugine febrifugine: antimalarials; structure	2.04	1	0	quinazolines
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	3.23	1	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	3.23	1	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
amantadine hydrochloride [no description available]	2.46	2	0	hydrochloride	antiviral agent; dopamine agonist; NMDA receptor antagonist
fenofibric acid fenofibric acid: RN given refers to parent cpd without isomeric designation; structure. fenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.	3.23	1	0	aromatic ketone; chlorobenzophenone; monocarboxylic acid	drug metabolite; marine xenobiotic metabolite
ursolic acid [no description available]	2.52	2	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	geroprotector; plant metabolite
betulinic acid [no description available]	2.25	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	3.23	1	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
amprenavir [no description available]	3.23	1	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	3.23	1	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
thymine arabinoside thymine arabinoside: selectively inhibits replication of herpes simplex virus	2.04	1	0	N-glycosyl compound
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	2.13	1	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
psicofuranine [no description available]	2.04	1	0	psicose derivative; purine nucleoside
dobutamine hydrochloride dobutamine hydrochloride : The hydrochloride salt of dobutamine. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used to increase the contractility of the heart in the management of acute heart failure.	2.46	2	0	hydrochloride	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
triciribine [no description available]	2.04	1	0	nucleoside analogue	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
iopamidol Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.	2.96	4	0	benzenedicarboxamide; organoiodine compound; pentol	environmental contaminant; radioopaque medium; xenobiotic
sulconazole, mononitrate, (+-)-isomer [no description available]	2.46	2	0	conazole antifungal drug; imidazole antifungal drug; organic nitrate salt
5-chloro-2'-deoxyuridine [no description available]	2.04	1	0
histamine phosphate histamine phosphate : A phosphate salt that is the diphosphate salt of histamine.	3.23	1	0	phosphate salt	histamine agonist
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	2.46	2	0	cephalosporin	fungal metabolite
imipramine n-oxide imipramine N-oxide: RN given refers to parent cpd; structure	2.04	1	0	dibenzooxazepine
tilbroquinol [no description available]	3.23	1	0	organohalogen compound; quinolines
bendamustine [no description available]	3.58	2	0	benzimidazoles
droxicam droxicam: structure given in first source. droxicam : An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.	3.23	1	0	organic heterotricyclic compound; pyridines	cyclooxygenase 1 inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor; prodrug
trofosfamide trofosfamide: cyclophosphamide analog; structure	2.04	1	0	ifosfamides
ceftezole ceftezole: RN given refers to (6R-(trans))-isomer; structure. ceftezole : A first-generation cephalosporin antibiotic having (1,3,4-thiadiazol-2-ylsulfanyl)methyl and [2-(1H-tetrazol-1-yl)acetamido side groups located at positions 3 and 7 respectively.	2.04	1	0	cephalosporin; thiadiazoles
4-aminobenzoic acid-n-xyloside 4-aminobenzoic acid-N-xyloside: K 247 refers to Na salt; RN given refers to (D)-isomer	2.04	1	0
fotrin fotrin: ethyleneamine derivative; antineoplastic; Russian drug; structure	2.04	1	0
sufosfamide sufosfamide: stronger immunosuppressive activity than cyclophosphamide; structure	2.04	1	0
flomoxef flomoxef: structure given in first source; RN given refers to sodium salt. flomoxef : A second-generation oxacephem antibiotic in which the oxazine ring is substituted at C-3 with a hydroxyethyl-substituted tetrazolylthiomethyl group and the azetidinone ring carries 7alpha-methoxy and 7beta-{2-[(difluoromethyl)thiomethyl]acetamido} substituents.	2.45	2	0	N-acyl-amino acid; organonitrogen heterocyclic antibiotic; oxacephem	antibacterial drug
ebrotidine ebrotidine: an H2-receptor antagonist and gastric mucosa protector	3.23	1	0	sulfonamide
fropenem [no description available]	2.98	4	0	faropenem
dexloxiglumide dexloxiglumide: a CCK receptor antagonist; structure given in first source	2.45	2	0	glutamic acid derivative
intoplicine intoplicine: structure in first source	2.04	1	0	pyridoindole
repaglinide [no description available]	3.85	3	0	piperidines
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	4.26	5	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
hexestrol bis(diethylaminoethyl ether) hexestrol bis(diethylaminoethyl ether): minor descriptor (75-84); on-line & Index Medicus search HEXESTROL/AA (75-84); RN given refers to parent cpd without isomeric designation	2.45	2	0	stilbenoid
propatyl nitrate propatyl nitrate: structure given in first source	2.04	1	0	nitrate ester
dexfenfluramine Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.	2.72	3	0	fenfluramine	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
sulfamidochrysoidine sulfamidochrysoidine: RN given refers to parent cpd; structure. prontosil : A diphenyldiazene compound having two amino substituents at the 2- and 4-positions and an aminosulphonyl substituent at the 4'-position. It was the first antibacterial drug, (introduced 1935) and the first of the sulfonamide antibiotics.	2.04	1	0
synthalin a synthalin A: RN given refers to parent cpd; structure. synthalin : A hydrochloride resulting from the reaction of decamethylenediguanidine with 2 mol eq. of hydrogen chloride.. synthalin A : A member of the class of guanidines that is decane having guanidino groups at the 1- and 10-positions.	2.05	1	0	guanidines	hepatotoxic agent; hypoglycemic agent; nephrotoxin
ethinyl estradiol-17-sulfate ethinyl estradiol-17-sulfate: RN given refers to the (17alpha)-isomer	2.04	1	0
trimethobenzamide monohydrochloride [no description available]	2.46	2	0
amiloride hydrochloride amiloride hydrochloride dihydrate : A hydrate that is the dihydrate of amiloride hydrochloride.	2.46	2	0	hydrate	diuretic; sodium channel blocker
miconazole nitrate miconazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-miconazole nitrate. An antifungal used for the treatment of athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	2.78	3	0
ibopamine ibopamine: structure given in UD 31;67a & in 2nd source	2.04	1	0	benzoate ester; phenols
disobutamide [no description available]	2.45	2	0	acetamides
ethinylestradiol-3-sulfate ethinylestradiol-3-sulfate: binds to albumin at 2 sites	2.04	1	0	17beta-hydroxy steroid; steroid sulfate	antineoplastic agent; estrogen
econazole nitrate econazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-econazole nitrate. Used to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.	2.46	2	0
sertraline Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.	4.54	7	0	dichlorobenzene; secondary amino compound; tetralins	antidepressant; serotonin uptake inhibitor
lomefloxacin hydrochloride lomefloxacin hydrochloride : The hydrochloride salt of lomefloxacin. It is administered by mouth to treat bacterial infections including bronchitis and urinary tract infections. It is also used topically as eye drops for the treatment of bacterial conjunctivitis, and as ear drops for the treatment of otitis externa and otitis media.	2.46	2	0	hydrochloride	antimicrobial agent; antitubercular agent; photosensitizing agent
cefcanel cefcanel: RN given refers to (6R-(6 alpha,7 beta(R*)))-isomer; structure	2.04	1	0
pumitepa pumitepa: structure; RN given refers to unlabeled cpd	2.04	1	0
arbekacin arbekacin: structure given in first source. arbekacin : A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring.	2.96	4	0	aminoglycoside; kanamycins	antibacterial agent; antibacterial drug; antimicrobial agent; protein synthesis inhibitor
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	3.85	3	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
epristeride epristeride: structure given in first source	2.45	2	0	steroid acid
talinolol [no description available]	2.45	2	0	ureas
elmustine elmustine: structure	2.04	1	0
flunoxaprofen flunoxaprofen: structure given in first source. flunoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group (the S-enantiomer). Although it was shown to be effective in treatment of rheumatoid arthritis and osteoarthritis, the clinical use of flunoxaprofen was discontinued due to possible hepatotoxic side-effects.	2.46	2	0	1,3-benzoxazoles; monocarboxylic acid; organofluorine compound	antirheumatic drug; hepatotoxic agent; non-steroidal anti-inflammatory drug; protein kinase C agonist
tianeptine tianeptine: structure given in first source. tianeptine : A racemate comprising of equimolar amounts of (R)- and (S)-tianeptine. It is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs).. 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid : A member of the class of dibenzothiazepines that is 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide substituted by a (6-carboxyhexyl)amino group at position 11.. (S)-tianeptine : The S-enantiomer of tianeptine.	2.46	2	0	dibenzothiazepine; monocarboxylic acid; organochlorine compound
forphenicinol [no description available]	2.04	1	0
dipropylacetamide dipropylacetamide: structure. valpromide : A fatty amide derived from valproic acid.	2.44	2	0	fatty amide	geroprotector; metabolite; teratogenic agent
denaverine denaverine: RN given refers to parent cpd; structure	2.04	1	0	diarylmethane
cefminox cefminox : A second-generation cephamycin antibiotic having [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and 2-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}acetamido side-groups located respectively at positions 3 and 7beta of the cephem nucleus. A broad-spectrum bactericide, it is especially effective against Gram-negative and anaerobic bacteria.	2.04	1	0	cephamycin; tetrazoles
acamprosate Acamprosate: Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM.. acamprosate : An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.	3.23	1	0	acetamides; organosulfonic acid	environmental contaminant; neurotransmitter agent; xenobiotic
isaxonine isaxonine: promotes nerve growth	3.23	1	0	aminopyrimidine
enrofloxacin Enrofloxacin: A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice.. enrofloxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary antibacterial agent used for the treatment of pets.	2.04	1	0	cyclopropanes; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone	antibacterial agent; antimicrobial agent; antineoplastic agent
diprafenone diprafenone: structure given in first source	2.45	2	0	aromatic compound
erythromycin propionate erythromycin propionate: form in which erythromycin estolate is principally absorbed	2.02	1	0	erythromycin derivative
nebivolol 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] : A member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group.	3.58	2	0	chromanes; diol; organofluorine compound; secondary alcohol; secondary amino compound
uk 68798 [no description available]	4.08	4	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
ljc 10627 biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.	2.45	2	0	carbapenems; organic sulfide; pyrazolotriazole	antibacterial drug
hp 873 iloperidone: an atypical, negative symptom antipsychotic agent. iloperidone : A member of the class of piperidines that is the 4-acetyl-2-methoxyphenyl ether of 3-(piperidin-1-yl)propan-1-ol which is substituted at position 4 of the piperidine ring by a 6-fluoro-1,2-benzoxazol-3-yl group. A member of the group of second generation antipsychotics (also known as an atypical antipsychotics), it is used for the treatment of schizophrenia.	3.23	1	0	1,2-benzoxazoles; aromatic ether; aromatic ketone; methyl ketone; monoamine; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; second generation antipsychotic; serotonergic antagonist
dexrazoxane Dexrazoxane: The (+)-enantiomorph of razoxane.	4.06	4	0	razoxane	antineoplastic agent; cardiovascular drug; chelator; immunosuppressive agent
loperamide hydrochloride loperamide hydrochloride : A hydrochloride obtained by combining loperamide with one equivalent of hydrochloric acid. Used for treatment of diarrhoea resulting from gastroenteritis or inflammatory bowel disease.	2.46	2	0	hydrochloride	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
fenoxypropazine [no description available]	3.23	1	0	aromatic ether
antebate betamethasone butyrate propionate: a topical corticosteroid	2.02	1	0	corticosteroid hormone
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	3.58	2	0	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
inproquone inproquone: major descriptor (78-80); replaced major descriptor Bayer E39 (63-77); on-line search AZIRINES (66-80); Index Medicus search Bayer E39 (63-77), INPROQUONE (78-80)	2.04	1	0
betamipron [no description available]	2.04	1	0	organonitrogen compound; organooxygen compound
penicillin n penicillin N: RN given refers to (2S-(2alpha,5alpha,6beta(S*)))-isomer; structure in Merck, 9th ed, #6887	2.07	1	0	penicillin
bufuralol bufuralol: RN given refers to cpd without isomeric designation; structure	2.45	2	0	benzofurans
aceclofenac [no description available]	3.23	1	0	amino acid; carboxylic ester; dichlorobenzene; monocarboxylic acid; secondary amino compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
clociguanil clociguanil: RN given refers to parent cpd; structure	2.45	2	0
nitrefazole [no description available]	3.23	1	0	imidazoles
panipenem panipenem: synthetic cpd; structure given in first source	2.04	1	0	organic molecular entity
perindoprilat perindoprilat : A dipeptide obtained by formal condensation of one of the carboxy groups of N-[(1S)-1-carboxyethyl]-L-norvaline with the amino group of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid. The major active metabolite of perindopril.	2.04	1	0	dicarboxylic acid; dipeptide; L-alanine derivative; organic heterobicyclic compound	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
7-hydroxystaurosporine [no description available]	2.04	1	0
gallocatechol (-)-epigallocatechin : A flavan-3,3',4',5,5',7-hexol having (2R,3R)-configuration.	2.13	1	0	catechin; flavan-3,3',4',5,5',7-hexol	antioxidant; food component; plant metabolite
methotrimeprazine Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.	2.04	1	0	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
neamine neamine: fragment of NEOMYCIN B; structure in first source. neamine : 2-Deoxy-D-streptamine glycosylated at the 4-oxygen with a 6-amino-alpha-D-glucosaminyl group.	2.15	1	0	2,6-dideoxy-alpha-D-glucoside; aminoglycoside	antibacterial agent
lividomycin [no description available]	2.04	1	0	lividomycins	metabolite
gentamicin c1 [no description available]	2.78	3	0
gentamicin c1a [no description available]	3.59	7	0	gentamycin C
9-aminocamptothecin [no description available]	2.04	1	0	pyranoindolizinoquinoline
sch 34343 Sch 34343: structure given in first source; RN given refers to (5R-(5alpha,6alpha))-isomer	2.45	2	0
grepafloxacin grepafloxacin: structure in first source	2.46	2	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
squalamine squalamine: from dogfish shark Squalus acanthias; structure given in first source	2.04	1	0	bile acid
2-(4'-methylpiperazino-1-methyl)-1,3-diazafluoranthene 1-oxide 2-(4'-methylpiperazino-1-methyl)-1,3-diazafluoranthene 1-oxide: structure	2.45	2	0
neplanocin a neplanocin A: neplanocins are antitumor antibiotics & carbocyclic analogs of purine nucleosides from Ampullarilla regularis A11079; see also neplanocin B, neplanocin C, neplanocin D & neplanocin F; structure in first source; a potent inhibitor of S-adenosylhomocysteine hydrolase	2.04	1	0
doripenem Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.	8.46	23	0	carbapenems
madecassic acid [no description available]	2.25	1	0	monocarboxylic acid; pentacyclic triterpenoid; tetrol	antioxidant; plant metabolite
arjunolic acid arjunolic acid: oleanane type; isol from Cochlospermum tinctorium (Bixaceae); structure given in first source; RN given refers to (2alpha,3beta,4alpha)-isomer; RN for cpd without isomeric designation not avail 12/89. arjunolic acid : A pentacyclic triterpenoid that is olean-12-en-28-oic acid substituted by hydroxy groups at positions 2, 3 and 23 (the 2alpha,3beta stereoisomer). Isolated from Symplocos lancifolia and Juglans sinensis, it exhibits antioxidant and antimicrobial activities.	2.06	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	antibacterial agent; antifungal agent; antioxidant; metabolite
maslinic acid (2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria	2.06	1	0	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite
stictic acid stictic acid: antioxidant from lichen, Usnea articulata; structure in first source	2.13	1	0	aromatic ether
8-hydroxy-2-quinolinecarboxylic acid [no description available]	2.41	1	0	quinolines
2-naphthylisothiocyanate [no description available]	2.46	2	0
atovaquone Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.	4.06	4	0	hydroxy-1,2-naphthoquinone
1-ethoxysilatrane [no description available]	2.04	1	0
rivastigmine [no description available]	3.85	3	0	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent
frovatriptan [no description available]	3.85	3	0	carbazoles
eletriptan eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.	3.58	2	0	indoles; N-alkylpyrrolidine; sulfone	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rosiglitazone [no description available]	4.41	6	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
bexarotene [no description available]	3.23	1	0	benzoic acids; naphthalenes; retinoid	antineoplastic agent
flunisolide flunisolide: flunisolide HFA is a formulation of flunisolide using hydrofluoroalkane (HFA) as propellant in place of chlorofluorocarbon (CFC) ones	2.44	2	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; primary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug; immunosuppressive agent
chloroquine diphosphate [no description available]	2.46	2	0
orphenadrine citrate orphenadrine citrate : A citrate salt which comprises equimolar amounts of orphenadrine and citric acid.	2.46	2	0	citrate salt	H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
ketorolac tromethamine Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.. ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.	2.46	2	0	organoammonium salt	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	4.76	9	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
tretazicar tretazicar: minor descriptor (75-84); on-line & Index Medicus search AZIRIDINES (75-84)	2.04	1	0
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.73	3	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
nsc-172755 butocin: S-substituted analog of mercaptopurine which functions as a cytostatic agent; minor descriptor (75-85); on-line search 6-MERCAPTOPURINE/AA (75-84); Index Medicus search MERCAPTOPURINE/analogs (75-84)	2.04	1	0
n-(3,5-dichlorophenyl)succinimide N-(3,5-dichlorophenyl)succinimide: nephrotoxic; post-treatment enhanced induction of renal cell tumors in rats by dimethylnitrosamine, pre-treatment inhibited induction of tumors, & alone caused interstitial nephritis but no tumors	2.46	2	0	pyrrolidines
moexipril [no description available]	3.84	3	0	peptide
phentolamine mesylate [no description available]	2.46	2	0
sennoside B sennoside B : A member of the class of sennosides that is (9R,9'S)-9,9',10,10'-tetrahydro-9,9'-bianthracene-2,2'-dicarboxylic acid which is substituted by hydroxy groups at positions 4 and 4', by beta-D-glucopyranosyloxy groups at positions 5 and 5', and by oxo groups at positions 10 and 10'.	2.04	1	0	oxo dicarboxylic acid; sennosides
streptovitacin a streptovitacin A: structure	2.04	1	0
oxybutynin hydrochloride [no description available]	2.46	2	0	hydrochloride
1-cyano-2-hydroxy-3-butene [no description available]	2.05	1	0	secondary alcohol
cordium bepridil hydrochloride monohydrate : The hydrochloride monohydrate of bepridril.	2.46	2	0	hydrate; hydrochloride
3-aminobenzeneboronic acid [no description available]	2.02	1	0
cb 10375 trimelamol: structure given in first source	2.04	1	0
mci 9038 [no description available]	3.58	2	0	peptide
uvaol uvaol: from Vauquelinia corymbosa (Rosaceae)	2.25	1	0	triterpenoid	metabolite
carbenicillin indanyl carbenicillin indanyl: acid stable indanyl ester of carbenicillin for oral use; same side-effects as carbenicillin; minor descriptor (75-86); on line & INDEX MEDICUS search CARBENICILLIN/AA (75-86); RN given refers to (mono-Na salt(2S-(2alpha,5alpha,6beta))-isomer)	2.04	1	0	penicillin
dimethacrine dimethacrine: minor descriptor (75-84); on-line & Index Medicus search ACRIDINES (75-84); RN given refers to parent cpd without isomeric designation	2.04	1	0	acridines
cb 1837 CB 1837: RN given refers to parent cpd; structure	2.04	1	0
hexaphosphamide hexaphosphamide: structure	2.04	1	0
dipin dipin: structure	2.04	1	0
phosphazine phosphazine: structure	2.04	1	0
2,8-dihydroxyquinoline [no description available]	2.41	1	0	dihydroxyquinoline; monohydroxyquinoline; quinolone
diiodobenzotepa diiodobenzotepa: structure	2.04	1	0
icig 1163 ICIG 1163: RN given refers to parent cpd; structure in first source	2.04	1	0
bimolane bimolane: structure given in first source	2.04	1	0
thiodipin thiodipin: structure	2.04	1	0
fluoxydine fluoxydine: structure	2.04	1	0
imiphos imiphos: structure	2.04	1	0
4-hydroxycarbazole 4-hydroxycarbazole: structure in first source	2.41	1	0
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	3.23	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	10.53	222	0	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
bosentan anhydrous Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.	4.08	4	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
aldophosphamide aldophosphamide: metabolite of cyclophosphamide	2.04	1	0	nitrogen mustard
perindopril Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.. perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline	3.85	3	0	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
asulacrine asulacrine: derivative of amsacrine; structure given in first source	2.04	1	0	acridines
hydroxycotinine hydroxycotinine: metabolite of nicotine; RN given refers to (S)-isomer; structure. trans-3-hydroxycotinine : An N-alkylpyrrolidine that is cotinine substituted at position C-3 by a hydroxy group (the 3R,5S-diastereomer).	2.04	1	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid
quinaprilat quinaprilat: metabolite of quinapril. quinaprilat : A dicarboxylic acid resulting from the hydrolysis of the ethyl ester group of quinapril to give the corresponding dicarboxylic acid. The active angiotensin-converting enzyme inhibitor (ACE inhibitor) of the prodrug quinapril.	2.45	2	0	dicarboxylic acid; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; vasodilator agent
2-hydroxyimipramine 2-hydroxyimipramine: RN given refers to parent cpd	2.45	2	0	dibenzoazepine
ecteinascidin 743 [no description available]	2.04	1	0	acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound	alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite
tadalafil [no description available]	3.23	1	0	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione: isolated from Streptomyces griseoluteus fermentation broth; RN given refers to cpd without isomeric designation; structure	2.04	1	0
5-hydroxydopamine 5-hydroxydopamine: RN given refers to parent cpd	2.45	2	0	catecholamine
florfenicol florfenicol: structure given in first source. florfenicol : A carboxamide that is the N-dichloroacetyl derivative of (1R,2S)-2-amino-3-fluoro-1-[4-(methanesulfonyl)phenyl]propan-1-ol. A synthetic veterinary antibiotic that is used for treatment of bovine respiratory disease and foot rot; also used in aquaculture.	2.07	1	0	organochlorine compound; organofluorine compound; secondary alcohol; secondary carboxamide; sulfone	antimicrobial agent
oxymatrine oxysophoridine: an alkaloid isolated from Sophra alope; structure in first source	2.04	1	0	alkaloid; tertiary amine oxide
paliperidone 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one : A member of the class of pyridopyrimidines that is 9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.. paliperidone : A racemate comprising equimolar amounts of (R)- and (S)-paliperidone. Paliperidone is the primary active metabolite of the older antipsychotic risperidone and is used for treatment of schizophrenia.	3.23	1	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine; secondary alcohol
nitisinone [no description available]	3.23	1	0	(trifluoromethyl)benzenes; C-nitro compound; cyclohexanones; mesotrione	EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
asiatic acid [no description available]	2.52	2	0	monocarboxylic acid; pentacyclic triterpenoid; triol	angiogenesis modulating agent; metabolite
clofarabine [no description available]	3.23	1	0	adenosines; organofluorine compound	antimetabolite; antineoplastic agent
1,1,2-trichloroethanol 1,1,2-trichloroethanol: metabolite of 1,1,2-trichloroethylene	2.04	1	0
pramipexole Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.	3.23	1	0	benzothiazoles; diamine	antidyskinesia agent; antiparkinson drug; dopamine agonist; radical scavenger
valdecoxib [no description available]	3.23	1	0	isoxazoles; sulfonamide	antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
almotriptan almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.	3.85	3	0	indoles; sulfonamide; tertiary amine	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
mk 0663 [no description available]	2.04	1	0	bipyridines; organochlorine compound; sulfone	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
tazobactam Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.	4.78	30	0	penicillanic acids; triazoles	antiinfective agent; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
gefitinib [no description available]	3.86	3	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
polymyxin b nonapeptide [no description available]	2.21	1	0
desloratadine desloratadine: major metabolite of loratadine. desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.	3.23	1	0	benzocycloheptapyridine	anti-allergic agent; cholinergic antagonist; drug metabolite; H1-receptor antagonist
desvenlafaxine O-desmethylvenlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine.	3.23	1	0	cyclohexanols; phenols; tertiary amino compound	antidepressant; drug metabolite; marine xenobiotic metabolite
iremycin iremycin: anthracycline antibiotic from Streptomyces violaceus subsp. iremyceticus; RN given refers to parent cpd(7R-trans)-isomer	2.04	1	0
methotrexate [no description available]	4.86	10	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
cefbuperazone cefbuperazone: RN given refers to parent cpd(6R-(6alpha,7alpha,7(2R,3S)))-isomer; structure. cefbuperazone : A second-generation cephamycin antibiotic having [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and {N-[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]-D-threonyl}amino side groups located at positions 3 and 7beta respectively.	2.04	1	0	cephalosporin; peptide
n,n'-bis((2-chloroethyl)nitrosocarbamoyl)cystamine N,N'-bis((2-chloroethyl)nitrosocarbamoyl)cystamine: structure given in first source	2.04	1	0
hainanensine hainanensine: structure in first source	2.04	1	0
tamsulosin [no description available]	3.85	3	0	5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide	alpha-adrenergic antagonist; antineoplastic agent
rufinamide rufinamide: for treatment of Lennox-Gastaut syndrome; structure in first source	3.23	1	0	aromatic amide; heteroarene
sulbactam [no description available]	4.53	23	0	penicillanic acids
olmesartan medoxomil Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.	3.23	1	0	biphenyls
dexpanthenol dexpanthenol: The alcohol of pantothenic acid	3.23	1	0	amino alcohol; monocarboxylic acid amide	cholinergic drug; provitamin
fosamprenavir fosamprenavir: a prodrug of the protease inhibitor amprenavir. fosamprenavir : A sulfonamide with a structure based on that of sulfanilamide substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}amino)butyl group. It is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir.	3.23	1	0	sulfonamide	prodrug
febuxostat Febuxostat: A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.. febuxostat : A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.	3.23	1	0	1,3-thiazolemonocarboxylic acid; aromatic ether; nitrile	EC 1.17.3.2 (xanthine oxidase) inhibitor
dilevalol (R,R)-labetalol : A 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide that has 1R,2R-configuration.	2.45	2	0	2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
xylose xylopyranose: structure in first source	2.04	1	0	D-xylose
ritrosulfan ritrosulfan: RN given refers to parent cpd(R,S)-isomer; structure	2.04	1	0
escitalopram Escitalopram: S-enantiomer of CITALOPRAM. Belongs to a class of drugs known as SELECTIVE SEROTONIN REUPTAKE INHIBITORS, used to treat depression and generalized anxiety disorder.. escitalopram : A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram.	3.23	1	0	1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile	antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
10-propargyl-10-deazaaminopterin 10-propargyl-10-deazaaminopterin: structure in first source. pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.	3.23	1	0	N-acyl-L-glutamic acid; pteridines; terminal acetylenic compound	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
docetaxel [no description available]	2.73	3	0	hydrate; secondary alpha-hydroxy ketone	antineoplastic agent
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	3.23	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
irofulven irofulven: structure in first source	2.04	1	0	cyclohexenones
atazanavir atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).	3.23	1	0	carbohydrazide	antiviral drug; HIV protease inhibitor
ym 872 YM 872: structure in first source	2.04	1	0
nsc-141549 [no description available]	2.46	2	0
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	10.56	63	1	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
ezetimibe Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.. ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).	3.23	1	0	azetidines; beta-lactam; organofluorine compound	anticholesteremic drug; antilipemic drug; antimetabolite
ertapenem Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.	8.97	58	0	carbapenemcarboxylic acid; pyrrolidinecarboxamide	antibacterial drug
dx 8951 [no description available]	2.04	1	0	pyranoindolizinoquinoline
cox 189 lumiracoxib: a COX-2 inhibitor. lumiracoxib : An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.	3.59	2	0	amino acid; monocarboxylic acid; organochlorine compound; organofluorine compound; secondary amino compound	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
cilomilast [no description available]	2.45	2	0	methoxybenzenes
conivaptan conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).	3.58	2	0	benzazepine	aquaretic; vasopressin receptor antagonist
tezosentan tezosentan: structure in first source	2.04	1	0
sabarubicin sabarubicin: structure given in first source	2.04	1	0
damvar damvar: structure	2.04	1	0
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	5.1	13	0	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
pralnacasan pralnacasan: NSAID, ICE inhibitor & metastasis inhibitor; RN & structure in first source	3.23	1	0
clevidipine clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source	3.58	2	0	dihydropyridine
solifenacin [no description available]	3.85	3	0	isoquinolines
dexmethylphenidate dexmethylphenidate : A methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have R configuration. It is the active enantiomer in the racemic drug methylphenidate.	3.23	1	0	methyl phenyl(piperidin-2-yl)acetate	adrenergic agent
hyoscyamine Hyoscyamine: The 3(S)-endo isomer of atropine.. (S)-atropine : An atropine with a 2S-configuration.	2.07	1	0	tropane alkaloid
xamoterol Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.	2.45	2	0	morpholines
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	4.25	5	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
cinacalcet cinacalcet : A secondary amino compound that is (1R)-1-(naphthalen-1-yl)ethanamine in which one of the hydrogens attached to the nitrogen is substituted by a 3-[3-(trifluoromethyl)phenyl]propyl group.	3.23	1	0	(trifluoromethyl)benzenes; naphthalenes; secondary amino compound	calcimimetic; P450 inhibitor
lubiprostone [no description available]	3.23	1	0
olmesartan olmesartan: an active metabolite of CS 866	2.47	2	0	biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent
telbivudine [no description available]	3.23	1	0	pyrimidine 2'-deoxyribonucleoside	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
clofibride clofibride: structure	2.04	1	0	monocarboxylic acid
benzo-tepa benzo-tepa: structure	2.04	1	0
tevenel tevenel: sulfamoyl analog of D-threo-chloramphenicol; structure	2.04	1	0	sulfonamide
tac 278 TAC 278: prodrug of 5-fluorouracil; RN given refers to cpd with unspecified isomeric designation	2.04	1	0
abanoquil [no description available]	2.04	1	0
tetraphenylphosphonium chloride [no description available]	2.05	1	0
paromomycin Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.	3.23	1	0	amino cyclitol glycoside; aminoglycoside antibiotic	anthelminthic drug; antibacterial drug; antiparasitic agent; antiprotozoal drug
anidulafungin Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.	3.58	2	0	antibiotic antifungal drug; azamacrocycle; echinocandin; heterodetic cyclic peptide; semisynthetic derivative
aminopterin Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.	2.44	2	0	dicarboxylic acid	EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen
17 alpha-hydroxyprogesterone caproate 17 alpha-Hydroxyprogesterone Caproate: Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS.	3.23	1	0	corticosteroid hormone
varenicline Varenicline: A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.. varenicline : An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.	3.23	1	0
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	2.46	2	0	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
temocillin temocillin: beta-lactam antibiotic with unusual spectrum of antibacterial activity & exceptional stability to bacterial beta-lactamases; RN given refers to di-Na salt (2S-(2alpha,5alpha,6alpha))-isomer; structure in first source. temocillin : A penicillin compound having a 6alpha-methoxy and 6beta-[2-carboxy(thiophen-3-yl)acetamido side-groups.	2.74	3	0	penicillin
(4r)-3-((2s)-3-mercapto-2-methylpropanoyl)-4- thiazolidinecarboxylic acid [no description available]	2.04	1	0
fiduxosin fiduxosin: fiduxosin (ABT-980) is the (3aR,9bR)-isomer; structure in first source	3.23	1	0
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	4.4	6	0
ropivacaine Ropivacaine: An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.. ropivacaine : The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.. (S)-ropivacaine : A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.	2.43	2	0	piperidinecarboxamide; ropivacaine	local anaesthetic
erlotinib [no description available]	3.23	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
l 694,458 DMP 777: structure given in first source	2.45	2	0
melagatran [no description available]	2.45	2	0	azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor
aflatoxin b1 Aflatoxin B1: A potent hepatotoxic and hepatocarcinogenic mycotoxin produced by the Aspergillus flavus group of fungi. It is also mutagenic, teratogenic, and causes immunosuppression in animals. It is found as a contaminant in peanuts, cottonseed meal, corn, and other grains. The mycotoxin requires epoxidation to aflatoxin B1 2,3-oxide for activation. Microsomal monooxygenases biotransform the toxin to the less toxic metabolites aflatoxin M1 and Q1.. aflatoxin B1 : An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.	2.46	2	0	aflatoxin; aromatic ether; aromatic ketone	carcinogenic agent; human metabolite
deflazacort deflazacort: structure	2.04	1	0	corticosteroid hormone
hexestrol diphosphate [no description available]	2.04	1	0
carbocysteine Carbocysteine: A compound formed when iodoacetic acid reacts with sulfhydryl groups in proteins. It has been used as an anti-infective nasal spray with mucolytic and expectorant action.. S-carboxymethyl-L-cysteine : An L-cysteine thioether that is L-cysteine in which the hydrogen of the thiol group has been replaced by a carboxymethyl group.	2.44	2	0	L-cysteine thioether; non-proteinogenic L-alpha-amino acid	mucolytic
etravirine [no description available]	3.23	1	0	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor
troleandomycin Troleandomycin: A macrolide antibiotic that is similar to ERYTHROMYCIN.. troleandomycin : A semi-synthetic macrolide antibiotic obtained by acetylation of the three free hydroxy groups of oleandomycin. Troleandomycin is only found in individuals that have taken the drug.	2.75	3	0	acetate ester; epoxide; macrolide antibiotic; monosaccharide derivative; polyketide; semisynthetic derivative	EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor; xenobiotic
dronedarone Dronedarone: A non-iodinated derivative of amiodarone that is used for the treatment of ARRHYTHMIA.. dronedarone : A member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias.	3.23	1	0	1-benzofurans; aromatic ether; aromatic ketone; sulfonamide; tertiary amino compound	anti-arrhythmia drug; environmental contaminant; xenobiotic
tesaglitazar tesaglitazar: structure in first source	2.45	2	0
ramelteon ramelteon: melatonin MT1/MT2 receptor agonist	3.23	1	0	indanes
lapatinib [no description available]	3.59	2	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
darunavir Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.	3.23	1	0	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
deferasirox Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.	3.23	1	0	benzoic acids; monocarboxylic acid; phenols; triazoles	iron chelator
bms204352 BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source	2.04	1	0
fosfluconazole fosfluconazole: prodrug of fluconazole	2.04	1	0	conazole antifungal drug; triazole antifungal drug; triazoles	prodrug
tbc-11251 sitaxsentan: endothelin A receptor antagonist; structure in first source	3.23	1	0	benzodioxoles
tolvaptan [no description available]	3.23	1	0	benzazepine; benzenedicarboxamide	aquaretic; vasopressin receptor antagonist
sorafenib [no description available]	3.23	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
lenalidomide [no description available]	3.23	1	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
regadenoson [no description available]	3.23	1	0	purine nucleoside
lacosamide Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.	3.23	1	0	N-acyl-amino acid
cp 101,606 traxoprodil mesylate: a selective NMDA antagonist; structure given in first source	2.45	2	0
demecolcine Demecolcine: An alkaloid isolated from Colchicum autumnale L. and used as an antineoplastic.. (-)-demecolcine : A secondary amino compound that is (S)-colchicine in which the N-acetyl group is replaced by an N-methyl group. Isolable from the autumn crocus, Colchicum autumnale, it is less toxic than colchicine and is used as an antineoplastic.	2.04	1	0	alkaloid; secondary amino compound	antineoplastic agent; microtubule-destabilising agent
deoxycholic acid Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.	2.45	2	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human blood serum metabolite
estradiol 3-benzoate 17beta-estradiol 3-benzoate : A benzoate ester resulting from the formal condensation of benzoic acid with the phenolic hydroxy group of 17beta-estradiol.	2.02	1	0	17beta-hydroxy steroid; benzoate ester	estrogen receptor agonist; xenoestrogen
dromostanolone propionate dromostanolone propionate: RN given refers to (2alpha,5alpha,17beta)-isomer	2.04	1	0	3-oxo-5alpha-steroid; steroid ester	antineoplastic agent
fludrocortisone acetate fludrocortisone acetate : An acetate ester resulting from the formal condensation of the primary hydroxy group of fludrocortisone with acetic acid. A synthetic corticosteroid, it has glucocorticoid actions about 10 times as potent as hydrocortisone, while its mineralocorticoid actions are over 100 times as potent. It is used in partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenal hyperplasia.	2.46	2	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; fluorinated steroid; mineralocorticoid; tertiary alpha-hydroxy ketone
3,6-dichlorocarbazole 3,6-dichlorocarbazole: from Bavarian soil; structure in first source	2.41	1	0
vincaleukoblastine [no description available]	3.23	1	0	acetate ester; indole alkaloid fundamental parent; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; immunosuppressive agent; microtubule-destabilising agent; plant metabolite
vincristine sulfate [no description available]	2.46	2	0	organic sulfate salt	antineoplastic agent; geroprotector
benzarone benzarone: antihemorrhagic agent; structure	3.23	1	0	1-benzofurans
nsc-89199 estramustine phosphate : A steroid phosphate which is the 17-O-phospho derivative of estramustine.	2.44	2	0	carbamate ester; organochlorine compound; steroid phosphate
estramustine Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.	3.84	3	0	17beta-hydroxy steroid; carbamate ester; organochlorine compound	alkylating agent; antineoplastic agent; radiation protective agent
lupeol [no description available]	2.25	1	0	pentacyclic triterpenoid; secondary alcohol	anti-inflammatory drug; plant metabolite
phenethicillin phenethicillin: minor descriptor (85); major descriptor (63-84); on-line search PENICILLIN, PHENOXYMETHYL/AA (66-85); Index Medicus search PHENETHICILLIN (63-84); RN given refers to (2S-(2alpha,5alpha,6beta))-isomer. phenethicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-phenoxypropanamido group.	2.73	3	0	penicillin allergen; penicillin
indicine-n-oxide indicine-N-oxide: RN given refers to (1R-(1alpha,7(2R,3S),7abeta))-isomer; structure	2.04	1	0
acivicin [no description available]	2.74	3	0	isoxazoles; non-proteinogenic L-alpha-amino acid; organochlorine compound	antileishmanial agent; antimetabolite; antimicrobial agent; antineoplastic agent; EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor; glutamine antagonist; metabolite
menthofuran menthofuran: RN given refers to cpd without isomeric designation; derives from cyclization of pulegone. menthofuran : A monoterpenoid that is 4,5,6,7-tetrahydro-1-benzofuran substituted by methyl groups at positions 3 and 6.	2.07	1	0	1-benzofurans; monoterpenoid	nematicide; plant metabolite
trimethoprim, sulfamethoxazole drug combination Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.	2.04	1	0
bortezomib [no description available]	3.58	2	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	4.07	4	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
dithiothreitol [no description available]	2.04	1	0	1,4-dithiothreitol
glucosamine D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.	2.75	3	0	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	3.58	2	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
bekanamycin bekanamycin: kanendomycin is the sulfate of bekanamycin; RN given refers to parent cpd; structure	2.04	1	0	kanamycins
puromycin [no description available]	2.46	2	0	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor
pentostatin Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.	3.84	3	0	coformycins	antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor
taurolithocholic acid Taurolithocholic Acid: A bile salt formed in the liver from lithocholic acid conjugation with taurine, usually as the sodium salt. It solubilizes fats for absorption and is itself absorbed. It is a cholagogue and choleretic.. taurolithocholic acid : The bile acid taurine conjugate of lithocholic acid.	2.05	1	0	bile acid taurine conjugate; monocarboxylic acid amide	human metabolite
(+)-limonene (4R)-limonene : An optically active form of limonene having (4R)-configuration.	2.46	2	0	limonene	plant metabolite
strychnine Strychnine: An alkaloid found in the seeds of STRYCHNOS NUX-VOMICA. It is a competitive antagonist at glycine receptors and thus a convulsant. It has been used as an analeptic, in the treatment of nonketotic hyperglycinemia and sleep apnea, and as a rat poison.. strychnine : A monoterpenoid indole alkaloid that is strychnidine bearing a keto substituent at the 10-position.	2.04	1	0	monoterpenoid indole alkaloid; organic heteroheptacyclic compound	avicide; cholinergic antagonist; glycine receptor antagonist; neurotransmitter agent; rodenticide
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	4.76	9	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	17.17	170	1	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
sq 27860 carbapenem-3-carboxylic acid: from species of Serratia & Erwinia; carbapenam antibiotic; structure given in first source. 1-carbapenem-3-carboxylic acid : A carbapenemcarboxylic acid that is the 3-carboxy derivative of 2,3-didehydro-1-carbapenam.	2.45	2	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid
griseofulvin Griseofulvin: An antifungal agent used in the treatment of TINEA infections.. griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.	4.54	7	0	1-benzofurans; antibiotic antifungal drug; benzofuran antifungal drug; organochlorine compound; oxaspiro compound	antibacterial agent; Penicillium metabolite
cefoxitin Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.	10.04	122	1	beta-lactam antibiotic allergen; cephalosporin; cephamycin; semisynthetic derivative	antibacterial drug
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	2.44	2	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
moxalactam disodium [no description available]	2.75	3	0
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	3.84	3	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
pancuronium Pancuronium: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release.. pancuronium : A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.	3.58	2	0	acetate ester; steroid ester	cholinergic antagonist; muscle relaxant; nicotinic antagonist
rocuronium Rocuronium: An androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM.. rocuronium : A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.	2.04	1	0	3alpha-hydroxy steroid; acetate ester; androstane; morpholines; quaternary ammonium ion; tertiary amino compound	drug allergen; muscle relaxant; neuromuscular agent
abacavir abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.	4.41	6	0	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor
netilmicin Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.	4.18	16	0
miglitol [no description available]	3.85	3	0	piperidines
7-aminocephalosporanic acid 7beta-aminocephalosporanic acid : The alpha,beta-unsaturated monocarboxylic acid that is the active nucleus for the synthesis of cephalosporins and intermediates.	2.02	1	0	alpha,beta-unsaturated monocarboxylic acid; amino acid zwitterion
mometasone furoate Mometasone Furoate: A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders.	2.46	2	0	11beta-hydroxy steroid; 2-furoate ester; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; organochlorine compound; steroid ester	anti-allergic agent; anti-inflammatory drug
metyrosine alpha-methyl-L-tyrosine : An L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.	3.85	3	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	antihypertensive agent; EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
rocuronium bromide rocuronium bromide : The organic bromide salt of a 5alpha androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.	2.02	1	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent
nortriptyline hydrochloride [no description available]	2.46	2	0	organic tricyclic compound	geroprotector
erythromycin estolate Erythromycin Estolate: A macrolide antibiotic, produced by Streptomyces erythreus. It is the lauryl sulfate salt of the propionic ester of erythromycin. This erythromycin salt acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.	2.46	2	0	aminoglycoside sulfate salt; erythromycin derivative	enzyme inhibitor
kanamycin sulfate [no description available]	2.46	2	0	aminoglycoside sulfate salt	antibacterial drug; geroprotector
paromomycin sulfate paromomycin sulfate : An aminoglycoside sulfate salt resulting from the treatment of paromomycin with sulfuric acid. A broad-spectrum antibiotic, it is used for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.	2.46	2	0
terconazole terconazole: structure & RN for (cis)-isomer from first source. terconazole : A racemate consisting of equimolar amounts of (2R,4S)- and (2S,4R)-terconazole. It has broad-spectrum antifungal activitiy and is used for the treatment of vaginal yeast infections (Candida).. (2R,4S)-terconazole : A 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine in which positions 2 and 4 of the 1,3-dioxolane moiety have R and S configuration, respectively.	2.02	1	0	1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine
bacampicillin bacampicillin: ester prodrug that is hydrolyzed to ampicillin after its absorption from the gastrointestinal tract; RN given refers to parent cpd; structure. bacampicillin : A penicillanic acid ester that is the 1-ethoxycarbonyloxyethyl ester of ampicillin. It is a semi-synthetic, microbiologically inactive prodrug of ampicillin.	2.43	2	0	penicillanic acid ester	prodrug
linezolid [no description available]	6.93	12	1	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
angustibalin angustibalin: sesquiterpene lactone from Balduina angustifolia (Pursh) Robins; structure	2.04	1	0	sesquiterpene lactone
hematoxylin haematoxylin : An organic heterotetracyclic compound 7,11b-dihydroindeno[2,1-c]chromene carrying five hydroxy substituents at positions 3, 4, 6a, 9 and 10. The most important and most used dye in histology, histochemistry, histopathology and in cytology.	2.13	1	0	haematoxylin
phenylalanine arginine beta-naphthylamide phenylalanine arginine beta-naphthylamide: a drug efflux pump inhibitor; structure in first source	2.49	2	0	peptide
chloramphenicol palmitate chloramphenicol palmitate: RN given refers to ((R-(R,R))-isomer)	2.46	2	0	hexadecanoate ester
clindamycin phosphate [no description available]	3.23	1	0
hetacillin [no description available]	2.04	1	0	penicillin	antibacterial drug
calcium pantothenate [no description available]	2.46	2	0	polymer
eplerenone Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.	3.23	1	0	3-oxo-Delta(4) steroid; epoxy steroid; gamma-lactone; methyl ester; organic heteropentacyclic compound; oxaspiro compound; steroid acid ester	aldosterone antagonist; antihypertensive agent
tolterodine [no description available]	3.85	3	0	tertiary amine	antispasmodic drug; muscarinic antagonist; muscle relaxant
doxorubicin hydrochloride [no description available]	2.46	2	0	anthracycline
metrizamide Metrizamide: A solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.	2.04	1	0	amino sugar
medigoxin Medigoxin: A semisynthetic digitalis glycoside with the general properties of DIGOXIN but more rapid onset of action. Its cardiotonic action is prolonged by its demethylation to DIGOXIN in the liver. It has been used in the treatment of congestive heart failure (HEART FAILURE).	2.04	1	0	cardenolide glycoside
erythromycin ethylsuccinate Erythromycin Ethylsuccinate: A macrolide antibiotic, produced by Streptomyces erythreus. This compound is an ester of erythromycin base and succinic acid. It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin ethylsuccinate : A erythromycin derivative that is erythromycin A in which the hydroxy group at position 3R is substituted by a (4-ethoxy-4-oxobutanoyl)oxy group. It is used for the treatment of a wide variety of bacterial infections.	2.02	1	0	cyclic ketone; erythromycin derivative; ethyl ester; succinate ester
amcinonide amcinonide: structure	2.02	1	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; acetate ester; corticosteroid; fluorinated steroid; spiroketal	anti-inflammatory drug
betamethasone acetate [no description available]	2.43	2	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; acetate ester; fluorinated steroid; steroid ester; tertiary alpha-hydroxy ketone
darifenacin darifenacin : 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.	3.58	2	0	1-benzofurans; monocarboxylic acid amide; pyrrolidines	antispasmodic drug; muscarinic antagonist
fluticasone propionate fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.	2.04	1	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; corticosteroid; fluorinated steroid; propanoate ester; steroid ester; thioester	adrenergic agent; anti-allergic agent; anti-asthmatic drug; anti-inflammatory drug; bronchodilator agent; dermatologic drug
acarbose [no description available]	2.73	3	0	amino cyclitol; glycoside
maleic acid maleic acid: RN given refers to parent cpd(Z)-isomer which is maleic acid; all RR's given refer to (Z)-isomer; (E)-isomer is fumaric acid. maleic acid : A butenedioic acid in which the double bond has cis- (Z)-configuration.	2.46	2	0	butenedioic acid	algal metabolite; mouse metabolite; plant metabolite
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	4.25	5	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.06	1	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
retinol Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.. vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).	3.85	3	0	retinol; vitamin A	human metabolite; mouse metabolite; plant metabolite
cyanoginosin lr cyanoginosin LR: cyclic heptapeptide from cyanobacterium Microcystis aeruginosa. microcystin-LR : A microcystin consisting of D-alanyl, L-leucyl, (3S)-3-methyl-D-beta-aspartyl,L-arginyl, 2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl, D-gamma-glutamyl, and 2,3-didehydro-N-methylalanyl residues joined into a 25-membered macrocycle. Produced by the cyanobacterium Microcystis aeruginosa, it is the most studied of the microcystins.	2.46	2	0	microcystin	bacterial metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; environmental contaminant; xenobiotic
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	3.85	3	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
cerivastatin cerivastatin: cerivastatin is the ((E)-(+))-isomer; structure given in first source. cerivastatin : (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.	3.15	5	0	dihydroxy monocarboxylic acid; pyridines; statin (synthetic)
rosuvastatin rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).	3.85	3	0	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	2.45	2	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	3.84	3	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
mupirocin Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.	2.02	1	0	alpha,beta-unsaturated carboxylic ester; epoxide; monocarboxylic acid; oxanes; secondary alcohol; triol	antibacterial drug; bacterial metabolite; protein synthesis inhibitor
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	6.49	13	1
fosfomycin Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.	4.53	7	0	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	5.4	18	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
formycin [no description available]	2.04	1	0	formycin	antineoplastic agent
drf 2725 ragaglitazar: a phenoxazine analogue of phenyl propanoic acid; Ragaglitazar is a coligand of PPARalpha and PPARgamma	2.46	2	0
diethylstilbestrol Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.	2.07	1	0	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen
bms 214662 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source. BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.	2.04	1	0	benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
octreotide [no description available]	3.23	1	0
eptifibatide [no description available]	3.58	2	0	homodetic cyclic peptide; macrocycle; organic disulfide	anticoagulant; platelet aggregation inhibitor
gs 4071 GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.	2.45	2	0	acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite
decitabine [no description available]	3.85	3	0	2'-deoxyribonucleoside
sm 8668 Sch 39304: Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive	2.04	1	0
teniposide [no description available]	4.24	5	0	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
troxacitabine troxacitabine: shows good anti-HIV activity without cytotoxicity	2.04	1	0	carbohydrate derivative; nucleobase-containing molecular entity
ketoconazole (2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.	2.15	1	0	cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
cefamandole Cefamandole: Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.. cefamandole : A cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups.	3.63	9	0	cephalosporin; semisynthetic derivative	antibacterial drug
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	4.25	5	0	actinomycin	mutagen
tiazofurin tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).	2.44	2	0	1,3-thiazoles; C-glycosyl compound; monocarboxylic acid amide	antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; prodrug
5-carboxy-8-hydroxyquinoline 5-carboxy-8-hydroxyquinoline: a JmjC histone demethylase inhibitor; structure in first source	2.41	1	0	quinolines
azaserine Azaserine: Antibiotic substance produced by various Streptomyces species. It is an inhibitor of enzymatic activities that involve glutamine and is used as an antineoplastic and immunosuppressive agent.. azaserine : A carboxylic ester resulting from the formal condensation of the carboxy group of diazoacetic acid with the alcoholic hydroxy group of L-serine. An antibiotic produced by a Streptomyces species.	2.97	4	0	carboxylic ester; diazo compound; L-serine derivative; non-proteinogenic L-alpha-amino acid	antifungal agent; antimetabolite; antimicrobial agent; antineoplastic agent; glutamine antagonist; immunosuppressive agent; metabolite
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	4.53	7	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
sitafloxacin [no description available]	2.45	2	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	3.85	3	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
Epigallocatechin 3,5-Digallate [no description available]	2.13	1	0	catechin
posaconazole [no description available]	3.23	1	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
dibekacin Dibekacin: Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties.. dibekacin : A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring.	2.96	4	0	kanamycins	antibacterial agent; protein synthesis inhibitor
micafungin Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.	3.58	2	0	antibiotic antifungal drug; echinocandin	antiinfective agent
riboflavin vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).	3.58	2	0	flavin; vitamin B2	anti-inflammatory agent; antioxidant; cofactor; Escherichia coli metabolite; food colouring; fundamental metabolite; human urinary metabolite; mouse metabolite; photosensitizing agent; plant metabolite
n,n'-ethylenediamine disuccinic acid N,N'-ethylenediamine disuccinic acid: from Actinomycetes MG417-CF17; structure given in first source	2.41	1	0
sodium bicarbonate Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.	3.59	2	0	one-carbon compound; organic sodium salt	antacid; food anticaking agent
arsenic trioxide Tetraarsenic Oxide: A form of As2O3 that exists as As4O6 in the solid state. It dissociates to As2O3 upon heating to the vapor phase above 800 degrees Celsius.	3.86	3	0	arsenic oxide	antineoplastic agent; insecticide
dipyrone Dipyrone: A drug that has analgesic, anti-inflammatory, and antipyretic properties. It is the sodium sulfonate of AMINOPYRINE.. metamizole sodium : An organic sodium salt of antipyrine substituted at C-4 by a methyl(sulfonatomethyl)amino group, commonly used as a powerful analgesic and antipyretic.	2.04	1	0	organic sodium salt	anti-inflammatory agent; antipyretic; antirheumatic drug; cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug; prodrug
4-[[bis(2-hydroxyethyl)amino]methyl]-2,6-ditert-butylphenol [no description available]	2.04	1	0	alkylbenzene
idarubicin hydrochloride [no description available]	2.46	2	0	anthracycline
aceglatone aceglatone: structure in Merck	2.04	1	0	organic molecular entity
sch 22219 alclometasone dipropionate : A prednisolone compound having an alpha-chloro substituent at the 7-position, an alpha-methyl substituent at the 16-position and O-propanoyl groups at the 17- and 21-positions.	2.02	1	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; glucocorticoid; propanoate ester; steroid ester	anti-inflammatory drug
sr 90107 fondaparinux sodium : An organic sodium salt, being the decasodium salt of fondaparinux.	3.23	1	0
carbenoxolone sodium Carbenoxolone: An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity.	2.46	2	0	triterpenoid
carbenoxolone [no description available]	2.04	1	0
cefpiramide cefpiramide: antipseudomonal cephalosporin derivative. cefpiramide : A third-generation cephalosporin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and (R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It has a broad spectrum of antibacterial activity.	2.1	1	0	carboxylic acid; cephalosporin	antibacterial drug
meglumine iodipamide [no description available]	3.23	1	0	organoammonium salt	radioopaque medium
thyrotropin-releasing hormone PR 546: no other info available 9/89. protirelin : A tripeptide composed of L-pyroglutamyl, L-histidyl and L-prolinamide residues joined in sequence.	3.23	1	0	peptide hormone; tripeptide	human metabolite
flavin mononucleotide [no description available]	2.04	1	0	flavin mononucleotide; vitamin B2	bacterial metabolite; coenzyme; cofactor; human metabolite; mouse metabolite
arginine vasopressin Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.	3.23	1	0	vasopressin	cardiovascular drug; hematologic agent; mitogen
s 1033 [no description available]	3.23	1	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
3,6-dimethoxy-9H-carbazole [no description available]	2.41	1	0	carbazoles
mezlocillin Mezlocillin: Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.. mezlocillin : A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido group.	3.14	5	0	penicillin allergen; penicillin	antibacterial drug
amygdalin (R)-amygdalin : An amygdalin in which the stereocentre on the cyanohydrin function has R-configuration.	2.04	1	0	amygdalin	antineoplastic agent; apoptosis inducer; plant metabolite
cefsulodin Cefsulodin: A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients.. cefsulodin : A pyridinium-substituted semi-synthetic, broad-spectrum, cephalosporin antibiotic.	2.75	3	0	cephalosporin; organosulfonic acid; primary carboxamide	antibacterial drug
cholinophyllin [no description available]	2.02	1	0
mitobronitol Mitobronitol: Brominated analog of MANNITOL which is an antineoplastic agent appearing to act as an alkylating agent.	2.44	2	0	alcohol; organobromine compound
tropisetron Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.	2.04	1	0	indolyl carboxylic acid
prednisolone hemisuccinate prednisolone hemisuccinate: RN given refers to (11 beta)-isomer. prednisolone succinate : A hemisuccinate resulting from the formal condensation of the 21-hydroxy group prednisolone with one of the carboxy groups of succinic acid. It is used to treat mild to moderate non-infectious eye allergies and inflammation, including damage caused by chemical and thermal burns.	2.04	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; hemisuccinate; tertiary alpha-hydroxy ketone	anti-inflammatory drug
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.74	3	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
octotropine methylbromide octotropine methylbromide: minor descriptor (65-86); on line & INDEX MEDICUS search TROPANES (69-86); RN given refers to endo-isomer. anisotropine methylbromide : A quaternary ammonium salt resulting from the reaction of the amino group of anisotropine with methyl bromide.	2.44	2	0
fludarabine [no description available]	2.72	3	0	purine nucleoside
propylthiouracil Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.	4.4	6	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
nsc 4347 NSC 4347: structure in first source	2.04	1	0
ipratropium bromide anhydrous [no description available]	2.02	1	0
ipratropium [no description available]	2.07	1	0
methylatropine nitrate [no description available]	2.04	1	0
etomidate Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.	4.06	4	0	ethyl ester; imidazoles	intravenous anaesthetic; sedative
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	4.76	9	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
thioinosine Thioinosine: Sulfhydryl analog of INOSINE that inhibits nucleoside transport across erythrocyte plasma membranes, and has immunosuppressive properties. It has been used similarly to MERCAPTOPURINE in the treatment of leukemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p503)	2.04	1	0
pyrantel Pyrantel: A depolarizing neuromuscular-blocking agent, that causes persistent nicotinic activation resulting in spastic paralysis of susceptible nematodes. It is a drug of second-choice after benzimidazoles for treatment of ascariasis, hookworm, and pinworm infections, being effective after a single dose. (From Smith and Reynard, Textbook of Pharmacology, 1992, p920). pyrantel : A carboxamidine that is 1,4,5,6-tetrahydropyrimidine that is substituted at position 1 by a methyl group and at position 2 by an (E)-2-(2-thienyl)vinyl group. It is used, particularly as the embonate [4,4'-methylenebis(3-hydroxy-2-naphthoate)] salt, as an anthelmintic that is effective against intestinal nematodes including threadworms, roundworms and hookworms, and is included in the WHO 'Model List of Essential Medicines'.	3.23	1	0	1,4,5,6-tetrahydropyrimidines; carboxamidine; thiophenes	antinematodal drug
lobeline [no description available]	2.04	1	0
cotinine Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.	2.04	1	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite
thiothixene [no description available]	4.25	5	0	N-methylpiperazine	anticoronaviral agent
eszopiclone Eszopiclone: A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA.. eszopiclone : The (5S)- (active) enantiomer of zopiclone. Unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia, eszopiclone is approved by the U.S. Food and Drug Administration for long-term use.	3.23	1	0	zopiclone	central nervous system depressant; sedative
benztropine Benztropine: A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.. benzatropine : Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.	3.84	3	0	diarylmethane
thiouracil Thiouracil: Occurs in seeds of Brassica and Crucifera species. Thiouracil has been used as antithyroid, coronary vasodilator, and in congestive heart failure although its use has been largely supplanted by other drugs. It is known to cause blood dyscrasias and suspected of terato- and carcinogenesis.. thiouracil : A nucleobase analogue that is uracil in which the oxo group at C-2 is replaced by a thioxo group.	2.44	2	0	nucleobase analogue; thiocarbonyl compound	antithyroid drug; metabolite
methimazole Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.	4.25	5	0	1,3-dihydroimidazole-2-thiones	antithyroid drug
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	4.41	6	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	2.46	2	0	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
enclomiphene Enclomiphene: The trans or (E)-isomer of clomiphene.	2.02	1	0
terbinafine [no description available]	3.84	3	0	acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor
1,4-benzoquinone guanylhydrazone thiosemicarbazone 1,4-benzoquinone guanylhydrazone thiosemicarbazone: structure given in first source	2.04	1	0
drotaverin drotaverin: Hungarian drug; RN given refers to parent cpd; structure	2.45	2	0	isoquinolines
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	4.25	5	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
(1R,2S)-tranylcypromine hydrochloride (1R,2S)-tranylcypromine hydrochloride : A hydrochloride obtained by combining (1R,2S)-tranylcypromine with one equivalent of hydrochloric acid.	2.46	2	0	hydrochloride
thioacetamide Thioacetamide: A crystalline compound used as a laboratory reagent in place of HYDROGEN SULFIDE. It is a potent hepatocarcinogen.. thioacetamide : A thiocarboxamide consiting of acetamide having the oxygen replaced by sulfur.	2.75	3	0	thiocarboxamide	hepatotoxic agent
succimer Succimer: A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.. succimer : A sulfur-containing carboxylic acid that is succinic acid bearing two mercapto substituents at positions 2 and 3. A lead chelator used as an antedote to lead poisoning.	3.56	2	0	dicarboxylic acid; dithiol; sulfur-containing carboxylic acid	chelator
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	4.66	8	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
6-thioguanosine 6-thioguanosine: RN given refers to cpd without isomeric designation	2.04	1	0	purine nucleoside
streptozocin [no description available]	4.25	5	0
tamoxifen [no description available]	4.54	7	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
ethionamide Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.	3.84	3	0	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug
cancidas [no description available]	3.58	2	0
5-nitro-8-(1-pyrrolidinyl)quinoline [no description available]	2.41	1	0	nitro compound; quinolines
zeranol Zeranol: A non-steroidal estrogen analog.	2.04	1	0	macrolide
fusidic acid Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.	2.77	3	0	11alpha-hydroxy steroid; 3alpha-hydroxy steroid; alpha,beta-unsaturated monocarboxylic acid; steroid acid; steroid antibiotic; sterol ester	EC 2.7.1.33 (pantothenate kinase) inhibitor; Escherichia coli metabolite; protein synthesis inhibitor
lincomycin Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.	4.07	4	0	carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound	antimicrobial agent; bacterial metabolite
thiopental Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	2.73	3	0	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
ranitidine Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.	3.23	1	0	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
aplaviroc aplaviroc: a spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1; structure in first source	3.23	1	0
thiocarlide thiocarlide: major descriptor (68-85); on-line search PHENYLTHIOUREA/AA (68-85); Index Medicus search THIOCARLIDE (68-85); Antitubercular Agent	2.04	1	0	thioureas
hmr 3647 [no description available]	4.41	6	0
maraviroc [no description available]	3.23	1	0	tropane alkaloid
toremifene Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.	3.58	2	0	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
nelarabine nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).	3.58	2	0	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine [no description available]	2.45	2	0	aromatic ether
albutoin albutoin: structure	2.04	1	0	organonitrogen compound; organooxygen compound
iodothiouracil [no description available]	2.04	1	0	organohalogen compound; pyrimidines
dermatan sulfate Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed). alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S : An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding alpha-L-idopyranuronoside.. dermatan sulfate : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated beta1->4-linked L-iduronyl-(alpha1->3)-N-acetyl-D-galactosamine units.	3.23	1	0	amino disaccharide; glycosylgalactose derivative; iduronic acids; oligosaccharide sulfate
dezocine dezocine: potent analgesic; RN given refers to ((5R-(5alpha,11alpha,13S*)))-isomer (dezocin); structure. dezocine : (7S,8S)-7-Amino-8-methyl-5,6,7,8-tetrahydronaphthalen-2-ol in which the hydrogen at position 8 and one of the hydrogens at position 6 are substituted by each end of a tetramethylene bridge. A synthetic opioid analgesic, it has mixed opiod agonist and antagonist properties. Although it is used for pain management, it can produce opioid withdrawal syndrome in patients already dependent on other opioids, and its clinical application is limited by side effects such as dizziness.	2.02	1	0	phenols; primary amino compound	opioid analgesic
dapiprazole [no description available]	2.02	1	0	N-alkylpiperazine; N-arylpiperazine; pyridines	alpha-adrenergic antagonist; antipsychotic agent; miotic; ophthalmology drug
dolasetron [no description available]	3.58	2	0	indolyl carboxylic acid
or 1259 [no description available]	2.04	1	0	hydrazone; nitrile; pyridazinone	anti-arrhythmia drug; cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; vasodilator agent
mannomustine Mannomustine: Nitrogen mustard derivative alkylating agent used as antineoplastic. It causes severe bone marrow depression and is a powerful vesicant.	2.04	1	0	amino alcohol
gestodene Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer	2.44	2	0	steroid	estrogen
glucametacin glucametacin: indomethacin analog; structure	2.04	1	0
orlistat Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.	3.23	1	0	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine [no description available]	4.26	5	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
1-(2-(2-(4-pyridyl)-2-imidazoline-1-yl)ethyl)-3-(4-carboxyphenyl)urea 1-(2-(2-(4-pyridyl)-2-imidazoline-1-yl)ethyl)-3-(4-carboxyphenyl)urea: RN given refers to parent cpd; structure in first source	2.04	1	0
isepamicin [no description available]	2.44	2	0
ifetroban ifetroban: thromboxane receptor antagonist; structure given in first source; a 7-oxabicyclo(2.2.1)heptane derivative	2.04	1	0	benzenes; monocarboxylic acid
lamifiban lamifiban: a nonpeptide glycoprotein IIb/IIIa antagonist; prevents platelet loss during experimental cardiopulmonary bypass	2.04	1	0	N-acylglycine
fospropofol [no description available]	3.23	1	0	alkylbenzene
rasagiline [no description available]	3.23	1	0	indanes; secondary amine; terminal acetylenic compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; neuroprotective agent
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	3.23	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
telavancin telavancin: an anti-infective agent; structure in first source. telavancin : A glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria.	2.04	1	0	glycopeptide	antibacterial drug; antimicrobial agent
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	2.44	2	0	organic sodium salt	detergent; protein denaturant
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	3.85	3	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
flosequinan [no description available]	2.02	1	0	quinolines
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	4.41	6	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
quercetin [no description available]	2.48	2	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
bilirubin [no description available]	2.45	2	0	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	2.04	1	0	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	3.84	3	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
beta carotene beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.	2.04	1	0	carotenoid beta-end derivative; cyclic carotene	antioxidant; biological pigment; cofactor; ferroptosis inhibitor; human metabolite; mouse metabolite; plant metabolite; provitamin A
retinol palmitate retinol palmitate: RN given refers to parent cpd; structure. retinyl palmitate : A palmitate ester of retinol with undefined geometry about the C=C bonds.. all-trans-retinyl palmitate : An all-trans-retinyl ester obtained by formal condensation of the carboxy group of palmitic (hexadecanoic acid) with the hydroxy group of all-trans-retinol. It is used in cosmetic products to treat various skin disorders such as acne, skin aging, wrinkles, dark spots, and also protect against psoriasis.	2.46	2	0	all-trans-retinyl ester; retinyl palmitate	antioxidant; Escherichia coli metabolite; human xenobiotic metabolite
hymecromone Hymecromone: A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent. It is also used in ANALYTICAL CHEMISTRY TECHNIQUES for the determination of NITRIC ACID.	2.04	1	0	hydroxycoumarin	antineoplastic agent; hyaluronic acid synthesis inhibitor
alprostadil [no description available]	2.73	3	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
vitamin d 2 Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.	3.86	3	0	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	4.97	11	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
clavulanic acid Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.	4.81	31	0	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	4.25	5	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
oxymetholone Oxymetholone: A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed). oxymetholone : A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects.	3.23	1	0
eprosartan eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.	4.41	6	0	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
montelukast montelukast: a leukotriene D4 receptor antagonist	4.41	6	0	aliphatic sulfide; monocarboxylic acid; quinolines	anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist
mivacurium Mivacurium: An isoquinoline derivative that is used as a short-acting non-depolarizing agent.	3.58	2	0	isoquinolines
timolol maleate (S)-timolol maleate : The maleic acid salt of the active (S)-enantiomer of timolol, comprising equimolar amounts of (S)-timolol and maleic acid.	2.46	2	0	maleate salt	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
brompheniramine maleate brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.46	2	0	maleate salt	anti-allergic agent
chlorpheniramine maleate [no description available]	2.46	2	0	organic molecular entity
clemastine fumarate clemastine fumarate : The fumaric acid salt of clemastine. An antihistamine with antimuscarinic and moderate sedative properties, it is used for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.	2.46	2	0	fumarate salt	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
olopatadine [no description available]	2.02	1	0
methylergonovine maleate [no description available]	2.46	2	0	ergoline alkaloid	geroprotector
hemabate carboprost tromethamine : The tromethamine salt of carboprost. It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy.	3.23	1	0
ethchlorvynol Ethchlorvynol: A sedative and hypnotic that has been used in the short-term management of INSOMNIA. Its use has been superseded by other drugs.. ethchlorvynol : Propargyl alcohol in which the methylene hydrogens are substituted by ethyl and 2-chlorovinyl groups. A hypnotic and sedative, it is used for treatment of insomnia in some cases where an intolerance or allergy to more commonly used drugs exists.	2.04	1	0
mycophenolate mofetil mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.	3.23	1	0	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
bw b1090u [no description available]	2.02	1	0	isoquinolines
entacapone entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.	4.26	5	0	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol [no description available]	3.85	3	0	hydroxy seco-steroid; seco-cholestane	antiparathyroid drug
cynarine cynarine: active principle of the artichoke; functions primarily as a cholagogue and choleretic and also as antilipemic agent	2.04	1	0	alkyl caffeate ester; quinic acid	plant metabolite
ellagic acid [no description available]	2.13	1	0	catechols; cyclic ketone; lactone; organic heterotetracyclic compound; polyphenol	antioxidant; EC 1.14.18.1 (tyrosinase) inhibitor; EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor; EC 2.4.1.1 (glycogen phosphorylase) inhibitor; EC 2.5.1.18 (glutathione transferase) inhibitor; EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor; EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor; EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; food additive; fungal metabolite; geroprotector; plant metabolite; skin lightening agent
flupenthixol cis-flupenthixol : A flupenthixol in which the double bond adopts a cis-configuration.	2.05	1	0	flupenthixol	dopaminergic antagonist
sdz psc 833 valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215	2.04	1	0	homodetic cyclic peptide
estradiol-17 beta-glucuronide 17beta-estradiol 17-glucosiduronic acid : A steroid glucosiduronic acid that consists of 17beta-estradiol having a beta-glucuronyl residue attached at position 17 via a glycosidic linkage.	2.46	2	0	3-hydroxy steroid; steroid glucosiduronic acid
rokitamycin rokitamycin: structure in first source	2.04	1	0	organic molecular entity
7432 s Ceftibuten: A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections.. ceftibuten : A third-generation cephalosporin antibiotic with a [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino substituent at the 7 position of the cephem skeleton. An orally-administered agent, ceftibuten is used as the dihydrate to treat urinary-tract and respiratory-tract infections.	4.06	4	0	cephalosporin; dicarboxylic acid	antibacterial drug
etretinate retinoid : Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.	2.43	2	0	enoate ester; ethyl ester; retinoid	keratolytic drug
isotretinoin Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.	4.07	4	0	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent
misoprostol Misoprostol: A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.. misoprostol : A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form.	2.43	2	0
epoprostenol [no description available]	3.84	3	0	prostaglandins I	mouse metabolite
indocyanine green [no description available]	3.58	2	0	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
triprolidine Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.	3.58	2	0	N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist
pitavastatin pitavastatin : A dihydroxy monocarboxylic acid that is (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoic acid in which the two hydroxy groups are located at positions 3 and 5 (the 3R,5S-stereoisomer). Used as its calcium salt for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise.	3.23	1	0	cyclopropanes; dihydroxy monocarboxylic acid; monofluorobenzenes; quinolines; statin (synthetic)	antioxidant
cis-flupenthixol dihydrochloride cis-flupenthixol dihydrochloride : The dihydrochloride salt of cis-flupenthixol.	2.05	1	0	hydrochloride	geroprotector
ethamolin monoethanolamine oleate: used for treatment of pyogenic granuloma	3.23	1	0	long-chain fatty acid
betamethasone benzoate [no description available]	2.02	1	0	21-hydroxy steroid
alatrofloxacin mesylate [no description available]	3.23	1	0
codeine [no description available]	4.07	4	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	4.54	7	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
phenoxybenzamine hydrochloride [no description available]	2.46	2	0	organic molecular entity
natamycin [no description available]	2.04	1	0	antibiotic antifungal drug; dicarboxylic acid monoester; epoxide; macrolide antibiotic; monosaccharide derivative; polyene antibiotic	antifungal agrochemical; antimicrobial food preservative; apoptosis inducer; bacterial metabolite; ophthalmology drug
acitretin Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.. acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.	3.86	3	0	acitretin; alpha,beta-unsaturated monocarboxylic acid; retinoid	keratolytic drug
cloprednol cloprednol: relative anti-inflammatory potency twice prednisolone; synthetic glucocorticoid; structure	2.04	1	0	21-hydroxy steroid
cyproterone Cyproterone: An anti-androgen that, in the form of its acetate (CYPROTERONE ACETATE), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.	2.46	2	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; chlorinated steroid; tertiary alpha-hydroxy ketone	androgen antagonist
dihydrocodeine dihydrocodeine: RN refers to parent cpd(5alpha,6alpha)-isomer	2.04	1	0	morphinane alkaloid
dorzolamide dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.	2.02	1	0	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
estropipate estropipate: used therapeutically in menopausal patients	3.58	2	0	piperazinium salt; steroid sulfate
hydrocodone Hydrocodone: Narcotic analgesic related to CODEINE, but more potent and more addicting by weight. It is used also as cough suppressant.. hydrocodone : A morphinane-like compound that is a semi-synthetic opioid synthesized from codeine.	2.07	1	0	morphinane-like compound; organic heteropentacyclic compound	antitussive; mu-opioid receptor agonist; opioid analgesic
hydromorphone Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.	4.07	4	0	morphinane alkaloid; organic heteropentacyclic compound	mu-opioid receptor agonist; opioid analgesic
hydroxystilbamidine hydroxystilbamidine: minor descriptor (63-86); on-line & INDEX MEDICUS search STILBAMIDINES (66-86); RN given refers to parent cpd	2.04	1	0
levetiracetam Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.	3.58	2	0	pyrrolidin-2-ones	anticonvulsant; environmental contaminant; xenobiotic
ly 163892 loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.	4.39	6	0	carbacephem; zwitterion	antibacterial drug; antimicrobial agent
meprednisone [no description available]	2.04	1	0	21-hydroxy steroid
nabilone nabilone: cannabinol deriv; RN given refers to cpd without isomeric designation; structure	3.23	1	0
nalmefene nalmefene: RN given refers to 5-alpha isomer	3.14	5	0	morphinane alkaloid
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	4.07	4	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
oxycodone Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.	3.85	3	0	organic heteropentacyclic compound; semisynthetic derivative	antitussive; mu-opioid receptor agonist; opioid analgesic
oxymorphone Oxymorphone: An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)	3.86	3	0	morphinane alkaloid
vitamin k 1 Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.	3.23	1	0	phylloquinones; vitamin K	cofactor; human metabolite; plant metabolite
acepreval acepreval: topical steroid used for skin disease therapy	2.04	1	0	corticosteroid hormone
proscillaridin Proscillaridin: A cardiotonic glycoside isolated from Scilla maritima var. alba (Squill).	2.04	1	0	organic molecular entity
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	3.23	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	3.85	3	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
trospium chloride trospium chloride : An organic chloride salt of trospium. It is an antispasmodic drug used for the treatment of overactive bladder.	3.23	1	0
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	2.04	1	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
calcipotriene [no description available]	2.02	1	0	cyclopropanes; hydroxy seco-steroid; seco-cholestane; secondary alcohol; triol	antipsoriatic; drug allergen
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	4.26	5	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
pactamycin Pactamycin: Antibiotic produced by Streptomyces pactum used as an antineoplastic agent. It is also used as a tool in biochemistry because it inhibits certain steps in protein synthesis.	2.04	1	0
demycarosylturimycin h [no description available]	2.04	1	0
anthramycin [no description available]	2.04	1	0
benzphetamine Benzphetamine: A sympathomimetic agent with properties similar to DEXTROAMPHETAMINE. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222). benzphetamine : Dextroamphetamine in which the the hydrogens attached to the amino group are substituted by a methyl and a benzyl group. A sympathomimetic agent with properties similar to dextroamphetamine, it is used as its hydrochloride salt in the treatment of obesity.	3.23	1	0	amphetamines; tertiary amine	adrenergic uptake inhibitor; appetite depressant; dopamine uptake inhibitor; sympathomimetic agent
cicaprost cicaprost: RN given refers to (3aS-(2E,3aalpha,4alpha(3R,4R),5beta,6aalpha))-isomer	2.04	1	0	monoterpenoid
clobetasol Clobetasol: A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression.. clobetasol : A 3-oxo-Delta(1),Delta(4)-steroid that is 16beta-methylpregna-1,4-diene-3,20-dione bearing hydroxy groups at the 11beta and 17alpha positions, fluorine at position 9, and a chlorine substituent at position 21. It is used as its 17alpha-propionate ester to treat various skin disorders, including exzema and psoriasis.	2.02	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; fluorinated steroid; glucocorticoid; tertiary alpha-hydroxy ketone	anti-inflammatory drug; SMO receptor agonist
deamino arginine vasopressin Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.	3.23	1	0	heterodetic cyclic peptide	diagnostic agent; renal agent; vasopressin receptor agonist
dexmedetomidine [no description available]	3.58	2	0	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative
fluticasone Fluticasone: A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.. fluticasone : A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis.	2.02	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 3-oxo-Delta(4) steroid; corticosteroid; fluorinated steroid; thioester	anti-allergic agent; anti-asthmatic drug
goserelin Goserelin: A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.	3.23	1	0	organic molecular entity
halobetasol halobetasol: used in ointment to treat psoriasis; Ulobetasol cream contains 0.05% 6-fluoroclobetasol 17-propionate	2.02	1	0	corticosteroid hormone
iloprost Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.	2.04	1	0	carbobicyclic compound; monocarboxylic acid; secondary alcohol	platelet aggregation inhibitor; vasodilator agent
lacidipine [no description available]	2.04	1	0	cinnamate ester; tert-butyl ester
latanoprost Latanoprost: A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.. latanoprost : A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.	2.02	1	0	isopropyl ester; prostaglandins Falpha; triol	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor; prodrug
cytochalasin b Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.	2.04	1	0	cytochalasin; lactam; lactone; organic heterotricyclic compound	actin polymerisation inhibitor; metabolite; mycotoxin; platelet aggregation inhibitor
nalbuphine Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.	4.25	5	0	organic heteropentacyclic compound	mu-opioid receptor antagonist; opioid analgesic
nateglinide Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.	4.08	4	0	phenylalanine derivative
rimexolone [no description available]	2.02	1	0	20-oxo steroid
vinorelbine [no description available]	4.24	5	0	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid	antineoplastic agent; photosensitizing agent
silodosin silodosin: an alpha(1a)-adrenoceptor-selective antagonist; structure given in first source	3.23	1	0	indolecarboxamide
irisquinone irisquinone: from seeds of Iris pallasii Iridaceae; RN given refers to (Z)-isomer	2.04	1	0
furazolidone [no description available]	2.46	2	0
fluvoxamine Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.	4.54	7	0	(trifluoromethyl)benzenes; 5-methoxyvalerophenone O-(2-aminoethyl)oxime	antidepressant; anxiolytic drug; serotonin uptake inhibitor
su 11248 [no description available]	3.23	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
mitoguazone Mitoguazone: Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.. mitoguazone : A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine.	2.04	1	0	guanidines; hydrazone	antineoplastic agent; apoptosis inducer; EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
stilbamidine stilbamidine: RN given refers to parent cpd	2.45	2	0
romidepsin depsipeptide : A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating.	2.04	1	0	cyclodepsipeptide; heterocyclic antibiotic; organic disulfide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.	4.06	4	0	dihydroxy monocarboxylic acid; indoles; organofluorine compound
oxiconazole oxiconazole: RN given refers to parent cpd(Z)-isomer; structure given in first source. oxiconazole : An oxime O-ether that is the 2,4-dichlorobenzyl ether of the oxime obtained by formal condensation of hydroxylamine with the carbonyl group of acetopnenone in which the phenyl group is substituted by chlorines at positions 2 and 4, and in which one of the hydrogens of the methyl group is replaced by a 1H-imidazol-1-yl group. An antifungal agent, it is used (generally as the nitrate salt) in creams and powders for the topical treatment of fungal skin infections.	2.02	1	0	conazole antifungal drug; dichlorobenzene; imidazole antifungal drug; imidazoles; oxime O-ether	antiinfective agent
octylmethoxycinnamate [no description available]	2.46	2	0	cinnamate ester
levorphanol Levorphanol: A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.	3.23	1	0	morphinane alkaloid
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	4.25	5	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
morphine-6-glucuronide morphine-6-glucuronide: RN given refers to (5alpha,6alpha)-isomer	2.04	1	0	morphinane alkaloid
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	3.23	1	0	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
butorphanol Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.	4.4	6	0	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
cefodizime cefodizime: RN given refers to (6R-(6alpha,7beta(Z)))-isomer. cefodizime : A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	2.44	2	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; EC 1.14.18.1 (tyrosinase) inhibitor
methylnaltrexone methylnaltrexone: RN given refers to parent cpd(5alpha)-isomer	2.04	1	0	phenanthrenes
cefixime [no description available]	4.74	9	0	cephalosporin	antibacterial drug; drug allergen
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	4.54	7	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.	4.25	5	0	benzazepine; dicarboxylic acid monoester; ethyl ester; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
ramipril Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.	3.84	3	0	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
verteporfin (2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid : The 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid.	3.23	1	0
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	4.25	5	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
zimeldine Zimeldine: One of the SEROTONIN UPTAKE INHIBITORS formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of GUILLAIN-BARRE SYNDROME associated with its use. (From Martindale, The Extra Pharmacopoeia, 29th ed, p385)	3.86	3	0	styrenes
norstictic acid norstictic acid: from Xanthoparmelia chlorochroa; structure in first source	2.13	1	0
enalapril Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).	3.84	3	0	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
vinblastine sulfate [no description available]	2.46	2	0
nitrofurazone Nitrofurazone: A topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial WOUNDS AND INJURIES and skin infections. Nitrofurazone has also been administered orally in the treatment of TRYPANOSOMIASIS.. nitrofurazone : A semicarbazone resulting from the formal condensation of semicarbazide with 5-nitrofuraldehyde. A broad spectrum antibacterial drug, although with little activity against Pseudomonas species, it is used as a local application for burns, ulcers, wounds and skin infections.	2.04	1	0
trientine hydrochloride [no description available]	3.86	3	0
artocarpin lectin artocarpin lectin: a mannose-specific lectin; from the seeds of Artocarpus integrifolia; a homotetramic protein distinct from jacalin, another jackfruit lectin; MW 65 kDa; devoid of covalently-attached carbohydrates; consists of 4 isolectins with pI 5 - 6.5; do not confuse with artocarpin flavone. artocarpin : A trihydroxyflavone that is flavone substituted by hydroxy groups at positions 5, 2', and 4', a methoxy group at position 7, a prenyl group at position 3 and a (1E)-3-methylbut-1-enyl group at position 6. Isolated from Artocarpus heterophyllus and Artocarpus integrifolia, it exhibits antineoplastic activity.	2.41	1	0	monomethoxyflavone; trihydroxyflavone	antineoplastic agent; metabolite
n-methylscopolamine bromide scopolamine methobromide : A quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide.	3.23	1	0
aztreonam [no description available]	2.31	1	0
bleomycin [no description available]	3.23	1	0	bleomycin	antineoplastic agent; metabolite
dextromethorphan hydrobromide dextromethorphan hydrobromide : The hydrobromide and monohydrate of the antitussive drug dextromethorphan.	2.46	2	0	hydrate; hydrobromide
indinavir sulfate [no description available]	2.05	1	0	azaheterocycle sulfate salt
enalaprilat anhydrous Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.	3.85	3	0	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefquinome cefquinome: broad spectrum antibiotic; RN given refers to (6R(6alpha,7beta(Z)-isomer); structure given in first source	2.4	2	0
ximelagatran ximelagatran: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this. ximelagatran : A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.	3.59	2	0	amidoxime; azetidines; carboxamide; ethyl ester; hydroxylamines; secondary amino compound; secondary carboxamide; tertiary carboxamide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; prodrug; serine protease inhibitor
cefuroxime [no description available]	6.7	69	0	3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether	drug allergen
ceftriaxone [no description available]	9.51	69	1	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	16.29	188	1	cephalosporin; oxime O-ether	antibacterial drug
hr 810 cefpirome: structure in first source. cefpirome : A fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	4.44	21	0	cephalosporin; cyclopentapyridine
pafuramidine pafuramidine: a prodrug of furamidine	3.23	1	0
trandolapril trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.	3.84	3	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
pregabalin Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.	3.23	1	0	gamma-amino acid	anticonvulsant; calcium channel blocker
cefetamet cefetamet: active against Neisseria gonorrhoeae; structure given in first source. cefetamet : A cephalosporin compound having methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a cephalosporin antibiotic active against Neisseria gonorrhoeae.	2.45	2	0	cephalosporin
alvimopan anhydrous alvimopan: mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain	3.23	1	0	peptide
aliskiren aliskiren: orally active nonpeptidic renin inhibitor. aliskiren : A monomethoxybenzene compound having a 3-methoxypropoxy group at the 2-position and a multi-substituted branched alkyl substituent at the 4-position.	3.23	1	0	monocarboxylic acid amide; monomethoxybenzene	antihypertensive agent
guanabenz Guanabenz: An alpha-2 selective adrenergic agonist used as an antihypertensive agent.	2.02	1	0	dichlorobenzene
famotidine [no description available]	4.65	8	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
fenoterol fenoterol hydrobromide : The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction.	2.46	2	0	hydrobromide	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	14	174	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
aztreonam [no description available]	9.26	164	0	beta-lactam antibiotic allergen; monobactam	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cci 15641 [no description available]	2.02	1	0	cephalosporin
ginkgolide b [no description available]	2.04	1	0
ceftiofur [no description available]	2.97	4	0
cefpodoxime [no description available]	4.25	5	0	carboxylic acid; cephalosporin	antibacterial drug
cefuzonam cefuzonam: article gives L-105 as synonym, however L 105 is a rifamycin derivative according to Chemline. cefuzonam : A second generation cephalosporin antibiotic.	2.06	1	0	cephalosporin	antibacterial drug
palonosetron Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.	3.58	2	0	azabicycloalkane; delta-lactam; organic heterotricyclic compound	antiemetic; serotonergic antagonist
cefatrizine Cefatrizine: Orally active semisynthetic cephalosporin antibiotic with broad-spectrum activity.. cefatrizine : A cephalosporin compound having (1H-1,2,3-triazol-4-ylsulfanyl)methyl and [(2R)-2-amino-2-(4-hydroxyphenyl)]acetamido side-groups. An antibacterial drug first prepared in the 1970s, it has more recently been found to be an inhibitor of eukaryotic elongation factor-2 kinase (eEF2K), which is known to regulate apoptosis, autophagy and ER stress in many types of human cancers.	2.45	2	0	amino acid amide; carboxylic acid; cephalosporin; phenols; semisynthetic derivative; triazoles	antibacterial drug; EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
enclomiphene citrate [no description available]	2.05	1	0
diphenoxylate hydrochloride diphenoxylate hydrochloride : The hydrochloride salt of diphenoxylate.	2.46	2	0	hydrochloride	antidiarrhoeal drug
eniporide eniporide: inhibits NHE-1 isoform; structure in first source	2.04	1	0
cilastatin [no description available]	2.73	3	0	carboxamide; L-cysteine derivative; non-proteinogenic L-alpha-amino acid; organic sulfide	EC 3.4.13.19 (membrane dipeptidase) inhibitor; environmental contaminant; protease inhibitor; xenobiotic
nitrocefin nitrocefin: chromogenic cephalosporin used for detection of beta-lactamase activity; Cefinase is name for nitrocefin on paper disc; RN given refers to (6R-(3(E),6 alpha,7 beta))-isomer; structure for mono-Na salt in second source	4.06	14	0
rifaximin [no description available]	3.23	1	0	acetate ester; cyclic ketal; lactam; macrocycle; organic heterohexacyclic compound; rifamycins; semisynthetic derivative	antimicrobial agent; gastrointestinal drug; orphan drug
ergonovine maleate ergometrine maleate : A maleate salt resulting form the reaction of equimolar amounts of maleic acid and ergometrine. It is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced.	2.46	2	0	maleate salt	diagnostic agent; oxytocic
sibiromycin [no description available]	2.04	1	0	aminoglycoside antibiotic; hemiaminal; phenols; pyrrolobenzodiazepine	antineoplastic agent; bacterial metabolite
everolimus [no description available]	3.23	1	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
ixabepilone [no description available]	3.58	2	0	1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle	antineoplastic agent; microtubule-destabilising agent
dirithromycin [no description available]	2.02	1	0	macrolide antibiotic	prodrug
azlocillin Azlocillin: A semisynthetic ampicillin-derived acylureido penicillin.. azlocillin : A semisynthetic penicillin having a 6beta-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae.	3.3	6	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial drug
verlukast verlukast: LTD4 receptor antagonist	2.04	1	0
cefpodoxime proxetil cefpodoxime proxetil: structure given in first source; prodrug for cefpodoxime. cefpodoxime proxetil : The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.	2.02	1	0	carboxylic acid; carboxylic ester; cephalosporin	antibacterial drug; prodrug
ceftizoxime [no description available]	4.38	6	0	cephalosporin	antibacterial drug
cefluprenam cefluprenam: has broad antibacterial spectrum; structure given in first source. cefluprenam : A fourth-generation cephalosporin antibiotic having (1E)-3-[(2-amino-2-oxoethyl)(ethyl)methylazaniumyl]prop-1-en-1-yl and {(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(fluoromethoxy)imino]acetyl}amino side groups located at positions 3 and 7 respectively.	2	1	0	cephalosporin; thiadiazoles	antimicrobial agent
1-methyl-d-lysergic acid butanolamide [no description available]	3.58	2	0	ergot alkaloid; monocarboxylic acid amide	serotonergic antagonist; sympatholytic agent; vasoconstrictor agent
carumonam carumonam: structure given in first source; RN given refers to (2S-(2alpha,3alpha(Z))-isomer. carumonam : An N-sulfonated monobactam antibiotic.	2.76	3	0	monobactam	antibacterial drug
dantrolene sodium dantrolene sodium (anhydrous) : The anhydrous sodium salt of dantrolene.	2.46	2	0
nitrofurantoin Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.	4.94	11	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
methampicillin methampicillin: RN given refers to parent cpd(2S-(2alpha,5alpha,6beta(S*)))-isomer. metampicillin : A penicillin compound having a 6beta-(2R)-2-(methylideneamino)-2-phenylacetamido side-group.	2.02	1	0	penicillin allergen; penicillin
butylscopolammonium bromide Butylscopolammonium Bromide: Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.	2.04	1	0
eritoran eritoran : A lipid A derivative used for the treatment of severe sepsis.	2.04	1	0	lipid As
dantrolene [no description available]	4.25	5	0
cefdinir [no description available]	3.81	3	0	cephalosporin; ketoxime	antibacterial drug
fumagillin [no description available]	2.04	1	0	antibiotic antifungal drug; carboxylic ester; dicarboxylic acid monoester; meroterpenoid; organooxygen heterocyclic antibiotic; spiro-epoxide	angiogenesis inhibitor; antibacterial drug; antimicrobial agent; antiprotozoal drug; fungal metabolite; methionine aminopeptidase 2 inhibitor
etonogestrel [no description available]	3.23	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	2.04	1	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
dexniguldipine niguldipine: structure given in first source; clinical modulator of multidrug resistance	2.04	1	0	diarylmethane
napsagatran napsagatran: structure given in first source	2.04	1	0
temsirolimus [no description available]	3.58	2	0	macrolide lactam
dutasteride Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.	3.23	1	0	(trifluoromethyl)benzenes; aza-steroid; delta-lactam	antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
lu 208075 ambrisentan: an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertension	3.23	1	0	diarylmethane
bms188797 [no description available]	2.04	1	0
bibx 1382bs BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001	3.23	1	0	substituted aniline
fesoterodine fesoterodine: a muscarinic antagonist for treatment of overactive bladder	3.23	1	0	diarylmethane
corosolic acid [no description available]	2.06	1	0	triterpenoid	metabolite
chlorhexidine Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.	2.05	1	0	biguanides; monochlorobenzenes	antibacterial agent; antiinfective agent
thioacetazone Thioacetazone: A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the International Union Against Tuberculosis and are used in some developing countries to reduce drug costs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p217). thiosemicarbazone : A hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-thioacylated nitrogen of thiosemicarbazide or its substituted derivatives.	2.04	1	0
azimilide azimilide: structure given in first source; RN given refers to dihydrochloride	2.04	1	0	imidazolidine-2,4-dione
cefozopran [no description available]	2.45	2	0	cephalosporin; imidazopyridazine; thiadiazoles
gemifloxacin Gemifloxacin: A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.. gemifloxacin : A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.	3.57	2	0	1,8-naphthyridine derivative; fluoroquinolone antibiotic; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; topoisomerase IV inhibitor
n-acetylglucosaminono-1,5-lactone o-(phenylcarbamoyl)oxime N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime: structure given in first source	2.03	1	0
dexlansoprazole Dexlansoprazole: The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.	3.23	1	0	benzimidazoles; sulfoxide
fosinopril [no description available]	3.84	3	0
armodafinil armodafinil : A 2-[(diphenylmethyl)sulfinyl]acetamide that has R configuration at the sulfur atom. Like its racemate, modafinil, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. Peak concentration in the blood later occurs later following administration than with modafinil, so it is thought that armodafinil may be more effective than modafinil in treating people with excessive daytime sleepiness.	3.23	1	0	2-[(diphenylmethyl)sulfinyl]acetamide	central nervous system stimulant; eugeroic
tomopenem [no description available]	2.73	3	0
sincalide Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.	3.23	1	0	oligopeptide
avibactam avibactam : A member of the class of azabicycloalkanes that is (2S,5R)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide in which the amino hydrogen at position 6 is replaced by a sulfooxy group. Used (in the form of its sodium salt) in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.	2.25	1	0	azabicycloalkane; hydroxylamine O-sulfonic acid; monocarboxylic acid amide; ureas	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
tapentadol Tapentadol: An opioid analgesic, MU OPIOID RECEPTOR agonist, and noradrenaline reuptake inhibitor that is used in the treatment of moderate to severe pain, and of pain associated with DIABETIC NEUROPATHIES.	3.23	1	0	alkylbenzene
ursodoxicoltaurine tauroursodeoxycholate : An organosulfonate oxoanion that is the conjugate base of tauroursodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.. tauroursodeoxycholic acid : A bile acid taurine conjugate derived from ursoodeoxycholic acid.	2.05	1	0	bile acid taurine conjugate	anti-inflammatory agent; apoptosis inhibitor; bone density conservation agent; cardioprotective agent; human metabolite; neuroprotective agent
bb-83698 BB-83698: peptide deformylase inhibitor	2.04	1	0
ppi-0903 ceftaroline : A cephalosporin that is the active metabolite of the prodrug ceftaroline fosamil. Used for the treatment of adults with acute bacterial skin and skin structure infections.	3.55	2	0	1,3-thiazoles; cephalosporin; iminium betaine; organic phosphoramidate; oxime O-ether; thiadiazoles	antibacterial drug; antimicrobial agent; prodrug
pentagastrin Pentagastrin: A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid.	3.23	1	0	organic molecular entity
abt-770 ABT-770: structure in first source	2.45	2	0
cefditoren cefditoren: structure given in first source; RN given refers to the (6R-(3(Z),6alpha,7beta(Z)))-isomer. cefditoren : A broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.	3.23	1	0	carboxylic acid; cephalosporin	antibacterial drug
zotarolimus zotarolimus: synthetic analog of rapamycin; structure in first source	2.04	1	0	lactam; macrolide
treosulfan treosulfan: immunosuppressant; RN given refers to (S-(R,R))-isomer	2.04	1	0	methanesulfonate ester
molindone hydrochloride [no description available]	2.46	2	0	indoles
9-n-(1-propyl)erythromyclamine 9-N-(1-propyl)erythromyclamine: structure given in first source	2.45	2	0
gentamicin sulfate [no description available]	7.28	93	1
bn 52020 [no description available]	2.04	1	0
nkp 608 [no description available]	2.04	1	0
rhodamine 123 [no description available]	2.05	1	0	organic chloride salt; xanthene dye	fluorochrome
ganu GANU: differs from chlorozotocin by placement of cytotoxic group on C-1 of the glucose ring; less myelosuppressive than chlorozotocin; structure	2.04	1	0
2-phenylbenzothiazole PBT2 compound: a metal-protein-attenuating compound that may be useful in treating Alzheimer's disesae	2.41	1	0
azacosterol Azacosterol: Diaza derivative of cholesterol which acts as a hypocholesteremic agent by blocking delta-24-reductase, which causes the accumulation of desmosterol.	2.45	2	0
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	3.23	1	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
prasugrel hydrochloride Prasugrel Hydrochloride: A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.. prasugrel hydrochloride : A racemate comprising equal amounts of (R)- and (S)-prasugrel hydrochloride. Used to prevent blood clots in people with acute coronary syndrome who are undergoing a procedure after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels.	3.23	1	0
besifloxacin [no description available]	2.05	1	0	quinolines
me1036 ME1036: structure in first source	3.14	1	0
homatropine methylbromide homatropine methylbromide: RN given refers to bromide (endo-(+-))-isomer	2.46	2	0
baci-im [no description available]	4.08	4	0	homodetic cyclic peptide; polypeptide; zwitterion	antibacterial agent; antimicrobial agent
sm-216601 SM-216601: exhibits potent activity against methicillin-resistant staphylococci (MRS) and vancomycin-resistant enterococci (VRE); structure in first source	3.14	1	0
metamelfalan [no description available]	2.04	1	0
polymyxin b(1) [no description available]	2.41	1	0
bms 477118 [no description available]	3.23	1	0	adamantanes; azabicycloalkane; monocarboxylic acid amide; nitrile; tertiary alcohol	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
nystatin a1 Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.	3.56	2	0	nystatins
chir 090 CHIR 090: structure in first source. CHIR-090 : An L-threonine derivative obtained by formal condensation of the carboxy group of 4-({4-[(morpholin-4-yl)methyl]phenyl}ethynyl)benzoic acid with the amino group of N-hydroxy-L-threoninamide.	2.07	1	0	acetylenic compound; benzamides; hydroxamic acid; L-threonine derivative; morpholines	antimicrobial agent; EC 3.5.1.108 (UDP-3-O-acyl-N-acetylglucosamine deacetylase) inhibitor; lipopolysaccharide biosynthesis inhibitor
cytidine diphosphate choline [no description available]	2.46	2	0	nucleotide-(amino alcohol)s; phosphocholines	human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite
milnacipran [no description available]	3.23	1	0	acetamides
vindesine [no description available]	2.73	3	0
hypoglycin a hypoglycin: RN given refers to cpd without isomeric designation. hypoglycin A : A diastereoisomeric mixture of (2S,4R)- and (2S,4S)- hypoglycin A, found in the edible part of the fruit of the Ackee, Blighia sapida (where the 2S,4R diastereoisomer is more dominant (17% d.e.) than its 2S,4S counterpart) as well as in the sycamore maple tree (Acer pseudoplatanus).	2.05	1	0	L-alpha-amino acid
diflucortolone Diflucortolone: A topical glucocorticoid used in various DERMATOSES. It is absorbed through the skin, bound to plasma albumin, and may cause adrenal suppression. It is also administered as the valerate.	2.04	1	0	21-hydroxy steroid
scopolamine hydrobromide [no description available]	3.58	2	0
2-((3-chloroethyl)-3-nitrosoureido)glucopyranose [no description available]	2.04	1	0
ro 6-4563 glibornuride: was MH 1975-92 (see under SULFONYLUREA COMPOUNDS 1975-90); use SULFONYLUREA COMPOUNDS to search GLIBORNURIDE 1975-92; an oral, sulfonylurea hypoglycemic agent which stimulates insulin secretion	2.04	1	0	monoterpenoid
riccardin d riccardin D: antifungal agent isolated from Dumortiera hirsute; structure in first source	2.13	1	0
amodiaquine hydrochloride [no description available]	2.75	3	0
clindamycin hydrochloride [no description available]	2.46	2	0	S-glycosyl compound
azamulin azamulin: a Cyp3A inhibitor; structure in first source	2.1	1	0
bisaramil [no description available]	2.04	1	0
bivalirudin bivalirudin: designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition. bivalirudin : A synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant.	3.23	1	0	polypeptide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor
teicoplanin teicoplanin A2-1 : A teicoplanin A2 that has (4Z)-dec-4-enoyl as the variable N-acyl group.	2.45	2	0
tannins gallotannin : A class of hydrolysable tannins obtained by condensation of the carboxy group of gallic acid (and its polymeric derivatives) with the hydroxy groups of a monosaccharide (most commonly glucose).	2.13	1	0	tannin
enfuvirtide Enfuvirtide: A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS.. enfuvirtide : A synthetic 36-amino acid peptide consisting of N-acetyltyrosyl, threonyl, seryl, leucyl, isoleucyl, histidyl, seryl, leucyl, isoleucyl, alpha-glutamyl, alpha-glutamyl, seryl, glutaminyl, asparaginyl, glutaminyl, glutaminyl, alpha-glutamyl, lysyl, asparaginyl, alpha-glutamyl, alpha-glutamyl, alpha-glutamyl, leucyl, leucyl, alpha-glutamyl, leucyl, alpha-aspartyl, lysyl, tryptophyl, alanyl, seryl, leucyl, tryptophyl, asparaginyl, tryptophyl, and phenylalaninamide residues joined in sequence. An HIV fusion inhibitor, it was the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It interferes with entry of HIV into cells by binding to the gp41 sub-unit of the viral envelope glycoprotein, so inhibiting fusion of viral and cellular membranes.	3.23	1	0
ganirelix [no description available]	3.23	1	0	polypeptide
pexiganan [no description available]	2.05	1	0
teriparatide [no description available]	3.23	1	0	polypeptide
forapin Forapin: used as ointment for treatment of myositis & arthritis; contains bee venom, salicylate, nicotinate & vanillylnonamide	3.13	4	0	peptidyl amide; polypeptide	animal metabolite; antineoplastic agent; apoptosis inducer; EC 2.7.11.13 (protein kinase C) inhibitor; hepatoprotective agent; neuroprotective agent; venom
salmon calcitonin [no description available]	3.23	1	0	heterodetic cyclic peptide; peptide hormone; polypeptide	bone density conservation agent; metabolite
ly-146032 [no description available]	4.07	4	0	heterodetic cyclic peptide; lipopeptide antibiotic; lipopeptide; macrocycle; macrolide	antibacterial drug; bacterial metabolite; calcium-dependent antibiotics
dalbavancin [no description available]	2.04	1	0	carbohydrate acid derivative; glycopeptide; monosaccharide derivative; semisynthetic derivative	antibacterial drug; antimicrobial agent
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide: FE-200486 is the acetate salt	3.23	1	0	polypeptide
exenatide [no description available]	3.23	1	0
ropocamptide ropocamptide: from granulocytes & keratinocytes, precursor to cathelicidins; MW 16-18 kDa; GenBank AJ224927 (eCATH-1). cathelicidin : A group of small, cationic polypeptides (consisting of 12-97 amino acids) that are found in humans and other species, including farm animals (E.g. cattle, horses, pigs, sheep etc). They show a broad spectrum of antimicrobial activity against bacteria, enveloped viruses and fungi.	2.05	1	0
quinine sulfate [no description available]	2.46	2	0	hydrate
flucloronide flucloronide: synthetic glucocorticoid with anti-inflammatory properties; minor descriptor (75-83); on-line & Index Medicus search PREGNADIENETROLS (75-83); RN given refers to (6alpha,11beta,16alpha)-isomer; structure	2.04	1	0	21-hydroxy steroid
cefotiam hydrochloride [no description available]	2.46	2	0
mesna Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.	3.56	2	0	organosulfonic acid
tazobactam sodium tazobactam sodium : An organic sodium salt having tazobactam(1-) as the counterion; used in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.	2	1	0	organic sodium salt	antiinfective agent; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
potassium aminobenzoate [no description available]	2.46	2	0
ampicillin sodium [no description available]	2.05	1	0	organic sodium salt
cefamandole nafate [no description available]	2.02	1	0	organic sodium salt	antibacterial drug; prodrug
sodium lactate Sodium Lactate: The sodium salt of racemic or inactive lactic acid. It is a hygroscopic agent used intravenously as a systemic and urinary alkalizer.. sodium lactate : An organic sodium salt having lactate as the counterion.	3.23	1	0	lactate salt; organic sodium salt	food acidity regulator; food preservative
sodium iothalamate [no description available]	3.23	1	0
methicillin sodium [no description available]	2.46	2	0	organic sodium salt
nafcillin sodium [no description available]	2.46	2	0	organic sodium salt
oxacillin sodium [no description available]	2.13	1	0	organic sodium salt
penicillin g sodium [no description available]	3.32	6	0	organic sodium salt
cefamandole nafate cefamandole sodium : An organic sodium salt that is the sodium salt of cefamandole.	2.46	2	0	organic sodium salt	antibacterial drug
cephapirin sodium cephapirin sodium : The sodium salt of cephapirin. A first-generation cephalosporin antibiotic, it is effective against gram-negative and gram-positive organisms. Being more resistant to beta-lactamases than penicillins, it is effective agains most staphylococci, though not methicillin-resistant staphylococci.	2.46	2	0	cephalosporin; organic sodium salt	antibacterial drug
sodium cephalothin [no description available]	2.46	2	0	organic sodium salt
dicloxacillin sodium [no description available]	2.46	2	0	hydrate
azlocillin sodium [no description available]	2.46	2	0	organic sodium salt
nxl 104 avibactam sodium : An organic sodium salt that is the monosodium salt of avibactam. Used in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.	2.21	1	0	organic sodium salt	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
cetrorelix cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.	3.58	2	0	oligopeptide	antineoplastic agent; GnRH antagonist
hainanolide hainanolide: from bark of Cephalotaxux hainensis	2.04	1	0
gliocladic acid gliocladic acid: from Gliocladium virens, Chaetomium globosum & Trichoderma viride; structure given in first source	2.04	1	0	p-menthane monoterpenoid
btz 043 [no description available]	2.17	1	0
achn 490 plazomicin: structure in first source	2.05	1	0
cleistanthin cleistanthin: lignan lactone toxic glycoside from Cleistanthus collinus (Roxb); structure. cleistanthin A : A member of the class of cleistanthins that is the 4-O-3,4-di-O-methyl-beta-D-xylopyranoside of 1,3-dihydronaphtho[2,3-c]furan-4-ol which is substituted by an oxo group at position 1, methoxy groups at positions 6 and 7, and a 1,3-benzodioxol-5-yl group at position 9. It is one of the toxic principles in Cleistanthus collinus.	2.04	1	0	cleistanthins; xylose derivative	alpha-adrenergic antagonist; antihypertensive agent; diuretic
nimorazole [no description available]	2.04	1	0
bal 30072 BAL 30072: a siderophore with antibacterial activity; structure in first source	2.5	2	0
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	4.08	4	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
raltegravir [no description available]	3.23	1	0	1,2,4-oxadiazole; dicarboxylic acid amide; hydroxypyrimidine; monofluorobenzenes; pyrimidone; secondary carboxamide	antiviral drug; HIV-1 integrase inhibitor
novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.	4.07	14	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	6.26	44	0
chlortetracycline Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.	3.14	5	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	4.07	4	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	5.64	23	0
piroxicam [no description available]	4.54	7	0	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
roquinimex roquinimex: structure in first source	2.04	1	0	aromatic amide
acenocoumarol Acenocoumarol: A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233). acenocoumarol : A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group.	2.46	2	0	C-nitro compound; hydroxycoumarin; methyl ketone	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
meclocycline [no description available]	2.02	1	0
bactobolin bactobolin: from Pseudomonas sp. BN-183; has MF C14-H20-Cl2-N2-O6; RN given refers to parent cpd(R*)-isomer	2.04	1	0	amino acid amide
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	4.26	5	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
mobiflex tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.	2.73	3	0	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
isoxicam isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.	2.96	4	0	benzothiazine; isoxazoles; monocarboxylic acid amide	antirheumatic drug; non-steroidal anti-inflammatory drug
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	4.65	8	0	benzenes; hydroxycoumarin; methyl ketone
bephenium hydroxynaphthoate bephenium hydroxynaphthoate: structure	2.04	1	0
demeclocycline Demeclocycline: A TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.. demeclocycline : Tetracycline which lacks the methyl substituent at position 7 and in which the hydrogen para- to the phenolic hydroxy group is substituted by chlorine. Like tetracycline, it is an antibiotic, but being excreted more slowly, effective blood levels are maintained for longer. It is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.	4.25	5	0
phenprocoumon Phenprocoumon: Coumarin derivative that acts as a long acting oral anticoagulant.. phenprocoumon : A hydroxycoumarin that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenylpropyl group.	2.04	1	0	hydroxycoumarin	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
tipranavir tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.	3.23	1	0	sulfonamide	antiviral drug; HIV protease inhibitor
chlortetracycline hydrochloride Alexomycin: a thiopeptide; a cyclic peptide antibiotic produced by Streptomyces arginensis isolated from the soil	2.46	2	0
rolitetracycline Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.	2.45	2	0
sudoxicam sudoxicam: proposed ant-inflammatory agent; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZINES (75-86)	2.05	1	0
methacycline monohydrochloride [no description available]	2.46	2	0
minocycline hydrochloride [no description available]	2.46	2	0
demeclocycline hydrochloride demeclocycline hydrochloride : The hydrochloride salt of demeclocycline. A tetracycline antibiotic, it is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.	2.46	2	0
tigecycline [no description available]	6.9	33	0
colistin sulfate [no description available]	2.03	1	0
fertinex [no description available]	3.23	1	0
cefiderocol cefiderocol: structure in first source. cefiderocol : A fourth-generation siderophore cephalosporin antibiotic having {1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidinium-1-yl}methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively, developed to combat a variety of bacterial pathogens, including beta-lactam- and carbapenem-resistant organisms.	2.25	1	0	carboxylic acid; cephalosporin	antibacterial drug; siderophore
entecavir entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.	3.23	1	0	2-aminopurines; oxopurine; primary alcohol; secondary alcohol	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	4.4	6	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	4.08	4	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
viomycin [no description available]	2.04	1	0	heterodetic cyclic peptide; peptide antibiotic	antitubercular agent
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	6.27	26	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	4.76	9	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	4.54	7	0	dacarbazine
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	4.54	7	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	4.4	6	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
valacyclovir Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.	3.56	2	0	L-valyl ester	antiviral drug
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	3.85	3	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
olanzapine Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.	4.07	4	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
penciclovir penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.	2.73	3	0	2-aminopurines; propane-1,3-diols	antiviral drug
vardenafil vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.	3.85	3	0	imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	4.85	10	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
azaguanine Azaguanine: One of the early purine analogs showing antineoplastic activity. It functions as an antimetabolite and is easily incorporated into ribonucleic acids.. 8-azaguanine : A triazolopyrimidine that consists of 3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidine bearing amino and oxo substituents at positions 5 and 7 respectively.	2.04	1	0	nucleobase analogue; triazolopyrimidines	antimetabolite; antineoplastic agent; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor
citrovorum factor [no description available]	3.86	3	0	tetrahydrofolic acid
leucovorin 5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5.	3.85	3	0	formyltetrahydrofolic acid	Escherichia coli metabolite; mouse metabolite
rifapentine rifapentine: cyclopentyl derivative of rifampicin	3.23	1	0	N-alkylpiperazine; N-iminopiperazine; rifamycins	antitubercular agent; leprostatic drug
alanosine [no description available]	2.04	1	0
bl 4162a anagrelide: imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia; structure in first source. anagrelide : A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.	3.23	1	0	imidazoquinazoline	anticoagulant; antifibrinolytic drug; cardiovascular drug; platelet aggregation inhibitor
tegaserod tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source	3.85	3	0	carboxamidine; guanidines; hydrazines; indoles	gastrointestinal drug; serotonergic agonist
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	3.23	1	0	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
7-deazaguanosine 7-deazaguanosine: structure given in first source	2.04	1	0
tirapazamine Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.	2.04	1	0	aromatic amine; benzotriazines; N-oxide	antibacterial agent; antineoplastic agent; apoptosis inducer
valganciclovir Valganciclovir: A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor.. valganciclovir : The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine.	3.23	1	0	L-valyl ester; purines	antiviral drug; prodrug
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	3.58	2	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
fosaprepitant fosaprepitant: a pro-drug form of aprepitant. fosaprepitant : A morpholine derivative that is the (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether of (3-{[(2R,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid.	3.23	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; phosphoramide; triazoles	antiemetic; neurokinin-1 receptor antagonist; prodrug
ceftobiprole ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).	9.93	8	1	cephalosporin; thiadiazoles	antimicrobial agent
pyrazofurin pirazofurin : A C-glycosyl compound that is 4-hydroxy-1H-pyrazole-5-carboxamide in which the hydrogen at position 3 has been replaced by a beta-D-ribofuranosyl group.	2.04	1	0	C-glycosyl compound; pyrazoles	antimetabolite; antimicrobial agent; antineoplastic agent; EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor
rifabutin [no description available]	4.4	6	0
n(10)-methylfolate [no description available]	2.04	1	0	folic acids
5-methyltetrahydrohomofolic acid 5-methyltetrahydrohomofolic acid: RN given refers to parent cpd	2.04	1	0
prodigiosin Prodigiosin: 4-Methoxy-5-((5-methyl-4-pentyl-2H-pyrrol-2-ylidene)methyl)- 2,2'-bi-1H-pyrrole. A toxic, bright red tripyrrole pigment from Serratia marcescens and others. It has antibacterial, anticoccidial, antimalarial, and antifungal activities, but is used mainly as a biochemical tool.. prodigiosin : A member of the class of tripyrroles that is a red-coloured pigment with antibiotic properties produced by Serratia marcescens.	2.1	1	0
ninopterin ninopterin: structure	2.04	1	0
levomefolate calcium levomefolate calcium: an ingredient in Contraceptives, Oral, Combined. levomefolate calcium : An organic calcium salt of (6S)-5-methyltetrahydrofolic acid.	3.23	1	0	organic calcium salt	antidepressant

Condition	Indicated	Relationship Strength	Studies	Trials
Bacterial Disease [description not available]	0	4.94	8	0
Bacterial Infections Infections by bacteria, general or unspecified.	1	6.94	8	0
Adverse Drug Event [description not available]	0	2.74	3	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	2.74	3	0
Acinetobacter Infections Infections with bacteria of the genus ACINETOBACTER.	0	5.15	17	0
Infections, Klebsiella [description not available]	0	5.31	20	0
Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA.	0	5.31	20	0
Disease, Pulmonary [description not available]	0	2.03	1	0
Infections, Pseudomonas [description not available]	0	6.33	35	1
Infection, Wound [description not available]	0	2.03	1	0
Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.	0	2.45	2	0
Lung Diseases Pathological processes involving any part of the LUNG.	0	2.03	1	0
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	0	6.33	35	1
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	1	4.03	1	0
Cystic Fibrosis of Pancreas [description not available]	0	4.82	7	1
B cepacia Infection [description not available]	0	2.03	1	0
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	1	11.82	7	1
Health Care Associated Infection [description not available]	0	7.54	27	0
Cross Infection Any infection which a patient contracts in a health-care institution.	0	7.54	27	0
E coli Infections [description not available]	0	4.06	14	0
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	0	4.06	14	0
Cronobacter Infections [description not available]	0	9.46	53	0
Enterobacteriaceae Infections Infections with bacteria of the family ENTEROBACTERIACEAE.	1	11.46	53	0
Bacterial Infections, Gram-Positive [description not available]	0	4.34	4	1
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	0	4.34	4	1
Ventilator-Associated Pneumonia [description not available]	0	2.03	1	0
Pneumonia, Ventilator-Associated Serious INFLAMMATION of the LUNG in patients who required the use of PULMONARY VENTILATOR. It is usually caused by bacterial CROSS INFECTION in hospitals.	0	2.03	1	0
Community Acquired Infection [description not available]	0	2.95	4	0
Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.	0	5.59	9	0
Critical Illness A disease or state in which death is possible or imminent.	0	2.03	1	0
Flavobacteriaceae Infections Infections with bacteria of the family FLAVOBACTERIACEAE.	0	2.03	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.89	4	0
Bacterial Pneumonia [description not available]	0	2.03	1	0
Pneumonia, Bacterial Inflammation of the lung parenchyma that is caused by bacterial infections.	0	2.03	1	0
Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.	1	4.03	1	0
Infections, Proteus [description not available]	0	2.45	2	0
Bacterial Infections, Gram-Negative [description not available]	0	4.68	6	1
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	2.04	1	0
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	0	4.68	6	1
Bacterial Skin Diseases [description not available]	0	3.43	1	1
Skin Diseases, Bacterial Skin diseases caused by bacteria.	0	3.43	1	1
Absence Seizure [description not available]	0	2.49	2	0
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	0	2.49	2	0
Infections, Salmonella [description not available]	0	2.05	1	0
Burkholderia pseudomallei Infection [description not available]	0	2.05	1	0
Dysentery, Shiga bacillus [description not available]	0	2.05	1	0
Dysentery, Bacillary DYSENTERY caused by gram-negative rod-shaped enteric bacteria (ENTEROBACTERIACEAE), most often by the genus SHIGELLA. Shigella dysentery, Shigellosis, is classified into subgroups according to syndrome severity and the infectious species. Group A: SHIGELLA DYSENTERIAE (severest); Group B: SHIGELLA FLEXNERI; Group C: SHIGELLA BOYDII; and Group D: SHIGELLA SONNEI (mildest).	0	2.05	1	0
Diabetic Glomerulosclerosis [description not available]	0	2.05	1	0
Chronic Kidney Failure [description not available]	0	2.05	1	0
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	0	2.05	1	0
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	0	2.05	1	0
Blood Poisoning [description not available]	0	2.46	2	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	0	2.46	2	0
Acute Liver Injury, Drug-Induced [description not available]	0	4.08	5	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	4.08	5	0
Lipidoses Conditions characterized by abnormal lipid deposition due to disturbance in lipid metabolism, such as hereditary diseases involving lysosomal enzymes required for lipid breakdown. They are classified either by the enzyme defect or by the type of lipid involved.	0	2.05	1	0
Infections, Serratia [description not available]	0	2.05	1	0
Candida Infection [description not available]	0	2.06	1	0
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	0	2.06	1	0
Fungal Diseases [description not available]	0	2.08	1	0
Mycoses Diseases caused by FUNGI.	0	2.08	1	0
Extravascular Hemolysis [description not available]	0	2.55	2	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	0	2.55	2	0
Koch's Disease [description not available]	0	2.17	1	0
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	0	2.17	1	0
Co-infection [description not available]	0	2.21	1	0
Eye Infections, Fungal Infection by a variety of fungi, usually through four possible mechanisms: superficial infection producing conjunctivitis, keratitis, or lacrimal obstruction; extension of infection from neighboring structures - skin, paranasal sinuses, nasopharynx; direct introduction during surgery or accidental penetrating trauma; or via the blood or lymphatic routes in patients with underlying mycoses.	0	2.21	1	0
Keratitis Inflammation of the cornea.	0	2.21	1	0
Infections, Staphylococcal [description not available]	0	2.41	1	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	0	2.41	1	0

ceftazidime

Cross-References

Synonyms (47)

Research Excerpts

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (2)

Protein Targets (57)

Inhibition Measurements

Other Measurements

Biological Processes (6)

Molecular Functions (4)

Ceullar Components (4)

Bioassays (4823)

Research

Studies (352)

Market Indicators

Research Demand Index: 100.74

Study Types

Clinical Trials (75)

Trial Overview

Trial Outcomes

Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the LFU Visit

Clinical Outcome in CE Patients at the Late Follow-up (LFU) Visit

Clinical Outcome in CE Patients at the TOC Visit

Clinical Outcome in Clinically Evaluable (CE) Patients at the End of Intravenous (IV) Therapy Visit

Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the End of IV Therapy Visit

Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the LFU Visit

Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the TOC Visit

Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the End of IV Therapy Visit

Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the TOC Visit

Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the End of IV Therapy Visit

Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the LFU Visit

Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the TOC Visit

Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the End of IV Therapy Visit

Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the TOC Visit

Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the End of IV Therapy Visit

Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the LFU Visit

Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the TOC Visit

Microbiological Outcome in ME Patients at the End of IV Therapy Visit

Microbiological Outcome in ME Patients at the LFU Visit

Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit

Number of Participants With Clinical Response at the Test of Cure (TOC) Visit

Number of Participants With Clinical Response in CE Participants at the End of IV Therapy

Number of Participants With Clinical Response in CE Participants at the Late Follow-up Visit

Number of Participants With Clinical Response in Clinically Evaluable (CE) Participants at the Test of Cure Visit

Number of Participants With Microbiological Response at the End of IV Therapy

Number of Participants With Microbiological Response at the Late Follow-up Visit

Number of Participants With Microbiological Response at the Test of Cure Visit

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Number of Participants With Clinical Response at the End of Intravenous (IV) Therapy

Number of Participants With Clinical Response at the Late Follow-up Visit

Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population

Microbiological Response at the TOC Visit in the Microbiologically Evaluable (ME) Population.

Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)

Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)

Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)

Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)

Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)

Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)

Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)

Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)

Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)

Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)

Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)

Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)

Per-patient Microbiological Response at LFU (mMITT Analysis Set)

Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)

Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)